| WASHINGTON STATE PATROL<br>PROFESSIONAL SERVICE CONTRACT<br>Toxicology Forensic Testing | WSP Contract No. K21620 |
|---|---|

This Contract is between the State of Washington, Washington State Patrol, hereinafter referred to as WSP, and the Contractor identified below, and is governed by chapter 39.26 RCW.

| **CONTRACTOR NAME**<br>National Medical Services, Inc. | **Contractor Doing Business As (DBA)**<br>NMS Labs |
|---|---|
| **Contractor Address**<br>200 Welsh Road<br>Horsham, PA 19044 | **Statewide Vendor Registration Number**<br>SWV# 0101036-00 |
| **Contact Name**<br>Camilla Green, Sr. Territory Manager-Forensics | **Contact Telephone**<br>215-824-6095 |
| **Contact Email**<br>Camilla.Green@NMSLABS.COM | **Administrative/Contracts Contact (Name/Email)** |

**WSP CONTACT INFORMATION**

| **WSP Contract Manager Name and Title**<br>Elizabeth Gough, Toxicology Laboratory Division Commander | **WSP Contract Manager Address**<br>2203 Airport Way S Bldg A, Suite 360<br>Seattle WA 98134-2045 |
|---|---|
| **Telephone**<br>206-262-6100 | **E-mail Address**<br>Elizabeth.Gough@wsp.wa.gov |
| **WSP Contract Specialist**<br>Jamie Roessler, Contracts Specialist 2 | **WSP Contract Specialist Address**<br>PO Box 42602<br>106 11th Ave SW, Ste. 3100, Olympia WA 98504 |
| **Telephone**<br>206-262-6146 | **E-mail Address**<br>Jamie.Roessler@wsp.wa.gov |

| **Contract Start Date**<br>August 14, 2025 | **Contract End Date**<br>August 13, 2026 | **Maximum Contract Amount**<br>$1,000,000.00<br>Plus applicable Taxes |
|---|---|---|

ATTACHMENTS. When the boxes below are marked with an X, the following Exhibits are attached to and incorporated into this Contract by reference:

- ☒ Exhibit A, Statement of Work.
- ☒ Exhibit B, General Terms and Conditions
- ☒ Exhibit C, 2025 Fee Schedules
- ☒ Exhibit D, Solicitation
- ☒ Exhibit E, Contractor's Proposal
- ☒ Exhibit F, Subcontractor Business Diversity Certification

This Contract, including the attached Terms and Conditions and any other documents incorporated by reference, contains all of the terms and conditions agreed upon by the parties. No other understandings or representations, oral or otherwise, regarding the subject matter of this Contract shall be deemed to exist or bind the parties. The parties signing below warrant that they have read and understand this Contract and have the authority to enter into this Contract.

| **FOR THE WASHINGTON STATE PATROL:** | **FOR THE CONTRACTOR:** |
|---|---|
| WSP Signature: Walter Hamilton - CFO<br>Digitally signed by Walter Hamilton - CFO<br>Date: 2025.08.08 09:11:12 -07'00' | Contractor Signature: David Delia<br>Date: 8/5/2025 |
| Printed Name and Title<br>John R. Batiste, Chief | Printed Name and Title<br>David Delia CEO |

APPROVED AS TO FORM BY THE OFFICE OF THE ATTORNEY GENERAL 10/16/2014

## 1.1 Purpose

The Contractor shall provide timely forensic toxicology analysis for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases that the Washington State Patrol (WSP) Toxicology Laboratory Division does not respectively have the resources to perform in-house, or for which WSP Toxicology Laboratory Division cannot detect the specific drugs. The Contractor shall be accredited by the ANSI National Accreditation Board (ANAB) to the ISO/IEC 17025 standard and American Board of Forensic Toxicology (ABFT) requirements. WSP Toxicology Laboratory Division shall send samples to be tested on a flow basis, according to the fee schedule provided by Bidder in its proposal.

## 1.2 Background

The WSP Toxicology Laboratory Division is accredited by ANAB to the ISO/IEC 17025 standard and ABFT requirements and provides toxicological testing of biological specimens for the presence of alcohol and other drugs, with case submissions from law enforcement agencies, medical examiners, coroners, and other agencies, statewide (the customer).

The WSP Toxicology Laboratory Division's ANAB accreditation requires that Contractors performing testing be evaluated and deemed competent to perform the work. The WSP Toxicology Laboratory Division is responsible to the customer for the work of the Contractor, and WSP Toxicology Laboratory Division internal policy requires that only approved Contractors may perform testing on evidence submitted to the Laboratory, unless otherwise specified by the customer.

## 1.2 Acceptance

All Services and Deliverables shall be subject to WSP's review and written Acceptance, including without limitation Deliverables, change orders and amendments to this Agreement. The process and forms for WSP's review or Acceptance of Services and Deliverables shall be established in writing between the parties at the start of the project.

**1. Definitions.**

***Contract***: This Professional Service Contract, including all documents attached or incorporated by reference.

***Contractor***: The entity performing services to this Contract and includes the Contractor's owners, members, officers, director, partners, employees and/or agents unless otherwise stated in this Contract. For purposes of any permitted Subcontract, "Contractor" includes any Subcontractor and its owners, members, officers, director, partners, employees and/or agents.

***General Terms and Conditions***: This Exhibit C.

***Lead Time:*** The period of time between when the Contractor receives the order and WSP receives the goods and/or services under this Contract.

***Statement of Work***: The Special Terms and Conditions of this Contract, Exhibit A.

***Subcontract***: A separate contract between the Contractor and an individual or entity ("Subcontractor") to perform all or a portion of the duties and obligations that the Contractor is obligated to perform pursuant to this Contract.

***RCW***: Revised Code of Washington. All references in the Contract to RCW chapters or sections shall include any successor, amended, or replacement statutes.

***USC***: United States Code. All references in the Contract to USC chapters or sections shall include any successor, amended or replacement statutes.

***WSP:*** State of Washington, Washington State Patrol, and its officers, directors, trustees, employees and/or agents.

**2. Attorneys' Fees and Costs.** If any litigation is brought to enforce any term, clause, provision or section of this Contract or as a result of this Contract in any way, the prevailing party shall be awarded its reasonable attorney's fees together with expenses and costs incurred with such litigation, including necessary fees, costs and expenses for services rendered at both trial and appellate levels as well as subsequent to judgement in obtaining execution thereof. In the event that parties to this Contract engage in arbitration, mediation or any other alternative dispute resolution forum to resolve a dispute in lieu of litigation, both parties shall share equally in the cost of the alternative dispute resolution, including the cost of mediation or arbitration services. Each party shall be responsible for their own attorney's fees incurred as a result of the alternative dispute resolution method.

**3. Period of Performance.** The initial period of performance of this Contract is listed on page One. WSP, in its sole discretion, may extend the contract for up to four (4) additional one-year terms or portions thereof, at the same terms and conditions. The total term, including the initial term and all subsequent extensions, shall not exceed five (5) years, unless an emergency exists and/or special circumstances require an additional term extension.

**4. Payment.** WSP shall reimburse the Contractor an amount not to exceed the Contract Maximum Amount specified on Page One of this Contract.

**5. Advance Payments.** WSP shall not make any payments in advance or anticipation of the delivery of goods or services provided by the Contractor pursuant to this Contract, except Pursuant to RCW 43.88.160(5), under certain conditions, payments for equipment maintenance services may be made up to twelve months in advance.

**6. Late Payments.** Under Chapter 39.76 RCW, (SAAM 85.32.50 if WSP fails to make timely payment(s), Contractor may invoice for 1% per month on the amount overdue or a minimum of $1.00. Payment will not be considered late if a check or warrant is mailed within the time specified. If no terms are specified, net 30 days will automatically apply.

7. **Overpayments to Contractors.** Upon notice of an erroneous payment or overpayment to which the Contractor is not entitled pursuant to this Contract, the Contractor shall promptly refund to WSP the full amount of any such payment or overpayment.

8. **Billing Procedure.** WSP shall reimburse the Contractor for work performed to the satisfaction of the WSP Project Manager. Compensation for services rendered shall be payable upon receipt of properly completed invoices, which shall be submitted not more often than monthly to the WSP Project Manager, except for payments made in advance pursuant to RCW 43.88.160(5) as stated in Section 6 above. The invoices shall describe and document to WSP's satisfaction a description of the work performed, activities accomplished, the progress of the project, fees and expenses, WSP's contract number, and the Contractor's Statewide Vendor registration number. The Contractor shall submit the final invoice not later than 60 calendar days from the Contract End Date.

9. **Assignment.** The work to be provided under this Contract, and any claim arising thereunder, is not assignable or delegable by the Contractor in whole or in part, without the express written consent of WSP.

10. **Conflict.** In the event of a conflict between the WSP terms and conditions contained herein and the Contractor's terms and conditions, the WSP terms and conditions shall prevail.

11. **Compliance with Civil Rights Laws.** During the period of performance for this Contract, the Contractor shall comply with all federal and state nondiscrimination laws.

12. **Confidentiality.** The Contractor shall not use or disclose any information concerning WSP, or information that may be classified as confidential, to any third party without the written permission of WSP. The Contractor shall either destroy or return all such information to the WSP Contract Manager at the end of this Contract.

13. **Contract Execution and Amendments.** This Contract shall be binding on WSP only upon signature by the Chief of WSP or designee. WSP and the Contractor may mutually amend this Contract. Such amendments shall not be binding unless they are in writing and signed by personnel authorized to bind WSP and the Contractor.

14. **Electronic Signatures.** A signed copy of this contract or any other ancillary document transmitted by facsimile, email, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original executed document for all purposes. Electronic signatures must be certified to be considered valid signatures.

15. **Contractor Certification Regarding Ethics.** The Contractor certifies that the Contractor is in compliance with Chapter 42.52 RCW, Ethics in Public Service, and will comply with Chapter 42.52 RCW throughout the term of the Contract.

16. **Debarment Certification**. The Contractor, by signature affixed hereto, certifies that the Contractor is not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department or agency from participating in transactions (Debarred). The Contractor also agrees to include the above requirements in any and all Subcontracts into which it enters. The Contractor shall immediately notify WSP if, during the term of this Contract, Contractor becomes Debarred. WSP may immediately terminate this Contract by providing Contractor written notice if Contractor becomes Debarred during the term hereof.

17. **Disputes.** In the event a bona fide dispute concerning a question of fact arises between WSP and Contractor and it cannot be resolved between the parties, either party may initiate the dispute resolution procedure provided herein.

The initiating party shall reduce its description of the dispute to writing and deliver it to the responding party. The responding party shall respond in writing within three (3) Business Days. The initiating party shall have three (3) Business Days to review the response.

**17.1** If after this review resolution cannot be reached, both parties shall have three (3) Business Days to negotiate in good faith to resolve the dispute. If the dispute cannot be resolved after three (3) Business Days, a Dispute Resolution Panel may be requested in writing by either party who shall also identify the first panel member. Within three (3) Business Days of receipt of the request, the other party will designate a panel member. Those two panel members will appoint a third individual to the dispute resolution panel within the next three (3) Business Days.

**17.2** The Dispute Resolution Panel will review the written descriptions of the dispute, gather additional information as needed, and render a decision on the dispute in the shortest practical time.

**17.3** Each party shall bear the cost for its panel member and share equally the cost of the third panel member.

**17.4** Both parties agree to be bound by the determination of the Dispute Resolution Panel.

**17.5** Both parties agree to exercise good faith in dispute resolution and to settle disputes prior to using a Dispute Resolution Panel whenever possible.

**17.6** Both parties agree that, the existence of a dispute notwithstanding, they will continue without delay to carry out all their respective responsibilities under this Contract that are not affected by the dispute.

**17.7** If the subject of the dispute is the amount due and payable by WSP for Services being provided by Contractor, Contractor shall continue providing Services pending resolution of the dispute provided WSP pays, in good faith, the amount WSP believes is due and payable, and places in escrow the difference between such amount and the amount Contractor, in good faith, believes is due and payable.

**18. Filing Requirement.** This Contract may be required to be filed with the Department of Enterprise Services pursuant to Chapter 39.26 RCW. No contract so filed is effective nor shall work commence under it until the tenth (10th) working day following the date of filing subject to DES approval.

**19. Governing Law.** This Contract shall be governed in all respects by the laws of the State of Washington. The jurisdiction for any action hereunder shall be the Superior Court for the State of Washington. The venue of any action hereunder shall be in the Superior Court for Thurston County, State of Washington.

**20. Indemnification.** The Contractor shall indemnify, defend and hold harmless WSP from and against all claims arising out of or resulting from the performance of this Contract. The Contractor expressly agrees to indemnify, defend and hold harmless WSP for any claim arising out of or incident to the Contractor's performance or failure to perform this Contract. The Contractor shall be required to indemnify, defend and hold WSP harmless to the extent any claim is caused in whole or in part by negligent acts or omissions of the Contractor.

**21. Independent Capacity.** The Contractor acknowledges that the Contractor is an independent contractor, and not an officer, employee or agent of WSP or the State of Washington. The Contractor shall not hold itself out as, nor claim status as, an officer, employee or agent of WSP or the State of Washington. The Contractor shall indemnify and hold WSP harmless from all

obligations to pay or withhold federal or state taxes or contributions on behalf of the Contractor or the Contractor's employees unless otherwise specified in this Contract.

**22. Insurance.** During the term of any Contract, the Contractor shall maintain in full force and effect, the insurance described in this section. The Contractor shall acquire such insurance from an insurance carrier or carriers licensed to conduct business in the state of Washington and having a rating of A-, Class VII or better, in the most recently published edition of Best's Reports. In the event of cancellation, non-renewal, revocation or other termination of any insurance coverage required by the Contract, the Contractor shall provide written notice of such to WSP within one (1) Business Day of the Contractor's receipt of such notice. Failure to buy and maintain the required insurance may, at WSP's sole option, result in the Contract's termination.

**22.1 Minimum Requirements**. The minimum acceptable limits shall be as indicated below, with no deductible for each of the following categories:

**22.1.1** Commercial General Liability covering the risks of bodily injury (including death), property damage and personal injury, including coverage for contractual liability, with a limit of not less than $1 million per occurrence/$2 million general aggregate;

**22.1.2** Business Automobile Liability (owned, hired, or non-owned) covering the risks of bodily injury (including death) and property damage, including coverage for contractual liability, with a limit of not less than $1 million per accident; and

**22.1.3** Employers Liability insurance covering the risks of the Contractor's employees' bodily injury by accident or disease with limits of not less than $1 million per accident for bodily injury by accident and $1 million per employee for bodily injury by disease.

**22.1.4** Industrial insurance coverage for Contractor's employees, as may be required of an "employer" as defined in Title 51 RCW, and maintain full compliance with Title 51 RCW during the period of performance for this Contract. WSP shall not be responsible for payment of industrial insurance premiums or for any other claim or benefit for the Contractor, or any subcontractor or employee of the Contractor, which might arise under the industrial insurance laws during the performance of duties and services under this Agreement.

**22.2 Requirements for Proof of Insurance**. The Contractor shall pay premiums on all insurance policies. Such insurance policies shall name WSP as an additional insured on all general liability and automobile liability policies. Such policies shall also reference the WSP Contract number and shall have a condition that they not be revoked by the insurer until forty-five (45) calendar days after notice of intended revocation thereof shall have been given to WSP by the insurer.

All insurance provided by the Contractor shall be primary as to any other insurance or self-insurance programs afforded to or maintained by the State and shall include a severability of interests (cross-liability) provision.

The Contractor shall include all Subcontractors as insured under all required insurance policies, or shall furnish separate certificates of insurance and endorsements for each Subcontractor. Subcontractor(s) shall comply fully with all insurance requirements stated herein. Failure of Subcontractor(s) to comply with insurance requirements does not limit the Contractor's liability or responsibility.

The Contractor shall furnish to WSP copies of certificates of all required insurance within thirty (30) calendar days of the Contract's Effective Date, and copies of renewal certificates

of all required insurance within thirty (30) days after the renewal date. These certificates of insurance must expressly indicate compliance with each and every insurance requirement specified in this section. Failure to provide evidence of coverage may, at WSP's sole option result in the Contract's termination.

By requiring insurance herein, WSP does not represent that coverage and limits will be adequate to protect the Contractor. Such coverage and limits shall not limit the Contractor's liability under the indemnities and reimbursements granted to the Contractor in the Contract.

**23. Inspection; Maintenance of Records.** During the term of this Contract and for one year following termination or expiration of this Contract, the Contractor shall give reasonable access to the Contractor's place of business and records to WSP and any other employee or agent of the State of Washington or the United States of America for the purpose of inspecting the Contractor's place of business and its records, and monitoring, auditing and evaluating the Contractor's performance and compliance with applicable laws, regulations, rules and this Contract.

During the term of this Contract and for six years following termination or expiration of this Contract, the Contractor shall maintain records sufficient to document (i) performance of all acts required by statute, regulation, rule, or this Contract; (ii) substantiate the Contractor's statement of its organization's structure, tax status, capabilities and performance; and (iii) demonstrate accounting procedures, practices and records that sufficiently and properly document the Contractor's invoices to WSP and all expenditures made by the Contractor to perform as required by this Contract.

**24. OSHA and WISHA Requirements.** The Contractor agrees to comply with conditions of the Federal Occupational Safety and Health Administration (OSHA) and, if manufactured or stored in the State of Washington, the Washington Industrial Safety and Health Act (WISHA) and the standards and regulations issued there under, and certifies that all items furnished and purchased will conform and comply with said laws, standards, and regulations. Contractor further agrees to indemnify and hold harmless WSP from all damages assessed against WSP as a result of the Contractor's failure to comply with those laws, standards, and regulations, and for failure of the items furnished under the Contractor to so comply.

**25. Order of Precedence.** In the event of any inconsistency in the terms of this Contract, or between its terms and any applicable statute or rule the inconsistency shall be resolved by giving precedence in the following order to:

Applicable federal and state law, regulations and rules;
Exhibit A, Statement of Work
Exhibit B, General Terms and Conditions
Exhibit E, Contractor's Proposal
Exhibit D, Solicitation WSP-RFQQ-TOXTST
Any other provision of this Contract; and
Any document incorporated by reference.

**26. Personnel.** The assignment of WSP personnel under this Contract shall be at the discretion of the Chief of WSP or designee. WSP employees performing work under the terms of this Contract (if any) shall be under the direct command and control of the Chief of WSP or designee, and shall perform duties required under this Contract in a manner consistent with WSP policy and regulations, and applicable federal, state and local laws.

27. **Prevailing Wage.** Contractor is responsible for ensuring that prevailing wage laws are followed pursuant to Charters 39.12 and 49.28 of the Revised Code of Washington, and WAC 296.127-022. The Contractor shall pay the prevailing rate of wages to all workers, laborers, or mechanics in the performance of any part of the work described in the contract in accordance with state law and Department of Labor and Industries rules and regulations. The Contractor shall comply with the filing requirements required by this statute, including Statement of Intent to Pay Prevailing Wage, and Affidavit of Wages Paid.

28. **Repair, Minor Alterations, or Extra Work.** Should the WSP require additional services covered under this contract the following shall apply.

    Except as otherwise provide in the contract, no payment for extras shall be made unless such extras and the price therefor have been authorized in writing by the WSP Contract/Project Manager. The WSP Contract/Project Manager shall provide the Contractor with a written scope of work for the repair or alteration. The Contractor shall provide the agency with a "not to exceed" price quote in using the labor, equipment rental, and materials pricing structure in this contract. Equipment and materials prices shall be net plus identified markup. The Contractor shall proceed with the work only upon receipt of written authorization from the contract officer. Any extra work, repair and/or minor alteration during the Contract term, cannot exceed the accumulated total of the contract maximum total listed on the contact face sheet.

29. **Rights in Data.** Unless otherwise provided, data that originates from this Contract shall be “works for hire” as defined by the U.S. Copyright Act of 1976 and shall be owned by WSP. Data shall include, but not be limited to, reports, documents, pamphlets, advertisements, books, magazines, surveys, studies, computer programs, films, tapes, and/or sound reproductions. Ownership includes the right to copyrights, patent, register, and the ability to transfer these rights.

    Material delivered by the Contractor under the terms of this Contract, but which does not originate therefrom, shall be transferred with a nonexclusive, royalty-free irrevocable license to publish, translate, reproduce, deliver, performs, dispose of, and to authorize others to do so, provided that such a license shall be limited to the extent which the Contractor has a right to grant such a license. The Contractor shall exert all reasonable efforts to advise WSP at the time of material delivery of all known or potential invasions of privacy contained therein and of any portion of such material which was not produce in performance of this Contract. WSP shall receive prompt written notice of each notice or claim of copyright infringement received by the Contractor with respect to any material delivered under this Contract. WSP shall have the right to modify or remove any restrictive markings placed upon the data by the Contractor.

30. **Savings.** In the event that funds WSP relied upon to establish this Contract are withdrawn, reduced or limited, or if additional or modified conditions are placed on such funding, WSP may immediately terminate this Contract by providing written notice to the Contractor. This termination shall be effective on the date specified in the notice of termination.

31. **Severability.** If any provision of this Contract or any provision of any document incorporated by reference shall be held invalid, such invalidity shall not affect the other provisions of this Contract which can be given effect without the invalid provision, if such remainder conforms to the requirements of applicable law and the fundamental purpose of this Contract, and to this end the provisions of this Contract are declared to be severable.

32. **Site Security.** While on WSP’s premises, the Contractor shall conform in all respects with physical, fire or other security regulations communicated to the Contractor by WSP.

33. **Statewide Payee Registration.** The Contractor is required to be registered as a Statewide Payee prior to submitting a request for payment under this Agreement. The Washington State Office of Financial Management (OFM) maintains the Statewide Payee Registration System; to obtain registration materials go to: https://ofm.wa.gov/it-systems/statewide-vendorpayee-services.

34. **Subcontracting.** Except as otherwise provided in this Contract, the Contractor may subcontract for any of the services provided under this Contract with the prior, written approval of WSP. The Contractor shall be responsible for the acts and omissions of any subcontractor. The terms and conditions of this Contract shall apply to all Subcontractors. If at any time Contractor wishes in the future to subcontract any of the services, or to change the subcontractor noted in *Exhibit E, Business Diversity Certification*, it must first obtain prior written approval of WSP and will be subject to the terms and conditions of DES Policy No. POL-DES-090-06, Supplier Diversity, with regard to subcontractors.

35. **Supervision of Employees and Workers**. Contractor shall be solely responsible for the safety of Contractor's employees and others relative to Contractor's work, work procedures, materials, equipment, transportation, and related activities and equipment. The Contractor shall take appropriate action to correct workers, whether employees or subcontractor, that disregard the contents of this contract, who are incompetent, careless and/ or insubordinate and do not exhibit proper dress and decorum expected in a WSP owned/ leased property

36. **Survivorship of Provisions.** Any terms, conditions and warranties contained in this Contract that by their sense and context are intended to survive performance by the parties to this Contract shall so survive the completion of the period of performance or termination of this Contract.

37. **Taxes**. WSP shall pay sales and use taxes imposed on services provided by the Contractor under this Contract if required by state law. Contractor is required to collect and pay such taxes on behalf of WSP and remit the taxes to the Department of Revenue. The Contractor shall pay all other taxes, including, but not limited to, Washington State Business and Occupation Tax, taxes based on the Contractor's income, or personal property taxes levied or assessed on the Contractor's personal property to which WSP does not own title.

38. **Termination.**

    **38.1 Termination for Convenience.** Except as otherwise provided in this Contract, either party may terminate this Contract upon thirty (30) calendar days written notification. If this Contract is so terminated, the terminating party shall be liable only for performance in accordance with the terms of this Contract for performance rendered prior to the effective date of termination.

    **38.2 Termination for Default.** WSP may terminate the Contract for default, in whole or in part, if WSP has a reasonable basis to believe that the Contractor failed to perform under any provision of this Contract; violated any applicable law, regulation, rule or ordinance; or otherwise breached any provision or condition of this Contract.

    WSP shall notify the Contractor in writing of the need to take corrective action. If corrective action is not taken within five (5) calendar days, the Contract may be terminated. WSP reserves the right to suspend all or part of the Contract, withhold further payments, or prohibit the Contractor from incurring additional obligations of funds during investigation of the alleged default and pending corrective action by the Contractor or a decision by WSP to terminate the Contract.

In the event of termination for default, the Contractor shall be liable for damages as authorized by law including, but not limited to, any cost difference between the original contract and the replacement or cover contract, and all administrative costs directly related to procuring the replacement contract. If it is determined that the Contractor was not in default the termination shall be deemed a termination for convenience. The rights and remedies of WSP provided under this Contract are not exclusive and are in addition to any other rights and remedies provided by law.

**38.3 Termination for Breach**. The right of either Party to terminate this Agreement, as provided herein, shall not be affected in any way by its waiver or failure to take action with respect to any previous material breach.

This Contract may be terminated for cause by the WSP, at the sole discretion of the WSP Chief Contracts Officer, for failure to perform a contractual requirement or for a material breach of any term or condition. Material breach of a term or condition of the Contract may include but is not limited to:

**38.3.1** Contractor failure to perform services or complete a deliverable by the date required or by an alternate date as mutually agreed in a written amendment to the Contract;

**38.3.2** Contractor failure to carry out any warranty or failure to perform or comply with any mandatory provision of the contract;

**38.3.3** Contractor becomes insolvent or in an unsound financial condition so as to endanger performance hereunder;

**38.3.4** Contractor becomes the subject of any proceeding under any law relating to bankruptcy, insolvency or reorganization, or relief from creditors and/or debtors that endangers the Contractor's proper performance hereunder;

**38.3.5** Appointment of any receiver, trustee, or similar official for Contractor or any of the Contractor's property and such appointment endangers the Contractor's proper performance hereunder;

**38.3.6** A determination that the Contractor is in violation of federal, state, or local laws or regulations and that such determination renders the Contractor unable to perform any aspect of the Contract.

**38.4 Opportunity to Cure**

In the event that Contractor fails to perform a contractual requirement or materially breaches any term or condition, WSP may issue a written cure notice. WSP May provide the Contractor a period of time in which to cure. The WSP is not required to allow the Contractor to cure defects if the opportunity for cure is not feasible as determined solely within the discretion of WSP. Time allowed for cure shall not diminish or eliminate Contractor's liability for liquidated or other damages, or otherwise affect any other remedies available against Contractor under the Contract or by law.

If the breach remains after Contractor has been provided the opportunity to cure, WSP may do any one or more of the following:

**38.4.1** Exercise any remedy provided by law;

**38.4.2** Terminate this Contract and any related Contracts or portions thereof;

**38.4.3** Procure replacements and impose damages as set forth elsewhere in this Contract;

**38.4.4** Impose actual or liquidated damages;

**38.4.5** Suspend or bar Contractor from receiving future Solicitations or other opportunities;

**38.4.6** Require Contractor to reimburse WSP for any loss or additional expense incurred as a result of default or failure to satisfactorily perform the terms of the Contract.

**38.5 Termination Procedure.** The following provisions shall survive and be binding on the parties to this Contract in the event this Contract is terminated.

**38.5.1** The Contractor shall stop work under this Contract on the date specified in the notice of termination, and shall comply with all instructions contained in the notice of termination.

**38.5.2** The Contractor shall deliver to the WSP Project Manager identified on the Face Sheet of this Contract, all WSP property in the Contractor's possession and any WSP property produced under this Contract. The Contractor grants WSP the right to enter upon the Contractor's premises for the sole purpose of recovering any WSP property that the Contractor fails to return within ten (10) calendar days of termination of the Contract. Upon failure to return WSP property within ten (10) calendar days of the Contract termination, the Contractor shall be charged with all reasonable costs of recovery, including transportation and attorney's fees. The Contractor shall protect and preserve any property of WSP that is in the possession of the Contractor pending return to WSP. The Contractor shall provide written certification to WSP that the Contractor has returned all WSP property in the Contractor's possession.

**38.5.3** WSP may direct assignment of the Contractor's rights to and interest in any subcontract or orders placed to WSP. WSP may terminate any subcontract or orders, and settle or pay any or all claims arising out of the termination of such orders and subcontracts.

**38.5.4** WSP shall be liable for and shall pay for only those services authorized and provided through the date of termination. WSP may pay an amount agreed to by the parties for partially completed work and services, if work products are useful to WSP.

**38.6 Withholding Payment**. In the event of termination for default or breach of contract, WSP may withhold a sum from the final payment to the Contractor that WSP determines necessary to protect WSP against loss or additional liability.

**39. Treatment of Assets.** Title to all property furnished by WSP to the Contractor under the terms of this Contract shall remain with WSP. Any property furnished by WSP to the Contractor under the terms of this Contract shall be used only for the performance of this Contract. The Contractor shall be responsible for any loss or damage of property provided to the Contractor by WSP resulting from the failure on the part of the Contractor to maintain and administer that property in accordance with sound management practices. Upon the discovery of loss or damage of WSP property, the Contractor shall notify WSP and take all reasonable steps to prevent any further loss or damage. Upon the termination or completion of this Contract, the Contractor shall surrender all WSP property to the WSP Project Manager indicated on the Face Sheet of this Contract.

**40. Waiver.** A failure by WSP to exercise its rights under this Contract shall not preclude WSP from subsequent exercise of such rights and shall not constitute a waiver of any other rights

under this Contract unless stated to be such in writing and signed by an authorized representative of WSP and attached to the original Contract.

**41. Workman's Compensation Law.** The Contractor shall comply with all the requirements and conditions of Sections 51.04 to 51.42 inclusive, of the Revised Codes of Washington, known as the Workmen's compensation Act, and will all amendments thereof, now in force or which shall hereafter be made; also with all rules, regulations and decisions made or promulgated there under. The Contractor shall save the WSP harmless for any loss, damage or expense which he may suffer or which he may be put at any time by failure of the Contractor to comply with the last preceding requirements.

In case of employees engaged in hazardous work under this contract and the site of the project is not protected under the statutory workmen's compensation statute, the Contractor shall provide and shall cause each subcontractor to provide compensation insurance with a private company in an amount equivalent to that provided by the workmen's compensation statute for the protection of his employees not otherwise protected.

**42. Background Checks and Security Awareness Training.** Any proposed Contractor team member or subcontractor who will have unaccompanied access to WSP facilities, electronic equipment, computers, data bases, or other sensitive or restricted information must submit to WSP criminal history fingerprint background checks (background check) at Contractor's expense. Each person that requires a background check must complete Fingerprint Background Checks forms before performing any work under this contract.

Contractor and all team members and subcontractors requiring a background check shall comply with WSP instructions on submitting fingerprints and provide all requested information to WSP in order to complete the background checks.

In addition, Contractor and all team members and subcontractors requiring a background check shall undergo security awareness training online annually. A link to the security awareness training will be provided by WSP upon completion of the fingerprint background check.

Failure of Contractor, Contractor team members or subcontractors to cooperate with WSP during the background check process or to complete security awareness training may result in termination of the contract.

**43. Antidiscrimination SB 5186.**

**43.1** Nondiscrimination Requirement. During the term of this Contract, Contractor, including any subcontractor, shall not discriminate on the bases enumerated at RCW 49.60.530(3). In addition, Contractor, including any subcontractor, shall give written notice of this nondiscrimination requirement to any labor organizations with which Contractor, or subcontractor, has a collective bargaining or other agreement.

**43.2** Obligation to Cooperate. Contractor, including any subcontractor, shall cooperate and comply with any Washington state agency investigation regarding any allegation that Contractor, including any subcontractor, has engaged in discrimination prohibited by this Contract pursuant to RCW 49.60.530(3),

**43.3** Default. Notwithstanding any provision to the contrary, Agency may suspend Contractor, including any subcontractor, upon notice of a failure to participate and cooperate with any state agency investigation into alleged discrimination prohibited by this Contract, pursuant to RCW 49.60.530(3). Any such suspension will remain in place until Agency receives notification that Contractor, including any subcontractor, is cooperating with the

investigating state agency. In the event Contractor, or subcontractor, is determined to have engaged in discrimination identified at RCW 49.60.530(3), Agency may terminate this Contract in whole or in part, and Contractor, subcontractor, or both, may be referred for debarment as provided in RCW 39.26.200. Contractor or subcontractor may be given a reasonable time in which to cure this noncompliance, including implementing conditions consistent with any court-ordered injunctive relief or settlement agreement.

**43.4** Remedies for Breach. Notwithstanding any provision to the contrary, in the event of Contract termination or suspension for engaging in discrimination, Contractor, subcontractor, or both, shall be liable for contract damages as authorized by law including, but not limited to, any cost difference between the original contract and the replacement or cover contract and all administrative costs directly related to the replacement contract, which damages are distinct from any penalties imposed under Chapter 49.60, RCW. Agency shall have the right to deduct from any monies due to Contractor or subcontractor, or that thereafter become due, an amount for damages Contractor or subcontractor will owe Agency for default under this provision.

**44. Public Disclosure.** The contractor acknowledges that WSP is subject to Chapter 42.56 RCW and that this contract shall be a public record as defined in the Public Records Act. Any specific information claimed by the contractor to be proprietary information must be clearly identified as such by the contractor. To the extent consistent with Chapter 42.56 RCW, the WSP shall maintain the confidentiality of all such information marked as proprietary information. If a public records request is received pursuant to Chapter 42.56 RCW for documents related to this agreement, the WSP will give the contractor ten days' written notice at the contractor's last know address before releasing any documents the contractor has marked as proprietary information. It is the contractor's responsibility to take legal action to obtain an injunction prior to the expiration of the ten days' notice. The contractor will indemnify, defend, and hold harmless the WSP for release of documents related to this contract as required by law. Nothing contained in this section or any other portion of this agreement affects or modifies the WSP's obligation to disclose public records under Chapter 42.56 RCW or other applicable law.

If the Contractor receives a public records request under Chapter 42.56 RCW for any records containing Data subject to this Agreement, Contractor agrees to notify the WSP RMD Public Records Officer within five (5) business days and to follow the procedure set out in this section before disclosing any records. The WSP Public Records Officer can be contacted at pubrecs@wsp.wa.gov.

The Contractor must provide a copy of the records with proposed redactions to WSP when they are available and ready. WSP will respond within ten (10) business days of receipt of the redacted records to identify concerns with disclosure of the records, propose any changes to the Contractor’s redactions, or request more time if needed. If the Contractor disagrees with any of WSP’s concerns or proposed changes, the Contractor must notify WSP of that disagreement and provide WSP with a minimum of fifteen (15) business days to obtain a restraining order or injunction under RCW 42.56.540 before disclosing any records.

**45. Force Majeure.** The parties hereto shall not be liable or responsible for cost, expense, or damage due to a delay in the performance of services hereunder, where such delay is due to causes beyond their reasonable control, including, but not limited to natural disasters, acts of government after the date of these Terms and Conditions, power failure, acts of God, labor disputes, riots, acts of war, epidemics, or material and transportation shortages.

**46. Supplier Diversity and Registration**.

**46.1** This contract is subject to the terms and conditions of DES Policy No. POL-DES-090-06, which may be found at the following link: https://des.wa.gov/policies-legal/supplier-diversity-des-090-06. The requirements of the policy are listed in this Section.

**46.2** Subcontractor and Business Diversity Certifications

**46.2.1** Contractor is required to complete, sign and return the Subcontractor Business Diversity Certifications, which shall be provided to Contractor by WSP and attached to this Contract as an Exhibit.

**46.3** Registration as a Certified OMWBE or Veteran business

**46.3.1** Contractor is encouraged to register with the Office of Minority and Women's Business Enterprises as a certified small or minority business. The Office of Minority and Women's Business Enterprises (OMWBE) certifies small businesses owned and controlled by minority, women, and socially and economically disadvantaged persons. OMWBE certifies business in order to increase contracting opportunities for certified businesses with state and local governments. More information about certifying can be found at the following link: https://omwbe.wa.gov/certification

**46.3.2** If Contractor is a veteran-owned business, contractor is encouraged to become certified through the Veteran's administration. More information about certifying can be obtained by sending an email to: ShamekiaM@DVA.WA.GOV . Certified veteran's businesses can be found at the following link: https://www.dva.wa.gov/veterans-their-families/veteran-owned-businesses/vob-search

**47. Subcontractor.**

**47.1** This contract Is ☐ Is Not ☒ Subject to the Subcontractor Payment Reporting

| Test | Test Name | List Price |
|---|---|---|
| 2358U | 1-Hydroxypyrene, Urine | $ 399.00 |
| 3124SP | 1-Naphthol, Serum/Plasma | $ 277.00 |
| 0094U | 2,5-Hexanedione, Urine | $ 309.00 |
| 0010B | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Blood | $ 286.00 |
| 0010SP | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Serum/Plasma | $ 179.00 |
| 0010U | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Urine | $ 179.00 |
| 0015B | 2-methyl AP-237 & AP-238, Blood | $ 556.00 |
| 0015SP | 2-methyl AP-237 & AP-238, Serum/Plasma | $ 556.00 |
| 0015U | 2-methyl AP-237 & AP-238, Urine | $ 556.00 |
| 0014B | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Blood | $ 286.00 |
| 0014SP | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Serum/Plasma | $ 179.00 |
| 0014U | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Urine | $ 179.00 |
| 0276SP | 4-Aminopyridine Exposure, Serum/Plasma | $ 648.00 |
| 0276U | 4-Aminopyridine Exposure, Urine | $ 648.00 |
| 8665B | 6-Monoacetylmorphine - Free (Unconjugated), Blood | $ 385.00 |
| 8665FL | 6-Monoacetylmorphine - Free (Unconjugated), Fluid | $ 331.00 |
| 8665SP | 6-Monoacetylmorphine - Free (Unconjugated), Serum/Plasma | $ 385.00 |
| 8665U | 6-Monoacetylmorphine - Free (Unconjugated), Urine | $ 385.00 |
| 0325U | 8-Hydroxy Amoxapine, Urine | $ 302.00 |
| 0013SP | Acamprosate, Serum/Plasma | $ 262.00 |
| 0012B | Acebutolol, Blood | $ 488.00 |
| 0012SP | Acebutolol, Serum/Plasma | $ 427.00 |
| 9101B | Acepromazine Screen, Blood | $ 297.00 |
| 9101SP | Acepromazine Screen, Serum/Plasma | $ 519.00 |
| 9101U | Acepromazine Screen, Urine | $ 359.00 |
| 0017B | Acepromazine, Blood | $ 515.00 |
| 0017SP | Acepromazine, Serum/Plasma | $ 323.00 |
| 0017U | Acepromazine, Urine | $ 323.00 |
| 0021B | Acetaldehyde, Blood | $ 137.00 |
| 0021SP | Acetaldehyde, Serum/Plasma | $ 87.00 |
| 0021U | Acetaldehyde, Urine | $ 123.00 |
| 0032B | Acetaminophen Screen, Blood | $ 103.00 |
| 0032SP | Acetaminophen Screen, Serum/Plasma | $ 107.00 |
| 0032U | Acetaminophen Screen, Urine | $ 64.00 |
| 0030B | Acetaminophen, Blood | $ 66.00 |
| 0030FL | Acetaminophen, Fluid | $ 281.00 |
| 0030SP | Acetaminophen, Serum/Plasma | $ 66.00 |
| 1788SP | Acetaminophen, Serum/Plasma | $ 110.00 |
| 0030TI | Acetaminophen, Tissue | $ 353.00 |
| 0030U | Acetaminophen, Urine | $ 66.00 |
| 0050B | Acetazolamide, Blood | $ 96.00 |
| 0050SP | Acetazolamide, Serum/Plasma | $ 142.00 |
| 0050U | Acetazolamide, Urine | $ 152.00 |
| 0060SP | Acetoacetate, Serum/Plasma | $ 208.00 |
| 0060U | Acetoacetate, Urine | $ 330.00 |
| 0080B | Acetone, Blood | $ 62.00 |
| 0080FL | Acetone, Fluid | $ 99.00 |
| 0080SP | Acetone, Serum/Plasma | $ 62.00 |
| 0080U | Acetone, Urine | $ 62.00 |
| 0088B | Acetonitrile Exposure Profile, Blood | $ 505.00 |
| 0088U | Acetonitrile Exposure Profile, Urine | $ 468.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0100SP | Acetophenazine, Serum/Plasma | $ 500.00 |
| 0205U | Acetyl Fentanyl and Metabolite, Urine | $ 192.00 |
| 9105B | Acetyl Fentanyl Screen, Blood | $ 192.00 |
| 9105SP | Acetyl Fentanyl Screen, Serum/Plasma | $ 192.00 |
| 9105U | Acetyl Fentanyl Screen, Urine | $ 192.00 |
| 0205B | Acetyl Fentanyl, Blood | $ 192.00 |
| 0205FL | Acetyl Fentanyl, Fluid | $ 386.00 |
| 0205SP | Acetyl Fentanyl, Serum/Plasma | $ 192.00 |
| 0205TI | Acetyl Fentanyl, Tissue | $ 386.00 |
| 0148B | Acrylonitrile Exposure Profile, Blood | $ 326.00 |
| 0148U | Acrylonitrile Exposure Profile, Urine | $ 411.00 |
| 0166B | Acyclovir, Blood | $ 334.00 |
| 0158SP | Acyclovir, Serum/Plasma | $ 197.00 |
| 0158U | Acyclovir, Urine | $ 197.00 |
| 0165B | Albuterol, Blood | $ 331.00 |
| 0165FL | Albuterol, Fluid | $ 401.00 |
| 0165SP | Albuterol, Serum/Plasma | $ 499.00 |
| 0165TI | Albuterol, Tissue | $ 436.00 |
| 0175B | Alcohol (DUID/DRE), Blood (Forensic) | $ 139.00 |
| 0175SP | Alcohol (DUID/DRE), Serum/Plasma (Forensic) | $ 228.00 |
| 0175U | Alcohol (DUID/DRE), Urine (Forensic) | $ 228.00 |
| 0170B | Alcohol Panel, Blood | $ 95.00 |
| 0170FL | Alcohol Panel, Fluid | $ 134.00 |
| 0170SP | Alcohol Panel, Serum/Plasma | $ 95.00 |
| 0170TI | Alcohol Panel, Tissue | $ 197.00 |
| 0170U | Alcohol Panel, Urine | $ 77.00 |
| 0171B | Alcohol Screen, Blood | $ 47.00 |
| 0171FL | Alcohol Screen, Fluid | $ 85.00 |
| 0171SP | Alcohol Screen, Serum/Plasma | $ 79.00 |
| 0171TI | Alcohol Screen, Tissue | $ 123.00 |
| 0171U | Alcohol Screen, Urine | $ 47.00 |
| 0230B | Alcohol with reflex to DUID Screen, Blood (Forensic) | $ 126.00 |
| 0190B | Aldrin/Dieldrin, Blood | $ 208.00 |
| 0190SP | Aldrin/Dieldrin, Serum/Plasma | $ 208.00 |
| 9103U | Alfentanil Screen, Urine | $ 330.00 |
| 0200B | Alfentanil, Blood | $ 252.00 |
| 0200SP | Alfentanil, Serum/Plasma | $ 412.00 |
| 0213SP | Allopurinol and Metabolite, Serum/Plasma | $ 167.00 |
| 3780B | Alpha-Pinene, Blood | $ 311.00 |
| 8646B | Alprazolam and Metabolite, Blood | $ 386.00 |
| 8646FL | Alprazolam and Metabolite, Fluid | $ 331.00 |
| 8646SP | Alprazolam and Metabolite, Serum/Plasma | $ 371.00 |
| 8646U | Alprazolam and Metabolite, Urine | $ 371.00 |
| 0260B | Alprazolam, Blood | $ 114.00 |
| 0260FL | Alprazolam, Fluid | $ 326.00 |
| 0260SP | Alprazolam, Serum/Plasma | $ 114.00 |
| 0260TI | Alprazolam, Tissue | $ 396.00 |
| 0264UH | Aluminum, 24 Hour Urine | $ 96.00 |
| 0264B | Aluminum, Blood | $ 167.00 |
| 0264FL | Aluminum, Fluid | $ 516.00 |
| 0264H | Aluminum, Hair | $ 541.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0264LI | Aluminum, Liquid | $ 482.00 |
| 0264R | Aluminum, RBCs | $ 93.00 |
| 0264SP | Aluminum, Serum/Plasma | $ 93.00 |
| 0264TI | Aluminum, Tissue | $ 499.00 |
| 0264U | Aluminum, Urine | $ 175.00 |
| 9308SP | Amantadine Screen, Serum/Plasma | $ 176.00 |
| 0265B | Amantadine, Blood | $ 159.00 |
| 0265FL | Amantadine, Fluid | $ 369.00 |
| 0265SP | Amantadine, Serum/Plasma | $ 104.00 |
| 0265U | Amantadine, Urine | $ 159.00 |
| 0269SP | Aminocaproic Acid, Serum/Plasma | $ 452.00 |
| 0307B | Amiodarone and Metabolite, Blood | $ 494.00 |
| 0307SP | Amiodarone and Metabolite, Serum/Plasma | $ 494.00 |
| 0308SP | Amisulpride, Serum/Plasma | $ 265.00 |
| 9432B | Amitriptyline and Metabolite Screen, Blood | $ 220.00 |
| 9432SP | Amitriptyline and Metabolite Screen, Serum/Plasma | $ 192.00 |
| 9432U | Amitriptyline and Metabolite Screen, Urine | $ 212.00 |
| 0310B | Amitriptyline and Metabolite, Blood | $ 132.00 |
| 0310FL | Amitriptyline and Metabolite, Fluid | $ 420.00 |
| 0310SP | Amitriptyline and Metabolite, Serum/Plasma | $ 209.00 |
| 0310TI | Amitriptyline and Metabolite, Tissue | $ 438.00 |
| 0310U | Amitriptyline and Metabolite, Urine | $ 209.00 |
| 0315B | Amlodipine, Blood | $ 371.00 |
| 0315SP | Amlodipine, Serum/Plasma | $ 371.00 |
| 0315TI | Amlodipine, Tissue | $ 396.00 |
| 0320SP | Amobarbital, Serum/Plasma | $ 209.00 |
| 0320U | Amobarbital, Urine | $ 132.00 |
| 0325B | Amoxapine and Metabolite, Blood | $ 302.00 |
| 0325SP | Amoxapine and Metabolite, Serum/Plasma | $ 456.00 |
| 0329B | Amphetamines (D/L Differentiation), Blood | $ 358.00 |
| 0329FL | Amphetamines (D/L Differentiation), Fluid | $ 560.00 |
| 0329SP | Amphetamines (D/L Differentiation), Serum/Plasma | $ 358.00 |
| 0329U | Amphetamines (D/L Differentiation), Urine | $ 358.00 |
| 8600ME | Amphetamines Panel (Qualitative), Meconium | $ 312.00 |
| 8890OF | Amphetamines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8600B | Amphetamines Panel, Blood | $ 256.00 |
| 8600FL | Amphetamines Panel, Fluid | $ 625.00 |
| 8600SP | Amphetamines Panel, Serum/Plasma | $ 256.00 |
| 8600TI | Amphetamines Panel, Tissue | $ 545.00 |
| 8600U | Amphetamines Panel, Urine | $ 256.00 |
| 0337B | Amphetamines Screen, Blood | $ 137.00 |
| 0337FL | Amphetamines Screen, Fluid | $ 347.00 |
| 6924H | Amphetamines Screen, Hair | $ 493.00 |
| 0337SP | Amphetamines Screen, Serum/Plasma | $ 149.00 |
| 0337U | Amphetamines Screen, Urine | $ 149.00 |
| 9306U | Anabolic Steroids Screen, Urine | $ 159.00 |
| 0406B | Anticoagulant Poisoning Panel (Qualitative), Blood | $ 1,377.00 |
| 0406SP | Anticoagulant Poisoning Panel (Qualitative), Serum/Plasma | $ 890.00 |
| 0406TI | Anticoagulant Poisoning Panel (Qualitative), Tissue | $ 1,162.00 |
| 4655B | Antidepressants Panel 1, Blood | $ 402.00 |
| 4655FL | Antidepressants Panel 1, Fluid | $ 476.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4655SP | Antidepressants Panel 1, Serum/Plasma | $ 402.00 |
| 4655TI | Antidepressants Panel 1, Tissue | $ 476.00 |
| 8700B | Antidepressants Panel, Blood | $ 483.00 |
| 8700SP | Antidepressants Panel, Serum/Plasma | $ 334.00 |
| 8700U | Antidepressants Panel, Urine | $ 334.00 |
| 9431B | Antidepressants Screen, Blood | $ 305.00 |
| 9431SP | Antidepressants Screen, Serum/Plasma | $ 264.00 |
| 9431U | Antidepressants Screen, Urine | $ 184.00 |
| 0410B | Antimony, Blood | $ 93.00 |
| 0410H | Antimony, Hair | $ 541.00 |
| 0410LI | Antimony, Liquid | $ 324.00 |
| 0410N | Antimony, Nails | $ 541.00 |
| 0410R | Antimony, RBCs | $ 93.00 |
| 0410SP | Antimony, Serum/Plasma | $ 93.00 |
| 0410U | Antimony, Urine | $ 93.00 |
| 0425B | Antipyrine, Blood | $ 519.00 |
| 0425SP | Antipyrine, Serum/Plasma | $ 337.00 |
| 0448SP | Apixaban, Serum/Plasma | $ 266.00 |
| 0451B | Aripiprazole, Blood | $ 215.00 |
| 0451SP | Aripiprazole, Serum/Plasma | $ 215.00 |
| 0785B | Aromatic Solvents Exposure Panel, Blood | $ 107.00 |
| 2416U | Aromatic Solvents Metabolites Panel, Urine | $ 249.00 |
| 0460UH | Arsenic, 24 Hour Urine | $ 115.00 |
| 0460B | Arsenic, Blood | $ 115.00 |
| 0460FL | Arsenic, Fluid | $ 327.00 |
| 0460H | Arsenic, Hair | $ 710.00 |
| 0460N | Arsenic, Nails | $ 487.00 |
| 0460R | Arsenic, RBCs | $ 115.00 |
| 0460SP | Arsenic, Serum/Plasma | $ 115.00 |
| 0460TI | Arsenic, Tissue | $ 398.00 |
| 0468UH | Arsenic, Total Inorganic, 24 Hour Urine | $ 168.00 |
| 0468U | Arsenic, Total Inorganic, Urine | $ 168.00 |
| 0460U | Arsenic, Urine | $ 115.00 |
| 0474SP | Asenapine, Serum/Plasma | $ 281.00 |
| 0483B | Atenolol, Blood | $ 220.00 |
| 0483SP | Atenolol, Serum/Plasma | $ 354.00 |
| 0483TI | Atenolol, Tissue | $ 502.00 |
| 0483U | Atenolol, Urine | $ 354.00 |
| 0486B | Atomoxetine, Blood | $ 545.00 |
| 0486SP | Atomoxetine, Serum/Plasma | $ 270.00 |
| 0486U | Atomoxetine, Urine | $ 270.00 |
| 0487SP | Atovaquone, Serum/Plasma | $ 506.00 |
| 0485B | Atrazine, Blood | $ 505.00 |
| 0485SP | Atrazine, Serum/Plasma | $ 398.00 |
| 0485U | Atrazine, Urine | $ 398.00 |
| 9109B | Atropine Screen, Blood | $ 791.00 |
| 9109SP | Atropine Screen, Serum/Plasma | $ 650.00 |
| 9109U | Atropine Screen, Urine | $ 761.00 |
| 0490B | Atropine, Blood | $ 749.00 |
| 0490SP | Atropine, Serum/Plasma | $ 749.00 |
| 0490U | Atropine, Urine | $ 749.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2111B | Baclofen, Blood | $ 371.00 |
| 2111FL | Baclofen, Fluid | $ 499.00 |
| 2111SP | Baclofen, Serum/Plasma | $ 233.00 |
| 2111TI | Baclofen, Tissue | $ 615.00 |
| 2111U | Baclofen, Urine | $ 371.00 |
| 0500B | Barbital, Blood | $ 542.00 |
| 0500SP | Barbital, Serum/Plasma | $ 440.00 |
| 0500U | Barbital, Urine | $ 542.00 |
| 8620ME | Barbiturates Panel (Qualitative), Meconium | $ 465.00 |
| 8620B | Barbiturates Panel, Blood | $ 233.00 |
| 8620FL | Barbiturates Panel, Fluid | $ 421.00 |
| 8620SP | Barbiturates Panel, Serum/Plasma | $ 371.00 |
| 8620TI | Barbiturates Panel, Tissue | $ 484.00 |
| 8620U | Barbiturates Panel, Urine | $ 233.00 |
| 0512B | Barbiturates Screen, Blood | $ 137.00 |
| 6921H | Barbiturates Screen, Hair | $ 501.00 |
| 0512SP | Barbiturates Screen, Serum/Plasma | $ 95.00 |
| 0512U | Barbiturates Screen, Urine | $ 149.00 |
| 0519B | Barium, Blood | $ 208.00 |
| 0519FL | Barium, Fluid | $ 213.00 |
| 0519H | Barium, Hair | $ 597.00 |
| 0519SP | Barium, Serum/Plasma | $ 138.00 |
| 0519TI | Barium, Tissue | $ 547.00 |
| 0519U | Barium, Urine | $ 138.00 |
| 9351UC | Basic Drug Screen, Umbilical Cord Tissue | $ 439.00 |
| 2626B | Bath Salts Panel (Qualitative), Blood | $ 271.00 |
| 2626SP | Bath Salts Panel (Qualitative), Serum/Plasma | $ 172.00 |
| 2626U | Bath Salts Panel (Qualitative), Urine | $ 172.00 |
| 0520B | Belladonna Alkaloids Panel, Blood | $ 427.00 |
| 0520SP | Belladonna Alkaloids Panel, Serum/Plasma | $ 452.00 |
| 0520U | Belladonna Alkaloids Panel, Urine | $ 452.00 |
| 0542U | Benzene Incident, Urine (OSHA) | $ 217.00 |
| 0543U | Benzene OSHA Exposure Panel, Urine | $ 121.00 |
| 0541B | Benzene, Blood | $ 105.00 |
| 0541TI | Benzene, Tissue | $ 383.00 |
| 0556U | Benzidine, Urine | $ 516.00 |
| 0560B | Benzocaine, Blood | $ 466.00 |
| 0560FL | Benzocaine, Fluid | $ 526.00 |
| 0560P | Benzocaine, Plasma | $ 268.00 |
| 0560U | Benzocaine, Urine | $ 170.00 |
| 9329ME | Benzodiazepines Panel (Qualitative), Meconium | $ 308.00 |
| 8891OF | Benzodiazepines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 9329B | Benzodiazepines Panel, Blood | $ 249.00 |
| 9329FL | Benzodiazepines Panel, Fluid | $ 285.00 |
| 9329SP | Benzodiazepines Panel, Serum/Plasma | $ 249.00 |
| 9329TI | Benzodiazepines Panel, Tissue | $ 321.00 |
| 9329U | Benzodiazepines Panel, Urine | $ 249.00 |
| 0568B | Benzodiazepines Screen, Blood | $ 189.00 |
| 0568FL | Benzodiazepines Screen, Fluid | $ 353.00 |
| 6922H | Benzodiazepines Screen, Hair | $ 502.00 |
| 0568SP | Benzodiazepines Screen, Serum/Plasma | $ 116.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0568U | Benzodiazepines Screen, Urine | $ 61.00 |
| 0585B | Benzonatate, Blood | $ 655.00 |
| 0585SP | Benzonatate, Serum/Plasma | $ 868.00 |
| 0585U | Benzonatate, Urine | $ 655.00 |
| 0610B | Benzphetamine as Metabolites, Blood | $ 236.00 |
| 0610SP | Benzphetamine as Metabolites, Serum/Plasma | $ 214.00 |
| 0610U | Benzphetamine as Metabolites, Urine | $ 149.00 |
| 0620B | Benztropine, Blood | $ 166.00 |
| 0620FL | Benztropine, Fluid | $ 215.00 |
| 0620SP | Benztropine, Serum/Plasma | $ 114.00 |
| 0620TI | Benztropine, Tissue | $ 407.00 |
| 0620U | Benztropine, Urine | $ 114.00 |
| 0638B | Beryllium, Blood | $ 96.00 |
| 0638LI | Beryllium, Liquid | $ 394.00 |
| 0638SP | Beryllium, Serum/Plasma | $ 96.00 |
| 0638U | Beryllium, Urine | $ 149.00 |
| 3227B | Beta-Blockers Panel, Blood | $ 366.00 |
| 3227SP | Beta-Blockers Panel, Serum/Plasma | $ 354.00 |
| 3227U | Beta-Blockers Panel, Urine | $ 354.00 |
| 0420B | Betahydroxybutyric Acid, Blood | $ 227.00 |
| 0420FL | Betahydroxybutyric Acid, Fluid | $ 297.00 |
| 0642SP | Betahydroxybutyric Acid, Serum/Plasma | $ 111.00 |
| 0642U | Betahydroxybutyric Acid, Urine | $ 111.00 |
| 0645FL | Bicarbonate, Fluid | $ 309.00 |
| 0645U | Bicarbonate, Urine | $ 96.00 |
| 7031B | Bio-Rad Geenius HIV 1/2 Supplemental Assay (Confirmation Test) - Send out | $ 409.00 |
| 0680B | Bismuth, Blood | $ 242.00 |
| 0680SP | Bismuth, Serum/Plasma | $ 93.00 |
| 0680U | Bismuth, Urine | $ 149.00 |
| 0690SP | Bisphenol A - Free (Unconjugated), Serum/Plasma | $ 296.00 |
| 0690U | Bisphenol A - Total (Conjugated/Unconjugated), Urine | $ 304.00 |
| 0711B | Boron, Blood | $ 74.00 |
| 0711SP | Boron, Serum/Plasma | $ 74.00 |
| 0711U | Boron, Urine | $ 74.00 |
| 0716SP | Brexpiprazole, Serum/Plasma | $ 227.00 |
| 0718B | Brivaracetam, Blood | $ 136.00 |
| 0718SP | Brivaracetam, Serum/Plasma | $ 136.00 |
| 0413B | Brodifacoum (Qualitative), Blood | $ 267.00 |
| 0413SP | Brodifacoum (Qualitative), Serum/Plasma | $ 267.00 |
| 0414SP | Bromadiolone (Qualitative), Serum/Plasma | $ 296.00 |
| 0719U | Bromazolam (Qualitative), Urine | $ 338.00 |
| 0719B | Bromazolam, Blood | $ 338.00 |
| 0719SP | Bromazolam, Serum/Plasma | $ 338.00 |
| 0720B | Bromine - Total, Blood | $ 431.00 |
| 0720SP | Bromine - Total, Serum/Plasma | $ 105.00 |
| 0720U | Bromine - Total, Urine | $ 173.00 |
| 9118B | Brompheniramine Screen, Blood | $ 153.00 |
| 0770B | Brompheniramine, Blood | $ 268.00 |
| 0770SP | Brompheniramine, Serum/Plasma | $ 268.00 |
| 0770TI | Brompheniramine, Tissue | $ 326.00 |
| 0770U | Brompheniramine, Urine | $ 244.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0771B | Brorphine, Blood | $ 477.00 |
| 0771SP | Brorphine, Serum/Plasma | $ 477.00 |
| 0771U | Brorphine, Urine | $ 477.00 |
| 0796B | Bumetanide, Blood | $ 706.00 |
| 0796SP | Bumetanide, Serum/Plasma | $ 861.00 |
| 0800B | Bupivacaine, Blood | $ 128.00 |
| 0800FL | Bupivacaine, Fluid | $ 336.00 |
| 0800SP | Bupivacaine, Serum/Plasma | $ 128.00 |
| 0800U | Bupivacaine, Urine | $ 212.00 |
| 0802B | Buprenorphine and Metabolite - Free (Unconjugated) Screen, Blood | $ 354.00 |
| 0802SP | Buprenorphine and Metabolite - Free (Unconjugated) Screen, Serum/Plasma | $ 354.00 |
| 0801B | Buprenorphine and Metabolite - Free (Unconjugated), Blood | $ 209.00 |
| 0801SP | Buprenorphine and Metabolite - Free (Unconjugated), Serum/Plasma | $ 209.00 |
| 0801ME | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 472.00 |
| 0801U | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 209.00 |
| 4127ME | Buprenorphine and Metabolite - Total (Qualitative), Meconium | $ 472.00 |
| 0802U | Buprenorphine Screen, Urine | $ 354.00 |
| 9122B | Bupropion and Metabolite Screen, Blood | $ 267.00 |
| 9122SP | Bupropion and Metabolite Screen, Serum/Plasma | $ 259.00 |
| 9122TI | Bupropion and Metabolite Screen, Tissue | $ 510.00 |
| 9122U | Bupropion and Metabolite Screen, Urine | $ 259.00 |
| 0803B | Bupropion and Metabolite, Blood | $ 160.00 |
| 0803FL | Bupropion and Metabolite, Fluid | $ 370.00 |
| 0803SP | Bupropion and Metabolite, Serum/Plasma | $ 160.00 |
| 0803TI | Bupropion and Metabolite, Tissue | $ 440.00 |
| 0803U | Bupropion and Metabolite, Urine | $ 259.00 |
| 0805B | Buspirone, Blood | $ 138.00 |
| 0805SP | Buspirone, Serum/Plasma | $ 138.00 |
| 0805U | Buspirone, Urine | $ 218.00 |
| 0820SP | Busulfan, Serum/Plasma | $ 257.00 |
| 0810B | Butabarbital, Blood | $ 311.00 |
| 0810SP | Butabarbital, Serum/Plasma | $ 209.00 |
| 0810U | Butabarbital, Urine | $ 190.00 |
| 0830B | Butalbital, Blood | $ 209.00 |
| 0830SP | Butalbital, Serum/Plasma | $ 213.00 |
| 0830U | Butalbital, Urine | $ 190.00 |
| 0835B | Butane and Isobutane, Blood | $ 426.00 |
| 0850B | Butanols, n-, iso-, Sec- and Tert, Blood | $ 194.00 |
| 0850SP | Butanols, n-, iso-, Sec- and Tert, Serum/Plasma | $ 194.00 |
| 0850U | Butanols, n-, iso-, Sec- and Tert, Urine | $ 194.00 |
| 0885B | Butorphanol - Free (Unconjugated), Blood | $ 527.00 |
| 0885SP | Butorphanol - Free (Unconjugated), Serum/Plasma | $ 330.00 |
| 0885U | Butorphanol - Total (Conjugated/Unconjugated), Urine | $ 330.00 |
| 0921UH | Cadmium, 24 Hour Urine | $ 92.00 |
| 0921B | Cadmium, Blood | $ 63.00 |
| 0921H | Cadmium, Hair | $ 436.00 |
| 0921N | Cadmium, Nails | $ 436.00 |
| 0921R | Cadmium, RBCs | $ 63.00 |
| 0921SP | Cadmium, Serum/Plasma | $ 63.00 |
| 0921TI | Cadmium, Tissue | $ 345.00 |
| 0921U | Cadmium, Urine | $ 67.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0930B | Caffeine, Blood | $ 159.00 |
| 0930FL | Caffeine, Fluid | $ 369.00 |
| 0930SP | Caffeine, Serum/Plasma | $ 159.00 |
| 0930U | Caffeine, Urine | $ 159.00 |
| 0939B | Calcium - Total, Postmortem, Blood (Forensic) | $ 130.00 |
| 0938FL | Calcium - Total, Postmortem, Fluid (Forensic) | $ 303.00 |
| 0938R | Calcium - Total, RBCs | $ 97.00 |
| 0938U | Calcium - Total, Urine | $ 159.00 |
| 0962B | Cannabidiol, Blood | $ 390.00 |
| 0962SP | Cannabidiol, Serum/Plasma | $ 390.00 |
| 0964U | Cannabinoid Metabolite, Urine | $ 176.00 |
| 92250 | Cannabinoids and Contaminants Profile - Send Out | $ 655.00 |
| 0960ME | Cannabinoids Panel (Qualitative), Meconium | $ 354.00 |
| 0960B | Cannabinoids Panel, Blood | $ 257.00 |
| 0960FL | Cannabinoids Panel, Fluid | $ 327.00 |
| 0960SP | Cannabinoids Panel, Serum/Plasma | $ 257.00 |
| 0960TI | Cannabinoids Panel, Tissue | $ 393.00 |
| 9356B | Cannabinoids Screen, Blood | $ 110.00 |
| 9356FL | Cannabinoids Screen, Fluid | $ 321.00 |
| 9356SP | Cannabinoids Screen, Serum/Plasma | $ 110.00 |
| 9356U | Cannabinoids Screen, Urine | $ 61.00 |
| 0966B | Cannabis Plus Recent Use Markers, Blood | $ 371.00 |
| 0966SP | Cannabis Plus Recent Use Markers, Serum/Plasma | $ 371.00 |
| 4207B | Canrenone (Spironolactone metabolite), Blood | $ 330.00 |
| 4207SP | Canrenone (Spironolactone metabolite), Serum/Plasma | $ 208.00 |
| 0971SP | Carbamazepine and Metabolite - Free, Serum/Plasma | $ 114.00 |
| 0972SP | Carbamazepine and Metabolite - Total/Free/Bound, Serum/Plasma | $ 208.00 |
| 0970B | Carbamazepine and Metabolite, Blood | $ 105.00 |
| 0970FL | Carbamazepine and Metabolite, Fluid | $ 319.00 |
| 0970SP | Carbamazepine and Metabolite, Serum/Plasma | $ 178.00 |
| 0970TI | Carbamazepine and Metabolite, Tissue | $ 390.00 |
| 0975SP | Carbamazepine-10,11-Epoxide, Serum/Plasma | $ 130.00 |
| 0975U | Carbamazepine-10,11-Epoxide, Urine | $ 81.00 |
| 0980SP | Carbaryl and Metabolite, Serum/Plasma | $ 350.00 |
| 0985B | Carbinoxamine, Blood | $ 179.00 |
| 0995U | Carbon Disulfide Exposure (TTCA), Urine | $ 509.00 |
| 1005B | Carbon Monoxide Exposure Screen, Blood | $ 224.00 |
| 1009B | Carbon Monoxide Exposure, Blood | $ 170.00 |
| 1006B | Carbon Monoxide Profile for Non-standard Samples, Blood | $ 503.00 |
| 1006TI | Carbon Monoxide Profile for Non-standard Samples, Tissue | $ 691.00 |
| 1002B | Carbon Monoxide Screen, Confirmation Separate Fee, Blood | $ 140.00 |
| 1010B | Carbon Tetrachloride, Blood | $ 262.00 |
| 1000B | Carboxy-, Met- and Sulf-Hemoglobin, Blood | $ 124.00 |
| 1019B | Carbrital Profile, Blood | $ 290.00 |
| 1019SP | Carbrital Profile, Serum/Plasma | $ 463.00 |
| 9129B | Carisoprodol and Metabolite Screen, Blood | $ 257.00 |
| 9129FL | Carisoprodol and Metabolite Screen, Fluid | $ 427.00 |
| 9129SP | Carisoprodol and Metabolite Screen, Serum/Plasma | $ 257.00 |
| 1030B | Carisoprodol and Metabolite, Blood | $ 160.00 |
| 1030FL | Carisoprodol and Metabolite, Fluid | $ 603.00 |
| 1030SP | Carisoprodol and Metabolite, Serum/Plasma | $ 259.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1030U | Carisoprodol and Metabolite, Urine | $ 160.00 |
| 1033ST | Cathartic Laxatives Profile, Stool | $ 330.00 |
| 1029SP | CBD, Serum/Plasma | $ 390.00 |
| 1055B | Celecoxib, Blood | $ 445.00 |
| 1055SP | Celecoxib, Serum/Plasma | $ 431.00 |
| 1056B | Cenobamate, Blood | $ 179.00 |
| 1056SP | Cenobamate, Serum/Plasma | $ 261.00 |
| 1042B | Cesium, Blood | $ 175.00 |
| 1042SP | Cesium, Serum/Plasma | $ 175.00 |
| 1042U | Cesium, Urine | $ 284.00 |
| 1040B | Cetirizine, Blood | $ 539.00 |
| 1040SP | Cetirizine, Serum/Plasma | $ 518.00 |
| 1040U | Cetirizine, Urine | $ 518.00 |
| 8031U | Child Drug Exposure Screen, Urine | $ 520.00 |
| 1044B | Chloral Hydrate, Blood | $ 179.00 |
| 1044SP | Chloral Hydrate, Serum/Plasma | $ 174.00 |
| 1050SP | Chloramphenicol, Serum/Plasma | $ 133.00 |
| 1070B | Chlordane and Metabolites, Blood | $ 184.00 |
| 1070SP | Chlordane and Metabolites, Serum/Plasma | $ 184.00 |
| 1080B | Chlordiazepoxide and Metabolite, Blood | $ 268.00 |
| 1080SP | Chlordiazepoxide and Metabolite, Serum/Plasma | $ 283.00 |
| 1080U | Chlordiazepoxide and Metabolite, Urine | $ 310.00 |
| 1111U | Chlorobenzene Exposure (p-Chlorophenol), Urine | $ 281.00 |
| 1110B | Chlorobenzene, Blood | $ 281.00 |
| 1110SP | Chlorobenzene, Serum/Plasma | $ 176.00 |
| 1130B | Chloroform, Blood | $ 201.00 |
| 0415SP | Chlorophacinone (Qualitative), Serum/Plasma | $ 296.00 |
| 1140B | Chloroquine, Blood | $ 470.00 |
| 1140P | Chloroquine, Plasma | $ 285.00 |
| 1140U | Chloroquine, Urine | $ 285.00 |
| 1180B | Chlorothiazide, Blood | $ 235.00 |
| 1180SP | Chlorothiazide, Serum/Plasma | $ 228.00 |
| 1190B | Chlorpheniramine, Blood | $ 209.00 |
| 1190SP | Chlorpheniramine, Serum/Plasma | $ 199.00 |
| 1190U | Chlorpheniramine, Urine | $ 209.00 |
| 9136B | Chlorpromazine Screen, Blood | $ 217.00 |
| 9136SP | Chlorpromazine Screen, Serum/Plasma | $ 131.00 |
| 9136U | Chlorpromazine Screen, Urine | $ 188.00 |
| 1210B | Chlorpromazine, Blood | $ 128.00 |
| 8681B | Chlorpromazine, Blood | $ 564.00 |
| 1210FL | Chlorpromazine, Fluid | $ 460.00 |
| 1210SP | Chlorpromazine, Serum/Plasma | $ 128.00 |
| 1210TI | Chlorpromazine, Tissue | $ 407.00 |
| 1210U | Chlorpromazine, Urine | $ 212.00 |
| 1220SP | Chlorpropamide, Serum/Plasma | $ 137.00 |
| 1250B | Chlorthalidone, Blood | $ 144.00 |
| 1250SP | Chlorthalidone, Serum/Plasma | $ 228.00 |
| 1255B | Chlorzoxazone, Blood | $ 695.00 |
| 1255SP | Chlorzoxazone, Serum/Plasma | $ 672.00 |
| 1265B | Chromium and Cobalt, Blood | $ 204.00 |
| 1265SP | Chromium and Cobalt, Serum/Plasma | $ 197.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1265U | Chromium and Cobalt, Urine | $ 197.00 |
| 1261B | Chromium, Blood | $ 138.00 |
| 1261FL | Chromium, Fluid | $ 343.00 |
| 1261H | Chromium, Hair | $ 431.00 |
| 1261N | Chromium, Nails | $ 431.00 |
| 1261R | Chromium, RBCs | $ 138.00 |
| 1261SP | Chromium, Serum/Plasma | $ 138.00 |
| 1261TI | Chromium, Tissue | $ 411.00 |
| 1261U | Chromium, Urine | $ 138.00 |
| 1262B | Cimetidine, Blood | $ 223.00 |
| 1262SP | Cimetidine, Serum/Plasma | $ 215.00 |
| 1262U | Cimetidine, Urine | $ 223.00 |
| 1272B | Citalopram, Blood | $ 201.00 |
| 1272FL | Citalopram, Fluid | $ 411.00 |
| 1272SP | Citalopram, Serum/Plasma | $ 201.00 |
| 1272TI | Citalopram, Tissue | $ 480.00 |
| 1272U | Citalopram, Urine | $ 320.00 |
| 7813B | Citrate Agar Confirmation - Send Out | $ 191.00 |
| 1269SP | Clobazam and Metabolite, Serum/Plasma | $ 172.00 |
| 1267B | Clobazam, Blood | $ 287.00 |
| 1267U | Clobazam, Urine | $ 287.00 |
| 9437B | Clomipramine and Metabolite Screen, Blood | $ 217.00 |
| 9437SP | Clomipramine and Metabolite Screen, Serum/Plasma | $ 217.00 |
| 9437U | Clomipramine and Metabolite Screen, Urine | $ 131.00 |
| 1268B | Clomipramine and Metabolite, Blood | $ 149.00 |
| 8707B | Clomipramine and Metabolite, Blood | $ 564.00 |
| 1268SP | Clomipramine and Metabolite, Serum/Plasma | $ 154.00 |
| 8707SP | Clomipramine and Metabolite, Serum/Plasma | $ 341.00 |
| 1268TI | Clomipramine and Metabolite, Tissue | $ 431.00 |
| 1268U | Clomipramine and Metabolite, Urine | $ 152.00 |
| 9139B | Clonazepam and Metabolite Screen, Blood | $ 301.00 |
| 9139FL | Clonazepam and Metabolite Screen, Fluid | $ 267.00 |
| 9139SP | Clonazepam and Metabolite Screen, Serum/Plasma | $ 302.00 |
| 1270B | Clonazepam and Metabolite, Blood | $ 97.00 |
| 1270FL | Clonazepam and Metabolite, Fluid | $ 134.00 |
| 1270SP | Clonazepam and Metabolite, Serum/Plasma | $ 97.00 |
| 1270TI | Clonazepam and Metabolite, Tissue | $ 170.00 |
| 9139U | Clonazepam as Metabolite Screen, Urine | $ 191.00 |
| 1270U | Clonazepam as Metabolite, Urine | $ 97.00 |
| 1271U | Clonazolam & 8-Aminoclonazolam (Qualitative), Urine | $ 338.00 |
| 1271B | Clonazolam & 8-Aminoclonazolam, Blood | $ 338.00 |
| 1271SP | Clonazolam & 8-Aminoclonazolam, Serum/Plasma | $ 338.00 |
| 1275B | Clonidine, Blood | $ 305.00 |
| 1275SP | Clonidine, Serum/Plasma | $ 305.00 |
| 1275U | Clonidine, Urine | $ 460.00 |
| 1280U | Clorazepate as Metabolite, Urine | $ 210.00 |
| 1287B | Clozapine and Metabolite, Blood | $ 147.00 |
| 1287FL | Clozapine and Metabolite, Fluid | $ 358.00 |
| 1287SP | Clozapine and Metabolite, Serum/Plasma | $ 147.00 |
| 1287TI | Clozapine and Metabolite, Tissue | $ 428.00 |
| 1287U | Clozapine and Metabolite, Urine | $ 233.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1290UH | Cobalt, 24 Hour Urine | $ 137.00 |
| 1290B | Cobalt, Blood | $ 114.00 |
| 1290FL | Cobalt, Fluid | $ 319.00 |
| 1290H | Cobalt, Hair | $ 486.00 |
| 1290N | Cobalt, Nails | $ 486.00 |
| 1290R | Cobalt, RBCs | $ 114.00 |
| 1290SP | Cobalt, Serum/Plasma | $ 114.00 |
| 1290TI | Cobalt, Tissue | $ 389.00 |
| 1290U | Cobalt, Urine | $ 186.00 |
| 1300ME | Cocaine and Metabolites (Qualitative), Meconium | $ 452.00 |
| 8893OF | Cocaine and Metabolites (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 0606B | Cocaine and Metabolites Screen, Blood | $ 159.00 |
| 0606FL | Cocaine and Metabolites Screen, Fluid | $ 332.00 |
| 6920H | Cocaine and Metabolites Screen, Hair | $ 737.00 |
| 0606SP | Cocaine and Metabolites Screen, Serum/Plasma | $ 100.00 |
| 0606U | Cocaine and Metabolites Screen, Urine | $ 100.00 |
| 1300B | Cocaine and Metabolites, Blood | $ 243.00 |
| 1300FL | Cocaine and Metabolites, Fluid | $ 432.00 |
| 1300SP | Cocaine and Metabolites, Serum/Plasma | $ 243.00 |
| 1300TI | Cocaine and Metabolites, Tissue | $ 495.00 |
| 1300U | Cocaine and Metabolites, Urine | $ 243.00 |
| 1303B | Cocaine and Products Panel, Blood | $ 553.00 |
| 1303SP | Cocaine and Products Panel, Serum/Plasma | $ 501.00 |
| 1303U | Cocaine and Products Panel, Urine | $ 501.00 |
| 1306U | Codeine - Total (Conjugated/Unconjugated) Screen, Urine | $ 235.00 |
| 8661B | Codeine and Metabolite - Free (Unconjugated), Blood | $ 330.00 |
| 8661SP | Codeine and Metabolite - Free (Unconjugated), Serum/Plasma | $ 218.00 |
| 8661U | Codeine and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 348.00 |
| 1320B | Colchicine, Blood | $ 926.00 |
| 1320SP | Colchicine, Serum/Plasma | $ 788.00 |
| 1320TI | Colchicine, Tissue | $ 1,187.00 |
| 9145UC | Comprehensive Drug Screen, Umbilical Cord Tissue | $ 745.00 |
| 2423B | Comprehensive Volatiles Panel, Blood | $ 515.00 |
| 2423TI | Comprehensive Volatiles Panel, Tissue | $ 536.00 |
| 1333SP | Copper - Free, Serum/Plasma | $ 105.00 |
| 1330B | Copper, Blood | $ 58.00 |
| 1330FL | Copper, Fluid | $ 267.00 |
| 1330H | Copper, Hair | $ 430.00 |
| 1330R | Copper, RBCs | $ 58.00 |
| 1330SP | Copper, Serum/Plasma | $ 58.00 |
| 1330TI | Copper, Tissue | $ 339.00 |
| 1330U | Copper, Urine | $ 58.00 |
| 3157U | Cotinine and Anabasine from Secondary Exposure, Urine | $ 262.00 |
| 1348U | Creatinine, Urine | $ 45.00 |
| 9142B | Cyanide Screen, Blood | $ 79.00 |
| 1380B | Cyanide, Blood | $ 79.00 |
| 1390B | Cyclizine and Metabolite, Blood | $ 288.00 |
| 1405B | Cyclobenzaprine, Blood | $ 114.00 |
| 1405FL | Cyclobenzaprine, Fluid | $ 326.00 |
| 1405SP | Cyclobenzaprine, Serum/Plasma | $ 114.00 |
| 1405TI | Cyclobenzaprine, Tissue | $ 396.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1405U | Cyclobenzaprine, Urine | $ 114.00 |
| 1407B | Cyclohexane, Blood | $ 309.00 |
| 1410U | Cyclohexanol - Total, Urine | $ 254.00 |
| 1409B | Cyclohexanone, Blood | $ 312.00 |
| 1409SP | Cyclohexanone, Serum/Plasma | $ 301.00 |
| 1409U | Cyclohexanone, Urine | $ 301.00 |
| 1415B | Cyclosporine, Blood | $ 315.00 |
| 1425B | Cyproheptadine, Blood | $ 297.00 |
| 1425SP | Cyproheptadine, Serum/Plasma | $ 288.00 |
| 1425U | Cyproheptadine, Urine | $ 232.00 |
| 0275SP | Dalfampridine, Serum/Plasma | $ 648.00 |
| 0275U | Dalfampridine, Urine | $ 648.00 |
| 1439B | Dantrolene, Blood | $ 336.00 |
| 1439SP | Dantrolene, Serum/Plasma | $ 129.00 |
| 1440B | Dapsone and Metabolite, Blood | $ 750.00 |
| 1440SP | Dapsone and Metabolite, Serum/Plasma | $ 427.00 |
| 1470B | DDT, DDD and DDE, Blood | $ 249.00 |
| 1470F | DDT, DDD and DDE, Fat | $ 529.00 |
| 1470SP | DDT, DDD and DDE, Serum/Plasma | $ 249.00 |
| 1479B | Delta-8 and Delta-9 Cannabinoids Panel (DUID/DRE), Blood (Forensic) | $ 395.00 |
| 1478B | Delta-8 and Delta-9 Cannabinoids Panel, Blood | $ 350.00 |
| 1476B | Delta-8 Cannabinoids Panel (DUID/DRE), Blood (Forensic) | $ 289.00 |
| 1477B | Delta-8 Cannabinoids Panel, Blood | $ 244.00 |
| 8892OF | Delta-9 THC (Qualitative), Oral Fluid (Saliva) | $ 80.00 |
| 8900OF | Delta-9 THC (Quantitative), Oral Fluid (Saliva) | $ 214.00 |
| 1483U | Desalkylgidazepam (Qualitative), Urine | $ 338.00 |
| 1483B | Desalkylgidazepam, Blood | $ 338.00 |
| 1483SP | Desalkylgidazepam, Serum/Plasma | $ 338.00 |
| 1481U | Deschloroetizolam, Meclonazepam, and Pyrazolam (Qualitative), Urine | $ 359.00 |
| 1481B | Deschloroetizolam, Meclonazepam, and Pyrazolam, Blood | $ 359.00 |
| 1481SP | Deschloroetizolam, Meclonazepam, and Pyrazolam, Serum/Plasma | $ 359.00 |
| 0570U | Designer Benzodiazepines (Qualitative), Urine | $ 361.00 |
| 0571B | Designer Benzodiazepines DUID/DRE Add-On, Blood (Forensic) | $ 215.00 |
| 0570B | Designer Benzodiazepines, Blood | $ 361.00 |
| 0570SP | Designer Benzodiazepines, Serum/Plasma | $ 361.00 |
| 1480U | Designer Opioids (Qualitative), Urine | $ 374.00 |
| 1480B | Designer Opioids, Blood | $ 374.00 |
| 1480SP | Designer Opioids, Serum/Plasma | $ 374.00 |
| 1490B | Desipramine, Blood | $ 140.00 |
| 8704B | Desipramine, Blood | $ 564.00 |
| 1490SP | Desipramine, Serum/Plasma | $ 140.00 |
| 1490U | Desipramine, Urine | $ 138.00 |
| 8704U | Desipramine, Urine | $ 543.00 |
| 1496U | Desmethylsertraline, Urine | $ 115.00 |
| 1491B | Desvenlafaxine, Blood | $ 262.00 |
| 1491SP | Desvenlafaxine, Serum/Plasma | $ 262.00 |
| 1491U | Desvenlafaxine, Urine | $ 262.00 |
| 2915U | Dextro / Levo Methorphan - Total, Urine | $ 225.00 |
| 9205U | Dextro / Levo Methorphan Screen - Total, Urine | $ 220.00 |
| 9205SP | Dextro / Levo Methorphan Screen, Serum/Plasma | $ 135.00 |
| 2915B | Dextro/Levo Methorphan, Blood | $ 132.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2915SP | Dextro/Levo Methorphan, Serum/Plasma | $ 199.00 |
| 2915TI | Dextro/Levo Methorphan, Tissue | $ 412.00 |
| 2917U | Dextromethorphan and Metabolite Ratio - Total, Urine | $ 317.00 |
| 9206U | Dextrorphan / Levorphanol Screen - Total, Urine | $ 293.00 |
| 2506B | Dextrorphan / Levorphanol Screen, Blood | $ 500.00 |
| 2506SP | Dextrorphan / Levorphanol Screen, Serum/Plasma | $ 482.00 |
| 1501B | Diazepam and Metabolites, Blood | $ 188.00 |
| 1501SP | Diazepam and Metabolites, Serum/Plasma | $ 188.00 |
| 1515B | Diazoxide, Blood | $ 407.00 |
| 1515SP | Diazoxide, Serum/Plasma | $ 496.00 |
| 1546B | Dichlorobenzenes, Blood | $ 194.00 |
| 1546SP | Dichlorobenzenes, Serum/Plasma | $ 322.00 |
| 1549U | Dichlorobenzidine, Urine | $ 360.00 |
| 1550B | Dichloroethane, Blood | $ 278.00 |
| 1560B | Dichloromethane and Carboxyhemoglobin, Blood | $ 197.00 |
| 1561B | Dichloromethane, Blood | $ 228.00 |
| 1561U | Dichloromethane, Urine | $ 239.00 |
| 1567U | Dichlorophenol 2,5-, Urine | $ 341.00 |
| 1569B | Diclofenac, Blood | $ 369.00 |
| 1569SP | Diclofenac, Serum/Plasma | $ 570.00 |
| 0416SP | Dicumarol (Qualitative), Serum/Plasma | $ 407.00 |
| 1575B | Dicyclomine, Blood | $ 330.00 |
| 1575SP | Dicyclomine, Serum/Plasma | $ 330.00 |
| 1575U | Dicyclomine, Urine | $ 330.00 |
| 1580B | Dieldrin, Blood | $ 218.00 |
| 1580SP | Dieldrin, Serum/Plasma | $ 209.00 |
| 1590B | Diethyl Ether, Blood | $ 189.00 |
| 1590SP | Diethyl Ether, Serum/Plasma | $ 210.00 |
| 1589B | Diethylene Glycol, Blood | $ 478.00 |
| 1589SP | Diethylene Glycol, Serum/Plasma | $ 478.00 |
| 1589U | Diethylene Glycol, Urine | $ 432.00 |
| 1482B | Diethyl-M-Toluamide, Blood | $ 901.00 |
| 1482SP | Diethyl-M-Toluamide, Serum/Plasma | $ 568.00 |
| 1482U | Diethyl-M-Toluamide, Urine | $ 901.00 |
| 1600B | Diethylpropion, Blood | $ 194.00 |
| 1600SP | Diethylpropion, Serum/Plasma | $ 236.00 |
| 1600U | Diethylpropion, Urine | $ 215.00 |
| 0417SP | Difenacoum (Qualitative), Serum/Plasma | $ 213.00 |
| 1613SP | Digitoxin, Serum/Plasma | $ 87.00 |
| 1615B | Digoxin, Blood | $ 374.00 |
| 1615FL | Digoxin, Fluid | $ 587.00 |
| 1615SP | Digoxin, Serum/Plasma | $ 468.00 |
| 1615TI | Digoxin, Tissue | $ 436.00 |
| 1615U | Digoxin, Urine | $ 567.00 |
| 8662B | Dihydrocodeine - Free (Unconjugated), Blood | $ 482.00 |
| 8662SP | Dihydrocodeine - Free (Unconjugated), Serum/Plasma | $ 482.00 |
| 8662U | Dihydrocodeine - Total (Conjugated/Unconjugated), Urine | $ 482.00 |
| 1640B | Diltiazem, Blood | $ 330.00 |
| 1640SP | Diltiazem, Serum/Plasma | $ 509.00 |
| 1640U | Diltiazem, Urine | $ 509.00 |
| 1683SP | Dimethadione, Serum/Plasma | $ 168.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1690B | Dimethylsulfoxide, Blood | $ 202.00 |
| 1690SP | Dimethylsulfoxide, Serum/Plasma | $ 324.00 |
| 1690U | Dimethylsulfoxide, Urine | $ 322.00 |
| 1693B | Dimethyltryptamine, Blood | $ 467.00 |
| 1693SP | Dimethyltryptamine, Serum/Plasma | $ 467.00 |
| 1693U | Dimethyltryptamine, Urine | $ 467.00 |
| 1740B | Dioxane-1,4, Blood | $ 298.00 |
| 1740SP | Dioxane-1,4, Serum/Plasma | $ 298.00 |
| 1740TI | Dioxane-1,4, Tissue | $ 545.00 |
| 0418SP | Diphacinone (Qualitative), Serum/Plasma | $ 296.00 |
| 1760B | Diphenhydramine, Blood | $ 95.00 |
| 1760FL | Diphenhydramine, Fluid | $ 308.00 |
| 1760SP | Diphenhydramine, Serum/Plasma | $ 95.00 |
| 1760TI | Diphenhydramine, Tissue | $ 381.00 |
| 1760U | Diphenhydramine, Urine | $ 149.00 |
| 1777B | Dipyridamole, Blood | $ 250.00 |
| 1777SP | Dipyridamole, Serum/Plasma | $ 239.00 |
| 1789B | Diquat, Blood | $ 2,052.00 |
| 1789SP | Diquat, Serum/Plasma | $ 2,052.00 |
| 9159B | Disopyramide Screen, Blood | $ 217.00 |
| 9159SP | Disopyramide Screen, Serum/Plasma | $ 188.00 |
| 1790SP | Disulfiram (DEDTC Metabolite) (Qualitative), Serum/Plasma | $ 417.00 |
| 1804SP | Diuretics Panel, Serum/Plasma | $ 142.00 |
| 9318U | Diuretics Screen, Urine | $ 196.00 |
| 1812B | Donepezil, Blood | $ 379.00 |
| 1812FL | Donepezil, Fluid | $ 446.00 |
| 1812SP | Donepezil, Serum/Plasma | $ 379.00 |
| 1905B | Dothiepin, Blood | $ 710.00 |
| 1815B | Doxazosin, Blood | $ 805.00 |
| 1815SP | Doxazosin, Serum/Plasma | $ 502.00 |
| 9435B | Doxepin and Metabolite Screen, Blood | $ 220.00 |
| 9435U | Doxepin and Metabolite Screen, Urine | $ 212.00 |
| 1810B | Doxepin and Metabolite, Blood | $ 144.00 |
| 8705B | Doxepin and Metabolite, Blood | $ 488.00 |
| 1810FL | Doxepin and Metabolite, Fluid | $ 355.00 |
| 1810SP | Doxepin and Metabolite, Serum/Plasma | $ 167.00 |
| 1810TI | Doxepin and Metabolite, Tissue | $ 433.00 |
| 1810U | Doxepin and Metabolite, Urine | $ 159.00 |
| 8705U | Doxepin and Metabolite, Urine | $ 341.00 |
| 9163B | Doxylamine Screen, Blood | $ 192.00 |
| 9163SP | Doxylamine Screen, Serum/Plasma | $ 135.00 |
| 1817B | Doxylamine, Blood | $ 190.00 |
| 1817FL | Doxylamine, Fluid | $ 401.00 |
| 1817SP | Doxylamine, Serum/Plasma | $ 209.00 |
| 1817TI | Doxylamine, Tissue | $ 438.00 |
| 1817U | Doxylamine, Urine | $ 209.00 |
| 1826SP | Dronabinol, Serum/Plasma | $ 414.00 |
| 1828B | Dronedarone, Blood | $ 184.00 |
| 1828SP | Dronedarone, Serum/Plasma | $ 184.00 |
| 8030B | Drug Facilitated Crime Panel, Blood (Forensic) | $ 551.00 |
| 8030SP | Drug Facilitated Crime Panel, Serum/Plasma (Forensic) | $ 551.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8030U | Drug Facilitated Crime Panel, Urine (Forensic) | $ 551.00 |
| 1876B | Drug Screen - Expanded, Blood | $ 426.00 |
| 1876FL | Drug Screen - Expanded, Fluid | $ 621.00 |
| 1876SP | Drug Screen - Expanded, Serum/Plasma | $ 426.00 |
| 1876U | Drug Screen - Expanded, Urine | $ 426.00 |
| 1874B | Drug Screen (10 Panel), Blood | $ 391.00 |
| 1874U | Drug Screen (9 Panel), Urine | $ 391.00 |
| 8098B | Drug Screen (GC/MS), Blood | $ 562.00 |
| 8098SP | Drug Screen (GC/MS), Serum/Plasma | $ 544.00 |
| 8098U | Drug Screen (GC/MS), Urine | $ 541.00 |
| 1858B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 130.00 |
| 8091B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 452.00 |
| 8101B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 189.00 |
| 1858FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 370.00 |
| 8091FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 642.00 |
| 8101FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 399.00 |
| 1858SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 130.00 |
| 8091SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 452.00 |
| 8101SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 189.00 |
| 1858TI | Drugs of Abuse (10 Panel) and Alcohol Screen, Tissue | $ 440.00 |
| 8091TI | Drugs of Abuse (10 Panel) and Alcohol Screen, Tissue | $ 711.00 |
| 8091U | Drugs of Abuse (11 Panel) and Alcohol Screen, Urine | $ 452.00 |
| 8101U | Drugs of Abuse (11 Panel) and Alcohol Screen, Urine | $ 189.00 |
| 8898OF | Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva) | $ 94.00 |
| 8897OF | Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva) | $ 146.00 |
| 1858U | Drugs of Abuse (9 Panel) and Alcohol Screen, Urine | $ 160.00 |
| 8096B | Drugs of Abuse Screen (10 Panel), Blood | $ 437.00 |
| 1864ME | Drugs of Abuse Screen (10 Panel), Meconium | $ 227.00 |
| 8096SP | Drugs of Abuse Screen (10 Panel), Serum/Plasma | $ 437.00 |
| 1864U | Drugs of Abuse Screen (10 Panel), Urine | $ 123.00 |
| 1864B | Drugs of Abuse Screen (11 Panel), Blood | $ 121.00 |
| 1864FL | Drugs of Abuse Screen (11 Panel), Fluid | $ 362.00 |
| 1864SP | Drugs of Abuse Screen (11 Panel), Serum/Plasma | $ 121.00 |
| 1864TI | Drugs of Abuse Screen (11 Panel), Tissue | $ 575.00 |
| 8096U | Drugs of Abuse Screen (11 Panel), Urine | $ 700.00 |
| 6943H | Drugs of Abuse Screen (6 Panel), Hair | $ 604.00 |
| 1861U | Drugs of Abuse Screen (6 Panel), Urine | $ 215.00 |
| 1861B | Drugs of Abuse Screen (7 Panel), Blood | $ 215.00 |
| 6904ME | Drugs of Abuse Screen (7 Panel), Meconium | $ 193.00 |
| 6946H | Drugs of Abuse Screen (9 Panel), Hair | $ 722.00 |
| 8158B | DUID/DRE Expanded Drug Screen (w/Alcohol), Blood (Forensic) | $ 457.00 |
| 8075U | DUID/DRE Expanded Drug Screen Add-On (Qualitative), Urine (Forensic) | $ 152.00 |
| 8152B | DUID/DRE Expanded Drug Screen Add-On, Blood (Forensic) | $ 166.00 |
| 8159B | DUID/DRE Expanded Drug Screen, Blood (Forensic) | $ 436.00 |
| 8082B | DUID/DRE Inhalants Add-On, Blood (Forensic) | $ 334.00 |
| 8071U | DUID/DRE Panel (Qualitative), Urine (Forensic) | $ 276.00 |
| 8070U | DUID/DRE Panel (w/Alcohol) (Qualitative), Urine (Forensic) | $ 298.00 |
| 8151B | DUID/DRE Panel (w/Alcohol), Blood (Forensic) | $ 365.00 |
| 8170U | DUID/DRE Panel (w/Alcohol), Urine (Forensic) | $ 335.00 |
| 8150B | DUID/DRE Panel, Blood (Forensic) | $ 344.00 |
| 8171U | DUID/DRE Panel, Urine (Forensic) | $ 313.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4666B | Duloxetine, Blood | $ 267.00 |
| 4666SP | Duloxetine, Serum/Plasma | $ 267.00 |
| 1900B | Dyazide, Blood | $ 419.00 |
| 1900SP | Dyazide, Serum/Plasma | $ 254.00 |
| 1919FL | Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic) | $ 119.00 |
| 7025U | Electrolytes Panel, Urine - Send Out | $ 123.00 |
| 1920B | Endrin, Blood | $ 173.00 |
| 1920SP | Endrin, Serum/Plasma | $ 173.00 |
| 1923B | Enflurane, Blood | $ 389.00 |
| 8103B | Environmental Exposure Screen, Blood | $ 915.00 |
| 9165B | Ephedrine Screen, Blood | $ 179.00 |
| 1950B | Ephedrine, Blood | $ 199.00 |
| 1950SP | Ephedrine, Serum/Plasma | $ 213.00 |
| 1950U | Ephedrine, Urine | $ 213.00 |
| 4023B | Ephedrines Panel, Blood | $ 310.00 |
| 4023SP | Ephedrines Panel, Serum/Plasma | $ 296.00 |
| 4023U | Ephedrines Panel, Urine | $ 283.00 |
| 2022SP | Eplerenone, Serum/Plasma | $ 166.00 |
| 1965B | Escitalopram, Blood | $ 320.00 |
| 1965FL | Escitalopram, Fluid | $ 355.00 |
| 1965SP | Escitalopram, Serum/Plasma | $ 201.00 |
| 1965U | Escitalopram, Urine | $ 320.00 |
| 1958B | Estazolam, Blood | $ 446.00 |
| 1958SP | Estazolam, Serum/Plasma | $ 446.00 |
| 1958U | Estazolam, Urine | $ 446.00 |
| 1968B | Eszopiclone / Zopiclone, Blood | $ 478.00 |
| 1968SP | Eszopiclone / Zopiclone, Serum/Plasma | $ 331.00 |
| 1968TI | Eszopiclone / Zopiclone, Tissue | $ 436.00 |
| 1968U | Eszopiclone / Zopiclone, Urine | $ 331.00 |
| 1959SP | Ethambutol, Serum/Plasma | $ 224.00 |
| 7542B | Ethanol - Title 17, Blood - Send Out | $ 142.00 |
| 7542SP | Ethanol - Title 17, Serum/Plasma - Send Out | $ 142.00 |
| 7542U | Ethanol - Title 17, Urine - Send Out | $ 142.00 |
| 1970U | Ethchlorvynol Overdose, Urine | $ 560.00 |
| 1970SP | Ethchlorvynol, Serum/Plasma | $ 417.00 |
| 1980B | Ethinamate, Blood | $ 104.00 |
| 1980SP | Ethinamate, Serum/Plasma | $ 159.00 |
| 9171B | Ethosuximide Screen, Blood | $ 152.00 |
| 9171SP | Ethosuximide Screen, Serum/Plasma | $ 217.00 |
| 9171U | Ethosuximide Screen, Urine | $ 152.00 |
| 2000B | Ethosuximide, Blood | $ 168.00 |
| 2000SP | Ethosuximide, Serum/Plasma | $ 217.00 |
| 2000U | Ethosuximide, Urine | $ 202.00 |
| 2010B | Ethotoin, Blood | $ 420.00 |
| 2010SP | Ethotoin, Serum/Plasma | $ 152.00 |
| 9146UC | Ethyl Glucuronide Screen, Umbilical Cord Tissue | $ 339.00 |
| 9361U | Ethyl Glucuronide Screen, Urine | $ 160.00 |
| 2081U | Ethyl Glucuronide, Urine | $ 160.00 |
| 9025U | Ethyl Sulfate Screen, Urine | $ 170.00 |
| 2029U | Ethylbenzene Exposure Biouptake, Urine | $ 249.00 |
| 2030B | Ethylbenzene, Blood | $ 230.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1038B | Ethylene Glycol Monobutyl Ether, Blood | $ 340.00 |
| 1038SP | Ethylene Glycol Monobutyl Ether, Serum/Plasma | $ 219.00 |
| 1039B | Ethylene Glycol Monoethyl Ether, Blood | $ 350.00 |
| 1039SP | Ethylene Glycol Monoethyl Ether, Serum/Plasma | $ 212.00 |
| 2055B | Ethylene Glycol Overexposure Profile, Blood | $ 423.00 |
| 2055SP | Ethylene Glycol Overexposure Profile, Serum/Plasma | $ 437.00 |
| 2062B | Ethylene Glycol, Blood | $ 254.00 |
| 2062FL | Ethylene Glycol, Fluid | $ 324.00 |
| 2062SP | Ethylene Glycol, Serum/Plasma | $ 159.00 |
| 2062TI | Ethylene Glycol, Tissue | $ 346.00 |
| 2062U | Ethylene Glycol, Urine | $ 236.00 |
| 2064SP | Ethylmorphine, Serum/Plasma | $ 401.00 |
| 2067B | Etodolac, Blood | $ 832.00 |
| 2067SP | Etodolac, Serum/Plasma | $ 804.00 |
| 2063B | Etomidate, Blood | $ 388.00 |
| 2063FL | Etomidate, Fluid | $ 580.00 |
| 2063P | Etomidate, Plasma | $ 431.00 |
| 1022U | Eutylone (Qualitative), Urine | $ 292.00 |
| 1022B | Eutylone, Blood | $ 292.00 |
| 1022SP | Eutylone, Serum/Plasma | $ 292.00 |
| 1022TI | Eutylone, Tissue | $ 540.00 |
| 2066B | Everolimus, Blood | $ 216.00 |
| 9352UC | Expanded Drug Screen, Umbilical Cord Tissue | $ 586.00 |
| 4025SP | Ezogabine and Metabolite, Serum/Plasma | $ 268.00 |
| 2068B | Famotidine, Blood | $ 806.00 |
| 2069B | Felbamate, Blood | $ 496.00 |
| 2069SP | Felbamate, Serum/Plasma | $ 209.00 |
| 2082SP | Fenoprofen, Serum/Plasma | $ 464.00 |
| 2079ME | Fentanyl and Metabolite (Qualitative), Meconium | $ 387.00 |
| 9176B | Fentanyl and Metabolite Screen, Blood | $ 132.00 |
| 9176FL | Fentanyl and Metabolite Screen, Fluid | $ 340.00 |
| 9176SP | Fentanyl and Metabolite Screen, Serum/Plasma | $ 132.00 |
| 9176TI | Fentanyl and Metabolite Screen, Tissue | $ 412.00 |
| 2079B | Fentanyl and Metabolite, Blood | $ 132.00 |
| 2079FL | Fentanyl and Metabolite, Fluid | $ 168.00 |
| 2079SP | Fentanyl and Metabolite, Serum/Plasma | $ 132.00 |
| 2079TI | Fentanyl and Metabolite, Tissue | $ 203.00 |
| 2079U | Fentanyl and Metabolite, Urine | $ 132.00 |
| 9291H | Fentanyl Screen, Hair | $ 1,242.00 |
| 6303B | Firefighter Core Baseline Profile, Blood | $ 341.00 |
| 6303U | Firefighter Core Baseline Profile, Urine | $ 526.00 |
| 2088B | Flecainide, Blood | $ 217.00 |
| 2088SP | Flecainide, Serum/Plasma | $ 208.00 |
| 2088U | Flecainide, Urine | $ 131.00 |
| 2089B | Fluconazole, Blood | $ 707.00 |
| 2089SP | Fluconazole, Serum/Plasma | $ 456.00 |
| 2085SP | Flucytosine, Serum/Plasma | $ 456.00 |
| 9341B | Flunitrazepam and Metabolites Screen, Blood | $ 267.00 |
| 9341SP | Flunitrazepam and Metabolites Screen, Serum/Plasma | $ 267.00 |
| 9341TI | Flunitrazepam and Metabolites Screen, Tissue | $ 371.00 |
| 9341U | Flunitrazepam and Metabolites Screen, Urine | $ 267.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2041U | Flunitrazepam and Metabolites, Urine | $ 326.00 |
| 2092B | Fluoride Preservative Determination, Blood | $ 488.00 |
| 2090LI | Fluoride Preservative Determination, Liquid | $ 503.00 |
| 2090B | Fluoride, Blood | $ 213.00 |
| 2090FL | Fluoride, Fluid | $ 213.00 |
| 2090SP | Fluoride, Serum/Plasma | $ 123.00 |
| 2090U | Fluoride, Urine | $ 93.00 |
| 2100B | Fluorocarbon 113, Blood | $ 464.00 |
| 2100TI | Fluorocarbon 113, Tissue | $ 386.00 |
| 9179B | Fluoxetine and Metabolite Screen, Blood | $ 212.00 |
| 9179SP | Fluoxetine and Metabolite Screen, Serum/Plasma | $ 201.00 |
| 9179U | Fluoxetine and Metabolite Screen, Urine | $ 212.00 |
| 2105B | Fluoxetine and Metabolite, Blood | $ 124.00 |
| 2105FL | Fluoxetine and Metabolite, Fluid | $ 205.00 |
| 2105SP | Fluoxetine and Metabolite, Serum/Plasma | $ 199.00 |
| 2105TI | Fluoxetine and Metabolite, Tissue | $ 192.00 |
| 2105U | Fluoxetine and Metabolite, Urine | $ 121.00 |
| 2110B | Fluphenazine, Blood | $ 205.00 |
| 2115SP | Fluphenazine, Serum/Plasma | $ 119.00 |
| 2110TI | Fluphenazine, Tissue | $ 457.00 |
| 2120B | Flurazepam and Metabolites, Blood | $ 310.00 |
| 2120SP | Flurazepam and Metabolites, Serum/Plasma | $ 368.00 |
| 2120U | Flurazepam as Metabolites, Urine | $ 368.00 |
| 2095SP | Flurbiprofen, Serum/Plasma | $ 191.00 |
| 2124B | Fluvoxamine, Blood | $ 201.00 |
| 2124FL | Fluvoxamine, Fluid | $ 411.00 |
| 2124SP | Fluvoxamine, Serum/Plasma | $ 128.00 |
| 2124U | Fluvoxamine, Urine | $ 128.00 |
| 2134B | Formic Acid, Blood | $ 140.00 |
| 2134SP | Formic Acid, Serum/Plasma | $ 140.00 |
| 2134U | Formic Acid, Urine | $ 173.00 |
| 2136B | Fosphenytoin as Metabolite, Blood | $ 159.00 |
| 2136SP | Fosphenytoin as Metabolite, Serum/Plasma | $ 159.00 |
| 2140B | Furosemide, Blood | $ 220.00 |
| 2140SP | Furosemide, Serum/Plasma | $ 139.00 |
| 2140U | Furosemide, Urine | $ 220.00 |
| 2143B | Gabapentin, Blood | $ 150.00 |
| 2143FL | Gabapentin, Fluid | $ 345.00 |
| 2143SP | Gabapentin, Serum/Plasma | $ 150.00 |
| 2143TI | Gabapentin, Tissue | $ 402.00 |
| 2143U | Gabapentin, Urine | $ 203.00 |
| 2148B | Galantamine, Blood | $ 386.00 |
| 2148SP | Galantamine, Serum/Plasma | $ 386.00 |
| 2150B | Gallium, Blood | $ 430.00 |
| 2150SP | Gallium, Serum/Plasma | $ 261.00 |
| 2150U | Gallium, Urine | $ 261.00 |
| 9326B | Gamma-Hydroxybutyric Acid Screen, Blood | $ 305.00 |
| 9326FL | Gamma-Hydroxybutyric Acid Screen, Fluid | $ 341.00 |
| 9326SP | Gamma-Hydroxybutyric Acid Screen, Serum/Plasma | $ 305.00 |
| 9326U | Gamma-Hydroxybutyric Acid Screen, Urine | $ 305.00 |
| 2187SP | Ganaxolone, Serum/Plasma | $ 482.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2162B | Ganciclovir, Blood | $ 276.00 |
| 2154SP | Ganciclovir, Serum/Plasma | $ 254.00 |
| 2154U | Ganciclovir, Urine | $ 640.00 |
| 2156SP | Germanium, Serum/Plasma | $ 411.00 |
| 2156U | Germanium, Urine | $ 394.00 |
| 2159B | Glimepiride, Blood | $ 137.00 |
| 2159SP | Glimepiride, Serum/Plasma | $ 137.00 |
| 2158B | Glipizide, Blood | $ 468.00 |
| 2158SP | Glipizide, Serum/Plasma | $ 281.00 |
| 2164FL | Glucose (Vitreous), Fluid (Forensic) | $ 25.00 |
| 7027SP | Glucose, Serum/Plasma - Send Out | $ 105.00 |
| 7027U | Glucose, Urine - Send Out | $ 107.00 |
| 9443B | Glutethimide Screen, Blood | $ 190.00 |
| 9443SP | Glutethimide Screen, Serum/Plasma | $ 242.00 |
| 2160B | Glutethimide, Blood | $ 152.00 |
| 2160SP | Glutethimide, Serum/Plasma | $ 220.00 |
| 2163SP | Glyburide, Serum/Plasma | $ 218.00 |
| 2165B | Glycols Panel, Blood | $ 331.00 |
| 2165FL | Glycols Panel, Fluid | $ 618.00 |
| 2165LI | Glycols Panel, Liquid | $ 673.00 |
| 2165SP | Glycols Panel, Serum/Plasma | $ 331.00 |
| 2165TI | Glycols Panel, Tissue | $ 716.00 |
| 2165U | Glycols Panel, Urine | $ 628.00 |
| 2171B | Gold, Blood | $ 93.00 |
| 2171SP | Gold, Serum/Plasma | $ 93.00 |
| 2171U | Gold, Urine | $ 93.00 |
| 7029O | Gram Stain (GRST) - Send Out | $ 107.00 |
| 2180SP | Griseofulvin, Serum/Plasma | $ 635.00 |
| 2185B | Guaifenesin, Blood | $ 411.00 |
| 2185SP | Guaifenesin, Serum/Plasma | $ 411.00 |
| 2185TI | Guaifenesin, Tissue | $ 561.00 |
| 2185U | Guaifenesin, Urine | $ 411.00 |
| 2186B | Guanfacine, Blood | $ 307.00 |
| 2186SP | Guanfacine, Serum/Plasma | $ 307.00 |
| 2186U | Guanfacine, Urine | $ 307.00 |
| HAIR KIT | Hair Kit/ Forensic | $ 19.00 |
| HAIRSEG | Hair Segmentation | $ 189.00 |
| HAIRSEG2 | Hair Segmentation II | $ 189.00 |
| 8758B | Hallucinogens Screen, Blood | $ 267.00 |
| 8758SP | Hallucinogens Screen, Serum/Plasma | $ 327.00 |
| 8758U | Hallucinogens Screen, Urine | $ 267.00 |
| 2212B | Halocarbons Panel, Blood | $ 284.00 |
| 9182B | Haloperidol Screen, Blood | $ 154.00 |
| 9182SP | Haloperidol Screen, Serum/Plasma | $ 138.00 |
| 2220B | Haloperidol, Blood | $ 105.00 |
| 2220FL | Haloperidol, Fluid | $ 304.00 |
| 2220SP | Haloperidol, Serum/Plasma | $ 173.00 |
| 2220TI | Haloperidol, Tissue | $ 390.00 |
| 2220U | Haloperidol, Urine | $ 304.00 |
| 7814B | Hemoglobin Cascade Confirmation - Send Out | $ 343.00 |
| 7812B | Hemoglobinopathy Screen (HGEL) - Send Out | $ 116.00 |

| Test | Test Name | List Price |
|---|---|---|
| 7026B | Hepatitis A Antibody, Blood - Send Out | $ 148.00 |
| 7072B | Hepatitis B Core Antibody, Blood - Send Out | $ 111.00 |
| 7047B | Hepatitis B Surface Antibody, Blood - Send Out | $ 177.00 |
| 7048B | Hepatitis B Surface Antigen Confirmatory Assay, Blood - Send Out | $ 456.00 |
| 7053B | Hepatitis B Surface Antigen, Blood - Send Out | $ 99.00 |
| 7049B | Hepatitis C Antibody, Blood - Send Out | $ 109.00 |
| 2260SP | Heptachlor and Metabolite, Serum/Plasma | $ 132.00 |
| 2270B | Heptane, n-, Blood | $ 309.00 |
| 2270SP | Heptane, n-, Serum/Plasma | $ 340.00 |
| 2278B | Herbicides Panel 2, Blood | $ 311.00 |
| 2278SP | Herbicides Panel 2, Serum/Plasma | $ 311.00 |
| 2278U | Herbicides Panel 2, Urine | $ 311.00 |
| 2276B | Heroin Metabolites - Free (Unconjugated), Blood | $ 320.00 |
| 2276SP | Heroin Metabolites - Free (Unconjugated), Serum/Plasma | $ 320.00 |
| 2276U | Heroin Metabolites - Free (Unconjugated), Urine | $ 320.00 |
| 9343B | Heroin Screen, Blood | $ 189.00 |
| 9343SP | Heroin Screen, Serum/Plasma | $ 116.00 |
| 9343U | Heroin Screen, Urine | $ 116.00 |
| 2283B | Hexachlorobenzene, Blood | $ 201.00 |
| 2283SP | Hexachlorobenzene, Serum/Plasma | $ 201.00 |
| 2290B | Hexane, n-, Blood | $ 189.00 |
| 2290SP | Hexane, n-, Serum/Plasma | $ 301.00 |
| 2291U | Hexanol - Total, 1 and 2-, Urine | $ 362.00 |
| 2306U | Hippuric Acid and Methylhippuric Acid, Urine | $ 212.00 |
| 2300U | Hippuric Acid, Urine | $ 120.00 |
| 7033B | HIV-1/HIV-2 Plus O EIA - Send Out | $ 100.00 |
| 7086O | Human metapneumovirus (HMPVP) - Send Out | $ 1,054.00 |
| 2308SP | Hydralazine, Serum/Plasma | $ 776.00 |
| 2321B | Hydrocarbon and Oxygenated Volatiles Panel, Blood | $ 119.00 |
| 2321FL | Hydrocarbon and Oxygenated Volatiles Panel, Fluid | $ 192.00 |
| 2321TI | Hydrocarbon and Oxygenated Volatiles Panel, Tissue | $ 239.00 |
| 2321U | Hydrocarbon and Oxygenated Volatiles Panel, Urine | $ 182.00 |
| 2330B | Hydrochlorothiazide, Blood | $ 220.00 |
| 2330SP | Hydrochlorothiazide, Serum/Plasma | $ 220.00 |
| 2330U | Hydrochlorothiazide, Urine | $ 220.00 |
| 2340B | Hydrocodone - Free (Unconjugated), Blood | $ 177.00 |
| 2340FL | Hydrocodone - Free (Unconjugated), Fluid | $ 173.00 |
| 2340SP | Hydrocodone - Free (Unconjugated), Serum/Plasma | $ 177.00 |
| 8663B | Hydrocodone and Metabolites - Free (Unconjugated), Blood | $ 257.00 |
| 8663FL | Hydrocodone and Metabolites - Free (Unconjugated), Fluid | $ 327.00 |
| 8663SP | Hydrocodone and Metabolites - Free (Unconjugated), Serum/Plasma | $ 257.00 |
| 8663TI | Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Tissue | $ 362.00 |
| 8663U | Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Urine | $ 257.00 |
| 9332B | Hydrocodone Screen, Blood | $ 190.00 |
| 9332SP | Hydrocodone Screen, Serum/Plasma | $ 190.00 |
| 8664B | Hydromorphone - Free (Unconjugated), Blood | $ 426.00 |
| 8664FL | Hydromorphone - Free (Unconjugated), Fluid | $ 362.00 |
| 8664SP | Hydromorphone - Free (Unconjugated), Serum/Plasma | $ 426.00 |
| 8664TI | Hydromorphone - Free (Unconjugated), Tissue | $ 396.00 |
| 8664U | Hydromorphone - Total (Conjugated/Unconjugated), Urine | $ 266.00 |
| 2362B | Hydroxychloroquine, Blood | $ 281.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2362FL | Hydroxychloroquine, Fluid | $ 317.00 |
| 2362SP | Hydroxychloroquine, Serum/Plasma | $ 281.00 |
| 2362TI | Hydroxychloroquine, Tissue | $ 353.00 |
| 2362U | Hydroxychloroquine, Urine | $ 402.00 |
| 2365B | Hydroxyzine and Metabolite, Blood | $ 132.00 |
| 2365FL | Hydroxyzine and Metabolite, Fluid | $ 348.00 |
| 2365SP | Hydroxyzine and Metabolite, Serum/Plasma | $ 209.00 |
| 2365U | Hydroxyzine and Metabolite, Urine | $ 209.00 |
| 2365TI | Hydroxyzine, Tissue | $ 387.00 |
| 2369B | Hyoscyamine, Blood | $ 347.00 |
| 2369SP | Hyoscyamine, Serum/Plasma | $ 217.00 |
| 2369U | Hyoscyamine, Urine | $ 217.00 |
| 4261B | Hypoglycemic Panel, Blood | $ 423.00 |
| 4261SP | Hypoglycemic Panel, Serum/Plasma | $ 423.00 |
| 2390B | Ibuprofen, Blood | $ 138.00 |
| 2390FL | Ibuprofen, Fluid | $ 348.00 |
| 2390SP | Ibuprofen, Serum/Plasma | $ 138.00 |
| 2390TI | Ibuprofen, Tissue | $ 370.00 |
| 2390U | Ibuprofen, Urine | $ 104.00 |
| 2395B | Iloperidone, Blood | $ 215.00 |
| 2395SP | Iloperidone, Serum/Plasma | $ 215.00 |
| 9434B | Imipramine and Metabolite Screen, Blood | $ 135.00 |
| 9434SP | Imipramine and Metabolite Screen, Serum/Plasma | $ 212.00 |
| 9434U | Imipramine and Metabolite Screen, Urine | $ 220.00 |
| 2400B | Imipramine and Metabolite, Blood | $ 128.00 |
| 8703B | Imipramine and Metabolite, Blood | $ 564.00 |
| 2400SP | Imipramine and Metabolite, Serum/Plasma | $ 137.00 |
| 8703SP | Imipramine and Metabolite, Serum/Plasma | $ 543.00 |
| 2400U | Imipramine and Metabolite, Urine | $ 92.00 |
| 8703U | Imipramine and Metabolite, Urine | $ 341.00 |
| 7028SP | Immunoglobulin E, Serum/Plasma - Send Out | $ 105.00 |
| 2397SP | Indapamide, Serum/Plasma | $ 176.00 |
| 2406B | Indium, Blood | $ 228.00 |
| 2406R | Indium, RBCs | $ 152.00 |
| 2406SP | Indium, Serum/Plasma | $ 228.00 |
| 2406U | Indium, Urine | $ 152.00 |
| 2410B | Indomethacin, Blood | $ 178.00 |
| 2410SP | Indomethacin, Serum/Plasma | $ 167.00 |
| 2410U | Indomethacin, Urine | $ 178.00 |
| 2412B | Inhalants Panel, Alkane Gases, Blood | $ 194.00 |
| 2412TI | Inhalants Panel, Alkane Gases, Tissue | $ 284.00 |
| 2421B | Inhalants Panel, Anesthetics, Blood | $ 854.00 |
| 2414B | Inhalants Panel, Halocarbons, Blood | $ 214.00 |
| 2414TI | Inhalants Panel, Halocarbons, Tissue | $ 319.00 |
| 2411B | Inhalants Panel, Solvents, Blood | $ 114.00 |
| 2411TI | Inhalants Panel, Solvents, Tissue | $ 225.00 |
| 6364R | Inorganic Panel 64, RBCs | $ 505.00 |
| 2428U | Iodine - Total, Urine | $ 139.00 |
| 2428FL | Iodine, Fluid | $ 335.00 |
| 2428SP | Iodine, Serum/Plasma | $ 139.00 |
| 2425B | Ipecac Use Markers Screen, Blood | $ 1,142.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2425FL | Ipecac Use Markers Screen, Fluid | $ 1,191.00 |
| 2425SP | Ipecac Use Markers Screen, Serum/Plasma | $ 967.00 |
| 2425U | Ipecac Use Markers Screen, Urine | $ 1,142.00 |
| 2430UH | Iron, 24 Hour Urine | $ 79.00 |
| 2430B | Iron, Blood | $ 79.00 |
| 2430SP | Iron, Serum/Plasma | $ 79.00 |
| 2430ST | Iron, Stool | $ 284.00 |
| 2430U | Iron, Urine | $ 79.00 |
| 2457SP | Isavuconazole, Serum/Plasma | $ 467.00 |
| 2436SP | Isobutanol, Serum/Plasma | $ 156.00 |
| 2437B | Isoflurane, Blood | $ 201.00 |
| 2440SP | Isoniazid, Serum/Plasma | $ 226.00 |
| 2445B | Isopropanol and Acetone, Blood | $ 77.00 |
| 2445SP | Isopropanol and Acetone, Serum/Plasma | $ 77.00 |
| 2445U | Isopropanol and Acetone, Urine | $ 77.00 |
| 2458SP | Isotretinoin and Metabolite, Serum/Plasma | $ 277.00 |
| 2456SP | Isotretinoin, Serum/Plasma | $ 242.00 |
| 2460B | Itraconazole, Blood | $ 750.00 |
| 2460SP | Itraconazole, Serum/Plasma | $ 480.00 |
| 9188B | Ketamine and Metabolite Screen, Blood | $ 119.00 |
| 9188SP | Ketamine and Metabolite Screen, Serum/Plasma | $ 119.00 |
| 9188U | Ketamine and Metabolite Screen, Urine | $ 119.00 |
| 2479B | Ketamine and Metabolite, Blood | $ 128.00 |
| 2479FL | Ketamine and Metabolite, Fluid | $ 196.00 |
| 2479SP | Ketamine and Metabolite, Serum/Plasma | $ 128.00 |
| 2479TI | Ketamine and Metabolite, Tissue | $ 407.00 |
| 2479U | Ketamine and Metabolite, Urine | $ 123.00 |
| 9190B | Ketoacidosis Screen, Postmortem, Blood (Forensic) | $ 176.00 |
| 9190FL | Ketoacidosis Screen, Postmortem, Fluid (Forensic) | $ 246.00 |
| 2485B | Ketoconazole, Blood | $ 577.00 |
| 2485SP | Ketoconazole, Serum/Plasma | $ 431.00 |
| 2480SP | Ketone Bodies Panel, Serum/Plasma | $ 339.00 |
| 2481B | Ketone Panel, Blood | $ 363.00 |
| 2481FL | Ketone Panel, Fluid | $ 313.00 |
| 2481U | Ketone Panel, Urine | $ 363.00 |
| 2486B | Ketoprofen, Blood | $ 457.00 |
| 2486SP | Ketoprofen, Serum/Plasma | $ 472.00 |
| 2482B | Ketorolac, Blood | $ 423.00 |
| 2482FL | Ketorolac, Fluid | $ 591.00 |
| 2482SP | Ketorolac, Serum/Plasma | $ 423.00 |
| 2488B | Labetalol, Blood | $ 613.00 |
| 2488FL | Labetalol, Fluid | $ 680.00 |
| 2488SP | Labetalol, Serum/Plasma | $ 420.00 |
| 2527B | Lacosamide, Blood | $ 213.00 |
| 2527FL | Lacosamide, Fluid | $ 421.00 |
| 2527SP | Lacosamide, Serum/Plasma | $ 213.00 |
| 2527U | Lacosamide, Urine | $ 213.00 |
| 2484B | Lamotrigine, Blood | $ 93.00 |
| 2484FL | Lamotrigine, Fluid | $ 290.00 |
| 2484SP | Lamotrigine, Serum/Plasma | $ 93.00 |
| 2484U | Lamotrigine, Urine | $ 142.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2499U | Laxatives Panel (Qualitative), Urine | $ 343.00 |
| 81868B | LC-TOF Add-On (Qualitative), Blood | $ 109.00 |
| 81868SP | LC-TOF Add-On (Qualitative), Serum/Plasma | $ 109.00 |
| 81868U | LC-TOF Add-On (Qualitative), Urine | $ 109.00 |
| 2490B | Lead and ZPP, Blood | $ 72.00 |
| 2492UH | Lead, 24 Hour Urine | $ 102.00 |
| 2492B | Lead, Blood | $ 50.00 |
| 2492FL | Lead, Fluid | $ 259.00 |
| 2492H | Lead, Hair | $ 420.00 |
| 2492LI | Lead, Liquid | $ 160.00 |
| 2492N | Lead, Nails | $ 420.00 |
| 2492R | Lead, RBCs | $ 85.00 |
| 2492SP | Lead, Serum/Plasma | $ 102.00 |
| 2492TI | Lead, Tissue | $ 330.00 |
| 2492U | Lead, Urine | $ 102.00 |
| 2532B | Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood | $ 346.00 |
| 2532SP | Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma | $ 346.00 |
| 2531B | Leflunomide as Metabolite (Therapeutic Drug Monitoring), Blood | $ 346.00 |
| 2531SP | Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma | $ 346.00 |
| 2501B | Levamisole, Blood | $ 326.00 |
| 2501SP | Levamisole, Serum/Plasma | $ 326.00 |
| 2501U | Levamisole, Urine | $ 326.00 |
| 2505B | Levetiracetam, Blood | $ 139.00 |
| 2505SP | Levetiracetam, Serum/Plasma | $ 139.00 |
| 2517B | Levocetirizine, Blood | $ 545.00 |
| 2517SP | Levocetirizine, Serum/Plasma | $ 602.00 |
| 2504SP | Levodopa, Serum/Plasma | $ 243.00 |
| 9317B | Lidocaine and Metabolite (MEGX) Screen, Blood | $ 252.00 |
| 9317SP | Lidocaine and Metabolite (MEGX) Screen, Serum/Plasma | $ 243.00 |
| 9317U | Lidocaine and Metabolite (MEGX) Screen, Urine | $ 243.00 |
| 2512B | Lidocaine and Metabolite (MEGX), Blood | $ 199.00 |
| 2512FL | Lidocaine and Metabolite (MEGX), Fluid | $ 409.00 |
| 2512SP | Lidocaine and Metabolite (MEGX), Serum/Plasma | $ 190.00 |
| 2512TI | Lidocaine and Metabolite (MEGX), Tissue | $ 479.00 |
| 2512U | Lidocaine and Metabolite (MEGX), Urine | $ 190.00 |
| 2511SP | Lidocaine, Serum/Plasma | $ 97.00 |
| 2516B | Lindane, Blood | $ 457.00 |
| 2516SP | Lindane, Serum/Plasma | $ 262.00 |
| 2800B | Lisdexamfetamine as Metabolite, Blood | $ 233.00 |
| 2800SP | Lisdexamfetamine as Metabolite, Serum/Plasma | $ 259.00 |
| 2800U | Lisdexamfetamine as Metabolite, Urine | $ 257.00 |
| 2534U | Lithium Exposure , Urine | $ 55.00 |
| 2534B | Lithium Exposure, Blood | $ 55.00 |
| 2534SP | Lithium Exposure, Serum/Plasma | $ 55.00 |
| 2520B | Lithium, Blood | $ 58.00 |
| 2520FL | Lithium, Fluid | $ 267.00 |
| 2520R | Lithium, RBCs | $ 92.00 |
| 2520SP | Lithium, Serum/Plasma | $ 58.00 |
| 2520TI | Lithium, Tissue | $ 339.00 |
| 2520U | Lithium, Urine | $ 58.00 |
| 2533B | Loperamide and Metabolite, Blood | $ 416.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2533SP | Loperamide and Metabolite, Serum/Plasma | $ 416.00 |
| 2525B | Loratadine and Metabolite, Blood | $ 304.00 |
| 2525SP | Loratadine and Metabolite, Serum/Plasma | $ 482.00 |
| 2525U | Loratadine and Metabolite, Urine | $ 482.00 |
| 2535B | Lorazepam, Blood | $ 184.00 |
| 2535FL | Lorazepam, Fluid | $ 358.00 |
| 2535SP | Lorazepam, Serum/Plasma | $ 113.00 |
| 2535U | Lorazepam, Urine | $ 173.00 |
| 2538B | Loxapine, Blood | $ 472.00 |
| 2538SP | Loxapine, Serum/Plasma | $ 302.00 |
| 2538U | Loxapine, Urine | $ 444.00 |
| 2541B | LSD Screen, Blood | $ 96.00 |
| 2541SP | LSD Screen, Serum/Plasma | $ 152.00 |
| 2541U | LSD Screen, Urine | $ 96.00 |
| 2540B | LSD Trace Analysis, Blood | $ 396.00 |
| 2540SP | LSD Trace Analysis, Serum/Plasma | $ 385.00 |
| 2540U | LSD Trace Analysis, Urine | $ 242.00 |
| 2543B | Lurasidone, Blood | $ 210.00 |
| 2543SP | Lurasidone, Serum/Plasma | $ 210.00 |
| 2551B | Magnesium - Total, Blood | $ 62.00 |
| 2551FL | Magnesium - Total, Fluid | $ 271.00 |
| 2551H | Magnesium - Total, Hair | $ 433.00 |
| 2551R | Magnesium - Total, RBCs | $ 62.00 |
| 2551SP | Magnesium - Total, Serum/Plasma | $ 62.00 |
| 2551ST | Magnesium - Total, Stool | $ 433.00 |
| 2551TI | Magnesium - Total, Tissue | $ 274.00 |
| 2551U | Magnesium - Total, Urine | $ 118.00 |
| 2570B | Manganese, Blood | $ 103.00 |
| 2570FL | Manganese, Fluid | $ 310.00 |
| 2570H | Manganese, Hair | $ 472.00 |
| 2570LI | Manganese, Liquid | $ 587.00 |
| 2570N | Manganese, Nails | $ 716.00 |
| 2570R | Manganese, RBCs | $ 103.00 |
| 2570SP | Manganese, Serum/Plasma | $ 103.00 |
| 2570TI | Manganese, Tissue | $ 381.00 |
| 2570U | Manganese, Urine | $ 103.00 |
| 2573B | Maprotiline, Blood | $ 399.00 |
| 2573SP | Maprotiline, Serum/Plasma | $ 386.00 |
| 2573U | Maprotiline, Urine | $ 243.00 |
| 9196SP | Meclizine Screen, Serum/Plasma | $ 199.00 |
| 2590B | Meclizine, Blood | $ 212.00 |
| 2590SP | Meclizine, Serum/Plasma | $ 184.00 |
| 2590TI | Meclizine, Tissue | $ 462.00 |
| 2595B | Mefloquine, Blood | $ 763.00 |
| 2595SP | Mefloquine, Serum/Plasma | $ 531.00 |
| 2604B | Melatonin, Blood | $ 292.00 |
| 2604FL | Melatonin, Fluid | $ 482.00 |
| 2604SP | Melatonin, Serum/Plasma | $ 292.00 |
| 2604TI | Melatonin, Tissue | $ 540.00 |
| 2604U | Melatonin, Urine | $ 292.00 |
| 2581B | Memantine, Blood | $ 379.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2581SP | Memantine, Serum/Plasma | $ 379.00 |
| 2605B | Menthol, Blood | $ 322.00 |
| 2605SP | Menthol, Serum/Plasma | $ 464.00 |
| 9440B | Meperidine and Metabolite Screen, Blood | $ 212.00 |
| 9440SP | Meperidine and Metabolite Screen, Serum/Plasma | $ 135.00 |
| 2610B | Meperidine and Metabolite, Blood | $ 209.00 |
| 8721B | Meperidine and Metabolite, Blood | $ 554.00 |
| 2610SP | Meperidine and Metabolite, Serum/Plasma | $ 209.00 |
| 8721SP | Meperidine and Metabolite, Serum/Plasma | $ 483.00 |
| 2610U | Meperidine and Metabolite, Urine | $ 132.00 |
| 8721U | Meperidine and Metabolite, Urine | $ 534.00 |
| 9444U | Meperidine Screen, Urine | $ 96.00 |
| 9200SP | Mepivacaine Screen, Serum/Plasma | $ 230.00 |
| 2640B | Mepivacaine, Blood | $ 192.00 |
| 2640SP | Mepivacaine, Serum/Plasma | $ 187.00 |
| 2650B | Meprobamate, Blood | $ 281.00 |
| 2650SP | Meprobamate, Serum/Plasma | $ 168.00 |
| 2650U | Meprobamate, Urine | $ 268.00 |
| 2665B | Mercaptopurine and Metabolites, Blood | $ 286.00 |
| 2670UH | Mercury, 24 Hour Urine | $ 77.00 |
| 2670B | Mercury, Blood | $ 55.00 |
| 2670FL | Mercury, Fluid | $ 267.00 |
| 2670H | Mercury, Hair | $ 623.00 |
| 2670LI | Mercury, Liquid | $ 270.00 |
| 2670N | Mercury, Nails | $ 430.00 |
| 2670R | Mercury, RBCs | $ 55.00 |
| 2670SP | Mercury, Serum/Plasma | $ 55.00 |
| 2670TI | Mercury, Tissue | $ 339.00 |
| 2670U | Mercury, Urine | $ 124.00 |
| 2680B | Mescaline Screen, Blood | $ 140.00 |
| 2680SP | Mescaline Screen, Serum/Plasma | $ 219.00 |
| 2680U | Mescaline Screen, Urine | $ 140.00 |
| 2679B | Mescaline, Blood | $ 482.00 |
| 2679SP | Mescaline, Serum/Plasma | $ 480.00 |
| 2679U | Mescaline, Urine | $ 303.00 |
| 2689SP | Mesoridazine, Serum/Plasma | $ 212.00 |
| 2664UH | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), 24 Hour Urine | $ 379.00 |
| 2664U | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), Urine | $ 379.00 |
| 2693B | Metals/Metalloids Acute Poisoning Panel, Blood | $ 465.00 |
| 2693FL | Metals/Metalloids Acute Poisoning Panel, Fluid | $ 680.00 |
| 2693H | Metals/Metalloids Acute Poisoning Panel, Hair | $ 661.00 |
| 2693R | Metals/Metalloids Acute Poisoning Panel, RBCs | $ 465.00 |
| 2693SP | Metals/Metalloids Acute Poisoning Panel, Serum/Plasma | $ 465.00 |
| 2693TI | Metals/Metalloids Acute Poisoning Panel, Tissue | $ 725.00 |
| 2693U | Metals/Metalloids Acute Poisoning Panel, Urine | $ 465.00 |
| 2661B | Metals/Metalloids Panel 1, Blood | $ 271.00 |
| 2661H | Metals/Metalloids Panel 1, Hair | $ 504.00 |
| 2661N | Metals/Metalloids Panel 1, Nails | $ 504.00 |
| 2661SP | Metals/Metalloids Panel 1, Serum/Plasma | $ 301.00 |
| 2661U | Metals/Metalloids Panel 1, Urine | $ 311.00 |
| 2662B | Metals/Metalloids Panel 2, Blood | $ 379.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2662H | Metals/Metalloids Panel 2, Hair | $ 583.00 |
| 2662N | Metals/Metalloids Panel 2, Nails | $ 583.00 |
| 2662SP | Metals/Metalloids Panel 2, Serum/Plasma | $ 379.00 |
| 2662U | Metals/Metalloids Panel 2, Urine | $ 598.00 |
| 2663B | Metals/Metalloids Panel 3, Blood | $ 419.00 |
| 2663H | Metals/Metalloids Panel 3, Hair | $ 631.00 |
| 2663N | Metals/Metalloids Panel 3, Nails | $ 631.00 |
| 2663SP | Metals/Metalloids Panel 3, Serum/Plasma | $ 432.00 |
| 2663U | Metals/Metalloids Panel 3, Urine | $ 668.00 |
| 2720B | Metaxalone, Blood | $ 236.00 |
| 2720SP | Metaxalone, Serum/Plasma | $ 236.00 |
| 2720U | Metaxalone, Urine | $ 236.00 |
| 2740B | Metformin, Blood | $ 180.00 |
| 2740FL | Metformin, Fluid | $ 387.00 |
| 2740SP | Metformin, Serum/Plasma | $ 180.00 |
| 2740U | Metformin, Urine | $ 270.00 |
| 2760ME | Methadone and Metabolite (Qualitative), Meconium | $ 358.00 |
| 8894OF | Methadone and Metabolite (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8722B | Methadone and Metabolite, Blood | $ 268.00 |
| 8722FL | Methadone and Metabolite, Fluid | $ 340.00 |
| 8722SP | Methadone and Metabolite, Serum/Plasma | $ 268.00 |
| 8722TI | Methadone and Metabolite, Tissue | $ 373.00 |
| 8722U | Methadone and Metabolite, Urine | $ 268.00 |
| 9324B | Methadone Screen, Blood | $ 154.00 |
| 9324SP | Methadone Screen, Serum/Plasma | $ 152.00 |
| 9324U | Methadone Screen, Urine | $ 149.00 |
| 9522B | Methamphetamine and Amphetamine Screen, Blood | $ 179.00 |
| 9522SP | Methamphetamine and Amphetamine Screen, Serum/Plasma | $ 179.00 |
| 9522U | Methamphetamine and Amphetamine Screen, Urine | $ 107.00 |
| 2810B | Methamphetamine and Metabolite, Blood | $ 243.00 |
| 2810FL | Methamphetamine and Metabolite, Fluid | $ 402.00 |
| 2810SP | Methamphetamine and Metabolite, Serum/Plasma | $ 160.00 |
| 2810U | Methamphetamine and Metabolite, Urine | $ 197.00 |
| 2745B | Methane, Blood | $ 602.00 |
| 2836U | Methanol Exposure Profile, Urine | $ 189.00 |
| 2837B | Methanol Poisoning Profile, Blood | $ 446.00 |
| 2837SP | Methanol Poisoning Profile, Serum/Plasma | $ 462.00 |
| 2835B | Methanol, Blood | $ 130.00 |
| 2835FL | Methanol, Fluid | $ 199.00 |
| 2835SP | Methanol, Serum/Plasma | $ 81.00 |
| 2835U | Methanol, Urine | $ 81.00 |
| 2849B | Methaqualone, Blood | $ 310.00 |
| 2849SP | Methaqualone, Serum/Plasma | $ 188.00 |
| 2849U | Methaqualone, Urine | $ 188.00 |
| 2860B | Metharbital and Metabolite, Blood | $ 420.00 |
| 2860SP | Metharbital and Metabolite, Serum/Plasma | $ 230.00 |
| 2860U | Metharbital and Metabolite, Urine | $ 420.00 |
| 2863SP | Methazolamide, Serum/Plasma | $ 190.00 |
| 2887B | Methemoglobin, Blood | $ 209.00 |
| 2892B | Methimazole, Blood | $ 463.00 |
| 2892SP | Methimazole, Serum/Plasma | $ 228.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2900B | Methocarbamol, Blood | $ 168.00 |
| 2900FL | Methocarbamol, Fluid | $ 379.00 |
| 2900SP | Methocarbamol, Serum/Plasma | $ 173.00 |
| 0649SP | Methotrexate, Serum/Plasma | $ 212.00 |
| 2930B | Methoxychlor, Blood | $ 152.00 |
| 2950B | Methsuximide as Metabolite, Blood | $ 452.00 |
| 2950SP | Methsuximide as Metabolite, Serum/Plasma | $ 159.00 |
| 4630B | Methyl Chloroform, Blood | $ 209.00 |
| 2990B | Methyl Ethyl Ketone, Blood | $ 149.00 |
| 2990SP | Methyl Ethyl Ketone, Serum/Plasma | $ 95.00 |
| 2990U | Methyl Ethyl Ketone, Urine | $ 69.00 |
| 2982B | Methyl Isobutyl Ketone, Blood | $ 257.00 |
| 2982U | Methyl Isobutyl Ketone, Urine | $ 257.00 |
| 2984U | Methyl n-Butyl Ketone Exposure Monitoring, Urine | $ 166.00 |
| 2980B | Methyl n-Butyl Ketone, Blood | $ 179.00 |
| 2051B | Methyl Tertiary Butyl Ether and Metabolite, Blood | $ 480.00 |
| 2051U | Methyl Tertiary Butyl Ether and Metabolite, Urine | $ 742.00 |
| 2050B | Methyl Tertiary Butyl Ether, Blood | $ 488.00 |
| 3005B | Methylchloroform Exposure, Blood | $ 149.00 |
| 3005SP | Methylchloroform Exposure, Serum/Plasma | $ 149.00 |
| 2986U | Methylenedianiline, Urine | $ 448.00 |
| 2584B | Methylenedioxyamphetamine, Blood | $ 427.00 |
| 2584SP | Methylenedioxyamphetamine, Serum/Plasma | $ 259.00 |
| 2584U | Methylenedioxyamphetamine, Urine | $ 259.00 |
| 9293B | Methylenedioxymethamphetamine and Metabolite Screen, Blood | $ 149.00 |
| 9293SP | Methylenedioxymethamphetamine and Metabolite Screen, Serum/Plasma | $ 228.00 |
| 9293U | Methylenedioxymethamphetamine and Metabolite Screen, Urine | $ 149.00 |
| 2585B | Methylenedioxymethamphetamine and Metabolite, Blood | $ 393.00 |
| 2585SP | Methylenedioxymethamphetamine and Metabolite, Serum/Plasma | $ 393.00 |
| 2585U | Methylenedioxymethamphetamine and Metabolite, Urine | $ 249.00 |
| 9193U | Methylphenidate and Metabolite Screen, Urine | $ 249.00 |
| 3020B | Methylphenidate and Metabolite, Blood | $ 131.00 |
| 3020SP | Methylphenidate and Metabolite, Serum/Plasma | $ 131.00 |
| 3020TI | Methylphenidate and Metabolite, Tissue | $ 235.00 |
| 3020U | Methylphenidate and Metabolite, Urine | $ 131.00 |
| 3041B | Metoclopramide, Blood | $ 601.00 |
| 3041SP | Metoclopramide, Serum/Plasma | $ 601.00 |
| 3041U | Metoclopramide, Urine | $ 601.00 |
| 3042B | Metolazone, Blood | $ 235.00 |
| 3042SP | Metolazone, Serum/Plasma | $ 228.00 |
| 3043B | Metoprolol, Blood | $ 153.00 |
| 3043FL | Metoprolol, Fluid | $ 224.00 |
| 3043SP | Metoprolol, Serum/Plasma | $ 248.00 |
| 3043U | Metoprolol, Urine | $ 248.00 |
| 3048SP | Metribuzin, Serum/Plasma | $ 463.00 |
| 3050B | Metronidazole, Blood | $ 405.00 |
| 3050SP | Metronidazole, Serum/Plasma | $ 386.00 |
| 9211B | Mexiletine Screen, Blood | $ 281.00 |
| 9211SP | Mexiletine Screen, Serum/Plasma | $ 268.00 |
| 3055B | Mexiletine, Blood | $ 640.00 |
| 3055SP | Mexiletine, Serum/Plasma | $ 107.00 |

| Test | Test Name | List Price |
|---|---|---|
| MICRO | Micro Specimen Surcharge | $ 95.00 |
| 3057U | Midazolam as Metabolite, Urine | $ 128.00 |
| 3057B | Midazolam, Blood | $ 128.00 |
| 3057FL | Midazolam, Fluid | $ 196.00 |
| 3057SP | Midazolam, Serum/Plasma | $ 201.00 |
| 3061B | Milnacipran/Levomilnacipran, Blood | $ 213.00 |
| 3061SP | Milnacipran/Levomilnacipran, Serum/Plasma | $ 213.00 |
| 3061U | Milnacipran/Levomilnacipran, Urine | $ 213.00 |
| 3066B | Mineral Profile, Blood | $ 610.00 |
| 3066R | Mineral Profile, RBCs | $ 394.00 |
| 3066SP | Mineral Profile, Serum/Plasma | $ 394.00 |
| 3075B | Mirtazapine, Blood | $ 132.00 |
| 3075SP | Mirtazapine, Serum/Plasma | $ 132.00 |
| 3075U | Mirtazapine, Urine | $ 209.00 |
| 3059B | Mitotane, Blood | $ 514.00 |
| 3059SP | Mitotane, Serum/Plasma | $ 153.00 |
| 3078U | Mitragynine (Qualitative), Urine | $ 187.00 |
| 3064B | Mitragynine, Blood | $ 196.00 |
| 3064SP | Mitragynine, Serum/Plasma | $ 196.00 |
| 3081U | MOCA and MDA Exposure Profile, Urine | $ 332.00 |
| 3080U | MOCA, Urine | $ 431.00 |
| 3045B | Modafinil / Armodafinil, Blood | $ 248.00 |
| 3045SP | Modafinil / Armodafinil, Serum/Plasma | $ 153.00 |
| 3082B | Molindone, Blood | $ 413.00 |
| 3082SP | Molindone, Serum/Plasma | $ 139.00 |
| 3082U | Molindone, Urine | $ 139.00 |
| 3090B | Molybdenum, Blood | $ 79.00 |
| 3090H | Molybdenum, Hair | $ 448.00 |
| 3090R | Molybdenum, RBCs | $ 79.00 |
| 3090SP | Molybdenum, Serum/Plasma | $ 79.00 |
| 3090U | Molybdenum, Urine | $ 92.00 |
| 3098U | Mono-n-butyl phthalate (MNBP), Urine | $ 296.00 |
| 3092SP | Moricizine, Serum/Plasma | $ 197.00 |
| 8666B | Morphine - Free (Unconjugated), Blood | $ 373.00 |
| 8666FL | Morphine - Free (Unconjugated), Fluid | $ 324.00 |
| 8666SP | Morphine - Free (Unconjugated), Serum/Plasma | $ 261.00 |
| 8666U | Morphine - Free (Unconjugated), Urine | $ 414.00 |
| 8673B | Morphine - Free and Total, Blood | $ 516.00 |
| 8673SP | Morphine - Free and Total, Serum/Plasma | $ 568.00 |
| 8673U | Morphine - Free and Total, Urine | $ 568.00 |
| 8672B | Morphine - Total (Conjugated/Unconjugated), Blood | $ 230.00 |
| 8672SP | Morphine - Total (Conjugated/Unconjugated), Serum/Plasma | $ 230.00 |
| 8672U | Morphine - Total (Conjugated/Unconjugated), Urine | $ 230.00 |
| 3085B | Morphine and Glucuronide Metabolites, Blood | $ 358.00 |
| 3085SP | Morphine and Glucuronide Metabolites, Serum/Plasma | $ 358.00 |
| 3063B | Mycophenolic Acid and Metabolite, Blood | $ 545.00 |
| 3063SP | Mycophenolic Acid and Metabolite, Serum/Plasma | $ 393.00 |
| 3063U | Mycophenolic Acid and Metabolite, Urine | $ 545.00 |
| 3060U | N,N-Dimethylacetamide Exposure (N-Methylacetamide), Urine | $ 742.00 |
| 3070U | N,N-Dimethylformamide (DMF) Exposure (N-Monomethylformamide), Urine | $ 285.00 |
| 3218B | N,N-Dimethylpentylone & Pentylone, Blood | $ 338.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3218SP | N,N-Dimethylpentylone & Pentylone, Serum/Plasma | $ 338.00 |
| 3218U | N,N-Dimethylpentylone & Pentylone, Urine | $ 338.00 |
| 3107B | Nabumetone as Metabolite, Blood | $ 212.00 |
| 3107SP | Nabumetone as Metabolite, Serum/Plasma | $ 201.00 |
| 3107U | Nabumetone as Metabolite, Urine | $ 212.00 |
| 3103B | Nadolol, Blood | $ 248.00 |
| 3103SP | Nadolol, Serum/Plasma | $ 248.00 |
| 3103U | Nadolol, Urine | $ 254.00 |
| 3110B | Nalbuphine - Free (Unconjugated), Blood | $ 346.00 |
| 3110SP | Nalbuphine - Free (Unconjugated), Serum/Plasma | $ 534.00 |
| 3110U | Nalbuphine - Total (Conjugated/Unconjugated), Urine | $ 550.00 |
| 3111B | Naloxone - Free (Unconjugated), Blood | $ 97.00 |
| 3111SP | Naloxone - Free (Unconjugated), Serum/Plasma | $ 97.00 |
| 3113U | Naloxone - Total (Conjugated/Unconjugated) Screen, Urine | $ 358.00 |
| 3111U | Naloxone - Total (Conjugated/Unconjugated), Urine | $ 97.00 |
| 3116B | Naltrexone and Metabolite - Free (Unconjugated), Blood | $ 486.00 |
| 3116SP | Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma | $ 468.00 |
| 3116U | Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 470.00 |
| 3130B | Naproxen, Blood | $ 119.00 |
| 3130FL | Naproxen, Fluid | $ 330.00 |
| 3130SP | Naproxen, Serum/Plasma | $ 190.00 |
| 3130U | Naproxen, Urine | $ 190.00 |
| 3118B | Nateglinide, Blood | $ 137.00 |
| 3118SP | Nateglinide, Serum/Plasma | $ 137.00 |
| 3145B | Nefazodone, Blood | $ 176.00 |
| 3145SP | Nefazodone, Serum/Plasma | $ 160.00 |
| 3145U | Nefazodone, Urine | $ 107.00 |
| 2292U | n-Hexane Exposure Monitoring, Urine | $ 312.00 |
| 3140B | Nickel, Blood | $ 79.00 |
| 3140FL | Nickel, Fluid | $ 284.00 |
| 3140H | Nickel, Hair | $ 448.00 |
| 3140N | Nickel, Nails | $ 448.00 |
| 3140R | Nickel, RBCs | $ 129.00 |
| 3140SP | Nickel, Serum/Plasma | $ 79.00 |
| 3140TI | Nickel, Tissue | $ 355.00 |
| 3140U | Nickel, Urine | $ 110.00 |
| 9404B | Nicotine and Metabolite Screen, Blood | $ 154.00 |
| 9404SP | Nicotine and Metabolite Screen, Serum/Plasma | $ 107.00 |
| 9404U | Nicotine and Metabolite with Anabasine Screen, Urine | $ 115.00 |
| 3150U | Nicotine and Metabolite with Anabasine, Urine | $ 132.00 |
| 3150B | Nicotine and Metabolite, Blood | $ 113.00 |
| 3150FL | Nicotine and Metabolite, Fluid | $ 324.00 |
| 3150SP | Nicotine and Metabolite, Serum/Plasma | $ 113.00 |
| 3150TI | Nicotine and Metabolite, Tissue | $ 394.00 |
| 3158B | Nifedipine, Blood | $ 345.00 |
| 3158SP | Nifedipine, Serum/Plasma | $ 385.00 |
| 3168B | Nitazenes Panel, Blood | $ 378.00 |
| 3168SP | Nitazenes Panel, Serum/Plasma | $ 378.00 |
| 3174B | Nitrate/Nitrite (Qualitative), Blood (Forensic) | $ 355.00 |
| 3174SP | Nitrate/Nitrite (Qualitative), Serum/Plasma | $ 355.00 |
| 9215B | Nitrazepam and Metabolite Screen, Blood | $ 271.00 |

| Test | Test Name | List Price |
|---|---|---|
| 9215SP | Nitrazepam and Metabolite Screen, Serum/Plasma | $ 189.00 |
| 3175B | Nitrazepam and Metabolite, Blood | $ 465.00 |
| 3175SP | Nitrazepam and Metabolite, Serum/Plasma | $ 448.00 |
| 3175U | Nitrazepam and Metabolite, Urine | $ 284.00 |
| 3214A | Nitrous Oxide, Air | $ 561.00 |
| 3214B | Nitrous Oxide, Blood | $ 527.00 |
| 3214FL | Nitrous Oxide, Fluid | $ 588.00 |
| 3214TI | Nitrous Oxide, Tissue | $ 631.00 |
| 3214U | Nitrous Oxide, Urine | $ 561.00 |
| 8054B | NMS TotalTox™ Panel, Blood (Forensic) | $ 595.00 |
| NONBIO/LIQ | Non-biological Fee (Liquid) | $ 146.00 |
| NONBIO/SOL | Non-biological Fee (Solid) | $ 214.00 |
| 3223SP | Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma | $ 457.00 |
| 3219B | Norchlorcyclizine, Blood | $ 258.00 |
| 3219FL | Norchlorcyclizine, Fluid | $ 258.00 |
| 3219SP | Norchlorcyclizine, Serum/Plasma | $ 258.00 |
| 3219TI | Norchlorcyclizine, Tissue | $ 285.00 |
| 3219U | Norchlorcyclizine, Urine | $ 258.00 |
| 3216B | Nordiazepam and Metabolite, Blood | $ 315.00 |
| 3216SP | Nordiazepam and Metabolite, Serum/Plasma | $ 315.00 |
| 3216U | Nordiazepam and Metabolite, Urine | $ 302.00 |
| 9433B | Nortriptyline Screen, Blood | $ 128.00 |
| 9433U | Nortriptyline Screen, Urine | $ 92.00 |
| 3220B | Nortriptyline, Blood | $ 137.00 |
| 8702B | Nortriptyline, Blood | $ 534.00 |
| 3220FL | Nortriptyline, Fluid | $ 333.00 |
| 3220SP | Nortriptyline, Serum/Plasma | $ 137.00 |
| 3220TI | Nortriptyline, Tissue | $ 418.00 |
| 3220U | Nortriptyline, Urine | $ 90.00 |
| 8702U | Nortriptyline, Urine | $ 534.00 |
| 8756B | Novel Psychoactive Substances (NPS) Screen 1, Blood | $ 389.00 |
| 8756SP | Novel Psychoactive Substances (NPS) Screen 1, Serum/Plasma | $ 389.00 |
| 8756U | Novel Psychoactive Substances (NPS) Screen 1, Urine | $ 389.00 |
| 3224B | NPS Stimulants (Qualitative), Blood | $ 286.00 |
| 3224SP | NPS Stimulants (Qualitative), Serum/Plasma | $ 179.00 |
| 3224U | NPS Stimulants (Qualitative), Urine | $ 179.00 |
| 3225SP | Nuedexta®, Serum/Plasma | $ 401.00 |
| 1352U | o-Cresol, Urine | $ 187.00 |
| 3226B | Olanzapine and Metabolite, Blood | $ 366.00 |
| 3226SP | Olanzapine and Metabolite, Serum/Plasma | $ 191.00 |
| 3226FL | Olanzapine, Fluid | $ 550.00 |
| 3226TI | Olanzapine, Tissue | $ 617.00 |
| 3232B | Omeprazole / Esomeprazole, Blood | $ 640.00 |
| 3232SP | Omeprazole / Esomeprazole, Serum/Plasma | $ 730.00 |
| 3241B | Opiates - Free (Unconjugated), Blood | $ 490.00 |
| 8660B | Opiates - Free (Unconjugated), Blood | $ 320.00 |
| 8660FL | Opiates - Free (Unconjugated), Fluid | $ 390.00 |
| 8660SP | Opiates - Free (Unconjugated), Serum/Plasma | $ 320.00 |
| 8660TI | Opiates - Free (Unconjugated), Tissue | $ 426.00 |
| 8660U | Opiates - Free (Unconjugated), Urine | $ 259.00 |
| 8671B | Opiates - Free and Total, Blood | $ 541.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8671SP | Opiates - Free and Total, Serum/Plasma | $ 541.00 |
| 8671U | Opiates - Free and Total, Urine | $ 541.00 |
| 8670ME | Opiates - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 373.00 |
| 8670B | Opiates - Total (Conjugated/Unconjugated), Blood | $ 315.00 |
| 8670FL | Opiates - Total (Conjugated/Unconjugated), Fluid | $ 350.00 |
| 8670SP | Opiates - Total (Conjugated/Unconjugated), Serum/Plasma | $ 315.00 |
| 8670TI | Opiates - Total (Conjugated/Unconjugated), Tissue | $ 488.00 |
| 8670U | Opiates - Total (Conjugated/Unconjugated), Urine | $ 315.00 |
| 8895OF | Opiates (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 3236B | Opiates Screen, Blood | $ 96.00 |
| 3236FL | Opiates Screen, Fluid | $ 309.00 |
| 6923H | Opiates Screen, Hair | $ 493.00 |
| 3236SP | Opiates Screen, Serum/Plasma | $ 152.00 |
| 3236TI | Opiates Screen, Tissue | $ 383.00 |
| 3236U | Opiates Screen, Urine | $ 100.00 |
| 3243B | Organochlorine Pesticides, Blood | $ 208.00 |
| 3243F | Organochlorine Pesticides, Fat | $ 699.00 |
| 3243SP | Organochlorine Pesticides, Serum/Plasma | $ 208.00 |
| 3243TI | Organochlorine Pesticides, Tissue | $ 587.00 |
| 9219B | Orphenadrine Screen, Blood | $ 246.00 |
| 3248B | Orphenadrine, Blood | $ 213.00 |
| 3248SP | Orphenadrine, Serum/Plasma | $ 220.00 |
| 3248U | Orphenadrine, Urine | $ 212.00 |
| 1355U | o-Toluidine, Urine | $ 331.00 |
| 3250SP | Oxalate, Serum/Plasma | $ 188.00 |
| 3286B | Oxaprozin, Blood | $ 506.00 |
| 3286SP | Oxaprozin, Serum/Plasma | $ 554.00 |
| 3260B | Oxazepam, Blood | $ 310.00 |
| 3260SP | Oxazepam, Serum/Plasma | $ 296.00 |
| 3260U | Oxazepam, Urine | $ 268.00 |
| 3265B | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Blood | $ 96.00 |
| 3265FL | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Fluid | $ 293.00 |
| 3265SP | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Serum/Plasma | $ 96.00 |
| 3266B | Oxybutynin and Metabolite, Blood | $ 500.00 |
| 3266SP | Oxybutynin and Metabolite, Serum/Plasma | $ 534.00 |
| 3266U | Oxybutynin and Metabolite, Urine | $ 534.00 |
| 3270B | Oxycodone - Free (Unconjugated), Blood | $ 132.00 |
| 3270FL | Oxycodone - Free (Unconjugated), Fluid | $ 203.00 |
| 3270SP | Oxycodone - Free (Unconjugated), Serum/Plasma | $ 132.00 |
| 8667B | Oxycodone and Metabolite - Free (Unconjugated), Blood | $ 162.00 |
| 8667FL | Oxycodone and Metabolite - Free (Unconjugated), Fluid | $ 199.00 |
| 8667SP | Oxycodone and Metabolite - Free (Unconjugated), Serum/Plasma | $ 162.00 |
| 8667TI | Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Tissue | $ 302.00 |
| 8667U | Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 162.00 |
| 9132B | Oxycodone Screen, Blood | $ 209.00 |
| 9132SP | Oxycodone Screen, Serum/Plasma | $ 209.00 |
| 8668B | Oxymorphone - Free (Unconjugated), Blood | $ 386.00 |
| 8668SP | Oxymorphone - Free (Unconjugated), Serum/Plasma | $ 385.00 |
| 8668U | Oxymorphone - Total (Conjugated/Unconjugated), Urine | $ 242.00 |
| 4113B | Paliperidone, Blood | $ 268.00 |
| 4113SP | Paliperidone, Serum/Plasma | $ 168.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4113TI | Paliperidone, Tissue | $ 420.00 |
| 4113U | Paliperidone, Urine | $ 281.00 |
| 3292B | Palladium, Blood | $ 225.00 |
| 3292SP | Palladium, Serum/Plasma | $ 187.00 |
| 3292U | Palladium, Urine | $ 187.00 |
| 9222B | Papaverine Screen, Blood | $ 179.00 |
| 3300B | Papaverine, Blood | $ 334.00 |
| 3300SP | Papaverine, Serum/Plasma | $ 302.00 |
| 3310B | Paraldehyde and Metabolite, Blood | $ 188.00 |
| 3310SP | Paraldehyde and Metabolite, Serum/Plasma | $ 123.00 |
| 3310U | Paraldehyde and Metabolite, Urine | $ 196.00 |
| 3320SP | Paramethadione, Serum/Plasma | $ 231.00 |
| 3325B | Paraquat, Blood | $ 2,052.00 |
| 3325SP | Paraquat, Serum/Plasma | $ 2,052.00 |
| 3360B | Paroxetine, Blood | $ 116.00 |
| 3360FL | Paroxetine, Fluid | $ 329.00 |
| 3360SP | Paroxetine, Serum/Plasma | $ 116.00 |
| 3360TI | Paroxetine, Tissue | $ 399.00 |
| 3360U | Paroxetine, Urine | $ 189.00 |
| 3371SP | PCB Panel, Congeners, Serum/Plasma | $ 156.00 |
| 3381SP | Penciclovir, Serum/Plasma | $ 398.00 |
| 3385B | Pentachlorophenol, Blood | $ 292.00 |
| 3385SP | Pentachlorophenol, Serum/Plasma | $ 292.00 |
| 3384U | Pentachlorophenol, Urine | $ 278.00 |
| 9441B | Pentazocine Screen, Blood | $ 135.00 |
| 9441SP | Pentazocine Screen, Serum/Plasma | $ 213.00 |
| 9441U | Pentazocine Screen, Urine | $ 220.00 |
| 3400B | Pentazocine, Blood | $ 135.00 |
| 8723B | Pentazocine, Blood | $ 341.00 |
| 3400FL | Pentazocine, Fluid | $ 347.00 |
| 3400SP | Pentazocine, Serum/Plasma | $ 209.00 |
| 3400TI | Pentazocine, Tissue | $ 389.00 |
| 3400U | Pentazocine, Urine | $ 132.00 |
| 3410B | Pentobarbital, Blood | $ 149.00 |
| 3410SP | Pentobarbital, Serum/Plasma | $ 149.00 |
| 3410U | Pentobarbital, Urine | $ 93.00 |
| 3433FL | Perampanel, Fluid | $ 514.00 |
| 3433SP | Perampanel, Serum/Plasma | $ 253.00 |
| 3432U | Perchloroethylene Exposure, Urine | $ 181.00 |
| 3436B | Percodan®, Blood | $ 199.00 |
| 3436SP | Percodan®, Serum/Plasma | $ 199.00 |
| 3427SP | Perfluoroalkyl Substances (PFAS), Serum/Plasma | $ 468.00 |
| 3426B | Perfluorooctanoic Acid, Blood | $ 662.00 |
| 3440B | Perphenazine, Blood | $ 189.00 |
| 3440SP | Perphenazine, Serum/Plasma | $ 116.00 |
| 3434SP | PFASure FT, Serum/Plasma | $ 510.00 |
| 3429SP | PFASure TM Expanded, Serum/Plasma | $ 551.00 |
| 3428SP | PFASure TM, Serum/Plasma | $ 510.00 |
| 3510B | Phenacetin and Metabolite, Blood | $ 142.00 |
| 3510U | Phenacetin and Metabolite, Urine | $ 285.00 |
| 3525B | Phenazopyridine, Blood | $ 212.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3525SP | Phenazopyridine, Serum/Plasma | $ 237.00 |
| 3525U | Phenazopyridine, Urine | $ 237.00 |
| 8761ME | Phencyclidine (Qualitative), Meconium | $ 439.00 |
| 8896OF | Phencyclidine and Dextromethorphan (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 3532B | Phencyclidine Screen, Blood | $ 167.00 |
| 3532FL | Phencyclidine Screen, Fluid | $ 374.00 |
| 6925H | Phencyclidine Screen, Hair | $ 501.00 |
| 3532SP | Phencyclidine Screen, Serum/Plasma | $ 188.00 |
| 3532U | Phencyclidine Screen, Urine | $ 100.00 |
| 8761B | Phencyclidine, Blood | $ 362.00 |
| 8761FL | Phencyclidine, Fluid | $ 314.00 |
| 8761SP | Phencyclidine, Serum/Plasma | $ 452.00 |
| 8761TI | Phencyclidine, Tissue | $ 353.00 |
| 8761U | Phencyclidine, Urine | $ 362.00 |
| 3550B | Phenelzine, Blood | $ 941.00 |
| 3550SP | Phenelzine, Serum/Plasma | $ 941.00 |
| 3550U | Phenelzine, Urine | $ 941.00 |
| 3560B | Pheniramine, Blood | $ 252.00 |
| 3582SP | Phenobarbital - Total/Unbound/Bound, Serum/Plasma | $ 201.00 |
| 3581SP | Phenobarbital - Unbound, Serum/Plasma | $ 128.00 |
| 9416B | Phenobarbital Screen, Blood | $ 220.00 |
| 3580B | Phenobarbital, Blood | $ 142.00 |
| 8633B | Phenobarbital, Blood | $ 564.00 |
| 3580SP | Phenobarbital, Serum/Plasma | $ 149.00 |
| 8633SP | Phenobarbital, Serum/Plasma | $ 488.00 |
| 8633U | Phenobarbital, Urine | $ 341.00 |
| 3621B | Phenol - Free and Total, Blood | $ 173.00 |
| 3621SP | Phenol - Free and Total, Serum/Plasma | $ 173.00 |
| 3621U | Phenol Exposure, Urine | $ 135.00 |
| 3623B | Phenol, Free, Blood | $ 138.00 |
| 3623SP | Phenol, Free, Serum/Plasma | $ 138.00 |
| 3624B | Phenol, Total, Blood | $ 138.00 |
| 9233B | Phensuximide Screen, Blood | $ 152.00 |
| 9233U | Phensuximide Screen, Urine | $ 152.00 |
| 3680B | Phensuximide, Blood | $ 310.00 |
| 3680SP | Phensuximide, Serum/Plasma | $ 230.00 |
| 3680U | Phensuximide, Urine | $ 420.00 |
| 3690B | Phentermine, Blood | $ 230.00 |
| 3690SP | Phentermine, Serum/Plasma | $ 147.00 |
| 3690U | Phentermine, Urine | $ 233.00 |
| 3704SP | Phenylephrine, Serum/Plasma | $ 432.00 |
| 3707B | Phenylethylmalonamide, Blood | $ 610.00 |
| 3707SP | Phenylethylmalonamide, Serum/Plasma | $ 201.00 |
| 9237U | Phenylpropanolamine Screen, Urine | $ 196.00 |
| 3720B | Phenylpropanolamine, Blood | $ 176.00 |
| 3720SP | Phenylpropanolamine, Serum/Plasma | $ 168.00 |
| 3720U | Phenylpropanolamine, Urine | $ 168.00 |
| 3740B | Phenyltoloxamine, Blood | $ 206.00 |
| 3740SP | Phenyltoloxamine, Serum/Plasma | $ 124.00 |
| 3743B | Phenytoin, Blood | $ 123.00 |
| 3743FL | Phenytoin, Fluid | $ 332.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3743SP | Phenytoin, Serum/Plasma | $ 110.00 |
| 3743TI | Phenytoin, Tissue | $ 402.00 |
| 3752B | Phosphatidylethanol, Blood | $ 137.00 |
| 3765B | Phosphorus - Total, Blood | $ 276.00 |
| 3765FL | Phosphorus - Total, Fluid | $ 488.00 |
| 3765SP | Phosphorus - Total, Serum/Plasma | $ 276.00 |
| 3765ST | Phosphorus - Total, Stool | $ 232.00 |
| 3765U | Phosphorus - Total, Urine | $ 276.00 |
| 3099U | Phthalates Panel, Urine | $ 396.00 |
| 3776B | Pimozide, Blood | $ 483.00 |
| 3776SP | Pimozide, Serum/Plasma | $ 483.00 |
| 3779B | Pioglitazone, Blood | $ 137.00 |
| 3779SP | Pioglitazone, Serum/Plasma | $ 137.00 |
| 3781B | Piroxicam, Blood | $ 537.00 |
| 3781SP | Piroxicam, Serum/Plasma | $ 554.00 |
| 3781U | Piroxicam, Urine | $ 346.00 |
| 3783B | Platinum, Blood | $ 191.00 |
| 3783FL | Platinum, Fluid | $ 394.00 |
| 3783SP | Platinum, Serum/Plasma | $ 191.00 |
| 3783U | Platinum, Urine | $ 315.00 |
| 3790B | Posaconazole, Blood | $ 707.00 |
| 3790SP | Posaconazole, Serum/Plasma | $ 456.00 |
| 8064B | Postmortem BHB and Alcohol Profile, Blood (Forensic) | $ 246.00 |
| 8155U | Postmortem Designer Opioids Add-On (Qualitative), Urine (Forensic) | $ 201.00 |
| 8155B | Postmortem Designer Opioids Add-On, Blood (Forensic) | $ 211.00 |
| 8155SP | Postmortem Designer Opioids Add-On, Serum/Plasma (Forensic) | $ 201.00 |
| 8063B | Postmortem, Basic to Expanded Upgrade, Blood (Forensic) | $ 182.00 |
| 8063FL | Postmortem, Basic to Expanded Upgrade, Fluid (Forensic) | $ 417.00 |
| 8063SP | Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic) | $ 182.00 |
| 8063TI | Postmortem, Basic to Expanded Upgrade, Tissue (Forensic) | $ 494.00 |
| 8063U | Postmortem, Basic to Expanded Upgrade, Urine (Forensic) | $ 182.00 |
| 8136B | Postmortem, Basic w/6-MAM Confirmation, Blood (Forensic) | $ 337.00 |
| 8061B | Postmortem, Basic w/o Alcohol, Blood (Forensic) | $ 239.00 |
| 8061TI | Postmortem, Basic w/o Alcohol, Tissue (Forensic) | $ 505.00 |
| 8061U | Postmortem, Basic w/o Alcohol, Urine (Forensic) | $ 239.00 |
| 8083B | Postmortem, Basic w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 375.00 |
| 8041B | Postmortem, Basic w/Vitreous Alcohol Confirmation, Blood (Forensic) | $ 337.00 |
| 8051B | Postmortem, Basic, Blood (Forensic) | $ 290.00 |
| 8051FL | Postmortem, Basic, Fluid (Forensic) | $ 443.00 |
| 8051SP | Postmortem, Basic, Serum/Plasma (Forensic) | $ 290.00 |
| 8051TI | Postmortem, Basic, Tissue (Forensic) | $ 520.00 |
| 8051U | Postmortem, Basic, Urine (Forensic) | $ 290.00 |
| 8135B | Postmortem, Expanded w/6-MAM Confirmation, Blood (Forensic) | $ 469.00 |
| 8062B | Postmortem, Expanded w/o Alcohol, Blood (Forensic) | $ 379.00 |
| 8062FL | Postmortem, Expanded w/o Alcohol, Fluid (Forensic) | $ 648.00 |
| 8062TI | Postmortem, Expanded w/o Alcohol, Tissue (Forensic) | $ 714.00 |
| 8062U | Postmortem, Expanded w/o Alcohol, Urine (Forensic) | $ 379.00 |
| 8084B | Postmortem, Expanded w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 508.00 |
| 8042B | Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) | $ 469.00 |
| 8052B | Postmortem, Expanded, Blood (Forensic) | $ 430.00 |
| 8052FL | Postmortem, Expanded, Fluid (Forensic) | $ 705.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8052SP | Postmortem, Expanded, Serum/Plasma (Forensic) | $ 430.00 |
| 8052TI | Postmortem, Expanded, Tissue (Forensic) | $ 780.00 |
| 8052U | Postmortem, Expanded, Urine (Forensic) | $ 430.00 |
| 8104B | Postmortem, Fire Death Screen, Blood (Forensic) | $ 514.00 |
| 8092B | Postmortem, Prescription Drugs Screen, Blood (Forensic) | $ 742.00 |
| 8092FL | Postmortem, Prescription Drugs Screen, Fluid (Forensic) | $ 941.00 |
| 8092SP | Postmortem, Prescription Drugs Screen, Serum/Plasma (Forensic) | $ 742.00 |
| 8092TI | Postmortem, Prescription Drugs Screen, Tissue (Forensic) | $ 1,007.00 |
| 8092U | Postmortem, Prescription Drugs Screen, Urine (Forensic) | $ 742.00 |
| 8043B | Postmortem, Prescription Screen w/Vitreous Alcohol, Blood (Forensic) | $ 760.00 |
| 8133B | Postmortem, TotalTox™ w/6-MAM Confirmation, Blood (Forensic) | $ 627.00 |
| 8130B | Postmortem, TotalTox™ w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 666.00 |
| 8044B | Postmortem, TotalTox™ w/Vitreous Alcohol, Blood (Forensic) | $ 627.00 |
| 8050U | Postmortem, Urine Screen Add-On (6-MAM Quantification only) (Forensic) | $ 43.00 |
| 3784B | Potassium - Total, Blood (Forensic) | $ 92.00 |
| 3784FL | Potassium - Total, Fluid | $ 213.00 |
| 3784R | Potassium - Total, RBCs | $ 92.00 |
| 3788B | Prazosin, Blood | $ 778.00 |
| 3788SP | Prazosin, Serum/Plasma | $ 483.00 |
| 3795B | Pregabalin, Blood | $ 345.00 |
| 3795SP | Pregabalin, Serum/Plasma | $ 168.00 |
| 3795U | Pregabalin, Urine | $ 460.00 |
| 3900B | Primidone, Phenobarbital and PEMA, Blood | $ 159.00 |
| 3900FL | Primidone, Phenobarbital and PEMA, Fluid | $ 369.00 |
| 3900SP | Primidone, Phenobarbital and PEMA, Serum/Plasma | $ 159.00 |
| 3901SP | Primidone, Serum/Plasma | $ 58.00 |
| 3950B | Prochlorperazine, Blood | $ 137.00 |
| 3950SP | Prochlorperazine, Serum/Plasma | $ 95.00 |
| 3957B | Procyclidine, Blood | $ 179.00 |
| 3957SP | Procyclidine, Serum/Plasma | $ 279.00 |
| 3957U | Procyclidine, Urine | $ 179.00 |
| 3970B | Promethazine, Blood | $ 168.00 |
| 3970SP | Promethazine, Serum/Plasma | $ 168.00 |
| 3970TI | Promethazine, Tissue | $ 446.00 |
| 3970U | Promethazine, Urine | $ 168.00 |
| 3976B | Propafenone, Blood | $ 218.00 |
| 3976SP | Propafenone, Serum/Plasma | $ 132.00 |
| 3974B | Propane, Blood | $ 374.00 |
| 9327B | Propane, Blood | $ 894.00 |
| 3974TI | Propane, Tissue | $ 383.00 |
| 3975B | Propanol, n-, Blood | $ 178.00 |
| 3975SP | Propanol, n-, Serum/Plasma | $ 173.00 |
| 3975U | Propanol, n-, Urine | $ 153.00 |
| 4018U | Propofol Glucuronide, Urine | $ 240.00 |
| 9253B | Propofol Screen, Blood | $ 204.00 |
| 9253SP | Propofol Screen, Serum/Plasma | $ 204.00 |
| 4015B | Propofol, Blood | $ 250.00 |
| 4015SP | Propofol, Serum/Plasma | $ 250.00 |
| 3990B | Propoxyphene and Metabolite, Blood | $ 194.00 |
| 3990FL | Propoxyphene and Metabolite, Fluid | $ 265.00 |
| 3990SP | Propoxyphene and Metabolite, Serum/Plasma | $ 310.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3990U | Propoxyphene and Metabolite, Urine | $ 194.00 |
| 9247B | Propranolol Screen, Blood | $ 96.00 |
| 9247SP | Propranolol Screen, Serum/Plasma | $ 129.00 |
| 4000B | Propranolol, Blood | $ 105.00 |
| 4000FL | Propranolol, Fluid | $ 314.00 |
| 4000SP | Propranolol, Serum/Plasma | $ 152.00 |
| 4000TI | Propranolol, Tissue | $ 383.00 |
| 4000U | Propranolol, Urine | $ 152.00 |
| 4003B | Propylene Glycol, Blood | $ 292.00 |
| 4003SP | Propylene Glycol, Serum/Plasma | $ 194.00 |
| 4003U | Propylene Glycol, Urine | $ 312.00 |
| 9436B | Protriptyline Screen, Blood | $ 190.00 |
| 9436SP | Protriptyline Screen, Serum/Plasma | $ 123.00 |
| 4010B | Protriptyline, Blood | $ 190.00 |
| 8706B | Protriptyline, Blood | $ 488.00 |
| 4010SP | Protriptyline, Serum/Plasma | $ 132.00 |
| 8706SP | Protriptyline, Serum/Plasma | $ 341.00 |
| 9248B | Pseudoephedrine Screen, Blood | $ 184.00 |
| 9248SP | Pseudoephedrine Screen, Serum/Plasma | $ 178.00 |
| 9248U | Pseudoephedrine Screen, Urine | $ 178.00 |
| 9249B | Pseudoephedrine vs Ephedrine Differentiation Screen, Blood | $ 315.00 |
| 9249U | Pseudoephedrine vs Ephedrine Differentiation Screen, Urine | $ 191.00 |
| 4020B | Pseudoephedrine, Blood | $ 154.00 |
| 4020SP | Pseudoephedrine, Serum/Plasma | $ 107.00 |
| 4020U | Pseudoephedrine, Urine | $ 107.00 |
| 4029B | Psilocybin as Psilocin (Qualitative), Blood | $ 467.00 |
| 4029SP | Psilocybin as Psilocin (Qualitative), Serum/Plasma | $ 467.00 |
| 4029U | Psilocybin as Psilocin (Qualitative), Urine | $ 467.00 |
| 4033SP | Pyrazinamide, Serum/Plasma | $ 573.00 |
| 4030B | Pyridine, Blood | $ 418.00 |
| 4030SP | Pyridine, Serum/Plasma | $ 642.00 |
| 4030U | Pyridine, Urine | $ 580.00 |
| 4038B | Pyridostigmine, Blood | $ 868.00 |
| 4038SP | Pyridostigmine, Serum/Plasma | $ 521.00 |
| 4038U | Pyridostigmine, Urine | $ 521.00 |
| 4045B | Pyrimethamine, Blood | $ 502.00 |
| 4045SP | Pyrimethamine, Serum/Plasma | $ 502.00 |
| 4047B | Pyrrolidinophenone Panel, Blood | $ 348.00 |
| 4047SP | Pyrrolidinophenone Panel, Serum/Plasma | $ 348.00 |
| 8088B | Qsymia®, Blood | $ 246.00 |
| 8088SP | Qsymia®, Serum/Plasma | $ 246.00 |
| 81869B | QTOF (MS/MS) Add-On (Qualitative), Blood | $ 107.00 |
| 4051B | Quetiapine, Blood | $ 180.00 |
| 4051FL | Quetiapine, Fluid | $ 391.00 |
| 4051SP | Quetiapine, Serum/Plasma | $ 180.00 |
| 4051TI | Quetiapine, Tissue | $ 462.00 |
| 4051U | Quetiapine, Urine | $ 297.00 |
| 4071B | Quinidine, Blood | $ 579.00 |
| 4071SP | Quinidine, Serum/Plasma | $ 386.00 |
| 4080B | Quinine, Blood | $ 181.00 |
| 4080SP | Quinine, Serum/Plasma | $ 181.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4080U | Quinine, Urine | $ 183.00 |
| 4075B | Quinine/Quinidine Differentiation, Blood | $ 228.00 |
| 4075SP | Quinine/Quinidine Differentiation, Serum/Plasma | $ 241.00 |
| 4086B | Ramelteon and Metabolite, Blood | $ 276.00 |
| 4086SP | Ramelteon and Metabolite, Serum/Plasma | $ 276.00 |
| 4086U | Ramelteon and Metabolite, Urine | $ 276.00 |
| 4085B | Ranitidine, Blood | $ 729.00 |
| 4085SP | Ranitidine, Serum/Plasma | $ 729.00 |
| 4085U | Ranitidine, Urine | $ 729.00 |
| 7064SP | Rapid Plasma Reagin Reflex (RPR) - Send Out | $ 78.00 |
| 7074SP | Rapid Plasma Reagin Titer Reflex (RPRT), Serum/Plasma - Send Out | $ 78.00 |
| 0965B | Recent Cannabis Use Markers, Blood | $ 343.00 |
| 0965SP | Recent Cannabis Use Markers, Serum/Plasma | $ 343.00 |
| 4101B | Repaglinide, Blood | $ 137.00 |
| 4101SP | Repaglinide, Serum/Plasma | $ 137.00 |
| 7087O | Respiratory Pathogen Profile (RP2P1) - Send Out | $ 672.00 |
| 7088O | Rhinovirus (RHINO) - Send Out | $ 1,054.00 |
| 4110SP | Rifampin, Serum/Plasma | $ 224.00 |
| 4105B | Risperidone and Metabolite, Blood | $ 177.00 |
| 4105FL | Risperidone and Metabolite, Fluid | $ 388.00 |
| 4105SP | Risperidone and Metabolite, Serum/Plasma | $ 177.00 |
| 4105TI | Risperidone and Metabolite, Tissue | $ 459.00 |
| 4105U | Risperidone and Metabolite, Urine | $ 292.00 |
| 4114SP | Rivaroxaban, Serum/Plasma | $ 266.00 |
| 4114U | Rivaroxaban, Urine | $ 457.00 |
| 4115B | Ropinirole, Blood | $ 246.00 |
| 4115SP | Ropinirole, Serum/Plasma | $ 246.00 |
| 4120B | Ropivacaine, Blood | $ 329.00 |
| 4120SP | Ropivacaine, Serum/Plasma | $ 348.00 |
| 4120U | Ropivacaine, Urine | $ 329.00 |
| 4102B | Rosiglitazone, Blood | $ 137.00 |
| 4102SP | Rosiglitazone, Serum/Plasma | $ 137.00 |
| 4124B | Rubidium, Blood | $ 228.00 |
| 4124R | Rubidium, RBCs | $ 344.00 |
| 4124SP | Rubidium, Serum/Plasma | $ 228.00 |
| 4124U | Rubidium, Urine | $ 228.00 |
| 4125B | Rufinamide, Blood | $ 208.00 |
| 4125SP | Rufinamide, Serum/Plasma | $ 213.00 |
| 4137B | Salicylate, Blood | $ 248.00 |
| 4137FL | Salicylate, Fluid | $ 226.00 |
| 4137SP | Salicylate, Serum/Plasma | $ 248.00 |
| 4137U | Salicylate, Urine | $ 248.00 |
| 8001B | Salicylates Screen, Blood | $ 80.00 |
| 8001FL | Salicylates Screen, Fluid | $ 290.00 |
| 8001SP | Salicylates Screen, Serum/Plasma | $ 47.00 |
| 8001TI | Salicylates Screen, Tissue | $ 361.00 |
| 8001U | Salicylates Screen, Urine | $ 80.00 |
| 9261B | Scopolamine Screen, Blood | $ 650.00 |
| 9261SP | Scopolamine Screen, Serum/Plasma | $ 650.00 |
| 9261U | Scopolamine Screen, Urine | $ 650.00 |
| 4160B | Scopolamine, Blood | $ 933.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4160SP | Scopolamine, Serum/Plasma | $ 764.00 |
| 4160U | Scopolamine, Urine | $ 764.00 |
| 4170B | Secobarbital, Blood | $ 83.00 |
| 4170SP | Secobarbital, Serum/Plasma | $ 135.00 |
| 4170U | Secobarbital, Urine | $ 132.00 |
| 4180B | Selenium, Blood | $ 113.00 |
| 4180H | Selenium, Hair | $ 541.00 |
| 4180LI | Selenium, Liquid | $ 686.00 |
| 4180N | Selenium, Nails | $ 541.00 |
| 4180R | Selenium, RBCs | $ 113.00 |
| 4180SP | Selenium, Serum/Plasma | $ 113.00 |
| 4180U | Selenium, Urine | $ 132.00 |
| 6317U | Semi Conductor Panel, Urine | $ 631.00 |
| 4195B | Sertraline and Desmethylsertraline, Blood | $ 116.00 |
| 4195FL | Sertraline and Desmethylsertraline, Fluid | $ 329.00 |
| 4195SP | Sertraline and Desmethylsertraline, Serum/Plasma | $ 116.00 |
| 4195TI | Sertraline and Desmethylsertraline, Tissue | $ 399.00 |
| 4195U | Sertraline, Urine | $ 163.00 |
| SHPCHG | Shipping Charge | $ 43.00 |
| 4197B | Sildenafil and Metabolite, Blood | $ 514.00 |
| 4197SP | Sildenafil and Metabolite, Serum/Plasma | $ 514.00 |
| 4197U | Sildenafil and Metabolite, Urine | $ 514.00 |
| 4190B | Silicon, Blood | $ 140.00 |
| 4190SP | Silicon, Serum/Plasma | $ 140.00 |
| 4190U | Silicon, Urine | $ 140.00 |
| 4200B | Silver, Blood | $ 103.00 |
| 4200SP | Silver, Serum/Plasma | $ 103.00 |
| 4200U | Silver, Urine | $ 103.00 |
| 4205SP | Sinemet®, Serum/Plasma | $ 414.00 |
| 4193B | Sirolimus, Blood | $ 216.00 |
| 0641B | Sotalol, Blood | $ 281.00 |
| 0641SP | Sotalol, Serum/Plasma | $ 176.00 |
| 7727SA | Special Request (ME) | $ 898.00 |
| HANDLING | Specimen Handling Fee | $ 49.00 |
| SPEC RET | Specimen Retention | $ 2,600.00 |
| RETURN | Specimen Return/Handling | $ 66.00 |
| 3475U | S-Phenylmercapturic Acid, Urine | $ 243.00 |
| 4211B | Stiripentol, Blood | $ 309.00 |
| 4211SP | Stiripentol, Serum/Plasma | $ 309.00 |
| 4212B | Strontium, Blood | $ 100.00 |
| 4212SP | Strontium, Serum/Plasma | $ 58.00 |
| 4212U | Strontium, Urine | $ 57.00 |
| 4215B | Strychnine, Blood | $ 179.00 |
| 4215FL | Strychnine, Fluid | $ 380.00 |
| 4215SP | Strychnine, Serum/Plasma | $ 179.00 |
| 4215TI | Strychnine, Tissue | $ 427.00 |
| 4215U | Strychnine, Urine | $ 179.00 |
| 4213U | Styrene Exposure Profile, Urine | $ 162.00 |
| 4232B | Styrene, Blood | $ 298.00 |
| 4232SP | Styrene, Serum/Plasma | $ 248.00 |
| 4127B | Suboxone® - Free, Blood | $ 402.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4127FL | Suboxone® - Free, Fluid | $ 441.00 |
| 4127SP | Suboxone® - Free, Serum/Plasma | $ 402.00 |
| 4127TI | Suboxone® - Total, Tissue | $ 470.00 |
| 4127U | Suboxone® - Total, Urine | $ 402.00 |
| 1021B | Substituted Cathinone Panel, Blood | $ 304.00 |
| 1021SP | Substituted Cathinone Panel, Serum/Plasma | $ 304.00 |
| 1021U | Substituted Cathinone Panel, Urine | $ 304.00 |
| 9264B | Sufentanil Screen, Blood | $ 301.00 |
| 9264U | Sufentanil Screen, Urine | $ 334.00 |
| 4240B | Sufentanil, Blood | $ 345.00 |
| 4240FL | Sufentanil, Fluid | $ 531.00 |
| 4240SP | Sufentanil, Serum/Plasma | $ 334.00 |
| 4240U | Sufentanil, Urine | $ 334.00 |
| 4235B | Sulfhemoglobin, Blood | $ 311.00 |
| 4235R | Sulfhemoglobin, RBCs | $ 197.00 |
| 4239SP | Sulfide Exposure Biouptake Marker, Serum/Plasma | $ 496.00 |
| 4245SP | Sulfonamides, Undifferentiated, Serum/Plasma | $ 138.00 |
| 4275B | Sumatriptan, Blood | $ 516.00 |
| 4275SP | Sumatriptan, Serum/Plasma | $ 500.00 |
| 4275U | Sumatriptan, Urine | $ 516.00 |
| 4236B | Suvorexant, Blood | $ 304.00 |
| 4236SP | Suvorexant, Serum/Plasma | $ 311.00 |
| 9562U | Synthetic Cannabinoid Metabolites Screen - Expanded, Urine | $ 140.00 |
| 4283U | Synthetic Cannabinoid Metabolites-Expanded (Qualitative), Urine | $ 104.00 |
| 4282SP | Synthetic Cannabinoids (Qualitative), Serum/Plasma | $ 304.00 |
| 9566B | Synthetic Cannabinoids Screen (Add-On), Blood | $ 204.00 |
| 9560B | Synthetic Cannabinoids Screen, Blood | $ 284.00 |
| 7073SP | Syphilis Serology (SYPHL), Serum/Plasma - Send Out | $ 109.00 |
| 4305B | Tacrine, Blood | $ 534.00 |
| 4305SP | Tacrine, Serum/Plasma | $ 550.00 |
| 4306B | Tacrolimus, Blood | $ 216.00 |
| 4297B | Tadalafil, Blood | $ 640.00 |
| 4297SP | Tadalafil, Serum/Plasma | $ 640.00 |
| 4300B | Talbutal, Blood | $ 261.00 |
| 4303U | Talwin® Nx, Urine | $ 346.00 |
| 4311B | Tamoxifen and Metabolites, Blood | $ 783.00 |
| 4311SP | Tamoxifen and Metabolites, Serum/Plasma | $ 487.00 |
| 4312B | Tapentadol - Free, Blood | $ 414.00 |
| 4312SP | Tapentadol - Free, Serum/Plasma | $ 208.00 |
| 4312U | Tapentadol - Total, Urine | $ 208.00 |
| 4320B | Tellurium, Blood | $ 249.00 |
| 4320SP | Tellurium, Serum/Plasma | $ 249.00 |
| 4320U | Tellurium, Urine | $ 249.00 |
| 4323B | Temazepam and Metabolite, Blood | $ 188.00 |
| 4323SP | Temazepam and Metabolite, Serum/Plasma | $ 188.00 |
| 4323U | Temazepam and Metabolite, Urine | $ 188.00 |
| 4329B | Terazosin, Blood | $ 778.00 |
| 4329SP | Terazosin, Serum/Plasma | $ 778.00 |
| 4326SP | Terbutaline, Serum/Plasma | $ 336.00 |
| 4367B | Teriflunomide (Pre-Pregnancy Monitoring), Blood | $ 346.00 |
| 4367SP | Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma | $ 346.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4366B | Teriflunomide (Therapeutic Drug Monitoring), Blood | $ 346.00 |
| 4366SP | Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma | $ 346.00 |
| 4327B | Terpineol, Blood | $ 271.00 |
| 4333B | Tetrachloroethane, Blood | $ 317.00 |
| 3430B | Tetrachloroethylene, Blood | $ 124.00 |
| 4351B | Tetrafluoroethane and Difluoroethane Panel Add-On, Blood | $ 371.00 |
| 1611A | Tetrafluoroethane and Difluoroethane Panel, Air | $ 478.00 |
| 1611B | Tetrafluoroethane and Difluoroethane Panel, Blood | $ 441.00 |
| 1611FL | Tetrafluoroethane and Difluoroethane Panel, Fluid | $ 623.00 |
| 1611TI | Tetrafluoroethane and Difluoroethane Panel, Tissue | $ 680.00 |
| 1611U | Tetrafluoroethane and Difluoroethane Panel, Urine | $ 478.00 |
| 4355B | Tetrahydrofuran, Blood | $ 249.00 |
| 4355SP | Tetrahydrofuran, Serum/Plasma | $ 292.00 |
| 4355U | Tetrahydrofuran, Urine | $ 264.00 |
| 4350B | Tetrahydrozoline, Blood | $ 405.00 |
| 4350SP | Tetrahydrozoline, Serum/Plasma | $ 405.00 |
| 4350U | Tetrahydrozoline, Urine | $ 405.00 |
| 4370B | Thallium, Blood | $ 149.00 |
| 4370H | Thallium, Hair | $ 414.00 |
| 4370LI | Thallium, Liquid | $ 366.00 |
| 4370N | Thallium, Nails | $ 414.00 |
| 4370SP | Thallium, Serum/Plasma | $ 93.00 |
| 4370U | Thallium, Urine | $ 98.00 |
| 9272B | Thebaine Screen, Blood | $ 831.00 |
| 9272U | Thebaine Screen, Urine | $ 831.00 |
| 4376B | Thebaine, Blood | $ 538.00 |
| 4380B | Theobromine, Blood | $ 176.00 |
| 4380SP | Theobromine, Serum/Plasma | $ 168.00 |
| 4380U | Theobromine, Urine | $ 176.00 |
| 4387B | Theophylline, Blood | $ 138.00 |
| 4387SP | Theophylline, Serum/Plasma | $ 138.00 |
| 4387U | Theophylline, Urine | $ 123.00 |
| 6945H | Therapeutic and Drugs of Abuse Screen, Hair | $ 1,473.00 |
| 4440B | Thiocyanate, Blood | $ 146.00 |
| 4440SP | Thiocyanate, Serum/Plasma | $ 105.00 |
| 4440U | Thiocyanate, Urine | $ 173.00 |
| 9419B | Thiopental and Metabolite Screen, Blood | $ 243.00 |
| 9419SP | Thiopental and Metabolite Screen, Serum/Plasma | $ 170.00 |
| 4450B | Thiopental and Metabolite, Blood | $ 226.00 |
| 8636B | Thiopental and Metabolite, Blood | $ 353.00 |
| 4450SP | Thiopental and Metabolite, Serum/Plasma | $ 215.00 |
| 8636SP | Thiopental and Metabolite, Serum/Plasma | $ 353.00 |
| 9427B | Thioridazine and Metabolite Screen, Blood | $ 190.00 |
| 9427SP | Thioridazine and Metabolite Screen, Serum/Plasma | $ 209.00 |
| 4461B | Thioridazine and Metabolite, Blood | $ 199.00 |
| 8689B | Thioridazine and Metabolite, Blood | $ 564.00 |
| 4461SP | Thioridazine and Metabolite, Serum/Plasma | $ 119.00 |
| 8689SP | Thioridazine and Metabolite, Serum/Plasma | $ 341.00 |
| 4461TI | Thioridazine and Metabolite, Tissue | $ 287.00 |
| 4461U | Thioridazine and Metabolite, Urine | $ 119.00 |
| 4472B | Thiosulfate, Blood | $ 257.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4472SP | Thiosulfate, Serum/Plasma | $ 257.00 |
| 4472U | Thiosulfate, Urine | $ 257.00 |
| 9276B | Thiothixene (Cis Isomer) Screen, Blood | $ 114.00 |
| 9276SP | Thiothixene (Cis Isomer) Screen, Serum/Plasma | $ 184.00 |
| 9276U | Thiothixene (Cis Isomer) Screen, Urine | $ 114.00 |
| 4469B | Thiothixene (Cis Isomer), Blood | $ 122.00 |
| 4469SP | Thiothixene (Cis Isomer), Serum/Plasma | $ 122.00 |
| 4469U | Thiothixene (Cis Isomer), Urine | $ 122.00 |
| 4478SP | Thorium, Serum/Plasma | $ 158.00 |
| 4478U | Thorium, Urine | $ 263.00 |
| 4479B | Tiagabine, Blood | $ 188.00 |
| 4479SP | Tiagabine, Serum/Plasma | $ 135.00 |
| 4483B | Tianeptine, Blood | $ 338.00 |
| 4483SP | Tianeptine, Serum/Plasma | $ 338.00 |
| 4483U | Tianeptine, Urine | $ 338.00 |
| 4482B | Timolol, Blood | $ 259.00 |
| 4482SP | Timolol, Serum/Plasma | $ 427.00 |
| 4485B | Tin - Total, Blood | $ 148.00 |
| 4485H | Tin - Total, Hair | $ 503.00 |
| 4485SP | Tin - Total, Serum/Plasma | $ 148.00 |
| 4485TI | Tin - Total, Tissue | $ 95.00 |
| 4485U | Tin - Total, Urine | $ 148.00 |
| 4486B | Titanium, Blood | $ 152.00 |
| 4486FL | Titanium, Fluid | $ 356.00 |
| 4486SP | Titanium, Serum/Plasma | $ 152.00 |
| 4486U | Titanium, Urine | $ 228.00 |
| 4487B | Tizanidine, Blood | $ 505.00 |
| 4487SP | Tizanidine, Serum/Plasma | $ 505.00 |
| 4489B | Tofacitinib, Blood | $ 315.00 |
| 4489SP | Tofacitinib, Serum/Plasma | $ 315.00 |
| 4490SP | Tolazamide, Serum/Plasma | $ 390.00 |
| 4500SP | Tolbutamide, Serum/Plasma | $ 390.00 |
| 4505B | Tolmetin, Blood | $ 412.00 |
| 4505SP | Tolmetin, Serum/Plasma | $ 456.00 |
| 4513U | Toluene Exposure, Urine | $ 190.00 |
| 4510B | Toluene, Blood | $ 124.00 |
| 4519B | Topiramate, Blood | $ 147.00 |
| 4519FL | Topiramate, Fluid | $ 217.00 |
| 4519SP | Topiramate, Serum/Plasma | $ 147.00 |
| 4519TI | Topiramate, Tissue | $ 399.00 |
| 4519U | Topiramate, Urine | $ 233.00 |
| 4525B | Torsemide, Blood | $ 168.00 |
| 4525SP | Torsemide, Serum/Plasma | $ 139.00 |
| 0470UH | Total, Inorganic Arsenic, 24 Hour Urine (+Creatinine) | $ 168.00 |
| 9288B | Tramadol and Metabolite Screen, Blood | $ 142.00 |
| 9288FL | Tramadol and Metabolite Screen, Fluid | $ 340.00 |
| 9288SP | Tramadol and Metabolite Screen, Serum/Plasma | $ 152.00 |
| 4531B | Tramadol and Metabolite, Blood | $ 341.00 |
| 4531SP | Tramadol and Metabolite, Serum/Plasma | $ 153.00 |
| 4533U | Tramadol and Metabolite, Urine | $ 341.00 |
| 9287U | Tramadol Screen, Urine | $ 96.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4535B | Trazodone and mCPP, Blood | $ 95.00 |
| 4535SP | Trazodone and mCPP, Serum/Plasma | $ 95.00 |
| 4535U | Trazodone and mCPP, Urine | $ 95.00 |
| 4535FL | Trazodone, Fluid | $ 308.00 |
| 4535TI | Trazodone, Tissue | $ 381.00 |
| 4540B | Triamterene, Blood | $ 750.00 |
| 4540SP | Triamterene, Serum/Plasma | $ 779.00 |
| 4543B | Triazolam and Metabolite, Blood | $ 168.00 |
| 4543SP | Triazolam and Metabolite, Serum/Plasma | $ 268.00 |
| 4543U | Triazolam as Metabolite, Urine | $ 168.00 |
| 4624B | Trichloroacetic Acid, Blood | $ 401.00 |
| 4624SP | Trichloroacetic Acid, Serum/Plasma | $ 401.00 |
| 4624U | Trichloroacetic Acid, Urine | $ 158.00 |
| 4640B | Trichloroethanol - Free, Blood | $ 431.00 |
| 4640SP | Trichloroethanol - Free, Serum/Plasma | $ 431.00 |
| 4658U | Trichloroethylene Exposure, Urine | $ 344.00 |
| 4650B | Trichloroethylene, Blood | $ 220.00 |
| 4650SP | Trichloroethylene, Serum/Plasma | $ 354.00 |
| 4660B | Trifluoperazine, Blood | $ 573.00 |
| 4660SP | Trifluoperazine, Serum/Plasma | $ 184.00 |
| 4680B | Trihexyphenidyl, Blood | $ 232.00 |
| 4680SP | Trihexyphenidyl, Serum/Plasma | $ 232.00 |
| 4680U | Trihexyphenidyl, Urine | $ 232.00 |
| 4700B | Trimethadione and Metabolite, Blood | $ 152.00 |
| 4700SP | Trimethadione and Metabolite, Serum/Plasma | $ 168.00 |
| 4700U | Trimethadione and Metabolite, Urine | $ 188.00 |
| 4704B | Trimethoprim, Blood | $ 190.00 |
| 4704SP | Trimethoprim, Serum/Plasma | $ 184.00 |
| 4704U | Trimethoprim, Urine | $ 184.00 |
| 4706B | Trimipramine and Metabolite, Blood | $ 218.00 |
| 8708B | Trimipramine and Metabolite, Blood | $ 341.00 |
| 4706SP | Trimipramine and Metabolite, Serum/Plasma | $ 209.00 |
| 8708SP | Trimipramine and Metabolite, Serum/Plasma | $ 564.00 |
| 4706U | Trimipramine and Metabolite, Urine | $ 132.00 |
| 8708U | Trimipramine and Metabolite, Urine | $ 488.00 |
| 4720B | Triprolidine, Blood | $ 159.00 |
| 4720SP | Triprolidine, Serum/Plasma | $ 259.00 |
| 7030SP | Tryptase, Serum/Plasma - Send Out | $ 154.00 |
| 4730B | Tungsten, Blood | $ 188.00 |
| 4730SP | Tungsten, Serum/Plasma | $ 188.00 |
| 4730U | Tungsten, Urine | $ 188.00 |
| 4755UH | Uranium, 24 Hour Urine | $ 188.00 |
| 4755U | Uranium, Urine | $ 188.00 |
| 4766SP | Valacyclovir as Metabolite, Serum/Plasma | $ 250.00 |
| 4759SP | Valproic Acid - Unbound and Total, Serum/Plasma | $ 205.00 |
| 4757B | Valproic Acid, Blood | $ 172.00 |
| 4757FL | Valproic Acid, Fluid | $ 240.00 |
| 4757SP | Valproic Acid, Serum/Plasma | $ 172.00 |
| 4757TI | Valproic Acid, Tissue | $ 451.00 |
| 4761SP | Valproic Acid, Unbound, Serum/Plasma | $ 130.00 |
| 4757U | Valproic Acid, Urine | $ 172.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4765B | Vanadium, Blood | $ 113.00 |
| 4765R | Vanadium, RBCs | $ 113.00 |
| 4765SP | Vanadium, Serum/Plasma | $ 113.00 |
| 4765U | Vanadium, Urine | $ 119.00 |
| 4764B | Vardenafil and Metabolite, Blood | $ 604.00 |
| 4764SP | Vardenafil and Metabolite, Serum/Plasma | $ 604.00 |
| 9447B | Venlafaxine and Metabolite Screen, Blood | $ 287.00 |
| 9447U | Venlafaxine and Metabolite Screen, Urine | $ 287.00 |
| 4767B | Venlafaxine and Metabolite, Blood | $ 347.00 |
| 4767FL | Venlafaxine and Metabolite, Fluid | $ 385.00 |
| 4767SP | Venlafaxine and Metabolite, Serum/Plasma | $ 347.00 |
| 4767TI | Venlafaxine and Metabolite, Tissue | $ 616.00 |
| 4767U | Venlafaxine and Metabolite, Urine | $ 536.00 |
| 4770B | Verapamil, Blood | $ 209.00 |
| 4770FL | Verapamil, Fluid | $ 366.00 |
| 4770SP | Verapamil, Serum/Plasma | $ 132.00 |
| 4770TI | Verapamil, Tissue | $ 438.00 |
| 4770U | Verapamil, Urine | $ 132.00 |
| 4774SP | Vigabatrin, Serum/Plasma | $ 445.00 |
| 4790B | Vilazodone, Blood | $ 254.00 |
| 4790SP | Vilazodone, Serum/Plasma | $ 254.00 |
| 4778U | Vinyl Chloride Metabolite, Urine | $ 464.00 |
| 4780SP | Vitamin B3 (Niacin and Metabolites), Serum/Plasma | $ 229.00 |
| 4783B | Voclosporin, Blood | $ 205.00 |
| 2415B | Volatile and Halocarbon Intoxicants, Blood | $ 131.00 |
| 2415FL | Volatile and Halocarbon Intoxicants, Fluid | $ 182.00 |
| 2415TI | Volatile and Halocarbon Intoxicants, Tissue | $ 212.00 |
| 4782B | Voriconazole, Blood | $ 190.00 |
| 4782SP | Voriconazole, Serum/Plasma | $ 467.00 |
| 4791FL | Vortioxetine, Fluid | $ 408.00 |
| 4791SP | Vortioxetine, Serum/Plasma | $ 215.00 |
| 4800B | Warfarin, Blood | $ 110.00 |
| 4800SP | Warfarin, Serum/Plasma | $ 110.00 |
| 4815B | Xylazine, Blood | $ 347.00 |
| 4815SP | Xylazine, Serum/Plasma | $ 347.00 |
| 4815TI | Xylazine, Tissue | $ 648.00 |
| 4815U | Xylazine, Urine | $ 347.00 |
| 4821U | Xylene Exposure Panel, Urine | $ 173.00 |
| 4820B | Xylenes Panel, Blood | $ 131.00 |
| 4830B | Yohimbine, Blood | $ 868.00 |
| 4830SP | Yohimbine, Serum/Plasma | $ 552.00 |
| 4830U | Yohimbine, Urine | $ 552.00 |
| 4835B | Zaleplon, Blood | $ 267.00 |
| 4835SP | Zaleplon, Serum/Plasma | $ 259.00 |
| 4835U | Zaleplon, Urine | $ 259.00 |
| 4844B | Zinc, Blood | $ 69.00 |
| 4844FL | Zinc, Fluid | $ 276.00 |
| 4844H | Zinc, Hair | $ 405.00 |
| 4844LI | Zinc, Liquid | $ 555.00 |
| 4844N | Zinc, Nails | $ 405.00 |
| 4844R | Zinc, RBCs | $ 69.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4844SP | Zinc, Serum/Plasma | $ 69.00 |
| 4844U | Zinc, Urine | $ 113.00 |
| 4860B | Ziprasidone, Blood | $ 158.00 |
| 4860SP | Ziprasidone, Serum/Plasma | $ 158.00 |
| 4870SP | Zirconium, Serum/Plasma | $ 203.00 |
| 2478U | Zolpidem and Metabolites, Urine | $ 267.00 |
| 2483B | Zolpidem, Blood | $ 203.00 |
| 2483FL | Zolpidem, Fluid | $ 412.00 |
| 2483SP | Zolpidem, Serum/Plasma | $ 203.00 |
| 2483TI | Zolpidem, Tissue | $ 482.00 |
| 4884B | Zonisamide, Blood | $ 208.00 |
| 4884SP | Zonisamide, Serum/Plasma | $ 208.00 |
| 4885B | ZPP (Zinc Protoporphyrin), Blood | $ 77.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING**<br>*NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5441B | Acepromazine Confirmation (Qualitative), Blood | $ 149.00 |
| 5441SP | Acepromazine Confirmation (Qualitative), Serum/Plasma | $ 149.00 |
| 5441U | Acepromazine Confirmation (Qualitative), Urine | $ 149.00 |
| 5401B | Acetaminophen Confirmation, Blood | $ 167.00 |
| 5401SP | Acetaminophen Confirmation, Serum/Plasma | $ 167.00 |
| 5401U | Acetaminophen Confirmation, Urine | $ 167.00 |
| 53250B | Alcohols and Acetone Confirmation, Blood | $ 92.00 |
| 53250FL | Alcohols and Acetone Confirmation, Fluid | $ 128.00 |
| 53250SP | Alcohols and Acetone Confirmation, Serum/Plasma | $ 92.00 |
| 53250U | Alcohols and Acetone Confirmation, Urine | $ 111.00 |
| 53249FL | Alcohols and Acetone Confirmation, Vitreous Fluid (Forensic) | $ 109.00 |
| 5659U | Alfentanil Confirmation, Urine | $ 131.00 |
| 5444SP | Amantadine Confirmation (Qualitative), Serum/Plasma | $ 262.00 |
| 5446B | Amitriptyline and Metabolite Confirmation (Qualitative), Blood | $ 151.00 |
| 5446SP | Amitriptyline and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 151.00 |
| 5446U | Amitriptyline and Metabolite Confirmation (Qualitative), Urine | $ 151.00 |
| 5684ME | Amphetamines Confirmation (Qualitative), Meconium | $ 284.00 |
| 5684B | Amphetamines Confirmation, Blood | $ 230.00 |
| 5684FL | Amphetamines Confirmation, Fluid | $ 440.00 |
| 5684SP | Amphetamines Confirmation, Serum/Plasma | $ 230.00 |
| 5684TI | Amphetamines Confirmation, Tissue | $ 370.00 |
| 5684U | Amphetamines Confirmation, Urine | $ 230.00 |
| 5223U | Amphetamines Quantitation/Confirmation, Urine | $ 213.00 |
| 5125U | Anabasine Confirmation, Urine | $ 135.00 |
| 5450B | Antidepressants Confirmation (Qualitative), Blood | $ 175.00 |
| 5450SP | Antidepressants Confirmation (Qualitative), Serum/Plasma | $ 175.00 |
| 5450U | Antidepressants Confirmation (Qualitative), Urine | $ 175.00 |
| 5454B | Atropine Confirmation, Blood | $ 590.00 |
| 5454SP | Atropine Confirmation, Serum/Plasma | $ 590.00 |
| 5454U | Atropine Confirmation, Urine | $ 590.00 |
| 5652ME | Barbiturates Confirmation (Qualitative), Meconium | $ 292.00 |
| 5652B | Barbiturates Confirmation, Blood | $ 292.00 |
| 5652FL | Barbiturates Confirmation, Fluid | $ 471.00 |
| 5652SP | Barbiturates Confirmation, Serum/Plasma | $ 292.00 |
| 5652TI | Barbiturates Confirmation, Tissue | $ 529.00 |
| 5652U | Barbiturates Confirmation, Urine | $ 201.00 |
| 5641ME | Benzodiazepines Confirmation (Qualitative), Meconium | $ 277.00 |
| 5641B | Benzodiazepines Confirmation, Blood | $ 224.00 |
| 5641FL | Benzodiazepines Confirmation, Fluid | $ 293.00 |
| 5641SP | Benzodiazepines Confirmation, Serum/Plasma | $ 224.00 |
| 5641TI | Benzodiazepines Confirmation, Tissue | $ 330.00 |
| 5641U | Benzodiazepines Confirmation, Urine | $ 218.00 |
| 5463B | Brompheniramine Confirmation (Qualitative), Blood | $ 172.00 |
| 53167U | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine | $ 93.00 |
| 5466B | Bupropion and Metabolite Confirmation, Blood | $ 160.00 |
| 5466SP | Bupropion and Metabolite Confirmation, Serum/Plasma | $ 160.00 |
| 5466TI | Bupropion and Metabolite Confirmation, Tissue | $ 440.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING**<br>*NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5466U | Bupropion and Metabolite Confirmation, Urine | $ 160.00 |
| 5646ME | Cannabinoids Confirmation (Qualitative), Meconium | $ 285.00 |
| 5646B | Cannabinoids Confirmation, Blood | $ 232.00 |
| 5646FL | Cannabinoids Confirmation, Fluid | $ 302.00 |
| 5646SP | Cannabinoids Confirmation, Serum/Plasma | $ 232.00 |
| 5646TI | Cannabinoids Confirmation, Tissue | $ 339.00 |
| 5646U | Cannabinoids Confirmation, Urine | $ 177.00 |
| 5654B | Carbon Monoxide Exposure Biouptake Confirmation, Blood | $ 104.00 |
| 5656B | Carbon Monoxide Exposure Biouptake Confirmation, Blood (Forensic) | $ 108.00 |
| 5479B | Carisoprodol and Metabolite Confirmation, Blood | $ 248.00 |
| 5479FL | Carisoprodol and Metabolite Confirmation, Fluid | $ 459.00 |
| 5479SP | Carisoprodol and Metabolite Confirmation, Serum/Plasma | $ 248.00 |
| 5485B | Chlorpromazine Confirmation (Qualitative), Blood | $ 220.00 |
| 5485SP | Chlorpromazine Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5485U | Chlorpromazine Confirmation (Qualitative), Urine | $ 220.00 |
| 5487B | Clomipramine and Metabolite Confirmation (Qualitative), Blood | $ 220.00 |
| 5487SP | Clomipramine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5487U | Clomipramine and Metabolite Confirmation (Qualitative), Urine | $ 220.00 |
| 5488B | Clonazepam and Metabolite Confirmation, Blood | $ 412.00 |
| 5488FL | Clonazepam and Metabolite Confirmation, Fluid | $ 332.00 |
| 5488SP | Clonazepam and Metabolite Confirmation, Serum/Plasma | $ 261.00 |
| 5489U | Clonazepam as Metabolite Confirmation, Urine | $ 261.00 |
| 5637ME | Cocaine and Metabolites Confirmation (Qualitative), Meconium | $ 271.00 |
| 5637B | Cocaine and Metabolites Confirmation, Blood | $ 218.00 |
| 5637FL | Cocaine and Metabolites Confirmation, Fluid | $ 408.00 |
| 5637SP | Cocaine and Metabolites Confirmation, Serum/Plasma | $ 218.00 |
| 5637TI | Cocaine and Metabolites Confirmation, Tissue | $ 470.00 |
| 5637U | Cocaine and Metabolites Confirmation, Urine | $ 218.00 |
| 5415U | Codeine - Total (Conjugated/Unconjugated) Confirmation, Urine | $ 248.00 |
| 5636B | Cyanide Confirmation (Qualitative), Blood | $ 112.00 |
| 5647B | Cyanide Confirmation, Blood (Forensic) | $ 104.00 |
| 5495U | Dextro / Levo Methorphan Confirmation - Total, Urine | $ 243.00 |
| 5495SP | Dextro / Levo Methorphan Confirmation, Serum/Plasma | $ 243.00 |
| 5506B | Disopyramide Confirmation (Qualitative), Blood | $ 124.00 |
| 5506SP | Disopyramide Confirmation (Qualitative), Serum/Plasma | $ 124.00 |
| 5509B | Doxepin and Metabolite Confirmation (Qualitative), Blood | $ 155.00 |
| 5509U | Doxepin and Metabolite Confirmation (Qualitative), Urine | $ 155.00 |
| 5510B | Doxylamine Confirmation (Qualitative), Blood | $ 196.00 |
| 5510SP | Doxylamine Confirmation (Qualitative), Serum/Plasma | $ 196.00 |
| 5511B | Ephedrine Confirmation, Blood | $ 154.00 |
| 53251B | Ethanol Confirmation, Blood | $ 93.00 |
| 53251FL | Ethanol Confirmation, Fluid | $ 130.00 |
| 53251SP | Ethanol Confirmation, Serum/Plasma | $ 93.00 |
| 53251TI | Ethanol Confirmation, Tissue | $ 166.00 |
| 53251U | Ethanol Confirmation, Urine | $ 114.00 |
| 5517B | Ethosuximide Confirmation (Qualitative), Blood | $ 189.00 |
| 5517SP | Ethosuximide Confirmation (Qualitative), Serum/Plasma | $ 189.00 |
| 5517U | Ethosuximide Confirmation (Qualitative), Urine | $ 189.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5643B | Fentanyl and Acetyl Fentanyl Confirmation, Blood | $ 232.00 |
| 5643FL | Fentanyl and Acetyl Fentanyl Confirmation, Fluid | $ 302.00 |
| 5643SP | Fentanyl and Acetyl Fentanyl Confirmation, Serum/Plasma | $ 232.00 |
| 5643TI | Fentanyl and Acetyl Fentanyl Confirmation, Tissue | $ 330.00 |
| 5643U | Fentanyl and Acetyl Fentanyl Confirmation, Urine | $ 232.00 |
| 5640B | Fentanyl and Metabolite Confirmation, Blood | $ 173.00 |
| 5640FL | Fentanyl and Metabolite Confirmation, Fluid | $ 242.00 |
| 5640SP | Fentanyl and Metabolite Confirmation, Serum/Plasma | $ 173.00 |
| 5640TI | Fentanyl and Metabolite Confirmation, Tissue | $ 276.00 |
| 5728B | Flunitrazepam and Metabolites Confirmation, Blood | $ 249.00 |
| 5728SP | Flunitrazepam and Metabolites Confirmation, Serum/Plasma | $ 249.00 |
| 5728TI | Flunitrazepam and Metabolites Confirmation, Tissue | $ 354.00 |
| 5728U | Flunitrazepam and Metabolites Confirmation, Urine | $ 249.00 |
| 5524B | Fluoxetine and Metabolite Confirmation, Blood | $ 139.00 |
| 5524SP | Fluoxetine and Metabolite Confirmation, Serum/Plasma | $ 139.00 |
| 5524U | Fluoxetine and Metabolite Confirmation, Urine | $ 139.00 |
| 5526B | Glutethimide Confirmation (Qualitative), Blood | $ 139.00 |
| 5526SP | Glutethimide Confirmation (Qualitative), Serum/Plasma | $ 139.00 |
| 5527B | Haloperidol Confirmation, Blood | $ 230.00 |
| 5527SP | Haloperidol Confirmation, Serum/Plasma | $ 230.00 |
| 5686B | Heroin Metabolites - Free (Unconjugated) Confirmation, Blood | $ 319.00 |
| 5686SP | Heroin Metabolites - Free (Unconjugated) Confirmation, Serum/Plasma | $ 319.00 |
| 5707U | Heroin Metabolites - Free (Unconjugated) Confirmation, Urine | $ 315.00 |
| 5536B | Hydrocodone and Metabolites - Free (Unconjugated) Confirmation, Blood | $ 235.00 |
| 5536SP | Hydrocodone and Metabolites - Free (Unconjugated) Confirmation, Serum/Plasma | $ 235.00 |
| 5532B | Imipramine and Metabolite Confirmation (Qualitative), Blood | $ 146.00 |
| 5532SP | Imipramine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 146.00 |
| 5532U | Imipramine and Metabolite Confirmation (Qualitative), Urine | $ 146.00 |
| 5534B | Ketamine and Metabolite Confirmation, Blood | $ 218.00 |
| 5534SP | Ketamine and Metabolite Confirmation, Serum/Plasma | $ 218.00 |
| 5534U | Ketamine and Metabolite Confirmation, Urine | $ 218.00 |
| 5613B | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Blood | $ 209.00 |
| 5613SP | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Serum/Plasma | $ 209.00 |
| 5613U | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Urine | $ 209.00 |
| 5811B | LSD Confirmation, Blood | $ 191.00 |
| 5811SP | LSD Confirmation, Serum/Plasma | $ 191.00 |
| 5811U | LSD Confirmation, Urine | $ 191.00 |
| 5553SP | Meclizine Confirmation, Serum/Plasma | $ 166.00 |
| 5555B | Meperidine and Metabolite Confirmation (Qualitative), Blood | $ 146.00 |
| 5555SP | Meperidine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 146.00 |
| 5555U | Meperidine and Metabolite Confirmation, Urine | $ 220.00 |
| 5560SP | Mepivacaine Confirmation (Qualitative), Serum/Plasma | $ 188.00 |
| 5417B | Mescaline Confirmation (Qualitative), Blood | $ 248.00 |
| 5417SP | Mescaline Confirmation (Qualitative), Serum/Plasma | $ 248.00 |
| 5417U | Mescaline Confirmation (Qualitative), Urine | $ 248.00 |
| 5682ME | Methadone and Metabolite Confirmation (Qualitative), Meconium | $ 305.00 |
| 5682B | Methadone and Metabolite Confirmation, Blood | $ 268.00 |
| 5682FL | Methadone and Metabolite Confirmation, Fluid | $ 340.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5682SP | Methadone and Metabolite Confirmation, Serum/Plasma | $ 268.00 |
| 5682TI | Methadone and Metabolite Confirmation, Tissue | $ 373.00 |
| 5682U | Methadone and Metabolite Confirmation, Urine | $ 268.00 |
| 5687B | Methamphetamine and Metabolite Confirmation, Blood | $ 191.00 |
| 5687SP | Methamphetamine and Metabolite Confirmation, Serum/Plasma | $ 160.00 |
| 5687U | Methamphetamine and Metabolite Confirmation, Urine | $ 356.00 |
| 5696B | Methylenedioxymethamphetamine and Metabolite Confirmation, Blood | $ 132.00 |
| 5696SP | Methylenedioxymethamphetamine and Metabolite Confirmation, Serum/Plasma | $ 132.00 |
| 5696U | Methylenedioxymethamphetamine and Metabolite Confirmation, Urine | $ 132.00 |
| 5584B | Mexiletine Confirmation (Qualitative), Blood | $ 150.00 |
| 5584SP | Mexiletine Confirmation (Qualitative), Serum/Plasma | $ 150.00 |
| 5674B | Nicotine and Metabolite Confirmation, Blood | $ 135.00 |
| 5674SP | Nicotine and Metabolite Confirmation, Serum/Plasma | $ 135.00 |
| 5674U | Nicotine and Metabolite with Anabasine Confirmation, Urine | $ 135.00 |
| 5589B | Nitrazepam and Metabolite Confirmation, Blood | $ 365.00 |
| 5589SP | Nitrazepam and Metabolite Confirmation, Serum/Plasma | $ 284.00 |
| 5593B | Nortriptyline Confirmation (Qualitative), Blood | $ 90.00 |
| 5593U | Nortriptyline Confirmation (Qualitative), Urine | $ 90.00 |
| 5645B | Opiates - Free (Unconjugated) Confirmation, Blood | $ 267.00 |
| 5645FL | Opiates - Free (Unconjugated) Confirmation, Fluid | $ 399.00 |
| 5645SP | Opiates - Free (Unconjugated) Confirmation, Serum/Plasma | $ 267.00 |
| 5645U | Opiates - Free (Unconjugated) Confirmation, Urine | $ 285.00 |
| 5645ME | Opiates - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Meconium | $ 386.00 |
| 5698TI | Opiates - Total (Conjugated/Unconjugated) Confirmation, Tissue | $ 456.00 |
| 5612B | Orphenadrine Confirmation (Qualitative), Blood | $ 220.00 |
| 5557B | Oxycodone and Metabolite - Free (Unconjugated) Confirmation, Blood | $ 190.00 |
| 5557SP | Oxycodone and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma | $ 116.00 |
| 5615B | Papaverine Confirmation (Qualitative), Blood | $ 203.00 |
| 5618B | Pentazocine Confirmation (Qualitative), Blood | $ 146.00 |
| 5618SP | Pentazocine Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5618U | Pentazocine Confirmation (Qualitative), Urine | $ 146.00 |
| 5657ME | Phencyclidine Confirmation (Qualitative), Meconium | $ 346.00 |
| 5657B | Phencyclidine Confirmation, Blood | $ 285.00 |
| 5657FL | Phencyclidine Confirmation, Fluid | $ 355.00 |
| 5657SP | Phencyclidine Confirmation, Serum/Plasma | $ 285.00 |
| 5657TI | Phencyclidine Confirmation, Tissue | $ 390.00 |
| 5657U | Phencyclidine Confirmation, Urine | $ 285.00 |
| 5544B | Phenobarbital Confirmation, Blood | $ 187.00 |
| 5546B | Phensuximide Confirmation (Qualitative), Blood | $ 189.00 |
| 5546U | Phensuximide Confirmation (Qualitative), Urine | $ 189.00 |
| 5548U | Phenylpropanolamine Confirmation, Urine | $ 104.00 |
| 5726B | Propofol Confirmation (Qualitative), Blood | $ 204.00 |
| 5726SP | Propofol Confirmation (Qualitative), Serum/Plasma | $ 204.00 |
| 5433B | Propranolol Confirmation, Blood | $ 96.00 |
| 5433SP | Propranolol Confirmation, Serum/Plasma | $ 96.00 |
| 5566B | Protriptyline Confirmation (Qualitative), Blood | $ 196.00 |
| 5566SP | Protriptyline Confirmation (Qualitative), Serum/Plasma | $ 196.00 |
| 5568B | Pseudoephedrine Confirmation, Blood | $ 139.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5568SP | Pseudoephedrine Confirmation, Serum/Plasma | $ 139.00 |
| 5568U | Pseudoephedrine Confirmation, Urine | $ 139.00 |
| 5569B | Pseudoephedrine vs Ephedrine Differentiation Confirmation, Blood | $ 230.00 |
| 5569U | Pseudoephedrine vs Ephedrine Differentiation Confirmation, Urine | $ 230.00 |
| 5438B | Salicylate Confirmation, Blood | $ 144.00 |
| 5438FL | Salicylate Confirmation, Fluid | $ 215.00 |
| 5438SP | Salicylate Confirmation, Serum/Plasma | $ 144.00 |
| 5438TI | Salicylate Confirmation, Tissue | $ 250.00 |
| 5438U | Salicylate Confirmation, Urine | $ 144.00 |
| 5583B | Scopolamine Confirmation, Blood | $ 836.00 |
| 5583SP | Scopolamine Confirmation, Serum/Plasma | $ 650.00 |
| 5583U | Scopolamine Confirmation, Urine | $ 650.00 |
| 5579B | Sufentanil Confirmation, Blood | $ 203.00 |
| 5579U | Sufentanil Confirmation, Urine | $ 320.00 |
| 5596B | Thebaine Confirmation (Qualitative), Blood | $ 228.00 |
| 5596U | Thebaine Confirmation (Qualitative), Urine | $ 228.00 |
| 5600B | Thiopental and Metabolite Confirmation (Qualitative), Blood | $ 193.00 |
| 5600SP | Thiopental and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 193.00 |
| 5693B | Thioridazine and Metabolite Confirmation (Qualitative), Blood | $ 148.00 |
| 5693SP | Thioridazine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 224.00 |
| 5602B | Thiothixene (Cis Isomer) Confirmation (Qualitative), Blood | $ 193.00 |
| 5602SP | Thiothixene (Cis Isomer) Confirmation (Qualitative), Serum/Plasma | $ 305.00 |
| 5602U | Thiothixene (Cis Isomer) Confirmation (Qualitative), Urine | $ 193.00 |
| 5626B | Tramadol and Metabolite Confirmation, Blood | $ 311.00 |
| 5626FL | Tramadol and Metabolite Confirmation, Fluid | $ 383.00 |
| 5626SP | Tramadol and Metabolite Confirmation, Serum/Plasma | $ 311.00 |
| 5626U | Tramadol and Metabolite Confirmation, Urine | $ 311.00 |
| 5727B | Venlafaxine and Metabolite Confirmation, Blood | $ 317.00 |
| 5727U | Venlafaxine and Metabolite Confirmation, Urine | $ 317.00 |

**CRIME LABORATORY SERVICES**

NMS Labs Crime Laboratory has a full menu of forensic chemistry services available, including illicit and pharmaceutical drug identification. For a current fee schedules for crime laboratory services, please contact us via email: forensics@nmslabs.com or by phone at:1-866-522-2216.

**EXPERT SERVICES**

NMS Labs scientists are available to provide expert opinions and scientifically sound support at various points in the investigation process including depositions, expert courtroom testimony and independent case review. For a current fee schedule for Expert Services, please contact us via emal: expertservices@nmslabs.com or by phone at 1-844-276-0768.

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 0264UH | Aluminum, 24 Hour Urine | $ 96.00 |
| 0264B | Aluminum, Blood | $ 167.00 |
| 0264FL | Aluminum, Fluid | $ 516.00 |
| 0264H | Aluminum, Hair | $ 541.00 |
| 0264LI | Aluminum, Liquid | $ 482.00 |
| 0264R | Aluminum, RBCs | $ 93.00 |
| 0264SP | Aluminum, Serum/Plasma | $ 93.00 |
| 0264TI | Aluminum, Tissue | $ 499.00 |
| 0264U | Aluminum, Urine | $ 175.00 |
| 0410B | Antimony, Blood | $ 93.00 |
| 0410H | Antimony, Hair | $ 541.00 |
| 0410LI | Antimony, Liquid | $ 324.00 |
| 0410N | Antimony, Nails | $ 541.00 |
| 0410R | Antimony, RBCs | $ 93.00 |
| 0410SP | Antimony, Serum/Plasma | $ 93.00 |
| 0410U | Antimony, Urine | $ 93.00 |
| 0460UH | Arsenic, 24 Hour Urine | $ 115.00 |
| 0460B | Arsenic, Blood | $ 115.00 |
| 0460FL | Arsenic, Fluid | $ 327.00 |
| 0460H | Arsenic, Hair | $ 710.00 |
| 0460N | Arsenic, Nails | $ 487.00 |
| 0460R | Arsenic, RBCs | $ 115.00 |
| 0460SP | Arsenic, Serum/Plasma | $ 115.00 |
| 0460TI | Arsenic, Tissue | $ 398.00 |
| 0468UH | Arsenic, Total Inorganic, 24 Hour Urine | $ 168.00 |
| 0468U | Arsenic, Total Inorganic, Urine | $ 168.00 |
| 0460U | Arsenic, Urine | $ 115.00 |
| 0519B | Barium, Blood | $ 208.00 |
| 0519FL | Barium, Fluid | $ 213.00 |
| 0519H | Barium, Hair | $ 597.00 |
| 0519SP | Barium, Serum/Plasma | $ 138.00 |
| 0519TI | Barium, Tissue | $ 547.00 |
| 0519U | Barium, Urine | $ 138.00 |
| 0638B | Beryllium, Blood | $ 96.00 |
| 0638LI | Beryllium, Liquid | $ 394.00 |
| 0638SP | Beryllium, Serum/Plasma | $ 96.00 |
| 0638U | Beryllium, Urine | $ 149.00 |
| 0680B | Bismuth, Blood | $ 242.00 |
| 0680SP | Bismuth, Serum/Plasma | $ 93.00 |
| 0680U | Bismuth, Urine | $ 149.00 |
| 0711B | Boron, Blood | $ 74.00 |
| 0711SP | Boron, Serum/Plasma | $ 74.00 |
| 0711U | Boron, Urine | $ 74.00 |
| 0720B | Bromine - Total, Blood | $ 431.00 |
| 0720SP | Bromine - Total, Serum/Plasma | $ 105.00 |
| 0720U | Bromine - Total, Urine | $ 173.00 |
| 0921UH | Cadmium, 24 Hour Urine | $ 92.00 |
| 0921B | Cadmium, Blood | $ 63.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 0921H | Cadmium, Hair | $ 436.00 |
| 0921N | Cadmium, Nails | $ 436.00 |
| 0921R | Cadmium, RBCs | $ 63.00 |
| 0921SP | Cadmium, Serum/Plasma | $ 63.00 |
| 0921TI | Cadmium, Tissue | $ 345.00 |
| 0921U | Cadmium, Urine | $ 67.00 |
| 0939B | Calcium - Total, Postmortem, Blood (Forensic) | $ 130.00 |
| 0938FL | Calcium - Total, Postmortem, Fluid (Forensic) | $ 303.00 |
| 0938R | Calcium - Total, RBCs | $ 97.00 |
| 0938U | Calcium - Total, Urine | $ 159.00 |
| 1006TI | Carbon Monoxide Profile for Non-standard Samples, Tissue | $ 691.00 |
| 1042B | Cesium, Blood | $ 175.00 |
| 1042SP | Cesium, Serum/Plasma | $ 175.00 |
| 1042U | Cesium, Urine | $ 284.00 |
| 1130B | Chloroform, Blood | $ 201.00 |
| 1265B | Chromium and Cobalt, Blood | $ 204.00 |
| 1265SP | Chromium and Cobalt, Serum/Plasma | $ 197.00 |
| 1265U | Chromium and Cobalt, Urine | $ 197.00 |
| 1261B | Chromium, Blood | $ 138.00 |
| 1261FL | Chromium, Fluid | $ 343.00 |
| 1261H | Chromium, Hair | $ 431.00 |
| 1261N | Chromium, Nails | $ 431.00 |
| 1261R | Chromium, RBCs | $ 138.00 |
| 1261SP | Chromium, Serum/Plasma | $ 138.00 |
| 1261TI | Chromium, Tissue | $ 411.00 |
| 1261U | Chromium, Urine | $ 138.00 |
| 1290UH | Cobalt, 24 Hour Urine | $ 137.00 |
| 1290B | Cobalt, Blood | $ 114.00 |
| 1290FL | Cobalt, Fluid | $ 319.00 |
| 1290H | Cobalt, Hair | $ 486.00 |
| 1290N | Cobalt, Nails | $ 486.00 |
| 1290R | Cobalt, RBCs | $ 114.00 |
| 1290SP | Cobalt, Serum/Plasma | $ 114.00 |
| 1290TI | Cobalt, Tissue | $ 389.00 |
| 1290U | Cobalt, Urine | $ 186.00 |
| 1333SP | Copper - Free, Serum/Plasma | $ 105.00 |
| 1330B | Copper, Blood | $ 58.00 |
| 1330FL | Copper, Fluid | $ 267.00 |
| 1330H | Copper, Hair | $ 430.00 |
| 1330R | Copper, RBCs | $ 58.00 |
| 1330SP | Copper, Serum/Plasma | $ 58.00 |
| 1330TI | Copper, Tissue | $ 339.00 |
| 1330U | Copper, Urine | $ 58.00 |
| 1919FL | Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic) | $ 119.00 |
| 8103B | Environmental Exposure Screen, Blood | 915 |
| 2090SP | Fluoride, Serum/Plasma | $ 123.00 |
| 2090U | Fluoride, Urine | $ 93.00 |
| 2150B | Gallium, Blood | $ 430.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 2150SP | Gallium, Serum/Plasma | $ 261.00 |
| 2150U | Gallium, Urine | $ 261.00 |
| 2156SP | Germanium, Serum/Plasma | $ 411.00 |
| 2156U | Germanium, Urine | $ 394.00 |
| 2171B | Gold, Blood | $ 93.00 |
| 2171SP | Gold, Serum/Plasma | $ 93.00 |
| 2171U | Gold, Urine | $ 93.00 |
| 2406B | Indium, Blood | $ 228.00 |
| 2406R | Indium, RBCs | $ 152.00 |
| 2406SP | Indium, Serum/Plasma | $ 228.00 |
| 2406U | Indium, Urine | $ 152.00 |
| 6364R | Inorganic Panel 64, RBCs | $ 505.00 |
| 2428U | Iodine - Total, Urine | $ 139.00 |
| 2428FL | Iodine, Fluid | $ 335.00 |
| 2428SP | Iodine, Serum/Plasma | $ 139.00 |
| 2430UH | Iron, 24 Hour Urine | $ 79.00 |
| 2430B | Iron, Blood | $ 79.00 |
| 2430SP | Iron, Serum/Plasma | $ 79.00 |
| 2430ST | Iron, Stool | $ 284.00 |
| 2430U | Iron, Urine | $ 79.00 |
| 2490B | Lead and ZPP, Blood | $ 72.00 |
| 2492UH | Lead, 24 Hour Urine | $ 102.00 |
| 2492B | Lead, Blood | $ 50.00 |
| 2492FL | Lead, Fluid | $ 259.00 |
| 2492H | Lead, Hair | $ 420.00 |
| 2492LI | Lead, Liquid | $ 160.00 |
| 2492N | Lead, Nails | $ 420.00 |
| 2492R | Lead, RBCs | $ 85.00 |
| 2492SP | Lead, Serum/Plasma | $ 102.00 |
| 2492TI | Lead, Tissue | $ 330.00 |
| 2492U | Lead, Urine | $ 102.00 |
| 2534U | Lithium Exposure , Urine | $ 55.00 |
| 2534B | Lithium Exposure, Blood | $ 55.00 |
| 2534SP | Lithium Exposure, Serum/Plasma | $ 55.00 |
| 2520B | Lithium, Blood | $ 58.00 |
| 2520FL | Lithium, Fluid | $ 267.00 |
| 2520R | Lithium, RBCs | $ 92.00 |
| 2520SP | Lithium, Serum/Plasma | $ 58.00 |
| 2520TI | Lithium, Tissue | $ 339.00 |
| 2520U | Lithium, Urine | $ 58.00 |
| 2551B | Magnesium - Total, Blood | $ 62.00 |
| 2551FL | Magnesium - Total, Fluid | $ 271.00 |
| 2551H | Magnesium - Total, Hair | $ 433.00 |
| 2551R | Magnesium - Total, RBCs | $ 62.00 |
| 2551SP | Magnesium - Total, Serum/Plasma | $ 62.00 |
| 2551ST | Magnesium - Total, Stool | $ 433.00 |
| 2551TI | Magnesium - Total, Tissue | $ 274.00 |
| 2551U | Magnesium - Total, Urine | $ 118.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 2570B | Manganese, Blood | $ 103.00 |
| 2570FL | Manganese, Fluid | $ 310.00 |
| 2570H | Manganese, Hair | $ 472.00 |
| 2570LI | Manganese, Liquid | $ 587.00 |
| 2570N | Manganese, Nails | $ 716.00 |
| 2570R | Manganese, RBCs | $ 103.00 |
| 2570SP | Manganese, Serum/Plasma | $ 103.00 |
| 2570TI | Manganese, Tissue | $ 381.00 |
| 2570U | Manganese, Urine | $ 103.00 |
| 2670UH | Mercury, 24 Hour Urine | $ 77.00 |
| 2670B | Mercury, Blood | $ 55.00 |
| 2670FL | Mercury, Fluid | $ 267.00 |
| 2670H | Mercury, Hair | $ 623.00 |
| 2670LI | Mercury, Liquid | $ 270.00 |
| 2670N | Mercury, Nails | $ 430.00 |
| 2670R | Mercury, RBCs | $ 55.00 |
| 2670SP | Mercury, Serum/Plasma | $ 55.00 |
| 2670TI | Mercury, Tissue | $ 339.00 |
| 2670U | Mercury, Urine | $ 124.00 |
| 2664UH | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), 24 Hour Urine | $ 379.00 |
| 2664U | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), Urine | $ 379.00 |
| 2693B | Metals/Metalloids Acute Poisoning Panel, Blood | $ 465.00 |
| 2693FL | Metals/Metalloids Acute Poisoning Panel, Fluid | $ 680.00 |
| 2693H | Metals/Metalloids Acute Poisoning Panel, Hair | $ 661.00 |
| 2693R | Metals/Metalloids Acute Poisoning Panel, RBCs | $ 465.00 |
| 2693SP | Metals/Metalloids Acute Poisoning Panel, Serum/Plasma | $ 465.00 |
| 2693TI | Metals/Metalloids Acute Poisoning Panel, Tissue | $ 725.00 |
| 2693U | Metals/Metalloids Acute Poisoning Panel, Urine | $ 465.00 |
| 2661B | Metals/Metalloids Panel 1, Blood | $ 271.00 |
| 2661H | Metals/Metalloids Panel 1, Hair | $ 504.00 |
| 2661N | Metals/Metalloids Panel 1, Nails | $ 504.00 |
| 2661SP | Metals/Metalloids Panel 1, Serum/Plasma | $ 301.00 |
| 2661U | Metals/Metalloids Panel 1, Urine | $ 311.00 |
| 2662B | Metals/Metalloids Panel 2, Blood | $ 379.00 |
| 2662H | Metals/Metalloids Panel 2, Hair | $ 583.00 |
| 2662N | Metals/Metalloids Panel 2, Nails | $ 583.00 |
| 2662SP | Metals/Metalloids Panel 2, Serum/Plasma | $ 379.00 |
| 2662U | Metals/Metalloids Panel 2, Urine | $ 598.00 |
| 2663B | Metals/Metalloids Panel 3, Blood | $ 419.00 |
| 2663H | Metals/Metalloids Panel 3, Hair | $ 631.00 |
| 2663N | Metals/Metalloids Panel 3, Nails | $ 631.00 |
| 2663SP | Metals/Metalloids Panel 3, Serum/Plasma | $ 432.00 |
| 2663U | Metals/Metalloids Panel 3, Urine | $ 668.00 |
| 3066B | Mineral Profile, Blood | $ 610.00 |
| 3066R | Mineral Profile, RBCs | $ 394.00 |
| 3066SP | Mineral Profile, Serum/Plasma | $ 394.00 |
| 3090B | Molybdenum, Blood | $ 79.00 |
| 3090H | Molybdenum, Hair | $ 448.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 3090R | Molybdenum, RBCs | $ 79.00 |
| 3090SP | Molybdenum, Serum/Plasma | $ 79.00 |
| 3090U | Molybdenum, Urine | $ 92.00 |
| 3140B | Nickel, Blood | $ 79.00 |
| 3140FL | Nickel, Fluid | $ 284.00 |
| 3140H | Nickel, Hair | $ 448.00 |
| 3140N | Nickel, Nails | $ 448.00 |
| 3140R | Nickel, RBCs | $ 129.00 |
| 3140SP | Nickel, Serum/Plasma | $ 79.00 |
| 3140TI | Nickel, Tissue | $ 355.00 |
| 3140U | Nickel, Urine | $ 110.00 |
| 3292B | Palladium, Blood | $ 225.00 |
| 3292SP | Palladium, Serum/Plasma | $ 187.00 |
| 3292U | Palladium, Urine | $ 187.00 |
| 3765B | Phosphorus - Total, Blood | $ 276.00 |
| 3765FL | Phosphorus - Total, Fluid | $ 488.00 |
| 3765SP | Phosphorus - Total, Serum/Plasma | $ 276.00 |
| 3765ST | Phosphorus - Total, Stool | $ 232.00 |
| 3765U | Phosphorus - Total, Urine | $ 276.00 |
| 3783B | Platinum, Blood | $ 191.00 |
| 3783FL | Platinum, Fluid | $ 394.00 |
| 3783SP | Platinum, Serum/Plasma | $ 191.00 |
| 3783U | Platinum, Urine | $ 315.00 |
| 3784B | Potassium - Total, Blood (Forensic) | $ 92.00 |
| 3784FL | Potassium - Total, Fluid | $ 213.00 |
| 3784R | Potassium - Total, RBCs | $ 92.00 |
| 4124B | Rubidium, Blood | $ 228.00 |
| 4124R | Rubidium, RBCs | $ 344.00 |
| 4124SP | Rubidium, Serum/Plasma | $ 228.00 |
| 4124U | Rubidium, Urine | $ 228.00 |
| 4180B | Selenium, Blood | $ 113.00 |
| 4180H | Selenium, Hair | $ 541.00 |
| 4180LI | Selenium, Liquid | $ 686.00 |
| 4180N | Selenium, Nails | $ 541.00 |
| 4180R | Selenium, RBCs | $ 113.00 |
| 4180SP | Selenium, Serum/Plasma | $ 113.00 |
| 4180U | Selenium, Urine | $ 132.00 |
| 6317U | Semi Conductor Panel, Urine | $ 631.00 |
| 4190B | Silicon, Blood | $ 140.00 |
| 4190SP | Silicon, Serum/Plasma | $ 140.00 |
| 4190U | Silicon, Urine | $ 140.00 |
| 4200B | Silver, Blood | $ 103.00 |
| 4200SP | Silver, Serum/Plasma | $ 103.00 |
| 4200U | Silver, Urine | $ 103.00 |
| 4212B | Strontium, Blood | $ 100.00 |
| 4212SP | Strontium, Serum/Plasma | $ 58.00 |
| 4212U | Strontium, Urine | $ 57.00 |
| 4320B | Tellurium, Blood | $ 249.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 4320SP | Tellurium, Serum/Plasma | $ 249.00 |
| 4320U | Tellurium, Urine | $ 249.00 |
| 4370B | Thallium, Blood | $ 149.00 |
| 4370H | Thallium, Hair | $ 414.00 |
| 4370LI | Thallium, Liquid | $ 366.00 |
| 4370N | Thallium, Nails | $ 414.00 |
| 4370SP | Thallium, Serum/Plasma | $ 93.00 |
| 4370U | Thallium, Urine | $ 98.00 |
| 4478SP | Thorium, Serum/Plasma | $ 158.00 |
| 4478U | Thorium, Urine | $ 263.00 |
| 4485B | Tin - Total, Blood | $ 148.00 |
| 4485H | Tin - Total, Hair | $ 503.00 |
| 4485SP | Tin - Total, Serum/Plasma | $ 148.00 |
| 4485TI | Tin - Total, Tissue | $ 95.00 |
| 4485U | Tin - Total, Urine | $ 148.00 |
| 4486B | Titanium, Blood | $ 152.00 |
| 4486FL | Titanium, Fluid | $ 356.00 |
| 4486SP | Titanium, Serum/Plasma | $ 152.00 |
| 4486U | Titanium, Urine | $ 228.00 |
| 0470UH | Total, Inorganic Arsenic, 24 Hour Urine (+Creatinine) | $ 168.00 |
| 4730B | Tungsten, Blood | $ 188.00 |
| 4730SP | Tungsten, Serum/Plasma | $ 188.00 |
| 4730U | Tungsten, Urine | $ 188.00 |
| 4755UH | Uranium, 24 Hour Urine | $ 188.00 |
| 4755U | Uranium, Urine | $ 188.00 |
| 4765B | Vanadium, Blood | $ 113.00 |
| 4765R | Vanadium, RBCs | $ 113.00 |
| 4765SP | Vanadium, Serum/Plasma | $ 113.00 |
| 4765U | Vanadium, Urine | $ 119.00 |
| 4844B | Zinc, Blood | $ 69.00 |
| 4844FL | Zinc, Fluid | $ 276.00 |
| 4844H | Zinc, Hair | $ 405.00 |
| 4844LI | Zinc, Liquid | $ 555.00 |
| 4844N | Zinc, Nails | $ 405.00 |
| 4844R | Zinc, RBCs | $ 69.00 |
| 4844SP | Zinc, Serum/Plasma | $ 69.00 |
| 4844U | Zinc, Urine | $ 113.00 |
| 4870SP | Zirconium, Serum/Plasma | $ 203.00 |
| 4885B | ZPP (Zinc Protoporphyrin), Blood | $ 77.00 |

| Test | Test Name | List Price |
|---|---|---|
| **MISCELLANEOUS SERVICES** | | |
| HAIR KIT | Hair Kit/ Forensic | $ 19.00 |
| HAIRSEG | Hair Segmentation | $ 189.00 |
| HAIRSEG2 | Hair Segmentation II | $ 189.00 |
| MICRO | Micro Specimen Surcharge | $ 95.00 |
| NONBIO/LIQ | Non-biological Fee (Liquid) | $ 146.00 |
| NONBIO/SOL | Non-biological Fee (Solid) | $ 214.00 |
| SHPCHG | Shipping Charge | $ 43.00 |
| HANDLING | Specimen Handling Fee | $ 49.00 |
| SPEC RET | Specimen Retention | $ 2,600.00 |
| RETURN | Specimen Return/Handling | $ 66.00 |
| **NEWBORN TOXICOLOGY** | | |
| 8600ME | Amphetamines Panel (Qualitative), Meconium | $ 312.00 |
| 8620ME | Barbiturates Panel (Qualitative), Meconium | $ 465.00 |
| 9351UC | Basic Drug Screen, Umbilical Cord Tissue | $ 439.00 |
| 9329ME | Benzodiazepines Panel (Qualitative), Meconium | $ 308.00 |
| 4127ME | Buprenorphine and Metabolite - Total (Qualitative), Meconium | $ 472.00 |
| 0960ME | Cannabinoids Panel (Qualitative), Meconium | $ 354.00 |
| 1300ME | Cocaine and Metabolites (Qualitative), Meconium | $ 452.00 |
| 9145UC | Comprehensive Drug Screen, Umbilical Cord Tissue | $ 745.00 |
| 1864ME | Drugs of Abuse Screen (10 Panel), Meconium | $ 227.00 |
| 6904ME | Drugs of Abuse Screen (7 Panel), Meconium | $ 193.00 |
| 9146UC | Ethyl Glucuronide Screen, Umbilical Cord Tissue | $ 339.00 |
| 9352UC | Expanded Drug Screen, Umbilical Cord Tissue | $ 586.00 |
| 2079ME | Fentanyl and Metabolite (Qualitative), Meconium | $ 387.00 |
| 2760ME | Methadone and Metabolite (Qualitative), Meconium | $ 358.00 |
| 8670ME | Opiates - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 373.00 |
| 8761ME | Phencyclidine (Qualitative), Meconium | $ 439.00 |
| **NOVEL PSYCHOACTIVE SUBSTANCES (NPS)** | | |
| 0010B | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Blood | $ 286.00 |
| 0010SP | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Serum/Plasma | $ 179.00 |
| 0010U | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Urine | $ 179.00 |
| 0015B | 2-methyl AP-237 & AP-238, Blood | $ 556.00 |
| 0015SP | 2-methyl AP-237 & AP-238, Serum/Plasma | $ 556.00 |
| 0015U | 2-methyl AP-237 & AP-238, Urine | $ 556.00 |
| 0014B | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Blood | $ 286.00 |
| 0014SP | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Serum/Plasma | $ 179.00 |
| 0014U | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Urine | $ 179.00 |
| 0205U | Acetyl Fentanyl and Metabolite, Urine | $ 192.00 |
| 9105B | Acetyl Fentanyl Screen, Blood | $ 192.00 |
| 9105SP | Acetyl Fentanyl Screen, Serum/Plasma | $ 192.00 |
| 9105U | Acetyl Fentanyl Screen, Urine | $ 192.00 |
| 0205B | Acetyl Fentanyl, Blood | $ 192.00 |
| 0205FL | Acetyl Fentanyl, Fluid | $ 386.00 |
| 0205SP | Acetyl Fentanyl, Serum/Plasma | $ 192.00 |
| 0205TI | Acetyl Fentanyl, Tissue | $ 386.00 |
| 2626B | Bath Salts Panel (Qualitative), Blood | $ 271.00 |

| Test | Test Name | List Price |
|---|---|---|
| **NOVEL PSYCHOACTIVE SUBSTANCES (NPS)** | | |
| 2626SP | Bath Salts Panel (Qualitative), Serum/Plasma | $ 172.00 |
| 2626U | Bath Salts Panel (Qualitative), Urine | $ 172.00 |
| 0771B | Brorphine, Blood | $ 477.00 |
| 0771SP | Brorphine, Serum/Plasma | $ 477.00 |
| 0771U | Brorphine, Urine | $ 477.00 |
| 1483U | Desalkylgidazepam (Qualitative), Urine | $ 338.00 |
| 1483B | Desalkylgidazepam, Blood | $ 338.00 |
| 1483SP | Desalkylgidazepam, Serum/Plasma | $ 338.00 |
| 1481U | Deschloroetizolam, Meclonazepam, and Pyrazolam (Qualitative), Urine | $ 359.00 |
| 1481B | Deschloroetizolam, Meclonazepam, and Pyrazolam, Blood | $ 359.00 |
| 1481SP | Deschloroetizolam, Meclonazepam, and Pyrazolam, Serum/Plasma | $ 359.00 |
| 0570U | Designer Benzodiazepines (Qualitative), Urine | $ 361.00 |
| 0570B | Designer Benzodiazepines, Blood | $ 361.00 |
| 0570SP | Designer Benzodiazepines, Serum/Plasma | $ 361.00 |
| 1480U | Designer Opioids (Qualitative), Urine | $ 374.00 |
| 1480B | Designer Opioids, Blood | $ 374.00 |
| 1480SP | Designer Opioids, Serum/Plasma | $ 374.00 |
| 1022U | Eutylone (Qualitative), Urine | $ 292.00 |
| 1022B | Eutylone, Blood | $ 292.00 |
| 1022SP | Eutylone, Serum/Plasma | $ 292.00 |
| 1022TI | Eutylone, Tissue | $ 540.00 |
| 3078U | Mitragynine (Qualitative), Urine | $ 187.00 |
| 3064B | Mitragynine, Blood | $ 196.00 |
| 3064SP | Mitragynine, Serum/Plasma | $ 196.00 |
| 3218B | N,N-Dimethylpentylone & Pentylone, Blood | $ 338.00 |
| 3218SP | N,N-Dimethylpentylone & Pentylone, Serum/Plasma | $ 338.00 |
| 3218U | N,N-Dimethylpentylone & Pentylone, Urine | $ 338.00 |
| 3168B | Nitazenes Panel, Blood | $ 378.00 |
| 3168SP | Nitazenes Panel, Serum/Plasma | $ 378.00 |
| 8756B | Novel Psychoactive Substances (NPS) Screen 1, Blood | $ 389.00 |
| 8756SP | Novel Psychoactive Substances (NPS) Screen 1, Serum/Plasma | $ 389.00 |
| 8756U | Novel Psychoactive Substances (NPS) Screen 1, Urine | $ 389.00 |
| 3224B | NPS Stimulants (Qualitative), Blood | $ 286.00 |
| 3224SP | NPS Stimulants (Qualitative), Serum/Plasma | $ 179.00 |
| 3224U | NPS Stimulants (Qualitative), Urine | $ 179.00 |
| 4047B | Pyrrolidinophenone Panel, Blood | $ 348.00 |
| 4047SP | Pyrrolidinophenone Panel, Serum/Plasma | $ 348.00 |
| 1021B | Substituted Cathinone Panel, Blood | $ 304.00 |
| 1021SP | Substituted Cathinone Panel, Serum/Plasma | $ 304.00 |
| 1021U | Substituted Cathinone Panel, Urine | $ 304.00 |
| 9562U | Synthetic Cannabinoid Metabolites Screen - Expanded, Urine | $ 140.00 |
| 4283U | Synthetic Cannabinoid Metabolites-Expanded (Qualitative), Urine | $ 104.00 |
| 4282SP | Synthetic Cannabinoids (Qualitative), Serum/Plasma | $ 304.00 |
| 9566B | Synthetic Cannabinoids Screen (Add-On), Blood | $ 204.00 |
| 9560B | Synthetic Cannabinoids Screen, Blood | $ 284.00 |

| Test | Test Name | List Price |
|---|---|---|
| **ORAL FLUID TESTING SERVICES** | | |
| 8890OF | Amphetamines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8891OF | Benzodiazepines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8893OF | Cocaine and Metabolites (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8892OF | Delta-9 THC (Qualitative), Oral Fluid (Saliva) | $ 80.00 |
| 8900OF | Delta-9 THC (Quantitative), Oral Fluid (Saliva) | $ 214.00 |
| 8898OF | Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva) | $ 94.00 |
| 8897OF | Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva) | $ 146.00 |
| 8894OF | Methadone and Metabolite (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8895OF | Opiates (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8896OF | Phencyclidine and Dextromethorphan (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| **PFAS TESTING SERVICES** | | |
| 3429SP | PFASure™ Expanded, Serum/Plasma | $ 551.00 |
| 3434SP | PFASure FT, Serum/Plasma | $ 510.00 |
| 3428SP | PFASure™, Serum/Plasma | $ 510.00 |
| 3427SP | Perfluoroalkyl Substances (PFAS), Serum/Plasma | $ 468.00 |
| 3426B | Perfluorooctanoic Acid, Blood | $ 662.00 |

NMS LABS

Expert Services

NMSlabs.com

# Expert Services Professional Support

Effective January 1 to December 31, 2025*

## Documents for Legal Proceedings

These are optional documents that may require subpoenas. Litigation Packages and Discovery Documentation require 4 to 6 weeks before trial to gather and process information within the laboratory.

| Documents | Fee |
|---|---|
| Affidavits | $93/each |
| Certified Lab Reports | $93/each |
| Litigation Package | $93/each |
| Discovery Documentation—Hourly Rate | $93/hour |

## Expert Opinions

NMS Labs toxicologists provide written reports that support analytical testing services. Fee includes the expert's time for consultation, documentation review, research, and preparation of a written report.

| Expert Opinion | Fee |
|---|---|
| Senior Toxicologist Review | $486/hour |
| Toxicologist Review | $426/hour |

## Court Testimony and Depositions

In-person or video testimony, depositions, pre-trial preparation, wait time, and travel time are all included.

| Expert Testimony | Fee |
|---|---|
| Hourly Rate | $305/hour |
| Daily Rate | $3,656/day |

Client is responsible for all travel-related expenses, mileage, meals, flights, hotels, etc. *All fees are calculated on an hourly basis. Daily rate will be applied after 10 hours of time is spent on any of the above activities, per day, related to each testimony event.*

For questions call Expert Services at **844.276.0768**

or email **ExpertServices@NMSlabs.com** for more information.

*Other terms and conditions may apply.


**Contact**

NMS Labs
200 Welsh Road, Horsham, PA 19044

T: 844.276.0768
F: 215.657.2972

www.NMSlabs.com

# STATE OF WASHINGTON
# Washington State Patrol
# Amendment Number One
# WSP-RFQQ-TOXTST
### March 5, 2025
**Project Title:** Toxicology Forensic Testing

This document shall serve as the sole official notification of answers to bidder questions regarding the above-referenced Solicitation and Amendment thereto, if applicable**.** This document amends the Solicitation with regard to the answers below. All other terms and conditions of the Solicitation remain in full force and effect.

| ***No.*** | ***Question*** | ***Response*** | ***Section Amended*** |
|---|---|---|---|
| 01 | How were the definitions in Attachment 6 revised? | The definitions of ANAB, ANSI, and Customer were updated by subject matter expert. The term AES was removed. | Attachment 6 Definitions |

| ***DEFINITIONS*** | |
|---|---|
| Term or Acronym | Definitions for the purposes of this RFQQ include: |
| ABFT | American Board of Forensic Toxicology |
| ANAB | ANSI National Accreditation Board |
| ANSI | American National Standards Institute is the sole U.S. representative and dues-paying member of the International Organization for Standardization (ISO). |
| ASB | Apparently Successful Bidder |
| BAFO | Best and Final Offer |
| Bidder | Individual, company, organization, public or private agency, or other entity submitting a proposal/response in order to attain a contract with WSP. |
| Customer | Agencies served by the WSP Toxicology Laboratory Division and the Criminal Justice System, to include coroners, medical examiners, prosecuting attorneys and statewide criminal justice agencies. |
| Contract | This document, all schedules and exhibits, Statements of Work, and all amendments hereto. |
| Contractor | Individual or company whose proposal has been accepted by the WSP and has been awarded a fully executed, written contract. |
| DUI | Driving Under the Influence |
| Effective Date | The first date this Contract is in full force and effect. It may be a specific date agreed to by the parties; or, if not so specified, the date of the last signature of a party to this Contract. |
| ISO/IEC | Standards for the testing and calibration of laboratories. ISO 17025 requirements may be found here: https://www.iso.org/ISO-IEC-17025-testing-and-calibration-laboratories.html |
| Letter of Interest | A letter created by the bidder to address the items in the Letter of Interest section to include a statement of understanding & compliance. |
| PTAC | Procurement Technical Assistance Center, also known as APEX Accelerator, assists businesses through the government-contracting marketplace. Additional information can be found here: https://washingtonapex.org/. |
| Proposal | A formal offer submitted in response to this solicitation. |
| OMWBE | Office of Minority and women's Business Enterprises. Additional information can be found here: https://omwbe.wa.gov/. |
| RCW | The Revised Code of Washington. All references to RCW chapters or sections shall include any successor, amendment, or replacement statue. |
| Request for Qualifications and Quotations (RFQQ) | A formal procurement document in which a service or need is identified and skills and expertise are being sought to deliver the service or meet the need. The purpose of an RFQQ is to solicit from the Bidder or consultant community to propose the qualified Bidder(s) and associated pricing/costs to provide the service and/or meet the identified need |
| RFQQ Coordinator | The WSP named solicitation Coordinator, or designee, employed by the WSP Contracts, and the individual responsible for conducting this RFQQ. |
| Responsible Bidder | A responsible bidder is one that has the experience, personnel, equipment, and finances to perform the requirements of the contract. |
| Services | Those services provided by the Vendor relating to grounds maintenance services and any related services that are appropriate to this Contract's Statement of Work. |

| | |
|---|---|
| Statement of Work | Those services to be provided by the Apparently Successful Vendor (ASV)/ Apparently Successful Bidder (ASB). |
| Subcontractor | One not in the employment of Vendor, who is performing all or part of the business activities under this Contract under a separate contract with Vendor. Subcontractors are not allowed under this Contract without permission, in writing, from the WSP Contract Administrator. |
| THC | Tetrahydrocannabinol is a cannabinoid found in cannabis. |
| Traceability | Property of a measurement result whereby the result can be related to a reference through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty. |
| Uncertainty of Measurement | The range of possible values within which the true value of the measurement lies. |
| WAC or Washington Administrative Code | The regulations of the Washington State executive branch agencies issued by authority of statutes. Like legislation and the Constitution, regulations are a source of primary law in Washington State. All references to WAC chapters or sections shall include any successor, amended, or replacement regulation. |
| WEBS or Washington's Electronic Business Solution. | The Washington State Department of Enterprise Services' (DES) on-line system which provides vendor registration and notification activities for governmental solicitations and procurements. WEBS provides vendors automatic email notification of new bidding opportunities, and is free to vendors and government organizations. The WEBS website is: https://fortress.wa.gov/ga/webs/. |
| WSP | The State of Washington, Washington State Patrol, and its officers, directors, trustees, employees and/or agents. |

# STATE OF WASHINGTON
# Washington State Patrol
# Amendment Number Two
# WSP-RFQQ-TOXTST

**March 25, 2025**

**Project Title:** Toxicology Forensic Testing

This document shall serve as the sole official notification of answers to bidder questions regarding the above-referenced Solicitation and Amendment thereto, if applicable**.** This document amends the Solicitation with regard to the answers below. All other terms and conditions of the Solicitation remain in full force and effect.

| ***No.*** | ***Question*** | ***Response*** | ***Section Amended*** |
|---|---|---|---|
| 01 | What percentage of the award is postmortem? | Primarily postmortem. The large majority will be postmortem. | |
| 02 | Is there a page limit on the bid responses? | There is no page limit. | |
| 03 | What was the caseload for 2024 PM cases? | WSP Toxicology Laboratory receives an average of 6,000 postmortem cases annually. | |
| 04 | Could vendors provide an alternate method to submit SOPs like an electronic link to view documents? | No, must be sent via email and multiple emails can be sent. | |
| 05 | In the human performance genre, can you identify the scope of these testing requests? | Emerging drugs as well as drugs that are not confirmed at the WSP Toxicology Laboratory. | |
| 06 | How many times did you need to call contractor witnesses to court in 2024? | That data is not available, but the need for contractor witnesses to appear in court is expected to be minimal. | |
| 07 | Are metals and toxins part of the ask for postmortem? | Generally, testing for metals and toxins are not included. However, if that service is available, it is something that WSP Toxicology Laboratory would be interested in for a small subset of cases. | |
| 08 | Would you like vendors to submit these questions in writing as well? | No, there is no need to submit these questions again in writing. | |
| 09 | Can we submit other questions before the deadline next week? | Any additional questions must be submitted no later than March 21st at 4:00 pm to the RFQQ | |

| | | | |
|---|---|---|---|
| | | Coordinator. | |
| 10 | Do you know if WEBS has a size limit for files? | WSP is not aware of a size limit for files in WEBS. | |
| 11 | How will the cost proposal be calculated from the price list? | The number of specimens is dependent on funding. At this time, it is anticipated that up to 200 cases may be submitted per week. However, the case count could vary from 10-20 cases per week up to 200. Testing needs may vary dependent on case type. | |
| 12 | Is there a list of specific tests desired? | Refer to the RFQQ. Forensic toxicology analysis for common or emerging drugs and/or alcohol in death and impaired driving cases. To include the ability to test for a broad array of therapeutic drugs and drugs of abuse (to include differentiation of delta-9 THC from cannabinoid analogs) and periodic updates to scope for emerging drugs. | |
| 13 | Are there estimated volumes of various products/types of products? | The number of specimens is dependent on funding. At this time, it is anticipated that up to 200 cases may be submitted per week. However, the case count could vary from 10-20 cases per week up to 200. | |
| 14 | Will those be applied in calculating the pricing? | See response to question 13. | |
| 15 | Do you currently have a backlog? | The Laboratory does have a backlog of cases awaiting analysis. This RFQQ is for incoming postmortem casework and for specific drugs in impaired driving casework that the WSP Toxicology Laboratory cannot detect/confirm. | |
| 16 | If so, why have you not cleared it with your current provider? | See response to question 15. | |
| 17 | How much potential backlog would be subject to this contract? | This RFQQ is for incoming postmortem casework and for specific drugs in impaired driving casework that the WSP Toxicology Laboratory cannot detect/confirm. | |
| 18 | Are there different products needed for the backlog work (like screen and confirmation panels)? | Both screening and confirmation testing is required. | |

| | | | |
|---|---|---|---|
| 19 | Section 4 Proposal Requirements and Bidder Obligations, 4.1 Minimum Qualifications states, *"Bidder must have the ability to provide litigation packages and/or expert testimony upon request by prosecuting/defense attorneys and provide WSP Toxicology Laboratory Division customers with continuity in service and presentation of results."* Due to the size of our litigation packages, we are unable to email a sample one (even as its own email message). Since proposal responses are to be emailed (per RFQQ Attachment 2 Proposal Submission Instructions), what other options are available? Would it be possible to submit via Box.com? Or may we provide a table of contents or other description of our litigation packages in lieu of a sample? | Submissions via Box.com are not acceptable. However, Bidders may provide a table of contents or other description of their litigation packages in lieu of a sample. | |
| 20 | RFQQ Appendix C, #4. Approach/Strategy refers to "Attachment 1 Statement of Work", but per the RFQQ document, there is no Attachment 1. Also, this seems to be a duplicate of Appendix C, #2 Bidder Qualifications and Experience as both specifications state, *"Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana)."* Is it acceptable for respondents to simply note "See response to #2 above" for the response to #4? | The reference to Attachment 1 Statement of Work has been removed from Question 4 Approach/Strategy of Appendix C. The revised Appendix C is uploaded to WEBS.<br><br>Yes, it is acceptable for Bidder's to state "see response to #2" in reference to Bidder's capacity to test for common or emerging drugs and/or alcohol. | Appendix C Bidder's Questionnaire |

**1. Bidder Organization (MANDATORY)**

Describe Organization, including size, areas of services, number of years in business, customer base, and any other pertinent information that would aid evaluators in formulating a determination about the capability, stability, and strength of the Bidder's organization.

*Click here to enter text.*

**2. Bidder Qualifications and Experience (MANDATORY/SCORED)**

Describe qualifications and experiences performing similar projects in terms of similar scope, services, government program, size, and project characteristics. Provide explanation of how Bidder meets minimum qualifications; i.e., include Bidder's experience and history with providing services described in this RFQQ.

Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

*Click here to enter text.*

**3. Quality Assurance (MANDATORY/SCORED)**

Proposal must describe Bidder's approach to Quality Assurance and how Bidder will implement quality control.

*Click here to enter text.*

**4. Approach/Strategy (MANDATORY/SCORED)**

Describe the Bidder's approach to the work as outlined in Section 1 Introduction of the solicitation. Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

*Click here to enter text.*

**5. Related Information (MANDATORY)**

**5.1 State Contracts.** Has the Bidder or any subcontractor contracted with the state of Washington during the past 24 months?

☐ No ☐ Yes

If Yes, indicate the name of the agency, the contract number and project description and/or other information available to identify the contract.

Has the Bidder ever been terminated for default in the last five years?

☐ No ☐ Yes

If Yes, describe such incident. Termination for default is defined as notice to stop performance due to the Bidder's non-performance or poor performance and the issue of performance was either (a) not litigated due to inaction on the part of the Bidder, or (b) litigated and such litigation determined that the Bidder was in default. Submit full details of the terms for default including the other party's name, address, and phone number. Present the Bidder's position on the matter. WSP will evaluate the facts and may, at its sole discretion, reject the response on the grounds of the past experience. If no such termination for default has been experienced by the Bidder in the past five years, so indicate.

*Click here to enter text.*

**5.2 State Employees.** Is anyone in the Bidder's staff or subcontractor's staff a former employee of the state of Washington during the past 24 months, or is currently a Washington State employee?

☐ No ☐ Yes

If Yes, identify the individual by name, the agency previously or currently employed by, job title or position held and separation date. Also identify any State employees or former State employees employed or on the Bidder's governing board as of the date of the response. Include their position and responsibilities within the Bidder's organization. Include any staff member(s) who will perform work on this contract and has retired from the State of Washington under the provisions of the 2008 Early Retirement Factors legislation. If following a review of this information, it is determined by WSP that a conflict of interest exists, the Bidder may be disqualified from further consideration for the award of a contract.

*Click here to enter text.*

# STATE OF WASHINGTON
# Washington State Patrol
# Amendment Number Three
# WSP-RFQQ-TOXTST
## April 28, 2025
**Project Title:** Toxicology Forensic Testing

This document shall serve as the sole official notification of answers to bidder questions regarding the above-referenced Solicitation and Amendment thereto, if applicable**.** This document amends the Solicitation with regard to the answers below. All other terms and conditions of the Solicitation remain in full force and effect.

| ***No.*** | ***Question*** | ***Response*** | ***Section Amended*** |
|---|---|---|---|
| 03 | How was Attachment 2, Proposal Submission Instructions revised? | The RFQQ Coordinator contact information was revised in Section 2 of Attachment 2, Proposal Submission Instructions. | Section 2 of Attachment 2, Proposal Submission instructions |

## 1. Submission of Proposals

The proposal must arrive at WSP RFQQ Coordinator at the email below no later than date and time listed within the *Anticipated Procurement Schedule* on page one of this RFQQ. All proposals and any accompanying documentation become the property of WSP and will not be returned.

**1.1** Letter of Submission Requirements. The Letter of Submittal must be signed and dated by a person authorized to legally bind the Bidder to a contractual relationship, e.g., the President or Executive Director if a corporation, the managing partner if a partnership, or the proprietor if a sole proprietorship.

The letter of submittal must contain the following:

- Company Introduction
- A list of attachments, including Appendices and other documents attached
- Any other information that would assist WSP to evaluate the proposal
- A hard-copy signature of the individual authorized to legally bind the company to a contract.
- Be submitted in PDF format
- Follow naming conventions as listed in Section 3.1.11 below.

**1.2** **Proposal Method of Delivery**. Bidder's proposal must be delivered to the RFQQ Coordinator via email.

**1.3** **Assumption of Risk.** Bidders assume the risk for the delivery of the proposal. WSP assumes no responsibility for delays caused by any delivery service. Late proposals will NOT be accepted and will be automatically disqualified from further consideration.

**1.4** **Referencing**. Do not respond by referencing material presented elsewhere. The proposal shall be considered complete and stand on its own merits.

**1.5** **Time**. Bidders should allow sufficient time to ensure timely receipt of the Proposal and related documents by the RFQQ Coordinator on or before the date and time indicated within the *Anticipated Procurement Schedule* on page one of this RFQQ.

## 2. Submission Address

Proposals must be submitted to the RFQQ coordinator via email to the below address:

| | |
|---|---|
| RFQQ Coordinator | Jamie Roessler |
| RFQQ Coordinator Email Address: | **Jamie.Roessler@wsp.wa.gov** |

## 3. Submission of Proposals

### 3.1 Electronic Submission of Proposals

3.1.1 Time of receipt is defined as the time that the RFQQ Coordinator's email inbox records that the response was received, NOT by the Bidder's transmittal stamp. WSP assumes no responsibility for delays caused by Bidder's e-mail, network problems or any other party. If WSP's Email is not working, appropriate allowances will be made. Any proposals received after 4:00 pm on the proposal due date will be rejected.

3.1.2 The use of links or objects inserted into a document or pointing to a cloud-based program, are not acceptable methods of submittal. Proposals submitted that include such links or objects will be rejected as non-responsive and will not receive further consideration.

3.1.3 Appendices noted on Appendix A, Bidders Checklist submitted utilizing the WSP form provided with this RFQQ. Bidders shall not copy and paste the form into their own document. Any proposals that do not utilize the actual form provided by WSP, or that copy and paste the Appendices into their own document will be rejected and will not be given further consideration.

3.1.4 All files in a Bidder's Response must be submitted in Microsoft Word, Microsoft Excel, or PDF. ***All signature pages must be submitted in PDF format***.

3.1.5 Formats not identified herein may be accepted only upon prior written approval of WSP. If prior approval is not obtained, the submission will be considered nonresponsive and will not be given further consideration.

3.1.6 Proposals and related documents shall be submitted as attachments to an email, and not included as part of the body of the email or as a link. Proposals that are not submitted as attachments will be considered nonresponsive and will not be given further consideration.

3.1.7 Bidder must include the RFQQ number and Bidder's company name in the Subject line of the email.

3.1.8 Bidders may break email submittals into multiple emails provided each email clearly indicates in the subject line its overall place in the series, as well as the total number of separate emails being sent.

For example, if Bidder is submitting their response in three (3) separate emails, the subject line of the first should be "Company Name_RFQQ-TOXTST_Response 1 of 3"; the next email's subject line would be "Company Name _ RFQQ-TOXTST_Response 2 of 3"; etc. Replace "RFQQ-TOXTST" in these examples with the number assigned to this solicitation. Replace "Company name" with your actual company's name.

3.1.9 Abbreviate your company's name as appropriate to keep the name as short as possible.

3.1.10 Documents must be attached to the email, not imbedded in the email.

3.1.11 Naming Conventions. All proposal attachments must strictly adhere to the following name convention expectations and be attached to the email in the indicated required format. Follow this naming convention with additional documents that may be submitted with the proposal. Follow these naming conventions exactly, substituting "RFQQ-TOXTST" with the RFQQ number of this solicitation and "Company Name" with your actual company's name. Follow the name naming convention for all documents included in your proposal. Failure to follow naming conventions will result in rejection of the proposal as unresponsive.

Abbreviate your company's name as appropriate to keep the name as short as possible.

Company Name-Letter of Submittal-RFQQ-TOXTST.
Company Name-Appendix A- RFQQ-TOXTST
Company Name-Appendix B- RFQQ-TOXTST
Company Name-Appendix C- RFQQ-TOXTST
Company Name-Appendix D- RFQQ-TOXTST
Company Name-Appendix E- RFQQ-TOXTST
Company Name-Appendix F- RFQQ-TOXTST
Company Name-Appendix G- RFQQ-TOXTST
Company Name-Appendix H- RFQQ-TOXTST
Company Name-Appendix I- RFQQ-TOXTST
Company Name-Appendix J- RFQQ-TOXTST
Company Name-Insurance- RFQQ-TOXTST
Company Name-Business License- RFQQ-TOXTST

**3.2 Hard Copy Proposals**

3.2.1 Hard copy proposals are not accepted. Hard copy proposals will be considered nonresponsive and will not be given further consideration.

STATE OF WASHINGTON
WASHINGTON STATE PATROL

REQUEST FOR QUALIFICATIONS AND QUOTATIONS

# RFQQ NO. WSP-RFQQ-TOXTST

PROJECT TITLE: Toxicology Forensic Testing

| Anticipated Procurement Schedule<br>WSP reserves the right to revise the schedule<br>Times are at Pacific Standard Time | |
|---|---|
| Post Request for Qualifications and Quotations | March 4, 2025 |
| Pre-Bid Conference | 9:00am PDT March 12, 2025 |
| Bidder may submit written questions until 4:00 PM | March 21, 2025 |
| WSP will post responses and amendments to RFQQ (if any) | March 26, 2025 |
| Bidder may submit complaint via email by 4:00 pm | April 18, 2025 |
| Bidder must submit Proposals by 4:00 PM (45 days from Posting) | April 29, 2025 |
| WSP Evaluation of Proposals | April 29, 2025 |
| Announce "Apparent Successful Bidder(s)" (ASB) and send notification via WEBS to unsuccessful Bidders. No time estimate. | When evaluations are finished |
| DEBRIEFING CONFERENCE: Unsuccessful Bidders may request Debriefing until 4:00 PM three business days from after ASB Announcement | |
| PROTEST: Bidder may submit protest until 4:00 PM no later than five business days from the Bidder's Debrief Conference | |
| Protest Period Ends: 4:00 pm five business days after Bidder's Debrief Conference | |

| Contract Terms | |
|---|---|
| Maximum Amount | $1,000,000.00 |
| Performance Period | August 15, 2025 through August 14, 2026 |
| Optional Extensions | See Section 5.1 Period of Performance |

| RFQQ Coordinator | RFQ Coordinator Email Address |
|---|---|
| Jamie Roessler | Jamie.Roessler@wsp.wa.gov |

BIDDER ELIGIBILITY: This procurement is open to those Bidders that satisfy the minimum qualifications as outlined in Section 4.1 herein.

TABLE OF CONTENTS

## 1. INTRODUCTION

### 1.1 Purpose

The purpose of this solicitation is to establish a contract with a forensic testing laboratory accredited by the ANSI National Accreditation Board (ANAB) to the ISO/IEC 17025 standard and American Board of Forensic Toxicology (ABFT) requirements which is capable of providing timely forensic toxicology analysis for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases that the Washington State Patrol (WSP) Toxicology Laboratory Division does not respectively have the resources to perform in-house, or for which WSP Toxicology Laboratory Division cannot detect the specific drugs. WSP may award one or more contracts to Bidders who submit proposals as a result of this RFQQ. WSP Toxicology Laboratory Division shall send samples to be tested on a flow basis, according to the fee schedule provided by Bidder in its proposal.

### 1.2 Background

The WSP Toxicology Laboratory Division is accredited by ANAB to the ISO/IEC 17025 standard and ABFT requirements and provides toxicological testing of biological specimens for the presence of alcohol and other drugs, with case submissions from law enforcement agencies, medical examiners, coroners, and other agencies, statewide (the customer).

The WSP Toxicology Laboratory Division's ANAB accreditation requires that Contractors performing testing be evaluated and deemed competent to perform the work. The WSP Toxicology Laboratory Division is responsible to the customer for the work of the Contractor, and WSP Toxicology Laboratory Division internal policy requires that only approved Contractors may perform testing on evidence submitted to the Laboratory, unless otherwise specified by the customer.

The WSP Toxicology Laboratory Division will perform an evaluation of all bidders under this RFQQ using the evaluation criteria set forth herein. In accordance with the WSP Toxicology Laboratory Division's accreditation requirements, once approved, the Contractor will be re-evaluated annually to ensure they continue to meet those standards on which the original evaluation/approval was based. The re-evaluation includes, but is not limited to, review of the Contractor's accreditation status, quality management system, metrological traceability, reporting and scope of testing.

## 2. SUBMISSION INSTRUCTIONS and RESPONSIVENESS

### 2.1 Proposal Submission

Proposals must be submitted in accordance with the instructions in *Attachment 2, Proposal Submission Instructions* to this RFQQ.

### 2.2 Responsiveness.

All proposals will be reviewed by the RFQQ Coordinator to determine compliance with this section. The Bidder is specifically notified that failure to comply with this section or to provide all documentation required, may result in rejection of Bidder's proposal as non-responsive. WSP reserves the right, however, in its sole discretion to waive minor administrative irregularities.

## 3. RFQQ ADMINISTRATION

### 3.1 RFQQ Coordinator

The RFQQ Coordinator is the sole point of contact in WSP for this procurement. All communication between the Bidder and WSP regarding this RFQQ shall be with the RFQQ Coordinator, listed on page one of this RFQQ.

Any other communication will be considered unofficial and non-binding on WSP. Bidders are to rely on written statements issued by the RFQQ Coordinator. Communication directed to parties other than the RFQQ Coordinator may result in disqualification of the Bidder.

### *3.2 Bidder's Questions and Answers*

Questions concerning this RFQQ must be submitted in writing via e-mail to the RFQQ Coordinator at the email address listed on page one of this RFQQ. Questions must be received by the RFQQ Coordinator no later than the date and time listed within the *Anticipated Procurement Schedule* on page one of this RFQQ. Answers to Bidder's questions will be posted on WEBS.

### *3.3 Amendments to the RFQQ*

If Bidder questions result in changes to the RFQQ, written amendments to the RFQQ will be issued and posted on WEBS.

### *3.4 Bidders' Conference*

The purpose of a Bidders' Conference is to answer questions so that all potential bidders understand the requirements of the solicitation. A Bidder's Conference will be held but is not mandatory for submission of a Bid.

### *3.5 Oral Presentation/Interview*

The purpose of Oral Presentations or Interviews is to assist WSP in making a determination of suitability of the Bidder's product or service for the purpose of this RFQQ, and to aid WSP in making selection of the ASB. WSP, in its sole discretion will determine if an Oral Presentation/Interview is necessary. WSP, in its sole discretion may contact the two or three top-scoring Bidders to schedule a date, time and location for the Presentation/Interview. Commitments made by the Bidder at the Oral Presentation/Interview, if any, will be considered binding. An Oral Presentation/Interview, if called by WSP shall be mandatory. Any Bidder that does not attend the Presentation/Interview shall be considered nonresponsive and shall not be given further consideration. The Oral Presentation/Interview will be scored only if scoring is included in *Attachment 3, Evaluations and Scoring*.

### *3.6 Contract Award Announcement*

WSP shall offer a contract to the Bidder chosen as the Apparently Successful Bidder (ASB) via email. Upon the ASB's acceptance of the contract, WSP shall issue a Notification of Award on WEBS: https://fortress.wa.gov/ga/webs to all responding Bidders announcing the ASB. WSP considers the Award Date as the date that Notification of Award is issued through WEBS.

### *3.7 Notification to Unsuccessful Bidders*

Bidders whose proposals have not been selected for award will be notified via WEBS.

## *4. PROPOSAL REQUIREMENTS and BIDDER OBLIGATIONS*

### *4.1 Minimum Qualifications*

Each proposal must show how the Bidder meets the following mandatory minimum qualifications:

- In order to enter into a contract with the WSP, the company must be licensed to do business in the State of Washington. If currently licensed the bidder must provide a copy of the license with its proposal. If not currently licensed in Washington and the bidder is chosen as the ASB, the bidder must produce a copy of its Washington Business License before a contract can be signed.
- The Bidder must meet insurance requirements as set forth in *Section 4.10*.
- Bidders for this project must be accredited by ANSI-ASQ National Accreditation Board (ANAB) to the ISO/EIC 17025 standard and ABFT requirements for forensic toxicology testing.
- Bidders must have the ability to test for a broad array of therapeutic drugs and drugs of abuse (to include differentiation of delta-9 THC from cannabinoid analogs) and update their scope of testing periodically to include emerging drugs.

- Bidder must have the ability to distinguish between the delta-8 and delta-9 isomers of THC (cannabis).
- Bidder must have the ability to provide litigation packages and/or expert testimony upon request by prosecuting/defense attorneys and provide WSP Toxicology Laboratory Division customers with continuity in service and presentation of results.
- Bidder's test results must include information on drug indications, typical therapeutic range, and test method information (e.g., limit of detection/quantitation, reporting range, instrumentation).
- Bidder's results must be accepted in criminal and administrative proceedings and hearings in Washington state, and that results have been relied on for issuance of death certifications.
- Upon WSP Toxicology Laboratory Division request, Bidder must provide WSP Toxicology Laboratory Division with "uncertainty of measurement" for every quantitative result that is reported.

- Bidder must provide the following with its proposal:
    - Certificate and Scope of ISO 17025 and ABFT Accreditation by ANAB
    - Traceability and Quality Control Processes
    - Standard Operating Procedures and/or relevant policies
    - Example test report for the requested tests/scope of testing
    - Example litigation package and litigation package and expert testimony pricing

### *4.2 Acceptance Period*

Proposals must provide 60 days for acceptance by WSP from the due date for receipt of proposals. Proposals that do not contain a 60-day acceptance period shall be considered non-responsive and will not receive further consideration.

### *4.3 Most Favorable Terms*

WSP reserves the right to make an award without further discussion of the proposal submitted. Therefore, the proposal should be submitted initially on the most favorable terms which the Bidder can propose. WSP, in its sole discretion, reserves the right conduct a Best and Final Offer (BAFO) concerning any item of evaluation contained within the solicitation. If a BAFO is conducted, Bidders are notified that failure to respond to the BAFO shall result in Bidder being disqualified from bidding. Additionally, WSP reserves the right to contact a specific Bidder for clarification on their proposal.

### *4.4 Cost to Propose*

WSP will not be liable for any costs incurred by the Bidder in preparation of a proposal, BAFO, or any other response submitted in response to this RFQQ, in conduct of a presentation, or any other activities related to responding to this RFQQ.

### *4.5 Wage Laws Certification*

Prior to awarding a contract, agencies are required to determine that a Bidder is a 'Responsible Bidder,' per RCW 39.26.160(2) & (4). Pursuant to legislative enactment in 2017, the Bidder shall certify that the Bidder has not willfully violated Washington's wage laws (See *Appendix B, Bidder's Certification*)

### *4.6 Workers' Rights, Executive Order 18-03 Certification*

Pursuant to RCW 39.26.160(3) (best value criteria) and consistent with Executive Order 18-03-Supporting Workers' Rights to Effectively Address Workplace Violations (dated June 12, 2018),

Washington State Patrol will evaluate bids for best value and provide a bid preference in the amount of 2% to any bidder who certifies that their firm does NOT require its employees, as a condition of employment, to sign or agree to mandatory individual arbitration clauses or class or collective action waiver. (See *Appendix B, Bidder's Certification*)

### *4.7 Minority and Women-Owned Businesses Participation*

The State of Washington encourages participation in all of its contracts by firms certified by the Office of Minority and Women's Business Enterprises (OMWBE). Preference Points, if any, will be noted on *Attachment 3, Evaluations and Scoring*. No minimum level of OMWBE participation shall be required as a condition for receiving an award. Proposals will not be rejected or considered non-responsive on that basis. ***Bidders are encouraged to register with OMWBE and may contact OMWBE at (866) 208-1064 or http://omwbe.wa.gov to obtain information on the certification process***. Bidder's shall indicate their participation in the OMWBE in *Appendix B, Bidder's Certification*).

### *4.8 Proprietary Information/Public Disclosure*

Materials submitted in response to this competitive procurement shall become the property of WSP. All proposals received shall remain confidential until the announcement of the Apparent Successful Bidder (ASB) by the Washington State Patrol; thereafter, the proposals shall be deemed public records as defined in RCW 42.56 (the Public Records Act) and RCW 39.26.030 (State Procurement Records - Disclosure).

Any information in the proposal that the Bidder desires to claim as proprietary and exempt from disclosure under the provisions of RCW 42.56 must be clearly designated. The page must be clearly identified by the word "confidential" printed on each page. Marking the entire proposal exempt from disclosure will not be honored. The Bidder must be reasonable in designating information as confidential.

WSP will consider a Bidder's request for exemption from disclosure and will make a decision predicated upon Chapter 42.56 RCW and Chapter 143-06 of the Washington Administrative Code. If any information Bidder has marked as confidential is deemed under the statute to be exempt from disclosure, such information will not be made available until the affected Bidder has been given an opportunity to seek a court injunction against the requested disclosure, pursuant to statutory requirements.

The Bidder should be prepared to accept this RFQQ and Bidder's Proposal for incorporation into a contract resulting from this RFQQ. Whether or not chosen as the ASB, Bidder's proposal will become a part of the official procurement file on this matter without obligation to WSP.

### *4.9 Washington Electronic Business Solution (WEBS)*

Notification of amendments and results of the solicitation will only be provided to those Bidders who have registered with WEBS and have downloaded the RFQQ from WEBS. Bidders accept full responsibility and liability for failing to receive any amendments resulting from their failure to register with and download documents from WEBS. By submitting a bid, Bidders hold the State of Washington harmless from all claims of injury or loss resulting from such failure. Bidders are solely responsible for:

- Properly registering with the Department of Enterprise Services WEBS at: https://pr-webs-vendor.des.wa.gov/.
- Maintaining an accurate Bidder profile in WEBS
- Downloading the solicitation consisting of the RFQQ with all attachments, appendices, and all current and subsequent Q&A and/or amendments to the solicitation.

### *4.10 Insurance Coverage*

If Bidder is chosen as the ASB, Bidder is required to carry commercial insurance in accordance with the instructions in *Attachment 5, Insurance Requirements*, to this RFQQ.

## *5. NOTIFICATIONS TO BIDDER*

### *5.1 Period of Performance*

The period of performance of any contract(s) resulting from this RFQQ is tentatively scheduled to begin and end on or about the dates indicated within the *Anticipated Procurement Schedule* on page one of this RFQQ. In its sole discretion, WSP reserves the option to revise the begin and end dates of the contract beyond what is anticipated. WSP, in its sole discretion, may extend the contract as needed at the same terms and conditions. In most cases, the total term, including the initial term and all subsequent extensions, is not expected to exceed five (5) years, unless an emergency exists and/or special circumstances require an additional term extension, to be determined by WSP in its sole discretion.

### *5.2 Funding*

The estimated funding for this first year of the project shall not exceed the amount indicated in the *Contract Terms* on page one of this procurement. Additional funding may be added to the contract with any extension of the Contract End Date. Any contract(s) awarded as a result of this procurement is contingent upon the availability of funding.

### *5.3 No Obligation to Contract*

This RFQQ does not obligate the State of Washington or WSP to contract for services specified herein. WSP reserves the right to cancel this RFQQ entirely, or to cancel and reissue the RFQQ in whole or in part at any time prior to the execution of a contract.

### *5.4 Evaluation and Scoring*

Proposals will be evaluated in accordance with the procedures outlined in *Attachment 3, Evaluations and Scoring*, to this RFQQ.

### *5.5 Complaint, Debrief & Protest Requirements*

Complaints, requests for Debrief and Protest Requirements must be submitted in accordance with the instructions in *Attachment 4, Complaint, Debrief & Protest*, to this RFQQ.

### *5.6 Rejection of Proposals*

WSP reserves the right in its sole discretion to reject all proposals received without penalty and to not issue a contract as a result of this RFQQ.

### *5.7 Commitment of Funds*

The Chief of the Washington State Patrol or those with authority delegated by the Chief of the Washington State Patrol are the only individuals who may legally commit WSP to the expenditures of funds for a contract resulting from this RFQQ. No cost chargeable to the proposed contract may be incurred before receipt of a fully executed contract. WSP shall not be responsible for or pay for any costs incurred by Bidder incurred before receipt of a fully executed contract.

### *5.8 Rejection Due to Unsatisfactory Performance*

Pursuant to the provisions of RCW 39.26.160, WSP may reject Proposals of any Bidder who has failed to perform satisfactorily under any previous contract. WSP shall notify the Bidder of such a rejection.

### *5.9 Sample Contract*

The Apparent Successful Bidder will be expected to enter into a contract which is substantially the same as *Attachment 7, Sample Contract* hereto. In no event is a Bidder to submit its own standard contract terms and conditions in response to this solicitation.

Issues, concerns, exceptions or objections to any of the terms or conditions contained in the Sample Contract shall be set forth in writing by the Bidder in Bidder's Proposal as exceptions to the Sample Contract, set forth in *Appendix I, Exceptions to Sample Contract*. The exceptions shall be listed by section or paragraph with a description of each issue, concern, exception and/or objection, not as a red-lined copy of the model contract. WSP reserves the right to reject any and all revision requests. If the Bidder does not notify WSP of any exceptions to the contract, the Bidder will be deemed to have accepted the terms of the Sample Contract.

Successful Bidders are expected to sign the final contract within 30 days of receipt. Contracts not signed within designated time may be voided and the offer to contract may be rescinded.

### *5.10 Background Checks – for Apparently Successful Bidder*

Any proposed Contractor team member or subcontractor who will have unaccompanied access to WSP facilities, electronic equipment, computers, data bases, or other sensitive or restricted information must submit to WSP criminal history fingerprint background checks (background check) at Contractor's expense. Each person that requires a background check must complete Fingerprint Background Checks forms before performing any work under a contract resulting from this RFQQ and before unaccompanied access is granted. Sample forms are attached as an Exhibit to *Attachment 7, Sample Contract*.

Contractor and all team members and subcontractors requiring a background check shall comply with WSP instructions on submitting fingerprints and provide all requested information to WSP in order to complete the background checks.

In addition, Contractor and all team members and subcontractors requiring a background check shall undergo security awareness training online annually. A link to the security awareness training will be provided to the person by WSP upon completion of the fingerprint background check.

Failure of Contractor, Contractor team members or subcontractors to cooperate with WSP during the background check process or to complete security awareness training may result in termination of the contract.

### *5.11 Procurement Technical Assistance Center (PTAC)*

Bidders are encouraged to visit the Procurement Technical Assistance Center (PTAC) for information and resources responding to this bid. The PTAC, also known as APEX Accelerator, advises businesses on how to win government contracts and subcontracts. The one-on-one technical assistance includes bid reviews, marketing assistance, contract performance, small business certifications, and more. PTAC and APEX Accelerators also hosts procurement training classes and seminars, and helps businesses register with the correct databases in order to compete for government contracts.

The Washington State PTAC, an APEX Accelerator, assists businesses through the government-contracting marketplace. Washington PTAC's mission is to increase the number of government contracts awarded to Washington firms so that those firms can grow. We provide no cost, confidential, one-on-one technical assistance in all aspects of selling to federal, state, and local governments.

With the help of PTAC, Washington State companies are awarded $300 million in government contracts each year. When you become a client of Washington PTAC you gain access to experienced counselors who can help you navigate the maze of government contracting. Our

services are free as are most of our events and workshops. To learn more about the benefits of becoming a client Click **here**.

## 6. *Supplier Diversity*

This procurement and any subsequent contracts entered into as a result of this procurement, are subject to the terms and conditions of the following:

- State of Washington Department of Enterprise Services Supplier Diversity Policy No. POL-DES-090-06
- State Law RCW 39.26.090(6)
- State Law RCW 39.26.005
- State Law 39.26.240
- State Law RCW 39.26.245
- State Law RCW 39.26.160(3)(b)
- State Law RCW 43.60A.200
- State Law RCW 39.26.010
- Executive Order 19-01
- Executive Order 22-01
- DES Policy 210-01
- Executive Order 05-03

### *6.1 Access Equity System (AES)*

The AES is the statewide system where subcontractor spending will be tracked and monitored. The purpose of this monitoring is to measure the progress the state has made toward increasing spending on contracts that include small or diverse vendors.

***Registration***: If the Bidder plans to subcontract any of the work under a contract entered into as a result of this solicitation, upon execution of a contract, the Bidder is required to register in the Access Equity System (AES). Please check the following link to the AES system to register for training and report spending: https://omwbe.diversitycompliance.com/ or through a direct link on the Office of Minority and Women's Business Enterprises (OMWBE) website at: https://omwbe.wa.gov/.

***Reporting***: Contractor will provide monthly reports via the AES of each payment received from WSP associated with the contract.

Training: If the contractor is subcontracting any of the work under a contract entered into as a result of this solicitation, the contractor will be required to attend two training Sessions on how to use the ACCESS Equity System which will be available around September. Contractor may access the AES at the following links: https://omwbe.diversitycompliance.com/ or through a direct link on the Office of Minority and Women's Business Enterprises (OMWBE) website at: https://omwbe.wa.gov/.

### *6.2 Diversity Participation*

In accordance with the intent of RCW 39.26.005, the state encourages agency purchases of goods and services from state small businesses. State small business, mini-business, and micro-business are defined in RCW 39.26.010 (16), (17), & (22) respectively. For information on how small business status impacts the scoring process, see *Attachment 3, Evaluations and Scoring*.

In accordance with RCW 43.60A.200, the state encourages participation in all of its procurement contracts from firms certified by the Washington State Department of Veterans Affairs (DVA). For information on these certified firms, Bidders may contact DVA at https://www.dva.wa.gov/doing-business-washington-state. For more information on how veteran-owned status impacts the scoring process, see *Attachment 3, Evaluations and Scoring.*

### *6.3 Washington State Economic Goals*

In support of the state's economic goals, bidders are encouraged to consider the following in responding to this Solicitation:

- Support for a diverse supplier pool, including veteran-owned, minority-owned, and women-owned business enterprises.
- Achievement of these goals is encouraged whether directly or through subcontractors.
- Bidders may contact the Office of Minority and Women's Business Enterprises for information on certified firms or to become certified.
- Veterans and U.S. active duty, reserve or National Guard service-members are eligible for the registry. The veteran or service-member must control and own at least fifty-one (51) percent of the business, and the business must be legally operating in the State of Washington. Control means the authority or ability to direct, regulate or influence day-to-day operations.

While participation in these programs is encouraged, no minimum level of participation shall be required as a condition for receiving an award and proposals shall not be rejected or considered non-responsive on that basis.

In some cases, a small business as described above may also be certified by the Office of Minority and Women's Business Enterprises (OMWBE) in accordance with RCW 39.19. For information of these certified firms, Bidders may contact OMWBE at: http://www.omwbe.wa.gov/.

Bidders must identify in *Appendix B, Certifications*, if they, or any subcontractors, meet the definitions and/or are certified as described above.

### *6.4 Posting of Winning Bid*

This procurement may, as required by law, be transparent by publicly posting bids and bid award documents on the WSP public website.

## 7. *RFQQ APPENDICES AND ATTACHMENTS*

The following Appendices are required and must be completed or answered and returned along with the Bidder's Proposal

| | |
|---|---|
| Appendix A – Bidder's Checklist (MANDATORY) | APPENDIX A-Bidders Checklist.docx |
| Appendix B – Certifications (MANDATORY) | APPENDIX B-Certifications.docx |
| Appendix C – Bidder Questionnaire (MANDATORY/SCORED) | APPENDIX C-Bidder's Questionnaire.docx |
| Appendix C1 – Laboratory Questionnaire (MANDATORY/SCORED) | APPENDIX C1-Laboratory Questi |
| Appendix D – Price Sheet (MANDATORY/SCORED) | APPENDIX D-Price Sheet.docx |
| Appendix E – Bidder's Profile (MANDATORY/SCORED) | APPENDIX E-Bidder's Profile.docx |
| Appendix F – Bidder's Reference Form (MANDATORY/SCORED) | APPENDIX F_Bidder's Reference Form.docx |
| Appendix G – Exceptions to Sample Contract | APPENDIX G_Exceptions to Mode |

The following Attachments are informational and contain critical instructions for submission of a Proposal.
Do not return the Attachments to WSP.

| | |
|---|---|
| Attachment 1 – Not Applicable | No Attachment |
| Attachment 2 – Proposal Submission Instructions | ATTACHMENT 2_Proposal Submissic |
| Attachment 3 – Evaluations and Scoring | ATTACHMENT 3_Evaluation Scoring |
| Attachment 4 – Complaint, Debrief & Protest | ATTACHMENT 4_Complaint Debrief F |
| Attachment 5 – Insurance Requirements | ATTACHMENT 5_Insurance Requirem |
| Attachment 6 – Definitions | ATTACHMENT 6_Definitions.docx |
| Attachment 7 – Sample Contract | ATTACHMENT 7-Sample Contract.do |
| Attachment 8 – Doing Business with the State of Washington | ATTACHMENT 8_Doing Business Wit |
| Attachment 9 – Pre-Bid Conference | ATTACHMENT 9-Pre Bid Conference.docx |

**COMPANY NAME:** _____

This checklist is provided for Bidder's convenience and identifies the documents to be submitted with each proposal.

***THE FOLLOWING ARE MANDATORY AND MUST BE PROVIDED FOR THE PROPOSAL TO BE CONSIDERED RESPONSIVE.***

***Signatures accepted: PDF Certified or wet-ink scanned***

☐ Letter of Submittal **/ hard signature and in PDF format**

☐ Proposal submitted on or before the date and time indicated within the *Anticipated Procurement Schedule* on page one of this Solicitation, or as amended.

☐ Appendix A: Bidder's Checklist

☐ Appendix B: Certifications **/ PDF Certified or wet-ink scanned signature and in PDF Format INCLUDE ALL REQUIRED DOCUMENTS**

☐ Appendix C: Bidder Questionnaire

☐ Appendix C1: Laboratory Questionnaire

☐ Appendix D: Price Sheet (**PDF Certified or wet-ink scanned signature and in PDF Format INCLUDE PRICE LIST**).

☐ Appendix E: Bidder's Profile

☐ Appendix F: Bidder's Reference Form

☐ Appendix G: Exceptions to Model Contract **/ PDF Certified or wet-ink scanned signature and in PDF Format**

☐ Certificate and Scope of ISO 17025 and ABFT Accreditation by ANAB

☐ Traceability and Quality Control Processes

☐ Standard Operating Procedures and/or relevant policies

☐ Example test report for the requested tests/scope of testing

☐ Example litigation package and litigation package and expert testimony pricing

**DOCUMENTS REQUIRED BEFORE CONTRACT CAN BE SIGNED:**

☐ A copy of the bidder's Washington Business License **/ in PDF format**

**NOTE:** *Corporate filing with the Washington Secretary of State is not a Washington Business License. Business license must be obtained from the Department of Revenue.*

☐ Copy of OMWBE certificate, if you have one **/ in PDF format**

☐ Proof of Liability Insurance

Bidder's Company Name:

Bidder has read and understands all information contained within this entire Solicitation package.

Bidder makes the following Certifications as a required element of the response to which it is attached, understanding that the truthfulness of the facts affirmed here and declare that all answers and statements made in the proposal are true and correct and the continuing compliance with these requirements are conditions precedent to the award or continuation of the related contracts.

## SECTION 1: GENERAL

***Check the boxes below to indicate understanding and acceptance of each certification below:***

☐ The prices and/or cost data/bid Interest information has been determined independently, without consultation, communication, or agreement with others for the purpose of restricting competition. However, Bidder may freely join with other persons or organizations for the purpose of presenting a single bid. No attempt has been made or will be made by the Bidder to induce any other person or firm to submit or not to submit a proposal for the purpose of restricting competition.

Unless otherwise required by law, the prices and/or cost data which have been submitted have not been knowingly disclosed by the Bidder and will not knowingly be disclosed by Bidder, directly or indirectly to any other Vendor or to any competitor until after a Contract has been executed.

☐ In preparing this proposal, Bidder had not been assisted by any current or former employee of the state of Washington whose duties relate (or did relate) to this proposal or prospective contract. Any exceptions to these assurances are described in full detail on a separate page and attached to this document.

☐ Bidder further offers to furnish materials, equipment or services in compliance with all terms, conditions, and specifications herein including all amendments.

☐ Bidder understands that WSP will not reimburse Bidder for any costs incurred in the preparation of this proposal. All proposals become the property of WSP, and Bidder claims no proprietary right to the ideas, writings, items, or samples, unless so stated in this proposal.

☐ Bidder agrees that submission of the attached proposal with an authorized signature constitutes complete understanding and acceptance of the solicitation contents and all incorporated and attached appendices, attachments, schedules, and amendments including the sample contract and general terms and conditions. Bidder further certifies that all necessary facilities or personnel are available and established at the time of bid submission. If there are any exceptions to these terms, Bidder has described those exceptions in detail in its proposal.

☐ The proposal submitted in response to this solicitation is a firm offer for a period of 180 days following receipt and it may be accepted by WSP without further negotiation except where obviously required by lack of certainty in key terms) at any time within the 180-day period.

## SECTION 2: DEBARMENT

☐ ***No Debarment***. Bidder and/or its principals, agents, or any subcontractor providing services under this procurement are <u>not</u> presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from contracting with any federal, state, or local governmental entity.

***OR***

☐ ***Debarment.*** As detailed on the attached explanation (Bidder to provide), Bidder and/or its principals, agents, or subcontractors, presently are debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from contracting with a federal, state, or local governmental entity.

## SECTION 3: EMPLOYEE RIGHTS

*Pursuant to the Washington State Governor's Executive Order 18-03 (dated June 12, 2018), the Washington State Patrol is seeking to contract with qualified entities and business owners who certify that their employees are not, as a condition of employment, subject to mandatory individual arbitration clauses and class or collective action waivers.*

I hereby certify, on behalf of the firm identified below, as follows (check one):

☐ NO MANDATORY INDIVIDUAL ARBITRATION CLAUSES AND CLASS OR COLLECTIVE ACTION WAIVERS FOR EMPLOYEES: This firm does NOT require its employees, as a condition of employment, to sign or agree to mandatory individual arbitration clauses or class or collective action waivers.

***OR***

☐ MANDATORY INDIVIDUAL ARBITRATION CLAUSES AND CLASS OR COLLECTIVE ACTION WAIVERS FOR EMPLOYEES: This firm requires its employees, as a condition of employment, to sign or agree to mandatory individual arbitration clauses or class or collection action waivers.

## SECTION 4: WAGE THEFT PREVENTION

Prior to awarding a contract, agencies are required to determine that a bidder is a 'responsible bidder.' See RCW 39.26.160(2) & (4). Pursuant to legislative enactment in 2017, the responsible bidder criteria include a contractor certification that the contractor has not willfully violated Washington's wage laws. See Chap. 258, 2017 Laws (enacting SSB 5301).

☐ **NO WAGE VIOLATIONS**. This firm has NOT been determined by a final and binding citation and notice of assessment issued by the Washington Department of Labor and Industries or through a civil judgment entered by a court of limited or general jurisdiction to have willfully violated, as defined in RCW 49.48.082, any provision of RCW chapters 49.46, 49.48, or 49.52 within three (3) years prior to the date of the above-referenced procurement solicitation date.

***OR***

☐ **VIOLATIONS OF WAGE LAWS**. This firm has been determined by a final and binding citation and notice of assessment issued by the Washington Department of Labor and Industries or through a civil judgment entered by a court of limited or general jurisdiction to have willfully violated, as defined in RCW 49.48.082, a provision of RCW chapters 49.46, 49.48, or 49.52 within three (3) years prior to the date of the above-referenced procurement solicitation date.

## SECTION 5: SMALL BUSINESS

***Washington Small Business***

☐ *Washington Small Business.* Bidder is a Washington Small Business as defined in RCW 39.26.010. To qualify as a Washington Small Business, Bidder must meet three (3) requirements:

- Location. Bidder's principal office/place of business must be located in and identified as being in the State of Washington. A principal office or principal place of business is a firm's headquarters where business decisions are made and the location for the firm's books and records as well as the firm's senior management personnel.
- Size. Bidder must be owned and operated independently from all other businesses and have either: (a) fifty (50) or fewer employees; or (b) gross revenue of less than seven million dollars ($7,000,000) annually as reported on Bidder's federal income tax return or its return filed with the Washington State Department of Revenue over the previous three consecutive years.
- WEBS Certification. Bidder must have certified its Washington Small Business status in Washington's Electronic Business Solution (WEBS).

***OR***

☐ *Not Washington Small Business.* Bidder is not a Washington Small Business as defined in RCW 39.26.010.

## SECTION 6: CERTIFIED VETERAN -OWNED BUSINESS

☐ *Certified Veteran-Owned Business.* Bidder is a Certified Veteran-Owned Business under RCW 43.60A.190. To qualify as a Certified Veteran-Owned Business, Bidder must meet four (4) requirements:

- 51% Ownership. Bidder must be at least fifty-one percent (51%) owned and controlled by:
  - A veteran as defined as every person who at the time he or she seeks certification has received a discharge with an honorable characterization or received a discharge for medical reasons with an honorable record, where applicable, and who has served in at least one of the capacities listed in RCW 41.04.007;
  - A person who is in receipt of disability compensation or pension from the department of veterans affairs; or
  - An active or reserve member in any branch of the armed forces of the United States, including the national guard, coast guard, and armed forces reserves.
- Washington Incorporation/Location. Bidder must be either an entity that is incorporated in the state of Washington as a Washington domestic corporation or, if not incorporated, an entity whose principal place of business is located within the State of Washington.
- WEBS Certification. Bidder must have certified its Veteran-Owned business status in Washington's Electronic Business Solution (WEBS).
- WDVA Certification. Bidder must have provided certification documentation to the Washington Department of Veterans' Affairs WDVA) and be certified by WDVA and listed as such on WDVA's website (WDVA – Veteran-Owned Businesses).

***OR***

☐ *Not A Certified Veteran-Owned Business*. Bidder is not a Certified Veteran-Owned Business under RCW 43.60A.190.

## SECTION 7: OFFICE OF MINORITY AND WOMEN OWNED BUSINESSES (OMWBE)

☐ Bidder is Certified as a small or minority business with the OMWBE

***OR***

☐ Bidder is NOT Certified as a small or minority business with the OMWBE

I hereby certify, under penalty of perjury under the laws of the State of Washington, that the certifications herein are true and correct and that I am authorized to make these certifications on behalf of the firm listed herein.

| | | |
|---|---|---|
| Click here to enter text. | Click here to enter text. | Click here to enter text. |
| Full Legal Name of Bidder | Business Address | Email Address |
| Click here to enter text. | | Click here to enter text. |
| Full Name, Title | Bidder's Signature | Date |

### 1. Bidder Organization (MANDATORY)

Describe Organization, including size, areas of services, number of years in business, customer base, and any other pertinent information that would aid evaluators in formulating a determination about the capability, stability, and strength of the Bidder's organization.

*Click here to enter text.*

### 2. Bidder Qualifications and Experience (MANDATORY/SCORED)

Describe qualifications and experiences performing similar projects in terms of similar scope, services, government program, size, and project characteristics. Provide explanation of how Bidder meets minimum qualifications; i.e., include Bidder's experience and history with providing services described in this RFQQ.

Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

*Click here to enter text.*

### 3. Quality Assurance (MANDATORY/SCORED)

Proposal must describe Bidder's approach to Quality Assurance and how Bidder will implement quality control.

*Click here to enter text.*

### 4. Approach/Strategy (MANDATORY/SCORED)

Describe the Bidder's approach to the work as outlined in Attachment 1, Statement of Work. Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

*Click here to enter text.*

### 5. Related Information (MANDATORY)

**5.1 State Contracts.** Has the Bidder or any subcontractor contracted with the state of Washington during the past 24 months?

☐ No ☐ Yes

If Yes, indicate the name of the agency, the contract number and project description and/or other information available to identify the contract.

Has the Bidder ever been terminated for default in the last five years?

☐ No ☐ Yes

If Yes, describe such incident. Termination for default is defined as notice to stop performance due to the Bidder's non-performance or poor performance and the issue of performance was either (a) not litigated due to inaction on the part of the Bidder, or (b) litigated and such litigation determined that the Bidder was in default. Submit full details of the terms for default including the other party's name, address, and phone number. Present the Bidder's position on the matter. WSP will evaluate the facts and may, at its sole discretion, reject the response on the grounds of the past experience. If no such termination for default has been experienced by the Bidder in the past five years, so indicate.

*Click here to enter text.*

**5.2 State Employees.** Is anyone in the Bidder's staff or subcontractor's staff a former employee of the state of Washington during the past 24 months, or is currently a Washington State employee?

☐ No ☐ Yes

If Yes, identify the individual by name, the agency previously or currently employed by, job title or position held and separation date. Also identify any State employees or former State employees employed or on the Bidder's governing board as of the date of the response. Include their position and responsibilities within the Bidder's organization. Include any staff member(s) who will perform work on this contract and has retired from the State of Washington under the provisions of the 2008 Early Retirement Factors legislation. If following a review of this information, it is determined by WSP that a conflict of interest exists, the Bidder may be disqualified from further consideration for the award of a contract.

*Click here to enter text.*

**WSP-TLD** | **LABORATORY QUESTIONNAIRE**

**RFQQ APPENDIX C1**

| | | | |
|---|---|---|---|
| LABORATORY NAME: | | | |
| ADDRESS: | | | |
| CITY: | | STATE: | |
| PHONE: | | ZIP CODE : | |
| WEBSITE: | | | |

Prospective laboratories: Complete this form for those forensic toxicology testing services listed below, as requested by the Washington State Patrol (WSP) Toxicology Laboratory Division. Where applicable, evidence of accreditation status, traceability and quality control processes must be included in your response. Copies of standard operating procedures or relevant policies must also be included as supporting material for answers to those questions below. The WSP Toxicology Laboratory Division may request additional documentation for evaluation/quality review of the prospective laboratory.

---

***Test/scope of testing requested by the WSP Toxicology Laboratory Division***: Testing is required for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases. Bidders must have the ability to perform comprehensive testing for a broad array of therapeutic drugs and drugs of abuse (to include differentiation of delta-9 THC from cannabinoid analogs) and update their scope of testing periodically to include emerging drugs.

---

***Question 1, Accreditation (Mandatory, Scored)***: List the current accreditation status of the laboratory, including accrediting body(ies). Provide the laboratory's certificate and scope of accreditation (however named) for the requested tests/scope of testing (or reference to documents located on the laboratory's website).

**Response**:

***Question 2, Traceability (Mandatory, Scored)***: Does the laboratory demonstrate traceability of reference materials/reference standards to SI units of measurement? If so, describe the laboratory's traceability policies and procedures.

**Response**:

***Question 3, Uncertainty of Measurement (Mandatory, Scored)***: Does the laboratory provide uncertainty of measurement for the requested tests/scope of testing? If so, describe the laboratory's policies and procedures for determination and reporting of uncertainty of measurement.

**Response**:

***Question 4, Quality (Mandatory, Scored)***: Describe the processes whereby the laboratory assures the quality of the test results in the requested tests/scope of testing (e.g. use of quality controls, method validation, proficiency testing).

**Response**:

***Question 5, Test Results (Mandatory, Scored)***: Does the laboratory's report of results include the evidence identifier, date of testing and test method used? If no, is this information documented in the laboratory's testing records and available upon request? Please provide an example of the test report for the requested tests/scope of testing.

**Response**:

***Question 6, Turnaround Time (Mandatory, Scored)***: State the average or median turnaround time for case completion (to include confirmation results). Provide any relevant details.

**Response**:

**RFQQ APPENDIX C1**

| | |
|---|---|
| Authorized Signature: | Date Signed: |
| Name and Title: | |

***1. COST:***

Although cost is a consideration when selecting the Apparent Successful Bidder, the evaluation process is designed to award this procurement not necessarily to the Bidder of least cost, but rather to the Bidder whose proposals best meet the requirements of this Solicitation.

***2. PRICING:***

Bid amounts must include all cost components needed to provide services as described in this Solicitation, including travel, labor and supplies. All costs associated with services must be incorporated into the price of the Bidder's Response, for the initial contract period and all potential contract extensions. Failure to identify all costs in a manner consistent with the instructions in this Solicitation will result in rejection of bidder's proposal as nonresponsive.

The Apparent Successful Bidder's (ASB) Quotation must remain fixed for the awarded Contract's period of performance. Price increases may occur at the time of contract renewal by mutual agreement of the parties, but in no case more than 5%.

Proposed costs shall include any applicable Washington State taxes associated with the contract work that the Bidders are required to pay. Bidders are required to collect and pay state taxes as applicable.

***3. BIDDER'S PRICE LIST:***

Bidder shall include with the proposal a complete list of testing services provided and the cost of each service.

| Company Name: | |
|---|---|
| Authorized Signature: | Date Signed: |
| Name and Title | |

| | | |
|---|---|---|
| Legal Company Name | Click here to enter text. | |
| Doing Business As | Click here to enter text. | |
| Legal Status | Click here to enter text. | |
| Year Company Established | Click here to enter text. | |
| Washington State Tax ID Number<br>OR<br>Universal Business Identifier Number (UBI) | Click here to enter text. | |
| Statewide Vending Number | Click here to enter text. | |
| Washington Business License Number | Click here to enter text. | Expiration Date |
| If you do not have a Washington Business License, please explain the status of your application. | Click here to enter text. | |
| Website URL Address | Click here to enter text. | |
| Street Address | Click here to enter text. | |
| Mailing Address, if different from Street Address | Click here to enter text. | |
| Billing Address | Click here to enter text. | |
| Company Contact Name | Click here to enter text. | |
| Contact Phone Number | Click here to enter text. | |
| Email | Click here to enter text. | |

**The following attachments are required:**

- Organizational chart
- List of principal officers including Name, Title, Address, and Telephone number
- Copy of Washington Business License
    - Note: A Washington Business License is required before a contract can be signed. If you do not have a business license, you may apply for one at the Washington Department of Revenue.

**BIDDER'S COMPANY NAME:**

WSP will conduct reference checks on top two or three scoring Bidders. Bidder shall furnish a minimum of three (3) references from different entities for which Bidder has performed or provided comparable service, similar in scope to this Solicitation. ***Do not use WSP as a reference***.

The WSP may contact one or more of the references provided. WSP will attempt to make contact with a Bidder's reference a maximum of two (2) times. If contact cannot be established then the reference may be deemed non-responsive and no further attempts will be made to contact that particular reference. If references give significant negative feedback, Bidder may be rejected and no longer considered for contract award.

The WSP reserves the right to solicit and substitute other references to determine the sufficiency of the Bidder's level of responsibility.

## Reference 1

| | |
|---|---|
| Company Name | Click here to enter text. |
| Company Address | Click here to enter text. |
| Contact Person's Name and Title | Click here to enter text. |
| Phone Number (Best # to reach them) | Click here to enter text. |
| Email address | Click here to enter text. |
| Time period you provided services | Click here to enter text. |
| Brief description of the services provided to this reference:<br><br>Click here to enter text. | |

## Reference 2

| | |
|---|---|
| Company Name | Click here to enter text. |
| Company Address | Click here to enter text. |
| Contact Person's Name and Title | Click here to enter text. |
| Phone Number (Best # to reach them) | Click here to enter text. |
| Email address | Click here to enter text. |
| Time period you provided services | Click here to enter text. |
| Brief description of the services provided to this reference:<br><br>Click here to enter text. | |

## Reference 3

| | |
|---|---|
| Company Name | Click here to enter text. |
| Company Address | Click here to enter text. |
| Contact Person's Name and Title | Click here to enter text. |
| Phone Number (Best # to reach them) | Click here to enter text. |
| Email address | Click here to enter text. |
| Time period you provided services | Click here to enter text. |
| Brief description of the services provided to this reference:<br><br>Click here to enter text. | |

## Company Name:

Bidders should use the following table for Appendix I: Exceptions to Model Contract.

| ID No. | Contract Section | Issue | Reasons for Proposed Change | Exact Proposed Alternative or Additional Language for the Contract (use track changes on text) |
|---|---|---|---|---|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |

## 1. Submission of Proposals

The proposal must arrive at WSP RFQQ Coordinator at the email below no later than date and time listed within the *Anticipated Procurement Schedule* on page one of this RFQQ. All proposals and any accompanying documentation become the property of WSP and will not be returned.

**1.1** Letter of Submission Requirements. The Letter of Submittal must be signed and dated by a person authorized to legally bind the Bidder to a contractual relationship, e.g., the President or Executive Director if a corporation, the managing partner if a partnership, or the proprietor if a sole proprietorship.

The letter of submittal must contain the following:

- Company Introduction
- A list of attachments, including Appendices and other documents attached
- Any other information that would assist WSP to evaluate the proposal
- A hard-copy signature of the individual authorized to legally bind the company to a contract.
- Be submitted in PDF format
- Follow naming conventions as listed in Section 3.1.11 below.

**1.2** **Proposal Method of Delivery**. Bidder's proposal must be delivered to the RFQQ Coordinator via email.

**1.3** **Assumption of Risk.** Bidders assume the risk for the delivery of the proposal. WSP assumes no responsibility for delays caused by any delivery service. Late proposals will NOT be accepted and will be automatically disqualified from further consideration.

**1.4** **Referencing**. Do not respond by referencing material presented elsewhere. The proposal shall be considered complete and stand on its own merits.

**1.5** **Time**. Bidders should allow sufficient time to ensure timely receipt of the Proposal and related documents by the RFQQ Coordinator on or before the date and time indicated within the *Anticipated Procurement Schedule* on page one of this RFQQ.

## 2. Submission Address

Proposals must be submitted to the RFQQ coordinator via email to the below address:

| | |
|---|---|
| RFQQ Coordinator | Shannon Oien |
| RFQQ Coordinator Email Address: | shannon.oien@wsp.wa.gov |

## 3. Submission of Proposals

### 3.1 Electronic Submission of Proposals

3.1.1 Time of receipt is defined as the time that the RFQQ Coordinator's email inbox records that the response was received, NOT by the Bidder's transmittal stamp. WSP assumes no responsibility for delays caused by Bidder's e-mail, network problems or any other party. If WSP's Email is not working, appropriate allowances will be made. Any proposals received after 4:00 pm on the proposal due date will be rejected.

3.1.2 The use of links or objects inserted into a document or pointing to a cloud-based program, are not acceptable methods of submittal. Proposals submitted that include such links or objects will be rejected as non-responsive and will not receive further consideration.

3.1.3 Appendices noted on Appendix A, Bidders Checklist submitted utilizing the WSP form provided with this RFQQ. Bidders shall not copy and paste the form into their own document. Any proposals that do not utilize the actual form provided by WSP, or that copy and paste the Appendices into their own document will be rejected and will not be given further consideration.

3.1.4 All files in a Bidder's Response must be submitted in Microsoft Word, Microsoft Excel, or PDF. ***All signature pages must be submitted in PDF format***.

3.1.5 Formats not identified herein may be accepted only upon prior written approval of WSP. If prior approval is not obtained, the submission will be considered nonresponsive and will not be given further consideration.

3.1.6 Proposals and related documents shall be submitted as attachments to an email, and not included as part of the body of the email or as a link. Proposals that are not submitted as attachments will be considered nonresponsive and will not be given further consideration.

3.1.7 Bidder must include the RFQQ number and Bidder's company name in the Subject line of the email.

3.1.8 Bidders may break email submittals into multiple emails provided each email clearly indicates in the subject line its overall place in the series, as well as the total number of separate emails being sent.

For example, if Bidder is submitting their response in three (3) separate emails, the subject line of the first should be "Company Name_RFQQ-TOXTST_Response 1 of 3"; the next email's subject line would be "Company Name _ RFQQ-TOXTST_Response 2 of 3"; etc. Replace "RFQQ-TOXTST" in these examples with the number assigned to this solicitation. Replace "Company name" with your actual company's name.

3.1.9 Abbreviate your company's name as appropriate to keep the name as short as possible.

3.1.10 Documents must be attached to the email, not imbedded in the email.

3.1.11 Naming Conventions. All proposal attachments must strictly adhere to the following name convention expectations and be attached to the email in the indicated required format. Follow this naming convention with additional documents that may be submitted with the proposal. Follow these naming conventions exactly, substituting "RFQQ-TOXTST" with the RFQQ number of this solicitation and "Company Name" with your actual company's name. Follow the name naming convention for all documents included in your proposal. Failure to follow naming conventions will result in rejection of the proposal as unresponsive.

Abbreviate your company's name as appropriate to keep the name as short as possible.

Company Name-Letter of Submittal-RFQQ-TOXTST.
Company Name-Appendix A- RFQQ-TOXTST
Company Name-Appendix B- RFQQ-TOXTST
Company Name-Appendix C- RFQQ-TOXTST
Company Name-Appendix D- RFQQ-TOXTST
Company Name-Appendix E- RFQQ-TOXTST
Company Name-Appendix F- RFQQ-TOXTST
Company Name-Appendix G- RFQQ-TOXTST
Company Name-Appendix H- RFQQ-TOXTST
Company Name-Appendix I- RFQQ-TOXTST
Company Name-Appendix J- RFQQ-TOXTST
Company Name-Insurance- RFQQ-TOXTST
Company Name-Business License- RFQQ-TOXTST

**3.2 Hard Copy Proposals**

3.2.1 Hard copy proposals are not accepted. Hard copy proposals will be considered nonresponsive and will not be given further consideration.

Table of Contents



## 1. GENERAL INFORMATION

1.1 All Bidder proposals and responses will be evaluated strictly in accordance with the requirements set forth in this solicitation and any amendments thereto.

1.2 The proposal must contain information that will demonstrate to the Evaluation Team the Bidder's understanding of the type of product proposed, the Bidder's ability to provide the product, and the ability to meet timeframes.

1.3 The evaluation process is designed to award this procurement not necessarily to the Bidder of the least cost, but rather the Bidder who is qualified, reliable, experienced, and capable of providing effective and quality services at a reasonable value and whose proposal best meets the requirements of this solicitation. Bidders are encouraged, however, to submit proposals which are consistent with state government efforts to conserve state resources.

## 2. RESPONSIVE/NONRESPONSIVE

2.1 Bidder proposals that do not include all required documents in *Appendix A, Bidder's Checklist* of this solicitation will be considered nonresponsive and will not receive further consideration.

2.2 Proposals that are not submitted on or before the date and time shown on the *Anticipated Procurement Schedule* on page one of this solicitation will be considered nonresponsive and will not receive further consideration.

2.3 Bidders that do not meet the minimum qualifications established in this RFQQ will be considered nonresponsive and will not receive further consideration.

2.4 Nonresponsive bidders will be notified by email of the reason for the nonresponsive decision.

## 3. EVALUATION OF PROPOSALS

WSP may require Bidders to attend a Bidder's Conference at a date, time and place determined by WSP for the purpose of conducting discussions to determine whether both parties have a full and complete understanding of the nature and scope of contractual requirements. In no manner shall such action be construed as negotiations or an indication of an intention to award. At WSP's discretion, the Bidder's Conference may be designated as mandatory on page one of this solicitation, in which case a bidder's failure to attend the Bidder's Conference will result in Bidder's proposal being rejected as nonresponsive.

During evaluation, WSP reserves the right to make reasonable inquiry to determine the responsibility of any Bidder. Requests may include, but are not limited to, financial statements, credit ratings, references, record of past performance, clarification of Bidder's offer, and on-site inspection of Bidder's or Bidder's

subcontractor's facilities. Failure to respond to said request(s) will result in a proposal being rejected as nonresponsive.

3.1 The evaluation of proposals shall be accomplished by an evaluation team to be designated by WSP, which will determine the ranking of the proposals.

3.2 The team will consider how well the Bidder's response meets all requirements detailed in this solicitation. Because of the potential diversity of skills within the evaluation team it is important that responses be clear and complete so that the evaluators can adequately understand all aspects of the Bidder's proposal.

3.3 The evaluation process will include, but not be limited to, evaluating Bidder information, written responses to the solicitation, references, and other public information available regarding the Bidder and its products.

3.4 Responsive proposals will be evaluated strictly in accordance with the requirements stated in this solicitation and any amendments issued.

3.5 Each scored item will be awarded points by each evaluator, or through a joint effort by the entire team. Points will be assigned based on the evaluator's interpretation of the effectiveness and efficiency of the Bidder's response to each requirement. In order to receive the most points possible Bidders are encouraged to provide as much clarifying detail as possible without being overly verbose.

## 4. EVALUATION PROCESS, SCORING, and WEIGHTING

4.1 **Process**. The scoring process will consist of the following steps:

| | |
|---|---|
| Step 1 | Screen to ensure proposals are responsive, include all required documentation and are submitted on time |
| Step 2 | Evaluation of Bidder's organization, experience, strategy, quality assurance and overall qualifications to perform the services as outlined in this RFQQ |
| Step 3 | Cost Scoring |
| Step 4 | Reference checks of top scoring Bidders |
| Step 5 | Bidder Demonstrations, oral interview or walkthrough, if required |
| Step 6 | Select the winning Apparent Successful Bidder (ASB) |

4.2 **Scoring**. The following evaluation elements and points will be assigned to the Bidder's proposal for evaluation purposes:

| Section | Possible Points | Minimum Points to be considered responsive (10% lowers than Possible Points) |
|---|---|---|
| Responsiveness – proposal is complete and submitted on time | Pass/Fail | Pass/Fail |
| Certificate and Scope of ISO 17025 and ABFT Accreditation by ANAB (Section 4.1, Solicitation) | Pass/Fail | Pass/Fail |
| Traceability and Quality Control Processes (Section 4.1, Solicitation) | Pass/Fail | Pass/Fail |
| Standard Operating Procedures and/or relevant policies (Section 4.1, Solicitation) | Pass/Fail | Pass/Fail |
| Example test report for the requested tests/scope of testing (Section 4.1, Solicitation) | Pass/Fail | Pass/Fail |
| Example litigation package and litigation package and expert testimony pricing (Section 4.1, Solicitation) | Pass/Fail | Pass/Fail |
| Bidder Organizational evaluation (Question 1, Appendix C) | 100 | 90 |
| Bidder Experience (Question 2, Appendix C) | 100 | 90 |
| Accreditation (Question 1, Appendix C1) | 100 | 90 |
| Traceability (Question 2, Appendix C1) | 100 | 90 |
| Uncertainty of Measurement (Question 3, Appendix C1) | 100 | 90 |
| Quality Assurance (Question 4, Appendix C1) | 100 | 90 |
| Test Results Reporting (Question 5, Appendix C1) | 100 | 90 |
| Turnaround Time (Question 6, Appendix C1) | 50 | 45 |
| Demonstration (if required by WSP) | 50 | 45 |
| Oral Interview (if required by WSP) | 50 | 45 |
| Cost/Pricing | 50 | 45 |
| References | 10 | 9 |
| Net Possible Points | 910 | 829 |
| Workers' Rights Preference Points (Appendix H) Maximum 2% of total points awarded | 18 | 17 |
| Veteran Owned Business | 10 | 9 |
| Certified OMWBE business (10%) | 10 | 9 |
| Total Possible Points | 94 | 864 |

4.3 **Weighting**. Points will be weighted as follows:

| **Score Guidelines** | | |
|---|---|---|
| Percentage | Placement | Explanation |
| 76% - 100% | Exceeds Expectations | Substantial Value Added – Exceeds expectations. Response indicates excellent capability and support of the requirements identified in the solicitation. Response stands above all others. There are no shortfalls. |
| 46% - 75% | Value Added Response | There are no critical shortfalls but does not exceed expectations |
| 26% - 45% | Meets requirements | Exhibits shortfalls in a few non-critical areas. No value added. |
| 1% - 25% | Incomplete | Substantial issues and concerns. The response is incomplete, or deficiencies exist. Fails to establish minimum expectations. Significant deficiencies identified. |
| 0 | Does not meet Expectations or is nonresponsive | Response is incomplete and serious shortfalls in capability exist. Does not meet the standard or the requirements are not addressed. |

**Example:**

| | | |
|---|---|---|
| 100% | of 25 points | = 25 |
| 75% | of 25 points | = 18.75 |
| 45% | of 25 points | = 11.25 |
| 25% | of 25 points | = 6.25 |
| 0% | of 25 points | = 0 |

## 5. SUPPLIER DIVERSITY-CERTIFIED BUSINESS MINIMUM POINTS FOR RESPONSIVENESS

5.1 Bidders that are certified with OMWBE or the Veterans Administration will be required to be awarded the minimum number of points to be considered responsive. It is the intention of this solicitation to award the bid to the highest responsible and responsive certified bidder. If the certified bidder does not meet the minimum points, then the bid will not be considered responsive and can be rejected.

## 6. SUPPLIER DIVERSITY – COST FACTORS

6.1 This solicitation has the flexibility for WSP to award the contract to a certified bidder at a higher dollar amount. A certified bid that exceeds the average of all other bids by 10% shall be deemed nonresponsive.

6.2 Cost and non-cost factors will be evaluated to determine the highest-ranking responsible and responsive certified bidder.

## 7. ORAL INTERVIEWS

Interviews may be required for the top 2 or 3 scoring Bidders. If interviews are required, WSP will schedule the interviews and notify the bidders of the interview date, time, and method of attendance. Oral interviews will be scheduled only when WSP requires clarification on certain items in Bidder's proposal. Bidders may not change their proposal, but may provide clarification. Bidders will receive a score on Oral Interviews according to the table in Section 4 of this document.

## 8. DEMONSTRATIONS

If required by this RFQQ, WSP may request the top 2 or 3 scoring Bidders to demonstrate their product. Bidders will receive a score on Demonstrations according to the table in Section 4 of this document. WSP at its discretion may waive the demonstrations even though it may be listed in Section 4, and notify bidders that no demonstrations will be held.

## 9. REFERENCES

9.1 Bidder shall furnish three (3) references from different entities for which Bidder has performed or provided services within the past five (5) years that are similar in scope to this solicitation.

9.2 WSP has sole discretion whether or not to conduct reference checks.

9.2.1 References are not scored, but WSP may at its sole discretion, reject a Bidder's proposal if references report Bidder's inability to comply with one or more of the mandatory requirements.

9.3 If reference checks are made, the following applies:

9.3.1 WSP may contact references for the top scoring 2 or 3 Bidders.

9.3.2 Reference contacts must be available for phone interviews at any time after the proposal Due Date and before the Announcement of the ASB.

9.3.3 WSP shall make a total of two (2) efforts to contact the Reference. WSP may, in its sole discretion require Bidders to provide additional references if the references cannot be reached.

9.4 Each reference will be asked to respond to the following questions.

9.4.1 Describe the work the Bidder performed for you. When was the work performed?

9.4.2 Did the Bidder complete the required scope of work and meet all deadlines and expectations?

9.4.3 Were you satisfied with the Bidder's Work? Explain why or why not.

9.4.4 How did the Bidder solve problems or resolve issues, if any? Were you satisfied with the Bidder's problem solving skills?

9.4.5 How would you rank the quality of the Bidder's performance?

9.4.6 Was the Bidder easy to work with?

9.4.7 Would you recommend the Bidder to other businesses?

9.5 WSP reserves the right to solicit and substitute other references to determine the sufficiency of the Bidder's level of responsibility.

## 10. METHODOLOGY

### 10.1 Cost proposal Computation.

The score for the cost proposal will be computed by dividing the lowest cost bid received by the Bidder's total cost bid. The resultant number will be multiplied by the maximum possible points for the cost proposal section.

The lowest cost proposal will receive the maximum amount of points with the highest cost proposal receiving the least amount of points.

In the following example, the Bidder with the lowest total project costs will receive the maximum (300) cost evaluation points. Bidders with higher total project costs will receive proportionately fewer cost evaluation points based upon the proposal with the lowest total project cost as follows:

Low bid / higher bid = % of avail. Points awarded * avail. Points = total cost points

| **EXAMPLE:** | Bidder A | Bidder B |
|---|---|---|
| Total project Cost | $90/Hr. (Low bid) | $100/per Hour |
| % of available points awarded | 100% | 90% |
| Cost points (300 available) | 300 | 270 |

8.2 **Non-Cost Evaluation** may include, but shall not be limited to, the following Bidder qualities. The items to be evaluated are listed in Section 4.2 above.

- Bidder's overall technical proposal, relevant experience and organization capabilities,
- The quality of the articles proposed to be supplied, their conformity with specifications, the purposes for which they are required and the times of delivery;
- The ability, capacity, and skill of the Bidder to perform the contract or provide the service required;
- The character, integrity, reputation, judgment, experience, and efficiency of the Bidder;
- Whether the Bidder can perform the contract within the timeframe specified;

- The previous and existing compliance by the Bidder with laws relating to the contract or services;
- Such other information as may be secured having a bearing on the decision to award the contract such as life cycle costing.

8.3 **Scoring Strategy**.

Each scored item will be awarded points by each evaluator, or by the team in total. Points will be assigned based on the evaluator's interpretation of the effectiveness and efficiency of the Bidder's response to each requirement. In order to receive the most points possible, Bidders are encouraged to provide as much clarifying detail as possible without being overly verbose.

8.4 **Final Score Computations**.

The final score shall be computed by the solicitation Coordinator and shall be the sum of the various sections of the response, and/or reference scores. The final score will be used to identify the ASB.

## 9. AWARD CRITERIA

Award will be based on the following criteria and will be in accordance with provisions identified in RCW 39.26.160, supplier diversity criteria in Sections 5 and 6 above, and other criteria identified in the solicitation.

9.1 **Selection of Apparent Successful Bidder**

To identify an apparent successful Bidder, each Bidder's points earned from the cost evaluation and the non-cost evaluation will be added together as the following example shows:

| | Bidder A | Bidder B |
|---|---|---|
| Cost points (300 Possible) | 300 | 265 |
| Non-cost score (600 Possible) | 550 | 423 |
| Interview Score (100 Possible) | 90 | 70 |
| Evaluation point total (1000 Possible) | 940 | 758 |

The Bidder with the highest evaluation point total, or the certified diverse vendor with the minimum number of points, will be declared the apparent successful Bidder. WSP may then enter into contract negotiations with the apparent successful Bidder.

Designation as an apparent successful Bidder does not imply that a Contract will be issued or awarded. This designation does allow WSP the opportunity to perform further analysis. WSP also reserves the right to re-review and determine whether a proposal is responsive as initially determined.

Bidders must not construe a notification of apparent successful Bidder, notification of award, or attempts to negotiate, etc. as a final award decision. Any assumptions are done so at the Bidder's own risk and expense.

Should negotiations for a Contract fail within 30 days of their initiation, WSP may, at its discretion, cease negotiations and declare the second-place Bidder the new apparent successful Bidder and enter into negotiations with that Bidder. This process will continue until a Contract is signed or no qualified Bidders remain.

**9.2 Notification of Apparent Successful Bidder(s) / Award Notification**

After all considerations, all Bidders will be notified via WEBS when WSP has confirmed its intent to award to the Apparent Successful Bidder(s).

### 9.3 Award

An award, in part or full, is made by WSP's signature on the Contract that is delivered to the apparent successful Bidder. In some circumstances, WSP may include an award letter which will accompany the signed Contract; an award letter will further define the award and is included by reference.

This attachment details the applicable requirements for complaints, debriefs, and protests.

## 1. Complaints

The complaint period is an opportunity for Bidders to voice objections, raise concerns, or suggest changes that were not addressed during the Question & Answer Period or at the Pre-Bid Conference. The complaint period ends five (5) business days before the proposal due date and time indicated on the Anticipated Procurement Schedule of the RFQQ.

*1.1 Criteria for Complaint*: A formal complaint may only be based on one or more of the following grounds: (a) The solicitation unnecessarily restricts competition; (b) The solicitation evaluation or scoring process is unfair or flawed; or (c) The solicitation requirements are inadequate or insufficient to prepare a response. Complaints based on other criteria will not be considered or addressed by WSP. A complaint should clearly articulate the basis of the complaint and include a proposed remedy.

*1.2 Initiating A Complaint*: A complaint must be submitted to the RFQQ Coordinator via email.

*1.3 Response*: When a complaint is received, the RFQQ Coordinator (or designee) will consider all the facts available and respond in writing prior to the deadline for proposal submittals, unless more time is needed. All responses to a complaint will be posted on WEBS.

*1.4 Response is Final*: The RFQQ Coordinator's response to the complaint is final and not subject to administrative appeal.

*1.5 Other*:

*1.5.1* Issues raised in a complaint may not be raised again during the protest period.

*1.5.2* Any issue, exception, addition, or omission not brought to the attention of the RFQQ Coordinator prior to proposal submittal may be deemed waived for protest purposes.

*1.5.3* WSP will consider all complaints but is not required to adopt a complaint, in part or full.

*1.5.4* If bidder complaints result in changes to the RFQQ, written amendments will be issued and posted on WEBS.

## 2. Debrief Conferences

A Debrief Conference is an opportunity for a bidder and WSP to meet and discuss the bidder's bid. A debrief is a required prerequisite for a bidder wishing to file a protest.

*2.1 Announcement*: Following the evaluation of the bids, WSP will issue an announcement on WEBS of the Apparent Successful Bidder (ASB) and send a Notification of Unsuccessful Bidder to all unsuccessful Bidders through WEBS.

*2.2 Debrief Request*: A Bidder's request for a debriefing conference must be received via email by the RFQQ Coordinator within three (3) business days after the Announcement of ASB and Notification of Unsuccessful Bidder is posted through WEBS.

*2.3 Debrief Conference*: When the Debrief Conference request is received, WSP will offer the requesting Bidder one meeting opportunity and notify the Bidder of the Debrief Conference place, date, and time.

2.4 WSP will not allow the debrief process to delay the award. Therefore, Bidders should plan for contingencies and alternate representatives. Bidders who do not attend the Debrief Conference will lose the opportunity to protest.

**3. Protests**

The protest procedure is available to Bidders who submitted a response to this solicitation document and have participated in a debriefing conference. Bidders protesting this procurement shall follow the procedures described below. Protests that do not follow these procedures shall not be considered. This protest constitutes the sole administrative remedy available to Bidders under this procurement.

Upon completing the Debriefing Conference, the Bidder is allowed five (5) business days to file a protest of the acquisition with the WSP Budget and Fiscal Services Administrator via email to the RFQQ Coordinator at the email address listed on Page 1 of the RFQQ.

*3.1 Criteria for a protest*: A protest may be based only on one or more of the following:

3.1.1 Bias, Discrimination, or conflict of interest on the part of an evaluator;

3.1.2 Error in computing evaluating scores; or

3.1.3 Non-compliance with any procedures described in the RFQQ.

*3.2 Criteria not met*: Protests not based on the above three issues will not be considered. Protests will be rejected as without merit if they address issues such as: 1) An evaluator's professional judgment on the quality of a proposal, or 2) WSP's assessment of its own and/or other agencies' needs or requirements.

3.3 Initiating a Protest: Any bidder that has filed a Complaint and a Request for Debrief Conference may protest selection of the ASB. A protest must:

3.3.1 Be in writing;

3.3.2 Include a specific and complete statement of facts forming the basis of the protest;

3.3.3 Include a description of the relief or corrective action requested

3.3.4 Be received in the WSP Budget and Fiscal Services on or before 5:00 pm on the fifth (5th) business day after the Bidder's Debrief Conference (not including the conference day).

*3.4 Protest Response*: Upon receipt of a protest, WSP will hold a protest review. The Chief of WSP or an employee delegated by the Chief who was not involved in the procurement will consider the record and all available facts and issue a decision within ten (10) business days of receipt of the protest. If additional time is required, the protesting party will be notified of the delay. In the event a protest may affect the interest of another Bidder that submitted a proposal, such Bidder will be given an opportunity to submit its views and any relevant information on the protest to the WSP Budget and Fiscal Services Administrator.

*3.5 Decision is Final*: The protest decision is final and not subject to administrative appeal. If the protesting Bidder does not accept WSP's protest response, the Bidder may seek relief in Thurston County Superior Court. The final determination of the protest shall:

*3.5.1* Find the protest lacking in merit and uphold the WSP's action; or

*3.5.2* Find only technical or harmless errors in the WSP's acquisition process and determine WSP to be in substantial compliance and reject the protest; or

*3.5.3* Find merit in the protest and provide options to WSP, including correcting errors and reevaluating all proposals; reissuing the solicitation document; or making other findings and determining other courses of action as appropriate.

*3.6* After reviewing the protest and available facts, WSP will issue a written response within ten (10) business days from receipt of the protest, unless additional time is needed.

If WSP determines that the protest is without merit, WSP will enter into a contract with the ASB. If the protest is determined to have merit, one of the alternatives noted in the preceding paragraph will be taken.

**4. Communication During Complaints, Debriefs, and Protests**

All communications about this RFQQ, including complaints, debriefs, and protests, must be addressed to the RFQQ Coordinator, in writing, at the email address listed on Page 1 of this RFQQ.

## 1) GENERAL INSURANCE REQUIREMENTS

Contractor shall, at its sole cost and expense, obtain, and, during the term of this Contract, maintain, in full force and effect, the insurance coverage described in this Section. The Contractor shall acquire such insurance from an insurance carrier or carriers licensed to conduct business in the state of Washington and having a rating of A-, Class VII or better, in the most recently published edition of Best's Reports. Contractor shall include WSP, its boards, agencies, contractors, offices, employees, agents and volunteers as additional insureds in Contractor's liability insurance policy obtained hereunder. In the event of cancellation, non-renewal, revocation or other termination of any insurance coverage required by the Contract, the Contractor shall provide written notice of such to WSP within one (1) Business Day of the Contractor's receipt of such notice. If Contractor fails to buy and maintain the insurance coverage described in this Section, WSP may deem this failure a material breach and terminate the contract as described herein for material breach of contract.

### *a) Premiums*

Premiums on all insurance policies shall be paid by Contractor or its Subcontractors. Such liability insurance policies provided for WSP pursuant to this Section shall expressly provide therein that WSP be named as additional insured, and that it shall not be revoked by the insurer until 30 days' Notice of intended revocation thereof shall have first been given to WSP by such insurer.

### *b) Cancellation*

Contractor's insurance policies shall not be canceled or non-renewed in scope of coverage without provision for equivalent substitute insurance and such cancellation or nonrenewal shall not take place or reduced in scope of coverage until five business days' written Notice has been given to WSP, attention WSP Project Director, and Contractor has replacement insurance policy(ies) in place that satisfy the requirements set forth in this Section. Contractor's insurance policies shall not be reduced in scope without WSP's prior written consent.

### c) *Insurance Documents*

Contractor shall furnish to WSP copies of policies of all required insurance within 10 business days of the date of announcement of the Apparent Successful Bidder, and copies of renewal certificates of all required insurance within 30 days after the renewal date. Contractor shall submit the certificates of coverage to the WSP Project Manager at an address designated in writing by WSP. These certificates of insurance must expressly indicate compliance with each and every insurance requirement specified in this Section and shall be executed by a duly authorized representative of each insurer. The Certificate of Insurance for each required policy shall reference the WSP Contract Number for the Contract. Failure to provide these documents shall be grounds for immediate termination or suspension of this Contract by WSP for material breach. Contractor is not required to submit to WSP copies of Certificates of Insurance for personal automobile insurance required of the Contractor's employees and volunteers under this Contract.

## *2) INSURANCE REQUIREMENTS*

### *a) Workers' Compensation Coverage*

Prior to performing Services under this Contract, Contractor shall provide or purchase worker's compensation coverage for its employees, as may be required of an "employer" as defined in Title 51 RCW, and shall maintain full compliance with Title 51 RCW during the course of this Contract. WSP will not be responsible for payment of premiums or for any other claim or benefit for Contractor, or any Subcontractor or employee of Contractor, which might arise under applicable laws during the performance of duties and Services under this Contract. However, should Contractor fail to secure insurance coverage or fail to pay premiums on behalf of its employees, WSP may deduct the amount of

premiums and any penalties owing from the amounts payable to Contractor under this Contract and transmit the same to the responsible State agency.

***b) Commercial General Liability***

Commercial General Liability with no deductible covering the risks of bodily injury (including death), property damage and personal injury, including coverage for contractual liability, with a limit of not less than $1 million per occurrence/$2 million general aggregate;

***c) Business Automobile Liability***

If Contractor will be using a business automobile in the services provided hereunder, then a Business Automobile Liability Policy with no deductible (owned, hired, or non-owned) covering the risks of bodily injury (including death) and property damage, including coverage for contractual liability, with a limit of not less than $1 million per accident; and

***d) Employers' Liability Insurance***

Employers Liability insurance covering the risks of Contractor's employees' bodily injury by accident or disease with limits of not less than $1 million per accident for bodily injury by accident and $1 million per employee for bodily injury by disease

***3. REQUIREMENTS FOR PROOF OF INSURANCE***

The Contractor shall pay premiums on all insurance policies. Such insurance policies shall name WSP as an additional insured on all general liability and automobile liability policies. Such policies shall also reference the WSP Contract number and shall have a condition that they not be revoked by the insurer until forty-five (45) calendar days after notice of intended revocation thereof shall have been given to WSP by the insurer.

All insurance provided by the Contractor shall be primary as to any other insurance or self-insurance programs afforded to or maintained by the State and shall include a severability of interests (cross-liability) provision.

The Contractor shall include all Subcontractors as insured under all required insurance policies, or shall furnish separate certificates of insurance and endorsements for each Subcontractor. Subcontractor(s) shall comply fully with all insurance requirements stated herein. Failure of Subcontractor(s) to comply with insurance requirements does not limit the Contractor's liability or responsibility.

The Contractor shall furnish to WSP copies of certificates of all required insurance within thirty (30) calendar days of the Contract's Effective Date, and copies of renewal certificates of all required insurance within thirty (30) days after the renewal date. These certificates of insurance must expressly indicate compliance with each and every insurance requirement specified in this section. Failure to provide evidence of coverage may, at WSP's sole option result in the Contract's termination.

By requiring insurance herein, WSP does not represent that coverage and limits will be adequate to protect the Contractor. Such coverage and limits shall not limit the Contractor's liability under the indemnities and reimbursements granted to the Contractor in the Contract.

| ***DEFINITIONS*** | |
|---|---|
| Term or Acronym | Definitions for the purposes of this RFQQ include: |
| ABFT | American Board of Forensic Toxicology |
| AES | Atomic Emission Spectroscopy is a technique used for analyzing the elemental composition of samples by measuring the light emitted from excited atoms. |
| ANAB | ANSI-ASQ National Accreditation Board |
| ANSI-ASQ | American National Standards Institute-American Society for Quality is the sole U.S. representative and dues-paying member of the International Organization for Standardization (ISO). |
| ASB | Apparently Successful Bidder |
| BAFO | Best and Final Offer |
| Bidder | Individual, company, organization, public or private agency, or other entity submitting a proposal/response in order to attain a contract with WSP. |
| Customer | Agencies served by the WSP Toxicology Laboratory Division and the Criminal Justice System. The WSP Toxicology Laboratory Division provides scientific and technical assistance to all coroners, medical examiners and prosecuting attorneys, as mandated by Revised Code of Washington (RCW) 43.43.670, 46.52.065, 46.61.506 and 68.50.107; and the Washington Administrative Code (WAC) 448-14, and statewide criminal justice agencies. |
| Contract | This document, all schedules and exhibits, Statements of Work, and all amendments hereto. |
| Contractor | Individual or company whose proposal has been accepted by the WSP and has been awarded a fully executed, written contract. |
| DUI | Driving Under the Influence refers to operating a vehicle whie impaired by alcohol or drugs. |
| Effective Date | The first date this Contract is in full force and effect. It may be a specific date agreed to by the parties; or, if not so specified, the date of the last signature of a party to this Contract. |
| ISO/IEC | Standards for the testing and calibration of laboratories. ISO 17025 requirements may be found here: https://www.iso.org/ISO-IEC-17025-testing-and-calibration-laboratories.html |
| Letter of Interest | A letter created by the bidder to address the items in the Letter of Interest section to include a statement of understanding & compliance. |
| PTAC | Procurement Technical Assistance Center, also known as APEX Accelerator, assists businesses through the government-contracting marketplace. Additional information can be found here: https://washingtonapex.org/. |
| Proposal | A formal offer submitted in response to this solicitation. |
| OMWBE | Office of Minority and women's Business Enterprises. Additional information can be found here: https://omwbe.wa.gov/. |
| RCW | The Revised Code of Washington. All references to RCW chapters or sections shall include any successor, amendment, or replacement statue. |
| Request for Qualifications and Quotations (RFQQ) | A formal procurement document in which a service or need is identified and skills and expertise are being sought to deliver the service or meet the need. The purpose of an RFQQ is to solicit from the Bidder or consultant community to propose the qualified Bidder(s) and associated pricing/costs to provide the service and/or meet the identified need |

| | |
|---|---|
| RFQQ Coordinator | The WSP named solicitation Coordinator, or designee, employed by the WSP Contracts, and the individual responsible for conducting this RFQQ. |
| Responsible Bidder | A responsible bidder is one that has the experience, personnel, equipment, and finances to perform the requirements of the contract. |
| Services | Those services provided by the Vendor relating to grounds maintenance services and any related services that are appropriate to this Contract's Statement of Work. |
| Statement of Work | Those services to be provided by the Apparently Successful Vendor (ASV)/ Apparently Successful Bidder (ASB). |
| Subcontractor | One not in the employment of Vendor, who is performing all or part of the business activities under this Contract under a separate contract with Vendor. Subcontractors are not allowed under this Contract without permission, in writing, from the WSP Contract Administrator. |
| THC | Tetrahydrocannabinol is a cannabinoid found in cannabis. |
| Traceability | Property of a measurement result whereby the result can be related to a reference through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty. |
| Uncertainty of Measurement | The range of possible values within which the true value of the measurement lies. |
| WAC or Washington Administrative Code | The regulations of the Washington State executive branch agencies issued by authority of statutes. Like legislation and the Constitution, regulations are a source of primary law in Washington State. All references to WAC chapters or sections shall include any successor, amended, or replacement regulation. |
| WEBS or Washington's Electronic Business Solution. | The Washington State Department of Enterprise Services' (DES) on-line system which provides vendor registration and notification activities for governmental solicitations and procurements. WEBS provides vendors automatic email notification of new bidding opportunities, and is free to vendors and government organizations. The WEBS website is: https://fortress.wa.gov/ga/webs/. |
| WSP | The State of Washington, Washington State Patrol, and its officers, directors, trustees, employees and/or agents. |

| WASHINGTON STATE PATROL<br>PROFESSIONAL SERVICE CONTRACT | **WSP Contract No.** |
|---|---|
| **Toxicology Forensic Testing** | **Contractor's Contract No.** |

This Contract is between the State of Washington, Washington State Patrol hereinafter referred to as WSP, and the Contractor identified below, and is governed by chapter 39.26 RCW.

| **Contractor** | |
|---|---|
| **Contractor Business Name**: | **Doing Business As (DBA)**: |
| **Address**: | **Statewide Vendor Registration Number**:<br>SWV# |
| **Contact Name and Title:** | **Telephone**: |
| **E-mail**: | **Administrative or Billing Contact Name and Email**<br>, |

| **WSP Contract Manager** | |
|---|---|
| **Contract Manager Name and Title**:<br>Elizabeth Gough, Toxicology Laboratory Division Commander | **Address**:<br>2203 Airport Way S Bldg A, Suite 360<br>Seattle WA 98134-2045 |
| **Telephone**: 206-262-6100 | **E-mail**: Elizabeth.Gough@wsp.wa.gov |

| **WSP Contract Specialist** | |
|---|---|
| **Name**: Jamie Roessler, Contracts Specialist 2 | **Address**:<br>PO Box 42602<br>106 11th Ave SW, Ste. 3100, Olympia WA 98504-2602 |
| **Telephone**: 206-262-6146 | **E-mail**: Jamie.Roessler@wsp.wa.gov |

| **Contract Details** | | |
|---|---|---|
| **Contract Start Date** | **Contract End Date**<br>- | **Contract Maximum Amount**<br>**$1,000,000.00 Plus applicable taxes** |

ATTACHMENTS. The following Exhibits are attached to and incorporated into this Contract by reference:

- ☐ Exhibit A, Statement of Work
- ☐ Exhibit B, Pricing
- ☐ Exhibit C, General Terms and Conditions
- ☐ Exhibit D, Contractor's Proposal / Response
- ☐ Exhibit E, Solicitation WSP-RFQQ-TOXTST
- ☐ Other:

This Contract, including the attached Terms and Conditions and any other documents incorporated by reference, contains all of the terms and conditions agreed upon by the parties. No other understandings or representations, oral or otherwise, regarding the subject matter of this Contract shall be deemed to exist or bind the parties. The parties signing below warrant that they have read and understand this Contract and have the authority to enter into this Contract.

| **FOR THE WASHINGTON STATE PATROL:** | **FOR THE CONTRACTOR:** |
|---|---|
| WSP Signature Date | Contractor Signature Date |
| Printed Name and Title<br>For: John R. Batiste, Chief | Printed Name and Title |

APPROVED AS TO FORM BY THE OFFICE OF THE ATTORNEY GENERAL 10/16/2014

## 1. BACKGROUND

The Washington State Patrol (WSP) Toxicology Laboratory Division is accredited by ANAB to the ISO/IEC 17025 standard and ABFT requirements and provides toxicological testing of biological specimens for the presence of alcohol and other drugs, with case submissions from law enforcement agencies, medical examiners, coroners, and other agencies, statewide (the customer).

The Contractor will provide timely forensic toxicology analysis for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases that the WSP Toxicology Laboratory Division does not respectively have the resources to perform in-house, or for which WSP Toxicology Laboratory Division cannot detect the specific drugs.

WSP Toxicology Laboratory Division shall send samples to be tested on a flow basis, according to the fee schedule attached hereto as Exhibit B.

Contractor shall be evaluated and deemed competent to perform the work in accordance with ANAB accreditation standards. The WSP Toxicology Laboratory Division is responsible to the Customer for the work of the Contractor, and that only approved laboratories may perform testing on evidence submitted to the Laboratory, unless otherwise specified by the customer.

In accordance with the WSP Toxicology Laboratory Division's accreditation requirements the laboratory will be re-evaluated annually to ensure they continue to meet the accreditation standards on which the original evaluation was based, which may include any updated accreditation standards as may be required by the accrediting agency. The re-evaluation includes, but is not limited to, review of the subcontracted laboratory's accreditation status, quality management system, metrological traceability, reporting and scope of testing.

## 2. ACCEPTANCE

All services, testing reports or documentation submitted by Contractor shall be subject to WSP's review and written Acceptance. The process and forms for WSP's review or Acceptance of Services and Deliverables shall be established in writing between the parties and set forth herein.

***1.*** *PRICING:*

Contractor's pricing includes all cost components needed to provide services as described in herein, including travel, labor and supplies for the initial contract period and all potential contract extensions.

Price increases may occur at the time of contract renewal by mutual agreement of the parties, but in no case more than 5%.

Proposed costs shall include any applicable Washington State taxes associated with the contract work that the Contractor is required to pay. Contractor is required to collect and pay state taxes as applicable.

***2.*** CONTRACTOR'S PRICE LIST:

**1. Definitions.**

***ABFT:*** American Board of Forensic Toxicology.

***AES:*** Atomic Emission Spectroscopy is a technique used for analyzing the elemental composition of samples by measuring the light emitted from excited atoms.

***ANAB:*** ANSI-ASQ National Accreditation Board.

***ANSI-ASQ:*** American National Standards Institute-American Society for Quality is the sole U.S. representative and dues-paying member of the International Organization for Standardization (ISO).

***Contract***: This Professional Service Contract, including all documents attached or incorporated by reference.

***Contractor***: The entity performing services to this Contract and includes the Contractor's owners, members, officers, director, partners, employees and/or agents unless otherwise stated in this Contract. For purposes of any permitted Subcontract, "Contractor" includes any Subcontractor and its owners, members, officers, director, partners, employees and/or agents.

***DUI:*** Driving Under the Influence refers to operating a vehicle whie impaired by alcohol or drugs.

***General Terms and Conditions***: This Exhibit C.

***ISO/IEC:*** Standards for the testing and calibration of laboratories. ISO 17025 requirements may be found here: https://www.iso.org/ISO-IEC-17025-testing-and-calibration-laboratories.html.

***Statement of Work***: The Special Terms and Conditions of this Contract, Exhibit A.

***Subcontract***: A separate contract between the Contractor and an individual or entity ("Subcontractor") to perform all or a portion of the duties and obligations that the Contractor is obligated to perform pursuant to this Contract.

***THC:*** Tetrahydrocannabinol is a cannabinoid found in cannabis.

***Traceability:*** Property of a measurement result whereby the result can be related to a reference through a documented unbroken chain of calibrations, each contributing to the measurement uncertainty.

***Uncertainty of Measurement:*** The range of possible values within which the true value of the measurement lies.

***RCW***: Revised Code of Washington. All references in the Contract to RCW chapters or sections shall include any successor, amended, or replacement statutes.

***USC***: United States Code. All references in the Contract to USC chapters or sections shall include any successor, amended or replacement statutes.

***WSP:*** State of Washington, Washington State Patrol, and its officers, directors, trustees, employees and/or agents.

**2. Attorneys' Fees and Costs.** If any litigation is brought to enforce any term, clause, provision or section of this Contract or as a result of this Contract in any way, the prevailing party shall be awarded its reasonable attorney's fees together with expenses and costs incurred with such litigation, including necessary fees, costs and expenses for services rendered at both trial and appellate levels as well as subsequent to judgement in obtaining execution thereof. In the event that parties to this Contract engage in arbitration, mediation or any other alternative dispute resolution forum to resolve a dispute in lieu of litigation, both parties shall share equally in the cost of the alternative dispute resolution, including the cost of mediation or arbitration services. Each party shall be responsible for their own attorney's fees incurred as a result of the alternative dispute resolution method.

3. **Period of Performance.** The initial period of performance of this Contract is listed on page One. WSP, in its sole discretion, may extend the contract for up to four (4) additional one-year terms or portions thereof, at the same terms and conditions. The total term, including the initial term and all subsequent extensions, shall not exceed five (5) years, unless an emergency exists and/or special circumstances require an additional term extension.

4. **Payment.** WSP shall reimburse the Contractor an amount not to exceed the Contract Maximum Amount specified on Page One of this Contract.

5. **Advance Payments.** WSP shall not make any payments in advance or anticipation of the delivery of goods or services provided by the Contractor pursuant to this Contract, except Pursuant to RCW 43.88.160(5), under certain conditions, payments for equipment maintenance services may be made up to twelve months in advance.

6. **Late Payments.** Under Chapter 39.76 RCW, (SAAM 85.32.50 if WSP fails to make timely payment(s), Contractor may invoice for 1% per month on the amount overdue or a minimum of $1.00. Payment will not be considered late if a check or warrant is mailed within the time specified. If no terms are specified, net 30 days will automatically apply.

7. **Overpayments to Contractors.** Upon notice of an erroneous payment or overpayment to which the Contractor is not entitled pursuant to this Contract, the Contractor shall promptly refund to WSP the full amount of any such payment or overpayment.

8. **Billing Procedure.** WSP shall reimburse the Contractor for work performed to the satisfaction of the WSP Project Manager. Compensation for services rendered shall be payable upon receipt of properly completed invoices, which shall be submitted not more often than monthly to the WSP Project Manager, except for payments made in advance pursuant to RCW 43.88.160(5) as stated in Section 6 above. The invoices shall describe and document to WSP's satisfaction a description of the work performed, activities accomplished, the progress of the project, fees and expenses, WSP's contract number, and the Contractor's Statewide Vendor registration number. The Contractor shall submit the final invoice not later than 60 calendar days from the Contract End Date.

9. **Assignment.** The work to be provided under this Contract, and any claim arising thereunder, is not assignable or delegable by the Contractor in whole or in part, without the express written consent of WSP.

10. **Conflict.** In the event of a conflict between the WSP terms and conditions contained herein and the Contractor's terms and conditions, the WSP terms and conditions shall prevail.

11. **Compliance with Civil Rights Laws.** During the period of performance for this Contract, the Contractor shall comply with all federal and state nondiscrimination laws.

12. **Confidentiality.** The Contractor shall not use or disclose any information concerning WSP, or information that may be classified as confidential, to any third party without the written permission of WSP. The Contractor shall either destroy or return all such information to the WSP Contract Manager at the end of this Contract.

13. **Contract Execution and Amendments.** This Contract shall be binding on WSP only upon signature by the Chief of WSP or designee. WSP and the Contractor may mutually amend this Contract. Such amendments shall not be binding unless they are in writing and signed by personnel authorized to bind WSP and the Contractor.

14. **Electronic Signatures.** A signed copy of this contract or any other ancillary document transmitted by facsimile, email, or other means of electronic transmission shall be deemed to

have the same legal effect as delivery of an original executed document for all purposes. Electronic signatures must be certified to be considered valid signatures.

15. **Contractor Certification Regarding Ethics.** The Contractor certifies that the Contractor is in compliance with Chapter 42.52 RCW, Ethics in Public Service, and will comply with Chapter 42.52 RCW throughout the term of the Contract.

16. **Debarment Certification**. The Contractor, by signature affixed hereto, certifies that the Contractor is not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any Federal department or agency from participating in transactions (Debarred). The Contractor also agrees to include the above requirements in any and all Subcontracts into which it enters. The Contractor shall immediately notify WSP if, during the term of this Contract, Contractor becomes Debarred. WSP may immediately terminate this Contract by providing Contractor written notice if Contractor becomes Debarred during the term hereof.

17. **Disputes.** In the event a bona fide dispute concerning a question of fact arises between WSP and Contractor and it cannot be resolved between the parties, either party may initiate the dispute resolution procedure provided herein.

    The initiating party shall reduce its description of the dispute to writing and deliver it to the responding party. The responding party shall respond in writing within three (3) Business Days. The initiating party shall have three (3) Business Days to review the response.

    17.1 If after this review resolution cannot be reached, both parties shall have three (3) Business Days to negotiate in good faith to resolve the dispute. If the dispute cannot be resolved after three (3) Business Days, a Dispute Resolution Panel may be requested in writing by either party who shall also identify the first panel member. Within three (3) Business Days of receipt of the request, the other party will designate a panel member. Those two panel members will appoint a third individual to the dispute resolution panel within the next three (3) Business Days.

    17.2 The Dispute Resolution Panel will review the written descriptions of the dispute, gather additional information as needed, and render a decision on the dispute in the shortest practical time.

    17.3 Each party shall bear the cost for its panel member and share equally the cost of the third panel member.

    17.4 Both parties agree to be bound by the determination of the Dispute Resolution Panel.

    17.5 Both parties agree to exercise good faith in dispute resolution and to settle disputes prior to using a Dispute Resolution Panel whenever possible.

    17.6 Both parties agree that, the existence of a dispute notwithstanding, they will continue without delay to carry out all their respective responsibilities under this Contract that are not affected by the dispute.

    17.7 If the subject of the dispute is the amount due and payable by WSP for Services being provided by Contractor, Contractor shall continue providing Services pending resolution of the dispute provided WSP pays, in good faith, the amount WSP believes is due and payable, and places in escrow the difference between such amount and the amount Contractor, in good faith, believes is due and payable.

18. **Filing Requirement.** This Contract may be required to be filed with the Department of Enterprise Services pursuant to Chapter 39.26 RCW. No contract so filed is effective nor shall

work commence under it until the tenth (10th) working day following the date of filing subject to DES approval.

**19. Governing Law.** This Contract shall be governed in all respects by the laws of the State of Washington. The jurisdiction for any action hereunder shall be the Superior Court for the State of Washington. The venue of any action hereunder shall be in the Superior Court for Thurston County, State of Washington.

**20. Indemnification.** The Contractor shall indemnify, defend and hold harmless WSP from and against all claims arising out of or resulting from the performance of this Contract. The Contractor expressly agrees to indemnify, defend and hold harmless WSP for any claim arising out of or incident to the Contractor's performance or failure to perform this Contract. The Contractor shall be required to indemnify, defend and hold WSP harmless to the extent any claim is caused in whole or in part by negligent acts or omissions of the Contractor.

**21. Independent Capacity.** The Contractor acknowledges that the Contractor is an independent contractor, and not an officer, employee or agent of WSP or the State of Washington. The Contractor shall not hold itself out as, nor claim status as, an officer, employee or agent of WSP or the State of Washington. The Contractor shall indemnify and hold WSP harmless from all obligations to pay or withhold federal or state taxes or contributions on behalf of the Contractor or the Contractor's employees unless otherwise specified in this Contract.

**22. Insurance.** During the term of any Contract, the Contractor shall maintain in full force and effect, the insurance described in this section. The Contractor shall acquire such insurance from an insurance carrier or carriers licensed to conduct business in the state of Washington and having a rating of A-, Class VII or better, in the most recently published edition of Best's Reports. In the event of cancellation, non-renewal, revocation or other termination of any insurance coverage required by the Contract, the Contractor shall provide written notice of such to WSP within one (1) Business Day of the Contractor's receipt of such notice. Failure to buy and maintain the required insurance may, at WSP's sole option, result in the Contract's termination.

22.1 **Minimum Requirements**. The minimum acceptable limits shall be as indicated below, with no deductible for each of the following categories:

22.1.1 Commercial General Liability covering the risks of bodily injury (including death), property damage and personal injury, including coverage for contractual liability, with a limit of not less than $1 million per occurrence/$2 million general aggregate;

22.1.2 Business Automobile Liability (owned, hired, or non-owned) covering the risks of bodily injury (including death) and property damage, including coverage for contractual liability, with a limit of not less than $1 million per accident; and

22.1.3 Employers Liability insurance covering the risks of the Contractor's employees' bodily injury by accident or disease with limits of not less than $1 million per accident for bodily injury by accident and $1 million per employee for bodily injury by disease.

22.1.4 Industrial insurance coverage for Contractor's employees, as may be required of an "employer" as defined in Title 51 RCW, and maintain full compliance with Title 51 RCW during the period of performance for this Contract. WSP shall not be responsible for payment of industrial insurance premiums or for any other claim or benefit for the Contractor, or any subcontractor or employee of the Contractor, which might arise under the industrial insurance laws during the performance of duties and services under this Agreement.

22.2 **Requirements for Proof of Insurance**. The Contractor shall pay premiums on all insurance policies. Such insurance policies shall name WSP as an additional insured on all general liability and automobile liability policies. Such policies shall also reference the WSP Contract number and shall have a condition that they not be revoked by the insurer until forty-five (45) calendar days after notice of intended revocation thereof shall have been given to WSP by the insurer.

All insurance provided by the Contractor shall be primary as to any other insurance or self-insurance programs afforded to or maintained by the State and shall include a severability of interests (cross-liability) provision.

The Contractor shall include all Subcontractors as insured under all required insurance policies, or shall furnish separate certificates of insurance and endorsements for each Subcontractor. Subcontractor(s) shall comply fully with all insurance requirements stated herein. Failure of Subcontractor(s) to comply with insurance requirements does not limit the Contractor's liability or responsibility.

The Contractor shall furnish to WSP copies of certificates of all required insurance within thirty (30) calendar days of the Contract's Effective Date, and copies of renewal certificates of all required insurance within thirty (30) days after the renewal date. These certificates of insurance must expressly indicate compliance with each and every insurance requirement specified in this section. Failure to provide evidence of coverage may, at WSP's sole option result in the Contract's termination.

By requiring insurance herein, WSP does not represent that coverage and limits will be adequate to protect the Contractor. Such coverage and limits shall not limit the Contractor's liability under the indemnities and reimbursements granted to the Contractor in the Contract.

**23. Inspection; Maintenance of Records.** During the term of this Contract and for one year following termination or expiration of this Contract, the Contractor shall give reasonable access to the Contractor's place of business and records to WSP and any other employee or agent of the State of Washington or the United States of America for the purpose of inspecting the Contractor's place of business and its records, and monitoring, auditing and evaluating the Contractor's performance and compliance with applicable laws, regulations, rules and this Contract.

During the term of this Contract and for six years following termination or expiration of this Contract, the Contractor shall maintain records sufficient to document (i) performance of all acts required by statute, regulation, rule, or this Contract; (ii) substantiate the Contractor's statement of its organization's structure, tax status, capabilities and performance; and (iii) demonstrate accounting procedures, practices and records that sufficiently and properly document the Contractor's invoices to WSP and all expenditures made by the Contractor to perform as required by this Contract.

**24. OSHA and WISHA Requirements.** The Contractor agrees to comply with conditions of the Federal Occupational Safety and Health Administration (OSHA) and, if manufactured or stored in the State of Washington, the Washington Industrial Safety and Health Act (WISHA) and the standards and regulations issued there under, and certifies that all items furnished and purchased will conform and comply with said laws, standards, and regulations. Contractor further agrees to indemnify and hold harmless WSP from all damages assessed against WSP as a result of the Contractor's failure to comply with those laws, standards, and regulations, and for failure of the items furnished under the Contractor to so comply.

**25. Order of Precedence.** In the event of any inconsistency in the terms of this Contract, or between its terms and any applicable statute or rule the inconsistency shall be resolved by giving precedence in the following order to:

Applicable federal and state law, regulations and rules;
Exhibit A, Statement of Work;
Exhibit G, Statewide Contract
Exhibit C, General Terms and Conditions
Exhibit D, Contractor's Proposal
Exhibit E, RFQQ-WSP-TOXTST
Any other provision of this Contract; and
Any document incorporated by reference.

**26. Personnel.** The assignment of WSP personnel under this Contract shall be at the discretion of the Chief of WSP or designee. WSP employees performing work under the terms of this Contract (if any) shall be under the direct command and control of the Chief of WSP or designee, and shall perform duties required under this Contract in a manner consistent with WSP policy and regulations, and applicable federal, state and local laws.

**27. Prevailing Wage.** Contractor is responsible for ensuring that prevailing wage laws are followed pursuant to Charters 39.12 and 49.28 of the Revised Code of Washington, and WAC 296.127-022. The Contractor shall pay the prevailing rate of wages to all workers, laborers, or mechanics in the performance of any part of the work described in the contract in accordance with state law and Department of Labor and Industries rules and regulations. The Contractor shall comply with the filing requirements required by this statute, including Statement of Intent to Pay Prevailing Wage, and Affidavit of Wages Paid.

**28. Repair, Minor Alterations, or Extra Work.** Should the WSP require additional services covered under this contract the following shall apply.

Except as otherwise provide in the contract, no payment for extras shall be made unless such extras and the price therefor have been authorized in writing by the WSP Contract/Project Manager. The WSP Contract/Project Manager shall provide the Contractor with a written scope of work for the repair or alteration. The Contractor shall provide the agency with a "not to exceed" price quote in using the labor, equipment rental, and materials pricing structure in this contract. Equipment and materials prices shall be net plus identified markup. The Contractor shall proceed with the work only upon receipt of written authorization from the contract officer. Any extra work, repair and/or minor alteration during the Contract term, cannot exceed the accumulated total of the contract maximum total listed on the contact face sheet.

**29. Rights in Data.** Unless otherwise provided, data that originates from this Contract shall be "works for hire" as defined by the U.S. Copyright Act of 1976 and shall be owned by WSP. Data shall include, but not be limited to, reports, documents, pamphlets, advertisements, books, magazines, surveys, studies, computer programs, films, tapes, and/or sound reproductions. Ownership includes the right to copyrights, patent, register, and the ability to transfer these rights.

Material delivered by the Contractor under the terms of this Contract, but which does not originate therefrom, shall be transferred with a nonexclusive, royalty-free irrevocable license to publish, translate, reproduce, deliver, performs, dispose of, and to authorize others to do so, provided that such a license shall be limited to the extent which the Contractor has a right to grant such a license. The Contractor shall exert all reasonable efforts to advise WSP at the time of material delivery of all known or potential invasions of privacy contained therein and of any portion of such material which was not produce in performance of this Contract. WSP shall

receive prompt written notice of each notice or claim of copyright infringement received by the Contractor with respect to any material delivered under this Contract. WSP shall have the right to modify or remove any restrictive markings placed upon the data by the Contractor.

30. **Savings.** In the event that funds WSP relied upon to establish this Contract are withdrawn, reduced or limited, or if additional or modified conditions are placed on such funding, WSP may immediately terminate this Contract by providing written notice to the Contractor. This termination shall be effective on the date specified in the notice of termination.

31. **Severability.** If any provision of this Contract or any provision of any document incorporated by reference shall be held invalid, such invalidity shall not affect the other provisions of this Contract which can be given effect without the invalid provision, if such remainder conforms to the requirements of applicable law and the fundamental purpose of this Contract, and to this end the provisions of this Contract are declared to be severable.

32. **Site Security.** While on WSP's premises, the Contractor shall conform in all respects with physical, fire or other security regulations communicated to the Contractor by WSP.

33. **Statewide Payee Registration.** The Contractor is required to be registered as a Statewide Payee prior to submitting a request for payment under this Agreement. The Washington State Office of Financial Management (OFM) maintains the Statewide Payee Registration System; to obtain registration materials go to: https://ofm.wa.gov/it-systems/statewide-vendorpayee-services.

34. **Subcontracting.** Except as otherwise provided in this Contract, the Contractor may subcontract for any of the services provided under this Contract with the prior, written approval of WSP. The Contractor shall be responsible for the acts and omissions of any subcontractor. The terms and conditions of this Contract shall apply to all Subcontractors. If at any time Contractor wishes in the future to subcontract any of the services, or to change the subcontractor noted in *Contractor's Proposal*, it must first obtain prior written approval of WSP and will be subject to the terms and conditions of DES Policy No. POL-DES-090-06, Supplier Diversity, with regard to subcontractors.

35. **Supervision of Employees and Workers**. Contractor shall be solely responsible for the safety of Contractor's employees and others relative to Contractor's work, work procedures, materials, equipment, transportation, and related activities and equipment. The Contractor shall take appropriate action to correct workers, whether employees or subcontractor, that disregard the contents of this contract, who are incompetent, careless and/ or insubordinate and do not exhibit proper dress and decorum expected in a WSP owned/ leased property

36. **Survivorship of Provisions.** Any terms, conditions and warranties contained in this Contract that by their sense and context are intended to survive performance by the parties to this Contract shall so survive the completion of the period of performance or termination of this Contract.

37. **Taxes**. WSP shall pay sales and use taxes imposed on services provided by the Contractor under this Contract if required by state law. Contractor is required to collect and pay such taxes on behalf of WSP and remit the taxes to the Department of Revenue. The Contractor shall pay all other taxes, including, but not limited to, Washington State Business and Occupation Tax, taxes based on the Contractor's income, or personal property taxes levied or assessed on the Contractor's personal property to which WSP does not own title.

38. **Termination.**

38.1 **Termination for Convenience.** Except as otherwise provided in this Contract, either party may terminate this Contract upon thirty (30) calendar days written notification. If this Contract is so terminated, the terminating party shall be liable only for performance in accordance with the terms of this Contract for performance rendered prior to the effective date of termination.

38.2 **Termination for Default.** WSP may terminate the Contract for default, in whole or in part, if WSP has a reasonable basis to believe that the Contractor failed to perform under any provision of this Contract; violated any applicable law, regulation, rule or ordinance; or otherwise breached any provision or condition of this Contract.

WSP shall notify the Contractor in writing of the need to take corrective action. If corrective action is not taken within five (5) calendar days, the Contract may be terminated. WSP reserves the right to suspend all or part of the Contract, withhold further payments, or prohibit the Contractor from incurring additional obligations of funds during investigation of the alleged default and pending corrective action by the Contractor or a decision by WSP to terminate the Contract.

In the event of termination for default, the Contractor shall be liable for damages as authorized by law including, but not limited to, any cost difference between the original contract and the replacement or cover contract, and all administrative costs directly related to procuring the replacement contract. If it is determined that the Contractor was not in default the termination shall be deemed a termination for convenience. The rights and remedies of WSP provided under this Contract are not exclusive and are in addition to any other rights and remedies provided by law.

38.3 **Termination for Breach**. The right of either Party to terminate this Agreement, as provided herein, shall not be affected in any way by its waiver or failure to take action with respect to any previous material breach.

This Contract may be terminated for cause by the WSP, at the sole discretion of the WSP Chief Contracts Officer, for failure to perform a contractual requirement or for a material breach of any term or condition. Material breach of a term or condition of the Contract may include but is not limited to:

38.3.1 Contractor failure to perform services or complete a deliverable by the date required or by an alternate date as mutually agreed in a written amendment to the Contract;

38.3.2 Contractor failure to carry out any warranty or failure to perform or comply with any mandatory provision of the contract;

38.3.3 Contractor becomes insolvent or in an unsound financial condition so as to endanger performance hereunder;

38.3.4 Contractor becomes the subject of any proceeding under any law relating to bankruptcy, insolvency or reorganization, or relief from creditors and/or debtors that endangers the Contractor's proper performance hereunder;

38.3.5 Appointment of any receiver, trustee, or similar official for Contractor or any of the Contractor's property and such appointment endangers the Contractor's proper performance hereunder;

38.3.6 A determination that the Contractor is in violation of federal, state, or local laws or regulations and that such determination renders the Contractor unable to perform any aspect of the Contract.

38.4 **Opportunity to Cure**

In the event that Contractor fails to perform a contractual requirement or materially breaches any term or condition, WSP may issue a written cure notice. WSP May provide the Contractor a period of time in which to cure. The WSP is not required to allow the Contractor to cure defects if the opportunity for cure is not feasible as determined solely within the discretion of WSP. Time allowed for cure shall not diminish or eliminate Contractor's liability for liquidated or other damages, or otherwise affect any other remedies available against Contractor under the Contract or by law.

If the breach remains after Contractor has been provided the opportunity to cure, WSP may do any one or more of the following:

38.4.1 Exercise any remedy provided by law;

38.4.2 Terminate this Contract and any related Contracts or portions thereof;

38.4.3 Procure replacements and impose damages as set forth elsewhere in this Contract;

38.4.4 Impose actual or liquidated damages;

38.4.5 Suspend or bar Contractor from receiving future Solicitations or other opportunities;

38.4.6 Require Contractor to reimburse WSP for any loss or additional expense incurred as a result of default or failure to satisfactorily perform the terms of the Contract.

38.5 **Termination Procedure.** The following provisions shall survive and be binding on the parties to this Contract in the event this Contract is terminated.

38.5.1 The Contractor shall stop work under this Contract on the date specified in the notice of termination, and shall comply with all instructions contained in the notice of termination.

38.5.2 The Contractor shall deliver to the WSP Project Manager identified on the Face Sheet of this Contract, all WSP property in the Contractor's possession and any WSP property produced under this Contract. The Contractor grants WSP the right to enter upon the Contractor's premises for the sole purpose of recovering any WSP property that the Contractor fails to return within ten (10) calendar days of termination of the Contract. Upon failure to return WSP property within ten (10) calendar days of the Contract termination, the Contractor shall be charged with all reasonable costs of recovery, including transportation and attorney's fees. The Contractor shall protect and preserve any property of WSP that is in the possession of the Contractor pending return to WSP. The Contractor shall provide written certification to WSP that the Contractor has returned all WSP property in the Contractor's possession.

38.5.3 WSP may direct assignment of the Contractor's rights to and interest in any subcontract or orders placed to WSP. WSP may terminate any subcontract or orders, and settle or pay any or all claims arising out of the termination of such orders and subcontracts.

38.5.4 WSP shall be liable for and shall pay for only those services authorized and provided through the date of termination. WSP may pay an amount agreed to by the parties for partially completed work and services, if work products are useful to WSP.

38.6 **Withholding Payment**. In the event of termination for default or breach of contract, WSP may withhold a sum from the final payment to the Contractor that WSP determines necessary to protect WSP against loss or additional liability.

**39. Treatment of Assets.** Title to all property furnished by WSP to the Contractor under the terms of this Contract shall remain with WSP. Any property furnished by WSP to the Contractor under the terms of this Contract shall be used only for the performance of this Contract. The Contractor shall be responsible for any loss or damage of property provided to the Contractor by WSP resulting from the failure on the part of the Contractor to maintain and administer that property in accordance with sound management practices. Upon the discovery of loss or damage of WSP property, the Contractor shall notify WSP and take all reasonable steps to prevent any further loss or damage. Upon the termination or completion of this Contract, the Contractor shall surrender all WSP property to the WSP Project Manager indicated on the Face Sheet of this Contract.

**40. Waiver.** A failure by WSP to exercise its rights under this Contract shall not preclude WSP from subsequent exercise of such rights and shall not constitute a waiver of any other rights under this Contract unless stated to be such in writing and signed by an authorized representative of WSP and attached to the original Contract.

**41. Workman's Compensation Law.** The Contractor shall comply with all the requirements and conditions of Sections 51.04 to 51.42 inclusive, of the Revised Codes of Washington, known as the Workmen's compensation Act, and will all amendments thereof, now in force or which shall hereafter be made; also with all rules, regulations and decisions made or promulgated there under. The Contractor shall save the WSP harmless for any loss, damage or expense which he may suffer or which he may be put at any time by failure of the Contractor to comply with the last preceding requirements.

In case of employees engaged in hazardous work under this contract and the site of the project is not protected under the statutory workmen's compensation statute, the Contractor shall provide and shall cause each subcontractor to provide compensation insurance with a private company in an amount equivalent to that provided by the workmen's compensation statute for the protection of his employees not otherwise protected.

**42. Background Checks and Security Awareness Training.** Any proposed Contractor team member or subcontractor who will have unaccompanied access to WSP facilities, electronic equipment, computers, data bases, or other sensitive or restricted information must submit to WSP criminal history fingerprint background checks (background check) at Contractor's expense. Each person that requires a background check must complete Fingerprint Background Checks forms before performing any work under this contract.

Contractor and all team members and subcontractors requiring a background check shall comply with WSP instructions on submitting fingerprints and provide all requested information to WSP in order to complete the background checks.

In addition, Contractor and all team members and subcontractors requiring a background check shall undergo security awareness training online annually. A link to the security awareness training will be provided by WSP upon completion of the fingerprint background check.

Failure of Contractor, Contractor team members or subcontractors to cooperate with WSP during the background check process or to complete security awareness training may result in termination of the contract.

**43. Antidiscrimination SB 5186.**

43.1 Nondiscrimination Requirement. During the term of this Contract, Contractor, including any subcontractor, shall not discriminate on the bases enumerated at RCW 49.60.530(3). In addition, Contractor, including any subcontractor, shall give written notice of this nondiscrimination requirement to any labor organizations with which Contractor, or subcontractor, has a collective bargaining or other agreement.

43.2 Obligation to Cooperate. Contractor, including any subcontractor, shall cooperate and comply with any Washington state agency investigation regarding any allegation that Contractor, including any subcontractor, has engaged in discrimination prohibited by this Contract pursuant to RCW 49.60.530(3),

43.3 Default. Notwithstanding any provision to the contrary, Agency may suspend Contractor, including any subcontractor, upon notice of a failure to participate and cooperate with any state agency investigation into alleged discrimination prohibited by this Contract, pursuant to RCW 49.60.530(3). Any such suspension will remain in place until Agency receives notification that Contractor, including any subcontractor, is cooperating with the investigating state agency. In the event Contractor, or subcontractor, is determined to have engaged in discrimination identified at RCW 49.60.530(3), Agency may terminate this Contract in whole or in part, and Contractor, subcontractor, or both, may be referred for debarment as provided in RCW 39.26.200. Contractor or subcontractor may be given a reasonable time in which to cure this noncompliance, including implementing conditions consistent with any court-ordered injunctive relief or settlement agreement.

43.4 Remedies for Breach. Notwithstanding any provision to the contrary, in the event of Contract termination or suspension for engaging in discrimination, Contractor, subcontractor, or both, shall be liable for contract damages as authorized by law including, but not limited to, any cost difference between the original contract and the replacement or cover contract and all administrative costs directly related to the replacement contract, which damages are distinct from any penalties imposed under Chapter 49.60, RCW. Agency shall have the right to deduct from any monies due to Contractor or subcontractor, or that thereafter become due, an amount for damages Contractor or subcontractor will owe Agency for default under this provision.

**44. Public Disclosure.** The contractor acknowledges that WSP is subject to Chapter 42.56 RCW and that this contract shall be a public record as defined in the Public Records Act. Any specific information claimed by the contractor to be proprietary information must be clearly identified as such by the contractor. To the extent consistent with Chapter 42.56 RCW, the WSP shall maintain the confidentiality of all such information marked as proprietary information. If a public records request is received pursuant to Chapter 42.56 RCW for documents related to this agreement, the WSP will give the contractor ten days' written notice at the contractor's last know address before releasing any documents the contractor has marked as proprietary information. It is the contractor's responsibility to take legal action to obtain an injunction prior to the expiration of the ten days' notice. The contractor will indemnify, defend, and hold harmless the WSP for release of documents related to this contract as required by law. Nothing contained in this section or any other portion of this agreement affects or modifies the WSP's obligation to disclose public records under Chapter 42.56 RCW or other applicable law.

If the Contractor receives a public records request under Chapter 42.56 RCW for any records containing Data subject to this Agreement, Contractor agrees to notify the WSP RMD Public Records Officer within five (5) business days and to follow the procedure set out in this section before disclosing any records. The WSP Public Records Officer can be contacted at pubrecs@wsp.wa.gov.

The Contractor must provide a copy of the records with proposed redactions to WSP when they are available and ready. WSP will respond within ten (10) business days of receipt of the redacted records to identify concerns with disclosure of the records, propose any changes to the Contractor's redactions, or request more time if needed. If the Contractor disagrees with any of WSP's concerns or proposed changes, the Contractor must notify WSP of that disagreement and provide WSP with a minimum of fifteen (15) business days to obtain a restraining order or injunction under RCW 42.56.540 before disclosing any records.

**45. Supplier Diversity**.

45.1 This contract Is ☐ Is Not ☐ Subject to the Subcontractor Payment Reporting

45.2 This contract is subject to the terms and conditions of DES Policy No. POL-DES-090-06, which may be found at the following link: https://des.wa.gov/policies-legal/supplier-diversity-des-090-06. The requirements of the policy are listed in this Section.

45.3 Subcontractor and Business Diversity Checklist

45.3.1 Contractor is required to complete, sign and return the Contractor Business Diversity Certification, which shall be provided to Contractor by WSP and attached to this Contract as an Exhibit.

45.4 Registration as a Certified OMWBE or Veteran business

45.4.1 Contractor is encouraged to register with the Office of Minority and Women's Business Enterprises as a certified small or minority business. The Office of Minority and Women's Business Enterprises (OMWBE) certifies small businesses owned and controlled by minority, women, and socially and economically disadvantaged persons. OMWBE certifies business in order to increase contracting opportunities for certified businesses with state and local governments. More information about certifying can be found at the following link: https://omwbe.wa.gov/certification

45.4.2 If Contractor is a veteran-owned business, contractor is encouraged to become certified through the Veteran's administration. More information about certifying can be obtained by sending an email to: ShamekiaM@DVA.WA.GOV . Certified veteran's businesses can be found at the following link: https://www.dva.wa.gov/veterans-their-families/veteran-owned-businesses/vob-search

45.5 **Subcontractor.**

**45.5.1 Definitions.**

| | |
|---|---|
| Subcontractor | One not in the employment of the Contractor (or "Prime" or "Primary" Contractor), who is performing all or part of those services through a separate contract with the Contractor, including sub-subcontractors. |
| Prime Contractor | The entity that enters into this Contract with the WSP. |

**45.5.2 Subcontractor Payment Reporting.**

If the Contractor is utilizing the services of a subcontractor, this Contract is subject to subcontractor payment tracking. The Contractor must enter all payments made to the Contractor by WSP into the Business Diversity Management System entitled *Access Equity*.

*Access Equity* is a web-based system that can be accessed at the Office of Minority and Women's Business Enterprises (OMWBE) at https://omwbe.diversitycompliance.com/.

Contact AccessEquity@omwbe.wa.gov and/or at 360-644-9750 and/or at Access Equity Help Center | Office of Minority and Women's Business Enterprises (wa.gov) for technical assistance in using the Access Equity system.

WSP shall notify Contractor when the *Access Equity* system is ready for data entry.

**45.5.3 Reporting Instructions.**

45.5.3.1 Register and enter subcontractor information, and require each subcontractor to register in *Access Equity* no later than 15 days after WSP creates the contract record in *Access Equity.*

45.5.3.2 Complete and require each subcontractor to complete the required user training (there are two one-hour online sessions) no later than 20 days after the contract record has been entered.

45.5.3.3 Report in *Access Equity* the amount and date of all payments received from the WSP and paid to subcontractors no later than 30 days after issuance of each payment made by the WSP to the Contractor.

45.5.3.4 Contractor shall mark as "Final" and report the final subcontractor payments into Access Equity no later than thirty (30) days after the final payment is due the subcontractor under the Contract, with all payment information entered no later than sixty (60) days after end of fiscal year.

45.5.3.5 Monitor contract payments and respond promptly to any requests or instructions from WSP or system-generated messages to provide information in Access Equity. Coordinate with subcontractors or WSP when necessary, to resolve discrepancies between reported payments and actual payments.

45.5.3.6 Contractor and all subcontractors shall respond to requests from WSP for additional information to be provided electronically through *Access Equity*.

45.5.3.7 Require each subcontractor of all tiers to: (i) register in Access Equity and complete the required user training; (ii) verify the amount and date of receipt of each payment from the Contractor or a higher tier subcontractor, if applicable, through *Access Equity*; (iii) report payments made to any lower tier subcontractors, if any, in the same manner as specified herein; (iv) respond promptly to any requests or instructions from the Contractor or system-generated messages to check or provide information in *Access Equity*; and (v) coordinate with Contractor, or WSP when necessary, to resolve promptly any discrepancies between reported and received payments.

45.6 **Subcontractor Inclusion Plans.**

45.6.1 **"Subcontractor Inclusion Plan" (SIP)** is created by bidders when subcontractors and/or authorized dealers will be a part of the contract. SIPs list the commitments that a contractor, vendor, or consultant makes to increase its

spending with small and/or veteran-owned businesses. SIPs also list the bidder's efforts to include small and/or veteran-owned businesses for ancillary services that the bidder does not directly perform.

45.6.2 Inclusion goals are aspirational While no minimum level of OMWBE certified, Veteran Owned, or Washington Small Business participation will be required as a condition for entering into this contract, contractors are encouraged to provide a SIP that includes the actions the contractor will take to increase subcontracting opportunities for those business types as follows:

45.6.2.1 Describe their efforts in engaging and reducing any barriers to participation by small/diverse businesses, including outreach, education/mentorship, and process changes designed to increase small/diverse business participation.

45.6.2.2 If the proposed subcontractors are self-identified diverse businesses, bidder will encourage and support efforts for their certification with the appropriate Washington state agencies.

45.6.2.3 WSP will review the Contractor's Anticipated Diverse Participation Goals & SIP for a genuine effort and the maximum opportunity to contribute toward WSP's aspirational goals. Contractors who utilize subcontractors will meet with WSP annually regarding their small/diverse business aspirational inclusion goals and outreach efforts set forth in their Bidder's Anticipated Diverse Participation Goals & SIP.

**46. Force Majeure.** The parties hereto shall not be liable or responsible for cost, expense, or damage due to a delay in the performance of services hereunder, where such delay is due to causes beyond their reasonable control, including, but not limited to natural disasters, acts of government after the date of these Terms and Conditions, power failure, acts of God, labor disputes, riots, acts of war, epidemics, or material and transportation shortages.

## DOING BUSINESS WITH THE STATE OF WASHINGTON

### Statewide Vendor Number

The successful bidder required to be registered as a Statewide Payee prior to submitting a request for payment under this Agreement. The Washington State Office of Financial Management (OFM) maintains the Statewide Payee Registration System; to obtain registration materials go to: https://ofm.wa.gov/it-systems/statewide-vendorpayee-services

### Washington's Public Records Disclosure Act

All documents submitted by bidders to WSP as part of this procurement will become public records. Such records are subject to public disclosure unless specifically exempt under Chapter 42.56 RCW. For more information refer to *Proprietary Information/Public Disclosure* Section in the RFQQ.

### Economic Goals

In support of the state's economic goals, although not an award factor (unless otherwise specified herein), bidders are encouraged to consider the following in responding to this RFQQ:

- Support for a diverse supplier pool, including small, veteran-owned, minority-owned and women-owned business enterprises. Achievement of these goals is encouraged whether directly or through subcontractors. Bidders may contact the Office of Minority and Women's Business Enterprises for information on certified firms or to become certified.
- WSP supports the purchase of goods and/services from Washington Small Businesses. If you qualify as a Washington small business, identify yourself in WEBS. Call WEBS Customer Service at 360-902-7400.
- Veterans and U.S. active duty, reserve or National Guard service-members are eligible for the registry. The veteran or service-member must control and own at least 51 percent of the business and the business must be legally operating in the State of Washington. Control means the authority or ability to direct, regulate or influence day-to-day operations.

### Environmental Goals

In support of the state's environmental goals, although not an award factor (unless otherwise specified herein), bidders are encouraged to consider the following in responding to this RFQQ:

- Use of environmentally preferable goods and services, including post-consumer waste and recycled content.
- Products made or grown in Washington.

### Other Resources

- Register for free for solicitation notices at the Washington Electronic Business Solution (WEBS) https://www.des.wa.gov/sell/how-work-state/register-bid-opportunities
- Contact the Washington State Department of Veterans' Affairs about certification at (360) 725-2169 or www.dva.wa.gov.

A Pre-Bid Conference for the Toxicology Forensic Testing RFQQ will be held as follows:

***Wednesday, March 12, 2025***
***9:00am – 10:00am Pacific Time***

The meeting will be held via a Teams Conference Call. Please attend the meeting through the following link:

Click Here to enter the meeting

Meeting ID: 256 612 699 892
Passcode: Vw6VY3dr

Bidder representatives may also call-in, and their attendance will be taken over the phone.

Dial by your location
+1 323-694-9686

WSP plans to present an overview of the project, expectations of proposals and other information to assist bidders in responding to the RFQQ. Bidders will be provided an opportunity to ask questions.

WSP will attempt to address all questions raised during the Bidders' Conference. However, nothing discussed during the Bidders' Conference will be binding on Bidders or WSP. Questions and answers discussed in the Bidders' Conference will be posted on WEBS.

***Note:*** Additional questions submitted in writing by email to the RQQ Coordinator by the date set out in the RFQQ Solicitation document Anticipated Procurement Schedule on Page One will also be addressed in writing and posted in WEBS.

# WASHINGTON STATE PATROL
# LABORATORY DIVISION

LETTER OF SUBMITTAL IN RESPONSE TO:

# REQUEST FOR QUALIFICATIONS AND QUOTATIONS
# RFQQ NO. WSP-RFQQ-TOXTST
# TOXICOLOGY FORENSIC TESTING

## APRIL 29, 2025

200 Welsh Road, Horsham, Pennsylvania 19044 T 800.522.6671 F 215.657.2972 www.nmslabs.com

## Title Page

**Washing State Patrol Laboratory Division**
**Letter of Submittal in Response to**
**RFQQ NO. WSP-RFQQ-TOXTST**
**Toxicology Forensic Testing**

---

| | |
|---|---|
| **Submitting Organization:** | National Medical Services, Inc.<br>dba NMS Labs<br>200 Welsh Road<br>Horsham, PA 19044<br>800.522.6671 |
| **Type of Organization:** | Corporation (private) |
| **Authorized Personnel for Contractual Obligation:** | David Delia<br>President and CEO<br>800.522.6671<br>nms@nmslabs.com |
| **Authorized Personnel for Contractual Clarification:** | Camilla Green<br>Sr. Territory Manager - Forensics<br>215.824.6095<br>Camilla.Green@nmslabs.com |

## Table of Contents



**Attachments:**

- NMS Labs-Appendix A-RFQQ-TOXTST
- NMS Labs-Appendix B-RFQQ-TOXTST
- NMS Labs-Appendix C-RFQQ-TOXTST
- NMS Labs-Appendix C1-RFQQ-TOXTST
- NMS Labs-Appendix D-RFQQ-TOXTST
- NMS Labs-Appendix E-RFQQ-TOXTST
  *(Organizational chart, List of principal officers, and Washington business license are attached with Appendix E)*
- NMS Labs-Appendix F-RFQQ-TOXTST
- NMS Labs-Appendix G-RFQQ-TOXTST
- NMS Labs-Insurance-RFQQ-TOXTST
- NMS Labs-2025 Fee Schedule-RFQQ-TOXTST
- NMS Labs-2025 Expert Services Fee Schedule-RFQQ-TOXTST

# Section 1

## Letter of Introduction

April 17, 2025

State of Washington
Washington State Patrol Laboratory Division

Re: RFQQ No. WSP-RFQQ-TOXTST, Toxicology Forensic Testing

To Whom It May Concern,

National Medical Services, Inc. dba NMS Labs appreciates the opportunity to present a proposal to provide Toxicology Forensic Testing for the Washington State Patrol Laboratory Division. NMS Labs is experienced and capable of successfully performing the scope of work as outlined in RFQQ No. WSP-RFQQ-TOXTST.

NMS Labs confirms that the procedures utilized in performing the scope of work outlined in this Request for Qualifications and Quotations shall be in compliance with all applicable federal and State laws. NMS Labs is uniquely capable of providing the full scope of work for the entire term of the proposed agreement. NMS Labs' proposal defines our services in line with the requirements of the RFQQ but encourages the Washington State Patrol Laboratory Division to contact us directly to clarify or expand in any areas of interest.

Sincerely,

David Delia
President and CEO

## Corporate Overview

NMS Labs was founded in 1970 and has since earned the reputation as a high-quality bioanalytical toxicology and forensic laboratory. For 54 years, NMS Labs has served the medicolegal community by providing broad-based forensic toxicological analyses. NMS Labs also supports the medicolegal community by offering drug identification testing and expert forensic services.

NMS Labs has a wealth of experience working with postmortem specimens, servicing medical examiners and coroners, law enforcement, attorneys, clinical laboratories, hospitals, private industry, and public crime labs. The scope of toxicology testing capabilities at NMS Labs is the broadest available in the United States from a private laboratory. NMS Labs toxicology capabilities include the analysis for drugs, metals and elements, solvents and environmental toxins in biological samples. Our lab routinely handles alternative samples necessary in death investigations such as tissue, decomposition fluid, gastric fluids, insect larvae and many other matrices.

The type of work NMS Labs performs for our forensic clients includes: all postmortem testing for a Medical Examiner or Coroner, law enforcement testing for drug and alcohol cases, reference toxicology testing for clients that have their own toxicology laboratories, backlog reduction of autopsy cases on a project basis and long-term outsourcing contracts from state and county agencies. NMS Labs also supports the death investigation needs of agencies with drug chemistry analysis of general unknown non-biological substances.

NMS Labs currently employs more than 450 highly trained professionals. NMS Labs has a staff dedicated to our forensic business including: 12 doctoral level toxicologists that are board certified Fellows by the American Board of Forensic Toxicology (F-ABFT), specially trained forensic specimen processors, forensic client support staff, criminalists and scientists, forensic sales and marketing representatives and expert services department. This dedicated forensic staffing allows NMS Labs to give individual attention to each of our forensic clients when necessary. In addition, our administrative support departments of quality assurance, accounting, expert services and business development are all able to support the specific needs of this anticipated contract. NMS Labs does not have any history of defaults, contract terminations or bankruptcies.

NMS Labs has always followed the most stringent standards available to assure our postmortem clients that we produce superior quality results guided by accepted professional standards. NMS Labs is accredited by ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 for:

- Toxicology
- Seized Drugs

This supports our goal of providing the highest quality forensic science services in a timely, confidential and professional manner. NMS Labs also holds national laboratory accreditations and licensures through the College of American Pathologists (CAP) Laboratory Accreditation Program (LAP), and College of American Pathologists (CAP) ISO 15189.

See complete list of licensures as well as copies of our ANAB/ASLCD-LAB certificates in Section 3.

NMS Labs forensic services extend beyond our main facilities in Horsham, PA. NMS Labs currently operates multiple secured forensic laboratories within the states of Texas, North Carolina, Pennsylvania and Florida. ANAB ISO 17025 accredits all of these facilities. The table below shows the ISO 17025 accredited disciplines held at each facility. NMS Labs combined resources offer a unique network of accredited laboratories which provide increased capacity, economies of efficiency and the operational flexibility to assist clients.

ISO 17025 Accredited Disciplines by Facility

| Facility | ISO 17025 Accredited Disciplines |
|---|---|
| Headquarters, Horsham, PA | Toxicology |
| Crime Lab, Willow Grove, PA | Seized Drugs |
| Bucks County, PA | Seized Drugs |
| El Paso, TX | Seized Drugs |
| Dallas-Fort Worth, TX | Seized Drugs |
| Winston-Salem, NC | Seized Drugs |
| Jacksonville, FL | Toxicology |

*Supplier Diversity:*

NMS Labs will not be subcontracting any of the work under a contract entered into as a result of this solicitation and as such will not be required to register in the Access Equity System (AES).

NMS Labs approaches Supplier Diversity from a companywide sourcing perspective at the time of evaluating new suppliers for an existing or new requirement. Supplier Diversity status is included as one of the source selection criteria. This approach is captured in a SOP. Additionally, for each Small Business Plan submitted against a unique contact, goals or metrics are monitored throughout the year on an individual basis and tracked and/or measured within the corresponding system for the specific contract.

The products and supplies that are utilized by a laboratory cannot reasonably be sequestered or aligned to individual contracts as they are shared. An example of this is our laboratory information system that is used to track incoming samples, sample status, invoicing and information on NMS Labs clients. It would be unfeasible to divide this type of product for the utilization of a single contract. NMS Labs has access to SBE/MBE/WBE businesses through state certified business directories and websites and does make a good faith effort to source services and supplies from SBE/MBE/WBEs.

We have carefully reviewed the Conditions, Provisions and Specifications put forth in the RFQQ. Our laboratory operations department has ample and excess capacity available to accept the sample volumes outlined in the bid as well as any additional case volume that may be needed for your office.

## Scope of Work

### Postmortem Toxicology Testing Services

NMS Labs currently provides analysis on over 2,700 therapeutic drugs, illicit drugs and other drugs of abuse and their metabolites, newly emerging synthetic designer drug compounds (synthetic cannabinoids, bath salts, and novel psychoactive stimulants), metals, poisons, inhalation drugs, and other toxic compounds. Analysis can be performed on routine and non-routine samples including:

- Fluids – blood, serum, plasma, urine, vitreous, gastric, bile
- Solids – tissues, all solid organs, bone, injection sites, hair, nails, teeth, decomposed tissue, embalmed bodies, exhumed bodies, insect larvae, bone marrow
- Biological stains on materials (clothing, paper, sheets, carpeting, etc.) for presence of compounds of toxicological interest
- Non-Biological Testing capabilities – tablets, powders, liquids, syringes, and other drug paraphernalia
- Documentable proof of method development capabilities for unique analytes

The NMS Labs portfolio of routine postmortem toxicology panels test for the presence of common drugs of abuse and therapeutic drugs. These panels are offered at a flat-fee price to include all screening and quantitative confirmation testing for compounds included in the scope of the requested toxicology panel. The postmortem portfolio of panels consists of Basic, Expanded, and TotalTox™. Basic and Expanded panels can be ordered with vitreous alcohol confirmation testing. We also offer specific testing panels for inhalational drugs, and carboxyhemoglobin testing. Testing for additional compounds beyond the scope of the routine panels can be requested on an 'a la carte' basis as needed for a specific case.

The primary postmortem panels that are used by NMS Labs clients are the Basic and Expanded Postmortem panels. These panels were developed by our toxicologists specifically to be applied to postmortem samples and results are reported with useful comments to assist death investigators in the interpretation of findings. These panels range in scope from common drugs of abuse (Basic panel) that includes Alcohols and 12 Classes of common drugs of abuse including Fentanyl, to an Expanded panel with over 250 compounds. Drug categories for the Expanded panel include, but are not limited to: Analgesics, Anesthetics, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotics, Bath Salts, Cardiovascular, Gastrointestinal, Narcotics, Neurological, Novel Psychoactive Substances (NPS), Opiates, Sedatives/Hypnotics, Stimulants, and Urological.

See Postmortem Toxicology Scope of Testing in Section 3 for a list of compounds in each panel.

### Human Performance Toxicology Testing Services

NMS Labs has toxicology testing services specifically designed for Drug Recognition Experts (DRE) and law enforcement agencies to investigate suspected incidents of drug-impaired driving and drug facilitated crimes. Our specialized testing services were developed with the oversight of Dr. Barry Logan, PhD, F-ABFT who is nationally recognized for his leadership and contributions to the IACP-DRE program. NMS Labs offers a broad scope of testing at sensitive reporting limits for the most relevant substances typically involved in impaired driving incidents. Additional testing related to the seven (7) DRE Drug Categories outlined by the International Drug Evaluation and Classification Program (DECP) may be added to the initial analysis request to expand the scope of testing.

NMS Labs has a Drug Facilitated Crimes (DFC) panel, previously named Drug Facilitated Sexual Assault panel. All testing performed includes a screen and quantitative confirmation analysis.

The unique features of NMS Labs DRE panels that will be available to the WSP include:

- Scope of Blood Testing - Broad scope of testing at sensitive reporting limits for the most relevant

substances typically involved in impaired driving incidents. Additional testing related to the seven (7) DRE Drug Categories outlined by the International Drug Evaluation and Classification Program (DECP) may be added to the initial analysis request to expand the scope of testing. All testing performed includes a screen and quantitative confirmation. NMS Labs extensive menu of tests prevents the need to outsource any testing to other labs for additional toxicology testing.

- Delta-9 Cannabinoid Isomer Resolution is a test that will provide quantitative results for Delta-8 THC and Delta-8 carboxyl THC, Delta-9 THC, Delta-9 carboxy THC and 11-OH Delta-9 THC. The Uncertainty of Measurement will be provided with this result.

- Urine testing is available and will report qualitatively.

- Interpretive Information – NMS Labs Drug Impaired Driving toxicology panels include specific comments authored by our toxicologists that relate to potential drug impairment while driving. These comments will generally relate the toxicological findings to the physical signs, symptoms and behaviors observed in typical DRE evaluations. The specific reference comments are included when applicable on reports at no additional charge. An Uncertainty of Measurement will be provided on all quantitative testing reported.

- Uncertainty of Measurement – NMS Labs has the ability to calculate Uncertainty of Measurement as a standard practice for testing panels specific for drug impairment cases. The Uncertainty of Measurement can be reported for other tests as needed.

See DUID/DRE Toxicology Scope of Testing in Section 3 for a list of compounds in each panel.

Additional Testing Panels

In addition to our Postmortem and DUID Toxicology panels, NMS Labs has specially designed panels specific for Fire Death, Drug Facilitated Crime, Novel Psychoactive Substances (NPS), Bath Salts, Synthetic Cannabinoids, metals, abused gases, solvents, insecticides and pesticides and a comprehensive metal and metalloids panel. NMS Labs also has targeted analysis methods that can detect and quantitate thousands of drugs and compounds. Refer to the 2025 NMS Labs Fee Schedule for a complete list of test offerings.

Novel Psychoactive Substances

The introduction of new Novel Psychoactive Substances (NPS) has created challenges for all laboratories due to their evolving development and discontinuations. NMS Labs is constantly evaluating information from the media, drug user forums and casework to identify NPS compounds, which may be of interest and develop mechanisms to report these findings to our clients when appropriate. Giving proper emphasis to this national phenomenon, we have developed a focused developmental team for the NPS drug market.

The NMS Labs' NPS Strategy Team tracks the changing NPS market, identifying novel and emerging drugs and anticipating the most popular new substances. Using a broad range of information resources including the latest medical and scientific literature, data from our forensic drug chemistry casework and monitoring chatter from online drug user networks, the mission of this group is to listen, anticipate and proactively provide analytical solutions for the needs of our customers. It is designed to monitor the state of analytical science practice in the United States and internationally; steer the development of new tests, technologies and market opportunities; and ensure that the needs of both the public safety and public health clients for innovative tests are being met in a timely manner.

In addition to the compounds listed in our Expanded Postmortem panel, NMS Labs has identified several NPS substances that may be detected as part of the analytical work performed in this analysis. All samples tested through our Expanded Postmortem panel, which undergo our LC/TOF-MS screen, are evaluated using an

internally developed secondary library specific to new and emerging NPS compounds to identify potential analytes of interest.

As of 10/28/24, the NMS Labs Surveillance Library includes the following as compounds that may be detected in forensic cases:

Expanded Panel Surveillance Compounds: 2-Furanylfentanyl, 2-Methyl AP-237, 3-hydroxy-PCP, 3-MeO-PCP, 3-Fluorophenmetrazine, Acrylfentanyl, alpha-PHP/alpha-PiHP, alpha-PVP, Amoxapine, AP-238, Benztropine, Bropheniramine, Brorphine, Bromazolam, Butylone, Butyrlfentanyl, Chloroquine, cis-3 Methylfentanyl, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Diclazepam, Ethylone, Eutylone, Flecainide, Flualprazolam, Fluphenazine, Flurazepam, Fluvoxamine, Hydroxychloroquine, Hydroxyethylflurazepam, Hydroxytriazolam, Isotonitazene / Protonitazene, MDEA, Meclonazepam, Meperidine, Mesoridazine, Metaxolone, Methaqualone, Metonitazene, N-desethyl Isotonitazene, N-ethyl Pentylone, N,N-Dimethylpentylone, N-pyrrolidino Etonitazene, N-pyrrolidino Protonitazene, Normeperidine, Norpropoxyphene, para-Fluoroisobutyrylfentanyl, Pentylone, Perphenazine, Phenacetin, Phenazepam, Pheniramine, Propoxyphene, Pyrazolam, Quinidine, Tianeptine, Tizanidine, Theophylline, Thioridazine, trans-3-Methylfentanyl, Trifluoperazine, Trimipramine, Tripolidine, Vardenafil, Yohimbine, Zaleplon

NMS TotalTox Surveillance Compounds: 2-Methyl AP-237, 3-Fluorophenmetrazine, AP-238, Brorphine, Chloroquine, Deschloroetizolam, Meclonazepam, Pyrazolam, Tianeptine

In situations where NMS Labs may detect the presence of these compounds, the client will be notified to consult with us on next steps given the case history and testing capabilities at the time. Additional fees will apply for confirmation testing of the above-listed compounds. It is expected that with our dedicated approach to identifying NPS compounds of interest, this library of compounds will be dynamic and will change over time.

See NPS Scope of Testing in Section 3 for a list of compounds in NMS Labs panels.

## True Forensic Testing

The scope of compounds and metabolites specified in NMS Labs forensic panels are analyzed by initial screening tests for preliminary identification and confirmed by more specific testing methods to provide quantitative identification of specific compounds identified by the initial screening. This includes using two analytical techniques on two separate aliquots.

The following is a list of the analytical techniques in general use within NMS Labs for screening and confirmation testing:

Screening
ELISA (Enzyme Linked Immunosorbent Assay)
EMIT (Enzyme Multiplied Immunoassay Technique)
FPIA (Fluorescence Polarized Immunoassay)
TLC (Thin-layer Chromatography)
Microdiffusion
Spectrophotometry
LC/MS/MS-TOF (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry/Time of Flight)
LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)
HPLC (High Performance Liquid Chromatography) with various forms of detection (UV, Fluorescence, Electrochemical)
GC/MS (Gas Chromatography/Mass Spectrometry)
GC (Gas Chromatography) with various forms of detection (NPD, FID, ECD)
ICP/MS (Inductively Coupled Plasma Mass Spectrometry)
GFAAS (Graphite Furnace Atomic Absorption Spectrophotometry)

Confirmation
LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)
LC/MS/MS-TOF (TOF = Time of Flight)
GC/MS (Gas Chromatography/Mass Spectrometry)
ICP/MS (Inductively Coupled Plasma Mass Spectrometry)

## Non-Biological Testing Capabilities

NMS Labs is capable and has experience performing non-biological testing. NMS Labs holds a DEA licensure and is currently accredited by ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 for laboratory analysis in the discipline of Seized Drugs.

Services that NMS Labs offers to assist the Washington State Patrol include:

- Detection of tampering and physical or chemical contamination in foods, beverages, drugs and other consumer products.
- Identification and evaluations of pills, powders, potions, poisons, plants and drug paraphernalia.

## Method Development for Unique Analytes

NMS Labs is the leading independent provider of clinical and forensic toxicology, and criminalistics laboratory services for the health care and forensic sciences communities. Since 1970, we have built a reputation as a provider of innovative, first-to-market and hard-to-find testing that has evolved to a broad menu of over 2,500 laboratory tests with documentable proof of method development. Customers worldwide have recognized NMS Labs for its world-class, full-service facility and emphasis on research and development.

Offering one of the largest arrays of esoteric laboratory testing and services, NMS Labs is the only commercial source for many new and hard-to-find tests in the areas of:

- Postmortem toxicology
- Clinical toxicology, including pain management and hundreds of monitored therapeutic drugs
- Environmental exposure and occupational monitoring, including volatile organics and metals
- Drug identification; investigation of drug diversion, tampering and fraud

## Quality Assurance and Quality Control

NMS Labs understands that Quality Assurance and Quality Control are an integral part of the laboratory. NMS Labs Quality Assurance department monitors and administers all internal and external QA/QC protocols.

NMS Labs participates in comprehensive external proficiency testing programs, which compares our performance with other laboratories performing the same analysis. These programs are supplemented by a comprehensive internal blind proficiency program that challenges analyses that are not formally evaluated by the external program. All data generated by these programs are remediated, as necessary, and approved by various management levels of review.

Additionally, all departments are subject to live audits by the Quality Assurance department on a rotating basis to assess compliance with our quality assurance program. All audits are documented in audit reports and are reviewed and approved by various levels of management. A complete listing of NMS Labs proficiency programs can be found on our website at: https://www.nmslabs.com/resources/accreditations-and-licensures, or is available upon request.

See SOP 10913 Quality Manual in Section 5.

## Supplies

Sample collection kits and supplies that are specially designed to handle postmortem and DUID samples will be provided (at no charge), along with printed analysis requisition forms with a chain of custody documentation to submit samples for analysis.

NMS Labs collection kits are produced and assembled in a quality-controlled environment. The blood collection containers that are provided have the optimum amount of preservative and anticoagulant that provides specimen integrity for accurate quantitation of alcohol and other toxins. These features of the NMS Labs collection kit help to support the highest quality forensic testing necessary for legal proceedings.

For routine shipment of samples, NMS Labs will provide all necessary supplies for prepaid shipping via Federal Express Standard Overnight service at no additional cost.

## Chain of Custody and Consultation

All samples received by the laboratory for analysis are maintained under strict chain-of custody from receipt at the laboratory until final disposition of the samples being discarded in the agreed upon timeframe or returned to the WSP upon request.

The following is a narrative description of how NMS Labs will operationally manage the Specimen Receipt/ Accessioning of samples received for analysis from the WSP. See, also, the following SOPs in Section 5:

- 10976 Receiving and Opening in Specimen Processing
- 10979 Specimen Processing Accessioning
- 10968 Electronic Chain of Custody and Transporting Samples

### Specimen Receipt/Accessioning Project Management

NMS Labs successfully manages forensic toxicology projects for clients throughout the United States for both routine and non-routine testing related to postmortem and human performance toxicology. Specific to the scope of work outlined for the WSP, NMS Labs would approach the project by working to establish mutually agreeable communication channels and assigned staff members as designated responsible parties.

*Supplies and Shipping:*

NMS Labs will provide Toxicology Analysis Requisition Forms with fields/areas to include incident case number, first and last name of subject, collection date of samples and the type of samples that are being submitted.

The forms have an area to capture chain of custody information. Sample collection kits will be provided (at no charge) that are specially designed to handle forensic samples. Specimens are to be transported in a tamper proof collection kit (provided by NMS Labs) under full chain of custody by Federal Express standard overnight at the expense of NMS Labs.

NMS Labs is also able to pick up existing chain of custodies that may already be in use. NMS Labs will have a full internal chain of custody established for the parent samples and individual aliquots as they move through the laboratory process.

*Sample Log in:*

NMS Labs staff is trained in the appropriate handling of forensic evidence. Each specimen is uniquely identified and logged in to the NMS Laboratory Information System to ensure traceability. Chain of custody is maintained for all samples. Lab access is limited to authorized personnel. All samples would be logged in through NMS Labs forensic specimen processing area, which is secured and has access by limited NMS Labs staff. Upon receipt in the laboratory, all paperwork is closely reviewed for accuracy and completeness, the integrity of the security seal is documented, and the internal chain of custody is

initiated. NMS Labs internal chain of custody follows all samples and aliquots throughout the analysis procedures, storage and/or subsequent return to the client.

*Sample Custody and Integrity:*

All cases are accessioned in a "one at a time" fashion to eliminate the possibility of mixing samples from different cases. As each case is logged in, every container received is assigned a unique identification number. This number appears in human-readable and barcode format on the labels that print after each container is entered into the LIMS. It is standard procedure at NMS Labs to apply the label to each container as it is printed, thereby ensuring that each container is labeled correctly. Only after the label has been applied to the container will the next container in a case be logged in. Only after all containers in a case have been logged in and labeled will another case be processed.

As samples from a case are sub-sampled for analysis, similar steps are taken to ensure the integrity and traceability of the sub-samples (aliquots). Aliquots are taken for only one sample at a time. The containers for each aliquot are again assigned unique identification numbers that link them back to the case, and human-readable and bar-coded labels with the unique identification number are affixed to the aliquots as they print. Only after all aliquots have been taken from a sample and the aliquots and parent sample have been labeled and capped will another sample be sub-sampled.

Parent samples never leave the Forensic Specimen Processing area. From the time they are received until they are returned or discarded, all parent samples are kept in a refrigerated storage area in a secured room with restricted access. Only aliquots are transferred to the respective NMS Labs testing departments for analysis.

Because each container is uniquely identified, NMS Labs has the ability to track the precise location of each container in the case. Within the Forensic Specimen Processing area, each transfer of a parent sample into or out of storage for sub-sampling is electronically documented by scanning the unique container identification number bar-coded on its label. Aliquots delivered to testing departments are tracked electronically, by the case identification number, from receipt in the department through analysis. In addition, sample identifications are scanned from the barcode label to create analytical batches, eliminating the possibility of incorrect sample identification.

*Analysis and Reporting:*

All samples will be analyzed in the main laboratory of NMS Labs, we do not subcontract toxicology testing. Upon completion of analytical testing, results are manually entered in the LIMS, and following a secondary technical review, results are forwarded to a Forensic Toxicologist for final review. All analytical data, requisition forms and any supplemental data provided are inspected by the Toxicologist during the final review and a certification signature is applied to each report for test codes designed to have additional toxicologist review. All analysis reports will be accurate and easy to read including interpretive comments explaining the identified compounds and the potential impairment effect related to the skills necessary for safe driving. Report delivery is available via our secure, on-line client portal, fax and US mail as requested.

Current NMS Labs Standard Operating Procedures (SOPs) support all of the activities in this example. These SOPs are reviewed annually and updated when procedures are changed. Documented training records for all staff involved in the chain-of-custody handling of submitted samples is available upon request. Authorized employees of the WSP are welcome to view NMS Labs Operational SOPs on site upon request.

<u>Client Web Portal</u>

NMS Labs offers a secure Client Portal for digital ordering of testing, monitoring test orders, order status, test results, and for retrieving requested Litigation Packets.

Order status is the first page displayed upon logging into the Client Portal and status options are: Pending Receipt, Received, In Progress, In Review, Reported, Canceled, or No Report. A tooltip for each Order Status is available by hovering over the individual status within the grid.

Order status grid columns can be customized (hidden/displayed, sorted, resized, rearranged) according to client preferences. Email notifications can be set for specific status options. Filtering capabilities are available on the column headers within the Order Status page and a general search option is available for a quick keyword search on the Order Status page. Clients can export a summary report based upon the period selected on the Order Status page. A Microsoft Excel® Export (Detail) report is also available with sample and test level information.

Test result reports are available electronically in a secure PDF format. The electronic reports are posted on the Client Portal as soon as the final report is reviewed and completed. Multiple users from the same organization can be notified via e-mail when laboratory reports are available and sign in with their own unique designated user ID/password to access laboratory reports. Reports are archived for two years on the Client Portal and can be sorted by patient name, case ID number, date of service, date of birth, sex or accession number for retrieval. Secure Socket Layer (SSL) encryption is activated when results are displayed.

All laboratory reports received are encrypted and cannot be intercepted during transmission. Preliminary reporting for urgent cases and inquiries is available through direct contact of our client support services department with a verbal discussion with a toxicologist reviewing the case, as necessary. Outside of the web portal for report delivery, online test ordering is also available at no additional charge to our clients.

All analysis reports will be accurate and easy to read using common units of measure. Final reports will include all information necessary to allow definitive identification of the case and its source along with comprehensive test results and interpretive comments. All final reports Laboratory results will be issued using an electronic format and will include detailed findings for positive results. These reports will include but are not limited to:

- Name or sample identification number
- Laboratory identification number (Workorder #)
- Name of submitting agency
- Date sample received
- Date results reported
- Specimen type and related test findings and interpretive/reference information
- Signature of approving individual for select tests

Report terminology is standardized to be in alignment with current industry expectations. All reports will be final reports unless otherwise specified and requested in advance of commencement of work. All final reports will include the same information that is presented in interim reports as applicable. Supplemental reports where additional testing is added after a final report is generated will be appropriately identified as such and will contain the same identifying information as the original report.

Upon request by the authorized agency, we will send a copy of the final report to another agency but only after positive identification is obtained. This authorization will be documented appropriately. On occasion it may be necessary to correct a final report after it has been released (error correction). In this instance a corrected report will be issued and will be clearly identified as Corrected and will contain the same identifying information as the original final report.

## Results Reporting

NMS Labs provides quantitated results on forensic panel tests within 2 weeks on average from the time of receipt. NMS Labs current production schedules support an expected turnaround time of 14-18 business days after receiving samples for analysis of our routine postmortem and DUID/DRE toxicology panels. Esoteric and

special request testing may exceed 18 days. NMS Labs will make every effort to handle every case received from the WSP in an expeditious manner. Our online test catalog publishes turnaround times by test code: https://www.nmslabs.com/tests.

A Forensic Toxicologist will issue a final report of analytical findings. Laboratory reports will include a summary of all positively identified substances with quantitative results of parent drug compounds and related metabolites. Toxicology reports are designed in alignment with our forensic accrediting body as well as requirements set forth by the National Association of Medical Examiners (NAME) to include agency name, agency case number, specimen description, source of sample, requested testing/type of screen, chain of custody information, test results, certification of test results statement with reviewing analyst signature, and date of report. From an analytical perspective NMS Labs includes the following information in our toxicology report: analytical methodology, minimum reporting limit, and general reference comments related to positively identified substances.

DUI/DUID cases will include the Uncertainty of Measurement. Other tests can provide the Uncertainty of Measurement if necessary.

See Sample Reports provided in Section 4.

**Test Catalog**

NMS Labs company website (www.nmslabs.com) has a complete directory of available testing services. The website is also a reliable resource for detailed reference information on the current and new tests available at NMS Labs.

Also, attached with our response is the NMS Labs 2025 Fee Schedule.

**Expert Consultation**

Our in-house staff of experts brings years of laboratory experience including many doctoral-level scientists and professionals who have appointments at major universities and medical schools, are members of esteemed professional organizations and routinely publish scientific papers in peer-reviewed journals. NMS Labs Expert Services Department will manage the delivery of on-site testimony, video testimony and conferences, litigation package requests, depositions and other services to assist with the WSP litigation. NMS Labs scientists are experts in communicating complex ideas to a non-scientific audience. With 54 years of experience providing testimony in thousands of criminal and civil cases, NMS is a recognized leader in assisting legal professionals to provide expert support for their cases involving toxicology or criminalistics.

Due to the size of an example litigation package, NMS will not be including an example in this bid response. As permitted in Amendment Two, NMS is providing a detailed table of contents of what is contained in the NMS Litigation package.

1) NMS Labs Laboratory Report
2) Sample Submission documents
    a. NMS Labs Requisition or Sample Submission documents
    b. External Chain-of-Custody documentation
    c. Airbill or Shipping documents
3) Login Verification
4) Internal Chain-of-Custody documentation
    a. Sample History Report
    b. Posting History Report
5) Sample Storage and Disposition documentation
6) Correspondence documentation
7) Licensures and Accreditations

a. Time of testing
b. Current (Date of request)

8) Analytical Documentation
    a. Run Sheet (if applicable)
    b. Batch Worklist
    c. Analytical Data
        1. Sequence Data
        2. Calibrators
            1. All calibrators pertaining to the acceptability of the analytical data associated with case
        3. Quality Control
            1. All controls pertaining to the acceptability of the analytical data associated with the case
    d. Workorder (Case) Data
        1. All applicable Analytical Data
            1. Chromatograms
            2. Manual Integrations
            3. Overlays
    e. Analyst's notes (if applicable)
9) Analytical Documentation (run failures)
    a. Run Sheet (if applicable)
    b. Batch Worklist
    c. Analytical Data
        1. Sequence Data
        2. Calibrators
            1. All calibrators pertaining to the acceptability of the analytical data associated with case
        3. Quality Control
            1. All controls pertaining to the acceptability of the analytical data associated with the case
    d. Workorder (Case) Data
        1. All applicable Analytical Data
            1. Chromatograms
            2. Manual Integrations
            3. Overlays
    e. Analyst's notes (if applicable)
10) Analytical Methods containing
    a. Reagent Data
    b. Analytical Procedure
    c. Quality Control Procedure
    d. Blank Procedure

<u>Support Services</u>

In addition to the analytical testing services, NMS Labs offers the following services to support our forensic clients:

*<u>Forensic Client Support Specialists</u>*

NMS Labs utilizes specially trained forensic client support staff to work with our forensic clients. NMS Labs has client support available by phone at (800) 522-6671 during the following hours:
Monday through Friday 5:00 am - 5:30 p.m. Pacific Time

NMS Labs also has client support available via e-mail at forensics@nmslabs.com. This e-mail is checked a minimum of every 30 minutes for activity during client support working hours. Many of our forensic clients find this service valuable, as it offers a timed documentable proof of communication. Our client support staff can handle routine inquires such as result status, test ordering, expected turnaround time, adding additional testing to existing cases, appropriate sample requirements, handling and packaging. NMS Labs client support is also able to handle explanation of NMS Labs scope of services. If the incoming question from our client is outside of the area of responsibility our client support staff, they will contact the appropriate NMS Labs staff member for immediate follow up.

*Toxicologist Consultation*

NMS Labs provides a unique program called DirecTox™. This program gives direct phone and email access to your assigned board-certified forensic toxicologist for questions concerning: Public health and safety emergencies, case history evaluation, sample collection guidance, test recommendations, test result review, and interpretation of findings. The program also provides access for phone consultations, video collaboration and webinars on matters including continuing education and collaboration on publications.

In addition to our DirecTox™ service, NMS Labs offers unique toxicologist support to our clients. NMS Labs has an accredited board-certified toxicologist available by phone Monday through Friday for our clients. This assigned toxicologist has their work schedule cleared for their assigned day so that they are available for our clients. This is to prevent our clients from the potential conflicts that other labs may have with their limited professional toxicology staff, which may not be available due to the inevitable times of professional or personal commitments outside of the laboratory. Toxicologists are also available to address inquiries via e-mail for our client's convenience. In the event that a written opinion or legal testimony is required, additional charges will apply for expert professional consultation.

## Forensic Toxicology Personnel and Key Scientific Staff

NMS Labs currently employs more than 250 highly trained professionals at our Headquarters and Laboratory at 200 Welsh Road, Horsham, PA 19044. Led by our staff of twelve doctoral level, F-ABFT (Fellow - American Board of Forensic Toxicology) board certified toxicologists, NMS Labs has a staff dedicated to our forensic business including: specially trained forensic specimen processors, forensic client support staff, criminalists and scientists, forensic sales and marketing representatives and expert services department. This dedicated forensic staffing allows NMS Labs to give individual attention to each of our forensic clients when necessary. Below are brief biographical summaries of the scientific leadership staff involved in the daily operations at NMS Labs. CVs are available upon request.

### Robert A. Middleberg, Ph.D., F-ABFT, DABCC-TC

***Core Laboratory Director and Forensic Toxicologist***

Dr. Robert A. Middleberg is the Core Laboratory Director at NMS Labs. He earned his Ph.D. in Pharmacology from Thomas Jefferson University and a Master's degree in Chemistry from the University of Pittsburgh. He is a Fellow of the American Board of Forensic Toxicology (F-ABFT) and a Diplomate in Toxicological Chemistry from the American Board of Clinical Chemistry (DABCC-TC). Dr. Middleberg is a faculty member at Thomas Jefferson University. He holds an active position on the Board of Directors for the American Board of Forensic Toxicology and served on the Board of Directors of the American Board of Clinical Chemistry. Dr. Middleberg was awarded the Rolla N. Harger award in 2013 for contributions to forensic toxicology by the Toxicology Section of the American Academy of Forensic Sciences. He is a member of many professional organizations, including the American Academy of Forensic Sciences, the Association for Diagnostics & Laboratory Medicine and the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Dr. Middleberg is a member of the College of American Pathologists Toxicology Committee and sat on the Editorial Board for the Journal of Forensic Sciences for many years.

**Barry K. Logan, Ph.D., F-ABFT**
***Sr. Vice President of Forensic Science Initiatives, Chief of Forensic Toxicology***
Dr. Barry K. Logan is a graduate of the University of Glasgow in Scotland graduating with degrees in chemistry and forensic toxicology in 1982 and 1986 respectively. He received four (4) years postdoctoral training in forensic toxicology at the University of Tennessee Center for Health Sciences in Memphis. In 1990, he was appointed State Toxicologist and Assistant Professor of laboratory medicine at the University of Washington in Seattle, and in 1999 he was appointed Director of Forensic Laboratory Services Bureau for the Washington State Patrol. He served in both positions until 2008, when he joined NMS Labs as National Director of Forensic and Toxicological Services. NMS Labs is a leading US provider of esoteric toxicological testing services, specializing in new drug detection and forensic analysis for the prosecution and defense in criminal justice and death investigation agencies. Dr. Logan's responsibilities include management of toxicology resources, new test design and development, quality management, and expert testimony in forensic toxicology and chemistry.

Dr. Logan is Board Certified by the American Board of Forensic Toxicologists (ABFT) and has over ninety (90) publications in toxicology and analytical chemistry, including treatises on the effects of methamphetamine, cocaine, marijuana, alcohol, hallucinogens and depressant drugs on drivers, and postmortem redistribution of drugs, and the toxicology and chemistry of novel psychoactive substances. His recent work has focused on the analytical and interpretive toxicology of emerging recreational and designer drugs. In 2002, Dr. Logan was appointed Executive Director of the Robert F Borkenstein Center for Studies of Law inaction at Indiana University where he directs the Borkenstein Courses. Since 2010, Dr. Logan has also served as Executive Director at the Center for Forensic Science Research and Education at the Fredric Rieders Family Renaissance Foundation in suburban Philadelphia. The Center supports educational programs in the forensic sciences for high school and graduate students and continuing professional education for forensic science professionals. Dr. Logan has made over three hundred (300) presentations to professional groups and conferences in the area of forensic science.

Dr. Logan is a member of many professional organizations in forensic science including the American Academy of Forensic Sciences (AAFS), the Society of Forensic Toxicologists, The American Society of Crime Laboratory Directors, The International Council on Alcohol, Drugs and Traffic Safety, and the Canadian Society of Forensic Sciences, and has served on the Transportation Research Board of the National Academies.

In recognition of his work and contributions, Dr. Logan has received International Association of Forensic Toxicologists mid-career achievement award in 2004, the AAFS Rolla N. Harger Award in 2010, the National Safety Council's Robert F. Borkenstein Award in 2011, and the Widmark Award from the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) in 2013. He has served in various positions on the Board of the AAFS since 2005, and as President in 2013.

**Lee Blum, Ph.D., F-ABFT, FAIHA**
***Assistant Laboratory Director, Forensic Toxicologist***
Dr. Blum is a Director at NMS Labs and is responsible for laboratory services, consulting, and testing for occupational and environmental toxicants. He is a Forensic Toxicologist and serves as Assistant Laboratory Director at NMS Labs. He earned a Ph.D. in Pharmacology from Thomas Jefferson University, a Master's degree in Forensic Chemistry from Northeastern University and is a graduate of Pennsylvania State University. Dr. Blum is a Fellow of the American Board of Forensic Toxicology and the American Industrial Hygiene Association. He serves on national committees in occupational biological monitoring and is a member of several professional organizations including the American Academy of Forensic Sciences, Society of Forensic Toxicology, American Conference of Governmental Industrial Hygienists, American Industrial Hygiene Association, American College of Occupational and Environmental Medicine, Association of Public Health Laboratories, and International Society of Exposure Science. He also teaches a course in Environmental Exposure Toxicology at Thomas Jefferson University in Philadelphia, PA.

Laura Labay, Ph.D., F-ABFT, DABCC-TC
*Principal Toxicologist*
Dr. Laura M. Labay is a Principal Toxicologist at NMS Labs. She earned a Bachelor's degree in Biochemistry and Molecular Biology from the University of California at Santa Cruz, and Masters and Doctorate degrees in the field of Toxicology from the University of Rochester. Prior to joining NMS Labs, Dr. Labay worked for several years in the Forensic Investigation Division of the New York City Police Department. At the NYPD her primary responsibilities included analyzing evidentiary material for the presence of controlled substances and testing blood samples for DUI investigation purposes. As a Forensic Toxicologist, Dr. Labay reviews a wide variety of cases including those related to postmortem, human performance impairment (DUI/DUID) and drug-facilitated crime investigations. She has been qualified numerous times in several courts throughout the country as an expert in forensic toxicology. In her 20-year career at NMS Labs she has held a variety of technical and management positions including Laboratory Supervisor, Director of Expert Services, Assistant Laboratory Director, and Director of Toxicological Services. In addition, she is a member of several professional organizations including the American Academy of Forensic Sciences (Toxicology Section), the Society of Forensic Toxicologists (SOFT), and the National Association of Medical Examiners (NAME). Dr. Labay is a Fellow at the Center for Forensic Science Research and Education, serves as the Course Director for the Postmortem Interpretive Toxicology Course, and helps to instruct and mentor graduate students. She is also the Toxicology Co-Chair for NAME, and an Advisory Board Member for the Professional Science Master's Program in Forensic Toxicology for Jefferson College of Biomedical Sciences and The Center for Forensic Science Research & Education. Dr. Labay has and maintains two board certifications; one from Board Certified by the American Board of Forensic Toxicology (ABFT) and one from the American Board of Clinical Chemistry (ABCC) in the area of Toxicological Chemistry.

Erin Spargo, Ph.D., F-ABFT
*Director of Toxicological Services, Assistant Laboratory Director for NMS Labs Drug Chemistry and Core Lab*
Dr. Spargo is responsible for oversight of the toxicology department, case report release and certification, and training and development of the toxicologists; she also has quality oversight responsibilities for drug chemistry and the core lab. Dr. Spargo previously served as Chief of Forensic Chemistry at the Southwestern Institute of Forensic Sciences (SWIFS) where she oversaw the Toxicology (postmortem, DWI/DUID, and DFC), Breath Alcohol, and Controlled Substances sections of the Institute. She also held an appointed assistant professor position at the University of Texas Southwestern Medical School. Dr. Spargo is active in several professional organizations and currently serves on the Board of Directors of the Society of Forensic Toxicologists (SOFT) as President. She is a recipient of the Educational Research Award from SOFT and the June K. Jones and Irving Sunshine awards from the Toxicology Section of the American Academy of Forensic Sciences (AAFS). She is a Fellow of the American Board of Forensic Toxicology and a certified technical assessor for ANAB in the disciplines of toxicology and controlled substances. She holds a Certificate of Qualifications from the New York State Department of Health and is licensed as a seized drug analyst and toxicologist (interpretive) by the Texas Forensic Science Commission. Dr. Spargo received her PhD from the University of Maryland at Baltimore, completing her graduate research work at the National Institute on Drug Abuse (NIDA).

Ayako Chan-Hosokawa, MS, D-ABFT-FT
*Toxicology Manager, Forensic Toxicologist*
Ayako (Aya) Chan-Hosokawa is a forensic toxicologist and toxicology team manager with NMS Labs in Horsham, PA. She earned her Bachelor of Science in Chemistry from Stockton University in 2004 and her Master of Science in Chemistry from the University of Minnesota in 2006. Ms. Chan-Hosokawa is also certified as a Diplomate through the American Board of Forensic Toxicology (ABFT) and holds a Texas Forensic Analyst License in the category of Toxicology (Interpretive). She is an active member of the Society of Forensic Toxicologists (SOFT), the American Academy of Forensic Sciences (AAFS), the International Association of Forensic Toxicologists (TIAFT), International Council on Alcohol, Drugs and Traffic Safety (ICADT) and National Safety Council (NSC) (Administrative Chair).

Professionally, Ms. Chan-Hosokawa's primary area of interest is drug-impaired driving (DUID); she evaluates

positivity data, the changes in drug trends and observed blood drug concentrations and has presented the findings at national conferences. Her emphasis is to help maintain NMS Labs' leadership role in human performance toxicology testing by developing appropriate scopes of analyses at the sensitivities required for DUID investigations and working closely with DREs on their observations and inputs. She has testified over 140 times in various jurisdictions (for both prosecution and defense) and routinely provides written expert opinion reports. She also serves as a faculty member for the Pennsylvania District Attorneys Institute (PDAI) for their annual training of prosecutors and investigators and the Borkenstein course on the Effects of Drugs on Human Performance and Behavior.

**Brittany Casey, PhD, F-ABFT**
***Toxicology Manager, Forensic Toxicologist***
Dr. Brittany Casey joined NMS labs in 2023; prior to that she was the Chief of Forensic Chemistry for the Dallas County Southwestern Institute of Forensic Sciences and oversaw the Toxicology (postmortem, DWI/DUID, and DFC), Breath Alcohol, and Controlled Substances sections of the Institute. An integral part of her work there was directing the design, validation, and implementation of new methodology in the Toxicology and Controlled Substances sections. She also held an appointed assistant professor position at the University of Texas Southwestern Medical School. Originally from North Texas, she completed her undergraduate studies in biochemistry at Baylor University in Waco, Texas, and participated in undergraduate research studying tissue bonding and meniscal repair using substituted napthalimides. She earned her doctoral degree in chemistry from Tulane University in New Orleans, Louisiana, where her research focused on the synthesis and characterization of dendritic mass spectral calibrants and transdermal drug carriers. Brittany is a fellow of the American Board of Forensic Toxicology and is active in professional organizations such as the Society of Forensic Toxicologists (SOFT) and the American Society for Mass Spectrometry (ASMS). She also holds a Texas Forensic Analyst License in the category of Toxicology (Interpretive).

**Dan Anderson, MS, D-ABFT-FT, ABC-GKE**
***Forensic Toxicologist***
Dan Anderson joined NMS Labs in 2021, bringing with him more than 30 years of experience in postmortem and human performance toxicology. Prior to joining NMS Labs, Dan served as the Toxicology program manager at the Colorado Bureau of Investigation (CBI) for 6 years developing and managing 3 laboratories within a single state system primarily focused on DUI/DID analysis. Previous to CBI, Dan was a toxicologist/manager at the Los Angeles County Department of Medical Examiner - Coroner in Los Angeles, CA for 24 years immersed in postmortem toxicology and one year at the Ventura County Sheriff's Department Toxicology laboratory. He received a Bachelor of Science Degree from Colorado State University in Fort Collins, CO in 1988 and a MS in Forensic Science-Criminalistics from the University of New Haven in West Haven, CT in 1990. Dan is certified by the American Board of Criminalistics-General Knowledge Exam (ABC-GKE 1998) and is a Diplomat -Forensic Toxicologist of the American Board of Forensic Toxicology (ABFT 2007).

Dan has given many presentations, posters, and published articles in forensic toxicology whose topics include Bupropion, Fentanyl (Duragesic® Patch), Flecainide, GHB, Oxycontin®, Mirtazapine, Paroxetine, Quetiapine, Duloxetine, and Zaleplon. He was recognized for his achievements with the 2011 recipient of the American Academy of Forensic Sciences Toxicology Section Ray Abernethy Award for being an outstanding Forensic Toxicology Practitioner. Dan is also very active in professional organizations, including currently serving on the Board of Directors of the American Academy of Forensic Sciences (AAFS) and as the 2023 Vice President of ABFT. Previously, he was the 2022 Academy Standards Board (ASB) Vice-Chair, held multiple board positions with the Society of Forensic Toxicologists (SOFT) culminating as President in 2013, and was the President of the California Association of Toxicologists (CAT) in 2005-2006. Lastly, Dan continues as a member of the NIST OSAC Toxicology sub-Committee (2014-2020, 2022-present), and is currently appointed to two Editorial Boards, Journal of Forensic Sciences and Journal of Analytical Toxicology.

**Daniel S. Isenschmid, Ph.D., F-ABFT**
***Forensic Toxicologist***
Dr. Dan Isenschmid is a forensic toxicologist at NMS Labs. He brings to the company over 40 years of experience in forensic toxicology and the many benefits of his years of leadership and casework in the field. Prior to joining the company in 2011, Dr. Isenschmid was Chief Toxicologist at the Wayne County Medical Examiner's Office in Detroit. He received his M.S. and Ph.D. degrees in pathology and forensic toxicology, respectively, from the University of Maryland at Baltimore, School of Medicine, and was the recipient of several Educational Research Awards from the Society of Forensic Toxicologists (SOFT). He was also the recipient of both the Irving Sunshine Award and Alexander O. Gettler Award from the American Academy of Forensic Sciences (AAFS). Dr. Isenschmid is a Fellow and past Vice President of the American Board of Forensic Toxicology. He is active in professional organizations including SOFT (Past President), AAFS (Fellow and past member of the Board of Directors), and The International Association of Forensic Toxicologists (TIAFT) (Past Secretary and Treasurer).

Dr. Isenschmid has published and presented on many topics related to postmortem forensic drug testing including medical examiner case reports, the interpretation of postmortem cocaine concentrations, the stability and analysis of cocaine and its metabolites, and the effects of cocaine on human performance. He has lectured extensively to toxicologists, graduate and undergraduate students, pathologists, law enforcement personnel and is a faculty member of the Borkenstein course on the Effects of Drugs on Human Performance and Behavior.

**Sherri Kacinko, Ph.D., F-ABFT**
***Forensic Toxicologist***
Dr. Sherri Kacinko has been a forensic toxicologist at NMS Labs toxicologist in Horsham, PA for over 15 years. She earned her B.S in Chemistry from the University of Pittsburgh (Johnstown) and her Ph.D. in toxicology from the University of Maryland – Baltimore. She also serves as an Instructor at the Center for Forensic Science Research & Education where she lectures in pharmacology, postmortem toxicology, and human performance toxicology courses. Current research interests include the identification and quantification of novel psychoactive substances and esoteric drugs and the use of data analytics to monitor drug use trends on a local and national level.

Dr. Kacinko is a fellow of the American Board of Forensic Toxicology (ABFT) and is a member of the Society of Forensic Toxicologists (SOFT), the International Association of Forensic Toxicologists (TIAFT), the American Academy of Forensic Sciences (AAFS), and holds a Certificate of Qualifications from the New York State Department of Health. She was presented with the American Academy of Forensic Sciences Toxicology Section Irving Sunshine Award in recognition of early career research and served as the program chair, secretary and chair of the AAFS toxicology section.

**Kari Midthun, Ph.D., F-ABFT**
***Forensic Toxicologist***
Dr. Kari Midthun joined NMS Labs in 2020, bringing with her experience in toxicology, forensic science, chemistry, biochemistry, nanotechnology and education. Prior to joining NMS Labs, Dr. Midthun served as the Assistant Laboratory Director at United States Drug Testing Laboratories, and previously worked as a forensic scientist at the New York State Police Forensic Investigation Center and intern with the FBI Laboratory. Dr. Midthun is active in several professional organizations, including the Society of Forensic Toxicologists (SOFT), the National Association of Medical Examiners (NAME), and the American Academy of Forensic Sciences (AAFS). She is the author of peer reviewed papers and is currently researching various aspects of umbilical cord tissue testing and postmortem pediatric trends. Dr. Midthun received dual Bachelor of Science degrees in Chemistry and Biochemistry from the University of Wisconsin-Madison, before earning a Master of Science and Doctor of Philosophy in Chemistry and Chemical Biology from Cornell University. She is a Fellow of the American Board of Forensic Toxicology and holds a Certificate of Qualifications from the New York State Department of Health.

**Donna Papsun, MS, D-ABFT-FT**
***Forensic Toxicologist & Business Scientist***
Donna Papsun is a forensic toxicologist at NMS Labs in Horsham, PA. She earned dual Bachelor of Science degrees in Chemistry and Forensic & Investigative Science from West Virginia University and a Master of Science degree in Pharmacology from Thomas Jefferson University. She is certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT) and is a member of both the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS).

Ms. Papsun has been with NMS Labs since 2008, first as a bench analyst before promotion to toxicologist in 2012. Primary responsibilities include reviewing toxicology case work and interpretation of those results in medicolegal investigations. Ms. Papsun's main area of interest is the identification of novel psychoactive substances (NPS) in biological specimens. As one of the two leaders of NMS's NPS strategy team, she continuously works to help maintain NMS's leadership in identifying the newest trends in the changing landscape of the designer drug market and implementing tests for their detection in forensic toxicology casework. Ms. Papsun also serves in a secondary role as a business scientist, working to align the technical and scientific expertise of NMS Labs with commercial efforts.

**Brianna Peterson, PhD, F-ABFT**
***Forensic Toxicologist***
Brianna Peterson is a forensic toxicologist with NMS Labs. She earned her Bachelor of Science in Chemistry from the University of Wisconsin-La Crosse, her Master of Science in Forensic Science from the University of Illinois at Chicago, and her Doctorate in Toxicology from the University of Georgia. Dr. Peterson is also certified as a Fellow through the American Board of Forensic Toxicology (ABFT) and is a member of the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS).
Prior to joining NMS Labs, Brianna worked for the Washington State Patrol (WSP) as the laboratory manager overseeing toxicology testing on postmortem and DUI cases. Previous to WSP, Brianna worked for two years as a forensic toxicologist for the Georgia Bureau of Investigation.

**Scott Larson, MS, D-ABFT-FT**
***Forensic Toxicologist***
Scott Larson is a forensic toxicologist with NMS Labs based in Montana. He earned a Bachelor of Science in Microbiology and a Master of Science in Pharmacology from the University of Montana. Prior to joining NMS, he spent 9 years at the Montana Forensic Science Division in various roles as a toxicologist, toxicology section supervisor and lab director. He has also worked for the Armed Forces Medical Examiner System, Washington D.C. Office of the Chief Medical Examiner, and the national New Zealand toxicology laboratory (ESR).

Scott is certified by the American Board of Forensic Toxicology as a Diplomat -Forensic Toxicologist and is a member of the Society of Forensic Toxicologists (SOFT). He has provided presentations or lectures to various government agencies, universities, and at professional meetings. In addition, he has published articles in peer-reviewed journals. Scott has been a member of the NIST OSAC Toxicology sub-committee since 2020.

**Jolene Bierly, MSFS, D-ABFT-FT**
***Forensic Toxicologist***
Jolene Bierly is a Forensic Toxicologist with NMS Labs based in Pennsylvania. Her employment history includes working for the New York State Police Crime Laboratory System (2013-2017) before joining NMS Labs in 2017. She earned a Master of Science in Forensic Science degree from Arcadia University and a Bachelor of Science in Biology from Messiah College.

Ms. Bierly is certified as a diplomat in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT) and is an active member in the Society of Forensic Toxicologists (SOFT), the American Academy of Forensic Sciences (AAFS), and the Northeastern Association of Forensic Scientists (NEAFS). She has authored peer reviewed papers on postmortem toxicology and drug-impaired driving (DUID).

**Justin Brower, PhD, F-ABFT**
*Forensic Toxicologist*
Dr. Brower is a forensic toxicologist and joined NMS Labs in 2022. He earned a Bachelor of Arts in Chemistry at Adams State University and a Doctorate in Organic Chemistry at the University of Nevada. He followed his graduate work with a postdoctoral fellowship from the Cancer Research Institute at the University of California, Irvine, where he researched peptides and protein-protein interactions. He then joined a start-up biotechnology company in Charleston, SC, and served as the Director of Chemistry, conducting drug discovery and development of targeting central nervous system disorders and pain. Dr. Brower started his toxicology career at the North Carolina Office of the Chief Medical Examiner in Raleigh, NC, where he was the laboratory supervisor and a forensic toxicologist.

From his drug discovery career, Dr. Brower holds multiple U.S. and international patents and published on the synthesis and studies of novel therapeutics. In the field of toxicology, he has published widely on the opioid mitragynine (Kratom) and regularly gives talks and presentations at scientific meetings and conferences. His interests include chemistry and toxicology education, scientific communication, postmortem toxicology, and natural toxins and poisons.

**Michael E. Lamb, MSFS, D-ABFT-FT**
*Forensic Toxicologist*
Michael Lamb is a forensic toxicologist at NMS Labs in Horsham, PA. He earned his Bachelor of Science in Neuroscience from Binghamton University in 2010 and his Master of Science in Forensic Science from Arcadia University in 2012. Mr. Lamb has been working at NMS Labs since 2012 where he started as an analyst in the lab responsible for the testing of thousands of samples a year for the presence of drugs, alcohol, poisons and other intoxicants.

Mr. Lamb is board certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT). He is an active member of both the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS). Mr. Lamb has presented at various conferences related to postmortem forensic toxicological testing.

**Estuardo (Estee) Miranda, MS**
*Forensic Toxicologist*
Estuardo Miranda is a forensic toxicologist and joined NMS labs in 2023. He earned his Bachelor of Science in Chemistry with a minor in Zoology and Master of Science in Zoology from Arizona State University. Prior to joining NMS, Estuardo worked at the Arizona Department of Public Safety (2009-2023) as a Forensic Scientists in toxicology where he reestablished the toxicology unit in the Tucson laboratory. Later he oversaw the Toxicology, Blood Alcohol, Controlled Substances and Latent Print units as a supervisor in the AZ DPS crime laboratory. Prior to that, he worked at the Washington State Patrol (2001-2009) as Supervising Forensic Scientist overseeing toxicology testing on postmortem and DUI cases and rendering court room testimony as an expert witness. Before WSP Estuardo worked for the Arizona Department of Public Safety Crime Laboratory in Phoenix (1998-2001) in DUID forensic toxicology. Estuardo brings 25 years of forensic toxicology knowledge with extensive experience in drug impaired (DUID) expert testimony.

**Stephanie Marco, Ph.D., F-ABFT**
*Forensic Toxicologist*
Dr. Stephanie Marco is a forensic toxicologist based out of Horsham, PA. She joined NMS Labs in 2019 as a postdoctoral toxicologist. Dr. Marco received her dual Bachelor of Science degrees in Chemistry and Forensic Science from the University of New Haven (2012) and her Doctorate in Toxicology at Rutgers University (2019).

Dr. Marco is a Fellow of the American Board of Forensic Toxicology (ABFT). Additionally, she is an active member of the Society of Forensic Toxicologists (SOFT) and the Academy of Forensic Sciences (AAFS), having presented

at several conferences. Dr. Marco received specialized training in postmortem interpretive toxicology and medico-legal alcohol topics through The Center for Forensic Sciences Research and Education and The Robert F. Borkenstein Course on Alcohol & Highway Safety, respectively.

**William M. Schroeder II, MS, D-ABFT-FT**
***Forensic Toxicologist***
William Schroeder earned his Bachelor of Science in Biochemistry with a Minor in Forensic Science from the University of the Sciences in Philadelphia in 2009 and his Master of Science in Biochemistry from Drexel University in 2014. Mr. Schroeder is certified by the American Board of Forensic Toxicology (ABFT) as well as an active member of both the American Academy of Forensic Sciences (AAFS) and the Society of Forensic Toxicologists (SOFT).

Mr. Schroeder has been with NMS Labs since 2012, when he was hired to perform analytical testing on samples for the presence of alcohol, drugs, and other intoxicants. He joined the toxicology department in January 2018 and is current responsibilities include toxicological case review as well as providing expert testimony for these cases.

**Jennifer L. Swatek, MSFS, D-ABFT-FT**
***Forensic Toxicologist***
Jennifer Swatek is a forensic toxicologist at NMS Labs based in the Greater Metro Detroit area of Michigan. She earned her Bachelor of Science in Forensic Biochemistry from Northern Michigan University (2011) and her Master of Science in Forensic Science from Arcadia University (2013). Ms. Swatek has been working at NMS Labs since 2012 where she started as an analyst in the lab responsible for the testing of thousands of samples a year for the presence of drugs and other intoxicants before promoting to the toxicology department in 2019.

Jennifer is board certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT). She is an active member of the Society of Forensic Toxicologists (SOFT), the American Academy of Forensic Sciences (AAFS), and the National Association of Medical Examiners (NAME). Ms. Swatek has presented at various conferences related to postmortem forensic toxicology and is currently researching drug and vitreous electrolyte trends in the pediatric postmortem population.

**Chelsey Deisher, MS, D-ABFT-FT**
***Forensic Toxicologist***
Chelsey Deisher is a toxicologist with NMS Labs in Horsham, PA . She obtained both her B.A. in Biochemistry and her Master's degree in Forensic Science and Law from Duquesne University. She is certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT) and holds a Texas Forensic Analyst License in the category of Toxicology (Interpretative) through the Texas Forensic Science Commission. She is also an active member of the Society of Forensic Toxicologists (SOFT).

Ms. Deisher has been with NMS Labs since 2014, where she started as an analyst in the laboratory before promotion to toxicologist in 2021. Her primary responsibilities include reviewing toxicological case work in medicolegal death investigations and offering expert testimony. Currently, her main area of interest surrounds the identification of novel psychoactive substances (NPS) in biological specimens.

**Amanda D'Orazio, MSFS, D-ABFT-FT**
***Forensic Toxicologist***
Amanda D'Orazio, M.S., D-ABFT-FT is a Forensic Toxicologist at NMS Labs in Horsham, PA. She earned her Bachelor of Science in Chemistry from Arcadia University in 2015 and her Master of Science in Forensic Science from Arcadia University in 2017. She is certified as a Diplomate through the American Board of Forensic Toxicology (ABFT). She is a member of the National Safety Council's Alcohol, Drugs, and Impairment Division through which she collaborates with other toxicologists in the field to regularly update the *Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities*,

research centered around drug testing in DUID/traffic fatality investigations. She is a member the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS) and has presented her research at various conferences. She currently serves on the SOFT/AAFS Oral Fluid Committee.

Emily Fenton, MSFS, MBA, D-ABFT-FT
*Forensic Toxicologist*
Emily Fenton is a toxicologist at NMS Labs in Horsham, PA. She earned her Bachelor of Arts in Chemistry and Biochemistry and Master of Business Administration from La Salle University in 2015 and 2016, respectively. Ms. Fenton also earned her Master of Science in Forensic Science from Arcadia University in 2021. Her graduate work focused on *The Stability of Drug Analytes in Umbilical Cord Tissue*. She has been working at NMS Labs since 2017 where she started in Specimen Processing and continued her career testing metals, alcohol and routine analyte cases; she promoted to a toxicologist in 2023.

Kristopher W Graf, MS, D-ABFT-FT
*Forensic Toxicologist*
Kristopher Graf is a toxicologist at NMS Labs in Horsham, PA. He earned his Bachelor of Science in Forensic and Toxicological Chemistry from West Chester University of Pennsylvania in 2006 and his Master of Science in Forensic Toxicology from Thomas Jefferson University in 2017. Mr. Graf has been working at NMS Labs since 2007 where he started as an analyst in the lab responsible for the testing of thousands of samples a year for the presence of drugs, alcohol, poisons and other intoxicants; he promoted to a toxicologist in 2019. Mr. Graf is board certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT). Mr. Graf has presented at various conferences related to postmortem forensic toxicological testing.

Meaghan R. Hessler, MSFS, D-ABFT-FT
*Forensic Toxicologist*
Meaghan R. Hessler is a toxicologist at NMS Labs in Horsham, PA. She earned her Bachelor of Science in Chemistry with a Mathematics minor from Arcadia University in 2016 and her Master of Science in Forensic Science from Arcadia University in 2018. Ms. Hessler has been working at NMS Labs since 2018 where she started as an analyst in the lab responsible for the testing of thousands of samples a year for the presence of drugs and other intoxicants; she joined the toxicology department in 2021. Meaghan is board certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology (ABFT). She is an active member of the Society of Forensic Toxicologists (SOFT) and an associate member of the American Academy of Forensic Sciences (AAFS). Ms. Hessler has both attended and presented at various conferences related to forensic toxicology.

Victoria Hill, MSFT
*Forensic Toxicologist*
Victoria Hill is a toxicologist at NMS Labs in Horsham, PA. She earned her Bachelor of Science in Forensic Science with a concentration in Chemistry from The Pennsylvania State University in 2017 and her Master of Science in Forensic Toxicology from Thomas Jefferson University in 2022. Victoria has been working at NMS Labs since 2017 where she started as a laboratory intern responsible for the testing of thousands of samples a year for the presence of drugs and other intoxicants. Prior to joining the Toxicology department in 2024, she was a member of the Operations Technical Improvement department and specified in laboratory staff training for sample preparation, data calculation, and secondary review in various analytical departments.

Nicholas Laraia, MSFS
*Forensic Toxicologist*
Nicholas Laraia is a toxicologist at NMS Labs in Horsham, PA. He earned his Bachelor of Science in Forensic Chemistry with a minor in Criminal Justice from the University of Scranton in 2016 and his Master of Science in Forensic Science from Cedar Crest College in 2019. Prior to NMS, Nicholas has presented research projects from both undergraduate and graduate education at multiple conferences. He is also currently in the application process for becoming a member of the American Board of Forensic Toxicology (ABFT) and the

Society of Forensic Toxicologists (SOFT). He has been working at NMS Labs since 2018 where he started in the Routine 1 department and continued his career in the Waters LCMS department. Nicholas joined the toxicology department in 2024.

# Section 2

## Pricing

Please refer to Section 3 for the detailed scope of compounds for the postmortem, DUID/DRE and NPS testing panels NMS Labs is offering the Washington State Patrol.

| Acode | Acode Description | NMS Labs Discount Pricing |
|---|---|---|
| 8051B | Postmortem, Basic, Blood (Forensic) | $154.00 |
| 8051FL | Postmortem, Basic, Fluid (Forensic) | $233.00 |
| 8051SP | Postmortem, Basic, Serum/Plasma (Forensic) | $154.00 |
| 8051TI | Postmortem, Basic, Tissue (Forensic) | $296.00 |
| 8051U | Postmortem, Basic, Urine (Forensic) | $154.00 |
| 8052B | Postmortem, Expanded, Blood (Forensic) | $237.00 |
| 8052FL | Postmortem, Expanded, Fluid (Forensic) | $591.00 |
| 8052SP | Postmortem, Expanded, Serum/Plasma (Forensic) | $237.00 |
| 8052TI | Postmortem, Expanded, Tissue (Forensic) | $634.00 |
| 8052U | Postmortem, Expanded, Urine (Forensic) | $237.00 |
| 8150B | DUID/DRE Panel ProofPOSITIVE®, Blood (Forensic) | $291.00 |
| 8151B | DUID/DRE Panel (w/Alcohol) ProofPOSITIVE®, Blood (Forensic) | $309.00 |
| 8152B | DUID/DRE Expanded Drug Screen Add-On ProofPOSITIVE®, Blood (Forensic) | $144.00 |
| 0570B | Designer Benzodiazepines, Blood (Forensic) | $196.00 |
| 8660B | Opiates - Free (Unconjugated), Blood | $226.00 |
| 9560B | Synthetic Cannabinoids Screen (2016 Scope), Blood | $264.00 |
| 8600B | Amphetamines Panel, Blood | $226.00 |
| 0960B/TBD | Delta-9 Cannabinoid Isomer Resolution (DUID/DRE), Blood (CSA) | $227.00 |
| 0960B | Cannabinoids Panel, Blood | $227.00 |
| 1479B | Delta-8 and Delta-9 Cannabinoids Panel, Blood | $243.00 |
| 8251B | Postmortem, Basic w/Delta-9 THC Confirmation, Blood | $164.00 |
| 8252B | Postmortem, Expanded w/Delta-9 THC Confirmation, Blood | $252.00 |
| 8180B | Postmortem, Blood Add-on for Delta-9 THC | $30.00 |
| 8030B | Drug Facilitated Crime Panel, Blood (Forensic) | $475.00 |
| 8030U | Drug Facilitated Crime Panel, Urine (Forensic) | $475.00 |

Prices quoted for each panel include cost of screening and quantitative confirmation testing for the compounds specified in the respective postmortem toxicology panels. All other testing ordered during the initial contract term will be billed at the fees referenced in the NMS Labs 2025 Fee Schedule. Expert Services will be billed at the 2025 Expert Services Fee Schedule.

Contract term is one (1) year with four (1) year renewals as options. Price increases may occur upon mutual agreement and increases are not to exceed 5% for each renewal period.

Detailed lists of drugs/compounds included the testing panels listed above are included in Section 3, Scope of Testing.

## Value Added Services

- NMS Labs Website – www.nmslabs.com offers clients an easy-to-use online resource for new tests, scope of testing, sample requirements, submission information, sample collection recommendations, staffing, and licensure information.

- NMS Labs is operational 24 hours a day 7 days a week to provide optimum turnaround time and efficiencies for our clients.

- All analytical testing is performed in-house, with no use of an outside reference laboratory for quantitative or confirmation testing.

- Prepaid shipping of samples via Federal Express Standard Overnight (next business day) delivery on Monday through Saturday.

- Forensic Client Support available via phone and email Monday through Friday 5:00am – 5:30pm Pacific Time.
  Phone: 1-866-522-2216
  Via email at forensics@nmslabs.com (email checked minimum of every 30 minutes)

- Access to a board-certified toxicologist for consultation by phone and/or email Monday through Friday.

- Client Portal – NMS Labs can report results via a secured web-based portal. This functionality delivers a PDF report that allows easy remote viewing and sharing results easily. NMS Labs also offers the options of auto fax and mail.

- Online ordering capabilities for the client to print labels for specimens, test requisitions with chain of custody, and manifest logs to ensure proper transport of cases to NMS Labs.

- Access to NMS Labs Comprehensive Antemortem and Postmortem Testing Capabilities and Esoteric testing.

- Access to NMS Labs full-service Criminalistics testing including drug identification testing.

# Section 3

# LABORATORY LICENSURE AS OF MARCH 2025

## NMS LABS TOXICOLOGY

1. **Clinical Laboratory Improvement Amendments (CLIA) Certificate of Accreditation:** Laboratory No. 39DO197898 (Expires May 7, 2026)

2. **College of American Pathologists (CAP) Laboratory Accreditation Program (LAP):** Accreditation No. 3030301 (Expires December 8, 2025)

3. **College of American Pathologists (CAP) International Standards - ISO 15189:2007 Accreditation:** Certification No. 3030301 (Expires August 22, 2025)

4. **ISO/IEC 17025:2017:** Certificate No. FT-0120 (Expires December 31, 2026)
   - **ANSI National Accreditation Board (ANAB) Forensic Science Testing and Calibration AR 3125:2023**
   - **ABFT Forensic Toxicology Laboratory Accreditation Requirements: 2023**

5. **California Department of Public Health:** Lab ID Number COS 800001(Expires May 28, 2025)

6. **Colorado Department of Public Health and Environment:** (Expires June 30, 2025)

7. **Illinois State Police License:** (Expires December 1, 2025)

8. **Louisiana Department of Public Safety and Corrections - Forensic Toxicology Analysis** (Tied to ANAB accreditation)

9. **Maine Department of Human Services:** Substance Abuse Testing (Expires February 26, 2026)

10. **Maryland Department of Health:**
    - Medical Laboratory Permit No. 580 (No expiration date)
    - Forensic Toxicology License No. FL009P (No expiration date)

11. **New York State Department of Health:** PFI No. 3772 (Expires June 30, 2025)

12. **Pennsylvania Department of Health:** Laboratory Permit No. 00504A (Expires August 15, 2025)

13. **Rhode Island Department of Health – Office of Facilities Regulation:** License No. LCO01266 (Expires December 30, 2026)

14. **Texas Forensic Science Commission Administration** (Tied to ANAB accreditation)

15. **FDA Registration:** Horsham No. 064341449 (December 31, 2025)

16. **DEA Registration:** (Expires October 31, 2025)

17. **National Provider Identifier (NPI)** Number – 1922177732 (No expiration date)

18. **Medicare** No. 39-8154 (No hard copy of license; covered under inspection by Commonwealth of PA)

Available current accreditations and certificates are located on the website at www.nmslabs.com.

# LABORATORY LICENSURE AS OF MARCH 2025

## NMS LABS CRIME LABORATORY

1. **ISO/IEC 17025:2017** Certificate No. FT-0120 (Expires December 31, 2026)
    - **ANSI National Accreditation Board (ANAB) Forensic Science Testing and Calibration AR 3125:2023**

2. **Texas Forensic Science Commission Administration:** (No expiration date – tied to ANAB accreditation)

3. **Maryland Department of Health:**
    - Willow Grove, PA License No. FL009X (No expiration date)
    - Bucks County, PA License No. FL009W (No expiration date)
    - Dallas/Fort Worth, TX License No. FL009G (No expiration date)
    - El Paso, TX License No. FL009E (No expiration date)
    - Winston-Salem, NC License No. FL009N (No expiration date)

4. **DEA Registration TX:** El Paso/Dallas Fort Worth (Expires October 31, 2025)

5. **DEA Registration NC:** Winston-Salem (Expires October 31, 2025)

6. **FDA Registration:** Willow Grove No. 949561885 (December 31, 2025)

7. **North Carolina Department of Health and Human Services Controlled Substances Registration Certificate:** Winston-Salem (Expires October 31, 2025)

8. **Washington DC Department of Health - Controlled Substance Registration**: Willow Grove, PA
    - Schedule I (Expires May 31, 2025)
    - Schedules II-V (Expires September 23, 2025)

9. **Washington DC Department of Health – Non-Resident Distributor License:** Willow Grove, PA (Expires September 30, 2025)

# CERTIFICATE OF ACCREDITATION

## The ANSI National Accreditation Board

Hereby attests that

## National Medical Services, Inc.
## dba NMS Labs

**200 Welsh Road, Horsham, Pennsylvania 19044 USA**

Fulfills the requirements of

## ISO/IEC 17025:2017

**ANAB Forensic Testing & Calibration AR 3125:2019**

**ABFT Forensic Toxicology Laboratory Accreditation Requirements:2021**

In the field of

## Forensic Testing

This certificate is valid only when accompanied by a current scope of accreditation document.
The current scope of accreditation can be verified at www.anab.org.

Pamela L. Sale, Vice President, Forensics

Expiry Date: 31 December 2026
Certificate Number: FT-0120

# SCOPE OF ACCREDITATION TO:
# ISO/IEC 17025:2017
## ANAB Forensic Testing & Calibration AR 3125:2019
## ABFT Forensic Toxicology Laboratory Accreditation Requirements:2021

## National Medical Services, Inc.
## dba NMS Labs
See locations listed below

## FORENSIC TESTING

Expiry Date: 31 December 2026 Certificate Number: FT-0120

**Willow Grove (IFS-WLG)**
2300 Stratford Avenue
Willow Grove, Pennsylvania 19090 USA

| **Discipline: Seized Drugs** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Botanical<br>Liquid<br>Solid | Chemical<br>Gas Chromatography<br>General Microscopy<br>Infrared Spectroscopy<br>Liquid Chromatography<br>Mass Spectrometry<br>Thin-Layer Chromatography<br>Ultraviolet Spectroscopy<br>Visual |
| Quantitative Measurement | Botanical<br>Liquid<br>Solid | Liquid Chromatography<br>Mass Spectrometry<br>Ultraviolet Spectroscopy |
| Weight Measurement | Botanical<br>Liquid<br>Solid | Balance |


2000 Regency Parkway, Suite 430, Cary, NC 27518
414-501-5494
www.anab.org

**Bucks County (IFS-BUX)**
850 Eagle Boulevard
Warminster, Pennsylvania 18974 USA

| **Discipline: Seized Drugs** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Botanical<br>Liquid<br>Solid | Chemical<br>Gas Chromatography<br>General Microscopy<br>Infrared Spectroscopy<br>Mass Spectrometry<br>Thin-Layer Chromatography<br>Visual |
| Weight Measurement | Botanical<br>Liquid<br>Solid | Balance |

**Dallas/Ft. Worth (IFS-DFW)**
2302 113th Street, Suite 200
Grand Prairie, Texas 75050 USA

| **Discipline: Seized Drugs** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Botanical<br>Liquid<br>Solid | Chemical<br>Gas Chromatography<br>General Microscopy<br>Infrared Spectroscopy<br>Mass Spectrometry<br>Thin-Layer Chromatography<br>Visual |
| Weight Measurement | Botanical<br>Liquid<br>Solid | Balance |

**El Paso (IFS-ELP)**
911 North Raynor Street
El Paso, Texas 79903 USA

| **Discipline: Seized Drugs** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Botanical<br>Liquid<br>Solid | Chemical<br>Gas Chromatography<br>General Microscopy<br>Infrared Spectroscopy<br>Mass Spectrometry<br>Thin-Layer Chromatography<br>Visual |

| | | |
|---|---|---|
| Weight Measurement | Botanical<br>Liquid<br>Solid | Balance |

**Winston-Salem (IFS-WIN)**
1200 North Patterson Avenue
Winston-Salem, North Carolina 27101 USA

| **Discipline: Seized Drugs** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Botanical<br>Liquid<br>Solid | Chemical<br>Gas Chromatography<br>General Microscopy<br>Infrared Spectroscopy<br>Mass Spectrometry<br>Thin-Layer Chromatography<br>Visual |
| Weight Measurement | Botanical<br>Liquid<br>Solid | Balance |

**CORE**
200 Welsh Road
Horsham, Pennsylvania 19044 USA

| **Discipline: Toxicology** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Ante-Mortem Biological Item<br>Post-Mortem Biological Item | Colorimetry<br>Diode Array Ultraviolet Spectrophotometry<br>Gas Chromatography<br>Immunoassay<br>Ion Specific Electrode<br>Liquid Chromatography<br>Mass Spectrometry<br>Microdiffusion |
| Qualitative Determination (Volatiles) | Ante-Mortem Biological Item<br>Liquid<br>Post-Mortem Biological Item | Chemical<br>Gas Chromatography<br>Mass Spectrometry |
| Quantitative Measurement | Ante-Mortem Biological Item<br>Post-Mortem Biological Item | Diode-Array Ultraviolet Spectrophotometry<br>Electrochemical<br>Gas Chromatography<br>Immunoassay<br>Liquid Chromatography<br>Mass Spectrometry<br>Optical Emission Spectrometry<br>Spectrofluorometry |



2000 Regency Parkway, Suite 430, Cary, NC 27518
414-501-5494
www.anab.org

| | | |
|---|---|---|
| Quantitative Measurement<br>(Volatiles) | Ante-Mortem Biological Item<br>Liquid<br>Post-Mortem Biological Item | Gas Chromatography<br>Mass Spectrometry |

**JAX**
2100 Jefferson Street
Jacksonville, Florida 32206 USA

| **Discipline: Toxicology** | | |
|---|---|---|
| **Component/Parameter** | **Item** | **Key Equipment/Technology** |
| Qualitative Determination | Ante-Mortem Biological Item<br>Post-Mortem Biological Item | Gas Chromatography<br>Immunoassay<br>Ultraviolet Spectroscopy |
| Qualitative Determination<br>(Volatiles) | Ante-Mortem Biological Item<br>Liquid<br>Post-Mortem Biological Item | Gas Chromatography |
| Quantitative Measurement<br>(Volatiles) | Ante-Mortem Biological Item<br>Liquid<br>Post-Mortem Biological Item | Gas Chromatography |

When published on a forensic service provider's Scope of Accreditation, ANAB has confirmed the competence required to develop and validate methods and perform on-going quality assurance for accredited activities. For a listed component/parameter, the forensic service provider may add or modify methods for activities without formal notice to ANAB for items and key equipment/technology listed. Contact the forensic service provider for information on the method utilized for accredited work.

Pamela L. Sale
Vice President, Forensics



2000 Regency Parkway, Suite 430, Cary, NC 27518
414-501-5494
www.anab.org

# POSTMORTEM TOXICOLOGY
# SCOPE OF TESTING

**For informational purposes only. Analytes are subject to change at any time.**

NOTE: When comparing a test with an ELISA screen to a test with a TOF screen, the scope may list drug classes for the ELISA test but not for the TOF test. This is because TOF does not use drug classes in its library (ex: Benzodiazepines). However, the individual analytes within the drug classes will appear in the scope listing (ex: Clonazepam and Lorazepam).



200 Welsh Road, Horsham, Pennsylvania 19044 T 800.522.6671 F 215.657.2972 www.nmslabs.com

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| 10-Hydroxycarbazepine | | X | X | |
| 11-Hydroxy Delta-9 THC | | X | X | |
| 2-Furanylfentanyl | | | X | |
| 3-hydroxy-PCP | | | X | |
| 3-MeO-PCP | | | X | |
| 4-ANPP | | X | X | |
| 6-Beta-Naltrexol - Free | | X | X | |
| 6-Monoacetylmorphine | | X | X | |
| 6-Monoacetylmorphine - Free | X | X | X | |
| 7-Amino Clonazepam | X | X | X | |
| 7-Amino Flunitrazepam | | X | X | |
| 8-Aminoclonazolam | | X | X | |
| 9-Hydroxyrisperidone | | X | X | |
| Acetaminophen | | X | X | |
| Acetone | X | X | X | |
| Acetyl Fentanyl | X | X | X | |
| Acrylfentanyl | | | X | |
| Alfentanil | | X | X | |
| Alpha-Hydroxyalprazolam | X | X | X | |
| Alpha-Hydroxyetizolam | | X | X | |
| alpha-PHP / alpha-PiHP | | | X | |
| alpha-PVP | | | X | |
| Alprazolam | X | X | X | |
| Amitriptyline | | X | X | |
| Amlodipine | | X | X | |
| Amoxapine | | | X | |
| Amphetamine | X | X | X | |
| Amphetamines | X | | | X |
| Aripiprazole | | X | X | |
| Atomoxetine | | X | X | |
| Atropine | | X | X | |
| Barbiturates | X | X | X | X |
| Benzodiazepines | X | | | X |
| Benzoylecgonine | X | X | X | |
| Benztropine | | | X | |
| Blood Alcohol Concentration (BAC) | X | X | X | |
| Bromazepam | | X | X | |
| Bromazolam | | | X | |
| Brompheniramine | | | X | |
| Buprenorphine | | X | X | |
| Buprenorphine - Free | X | X | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Buprenorphine / Metabolite | X | | | |
| Bupropion | | X | X | |
| Buspirone | | X | X | |
| Butalbital | X | X | X | |
| Butyrylfentanyl | | | X | |
| Caffeine | | X | X | |
| Cannabinoids | X | X | X | X |
| Carbamazepine | | X | X | |
| Carbamazepine-10,11-Epoxide | | X | X | |
| Carfentanil | | X | X | |
| Carisoprodol | | X | X | |
| Chlordiazepoxide | X | X | X | |
| Chlorpheniramine | | X | X | |
| Chlorpromazine | | X | X | |
| cis-3-Methylfentanyl | | | X | |
| Citalopram / Escitalopram | | X | X | |
| Clobazam | X | X | X | |
| Clomipramine | | X | X | |
| Clonazepam | X | X | X | |
| Clonazolam | | X | X | |
| Clonidine | | X | X | |
| Clozapine | | X | X | |
| Cocaethylene | X | X | X | |
| Cocaine | X | X | X | |
| Cocaine / Metabolites | X | | | X |
| Codeine | | X | X | |
| Codeine - Free | X | X | X | |
| Cotinine | | X | X | |
| Cyclobenzaprine | | X | X | |
| Cyclopropylfentanyl | | | X | |
| Delorazepam | | | X | |
| Delta-9 Carboxy THC | | X | X | |
| Delta-9 THC | | X | X | |
| Desalkylflurazepam | | | X | |
| Desethylvardenafil | | | X | |
| Desipramine | | X | X | |
| Desmethylclomipramine | | X | X | |
| Desmethyldoxepin | | X | X | |
| Desmethylloperamide | | X | X | |
| Desmethylsertraline | | X | X | |
| Desmethyltrimipramine | | | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Dextro / Levo Methorphan | | X | X | |
| Dextrorphan / Levorphanol | | X | X | |
| Diazepam | X | X | X | |
| Diclazepam | | | X | |
| Dicyclomine | | X | X | |
| Dihydrocodeine / Hydrocodol | | X | X | |
| Dihydrocodeine / Hydrocodol - Free | X | X | X | |
| Diltiazem | | X | X | |
| Diphenhydramine | | X | X | |
| Donepezil | | X | X | |
| Doxepin | | X | X | |
| Doxylamine | | X | X | |
| Duloxetine | | X | X | |
| Ecgonine Methyl Ester | X | X | X | |
| EDDP | X | X | X | |
| Ephedrine | | X | X | |
| Eszopiclone / Zopiclone | | X | X | |
| Ethanol | X | X | X | |
| Ethylone | | | X | |
| Etizolam | | X | X | |
| Eutylone | | | X | |
| Fentanyl | X | X | X | |
| Fentanyl / Acetyl Fentanyl | X | | | |
| Fentanyl / Metabolite | | | | X |
| Flecainide | | | X | |
| Flualprazolam | | X | X | |
| Flubromazepam | | X | X | |
| Flubromazolam | | X | X | |
| Flunitrazepam | | X | X | |
| Fluoxetine | | X | X | |
| Fluphenazine | | | X | |
| Flurazepam | | | X | |
| Fluvoxamine | | | X | |
| Gabapentin | | X | X | |
| Guaifenesin | | X | X | |
| Haloperidol | | X | X | |
| Hydrocodone | | X | X | |
| Hydrocodone - Free | X | X | X | |
| Hydromorphone | | X | X | |
| Hydromorphone - Free | X | X | X | |
| Hydroxybupropion | | X | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Hydroxychloroquine | | | X | |
| Hydroxyethylflurazepam | | | X | |
| Hydroxytriazolam | | | X | |
| Hydroxyzine | | X | X | |
| Imipramine | | X | X | |
| Isopropanol | X | X | X | |
| Isotonitazene | | | X | |
| Isotonitazene / Protonitazene | | | X | |
| Ketamine | | X | X | |
| Lacosamide | | X | X | |
| Lamotrigine | | X | X | |
| Levamisole | | X | X | |
| Levetiracetam | | X | X | |
| Lidocaine | | X | X | |
| Loperamide | | X | X | |
| Lorazepam | X | X | X | |
| LSD | | X | X | |
| mCPP | | X | X | |
| MDA | X | X | X | |
| MDEA | | | X | |
| MDMA | X | X | X | |
| Memantine | | X | X | |
| Meperidine | | | X | |
| Meprobamate | | X | X | |
| Mescaline | | X | X | |
| Mesoridazine | | | X | |
| Metaxalone | | | X | |
| Methadone | X | X | X | |
| Methadone / Metabolite | X | | | X |
| Methamphetamine | X | X | X | |
| Methamphetamine / MDMA | X | | | |
| Methanol | X | X | X | |
| Methaqualone | | | X | |
| Methocarbamol | | X | X | |
| Methoxetamine | | | X | |
| Methylphenidate | | X | X | |
| Metonitazene | | | X | |
| Metoprolol | | X | X | |
| Midazolam | X | X | X | |
| Mirtazapine | | X | X | |
| Mitragynine | | X | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Morphine | | X | X | |
| Morphine - Free | X | X | X | |
| N,N-Dimethylpentylone | | | X | |
| Naloxone | | X | X | |
| Naltrexone | | X | X | |
| Naltrexone - Free | | X | X | |
| Naproxen | | X | X | |
| N-desethyl Isotonitazene | | | X | |
| N-Desmethylsildenafil | | X | X | |
| N-ethyl Pentylone | | | X | |
| Nicotine | | X | X | |
| Norbuprenorphine | | X | X | |
| Norbuprenorphine - Free | X | X | X | |
| Norclozapine | | X | X | |
| Nordiazepam | X | X | X | |
| Norfentanyl | X | X | X | |
| Norflunitrazepam | | X | X | |
| Norfluoxetine | | X | X | |
| Norketamine | | X | X | |
| Normeperidine | | | X | |
| Norpropoxyphene | | | X | |
| Norpseudoephedrine | | X | X | |
| Nortriptyline | | X | X | |
| N-pyrrolidino Etonitazene | | | X | |
| N-pyrrolidino Protonitazene | | | X | |
| O-Desmethyltramadol | | X | X | |
| O-Desmethylvenlafaxine | | X | X | |
| Olanzapine | | X | X | |
| Opiates | X | | | X |
| Oxazepam | X | X | X | |
| Oxycodone | | X | X | |
| Oxycodone - Free | X | X | X | |
| Oxycodone / Oxymorphone | X | | | X |
| Oxymorphone | | X | X | |
| Oxymorphone - Free | X | X | X | |
| para-Fluorofentanyl | | X | X | |
| para-Fluoroisobutyrylfentanyl | | | X | |
| Paroxetine | | X | X | |
| Pentobarbital | X | X | X | |
| Pentylone | | | X | |
| Perphenazine | | | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Phenacetin | | | X | |
| Phenazepam | | | X | |
| Phencyclidine | X | X | X | X |
| Pheniramine | | | X | |
| Phenobarbital | X | X | X | |
| Phentermine | | X | X | |
| Phenylethylmalonamide (PEMA) | | X | X | |
| Phenylpropanolamine | | X | X | |
| Phenytoin | | X | X | |
| Primidone | | X | X | |
| Prochlorperazine | | X | X | |
| Promethazine | | X | X | |
| Propoxyphene | | | X | |
| Protonitazene | | | X | |
| Pseudoephedrine | | X | X | |
| Psilocin | | X | X | |
| Quetiapine | | X | X | |
| Quinidine | | | X | |
| Quinine | | X | X | |
| Risperidone | | X | X | |
| Ritalinic Acid | | X | X | |
| Salicylate | | X | X | |
| Salicylates | | X | X | |
| Scope Statement | | X | X | |
| Secobarbital | X | X | X | |
| Sertraline | | X | X | |
| Sildenafil | | X | X | |
| Strychnine | | X | X | |
| Sufentanil | | X | X | |
| Tadalafil | | X | X | |
| Tapentadol | | X | X | |
| Tapentadol - Free | | X | X | |
| Temazepam | X | X | X | |
| Tetrahydrozoline | | X | X | |
| Theophylline | | | X | |
| Thioridazine | | | X | |
| Tizanidine | | | X | |
| Topiramate | | X | X | |
| Tramadol | | X | X | |
| trans-3-Methylfentanyl | | | X | |
| Trazodone | | X | X | |

| Analyte | 8051B Basic | 8052B* Expanded | 8054B* TotalTox™ | 8050U Urine Screen Add-on (6-MAM Quant) |
|---|---|---|---|---|
| Triazolam | | | X | |
| Trifluoperazine | | | X | |
| Trimipramine | | | X | |
| Triprolidine | | | X | |
| U-47700 | | | X | |
| Valerylfentanyl | | | X | |
| Vardenafil | | | X | |
| Venlafaxine | | X | X | |
| Verapamil | | X | X | |
| Warfarin | | X | X | |
| Xylazine | | X | X | |
| Yohimbine | | | X | |
| Zaleplon | | | X | |
| Ziprasidone | | X | X | |
| Zolpidem | | X | X | |
| Zonisamide | | X | X | |

*** Drug Trend Analysis and Surveillance Library**

NMS Labs has a specialized team of experts focused on tracking evolving Novel Psychoactive Substances (NPS) trends, identifying novel and emerging drugs and anticipating the most prevalent new substances. Using a broad range of resources including the latest medical and scientific literature, collaboration with the Center for Forensic Science Research and Education (CFSRE), data from our forensic drug chemistry casework and monitoring chatter from on-line drug user networks, the mission of this team is to listen, anticipate and proactively provide the latest in analytical testing options for our customers. Ensuring responsiveness to the needs of public safety and public health clients with innovative solutions is a top priority. With this dedicated approach to identifying NPS compounds, the scope of compounds is dynamic and changes over time.

All samples tested on our LC/TOF-MS are evaluated by toxicologists using an internally developed analytical library specific to emerging NPS compounds and other esoteric compounds. We call this supplemental library of NPS and esoteric compounds the NMS Labs Surveillance Library.

As of 10/28/24, the NMS Labs Surveillance Library includes:

**Expanded Panel Test Codes (ex. 8052B)**

• Expanded Panel surveillance findings require client approval for confirmation and payment of the requisite fee.
• In situations where an additional charge for confirming a surveillance finding is required, the client will be notified and may consult with our Toxicology staff on the most appropriate approach given the case history and options available.

**Expanded Panel Surveillance Compounds:** 2-Furanylfentanyl, 2-Methyl AP-237, 3-hydroxy-PCP, 3-MeO-PCP, 3-Fluorophenmetrazine, Acrylfentanyl, alpha-PHP/alpha-PiHP, alpha-PVP, Amoxapine, AP-238, Benztropine, Bropheniramine, Brorphine, Bromazolam, Butylone, Butyrlfentanyl, Chloroquine, cis-3 Methylfentanyl, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Diclazepam, Ethylone, Eutylone, Flecainide, Flualprazolam, Fluphenazine, Flurazepam, Fluvoxamine, Hydroxychloroquine, Hydroxyethylflurazepam, Hydroxytriazolam, Isotonitazene / Protonitazene, MDEA, Meclonazepam, Meperidine, Mesoridazine, Metaxolone, Methaqualone, Metonitazene, N-desethyl Isotonitazene, N-ethyl Pentylone, N,N-Dimethylpentylone, N-pyrrolidino Etonitazene, N-pyrrolidino Protonitazene, Normeperidine, Norpropoxyphene, para-Fluoroisobutyrylfentanyl, Pentylone, Perphenazine, Phenacetin, Phenazepam, Pheniramine, Propoxyphene, Pyrazolam, Quinidine, Tianeptine, Tizanidine, Theophylline, Thioridazine, trans-3-Methylfentanyl, Trifluoperazine, Trimipramine, Tripolidine, Vardenafil, Yohimbine, Zaleplon

**NMS TotalTox™ (ex 8054B) & Novel Psychoactive Substances (NPS) (ex. 8756B)**

• The NMS TotalTox™ products are our premium NPS panels. Many of the Expanded Surveillance Compounds are included within the NMS TotalTox test scope which explains why this Surveillance Library contains fewer compounds.
• NMS TotalTox surveillance findings will be automatically confirmed for NO charge resulting in faster reporting.

**NMS TotalTox™ Surveillance Compounds:** 2-Methyl AP-237, 3-Fluorophenmetrazine, AP-238, Brorphine, Chloroquine, Deschloroetizolam, Meclonazepam, Pyrazolam, Tianeptine

# DUID/DRE TOXICOLOGY
# SCOPE OF TESTING

**For informational purposes only. Analytes are subject to change at any time.**

NOTE: When comparing a test with an ELISA screen to a test with a TOF screen, the scope may list drug classes for the ELISA test but not for the TOF test. This is because TOF does not use drug classes in its library (ex: Benzodiazepines). However, the individual analytes within the drug classes will appear in the scope listing (ex: Clonazepam and Lorazepam).



200 Welsh Road, Horsham, Pennsylvania 19044 T 800.522.6671 F 215.657.2972 www.nmslabs.com

| Analyte | 8150B DUID/DRE | 8151B DUID/DRE w/alcohol | 8152B* DUID/DRE Expanded Drug Screen Add-on | 8030B Drug Facilitated Crime Panel | 8660B Opiates |
|---|---|---|---|---|---|
| 10-Hydroxycarbazepine | | | X | | |
| 11-Hydroxy Delta-9 THC | X | X | | X | |
| 6-Monoacetylmorphine | | | | X | |
| 6-Monoacetylmorphine - Free | X | X | | X | X |
| 7-Amino Clonazepam | X | X | | X | |
| 7-Amino Flunitrazepam | | | X | X | |
| 8-Aminoclonazolam | | | X | | |
| 9-Hydroxyrisperidone | | | X | | |
| Acetone | | X | | X | |
| Acetyl Fentanyl | X | X | | X | |
| Alfentanil | | | X | | |
| Alpha-Hydroxyalprazolam | X | X | | X | |
| Alpha-Hydroxyetizolam | | | X | | |
| Alprazolam | X | X | | X | |
| Amitriptyline | | | X | X | |
| Amphetamine | X | X | | X | |
| Amphetamines | X | X | | | |
| Aripiprazole | | | X | | |
| Barbiturates | | | X | X | |
| Benzodiazepines | X | X | | | |
| Benzoylecgonine | X | X | | X | |
| Blood Alcohol Concentration (BAC) | | X | | X | |
| Brompheniramine | | | | X | |
| Buprenorphine | | | | X | |
| Buprenorphine - Free | X | X | | X | |
| Buprenorphine / Metabolite | X | X | | | |
| Bupropion | | | X | | |
| Buspirone | | | X | | |
| Butalbital | | | X | X | |
| Caffeine | | | X | | |
| Cannabinoids | X | X | | X | |
| Carbamazepine | | | X | | |
| Carbamazepine-10,11-Epoxide | | | X | | |
| Carfentanil | | | X | | |
| Carisoprodol | | | X | X | |
| Chlordiazepoxide | X | X | | X | |
| Chlorpheniramine | | | X | X | |
| Chlorpromazine | | | X | | |
| Citalopram / Escitalopram | | | X | X | |
| Clobazam | | | X | X | |
| Clomipramine | | | X | | |
| Clonazepam | X | X | | X | |
| Clonazolam | | | X | | |
| Clonidine | | | X | X | |
| Clozapine | | | X | | |
| Cocaethylene | X | X | | X | |
| Cocaine | X | X | | X | |
| Cocaine / Metabolites | X | X | | | |
| Codeine | | | | X | |
| Codeine - Free | X | X | | X | X |

| Analyte | 8150B DUID/DRE | 8151B DUID/DRE w/alcohol | 8152B* DUID/DRE Expanded Drug Screen Add-on | 8030B Drug Facilitated Crime Panel | 8660B Opiates |
|---|---|---|---|---|---|
| Cyclobenzaprine | | | X | X | |
| Delta-9 Carboxy THC | X | X | | X | |
| Delta-9 THC | X | X | | X | |
| Desalkylflurazepam | | | | X | |
| Desipramine | | | X | X | |
| Desmethylclomipramine | | | X | | |
| Desmethyldoxepin | | | X | X | |
| Desmethylsertraline | | | X | X | |
| Dextro / Levo Methorphan | | | X | X | |
| Dextrorphan / Levorphanol | | | X | X | |
| Diazepam | X | X | | X | |
| Dicyclomine | | | X | | |
| Dihydrocodeine / Hydrocodol | | | | X | |
| Dihydrocodeine / Hydrocodol - Free | X | X | | X | X |
| Diltiazem | | | X | | |
| Diphenhydramine | | | X | X | |
| Doxepin | | | X | X | |
| Doxylamine | | | X | X | |
| Duloxetine | | | X | | |
| Ecgonine Methyl Ester | | | | X | |
| EDDP | X | X | | X | |
| Ephedrine | | | X | | |
| Estazolam | | | | X | |
| Eszopiclone / Zopiclone | | | X | X | |
| Ethanol | | X | | X | |
| Etizolam | | | X | | |
| Fentanyl | X | X | | X | |
| Fentanyl / Acetyl Fentanyl | X | X | | | |
| Flualprazolam | | | X | | |
| Flubromazepam | | | X | | |
| Flubromazolam | | | X | | |
| Flunitrazepam | | | X | X | |
| Fluoxetine | | | X | X | |
| Flurazepam | | | | X | |
| Gabapentin | X | X | | | |
| Gamma-Hydroxybutyric Acid | | | | X | |
| Haloperidol | | | X | | |
| Hydrocodone | | | | X | |
| Hydrocodone - Free | X | X | | X | X |
| Hydromorphone | | | | X | |
| Hydromorphone - Free | X | X | | X | X |
| Hydroxybupropion | | | X | | |
| Hydroxyethylflurazepam | | | | X | |
| Hydroxytriazolam | | | | X | |
| Hydroxyzine | | | X | | |
| Imipramine | | | X | X | |
| Isopropanol | | X | | X | |
| Ketamine | | | X | X | |
| Lamotrigine | | | X | | |
| Levetiracetam | | | X | | |

| Analyte | 8150B DUID/DRE | 8151B DUID/DRE w/alcohol | 8152B* DUID/DRE Expanded Drug Screen Add-on | 8030B Drug Facilitated Crime Panel | 8660B Opiates |
|---|---|---|---|---|---|
| Lidocaine | | | | X | |
| Lorazepam | X | X | | X | |
| LSD | | | X | | |
| mCPP | | | X | X | |
| MDA | X | X | | X | |
| MDMA | X | X | | X | |
| Meperidine | | | | X | |
| Meprobamate | | | X | X | |
| Mescaline | | | X | | |
| Methadone | X | X | | X | |
| Methadone / Metabolite | X | X | | | |
| Methamphetamine | X | X | | X | |
| Methamphetamine / MDMA | X | X | | | |
| Methanol | | X | | X | |
| Methocarbamol | | | X | | |
| Methylphenidate | | | X | | |
| Midazolam | X | X | | X | |
| Mirtazapine | | | X | | |
| Mitragynine | | | X | | |
| Monoethylglycinexylidide (MEGX) | | | | X | |
| Morphine | | | | X | |
| Morphine - Free | X | X | | X | X |
| Norbuprenorphine | | | | X | |
| Norbuprenorphine - Free | X | X | | X | |
| Norchlorcyclizine | | | | X | |
| Norclozapine | | | X | | |
| Nordiazepam | X | X | | X | |
| Norfentanyl | X | X | | X | |
| Norflunitrazepam | | | X | X | |
| Norfluoxetine | | | X | X | |
| Norketamine | | | X | X | |
| Normeperidine | | | | X | |
| Norpropoxyphene | | | | X | |
| Norpseudoephedrine | | | X | | |
| Nortriptyline | | | X | X | |
| O-Desmethyltramadol | X | X | | X | |
| O-Desmethylvenlafaxine | | | X | | |
| Olanzapine | | | X | | |
| Opiates | X | X | | | |
| Oxazepam | X | X | | X | |
| Oxycodone | | | | X | |
| Oxycodone - Free | X | X | | X | X |
| Oxycodone / Oxymorphone | X | X | | | |
| Oxymorphone | | | | X | |
| Oxymorphone - Free | X | X | | X | X |
| para-Fluorofentanyl | | | X | | |
| Paroxetine | | | X | X | |
| Pentobarbital | | | | X | |
| Phencyclidine | X | X | | X | |
| Phenobarbital | | | X | X | |

| Analyte | 8150B DUID/DRE | 8151B DUID/DRE w/alcohol | 8152B* DUID/DRE Expanded Drug Screen Add-on | 8030B Drug Facilitated Crime Panel | 8660B Opiates |
|---|---|---|---|---|---|
| Phentermine | | | X | | |
| Phenylethylmalonamide (PEMA) | | | X | | |
| Phenylpropanolamine | | | X | | |
| Phenytoin | | | X | X | |
| Primidone | | | X | | |
| Promethazine | | | X | | |
| Propoxyphene | | | | X | |
| Pseudoephedrine | | | X | | |
| Psilocin | | | X | | |
| Quetiapine | | | X | | |
| Risperidone | | | X | | |
| Ritalinic Acid | | | X | | |
| Scope Statement | | | X | X | |
| Scopolamine | | | | X | |
| Secobarbital | | | | X | |
| Sertraline | | | X | X | |
| Sufentanil | | | X | | |
| Tapentadol | | | X | | |
| Tapentadol - Free | | | X | | |
| Temazepam | X | X | | X | |
| Tetrahydrozoline | | | | X | |
| Topiramate | | | X | | |
| Tramadol | X | X | | X | |
| Tramadol / Metabolite | X | X | | | |
| Trazodone | | | X | X | |
| Triazolam | | | | X | |
| Venlafaxine | | | X | | |
| Verapamil | | | X | | |
| Xylazine | | | X | | |
| Zaleplon | | | | X | |
| Ziprasidone | | | X | X | |
| Zolpidem | X | X | | X | |
| Zonisamide | | | X | | |

*** Drug Trend Analysis and Surveillance Library**

NMS Labs has a specialized team of experts focused on tracking evolving Novel Psychoactive Substances (NPS) trends, identifying novel and emerging drugs and anticipating the most prevalent new substances. Using a broad range of resources including the latest medical and scientific literature, collaboration with the Center for Forensic Science Research and Education (CFSRE), data from our forensic drug chemistry casework and monitoring chatter from on-line drug user networks, the mission of this team is to listen, anticipate and proactively provide the latest in analytical testing options for our customers. Ensuring responsiveness to the needs of public safety and public health clients with innovative solutions is a top priority. With this dedicated approach to identifying NPS compounds, the scope of compounds is dynamic and changes over time.

All samples tested on our LC/TOF-MS are evaluated by toxicologists using an internally developed analytical library specific to emerging NPS compounds and other esoteric compounds. We call this supplemental library of NPS and esoteric compounds the NMS Labs Surveillance Library.

As of 10/28/24, the NMS Labs Surveillance Library includes:

**Expanded Panel Test Codes (ex. 8152B)**

- Expanded Panel surveillance findings require client approval for confirmation and payment of the requisite fee.
- In situations where an additional charge for confirming a surveillance finding is required, the client will be notified and may consult with our Toxicology staff on the most appropriate approach given the case history and options available.

**Expanded Panel Surveillance Compounds:** 2-Furanylfentanyl, 2-Methyl AP-237, 3-hydroxy-PCP, 3-MeO-PCP, 3-Fluorophenmetrazine, Acrylfentanyl, alpha-PHP/alpha-PiHP, alpha-PVP, Amoxapine, AP-238, Benztropine, Bropheniramine, Brorphine, Bromazolam, Butylone, Butyrlfentanyl, Chloroquine, cis-3 Methylfentanyl, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Diclazepam, Ethylone, Eutylone, Flecainide, Flualprazolam, Fluphenazine, Flurazepam, Fluvoxamine, Hydroxychloroquine, Hydroxyethylflurazepam, Hydroxytriazolam, Isotonitazene / Protonitazene, MDEA, Meclonazepam, Meperidine, Mesoridazine, Metaxolone, Methaqualone, Metonitazene, N-desethyl Isotonitazene, N-ethyl Pentylone, N,N-Dimethylpentylone, N-pyrrolidino Etonitazene, N-pyrrolidino Protonitazene, Normeperidine, Norpropoxyphene, para-Fluoroisobutyrylfentanyl, Pentylone, Perphenazine, Phenacetin, Phenazepam, Pheniramine, Propoxyphene, Pyrazolam, Quinidine, Tianeptine, Tizanidine, Theophylline, Thioridazine, trans-3-Methylfentanyl, Trifluoperazine, Trimipramine, Tripolidine, Vardenafil, Yohimbine, Zaleplon

# NOVEL PSYCHOACTIVE SUBSTANCES (NPS) SCOPE OF TESTING

**For informational purposes only. Analytes are subject to change at any time.**

NOTE: When comparing a test with an ELISA screen to a test with a TOF screen, the scope may list drug classes for the ELISA test but not for the TOF test. This is because TOF does not use drug classes in its library (ex: Benzodiazepines). However, the individual analytes within the drug classes will appear in the scope listing (ex: Clonazepam and Lorazepam).



200 Welsh Road, Horsham, Pennsylvania 19044 T 800.522.6671 F 215.657.2972 www.nmslabs.com

| Analyte | 0570B<br>Designer Benzos | 1480B<br>Designer Opioids | 8756B*<br>NPS Screen | 9560B<br>Synthetic Cannabinoids |
|---|---|---|---|---|
| 2-Furanylfentanyl | | X | X | |
| 3-hydroxy-PCP | | | X | |
| 3-MeO-PCP | | | X | |
| 4-ANPP | | | X | |
| 4'-chloro Deschloroalprazolam | X | | | |
| 4-fluoro-BINACA 3,3-dimethylbutanoic acid | | | | X |
| 4-fluoro-MDMB-BINACA | | | | X |
| 5-fluoro-MDMB-PICA / 5-fluoro-EMB-PICA | | | | X |
| 5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA | | | | X |
| 5-fluoro-PICA 3,3-dimethylbutanoic acid | | | | X |
| 5-fluoro-PINACA 3,3-dimethylbutanoic acid | | | | X |
| 5-fluoro-PINACA 3-methylbutanoic acid | | | | X |
| 8-Aminoclonazolam | X | | X | |
| Acetyl Fentanyl | | | X | |
| Acrylfentanyl | | X | X | |
| ADMB-CHMINACA | | | | X |
| ADMB-FUBINACA | | | | X |
| Alpha-Hydroxyetizolam | X | | X | |
| alpha-PHP / alpha-PiHP | | | X | |
| alpha-PVP | | | X | |
| APP-BINACA | | | | X |
| Bromazepam | X | | X | |
| Bromazolam | X | | X | |
| Butyrylfentanyl | | X | X | |
| Carfentanil | | X | X | |
| cis-3-Methylfentanyl | | X | X | |
| Clonazolam | X | | X | |
| Cyclopropylfentanyl | | X | X | |
| Delorazepam | X | | X | |
| Diclazepam | X | | X | |
| Ethylone | | | X | |
| Etizolam | X | | X | |
| Eutylone | | | X | |
| Fentanyl | | | X | |
| Flualprazolam | X | | X | |
| Flubromazepam | X | | X | |
| Flubromazolam | X | | X | |
| FUBINACA 3,3-dimethylbutanoic acid | | | | X |
| FUBINACA 3-methylbutanoic acid | | | | X |
| Isotonitazene | | | X | |
| Isotonitazene / Protonitazene | | | X | |
| MDMB-4en-PINACA | | | | X |
| Metonitazene | | | X | |
| Mitragynine | | | X | |
| MMB-FUBINACA | | | | X |
| N,N-Dimethylpentylone | | | X | |

| Analyte | 0570B Designer Benzos | 1480B Designer Opioids | 8756B* NPS Screen | 9560B Synthetic Cannabinoids |
|---|---|---|---|---|
| N-desethyl Isotonitazene | | | X | |
| N-ethyl Pentylone | | | X | |
| Norfentanyl | | | X | |
| N-pyrrolidino Etonitazene | | | X | |
| N-pyrrolidino Protonitazene | | | X | |
| para-Fluorofentanyl | | X | X | |
| para-Fluoroisobutyrylfentanyl | | X | X | |
| Pentylone | | | X | |
| Phenazepam | X | | X | |
| Protonitazene | | | X | |
| trans-3-Methylfentanyl | | X | X | |
| U-47700 | | X | X | |
| Valerylfentanyl | | X | X | |

*** Drug Trend Analysis and Surveillance Library**

NMS Labs has a specialized team of experts focused on tracking evolving Novel Psychoactive Substances (NPS) trends, identifying novel and emerging drugs and anticipating the most prevalent new substances. Using a broad range of resources including the latest medical and scientific literature, collaboration with the Center for Forensic Science Research and Education (CFSRE), data from our forensic drug chemistry casework and monitoring chatter from on-line drug user networks, the mission of this team is to listen, anticipate and proactively provide the latest in analytical testing options for our customers. Ensuring responsiveness to the needs of public safety and public health clients with innovative solutions is a top priority. With this dedicated approach to identifying NPS compounds, the scope of compounds is dynamic and changes over time.

All samples tested on our LC/TOF-MS are evaluated by toxicologists using an internally developed analytical library specific to emerging NPS compounds and other esoteric compounds. We call this supplemental library of NPS and esoteric compounds the NMS Labs Surveillance Library.

As of 10/28/24, the NMS Labs Surveillance Library includes:

**NMS TotalTox™ (ex 8054B) & Novel Psychoactive Substances (NPS) (ex. 8756B)**

• The NMS TotalTox™ products are our premium NPS panels. Many of the Expanded Surveillance Compounds are included within the NMS TotalTox test scope which explains why this Surveillance Library contains fewer compounds.
• NMS TotalTox surveillance findings will be automatically confirmed for NO charge resulting in faster reporting.

**NMS TotalTox™ Surveillance Compounds:** 2-Methyl AP-237, 3-Fluorophenmetrazine, AP-238, Brorphine, Chloroquine, Deschloroetizolam, Meclonazepam, Pyrazolam, Tianeptine

# Section 4

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**CONFIDENTIAL**

# Demo Report

**Report Issued** 11/01/2024 08:06

**To:** **88888**
Forensic Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

| | |
|---|---|
| **Patient Name** | 8052B-POS |
| **Patient ID** | 8052B-POS |
| **Chain** | 14425 |
| **DOB** | Not Given |
| **Sex** | Not Given |
| **Workorder** | 24001313 |



## Positive Findings:

| Analyte | Result | Units | Matrix Source |
|---|---|---|---|
| **Ethanol** | **85** | **mg/dL** | **001 - Blood** |
| **Blood Alcohol Concentration (BAC)** | **0.085** | **g/100 mL** | **001 - Blood** |
| **Cocaine** | **30** | **ng/mL** | **001 - Blood** |
| **Morphine - Free** | **10** | **ng/mL** | **001 - Blood** |
| **6-Monoacetylmorphine - Free** | **10** | **ng/mL** | **001 - Blood** |
| **Gabapentin** | **3.0** | **mcg/mL** | **001 - Blood** |
| **Delta-9 THC** | **2.0** | **ng/mL** | **001 - Blood** |
| **Fentanyl** | **10** | **ng/mL** | **001 - Blood** |
| **4-ANPP** | **10** | **ng/mL** | **001 - Blood** |
| **Alprazolam** | **20** | **ng/mL** | **001 - Blood** |

See Detailed Findings section for additional information

## Testing Requested:

| Test | Test Name |
|---|---|
| 8052B | Postmortem, Expanded, Blood (Forensic) |

## Specimens Received:

| ID | Tube/Container | Volume/ Mass | Collection Date/Time | Matrix Source | Labeled As |
|---|---|---|---|---|---|
| 001 | Other | Not Given | Not Given | Blood | Not Applicable |

All sample volumes/weights are approximations.

Specimens received on 08/21/2024.

## Detailed Findings:

| Analysis and Comments | Result | Units | Rpt. Limit | Specimen Source | Analysis By |
|---|---|---|---|---|---|
| Ethanol | 85 | mg/dL | 10 | 001 - Blood | Headspace GC |
| Blood Alcohol Concentration (BAC) | 0.085 | g/100 mL | 0.010 | 001 - Blood | Headspace GC |
| Cocaine | 30 | ng/mL | 10 | 001 - Blood | LC-MS/MS |
| Morphine - Free | 10 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| 6-Monoacetylmorphine - Free | 10 | ng/mL | 1.0 | 001 - Blood | LC-MS/MS |
| Gabapentin | 3.0 | mcg/mL | 1.0 | 001 - Blood | LC-MS/MS |
| Delta-9 THC | 2.0 | ng/mL | 0.50 | 001 - Blood | LC-MS/MS |
| Ethanol | Confirmed | mg/dL | 10 | 001 - Blood | Headspace GC |
| Fentanyl | 10 | ng/mL | 1.0 | 001 - Blood | LC-MS/MS |
| 4-ANPP | 10 | ng/mL | 0.20 | 001 - Blood | LC-MS/MS |
| Alprazolam | 20 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |

**Examination of the specimen(s) submitted did not reveal any reportable findings by procedure(s) outlined in the accompanying Analysis Summary, other than those listed above. Interpretation of reported findings should be based on the totality of available case information. Reference information is not case-specific but is provided as a general guide.**

## Reference Comments:

1. 4-ANPP (Despropionyl fentanyl) - Blood:

   4-ANPP (despropionylfentanyl) is a precursor chemical used in the production of fentanyl/fentanyl related analytes and is also a fentanyl metabolite and may be a metabolite of other fentanyl-related analytes. It is considered to be pharmacologically weak.

2. 6-Monoacetylmorphine - Free (6-MAM; Heroin Metabolite) - Blood:

   6-monoacetylmorphine (6-MAM) is the 6-monoacetylated form of morphine, which is pharmacologically active. When present, it is generally indicative of heroin (diacetylmorphine) use. 6-MAM has also been reported to occur as an artifact in samples with unusually high blood morphine concentrations.

   A healthy man administered 12 mg heroin intravenously achieved peak blood concentrations at two minutes post injection of 150 ng/mL of 6-MAM and 44 ng/mL of morphine, which declined with half-lives of 7 minutes and 33 minutes, respectively.

   Eight subjects who died within fifteen minutes of heroin administration had postmortem blood 6-MAM concentrations averaging 19 ng/mL with a range from less than 1.0 to 82 ng/mL.

3. Alprazolam (Xanax®) - Blood:

   Alprazolam is a low-dose benzodiazepine used for the treatment of anxiety disorders and short-term relief of anxiety associated with depressive symptoms. Alpha-hydroxyalprazolam is an active metabolite of alprazolam. They share the actions and adverse reactions of other CNS-depressants. Common adverse effects of alprazolam include drowsiness and fatigue.

   Reported therapeutic plasma concentrations of alprazolam are proportional to dose given: 3 mg/day produced steady-state levels of 30 ng/mL; 6 mg/day, 60 ng/mL; and 9 mg/day, 100 ng/mL.

   In reported cases involving driving under the influence, alprazolam concentrations ranged from 8 - 640 ng/mL. Alcohol greatly enhances the activity of benzodiazepines.

   Reported blood concentrations of alprazolam in alprazolam-related fatalities ranged from 100 - 400 ng/mL (mean, 200 ng/mL). In combination with other central nervous system depressants such as ethyl alcohol, alprazolam can become toxic at low concentrations.

## Reference Comments:

4. Cocaine - Blood:

   Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Effects following cocaine use can include euphoria, excitement, restlessness, risk taking, sleep disturbance, and aggression. A period of mental and physical fatigue and somnolence follow the use of cocaine after the excitant-stimulant effects wear off. Cocaine is metabolized to the inactive analytes benzoylecgonine, ecgonine methyl ester, and ecgonine. Benzoylecgonine and ecgonine methyl ester can form from cocaine breakdown after death and even after sample collection. The average blood cocaine concentration in 906 impaired drivers was 87 ng/mL (range 5-2390 ng/mL). Blood cocaine concentrations in patients admitted to an emergency room for cocaine related medical complaints were 260 ng/mL (SD = 500 ng/mL). Cocaine concentrations in plasma following oral administration of 2 g/day over 6 days, averaged 1260 ng/mL. The average blood cocaine concentration in 37 cocaine related fatalities was 4600 ng/mL (range 40-31000 ng/mL).

5. Delta-9 THC (Active Ingredient of Marijuana) - Blood:

   Delta-9 THC is the principle psychoactive ingredient of marijuana (cannabis, hashish). It is also the active component of the prescription medication Marinol®. Marijuana use causes relaxation, distorted perception, euphoria and feelings of well being, along with confusion, dizziness, somnolence, ataxia, speech difficulties, lethargy and muscular weakness.

   After smoking a user-preferred 300 mcg/kg dose average plasma THC concentrations at 35 minutes were reported at 16.1 (range 4.7-30.9) ng/mL, and had declined to 1.5 (range 0.4-3.2) ng/mL after 190 minutes. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50-270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs. Whole blood THC concentrations are typically half those in a corresponding plasma sample.

6. Ethanol (Ethyl Alcohol) - Blood:

   Ethyl alcohol (ethanol, drinking alcohol) is a central nervous system depressant and can cause effects such as impaired judgment, reduced alertness and impaired muscular coordination. Ethanol can also be a product of decomposition or degradation of biological samples.

7. Fentanyl (Duragesic®; Sublimaze®) - Blood:

   Fentanyl is a prescription opioid commonly used as an anesthetic/analgesic. It is reported to be 80 to 200 times as potent as morphine and has a rapid onset of action as well as addictive properties. Illicit fentanyl is readily available due to low production cost and its high potency. It is often sold as heroin and is commonly found in combination with other illicit drugs. Signs associated with fentanyl toxicity include severe respiratory depression, muscle rigidity, seizures, hypotension, coma and death.

   When used clinically as a transdermal preparation (25-100 mcg/hour patch), serum fentanyl concentrations up to 3.8 ng/mL have been reported within 24 hours. Following removal of the patch, serum fentanyl concentrations are reported to decrease with a mean elimination half-life of 17 hours (range, 13-22 hours). The mean peak plasma serum fentanyl concentration in adults given an 800 mcg oral transmucosal fentanyl preparation over 15 minutes is reported at 2.1 ng/mL (range, 1.4-3.0 ng/mL) at approximately 0.40 hours.

   It is reported that patients lost consciousness at mean plasma levels of fentanyl of 34 ng/mL when infused with 75 mcg/Kg over a 15 min period; peak plasma levels averaged 50 ng/mL. In fatalities from fentanyl, blood concentrations are variable and have been reported as low as 3 ng/mL. Postmortem blood fentanyl concentrations ranged from 0.30-110 ng/mL (median 11 ng/mL) in 301 femoral blood specimens obtained from accidental drug overdose death investigations. These concentrations ranged from 9.7-41.3 ng/mL (median 17.2 ng/mL) in 7 fentanyl only cases in another published case series.

   The blood to serum or plasma ratio is 0.8-1.0

8. Gabapentin (Neurontin®) - Blood:

   Gabapentin is an antiepileptic/anticonvulsant drug used in adults and children. Gabapentin is marketed in capsules (100, 200 and 300 mg), tablets (600 and 800 mg) and an oral solution (250 mg/5 mL). The common daily oral dose range for adults is from 900 to 1800 mg per day in divided doses; pediatric doses (3 to 12 years of age) are dependent of the child's body weight and range from 10 to 15 mg/kg per day.

   Mean steady-state plasma levels (+/- SD) following daily regimens of:
   900 mg/day = 1.88 (+/- 0.70) mcg/mL
   1200 mg/day= 2.62 (+/- 0.86) mcg/mL
   Reported threshold for seizure control: Greater than 2 mcg/mL.

## Reference Comments:

The drug is also used to treat postherpetic neuralgia in adults. The common adult dosage for this indication is 1800 mg per day in divided doses following lower doses during initial treatment.

The most common adverse effects of gabapentin are related to the central nervous system and include sedation, dizziness, nystagmus, ataxia and fatigue. All of these adverse effects are reversible and subside with reduction of dosage or discontinuation of therapy with the drug.

9. Morphine - Free (Codeine Metabolite) - Blood:

Morphine (Duramorph, Roxanol, MS-Contin) is a DEA Schedule II opiate narcotic analgesic. It can be a metabolite or breakdown product of codeine and heroin. If found together with 6-monoacetylmorphine (6-MAM), likely source is heroin. A large portion of the morphine may be conjugated; the portion not conjugated is termed 'free morphine', the active biologic agent which is a powerful painkilling drug whose diverse effects that may include analgesia, drowsiness, nausea and respiratory depression. Hydromorphone is a reported metabolite of morphine.
Morphine peak serum concentrations occur within 10 to 20 minutes of a 10 mg/70 kg intramuscular dose, average 60 ng/mL 30 minutes following administration. IV administration of 10 mg/70 kg, average 80 ng/mL after 30 minutes. Chronic pain patients receiving an average of 90 mg (range 20-1460) daily oral morphine had average serum concentrations of 73 ng/mL (range 13-710) morphine. In 15 cases where cause of death was attributed to opiate toxicity (heroin, morphine or both), free morphine concentrations were 0-3700 ng/mL (average 420 +/- 940). In comparison, in cases where COD was unrelated to opiates (n=20) free morphine was 0-850 ng/mL (average 90 +/- 200). The ratio of whole blood concentration to serum or plasma concentration is approximately one. In a population of 676 drivers arrested for driving under the influence, Morphine concentrations ranged from 1.25-1290 ng/mL, with an average of 52 ng/mL.
Following excessive opiate use, pupils are typically constricted and unreactive to light. Pulse and blood pressure, and body temperature can be lowered. Psychomotor impairment is generally present, with increased body sway, and poor performance in divided attention tests. Users are sometimes described as 'on the nod', falling asleep in the middle of conversations or at inappropriate times. Tolerance can develop to the effects of opiates, and more experienced users are less susceptible to the impairing effects.

## Analysis Summary and Reporting Limits:

The following test(s) were performed for this case; the scope of each test includes the analyte(s) listed along with the associated reporting limit(s). The reporting limit is the lowest concentration of the analyte that will be reported as positive. Only results that meet reporting criteria at or above the reporting limit appear in the Positive Findings section of the report.

Test 50014B - Cocaine and Metabolites Confirmation, Blood - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Benzoylecgonine | 50 ng/mL | Cocaine | 10 ng/mL |
| Cocaethylene | 10 ng/mL | Ecgonine Methyl Ester | 50 ng/mL |

Test 50016B - Opiates - Free (Unconjugated) Confirmation, Blood - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 6-Monoacetylmorphine - Free | 1.0 ng/mL | Hydromorphone - Free | 1.0 ng/mL |
| Codeine - Free | 5.0 ng/mL | Morphine - Free | 5.0 ng/mL |
| Dihydrocodeine / Hydrocodol - Free | 5.0 ng/mL | Oxycodone - Free | 5.0 ng/mL |
| Hydrocodone - Free | 5.0 ng/mL | Oxymorphone - Free | 1.0 ng/mL |

Test 52144B - Gabapentin Confirmation, Blood - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

## Analysis Summary and Reporting Limits:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Gabapentin | 1.0 mcg/mL | | |

Test 52198B - Cannabinoids Confirmation, Blood - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 11-Hydroxy Delta-9 THC | 1.0 ng/mL | Delta-9 THC | 0.50 ng/mL |
| Delta-9 Carboxy THC | 5.0 ng/mL | | |

Test 52250B - Alcohols and Acetone Confirmation, Blood (Forensic) - Blood

-Analysis by Headspace Gas Chromatography (GC) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Acetone | 5.0 mg/dL | Isopropanol | 5.0 mg/dL |
| Ethanol | 10 mg/dL | Methanol | 10 mg/dL |

Test 52486B - Fentanyl and 4-ANPP Confirmation, Blood - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 4-ANPP | 0.20 ng/mL | Fentanyl | 1.0 ng/mL |
| Acetyl Fentanyl | 0.20 ng/mL | Norfentanyl | 0.40 ng/mL |

Test 53154B - Benzodiazepines Confirmation, Blood (Forensic) - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 7-Amino Clonazepam | 5.0 ng/mL | Diazepam | 20 ng/mL |
| Alpha-Hydroxyalprazolam | 5.0 ng/mL | Lorazepam | 5.0 ng/mL |
| Alprazolam | 5.0 ng/mL | Midazolam | 5.0 ng/mL |
| Chlordiazepoxide | 20 ng/mL | Nordiazepam | 20 ng/mL |
| Clobazam | 20 ng/mL | Oxazepam | 20 ng/mL |
| Clonazepam | 2.0 ng/mL | Temazepam | 20 ng/mL |

Test 8052B - Postmortem, Expanded, Blood (Forensic) - Blood

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Barbiturates | 0.040 mcg/mL | Gabapentin | 5.0 mcg/mL |
| Cannabinoids | 10 ng/mL | Salicylates | 120 mcg/mL |

-Analysis by Headspace Gas Chromatography (GC) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Acetone | 5.0 mg/dL | Isopropanol | 5.0 mg/dL |
| Ethanol | 10 mg/dL | Methanol | 10 mg/dL |

**Analysis Summary and Reporting Limits:**

-Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS) for: The following is a general list of analyte classes included in this screen. The detection of any specific analyte is concentration-dependent. Note, not all known analytes in each specified analyte class are included. Some specific analytes outside of these classes are also included. For a detailed list of all analytes and reporting limits, please contact NMS Labs. Amphetamines, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotics, Benzodiazepines, CNS Stimulants, Cocaine and Metabolites, Hallucinogens, Hypnosedatives, Muscle Relaxants, Non-Steroidal Anti-Inflammatory Agents, Opiates and Opioids.

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**CONFIDENTIAL**

# Demo Report

**Report Issued** 02/03/2025 06:30

**To:** **88888**
Forensic Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

| | |
|---|---|
| **Patient Name** | 8151B-POS |
| **Patient ID** | 8151B-POS |
| **Chain** | 14471 |
| **DOB** | Not Given |
| **Sex** | Not Given |
| **Workorder** | 24001741 |



## Positive Findings:

| Analyte | Result | Units | Matrix Source |
|---|---|---|---|
| **Ethanol** | **85 ±6** | **mg/dL** | **001 - Blood** |
| **Blood Alcohol Concentration (BAC)** | **0.085 ±0.006** | **g/100 mL** | **001 - Blood** |
| **Alprazolam** | **20 ±6** | **ng/mL** | **001 - Blood** |
| **11-Hydroxy Delta-9 THC** | **3.0 ±0.9** | **ng/mL** | **001 - Blood** |
| **Delta-9 Carboxy THC** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **Delta-9 THC** | **1.5 ±0.5** | **ng/mL** | **001 - Blood** |
| **Cocaine** | **30 ±9** | **ng/mL** | **001 - Blood** |
| **Methadone** | **60 ±18** | **ng/mL** | **001 - Blood** |
| **EDDP** | **60 ±18** | **ng/mL** | **001 - Blood** |
| **Morphine - Free** | **10 ±3** | **ng/mL** | **001 - Blood** |
| **6-Monoacetylmorphine - Free** | **10 ±3** | **ng/mL** | **001 - Blood** |
| **Phencyclidine** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **Amphetamine** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **Methamphetamine** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **MDA** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **MDMA** | **15 ±5** | **ng/mL** | **001 - Blood** |
| **Tramadol** | **60 ±18** | **ng/mL** | **001 - Blood** |
| **O-Desmethyltramadol** | **60 ±18** | **ng/mL** | **001 - Blood** |
| **Zolpidem** | **12 ±4** | **ng/mL** | **001 - Blood** |
| **Gabapentin** | **3.0 ±0.9** | **mcg/mL** | **001 - Blood** |
| **Fentanyl** | **10 ±3** | **ng/mL** | **001 - Blood** |
| **Buprenorphine - Free** | **1.5 ±0.5** | **ng/mL** | **001 - Blood** |
| **Norbuprenorphine - Free** | **1.5 ±0.5** | **ng/mL** | **001 - Blood** |

Quantitative results are reported as Result +/- Uncertainty of Measurement (UM). Ethanol results are reported at a coverage probability of 99.73%; all other analytes are reported at a coverage probability of 95.45%.

See Detailed Findings section for additional information

## Testing Requested:

| Test | Test Name |
|---|---|
| 8151B | DUID/DRE Panel (w/Alcohol), Blood (Forensic) |

## Specimens Received:

| ID | Tube/Container | Volume/ Mass | Collection Date/Time | Matrix Source | Labeled As |
|---|---|---|---|---|---|

| ID | Tube/Container | Volume/ Mass | Collection Date/Time | Matrix Source | Labeled As |
|---|---|---|---|---|---|
| 001 | Other | Not Given | Not Given | Blood | Not Applicable |

All sample volumes/weights are approximations.
Specimens received on 10/21/2024.

## Detailed Findings:

| Analysis and Comments | Result | Units | Rpt. Limit | Specimen Source | Analysis By |
|---|---|---|---|---|---|
| Ethanol | 85 | mg/dL | 10 | 001 - Blood | Headspace GC |
| Blood Alcohol Concentration (BAC) | 0.085 | g/100 mL | 0.010 | 001 - Blood | Headspace GC |
| Ethanol | Confirmed | mg/dL | 10 | 001 - Blood | Headspace GC |
| Alprazolam | 20 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| 11-Hydroxy Delta-9 THC | 3.0 | ng/mL | 1.0 | 001 - Blood | LC-MS/MS |
| Delta-9 Carboxy THC | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| Delta-9 THC | 1.5 | ng/mL | 0.50 | 001 - Blood | LC-MS/MS |
| Cocaine | 30 | ng/mL | 10 | 001 - Blood | LC-MS/MS |
| Methadone | 60 | ng/mL | 20 | 001 - Blood | LC-MS/MS |
| EDDP | 60 | ng/mL | 20 | 001 - Blood | LC-MS/MS |
| Morphine - Free | 10 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| 6-Monoacetylmorphine - Free | 10 | ng/mL | 1.0 | 001 - Blood | LC-MS/MS |
| Phencyclidine | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| Amphetamine | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| Methamphetamine | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| MDA | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| MDMA | 15 | ng/mL | 5.0 | 001 - Blood | LC-MS/MS |
| Tramadol | 60 | ng/mL | 20 | 001 - Blood | LC-MS/MS |
| O-Desmethyltramadol | 60 | ng/mL | 20 | 001 - Blood | LC-MS/MS |
| Zolpidem | 12 | ng/mL | 4.0 | 001 - Blood | LC-MS/MS |
| Gabapentin | 3.0 | mcg/mL | 1.0 | 001 - Blood | LC-MS/MS |
| Fentanyl | 10 | ng/mL | 0.20 | 001 - Blood | LC-MS/MS |
| Buprenorphine - Free | 1.5 | ng/mL | 0.50 | 001 - Blood | LC-MS/MS |
| Norbuprenorphine - Free | 1.5 | ng/mL | 0.50 | 001 - Blood | LC-MS/MS |

**Examination of the specimen(s) submitted did not reveal any reportable findings by procedure(s) outlined in the accompanying Analysis Summary, other than those listed above. Interpretation of reported findings should be based on the totality of available case information. Reference information is not case-specific but is provided as a general guide.**

## Reference Comments:

1. 11-Hydroxy Delta-9 THC (Active Metabolite) - Blood:

   11-hydroxy-THC is a psychoactive THC metabolite. 11-OH-THC was detectable in blood, with a 0.5 ng/mL cutoff, for 1.5 hours (range: 0.25-3.5) when cannabis was smoked by occasional users. 11-OH-THC may be present over 72 hours in chronic, frequent cannabis users.

   In occasional cannabis users, median (range) peak blood concentrations after smoking of 6.9% (50 mg) THC were 1.9 (0.5-8.7) ng/mL with median times of maximum concentrations at approximately 11 minutes. In chronic, frequent cannabis users, median (range) peak blood concentrations after smoking 6.9% THC were 7.2 (1.9-30.9) ng/mL, with median times of maximum concentrations at approximately 12 minutes. Usual peak levels are less than 10% of THC levels after smoking.

2. 6-Monoacetylmorphine - Free (6-MAM; Heroin Metabolite) - Blood:

   6-monoacetylmorphine (6-MAM) is the 6-monoacetylated form of morphine, which is pharmacologically active. When present, it is generally indicative of heroin (diacetylmorphine) use. 6-MAM has also been reported to occur as an artifact in samples with unusually high blood morphine concentrations.

   A healthy man administered 12 mg heroin intravenously achieved peak blood concentrations at two minutes post injection of 150 ng/mL of 6-MAM and 44 ng/mL of morphine, which declined with half-lives of 6 minutes and 33 minutes, respectively.

3. Alprazolam (Xanax®) - Blood:

   Alprazolam is a low-dose benzodiazepine used for the treatment of anxiety disorders and short-term relief of anxiety associated with depressive symptoms. Alpha-hydroxyalprazolam is an active metabolite of alprazolam. They share the actions and adverse reactions of other CNS-depressants. Alcohol greatly enhances the activity of benzodiazepines. Common adverse effects of alprazolam include drowsiness, fatigue, sedation, dizziness, weakness, unsteadiness and disorientation. Signs of CNS depression can include the presence of horizontal gaze nystagmus, lack of convergence of the eyes, normal pupil size with slow reaction to light and reduced pulse and blood pressure. Reported therapeutic plasma concentrations of alprazolam are proportional to dose given: 3 mg/day produced steady-state levels of 30 ng/mL; 6 mg/day: 60 ng/mL; and 9 mg/day: 100 ng/mL. In a population of 219 drivers arrested for driving under the influence, Alprazolam concentrations ranged from 5 - 1580 ng/mL, with a mean of 103 ng/mL. Other drugs may also have been present. Studies confirm that alprazolam may cause significant impairment to driving and psychomotor abilities across a wide range of concentrations.

4. Amphetamine - Blood:

   Amphetamine (Adderall, Dexedrine) is a central nervous system stimulant. Amphetamine is also a metabolite of methamphetamine, benzphetamine and selegiline. It is used therapeutically in the treatment of narcolepsy and obesity and also in the treatment of attention-deficit hyperactivity disorder (ADHD). Amphetamine has a high potential for abuse. At low doses, amphetamine causes mild stimulation, offset of fatigue, and increase in alertness. It also causes changes in attitude, judgment and impulsivity. At higher doses, amphetamine causes euphoria, excitation, agitation, hypervigilance, rapid speech, dilated pupils which react slowly to light and increased motor restlessness. Pulse and blood pressure may be elevated. Performance in divided attention tests is often poor. Withdrawal from amphetamine following abuse can result in extreme fatigue and uncontrollable sleepiness, agitation, and depression. In the treatment of narcolepsy, amphetamine is administered in daily divided doses of 5 to 60 mg. In abuse doses of several grams may be used on a daily basis in 'runs' lasting a week or more.

   Following a single oral dose of 10 mg amphetamine sulfate, a reported peak blood concentration of 40 ng/mL was reached at 2 hr. Following a single 30 mg dose to adults, an average peak plasma level of 100 ng/mL was reported at 2.5 hr. A steady-state blood level of 2000-3000 ng/mL was reported in an addict who consumed approximately 1000 mg daily.

   In a population of 539 drivers arrested for driving under the influence, amphetamine concentrations ranged from 5-5090 ng/mL, with a mean of 76 ng/mL. Other drugs may also have been present. Amphetamine abuse can cause impairment in the skills necessary for safe driving both during the acute phase of intoxication and during withdrawal, across a wide range of blood concentrations.

## Reference Comments:

5. Blood Alcohol Concentration (BAC) - Blood:

   I certify that I am the analyst of record for this report. In this capacity, I am authorized by NMS Labs to provide the final analytical review of the results in this case. This report cannot be released without my review, and I am responsible for the accuracy of results contained herein. This laboratory is accredited and licensed, and complies with accreditation standards for internal chain of custody, standard operating procedures, analysis of appropriate blanks, calibrators and controls, and other quality control and quality assurance measures, all of which I am familiar with, and that ensure test result accuracy. A complete list of accreditations and licensures are listed on our website at www.nmslabs.com. I have considered the information available to me at this time, and it is my opinion that testing was properly performed in compliance with laboratory standards and policies, and the results are supported by the analytical data and accurately reflect the toxicological findings for this subject. If lawfully subpoenaed, I will testify to the above facts in a court of law.

6. Buprenorphine - Free (Buprenex®) - Blood:

   Buprenorphine is a Schedule III controlled synthetic opioid that has both analgesic and opioid antagonist activities. It is only available in the United States in a formulation which also contains the opiate antagonist naloxone. Some portion of the buprenorphine may be conjugated; the portion which is not conjugated is termed 'free buprenorphine'. While buprenorphine can counteract some of the effects of powerful opiates it also has opiate-like effects of its own. These include analgesia, drowsiness, and sedation. Following buprenorphine use pupils may be constricted. Pulse, blood pressure and body temperature can be lowered. Following abuse, psychomotor impairment is generally present, with increased body sway and poor performance in divided attention tests. Users may be 'on the nod', falling asleep in the middle of conversations or at inappropriate times. Tolerance can develop to the effects of opiates and more experienced users are less susceptible to the impairing effects. Patients taking carefully controlled opiates under a doctor's supervision are less likely to be impaired than if abusing the medication. Typical doses are 12 to 16 mg buprenorphine per day, although higher doses can be prescribed. Maximum plasma buprenorphine concentrations in patients maintained on varying buprenorphine doses were:
   2 mg/day: 0.3 +/- 0.1 ng/mL
   16 mg/day: 6.3 +/- 0.9 ng/mL
   32 mg/day: 13 +/- 4.2 ng/mL
   In 16 DUI cases involving buprenorphine the mean blood concentration was 2.2 ng/mL (range 0.2 - 9.0 ng/mL). Other drugs may also have been present. The blood to serum or plasma ratio is 1.0-1.4. The narcotic effects of buprenorphine have the potential to cause significant impairment of the skills necessary for safe driving.

7. Cocaine - Blood:

   Cocaine is a DEA Schedule II controlled central nervous stimulant drug. Effects following cocaine use can include euphoria, excitement, restlessness, risk taking, sleep disturbance, and aggression. A period of mental and physical fatigue and somnolence follow the use of cocaine after the excitant-stimulant effects wear off. Cocaine is metabolized to the inactive analytes benzoylecgonine, ecgonine methyl ester, and ecgonine. Benzoylecgonine and ecgonine methyl ester can form from cocaine breakdown after sample collection. The average blood cocaine concentration in 906 impaired drivers was 87 ng/mL (range 5-2390 ng/mL). Blood cocaine concentrations in patients admitted to an emergency room for cocaine related medical complaints were 260 ng/mL (SD = 500 ng/mL). Cocaine concentrations in plasma following oral administration of 2 g/day over 6 days, averaged 1260 ng/mL.

8. Delta-9 Carboxy THC (Inactive Metabolite) - Blood:

   Delta-9 carboxy THC (THCC) is the inactive metabolite of THC (tetrahydrocannabinol) the major active component of marijuana, and cannabis. After smoking a user-preferred 300 mcg/kg dose average plasma THC concentrations at 35 minutes were reported at 16.1 (range 4.7-30.9) ng/mL, and had declined to 1.5 (range 0.4-3.2) ng/mL after 190 minutes. Corresponding concentrations of THCC were 15.3 (range 4.2-39.6) at 35 minutes last use, and 10.0 (range 1.5-36.3) at 190 minutes. While THC disappears from the blood rapidly, THCC may persist for several hours, and in heavy chronic use may be present at low concentrations for several days. In a population of 318 drivers arrested for driving under the influence, THCC concentrations in blood ranged from 2.0 to 720 ng/mL, with a median of 41 ng/mL. Other substances may have been present.

## Reference Comments:

9. Delta-9 THC (Active Ingredient of Marijuana) - Blood:

   Delta-9 THC is the principle psychoactive ingredient of marijuana (cannabis, hashish). It is also the active component of the prescription medication Marinol®. Marijuana use causes relaxation, distorted perception, euphoria and feelings of well being, along with confusion, dizziness, somnolence, ataxia, speech difficulties, lethargy and muscular weakness.

   After smoking a user-preferred 300 mcg/kg dose average plasma THC concentrations at 35 minutes were reported at 16.1 (range 4.7-30.9) ng/mL, and had declined to 1.5 (range 0.4-3.2) ng/mL after 190 minutes. Usual peak levels in serum for 1.75% or 3.55% THC marijuana cigarettes: 50-270 ng/mL at 6 to 9 minutes after beginning smoking, decreasing to less than 5 ng/mL by 2 hrs. Whole blood THC concentrations are typically half those in a corresponding plasma sample.

   Effects of marijuana use on driving ability may include weaving, inattention, poor coordination and slowed reaction time with increased error rates in complex tasks. These effects worsen with increased THC concentrations. Peak effects typically last from 1-4 hours. THC concentrations in the blood decline rapidly after use, and may be undetectable within 1-3 hours following smoking. Numerous studies have associated marijuana use with impaired driving performance.

10. Ethanol (Ethyl Alcohol) - Blood:

    Ethanol (beverage alcohol) is a central nervous system depressant. It causes impairment of cognitive, perceptual and psychomotor capabilities manifested as decrements in alertness, judgment, perception, coordination, response time and sense of care and caution. Potential effects on driving include, but are not limited to, weaving, crossing center or fog lines, failure to obey traffic signals, wide turns, inappropriate speed for conditions, and involvement in collisions. Generally, a person's level of intoxication will increase with rising blood alcohol concentration. Effects are more pronounced in individuals with limited tolerance, especially minors, however at blood alcohol concentrations of 80 mg/dL (0.08 g/100 mL or 0.08% w/v), virtually all individuals exhibit impairment on some critical driving measures.

    Analysis performed in duplicate by, internally standardized, headspace Gas Chromatography (GC). The average of the two headspace GC results is reported.

    NMS Labs is an approved Laboratory for Alcohol analysis in the Commonwealth of Pennsylvania.

11. Fentanyl (Duragesic®; Sublimaze®) - Blood:

    Fentanyl is a prescription opioid commonly used as an anesthetic/analgesic. It is reported to be 80 to 200 times as potent as morphine and has a rapid onset of action as well as addictive properties. Illicit fentanyl is readily available due to low production cost and its high potency. It is often sold as heroin and is commonly found in combination with other illicit drugs. Fentanyl can cause euphoria, confusion, drowsiness, dizziness, constricted pupils, and respiratory depression.

    When used clinically as a transdermal preparation (25-100 mcg/hour patch), serum fentanyl concentrations up to 3.8 ng/mL have been reported within 24 hours. Following removal of the patch, serum fentanyl concentrations are reported to decrease with a mean elimination half-life of 17 hours (range, 13-22 hours). The mean peak plasma serum fentanyl concentration in adults given an 800 mcg oral transmucosal fentanyl preparation over 15 minutes is reported at 2.1 ng/mL (range, 1.4-3.0 ng/mL) at approximately 0.40 hours.

    Blood fentanyl concentrations averaged 9.6 ng/mL (range, 0.10-310 ng/mL) in 2,317 persons arrested for impaired driving. CNS depressant indicators such as poor balance and coordination, slow speech, and constricted pupils were observed in drivers under the influence of fentanyl. Driving behaviors including collisions, weaving, crossing the center line, and driving off the roadway have also been reported.

    The blood to serum or plasma ratio is 0.8-1.0

12. Gabapentin (Neurontin®) - Blood:

    Gabapentin is an antiepileptic/anticonvulsant drug used in adults and children. Gabapentin is marketed in capsules (100, 200 and 300 mg), tablets (600 and 800 mg) and an oral solution (250 mg/5 mL). The common daily oral dose range for adults is from 900 to 1800 mg per day in divided doses; pediatric doses (3 to 12 years of age) are dependent of the child's body weight and range from 10 to 15 mg/kg per day.

    Mean steady-state plasma levels (+/- SD) following daily regimens of:
    900 mg/day = 1.88 (+/- 0.70) mcg/mL

**Reference Comments:**

1200 mg/day= 2.62 (+/- 0.86) mcg/mL
Reported threshold for seizure control: Greater than 2 mcg/mL.

The drug is also used to treat postherpetic neuralgia in adults. The common adult dosage for this indication is 1800 mg per day in divided doses following lower doses during initial treatment.

The most common adverse effects of gabapentin are related to the central nervous system and include sedation, dizziness, nystagmus, ataxia and fatigue. All of these adverse effects are reversible and subside with reduction of dosage or discontinuation of therapy with the drug.

13. MDA (3,4-Methylenedioxyamphetamine; Adam; MDMA Metabolite) - Blood:

    3,4-Methylenedioxyamphetamine (MDA) is an amphetamine derivative and a chemical analogue and metabolite of 3,4-methylenedioxymethamphetamine (MDMA). This compound is abused for its central nervous system stimulant and hallucinogenic properties. It displays mixed stimulant, and hallucinogenic properties. Users report that MDA promotes empathy and feelings of love, or emotional closeness to others. Users also report visual and tactile hallucinations, confusion, agitation and coma. Acutely, users typically have elevated pulse, blood pressure and dilated pupils, with slow reaction to light. Typical doses of MDMA are in the range 50 to 200 mg. When present as an MDMA metabolite, MDA concentrations peaked at 4 to 6 hours and never exceeded 5% of the parent compound. The mixed stimulant and hallucinogenic effects of recreational use of this drug create a risk for impairment of the skills needed for safe driving.

14. MDMA (3,4-Methylenedioxymethamphetamine; Ecstasy) - Blood:

    3,4-Methylenedioxymethamphetamine (MDMA) is a DEA Schedule I controlled substance and a sympathomimetic analyte with mixed stimulant and hallucinogenic properties. Users report that MDMA promotes empathy and feelings of love, or emotional closeness to others. Users also report visual and tactile hallucinations, confusion, agitation and coma. Acutely, users typically have elevated pulse and blood pressure and dilated pupils, with slow reaction to light.

    A single 100 mg oral dose administered to 9 young, healthy males produced peak mean MDMA concentrations of 180 ng/mL at 2 hours and 11 ng/mL of MDA at 4 hours. The elimination half-lives for MDMA and MDA were 7 and 13 hours, respectively.

    Drivers arrested under suspicion of MDMA intoxication generally displayed erratic driving, weaving, failure to obey stop signs, speeding and involvement in collisions. MDMA concentrations in blood from 493 drivers ranged from 5-3900 ng/mL (median 100 ng/mL). Other drugs may also have been present. The mixed stimulant and hallucinogenic effects of recreational use of this drug create a risk for impairment of the skills needed for safe driving.

15. Methadone (Dolophine®) - Blood:

    Methadone is a DEA Schedule II opioid analgesic used in the treatment of opiate addiction, and in the treatment of pain. Methadone is subject to abuse. Major metabolites of methadone include EDDP and EMDP. A single 10 mg oral dose of methadone produced a reported peak plasma concentration of 43 ng/mL at 2.1 hours. Patients with chronic pain who received 10 to 100 mg of methadone daily for 9 months had trough serum concentrations that ranged from 110 to 550 ng/mL. Chronic daily oral doses of 100 to 200 mg in tolerant patients produced reported peak plasma concentrations ranging from 570 to 1100 ng/mL. Methadone has a long elimination half-life, estimated to be between 15 and 55 hours. Adverse effects from methadone are characterized by sedation, dizziness, lethargy, pupillary constriction, constipation, respiratory depression, bradycardia and coma. Patients receiving methadone as part of a maintenance program may take as much as 180 mg daily. In a population of 273 drivers arrested for driving under the influence, Methadone concentrations ranged from 5-1740 ng/mL, with a mean of 180 ng/mL. Other drugs may also have been present. Studies of drivers receiving methadone suggest that patients who are taking regular controlled doses of the drug under the care of a physician, are less susceptible to adverse effects. Individuals taking single doses, abusing or misusing the drug, changing doses, or taking extra doses are more likely to exhibit adverse effects, including sedation and impaired reaction time, necessary for safe driving.

16. Methamphetamine - Blood:

    Methamphetamine is a central nervous system stimulant. It is used therapeutically in the treatment of narcolepsy and obesity and also in the treatment of attention-deficit hyperactivity disorder (ADHD). Methamphetamine has a high potential for abuse. At low doses, methamphetamine causes mild stimulation, offset of fatigue and increase in alertness. It also causes changes in attitude, judgment and impulsivity. At doses taken in abuse, methamphetamine causes euphoria, excitation, agitation, hypervigilance, rapid speech, dilated pupils which react slowly to light, and increased motor restlessness. Pulse and blood pressure may be

**Reference Comments:**

elevated. Performance in divided attention tests is often poor. Driving behaviors associated with methamphetamine abuse include, weaving erratic driving, driving off the road, crossing the centerline and speeding. Withdrawal from methamphetamine following abuse can result in extreme fatigue and uncontrollable sleepiness, agitation and depression. In the treatment of narcolepsy, methamphetamine is administered in daily divided doses of 5 to 60 mg. In abuse, doses of several grams may be used on a daily basis in 'runs' lasting a week or more. A peak blood concentration of methamphetamine of 20 ng/mL was reported at 2.5 hr after an oral dosage of 12.5 mg. In a population of 1159 drivers arrested for driving under the influence, Methamphetamine concentrations ranged from 10-9460 ng/mL, with a mean of 310 ng/mL. Other drugs may also have been present. Methamphetamine abuse can cause impairment in the skills necessary for safe driving both during the acute phase of intoxication and during withdrawal, across a wide range of blood concentrations.

*In this case, the level of methamphetamine determined has not been differentiated according to its isomeric forms. Differentiation of the isomers of methamphetamine is available upon request.

17. Morphine - Free - Blood:

Morphine (Duramorph, Roxanol, MS-Contin) is an opiate narcotic analgesic. It is also commonly found as a metabolite or breakdown product of codeine and heroin. A large portion of the morphine may be conjugated; the portion which is not conjugated is termed 'free morphine'. When found together with 6-monoacetylmorphine (6-MAM), it is an indicator that the likely source was heroin. Morphine is a powerful painkilling drug whose effects include analgesia, drowsiness, and sedation. Following excessive opiate use, pupils are typically constricted and unreactive to light. Pulse and blood pressure, and body temperature can be lowered. Psychomotor impairment is generally present, with increased body sway, and poor performance in divided attention tests. Users are sometimes described as 'on the nod', falling asleep in the middle of conversations or at inappropriate times. Tolerance can develop to the effects of opiates, and more experienced users are less susceptible to the impairing effects. Patients taking carefully controlled opiates under a doctor's supervision are less likely to be impaired than if abusing the medication. Intravenous administration of 10 mg morphine produced reported peak therapeutic blood levels of 60 ng/mL, which declined to 3 ng/mL after 36 hr. In a population of 676 drivers arrested for driving under the influence, Morphine concentrations ranged from 1.25 - 1290 ng/mL, with a mean of 52 ng/mL. Other drugs may also have been present. The narcotic and sedative effects of morphine may result in significant impairment of the skills necessary for safe driving.

18. Norbuprenorphine - Free (Buprenorphine Metabolite) - Blood:

Buprenorphine (Suboxone, Subutex) is a semi-synthetic opiate with partial agonist and antagonist actions. Buprenorphine is only available in the United States in a formulation which also contains the opiate antagonist naloxone. Buprenorphine is metabolized in the liver by N-dealkylation to norbuprenorphine and both buprenorphine and norbuprenorphine undergo glucuronide conjugation. Maximum plasma norbuprenorphine concentrations in patients maintained on varying buprenorphine doses were:
2 mg/day: 0.7 +/- 0.2 ng/mL
16 mg/day: 5.4 +/- 1.3 ng/mL
32 mg/day: 14 +/- 2.9 ng/mL

In 20 fatalities where buprenorphine was detected, blood concentrations of norbuprenorphine were 0.2-13 ng/mL (mean=2.6 ng/mL). Other drugs were present in 19 cases, 18 of which were positive for benzodiazepines, primarily nordiazepam. The blood to serum or plasma ratio is unknown.

19. O-Desmethyltramadol (Tramadol Metabolite) - Blood:

Tramadol is a synthetic opioid receptor agonist used for the management of moderate to moderately severe pain. O-Desmethyltramadol is a tramadol metabolite. It has been reported as being present in some 'Legal High' or 'Bath Salts' products, often in combination with mitragynine.

Peak plasma concentration for O-Desmethyltramadol following a single 100 mg oral dose: 35-75 ng/mL. Steady-state plasma concentration following a 100 mg 4 times daily regimen: 80-140 ng/mL. The presence of O-desmethyltramadol in the absence of tramadol should be interpreted with caution. O-desmethyltramadol is currently not scheduled in the United States.

The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.

## Reference Comments:

20. Phencyclidine (Angel Dust; PCP; Sherm) - Blood:

    Phencyclidine is a DEA Schedule II controlled dissociative anesthetic. It is abused for its dissociative and hallucinogenic effects. The physiological effects of PCP can be classified as low or high dose. In low doses, PCP can elicit visual disturbances, drowsiness, agitation, hallucinations, aggressiveness, increased pulse rate and blood pressure, bronchospasm, increased respiratory rate and hyperthermia. In high doses, PCP can elicit convulsions, opisthotonos, coma, arrhythmias, decreased blood pressure and respirations and rhabdomyolysis.

    Signs of a person under the influence of PCP can include horizontal and vertical gaze nystagmus, lack of convergence of the eyes, normal pupil size, and increased pulse and blood pressure, and elevated body temperature. Performance in divided attention tests is generally poor. It has been reported that blood levels of PCP ranged from 12-118 ng/mL (mean 51 ng/mL) in individuals arrested for driving under the influence of drugs. Other drugs may also have been present. As a hallucinogenic drug which causes dissociation and central nervous system depression, PCP is capable of causing significant impairment to driving and psychomotor abilities.

21. Tramadol (Ultram®; Ultrex®) - Blood:

    Tramadol is a synthetic opioid receptor agonist used for the management of moderate to moderately severe pain. Peak plasma levels of tramadol following a single 100 mg oral dose range from 230-380 ng/mL and peak levels of the active metabolite, O-desmethyltramadol, range from 35-75 ng/mL. Steady-state plasma levels following an oral dosage regimen of 100 mg of tramadol administered 4 times a day range from 420-770 ng/mL. The elimination half-lives of tramadol and O-desmethyltramadol are 5 to 8 hrs and 6 to 9 hrs, respectively.

    Common adverse reactions to tramadol include sedation, dizziness, headache, and constipation. Higher doses may elicit agitation, tachycardia, hypertension and seizures. The mean postmortem femoral blood concentration of tramadol in 5 individuals who died due to tramadol overdose was reported as 6100 ng/mL.

22. Zolpidem (Ambien®) - Blood:

    Zolpidem is a sedative hypnotic. It is used for the short-term treatment of insomnia. It is available in immediate release and extended release formulations. Plasma concentrations following single oral 5 mg and 10 mg immediate release doses range from 29-110 ng/mL (mean 59 ng/mL) and 58-270 ng/mL (mean 120 ng/mL), respectively, occurring at a mean time of 1.6 hr. Peak plasma concentrations following a single oral 12.5 mg extended release dose ranged from 69-190 ng/mL (mean 130 ng/mL) occurring at a mean time of 1.5 hr.

    In 5 suspected impaired driving cases where zolpidem was the only drug detected, blood concentrations ranged from 80-1400 ng/mL (mean 650 ng/mL, median = 470 ng/mL).

    Adverse effects include drowsiness, dizziness, amnesia, headache and nausea. A zolpidem plasma concentration of 600 ng/mL was measured 3 hours after ingestion of 300 mg of drug in a patient who survived the overdose. In seven deaths involving zolpidem and at least one other drug zolpidem heart-blood concentrations averaged 2800 ng/mL (1100-4500 ng/mL).

    The ratio of whole blood concentration to serum or plasma concentration is approximately 0.6 to 0.8.

## Analysis Summary and Reporting Limits:

The following test(s) were performed for this case; the scope of each test includes the analyte(s) listed along with the associated reporting limit(s). The reporting limit is the lowest concentration of the analyte that will be reported as positive. Only results that meet reporting criteria at or above the reporting limit appear in the Positive Findings section of the report.

Test 54002B - Benzodiazepines Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 7-Amino Clonazepam | 5.0 ng/mL | Chlordiazepoxide | 20 ng/mL |
| Alpha-Hydroxyalprazolam | 5.0 ng/mL | Clonazepam | 2.0 ng/mL |
| Alprazolam | 5.0 ng/mL | Diazepam | 20 ng/mL |

**Analysis Summary and Reporting Limits:**

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Lorazepam | 5.0 ng/mL | Oxazepam | 20 ng/mL |
| Midazolam | 5.0 ng/mL | Temazepam | 20 ng/mL |
| Nordiazepam | 20 ng/mL | | |

Test 54003B - Cannabinoids Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 11-Hydroxy Delta-9 THC | 1.0 ng/mL | Delta-9 THC | 0.50 ng/mL |
| Delta-9 Carboxy THC | 5.0 ng/mL | | |

Test 54004B - Cocaine and Metabolites Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Benzoylecgonine | 50 ng/mL | Cocaine | 10 ng/mL |
| Cocaethylene | 10 ng/mL | | |

Test 54005B - Methadone and Metabolite Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| EDDP | 20 ng/mL | Methadone | 20 ng/mL |

Test 54006B - Opiates - Free (Unconjugated) Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| 6-Monoacetylmorphine - Free | 1.0 ng/mL | Hydromorphone - Free | 1.0 ng/mL |
| Codeine - Free | 5.0 ng/mL | Morphine - Free | 5.0 ng/mL |
| Dihydrocodeine / Hydrocodol - Free | 5.0 ng/mL | Oxycodone - Free | 5.0 ng/mL |
| Hydrocodone - Free | 5.0 ng/mL | Oxymorphone - Free | 1.0 ng/mL |

Test 54007B - Phencyclidine Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Phencyclidine | 5.0 ng/mL | | |

Test 54024B - Amphetamines Confirmation (DUID/DRE), Blood (Forensic): 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Amphetamine | 5.0 ng/mL | MDMA | 5.0 ng/mL |
| MDA | 5.0 ng/mL | Methamphetamine | 5.0 ng/mL |

## Analysis Summary and Reporting Limits:

Test 54128B - Tramadol and Metabolite Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| O-Desmethyltramadol | 20 ng/mL | Tramadol | 20 ng/mL |

Test 54139B - Zolpidem Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Zolpidem | 4.0 ng/mL | | |

Test 54244B - Gabapentin Confirmation (DUID/DRE), Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Gabapentin | 1.0 mcg/mL | | |

Test 54459B - DUID/DRE Fentanyl and Acetyl Fentanyl Confirmation, Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Acetyl Fentanyl | 0.20 ng/mL | Norfentanyl | 0.40 ng/mL |
| Fentanyl | 0.20 ng/mL | | |

Test 54460B - DUID/DRE Buprenorphine and Metabolite Free (Unconjugated) Confirmation, Blood: 001 - Blood

-Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Buprenorphine - Free | 0.50 ng/mL | Norbuprenorphine - Free | 0.50 ng/mL |

Test 8151B - DUID/DRE Panel (w/Alcohol), Blood (Forensic): 001 - Blood

-Analysis by Enzyme-Linked Immunosorbent Assay (ELISA) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Amphetamines | 20 ng/mL | Methadone / Metabolite | 25 ng/mL |
| Benzodiazepines | 20 ng/mL | Methamphetamine / MDMA | 20 ng/mL |
| Buprenorphine / Metabolite | 0.50 ng/mL | Opiates | 20 ng/mL |
| Cannabinoids | 10 ng/mL | Oxycodone / Oxymorphone | 10 ng/mL |
| Cocaine / Metabolites | 20 ng/mL | Phencyclidine | 10 ng/mL |
| Fentanyl / Acetyl Fentanyl | 0.50 ng/mL | Tramadol / Metabolite | 50 ng/mL |
| Gabapentin | 5.0 mcg/mL | Zolpidem | 5.0 ng/mL |

-Analysis by Headspace Gas Chromatography (GC) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Acetone | 5.0 mg/dL | Ethanol | 10 mg/dL |

## Analysis Summary and Reporting Limits:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Isopropanol | 5.0 mg/dL | Methanol | 5.0 mg/dL |

-Analysis by Headspace Gas Chromatography (GC) for:

| Analyte | Rpt. Limit | Analyte | Rpt. Limit |
|---|---|---|---|
| Acetone | 5.0 mg/dL | Isopropanol | 5.0 mg/dL |
| Ethanol | 10 mg/dL | Methanol | 5.0 mg/dL |

# Section 5

# Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT

**PURPOSE:** No measurement, no matter how carefully obtained, is exact. The uncertainty associated with a measurement must be considered part of the analytical result. The measurement uncertainty is expressed by reporting the result obtained in the laboratory setting, identifying and quantifying significant contributors to the variability of that measurement, and reporting an estimate of the magnitude of that variability at a selected confidence level. The International Bureau of Weights and Measures has issued a guidance document on the calculation of measurement uncertainty which is commonly referred to as the GUM approach. The National Institute on Standards and Technology has summarized this approach which can be applied to all analytical methods in the laboratory. Specific measurement uncertainty (MU) formulas for an uncertainty budget are described here within.

**SCOPE:** MU for all quantitative analyses.

**KEY WORDS:**

See SOP 11214 Laboratory Definitions for full definitions for the following:

| | |
|---|---|
| % RSD (Relative Standard Deviation) | Measurand |
| COA (Certificate of Analysis) | MU (Measurement Uncertainty) |
| CRM (Certified Reference Material) | u (Standard Uncertainty) |

**PROCEDURE:**

**1. Quantifying Uncertainty Components**

1.1. The following nomenclature and instructions refer to use of SOP 10942 Method Validation for Quantitative Bioanalytical Testing Procedures, Document 11804 Method Validation for Quantitative Bioanalytical Testing Procedures Template, and SOP 10944 Method Validation for Qualitative Bioanalytical Testing Procedures. All provided calculations are documented and performed automatically in the validated workbook unless otherwise stated.

1.2. Measurement Reproducibility ($\%u^2_{MET}$)

1.2.1. If the number of control replicates (≥3 concentrations ideal) in same matrix as samples is ≥55 and samples are analyzed ideally in singlet, a maximum %RSD can be used.

1.2.1.1. Use all controls from the most recent control lots that have a minimum of 55 points completed. It is preferable to use as large an N as possible.

1.2.1.2. Enter data into Imprecision and Bias Tab.

1.2.1.3. The maximum %RSD across control concentrations and days is used in the combined uncertainty estimate.

1.2.2. If the number of control replicates is <55, then the acceptance criteria or other estimate of reproducibility for control data should be used as the %RSD. For example, use of Total Allowable Error (e.g., 20%) or imprecision estimates from a subset of data may be used. Imprecision data should be placed into the Imprecision and Bias Tab.

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

***Note:*** *The majority of assays report results based on a single analysis. All police and positive post-mortem methanol, ethanol, isopropanol and acetone concentrations are reported as the average of duplicate analyses. See document 10935 Example method reproducibility component for specimens analyzed and reported as an average concentration for more information on this calculation.*

1.3. Method Bias ($\%u^2_{METHODBIAS}$)

1.3.1. Use matrix matched control data to calculate method bias. Enter data into the Imprecision and Bias tab including applicable lot numbers. The maximum % Bias across all controls from their established targets is used in the combined uncertainty.

1.3.2. If the number of control replicates is <55, the bias from back-calculated, standard-curve replicates may be used. Enter the data into the Standard Curve Tab. The calculated % Bias is used in the combined uncertainty.

1.4. Matrix Bias ($\%u^2_{MATRIX}$)

1.4.1. This parameter is only required if the quality controls are in a different matrix than the unknown samples to which the calculated measurement uncertainty will be applied.

1.4.2. Use matrix matched control data or collect a minimum of 15 data points as part of a matrix matching experiment. Enter data into Matrix Matching Tab. The maximum % Bias across all matrices is used in the combined uncertainty estimate.

1.4.3. Alternatively, the estimate of the upper limit of % Bias from matrix matched control data can be used. Enter data into the Imprecision and Bias Tab. The maximum % Bias across all controls included is used in the combined uncertainty.

1.5. Uncertainty of RM ($\%u^2_{RM}$)

1.5.1. Enter required data into the Stock Standard Verification Tab.

1.5.2. Select the form of the RM (CRM, liquid, or powder) and complete the required user entry as denoted by the yellow cells.

1.5.2.1. % Standard uncertainty will be calculated and transferred to the UM Matrix Tab.

***Note:*** *% Bias is calculated only for powders and is used as an accuracy check for stock standard preparation. This value is not used in the combined uncertainty estimate as it is expected the empirically established target will be used and eliminate any stock standard bias.*

1.6. Calibrator Preparation ($\%u^2_{CAL}$)

1.6.1. Historically, prior to the publication of version 8 of 11804 and version 5 of 10934, the empirically derived upper limit of relative uncertainty of 7.5% has been used for the preparation of working calibrators for quantitative analyses in blood, serum/plasma and urine unless otherwise noted. It was determined that 7.5% is an overestimation of the contribution of the preparation of calibrators, utilizing traceable pipettes and volumetric

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

flasks, to the total combined uncertainty. See SOP 10814 Pipette Calibrations and SOP 11070 Equipment Use and Maintenance.

1.6.2. Following the publication of version 8 of 11804 and version 5 of 10934, the actual contribution of the preparation of working calibrators to the total combined uncertainty utilizing traceable pipettes and volumetric flasks is determined using the Calibrator Preparation Step Template. See SOP 10814 Pipette Calibrations and SOP 11070 Equipment Use and Maintenance.

1.6.3. Completion of Document 53191 the Calibrator Preparation Step Template
1.6.4. The completed Calibrator Preparation Step Template is saved in the applicable PTN.
1.6.4.1. Form Tab
1.6.4.1.1. Enter the following information into the fields designated as user entry fields.
1.6.4.1.1.1. Procedure Name
1.6.4.1.1.2. Analyte Name
1.6.4.1.1.3. Method Version, Publication Date
1.6.4.1.1.4. Department
1.6.4.1.1.5. Units
1.6.4.1.1.6. Standard Lot #s
1.6.4.1.1.7. Number of calibrators
1.6.4.1.1.8. Is the starting material a powder or a liquid?
1.6.4.1.1.9. Balance used
1.6.4.1.1.10. Equipment used
1.6.4.1.1.11. Are there any serial dilutions in the preparation?
1.6.4.1.1.11.1. If yes, which step(s) contain a serial dilution?
1.6.4.1.1.12. Is there more than one dispensing event in the preparation of any solution?
1.6.4.1.1.12.1. If yes, which step(s) contain multiple dispensing events?
1.6.4.1.1.12.2. Comment, as applicable
1.6.4.1.1.12.3. Conclusion, as applicable
1.6.4.1.1.12.4. The combined uncertainty for each working calibrator automatically populates based on the calculations in the Preparations MU Tab. The working calibrator with the highest combined uncertainty is selected for entry into the Calibrator Preparation line item in the Measurement Uncertainty Budget.
1.6.4.2. Standard Prep Sheets Tab
1.6.4.2.1. Paste screenshots of applicable certificates of analysis and/or prep sheets.
1.6.4.3. Preparations MU Tab
1.6.4.3.1. If the starting material is a CRM, enter the units, concentration, and relative uncertainty applicable to the CRM in the user entry fields as shown in the example below.

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

| Working Calibrator Preparations | SOP 10934 |
|---|---|
| **Procedure:** | PTN 645 |
| **Analyte:** | Xylazine |
| **Method Version, Publication Date:** | Xylazine Analysis by Multiplexed LC_MS_MS |
| **Department:** | GC StreamSelect |
| **Standard Lot No.:** | 031023JD |

Summary table of Standard Solutions

| | Units | Concentration | Relative Uncertainty |
|---|---|---|---|
| Stock Std | ng/mcL | 100 | 0.02236068 |
| Stock Std CRM | Concentration | 100 | 0 |

1.6.4.3.1.1. If MU is calculated as part of new method development and/or validation, the relative uncertainty should be set to 0, as the uncertainty associated with the CRM is captured as part of Uncertainty of RM line item in the Measurement Uncertainty Budget (%$u^2$RM).

1.6.4.3.1.2. If MU is calculated as part of an update to an existing method, the relative uncertainty from the COA for the CRM should be entered.

1.6.4.3.1.3. Skip step 1 under the Standard Solutions heading.

1.6.4.3.2. If the starting material is a powder, begin with step 1 under the Standard Solutions heading.

1.6.4.3.2.1. For the fields designated as user entry, enter the amount of powder added, the dispensing device, and the expected concentration of the resulting solution obtained from the prep sheet, as shown in the example below.

**STANDARD SOLUTIONS**

| | Standard prep from powder or from powder CRM. | | Amt Powder Added | Dispensing Device | Stock Std |
|---|---|---|---|---|---|
| | | | mg | mL | ng/mcL |
| 1 | | Conc or Volume | 1.167 | 11.675 | 100 |
| | | Rel Unc | 1.0000% | 2.0000% | 2.2361% |

1.6.4.3.2.2. For the fields denoted as drop downs, select the units, relative uncertainty, and solution name associated with the fields.

1.6.4.3.2.2.1. Applicable balance, volumetric flask, and pipette tolerances are listed at the top of the Preparations MU Tab.

1.6.4.3.2.2.1.1. In general, the tolerance is estimated and assigned taking into consideration the relevant calibration criteria and the intended use of the equipment.

1.6.4.3.3. Step 2 under the Standard Solutions heading is completed in all situations, regardless of whether a liquid CRM or a powder is used as the starting material. See below for an example.

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

| | Cal Std A | Stock Std | Solvent | Stock Std | Total Volume* | Cal Std A |
|---|---|---|---|---|---|---|
| 2 | | ng/mcL | mcL | mcL | mcL | ng/mcL |
| | Conc or Volume | 100.000 | 9000 | 1000 | 10000 | 10.000 |
| | Rel Unc | 2.2361% | 2.0000% | 2.0000% | 0.0000% | 3.6056% |

1.6.4.3.3.1. Cell references in this section will specifically reference those in Step 2; however, rows following Step 2 function similarly and should be completed for each standard solution prepared as part of the method.
1.6.4.3.3.2. Select the applicable name of the solution from the drop down in cell G40.
1.6.4.3.3.3. Select the name of the starting material from the drop down in C40. The units, concentration, and uncertainty associated with that solution will automatically populate.
1.6.4.3.3.4. Select the applicable descriptor from the drop down in D40.
1.6.4.3.3.5. Select the appropriate units for cells D41, E41, F41, and G41.
1.6.4.3.3.6. Enter the volume of solvent/diluent/matrix used in D42, the volume of solution used in E42 (this is the solution previously selected in C40), and the total volume prepared in F42.
1.6.4.3.3.7. Enter the applicable uncertainty for the pipette or volumetric flask used in D43, E43, and F43.
1.6.4.3.3.7.1. If a volumetric flask is used as a measuring device, use the applicable uncertainty associated with the total flask volume. If a volumetric flask is used as a convenience container, the associated uncertainty is set to 0%.
1.6.4.3.3.7.2. If multiple dispensing events occur, the tolerance associated with the pipette(s) should be added together and selected from the drop down.
1.6.4.3.3.8. Complete additional rows as needed for each standard solution prepared as part of the method.
1.6.4.3.4. Beginning with Step 2, each row completed under the Standard Solutions heading corresponds to a row to the right under the Working Calibrators heading.
1.6.4.3.4.1. Cell references in this section will specifically reference the row directly to the right of Step 2; however, rows following this function similarly and should be completed for each working calibrator prepared as part of the method.
1.6.4.3.4.2. Select the applicable name/level of the working calibrator from the drop down in cell P40.
1.6.4.3.4.3. Select the name of the applicable standard solution from the drop down in K40. The units, concentration, and uncertainty associated with that solution will automatically populate.
1.6.4.3.4.4. It may be necessary to covert the units in the Standard Solutions section so that they correspond to the units in the method. Select the desired units in cell L41 and the appropriate conversion factor in L42.
1.6.4.3.4.5. Select the applicable descriptor from the drop down in M40.
1.6.4.3.4.6. Select the appropriate units for cells M41, N41, O41, and P41.
1.6.4.3.4.7. Enter the volume of solvent/diluent/matrix used in M42, the volume of standard solution used in N42 (this is the solution previously selected in K40), and the total volume extracted in O42.

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

1.6.4.3.4.7.1. If the entire spiked matrix volume is extracted then the total matrix volume equals the blank matrix volume. If only a portion of the sample volume is extracted, then the total volume equals the blank matrix volume plus the volume of the spike.
1.6.4.3.4.8. Enter the applicable uncertainty for the pipette or volumetric flask used in M43, N43, and O43.
1.6.4.3.4.8.1. If a volumetric flask is used as a measuring device, use the applicable uncertainty associated with the total flask volume. If a volumetric flask is used as a convenience container, the associated uncertainty is set to 0%.
1.6.4.3.4.8.2. The combined uncertainty associated with this working calibrator level is calculated and displayed in P43.
1.6.4.3.4.9. Complete additional rows as needed for each working calibrator level prepared as part of the method.

1.7. Pipetting of sample matrix ($\%u^2_{SPEC}$)
1.7.1. Sample volume will be used as stated in the associated method. Pipette tolerances will be used according to the maximum allowed by NMS laboratory policy (see SOP 10814 Pipette Calibrations)

1.8. For some types of measurements, it is acceptable to use a percentage of the smallest unit of measurement as the standard uncertainty for the measuring device (e.g. the standard uncertainty associated with a graduated cylinder or calipers).

**2. Converting Quantities to Standard Uncertainties (u)**
2.1. The standard uncertainty of each component is calculated in the Standard Uncertainty column of the UM Matrix Tab.
2.2. Selection of the Distribution is critical to the correct uncertainty being calculated. See below and the approved template for explanations.

| Distribution | Divisor | Explanation |
|---|---|---|
| Normal | 1 | Based on empirically collected, laboratory generated Type A data with adequate number of observations (e.g., ≥55). |
| Normal_E or Triangular* | √6 | Assumes values of the quantity in question will fall near the center of the limits more often than values close to the limits. |
| Rectangular | √3 | Assumes values of the quantity in question are equally likely to fall anywhere between established bounds. Rectangular distribution is typically chosen for Type B data when the distribution is not already known or specified by the vendor. |

**Normal_E and Triangular are synonymous and have been used historically to internally determine source of data in the template.*

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

**3. Calculating the Combined Standard Uncertainty**

$$u_{COMBINED} = \sqrt{u_{MET}^2 + u_{MATRIX}^2 + u_{METHODBIAS}^2 + u_{CRM}^2 + u_{CAL}^2 + u_{SPEC}^2}$$

**4. Expanding the Combined Standard Uncertainty (U)**

4.1. The coverage factor is used to expand the uncertainty to encompass the desired probability.
4.1.1. Use k=2 for 95.45% Confidence Interval
4.1.2. Use k=3 for 99.73% confidence interval

**5. Determination of LIMS variables**

5.1. **VAR1**: Sum of Squares (all but Measurement Reproducibility)
5.2. **VAR2**: Measurement Reproducibility (Slope)
5.2.1. If the number of control replicates is >55, the slope will be based on the standard deviation measured at each QC value vs. the QC concentration from the Mtd. Reproduc & Bias Tab.
5.2.2. If the number of control replicates is <55, the slope will be based on the standard deviation measured at each concentration on the Imprecision & Bias Tab vs. the target concentrations.
5.3. Uncertainty of measurement determinations made prior to version 8 of 11804 and version 5 of 10934 may have used VAR3 (shown below); determinations made after the publication of version 7 of 11804 and version 5 of 10934 do not use VAR3.
5.3.1. **VAR3**: Measurement Reproducibility (Intercept)
5.3.1.1. If the number of control replicates is >55, the intercept will be based on the standard deviation measured at each QC value vs. the QC concentration from the Mtd. Reproduc & Bias Tab.
5.3.1.2. If the number of control replicates is <55, the intercept will be based on the standard deviation measured at each concentration on the Imprecision & Bias Tab vs. the target concentrations.

5.4. **n**: Number of measurements taken per sample to determine the final result.

5.5. **k**: Coverage factor for expansion based on desired probability estimate.

5.6. **VAR1, VAR2 and VAR3** are rounded to the 100ths place in MSExcel© (Note: BAC is entered with the same number of digits as Ethanol) using normal MSExcel© rounding rules.

5.7. The final expanded uncertainty is calculated in the LIMS system. To achieve this calculation five factors are entered. For ethanol and BAC these factors are based on the following:
5.7.1. **VAR1** = Sum of Squares (all but Measurement Reproducibility)
5.7.2. **VAR2** = slope of conc. vs. standard deviation line x 100
5.7.3. **VAR3** = intercept of conc. vs. standard deviation line x 100
5.7.4. **n** = 2


Dependencies: (10935) Example method reproducibility component for specimens analyzed and reported as an average concentration. , (10937) Data Entry of Factors and Variables, (21704) UMCALC TEMPLATE, (53191) Calibrator Preparation Step Template

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

5.7.5. **k** = 3

5.8. For all other analytes unless specified these factors are based on the following:
5.8.1. **VAR1** = Sum of Squares (all but Measurement Reproducibility)
5.8.2. **VAR2** = $u_{MET}$
5.8.3. **VAR3** = 0
5.8.4. **n** = 1 (Note: The n will be adjusted based on the number of replicates needed to calculate the reported result)
5.8.5. **k** = 2

**6. Calculation of Expanded Uncertainty**

6.1. The following components are used to derive a Sliding Measurement Reproducibility term that incorporates the reported result:

$$u_{MET} = \frac{mx + b}{x}$$

6.1.1. x = concentration of the result
6.1.2. m = VAR2
6.1.3. b = VAR3

***Note:*** *The regression equation based on the relationship between standard deviation and concentration is used to solve for the standard deviation (y) at the reported concentration (x). The standard deviation is then divided by the concentration (x) and the result is multiplied by 100 to provide a %RSD. This provides an estimate of %RSD at the specified concentration reported.*

6.2. The expanded uncertainty as calculated in LIMS uses the following equation which is a derivation of the $u_{COMBINED}$ equation to incorporate the reported result using the rearranged $u_{MET}$ equation. For analytes using a static reproducibility with a maximum error throughout the AMR, VAR2 will be equal to a static uncertainty and VAR3 will be 0 (effectively canceling out the use of the reported result). For analytes using the regression equation for a sliding uncertainty estimated based on the reported result, VAR2 will be the slope and VAR3 will be the intercept of the regression equation. Both scenarios use the following LIMS equation for final uncertainty calculation (where RR = Reported Result, and n = number of replicates in the final measurement):

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

$$\text{Expanded MU} = k \times \left( \frac{\sqrt{\left( \frac{\left( \text{VAR2} + \frac{\text{VAR3}}{\text{RR}} \right)^2}{\sqrt{n}} \right) + \text{VAR1}}}{100} \right)$$

***Note:*** *The LIMS system does not round the expanded uncertainty before applying it to the reported result.*

**7. Evaluate Expanded Uncertainty**

7.1. The calculated uncertainty should be evaluated to ensure it is reasonable and appropriate for the method. If the uncertainty is not reasonable and/or appropriate, then the following steps should be followed:

7.2. Review calculation for errors.

7.3. Determine if method improvement is necessary.

**8. Report the MU**

8.1. MU is reported as y+/-U where

8.1.1. y is the quantity measured by the analytical process, (i.e., the result the analyst measured or quantitated using the appropriate analytical procedure).

8.1.2. U is the associated expanded uncertainty, i.e., an estimate of the variability in the reported result based upon information known about the specific measurement procedure at a selected coverage probability.

8.2. All reported MUs are required to have the coverage probability of the expanded uncertainty be at least 95.45% which corresponds to k=2.

8.3. MU uncertainty is expressed as an expanded uncertainty including the coverage probability (99.73% for ethanol; 95.45% for all other compounds unless otherwise specified).

8.4. The measurand and rounded uncertainty are reported to the same level of significance. Therefore, the reported uncertainty is rounded to the same place as the last significant digit in the reported results.

8.5. The following comment is placed on all reports where uncertainty is reported: Quantitative results are reported as Result ± Uncertainty of Measurement (UM). Measurement uncertainty is reported at a 95.45% level of confidence for all toxicological analyses except blood ethanol which is reported at a 99.73% level of confidence.

8.6. Examples of Reported MU

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

| Analyte | Calculated Result | Calculated Uncertainty | Reported Result |
|---|---|---|---|
| Morphine – Free, Blood | 10.7 ng/mL | ± 3.286 ng/mL | 10 ± 3 ng/mL |
| Ethanol, Blood | 85.7 mg/dL | ± 5.58 mg/dL | 85 ± 6 mg/dL |
| BAC | 0.0857 g/100mL | ± 0.0056 g/100mL | 0.085 ± 0.006 g/100mL |
| Cocaine, Blood | 50.86 ng/mL | ± 15.632 ng/mL | 50 ± 15 ng/mL |

## 9. Data Entry of Factors and Variables

9.1. Rather than using analyte specific Variables, system set points are used to generate Variables for LIMS calculations (except for BAC and Ethanol) when analyte specific variables are less than the system set points. The variables are as follows:

| Matrix | VAR1 | VAR2 | VAR3 |
|---|---|---|---|
| Matrix 1 | 99.75 | 11.55 | 0 |
| Matrix 2 | 174.75 | 11.55 | 0 |

9.2. The system set points used with rectangular distributions to generate the LIMS Variables are as follows:

| Parameter | Relative Uncertainty |
|---|---|
| Reproducibility | 20% |
| Method Bias | 15% |
| Secondary Matrix Bias | 15% |
| CRM | 3% |
| Calibrator Prep | 7.5% |
| Pipetting of Sample | 3% |

9.3. The system set points listed above are general guidelines but do not preclude the use of a larger value for a particular line item in the Measurement Uncertainty Budget. The overall expanded uncertainty of measurement is used as the determining factor for acceptability of the system set points.

9.3.1. If the Expanded Uncertainty at K=2 is greater than 31% for Matrix 1, the Analyte Specific Variables (ASV) are used for both VAR1 and VAR2.

9.3.2. If the Expanded Uncertainty at K=2 is greater than 35% for Matrix 2, the ASV are used for both VAR1 and VAR2.

9.3.3. If the Expanded Uncertainty is greater than 31% or 35%, respectively from Matrix 1 and Matrix 2, notify the approving personnel.

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

9.4. Uncertainty of measurement determinations made prior to version 8 of 11804 and version 5 of 10934 may have used analyte specific MU variables if the system set points were not adequate (i.e., the analyte specific variables are greater than the system set points).
9.5. Please refer to document 10937 Data Entry of Factors and Variables for instructions on transcribing factors and variables into the LIMS system, using the Uncertainty of Measurement application in the NMS Labs Intranet.

**10. Initiation of a MU Request from a Client**

10.1. This section details the communication and responsibility for completion of MU generation when requested by a client (i.e. not available in the current MU test list scope). This process is utilized for analytes and procedures not included within a DUID specific test.
10.2. A client initiates communication with the Client Services Department requesting MU for an analyte to be added to their report.
10.3. The client services representative submits necessary information to QA department via the TIQ-QA mailbox, along with a direct CC to the department supervisor.
10.4. The assigned QA member will proceed with the following:
10.4.1.1. Calculate the UoM from the system variables using 21704 UMCALC TEMPLATE and save a copy in the Client Requests folder with the NMS Labs workorder number as the name.
10.4.1.1.1. Note, making a copy of the main calculator page can be done for multiple analytes on a single work order.
10.4.2. QA will notify Client Services /Toxicologist that the MU is available to be added to the report.

**11. Guidelines for Re-evaluation of Uncertainty of Measurement**

11.1. Measurement uncertainty (MU) for a given analyte must be re-evaluated and approved by QA if the system set points are modified.
11.2. Periodic re-evaluation of MU will occur in intervals of every 5 years if no changes have occurred to the system set points.
11.3. For analyte specific MU, completed forms and any associated data or workbooks will be sent to TIQ-QA and filed according to the established practices for document retention found in SOP 10891 Records Retention Storage and Retrieval.

**12. References:**

12.1. “AL-PD-3060: Policy on Measurement Uncertainty v1.1.” 2013. ASCLD/LAB.
12.2. “AL-PD-3061: Guidance on the Estimation of Measurement Uncertainty - Overview v1.0.” 2013. ASCLD/LAB
12.3. “AL-PD-3062: Guidance on the Estimation of Uncertainty - Annex A - Details on the NIST 8-Step Process v1.0.” 2013.
12.4. “AL-PD-3065: Guidance on the Estimation of Uncertainty - Annex D - Toxicology Testing Discipline Example - Concentration of Ethanol in an Ante-Mortem Blood Specimen v1.0.” 2013. ASCLD/LAB

**Title: DETERMINATION OF UNCERTAINTY OF MEASUREMENT**

12.5. Ellison, SLR, and A Williams. 2014. Eurachem/CITAC Guide: Quantifying Uncertainty in Analytical Measurement. 3rd ed. www.eurachem.org. Accessed November 21. http://www.citac.cc/QUAM2012 P1.pdf.
12.6. Gullberg, Rod G. 2012. “Estimating the Measurement Uncertainty in Forensic Blood Alcohol Analysis.” Journal of Analytical Toxicology 36 (3): 153–61. doi:10.1093/jat/bks012.

Table of Contents






Dependencies:

**PURPOSE:** The Quality Policy Manual defines NMS Lab's overall commitment to quality and provides information about the processes that are used to generate indicators that continually measure/monitor the systems and the activities that are part of the Quality Management System. Our commitment for delivering accurate and timely service through metric evaluation and risk management provides an accurate assessment of client satisfaction and solidifies the foundation for improvement of services to our clients.

**SCOPE:** The Quality System and Management System will cover work carried out in the laboratory's permanent facilities (Horsham, PA, Willow Grove, PA, Bucks County, PA, Winston-Salem, NC, Dallas/Ft. Worth, TX, Jacksonville, FL, and El Paso, TX), at sites away from its permanent facilities, or in associated temporary or mobile facilities. Knowledge of the contents of this manual is the responsibility of all employees of NMS Labs at all locations.

**PROCEDURE:**

**1. INTRODUCTION AND COMPANY PROFILE:**

1.1. NMS Labs is a multi-site, privately owned clinical and forensic toxicology and criminalistics laboratory system with the headquarters located in Horsham, PA. For more than 50 years, NMS Labs has been setting the standard for excellence in clinical toxicology and forensic testing—responding to the needs of healthcare providers, medical researchers, coroners and medical examiners, and the criminal and civil justice systems with state-of-the-art tests that other labs do not or cannot provide. As a national reference laboratory, NMS Labs is proud of its scope of tests, accuracy of results, client service, scientific expertise, and innovation in the areas of:

1.1.1. Forensic toxicology
1.1.2. Clinical toxicology and esoteric testing
1.1.3. Clinical research support
1.1.4. Forensic drug identification
1.1.5. Blood alcohol concentration
1.1.6. Expert consultative services

1.2. At its state-of-the-art sites, which include clinical, forensic and research facilities, a dedicated and secure crime laboratory network, and a staff of highly trained professionals, NMS Labs successfully handles the needs of thousands of clients worldwide each year. NMS Labs provides services and capabilities to meet the needs of, amongst others:

1.2.1. Reference laboratories

1.2.2. Hospital core and regional laboratories
1.2.3. Clinical research organizations (CROs)
1.2.4. Medical examiners and coroners
1.2.5. Law enforcement agencies
1.2.6. Corporations
1.2.7. University researchers
1.2.8. Government agencies
1.2.9. Attorneys
1.2.10. Pharmaceutical and medical device firms
1.2.11. Courts of law

1.3. NMS Labs has structured research and development capabilities that allow for innovation of new test methods, resulting in a rapid response to the needs of the clients.

1.4. As part of our services, NMS Labs' professionals interpret our laboratory testing results to resolve client-specific issues and provide expert witness testimony and consulting support for both civil and criminal judicial proceedings.

## 2. MISSION AND VISION STATEMENT:

2.1. Our Mission Statement: Delivering science-based forensic and clinical services of the highest quality while upholding our core values for our employees, customers, and the communities we serve.

2.2. Our Vision is: We serve the global health and safety community with unsurpassed scientific expertise.

## 3. QUALITY POLICY STATEMENT:

3.1. NMS Labs pledges to provide the highest level of confidence in performance accuracy and quality testing by proactively and collaboratively designing, implementing, and monitoring systems that meet patient and customer needs, compliance requirements, and corporate goals.

## 4. CORPORATE CORE VALUES:

4.1. NMS Labs management is committed to sustainable services to clients and continual compliance with all International (ISO/IEC 15189, ISO/IEC 17025), federal (CLIA, DEA), state (applicable State Departments of Health) and accrediting body (CAP-LAP, ABFT, ANAB) requirements that regulate the type of work performed by NMS Labs at any of its sites. In order to achieve these commitments, we have set forth the following Core Values:

4.1.1. Quality
4.1.2. Integrity
4.1.3. Service

4.1.4. Innovation
4.1.5. Community

4.2. These Core Values will drive the day-to-day operations and long-term business plans to guarantee longevity and growth of NMS Labs. These Core Values will have pre-determined measurements assigned so that progress towards the goals is visible and improvement activities are initiated as needed. Improvement activities will be evaluated for the effectiveness of solutions, and where necessary will be changed to mitigate any risks that were intended to be addressed.

4.3. Under the applicable Core Values, department objectives (direct and indirect) are aligned to support and measure our performance. The indicators will be identified by the department managers and updated as needed. Select quality indicators will be incorporated into the Quality Management Review process as applicable. On a regular basis each department will report to senior management on the health of their individual department operation, having data to support any deviation or trend away from the goals and quality policy.

**5. GENERAL REQUIREMENTS:**

5.1. The following quality system essentials comprise the Quality Management System and are provided as an overview. Within each essential are the high-level quality statements about how NMS Labs will address each essential. Specific operational Standard Operating Procedures (SOPs) may be listed which drive the process by further defining specific practices.

5.2. **Impartiality**

5.2.1. NMS Labs laboratory activities are impartial and are structured and managed so as to safeguard impartiality.

5.2.2. Policies and SOPs exist for avoiding involvement in any activities that would diminish confidence in management's competence, impartiality, judgment or operational integrity ensuring no commercial, financial, political or other pressures compromise impartiality or the quality of work. Such policies are documented in Document 34259 NMS Labs Employee Handbook and a link to the document is located on the NMS Intranet page. Should such conflicts occur, personnel are required to communicate with the appropriate level of Management such that the situation can be remediated.

5.2.3. All employees will treat testing and reporting fairly, objectively, and unambiguously without regard to outside influences. Patient/subject welfare and interest are always the first consideration and take precedence.

5.2.4. If a risk to impartiality is identified, a review will be conducted to ensure that proper corrective action is taken and, if necessary, appropriate disciplinary action is enforced. See Document 34259 NMS Labs Employee Handbook.

5.3. **Confidentiality**

5.3.1. Personnel, including contractors, personnel of external bodies, or individuals acting on the laboratory's behalf will keep confidential all information obtained or created during the performance of laboratory activities, except as required by law. Refer to SOP 10910 HIPAA Compliance Plan – Privacy Standards, SOP 10914 Corporate Compliance Plan, SOP 10529 Information Inquiries, SOP 10505 Confidentiality and Third Party Authorization and SOP 10655 Client Communications.

5.3.2. Results of laboratory examinations are confidential unless disclosure is authorized and are handled as such (refer to SOP 10529 Information Inquiries). Results are only reported to the NMS client requesting the analysis or as required by law. Results that have been de-identified may be used for quality management or statistical purposes without authorization, unless specifically prohibited by contractual obligations.

5.3.3. As detailed in SOP 10505 Confidentiality and Third Party Authorization, the appropriate NMS Labs personnel will cooperate with customers and their representatives to determine the appropriate tests, work product, and results to ensure the confidentiality and quality of the test results. When the laboratory is required by law or authorized by contractual arrangements to release confidential information, the customer or individual concerned will, unless prohibited by law, be notified of the information provided.

5.3.4. Information about the customer obtained from sources other than the customer (e.g., complainant, regulators) will be confidential between the customer and the laboratory. The provider (source) of this information will be confidential to the laboratory and will not be shared with the customer, unless agreed by the source.

5.4. **Ethics and Data Integrity**

5.4.1. All NMS Labs staff will be trained annually in the contents of “Guiding Principles of Professional Responsibility for Forensic Science Providers and Forensic Personnel”, or an equivalent document, and will embrace and apply the principles learned to their daily work. Documentation of training is maintained. Conformance with these principles is determined through external assessments, testimony monitoring feedback, peer-review, and/or annual competency reviews including but not limited to observations gleaned through normal work performance, etc.

5.4.2. All employees who actively participate in the generation of a test result will be responsible for their part of ensuring data integrity. Data integrity is defined as generating, transforming, maintaining and assuring the accuracy,

completeness and consistency of data for a sample over its entire life cycle in compliance with applicable regulations. All laboratory examinations will be carried out according to established procedures. Fabrication of results is unacceptable.

5.4.3. NMS Labs will collect adequate information for the proper identification of the sample to enable the requested laboratory procedures to be carried out but will not collect unnecessary personal information.

5.4.4. Laboratory personnel are responsible to recognize and take action if a sample arrives for testing in a condition that is unsuitable for the requested examination. Actions may include canceling the test, contacting the client, or adding a disclaimer to the report.

5.4.5. In addition to accurate reporting of results, it is NMS Labs' responsibility to ensure, as best as possible, that results are correctly interpreted by providing specific reference/interpretive information either on the report form or via specialist advice.

5.4.6. NMS does not enter into financial arrangements directly with the physician such that independent assessment of what is best for the patient is jeopardized.

5.4.7. Conflicts of interest are avoided where possible. If not possible, full disclosure to the appropriate management are made and steps taken to minimize the impact and/or perceived bias. At the time a potential conflict is identified, all work in the case must be appropriately handled. Documentation of all actions is required.

## 6. STRUCTURAL REQUIREMENTS AND ORGANIZATION:

### 6.1. Organization Structure and Job Descriptions

6.1.1. The NMS Labs Organizational Chart (Org Chart) defines the organization and management structure of the laboratory, its place in the NMS Labs Corporate operations, and the relationships between management, technical operations, quality assurance, and support services.

6.1.2. This structure is organized such that the Quality Assurance Department (QA) functions independent of Operations and that there is sufficient management staffing to provide appropriate oversight and carry out the mission and vision of NMS Labs.

6.1.3. Management will ensure that a current organizational chart is available and details the operational and reporting structure of the company. Human Resources department is responsible for maintaining and updating the Organizational Chart. Refer to the current Organizational Chart for specifics.

6.1.4. Job Descriptions, along with the organization chart, specify the responsibility, authority and interrelationship of all personnel who manage, perform, or verify work affecting the results of laboratory activities.

6.1.5. NMS Labs is legally responsible for its laboratory activities.

6.1.6. For an absence in a management position, another qualified person may temporarily take over responsibilities, as applicable.

6.1.6.1. These designations will be effectively communicated.

6.2. **Management types and responsibilities:**

6.2.1. **Executive Management** at NMS Labs is defined as members of the Executive Team who are responsible for the direction of the company and implementation of the Quality Management System (CEO, Senior Vice Presidents, and Laboratory Director(s)). This includes the management of staff and liaising with internal and external clients.

6.2.2. **Executive Management will:**

6.2.2.1. Ensure that the laboratory environment does not adversely affect the integrity of the sample or the quality of the result.

6.2.2.2. Ensure that qualified and competent managers are assigned to key functions of company operations to facilitate attainment of the quality policy and corporate goals.

6.2.2.3. Ensure that physical spaces are designed for efficiency of operations such that risk of injury and occupational illness of employees are minimized in an environment suitable for the tasks carried out.

6.2.2.4. Provide guidance on the direction of the business based on customer needs and industry trends.

6.2.2.5. Assign responsibility for maintenance of the Quality Management System to designated individual(s).

6.2.2.6. Ensure that a documented annual budgeting process is in effect such that appropriate resources are available to handle the projected workload and provide the necessary Quality Management tools to monitor process improvements.

6.2.2.7. Approve and authorize changes to SOPs, as applicable.

6.2.2.8. Ensure that personnel, resources, facilities, equipment, materials and methods are of a high quality and available as scheduled in order to meet customer requirements and business agreements.

6.2.2.9. Ensure personnel are properly trained by qualified individuals and training is documented.

6.2.2.10. Ensure that job responsibilities are specified and documented and that personnel report only to one supervisor at a time.

6.2.2.11. Direct activities in a planned and systematic approach that is intended to monitor the quality and appropriateness of services and identify risks to success.

6.2.2.12. Involve all company personnel in the quality process.

6.2.2.13. Ensure that all laboratory operations, both current and proposed, are in conformance with applicable regulatory requirements. This includes notifying the appropriate regulatory agencies when there is a change in laboratory test menu, location, ownership, or directorship. Notification to the College of American Pathologists (CAP) must occur no later than 30 days prior to the

change(s) or, in the case of unexpected changes, no later than 2 working days afterwards.

6.2.2.14. Promptly notify the respective agency if NMS Labs is the subject of an investigation by a state or federal agency. NMS Labs will cooperate with all external investigations.

6.2.2.15. Promptly notify appropriate agencies of significant quality issues, adverse media attention, or complaint investigations. Notification must occur within 2 working days for CAP.

6.2.2.16. Notify appropriate agencies when laboratory personnel actions are identified that violate national, state, local regulations that concern the integrity of the individual, the test results or NMS Labs.

6.2.2.17. Promptly notify CAP if NMS Labs is the subject of a validation inspection for a substantial allegation of noncompliance.

6.2.2.18. Provide an inspection team comparable in size and scope to the CAP team if requested by CAP.

6.3. **Laboratory Directors of Record**

6.3.1. The Laboratory Directors are responsible for administering the day-to-day technical and quality/regulatory compliance management of the laboratory environment and maintenance of accreditations. The following is a brief summary of these responsibilities:

6.3.2. The responsibilities of the Laboratory Director of Record are defined by individual regulating bodies. NMS Labs adheres to the most stringent of such responsibilities.

6.3.3. The Laboratory Director of Record is the senior qualified scientific individual that is responsible for laboratory performance and the laboratory quality management system as defined by each applicable regulatory agency.

6.3.4. Duties will be carried out directly or by written delegation to qualified individuals, to ensure regulatory compliance and adherence to this Quality Policy Manual.

6.3.5. Ensure that the personnel employed by the laboratory are competent to carry out their assigned tasks. Technical personnel must qualify under the most stringent requirements of the regulatory agencies.

6.3.6. Ensure that each procedure in the laboratory is designed to yield results of optimum accuracy, precision, efficiency, and medical utility. Each new procedure will be validated and fully documented as per NMS SOP before use, reviewed at minimum every two years and signed by the Laboratory Director or designee, as applicable. Legacy methods prior to 2/95 may not have data consistent with this current standard.

6.3.7. Ensure, either directly or through SOP or designee, that equipment and instrumentation used in the laboratory are properly maintained on a regular schedule according to manufacturer's operation manuals, and all critical functions periodically tested to ensure optimum performance and safety.

6.3.8. Ensure that there are systems to facilitate sample integrity, the reliability of reports, and responsiveness to the needs of the client.
6.3.9. Ensure that the laboratory is properly maintained to provide a safe environment for employees, visitors, and the surrounding community. The activities of the NMS Safety Committee (referred to in SOP 10909 Safety Manual) will facilitate this requirement.
6.3.10. Ensure that the collection, preparation, and transportation requirements for laboratory specimens and samples are defined, clearly and accurately conveyed to clients, and strictly adhered to in the laboratory to support a high standard of quality in the delivery of meaningful medical and forensic information.
6.3.11. Ensure that the laboratory has proper mechanisms to report results to clients that are clear and of general utility.
6.3.12. Oversee the appropriate notification of disclosable events.

6.4. **Technical Management includes:**
6.4.1. Assistant Laboratory Directors (ALDs), Directors, Managers, Supervisors, Technical Team Leaders, and Technical Trainers, who are responsible for the implementation of the day-to-day business operations and for compliance to regulatory and accreditation requirements.
6.4.2. Technical Management's responsibilities include quality assurance, quality control, training, testing improvements, and systems improvements. Staff will be appropriately trained on relevant procedures.
6.4.3. **Technical Management is responsible for:**
6.4.3.1. Implementation and on-going maintenance of departmental technical/operational procedures and requests for the approval/purchase of new instrumentation/technology,
6.4.3.2. Working with other managers and supervisory personnel within the organization to ensure smooth operational workflow and attainment of the corporate goals,
6.4.3.3. Ensuring that laboratory operations are effectively separated from administrative operations with appropriate levels of controlled access to protect samples and resources, and
6.4.3.4. Ensuring that work areas are safe, clean, and well-maintained, that hazardous materials are stored/disposed safely, and the staff is appropriately trained on relevant procedures.

6.5. **Quality Management** of the Laboratory is the responsibility of the Quality Assurance Department. The Quality Assurance Department has two units: Regulatory and Compliance. The Regulatory unit monitors and researches external governing statutes, standards and policies to translate the requirements to SOPs for NMS Labs. The Compliance unit is responsible for ensuring NMS Labs is compliant with requirements specified by respective licensing, accrediting and regulatory agencies.

6.5.1. **Quality Management is responsible for promulgating technical and administrative policies regarding, but not limited to,**

6.5.1.1. Agency checklist requirements
6.5.1.2. Shipping infectious or diagnostic materials
6.5.1.3. Personnel qualifications
6.5.1.4. Retention of specimens and records
6.5.1.5. Hazardous waste disposal
6.5.1.6. Fire codes
6.5.1.7. Medical Examiner or coroner expectations
6.5.1.8. Legal testing
6.5.1.9. Acceptance of specimens/samples only from authorized personnel
6.5.1.10. Handling controlled substances
6.5.1.11. Patient consent for testing
6.5.1.12. Confidentiality of test results
6.5.1.13. Reporting of specific test results to the appropriate agencies
6.5.1.14. Conformance with the requirements of accreditation agencies regarding the use of accreditation symbols and claims of accreditation status
6.5.1.15. FDA Adverse Event Reporting
6.5.1.16. Assurance that the Quality Management System is appropriately documented, maintained in a current state and meets regulatory compliance with all regulating entities of NMS Labs.
6.5.1.17. Assurance that the Quality Policy Manual is maintained, updated, reviewed and approved by the Laboratory Directors of Record.

6.6. **Personnel**

6.6.1. **All Personnel**

6.6.1.1. NMS Labs is an Equal Employment Opportunity employer and follows the federally mandated requirements. See Document 34259 NMS Labs Employee Handbook for specific requirements and details on personnel policies.
6.6.1.2. Human Resources is responsible for managing the recruitment and hiring of all employees.
6.6.1.3. Job qualifications will be based on the most stringent requirements of the regulatory agencies.
6.6.1.4. Management will communicate to personnel their duties, responsibilities, and authorities through the review of their Job Description. The laboratory will document the competency requirements, the duties, and responsibilities of laboratory personnel in job descriptions and/or training plans. The job description will include education, qualification, training, technical knowledge, skills and experience. Employees will acknowledge their understanding of their job by signing/dating their respective job description(s). Job descriptions will be retained in the respective employee training files.

6.6.1.5. All employees must be appropriately trained in their job prior to functioning independently. See SOP 11397 Personnel Training and NMS Labs Learning Management Software for documentation. Training will occur for both trainers and new employees. Training will be provided when new procedures are implemented, when procedures are changed and when training needs are identified. Such training must be documented.

6.6.1.6. Training will be provided as required and relevant authorizations will be documented. Training programs are designed to cover the relevant knowledge and performance elements of each aspect of job responsibility and ensure the competence of the analyst.

6.6.1.7. Continuing education (CE) will be made available to employees, as applicable. Continuing education can be either individual or group and both internal and external. See SOP 10860 Employee Continuing Education for details on the structure of the CE program. Continuing education will be required for some staff and optional for others depending on regulatory requirements. The continuing education series is intended to engage the staff in scientific discussion as applicable to the topic. Continuing education attendance will be documented in employee training files. The documentation will be maintained as a training record in Learning Management Software and will follow the training record retention schedule. Laboratory management must provide the opportunity to comply with these requirements. NMS Labs maintains reference materials in both printed and electronic format for employee continuing education.

6.6.1.8. Personnel will participate in professional development or other professional liaison activities as applicable to the job they perform. Professional development activities may/may not be subsidized by NMS Labs with preapproval notification.

6.6.1.9. Performance reviews must be conducted at a minimum annually and signed by both the employee and his/her supervisor. Performance reviews will ensure that personnel are supervised, performing their duties, and that they are working within the laboratory's quality management system.

6.6.1.10. All staff shares the authority and responsibility for the Quality Management System and identifying non-compliances and possible improvements and recording these instances. Refer to SOP 10950 Nonconformities Assessment Program and SOP 10952 Continual Improvement.

6.6.2. **Technical Personnel**

6.6.2.1. All Technical Personnel will familiarize themselves with relevant standards and procedures as they apply to their job responsibilities and will implement and comply with applicable policies and procedures at all times.

6.6.2.2. Following appropriate training, the competence of each person to perform assigned supervisory or technical tasks according to established criteria is assessed and documented. See SOP 11397 Personnel Training for specifics.

6.6.2.2.1. Competency re-assessment will be monitored periodically and documented. Retraining will occur as necessary.

6.6.2.2.2. Competency tests for supervisory and technical personnel will be successfully completed prior to assuming unsupervised casework or new technical duties and will cover the spectrum of anticipated activities related to the test performed.

6.6.2.3. The Laboratory will authorize personnel to perform specific laboratory activities, including but not limited to the following: the use of equipment; the development, modification, verification and validation of methods; analysis of results, including statements of conformity or opinions and interpretations; and report, review and authorization of results.

6.6.2.4. Personnel who review and authorize results, an opinion or an interpretation or perform technical review of results or testimony, will be evaluated for competency prior to performing these tasks. These persons will be proficiency tested to the extent of their duties and, if performing testing from states requiring licensure for analysis, must obtain a license. See SOP 10615 Testimony Monitoring and Document 22312 Required Documents and Personnel License Instructions.

## 7. FACILITIES, SAFETY AND ENVIRONMENT CONDITIONS:

7.1. NMS Labs has available personnel, facilities, equipment, systems, and support services necessary to manage and perform its laboratory activities.

7.2. The facility will be maintained in a clean and orderly state to provide safe employee access and reliable working conditions without interruption of service to the customer (see SOP 10836 Business Continuity Plan).

7.3. Workflow will be structured such that samples flow easily and safely through the system. Designated environmental conditions will be monitored and controlled such that the quality of test results is not adversely affected (see SOP 10829 Noise Level Monitoring, SOP 10824 Electrical Inspection and Testing Procedures, SOP 10830 Pest Control, SOP 10828 Manual Start for Backup Generator and SOP 10817 Quality Control and Preventive Maintenance of Refrigerators Freezers Ovens and Heat Blocks.

7.4. The Laboratory is designed in such a way as to prevent cross contamination, limit access to authorized individuals, and ensure general good housekeeping with effective separation between areas with incompatible laboratory activities.

7.5. The laboratory and associated office facilities provide an environment suitable for the tasks to be undertaken and to ensure the following conditions are met (see SOP 10872 Security and SOP 10908 Visitor Policy).

7.6. The section Supervisors will have the authority to STOP casework if specified environmental factors are out of range and will only resume when the factors have returned to acceptable ranges.

7.7. The facility is secured, and all samples and associated information are safeguarded from unauthorized access (see SOP 10872 Security, SOP 10853 IFS Access Procedure, and SOP 10910 HIPAA Compliance Plan – Privacy Standards).

**NOTE:** Safety policies must be in writing and must be enforced. A safe workplace will be maintained in order to ensure employee safety. NMS Labs will have a designee who is responsible for implementing a health and safety program which conforms with the regulations of the pertinent federal, state and local health and safety authorities and NMS' SOPs. See SOP 10909 Safety Manual, SOP 10880 Chemical Hygiene and SOP 10875 Bloodborne Pathogen Exposure Control Plan for details.

## 8. EXTERNAL PRODUCTS AND SERVICES:

8.1. The Purchasing department has defined and documented its policies and procedures for the selection and use of purchased external services, equipment and consumable supplies that affect the quality of the results. Purchased items should consistently meet the laboratory's quality requirements. See SOP 10489 Purchasing Procedures – Capital Equipment and SOP 10490 Purchasing Procedures – Lab Supplies and Services.

8.2. Vendors are approved initially and ongoing as needed, and documentation of the evaluation is maintained. See SOP 10485 New Vendor Approval Process and SOP 10492 Vendor Evaluation Process. A list of approved vendors will be maintained by the Purchasing Department.

8.3. Critical supplies and services will be identified, and arrangements made with each vendor to ensure timeliness of delivery and uninterrupted supply/service. Standing orders are defined, as necessary. See SOP 10490 Purchasing Procedures – Laboratory Supplies and Services. The quality of the product needed is defined by appropriate lab staff and communicated to Purchasing at the time of order.

8.4. Purchasing and the end user will determine vendor qualification with the assistance of QA as needed. See SOPs 10485 New Vendor Approval Process, 10492 Vendor Evaluation Process, 10814 Pipette Calibrations, 11017 Preparation of Analytical Standards, 10647 Performance Verification and Calibration of Mettler Toledo Benchtop Balances, and 10645 Performance Verification and Calibration of Calipers.

8.5. Special services and handling of supplies that will be shipped to clients will be communicated to the appropriate staff.

8.6. All supplies will be received, inspected, accepted/rejected, and stored appropriately. When supply chains cannot keep up demand, all possible avenues to obtain the item(s) will be exhausted and Management will conduct a risk assessment to determine the best action. See SOP 10491 Receiving, Inspection and Stocking of Supplies and SOP 10490 Purchasing Procedures – Lab Supplies and Services.

8.7. Materials that affect the quality of tests will be tested by an appropriate department to determine if they meet technical specifications, and appropriate records will be maintained, if applicable.
8.8. NMS Labs will select providers that can accommodate the acceptance criteria needed, as appropriate.
8.9. Testing may be referred to other laboratories. See SOP 10960 Reference Laboratory - Evaluation and Use for details.

## 9. EQUIPMENT:

9.1. **General**

9.1.1. NMS Labs personnel will have the required equipment for the correct performance of tests. Each item of equipment will be operated by authorized personnel, and when practicable, uniquely identified. The laboratory has procedures for safe handling, transport, storage, use and planned maintenance of measuring equipment to ensure proper functioning and in order to prevent contamination or deterioration. Test equipment, including both hardware and software, will be safeguarded from adjustments which would invalidate the test and/or calibration results.
9.1.2. Laboratory equipment will be selected based on the specifications generated by the department, the quality of the product, and the relationship with the vendor. All equipment selections must be justified, in writing, to ensure the appropriate purchase. All appropriate management must approve major equipment purchases.
9.1.3. Whenever practicable, all equipment under the control of the laboratory will be labeled, coded or otherwise identified. The period of validity or calibration for applicable equipment will be readily available to the user.
9.1.4. Equipment that affects the accuracy and quality of the results meet the following requirements:
9.1.4.1. Equipment installations will be coordinated with the appropriate internal resources. See SOPs 11070 Equipment Use and Maintenance and SOP 10716 Lab Site Prep Instrument and Equipment for details.
9.1.4.2. Equipment should be installed, calibrated, maintained, and used in accordance with the manufacturer's instructions. Calibration specified requirements for the calibration, the interval of calibration, operation procedures will be in writing and will be available to the staff as a reference in addition to the instrument manufacturer's manual(s) and used in metrological traceability, as applicable. See SOP 11070 Equipment Use and Maintenance and respective technical department instrument SOPs for details. Deviations from the Manufacturer operating manual must be documented and validated.
9.1.4.3. Equipment will be appropriately qualified when initially used and when returned to service. The equipment must be deemed suitable for use prior to reporting results on samples. See SOP 10920 Analytical Instrument Qualification.
9.1.4.4. All regulatory requirements for laboratory equipment must be followed.

9.1.4.5. Equipment maintenance will be appropriately documented and reviewed at specified intervals.

9.1.4.6. Identified key equipment will be maintained during power disruptions through use of a generator back-up and/or UPS such that data is not lost, or sample integrity compromised. The generator is tested weekly to assure functionality. See SOP 10836 Business Continuity Plan.

9.1.5. Prepared reagents will be labeled with, at a minimum, the identity of the reagent and the date of preparation or lot number. Records shall be maintained identifying who made the reagent and the components used in preparation. See SOP 10644 Drug Chemistry Reagents or SOP 11129 Reagents - Preparation and Storage.

9.2. **Inventory**

9.2.1. Inventories will be maintained at a volume and frequency to ensure uninterrupted workflow in the laboratory and administrative areas.

9.2.2. Inventory will be maintained under appropriate storage conditions so as to not affect integrity. For consumables, follow manufacturer storage instructions. For Core reagents, see SOP 11129 Reagents - Preparation and Storage for guidance. For Drug Chemistry reagents, see SOP 10644 Drug Chemistry Reagents.

9.2.3. An expired inventory may not be used unless allowed by an SOP/method and with appropriate testing performed and documented.

9.2.4. Drug Chemistry maintains a current inventory of supplies, chemicals, and materials. See I:/Lab Operations IFS/ Chemical Inventory or /Equipment Inventory.

9.3. **Traceability**

9.3.1. Metrological traceability is a documented unbroken chain of calibrations, each contributing to the measurement uncertainty, and linked to an appropriate reference.

9.3.2. All reported weight measurements will comply with SOP 10647 Performance Verification and Calibration of Mettler Toledo Benchtop Balances to report traceable results.

9.3.3. Designated pipettes and syringes used for quantitative methods will comply with SOP 10814 Pipette Calibration.

9.3.4. Analytical standards should be prepared from certified reference material provided by a competent vendor, if such material is available. The Purchasing Department will verify annually during the evaluation process that the vendor continues to maintain the required qualifications and/or certifications. See SOP 11017 Preparation of Analytical Standards.

9.3.5. Balances utilized to weigh certified reference material will comply with SOP 10821 Verification and Preventive Maintenance for Analytical Balances and Mass Weights.

9.3.6. NMS Labs measuring equipment (Pipettes, syringes, and volumetric glassware) utilized to modify certified reference materials will be documented to establish appropriate traceability.
9.3.7. Traceability documentation of certified reference material and equipment used for preparation of working calibrators are used to establish uncertainty of measurement.
9.3.8. Technical Management is responsible to ensure that appropriate traceability to national standards, where possible, is implemented.

## 10. PROCESS REQUIREMENTS:

10.1. **Selection, Verification, and Validation of Methods**

10.1.1. NMS Labs will use appropriate methods and procedures for all laboratory activities. Comprehensive and current analytical methods are maintained in order for work to be performed consistently and expeditiously. Methods for each department may be found in document control in the compliance software.
10.1.2. Evaluation of the measurement uncertainty and statistical techniques for analysis of data will be appropriately applied as needed. All test methods that involve the comparison of an unknown to a known will require the evaluation of the unknown item(s) to identify characteristics suitable for comparison.
10.1.3. When method development is required, this will be a planned activity and will be assigned to competent and authorized personnel equipped with adequate resources. As method development proceeds, periodic review will be carried out to confirm that the needs of the customer are still being fulfilled. Any modifications to the development plan will be approved and authorized. See SOP 10942 Method Validation for Quantitative Bioanalytical Testing Procedures.
10.1.4. NMS Labs will validate standard methods, non-standard methods, laboratory-developed methods and standard methods used outside their intended scope or otherwise modified. The validation will be as extensive as is necessary to meet the needs of the given application or field of application, as determined by the Laboratory Director or ALD.
10.1.5. All routine test procedures (analytical methods) will be appropriately validated and approved prior to issue of results. See SOP 10942 Method Validation for Quantitative Bioanalytical Testing Procedures, SOP 10944 Method Validation for Reportable Qualitative Bioanalytical Testing Procedures, SOP 28974 Drug Chemistry Method Validation and Instrument Qualification, and SOP 10634 GC/MS Database Updates.
10.1.6. Validation summary data will be provided to clients upon written request. All requests will be handled by the QA Department.

10.2. **Review of Requests, Tenders and Contracts**

10.2.1. The appropriate NMS Labs personnel will conduct reviews of requests, tenders and contracts. This includes formal business contracts for analytical services involving Sales, as well as individual requests documented on test submission requisitions. Business contracts will be generated and maintained by the Marketing and Sales departments and will define the specific services provided, the process for generating a contract and any actions to be taken if the contract cannot be fulfilled or needs amending, as applicable. See SOP 10832 Bid Review and Processing.

10.2.2. Each request (requisition) form accepted by the laboratory for examination is considered an agreement with the client. The information on the request form must be sufficiently clear to delineate the testing to be performed.

10.2.2.1. If the information on the request form is unclear, unspecified, unsuitable, or out of date, the order will be clarified upon receipt and the client contacted to address the discrepancies. Testing will only be performed with a specific directive from the client. See SOP 10966 Clarify Procedures, SOP 10500 ClarifyMQ Report and SOP 10625 Evidence Handling.

10.2.3. All communications and directives with the client will be documented in the appropriate Phone Logs for future reference.

10.2.4. Substantial delays in testing turnaround time commitments will be communicated directly with the client.

10.2.5. Any differences between the request or tender and the contract will be resolved before laboratory activities commence. Each contract will be acceptable both to the laboratory and the customer. Deviations requested by the customer must not impact the integrity of the laboratory or the validity of the results.

10.3. **Pre-examination Procedures**

10.3.1. NMS documents its procedures to the extent necessary to ensure the consistent application of its laboratory activities and the validity of the results. Procedures are located electronically in the compliance software.

10.3.2. A comprehensive Directory of Services is maintained and available to clients on the NMS website at www.nmslabs.com. Updates to the NMS Test Catalog will be communicated to clients in an appropriate manner and timeframe.

10.3.3. An appropriate process must be implemented at all times to prevent sample mix-up, to ensure agreed upon turn-around time commitments and protect the integrity of the test sample(s).

10.4. **Handling of Test Items**

10.4.1. NMS Labs has procedures for the transportation, receipt, unique identification, handling, protection, retention, and disposal or return of test items, including all provisions necessary to protect the integrity of the test item, and to protect the interests of the laboratory and the customer. Precautions are taken to avoid deterioration, contamination, loss or damage to the item during handling, transporting, storing/waiting, and preparation for testing. Handling

instructions provided with the item should be followed. See SOPs 10625 Evidence Handling (for Criminalistics evidence), 10979 Specimen Processing Accessioning, 10519 Specimen Storage Retention Handling, 10984 Specimen Storage (SpecStor) Program, and SOP 11139 Sample Handling Techniques.

10.5. **Sampling in the Drug Identification Unit**

10.5.1. NMS Labs has a sampling plan and method when it carries out sampling of substances, materials or products for subsequent testing or calibration. The sampling method addresses the factors to be controlled to ensure the validity of subsequent testing or calibration results. The sampling plan and method is available at the site where sampling is undertaken. Sampling plans, whenever reasonable, are based on appropriate statistical methods. See Chemistry Methods 32260 CLD-001 Protocols for Controlled Substances Sampling, Testing, and Reporting for Law Enforcement Agencies.

10.6. **Post Examination Procedures**

10.6.1. There are procedures for the technical review of technical records, including reports, and testimony, as applicable.

10.6.2. All clinical and forensic toxicology data generated are reviewed in accordance with the appropriate SOP by a calculating analyst and secondarily reviewed by a different independent analyst prior to release. All reviews are documented. See specific technical department data calculation and review SOPs for details.

10.6.2.1. An additional review by a toxicologist to provide a professional opinion may take place if requested by a client or by the scope of the testing performed. See SOP 11082 Forensic Sample Flow Case Documentation and Review Practices - Toxicology.

10.6.3. All Forensic Chemistry data are reviewed in accordance with SOP 11659 Case Documentation and Review Practices.

10.7. **Ensuring the Validity of Results**

10.7.1. NMS Labs ensures the quality of the examination procedures by following appropriate SOPs/Methods. All staff are adequately trained, and proficiency tested, as applicable. NMS Labs has a comprehensive Quality Management System and Quality Control Program in place to ensure all appropriate regulatory standards are followed.

10.7.2. A comprehensive Quality Control Program is in writing with acceptance criteria defined. Quality control data must be used to accept/reject analytical run data. All quality control data must be documented and reviewed regularly for trends/biases and documented when investigations are initiated, as appropriate. See SOP 11086 In-Process Quality Control for Clinical and Forensic Testing.

10.7.3. Method specific acceptance criteria that differ from the established QC program will be defined in the respective analytical method. Method specific QC acceptance criteria will supersede the general QC policy.

10.7.4. The External Proficiency programs cover, where possible, the scope of routine testing in order to verify the accuracy of tests and the associated processes.

10.7.5. Internal Proficiency testing (Blinds Program) will supplement the External programs. Management must review all proficiency data (in detail or in summary), corrective actions must be initiated where necessary, and documentation retained for an appropriate time period. See SOP 10957 Proficiency Testing Program External Quality Control and SOP 10916 Alternate Assessment Internal Quality Control for details.

10.7.6. The performance of personnel is monitored to ensure that all personnel who influence the results of testing successfully complete at least one intralaboratory comparison, interlaboratory comparison or proficiency test per calendar year in each discipline on the scope of accreditation in which the individual conducts work. See SOP 10957 Proficiency Testing Program External Quality Control.

10.8. **Measurement Uncertainty**

10.8.1. Estimation of measurement uncertainty is an element of traceable quantitative measurement and a requirement for ISO/IEC 17025/15189 accreditations.

10.8.2. Procedures to estimate the uncertainty of measurement will be documented and available as needed or upon request. See SOP 10934 Determination of Uncertainty of Measurement for specifics.

10.8.3. The Laboratory Director will determine if, when and how the Uncertainty of Measurement calculation is to be reported. A client may always request that Uncertainty of Measurement be included on their respective reports.

10.8.4. At a minimum, Uncertainty of Measurement is applicable when it impacts evaluation of a specification limit as stated by a regulatory body, a statute, case law or other legal requirement enforced by someone external to the laboratory.

10.8.5. NMS Labs has identified the contributions to measurement uncertainty. When evaluating measurement uncertainty, all contributions that are of significance are taken into account using appropriate methods of analysis.

10.8.6. Measurement uncertainty is evaluated, or estimated, when applicable for reported quantitative results. See SOP 10848 Determination of Uncertainty of Measurement for Weights and SOP 10934 Determination of Uncertainty of Measurement.

10.8.7. Reference standard purity will be part of the Uncertainty of Measurement calculation, as applicable. Reference analytical standards should be purchased from a competent vendor if possible, and these products must be carefully chosen to be NIST-traceable or standards with a Certificate of Analysis taking priority. Analytical standards will be appropriately maintained

to prevent deterioration. Refer to SOP 11017 Preparation of Analytical Standards for requirements for analytical standards and competent vendors.

10.9. **Toxicology Consultation Services**

10.9.1. Toxicology consultation services are available to customers during regular business hours.

10.9.2. Customers have daily access to a staff of Toxicologists to assist with questions that are outside the scope of the Customer Support Services department.

10.9.2.1. Toxicology consultations offer advice and guidance in technical matters, opinions and interpretations based on test results and recommendations on the appropriate testing to perform based on case history and customer needs.

10.9.3. Toxicology workorder specific consultation notes are captured in the Phone Log Notes.

## 11. REPORTING OF RESULTS:

11.1. General

11.1.1. Test results will be provided promptly, accurately, clearly, unambiguously and objectively in a report. The report will include all the information agreed upon with the customer and information necessary, when available, for the interpretation of the results. Results will be reported only to the authorized person or organization that requested the testing unless obligated by law.

11.1.2. The results are reviewed and authorized prior to release. See appropriate SOPs for review processes.

11.1.3. Proper case review of analytical data must be documented when a report is generated by a person who did not perform the examinations.

11.1.4. A report will be prepared for all testing conducted and will be issued to the client.

11.1.5. Final report format must be approved by the Laboratory Director or designee.

11.1.6. The following SOPs govern the reporting of results and required elements: SOP 11077 Final Report Formatting, SOP 10786 Reporting of Forensic Toxicological Cases, and Method 32260 CLD-001 Protocols for Controlled Substances Sampling, Testing, and Reporting for Law Enforcement Agencies.

11.1.7. When agreed with the customer, the results may be reported in a simplified way which may differ from standard report formatting (e.g., electronic interface). Any required information that is not reported to the customer in the simplified report will be readily available. Reporting will be done via a secure format either via Webportal, Electronic Data Interface, encrypted email or by US mail. Electronic copies of final reports will be retained to be retrieved upon request.

11.1.8. When no definitive conclusions can be reached (e.g., results are “inconclusive”), the reason will be clearly stated, as applicable.

11.1.9. All final reports will be uniquely identified by a workorder or case number.

11.1.10. All issued reports are retained as technical records.

11.1.11. Results that are corrected or amended must be clearly marked as such.
11.1.12. NMS Labs is responsible for all the information provided in the report, except when information is provided by the customer or send out laboratory.
11.2. Reporting Opinions and Interpretations
11.2.1. NMS Labs will ensure that only personnel authorized for the expression of opinions and interpretations release the respective statement. The report will state that opinions and interpretations have been made.
11.2.2. When opinions and interpretations are directly communicated by dialogue with the customer, a record of the dialogue will be retained in the LIMS communication log.

## 12. INFORMATION MANAGEMENT:

12.1. **Document Control**

12.1.1. NMS Labs has established and will maintain procedures to control internal documents that are under its direct control, and to incorporate external documents that are not under its direct control, so that the combinations of both internal and external documents comprise the Quality Management System at NMS Labs. These documents will provide regulatory guidance and structure to operations surrounding all laboratory technical and related processes associated with the generation of a test result. In this context, “document“ is any: operational SOP document created under SOP 9951 Document Control and Standard Operating Procedures, analytical method SOPs created under SOP 10924 Analytical Methods Format Maintenance and Training, the NMS Test Directory, and external regulatory standards and checklists as provided by the respective regulatory agency. Refer to SOP 9951 Document Control and Standard Operating Procedures for details of the scope of control and a listing of those documents that will be controlled.
12.1.2. Analytical methods and operational SOPs will be uniformly structured, uniquely identified and version controlled to track necessary changes and ensure that the current version is in use.
12.1.3. All controlled documents will be uniquely identified, secured from unauthorized changes, and reviewed on a regular basis as determined by regulatory requirements, with updates performed as necessary. All version changes will be disseminated to the appropriate NMS staff for review and training. Documentation of review and training on the applicable SOP changes will be maintained in the training files.
12.1.4. Retired versions of controlled documents will be archived for an appropriate period of time as defined by the respective regulatory requirements.
12.1.5. Record retention will be the longest period required by the respective regulatory agencies and legal requirements. Record retention timeframes and archiving system must be in writing. See Record Retention Matrix located at i:/Record Retention. This list will be periodically reviewed and updated to conform to changes in retention requirements. See SOP 10891 Records Retention

Storage and Retrieval for details. Records may be in paper or electronic format.

12.1.6. Paper records that exceed the defined storage period will be destroyed appropriately to protect the confidentiality of the information. Such destruction should be documented according to SOP 10891 Records Retention Storage and Retrieval.

12.1.7. Reference materials of applicable regulations, standards and documents are maintained by the Quality Assurance department and updated as necessary. These documents must be readily available to staff.

12.2. **Technical Records**

12.2.1. NMS Labs ensures that technical records for each laboratory activity contain the results, report, and sufficient information to facilitate, if possible, identification of factors affecting the measurement result and its associated measurement uncertainty. Technical Records contain information that enable the repetition of the laboratory activity under conditions as close as possible to the original. The technical records include the date and the identity of personnel responsible for each laboratory activity and for checking data and results. Original observations, data and calculations are recorded at the time they are made and are identifiable with the specific task.

12.2.2. Technical record(s) retention information can be found in the Record Retention Matrix. See I:\Record Retention or in respective SOPs.

12.2.3. Where abbreviations or symbols are used, the meaning of the abbreviations or symbols are defined.

12.2.4. Technical records used to support a report (including results, opinions, and interpretations) are such that, another reviewer possessing the relevant knowledge, skills, and abilities could evaluate what was done and interpret the data. See SOP 11659 Case Documentation and Review Practices and SOP 11082 Forensic Sample Flow, Case Documentation and Review Practices-Toxicology. Technical documents are defined in SOP 11214 Laboratory Definitions.

12.2.5. Records are created or maintained in a permanent manner, as applicable. See SOP 10619 Control and Maintenance of Case Files and SOP 11082 Forensic Sample Flow, Case Documentation and Review Practices-Toxicology.

12.2.6. If an observation, data, or calculation is rejected, the reason, the identity of the individual(s) taking the action and the date is recorded in the technical record. The laboratory will ensure that amendments to technical records are clearly identified and documented. Amendments can be tracked to previous versions or to original observations. Both the original and amended data and files will be retained, including the date of alteration, an indication of the alterations and the personnel responsible for the alterations. NOTE: Contemporaneous revisions are not considered amendments.

12.3. **Control of Information Management Systems**

12.3.1. The NMS Labs information management systems (Horizon/StarLIMS) used for the collection, processing, recording, reporting, storage or retrieval of data are validated for functionality, including the proper functioning of interfaces within the laboratory information management system(s) by the IT Department before introduction and after changes are made. See SOP 10725 IT Testing and Validation, SOP 10690 Horizon Test Code Validation, and SOP 10727 StarLIMS Instrument Interface Software Validation.

12.3.2. When the laboratory information management system is managed and maintained off-site or through an external provider, NMS Labs will ensure that the provider or operator of the system complies with all applicable requirements.

12.3.3. Whenever there are any changes, including laboratory software configuration or modifications to commercial off-the-shelf software, they will be authorized, documented and validated before implementation. See SOP 10728 System Development Life Cycle (SDLC).

12.3.4. The system must be checked after each back-up or restoration of data files in order to ensure that no inadvertent alterations have occurred. System failures detected during system backup must be documented, along with corrective action taken, and reported to Management. See SOP 10708 General Server Backup, SOP 10726 SQL Server Backup Policy and SOP 10722 Restoration and Validation of System Backup Data.

12.3.5. A written procedure and a complete record of all preventive maintenance for all computer hardware will be readily available. See SOP 10734 Computer Hardware/Software Maintenance and Repair for details.

12.3.6. The laboratory information management system(s) will be protected from unauthorized access to safeguard against tampering and loss. Systems are maintained in a manner that ensures the integrity of the data and information. See SOP 10895 Password Policy and SOP 10723 Security Logging Procedures for the NMS Labs LAN & WAN.

12.3.7. In the case of non-computerized systems, NMS Labs provides conditions which safeguard the accuracy of manual recording and transcription.

12.3.8. Test code calculations and data transfers will be checked in an appropriate and systematic manner. The technical record will indicate the check was performed and who performed the check. When possible, this check will not be conducted by the person who performed the calculation(s) or the data transfers.

12.3.9. The Laboratory Director or designee is responsible for the accurate and effective delivery of examination results to the requesting clients and should approve all changes in the computer system that may affect patient care. See SOP 10697 Change Control Policy for Horizon LIMS Database Modifications and SOP 10728 System Development Life Cycle (SDLC).

12.3.10. NMS LABS will ensure that instructions, manuals and reference data relevant to the laboratory information management system(s) are made readily available to personnel. All users of the computer system are taught how to use a new system or modification of the old system. See SOPs 10900 LIMS Training and SOP 10717 Laboratory Information Management System User Guides/Manuals for specifics.

12.3.11. The laboratory has available designated staff to which all significant computer malfunctions are to be promptly reported. Reporting can be accomplished by calling Extension 1300 for immediate emergency notification, or by entering a ticket in Helpdesk, located on the Intranet under IT Support for normal reporting.

## 13. NON-CONFORMING WORK:

### 13.1. General

13.1.1. The QA Department in conjunction with appropriate laboratory personnel will maintain procedures to immediately address when any aspect of its laboratory activities or results of this work do not conform to its own procedures or the agreed requirements of the customer (e.g. equipment or environmental conditions are out of specified limits, results of monitoring fail to meet specified criteria). Software programs are used to track Quality Metrics that are visible and presented to Management. See SOP 10950 Nonconformities Assessment Program for details.

13.1.2. Quality control nonconformances will be recorded immediately in the appropriate control chart.

### 13.2. Incident Management

13.2.1. All nonconformities, not including quality control failures, will begin as incidents and will be logged into the compliance software.

13.2.2. Incidents must be regularly monitored by the respective department management as a tool to improve operations.

13.2.3. Management will be responsible for assuring that appropriate corrective and preventive action is implemented to fix issues.

13.2.4. Changes to SOPs and procedures as necessary must be documented to reinforce such changes.

13.2.5. Training of appropriate staff on the changes must be conducted and documented appropriately in the training files.

### 13.3. Corrective Actions

13.3.1. Reports corrected for technical issues and other significant errors, discrepancies or other deviations automatically require generation of a corrective action. Corrective Actions will be logged into the compliance software as an Incident Report and escalated to a Corrective Action. See SOP 10950

Nonconformities Assessment Program for details. Demographic information changes from a client do not require corrective actions.

13.3.2. The procedure for documenting corrective actions must be a standardized format and data must be electronically retained and available for statistical analysis.

13.3.3. All corrective actions will be reviewed and approved by appropriate management.

13.3.4. Corrective actions will be completed within a reasonable timeframe. The QA Department will monitor the backlog notifying responsible Management as needed. Management will utilize a coding system to summarize the data. Summarized data will be available to Management to analyze for trends.

13.3.5. Management monitors for critical trends that arise from corrective actions and will address trends with the appropriate problem resolution processes and preventive measures.

13.3.6. The QA Department will ensure an appropriate root cause was identified in the corrective action. Effectiveness of corrective /preventive action are evaluated as applicable. When improvement opportunities are identified, action plans will be developed, implemented and monitored to reduce the likelihood that a non-conformity will occur. Significant corrective actions will be reported and reviewed at the next Quality Management Meeting, individually or as trended data.

13.4. **Deviation Requests**

13.4.1. There may be instances when it is appropriate to prospectively deviate from an SOP or analytical method.

13.4.2. All planned deviations from analytical methods and SOPs will be logged into the compliance software Deviation workflow.

13.4.3. This documentation must be generated by the approving ALD.

13.4.4. Documentation will be maintained in the compliance software within the Deviation workflow.

13.4.5. QA Compliance and QA Regulatory will review all planned deviations to monitor for trends.

## 14. QUALITY MANAGEMENT SYSTEM:

14.1. **General**

14.1.1. The Quality Management System will encompass all areas of business operation and will continually review and implement activities designed to prevent errors, reduce risk to the organization and improve quality.

14.1.2. Internal processes will be aligned with the Quality Policy.

14.1.3. Internal processes must be documented and defined in SOPs (see SOP 9951 Document Control and Standard Operating Procedures, and the Quality Manual Table of Contents) for all areas allowing for the structured

management, dissemination and documentation of review of the contents as applicable.

14.1.4. **Business Health**

14.1.5. It is the objective of the Quality Management System to ensure that the analytical testing procedures and reporting of results are monitored by means of quality control (QC) standards, proficiency tests, and audits on a routine basis.

14.1.6. At times of disruptions, NMS Labs strives to continually generate results to its clients. See SOP 10836 Business Continuity Plan.

14.2. **Risks and Opportunities**

14.2.1. NMS Labs will consider the risks and opportunities associated with the laboratory activities in order to ensure that the management system achieves its intended results. See SOP 10950 Nonconformities Assessment Program.

14.2.2. Risk assessment is a systemic process of evaluating the potential risks that may be involved in an activity. It is a combined effort of identification, analysis and evaluation of potential events to determine the action to be taken when appropriate.

14.2.3. NMS Labs will plan actions to address these risks and opportunities, including those related to health and safety; how to integrate and implement these actions into its management system; and to evaluate the effectiveness of these actions.

14.2.4. Actions taken to address risks and opportunities will be proportional to the potential impact on the validity of laboratory results.

14.3. **Internal Audits**

14.3.1. Internal audits are systematic processes for measuring and evaluating the laboratory's conformance to its own requirements for effective implementation and maintenance of the management system, compliance with regulatory requirements, adherence to quality system essentials and customer service operations.

14.3.2. Quality Assurance will ensure that regular internal audits are conducted and documented such that key areas of operations are routinely reviewed. See SOP 10938 Lab Audit Plan for Internal and External Audits for details.

14.3.3. Audits will be under the general direction of the Laboratory Director who will determine which system essentials are critical to achieving quality products and services.

14.4. **External Audits**

14.4.1. Quality Assurance will coordinate all audits by external sources to ensure the needs of the auditors are met in a timely fashion.

14.4.2. Quality Assurance will be responsible for coordinating any follow-up remediation as necessary and within appropriate designated timeframes.

## 15. MANAGEMENT SYSTEM REQUIREMENTS:

15.1. **General**

15.1.1. NMS Labs has a Management System that is capable of supporting and demonstrating the consistent achievement of the accreditation requirements and assuring the quality of the laboratory results.

15.2. **Complaints and Compliments**

15.2.1. NMS Labs has documented processes to receive, evaluate and make decisions on complaints and compliments. See Document 34259 NMS Labs Employee Handbook and SOP 10502 Client Concern/Feedback Documentation Process.

15.2.2. The process for handling complaints is available to any interested party. Upon receipt of a complaint, the laboratory will confirm whether the complaint relates to laboratory activities, and if so, will investigate it.

15.2.3. Any stakeholder (employee, intern, vendor, client) may, at any time, raise a complaint concerning the Quality System. This complaint must be documented appropriately but does not need to denote the originator of the complaint (may be anonymous).

15.3. **Client Satisfaction and Surveys**

15.3.1. The Laboratory will seek feedback, both positive and negative, from its customers. The feedback will be analyzed and used to improve the management system, laboratory activities and customer service. See SOP 10502 Client Concern/Feedback Documentation Process and SOP 10834 Customer Survey.

15.3.2. Client Services, Marketing and Sales are responsible for the determination and measurement of client satisfaction with products and services. This may be in the form of periodic client surveys or regular written or verbal feedback on specific client issues. See SOP 10834 Customer Survey for details on the customer survey process. SOP 10502 Client Concern Feedback Documentation Process

15.3.3. Marketing and Sales will regularly monitor our pricing structure to determine if our prices are competitive within the industry and that our services match the needs of our clients.

15.3.4. Client satisfaction will be regularly communicated with NMS Management to ensure that products and services are appropriate.

15.3.5. Client satisfaction will be continually monitored with the appropriate tools.

15.4. **Staff Suggestions, Complaints, and Concerns**

15.4.1. Management encourages staff to provide suggestions on the improvement of any aspect of the laboratory operations or administrative support areas. All

suggestions are evaluated and implemented as appropriate. See SOP 10952 Continual Improvement.

15.4.2. Staff suggestions are also collected through the use of the Ask the Executives Suggestion Box. All suggestions are addressed by Executive Management, shared during a Town Hall meeting and tracked.

15.4.3. How NMS Labs addresses staff complaints/concerns can be located in Document 34259 NMS Labs Employee Handbook Complaint procedure and Open-Door Policy. All employees are encouraged to speak directly with their supervisor, or if that is not feasible then discussing concerns/complaints with a higher-level manager is encouraged. Human Resources is available to assist with employee complaints/concerns.

15.4.4. In the event of an unresolved disagreement between an employee and their direct manager, the matter will be referred to the next level of management in the department. Either party may additionally seek assistance from a representative from Human Resources, Quality Assurance, and/or Executive Management without undue influence or reprisal if it is felt that the matter is not being satisfactorily addressed. See Document 34259 NMS Labs Employee Handbook for Anti-Discrimination and Anti-Harassment Policy.

15.4.5. Significant clinical patient testing or laboratory safety concerns that are not being addressed within NMS Labs may be reported through the CAP hotline at 866-236-7212 (US Toll Free). The CAP sign is prominently located at NMS Labs.

15.4.6. NMS has established an anonymous hotline number for leaving voice mail messages related to compliance issues 215 - 366 – 1510 or EXT. 1510 which will be monitored regularly. See SOP 10914 Corporate Compliance Plan.

15.5. **Continual Improvement**

15.5.1. NMS Labs Management and personnel will continually improve the effectiveness of its Management System using quality policy, quality objectives, audit results, data analysis, corrective actions, Incident Log entries, and management review.

15.5.2. Preventive activities will be implemented to improve service to customers, reduce internal costs, improve efficiency of processes, and prevent occurrences. These activities may have an impact on results that are released but are not in direct response to corrective actions. Improvement activities are directed at areas of highest priority based on risk assessment.

15.5.3. The preventive action program will be coordinated by the QA Department who will maintain the process.

15.5.4. SOP 10952 Continual Improvement details, data (charting or graphics) and action documentation for pro-active quality improvements. Joint Quality Improvements (JQIs), another tool to positively affect quality, will reside on the quality success metric page in Nucleus where it is accessible to management.

15.5.5. Management will ensure that the laboratory participates in continual improvement activities that encompass relevant areas and outcomes of patient care/testing.

15.5.6. Key indicators that align with the corporate goals will be defined by Management, measured through use of statistical charts, and made available for management staff to monitor progress on a regular basis.

15.5.7. Management sponsored meetings provide a forum to track key deliverables such as test turnaround time, test delays, client concerns, and regulatory and operational issues.

15.5.8. Data will be reviewed at appropriate intervals and mechanisms developed to change processes to improve performance. Responsible persons will be assigned to review data and correct issues.

15.5.9. Statistical tools may be used as appropriate and necessary to measure occurrence information and corresponding improvement. These may be in the form of customized LIMS reports, summarized data or charts/graphs reflecting measured data.

15.5.10. Management will periodically summarize key performance indicators in the form of a dashboard or reports to Executive Management. These reports will utilize existing data (e.g., corrective actions, proficiency testing, potential HIPAA issues, audits, TNPs, client concerns, repeat test rates, etc.) for such purposes.

15.5.11. When the continual improvement program identifies opportunities for improvement, management will address them regardless of where they occur.

15.5.12. Management will communicate to staff improvement plans and related goals (e.g., town hall meetings).

15.6. **Quality Management Reviews**

15.6.1. NMS Labs Management will review its Management System at planned intervals to ensure its continuing suitability, adequacy, and effectiveness, including the stated policies and objectives related to the fulfilment of all regulatory bodies, including and ISO/IEC 17025 and 15189. See SOP 10939 Management Review of Quality Systems.




Dependencies:

**Title: Receiving and Opening in Specimen Processing**

**PURPOSE:** To provide a standardized format for the receipt, processing and handling of specimens in the Processing Department and to ensure that all specimens received at NMS Labs in Specimen Processing are accounted for and processed correctly.

**SCOPE:** This SOP is to be used by NMS-Core Specimen Processing personnel.

**PROCEDURE:**

**1. TYPES OF PACKAGES RECEIVED:**

1.1. NMS courier will pick up a portion of the FedEx packages from the FedEx facility and deliver them to the processing loading dock at approximately 9:00 AM. The courier will return to FedEx and pick up the remaining packages. Approximate arrival time for 2nd shipment: 10:00 AM. The courier will then pick up samples from local clients,(2300 NMS Criminalistics Lab and NMS Bucks Lab).

1.2. UPS shipments will be brought to processing by the NMS receiving department.

**2. RECEIPT, SORT, AND SCAN PACKAGES:**

2.1. Receive packages and verify they are addressed to NMS Labs. If the package has been delivered to NMS in error return to:

2.1.1. Monday -> Friday

2.1.1.1. NMS courier – if it was received in first shipment

2.1.1.2. Place in Federal Express pick up bin on dock– if it was received after second shipment

2.1.1.3. Return to NMS shipping and receiving department if UPS.

2.1.2. Saturday

2.1.2.1. Call Federal Express and ask them to pick up the package. Place in the Federal Express pick up bin on the dock.

2.2. Scan the barcode of each package received. The tracker number will automatically upload into the Excel spreadsheet. This usually encompasses Federal Express, UPS, USMail and any other courier services.

2.2.1. Any packages not for the Processing department are scanned last and documented in the FedEx tracker.

2.3. While scanning into the Excel spreadsheet, special notations must be added in the column marked Comments next to the corresponding airbill. For example: packages that are brought to processing from the Receiving Department would have “From Receiving” in the column marked Comments. Packages that are to be given to the Receiving Department would state “To Receiving”.

**Title: Receiving and Opening in Specimen Processing**

2.4. The tracker numbers for the packages that will be given to the Receiving Department will be copied and pasted onto the Packages for Receiving Form and printed.
2.4.1. This form can be found in the Federal Express folder.
2.4.2. The form is then placed with the packages on the dock and will be signed by the Receiving Department.
2.4.3. The signed copy of this form is then placed in the binder marked “Packages for Receiving”.
2.4.4. These copies will be discarded after three months.

2.5. Once a package is scanned it is sorted into one of four categories:
2.5.1. Criminalistics (non-biological samples)
2.5.2. Packages Sent in Error
2.5.3. Clinical Samples
2.5.4. Forensic Samples

**3. CRIMINALISTIC SAMPLES**
3.1. Unopened packages addressed to the Criminalistic Lab will be scanned, notated in the tracker and the NMS courier will deliver directly to the 2300 Stratford location
3.2. Opened packages for the Criminalistic Lab:
3.2.1. If a Processor opened the package, and samples remain in the original shipping condition, they need to reseal the package with evidence tape and properly initial and date the seal.
3.2.2. If a Processor opened the packages, and the samples do not remain in the original shipping condition, the sample(s) need to be returned into original shipping condition, then placed into a plastic bag and heat sealed. The seal must be initialed and dated with the current date.
3.3. Complete the NMS Department COC Form (see document 10975) and place it with the package. These packages will be delivered to our 2300 Stratford site via the NMS courier.
3.4. “SP” (in the Relinquished By field) represents all employees working in the Specimen Processing department.

**4. PACKAGES SENT TO NMS IN ERROR**
4.1. These are packages sent to NMS; however, the samples were to be sent to another lab. These are client errors.
4.1.1. Document that these packages are misdelivered and place in the FedEx pickup bin.

**5. HOW TO USE THE IPAD TO TAKE AIRBILL PHOTOS**
5.1. Log In Instructions
5.1.1. Enter the Passcode “200200” to unlock the screen


Dependencies: (10975) NMS Department COC Form

**Title: Receiving and Opening in Specimen Processing**

5.1.2. Click on the Paperless app and enter your network credentials.
5.2. Taking photos of airbills
5.2.1. Place each hand on either side of the IPad and hover it above the airbill.
5.2.2. Select Choose File – located on your screen.
5.2.3. Make sure your barcode is located in the bottom right-hand corner. Hold a finger on the barcode to focus. "AE/AF Lock" will appear at the top of your screen.
5.2.4. Using the white button on the right side of the IPad take photo.
5.2.5. A preview photo will appear. In bottom right-hand corner, select Use Photo.
5.2.6. Screen will change showing Carrier and Airbill #. Check to make sure both are correct.
5.2.6.1. If incorrect, repeat steps 5.2.1 forward.
5.2.6.1.1. If the IPAD cannot read the barcode, the airbill number must be manually entered in the airbill # field, and the courier must be updated appropriately.
5.2.6.1.1.1. If this occurs you must circle the airbill number on the physical airbill.
5.2.7. Select Save

**6. CLINICAL PACKAGES**
6.1. Separate packages into two categories.
6.1.1. Frozen and Non-Frozen
6.2. Boxes/bags labeled "Cords" should always be opened first.
6.3. Using the iPad, take a photo of the complete airbill including some of the box / bag. This allows us to see what type of package the samples arrived in.
6.4. Using a box cutter - cut out the airbill
6.5. Open the box or bag. Always cut away from your body and guide the box cutter with your index finger on the handle above the blade.
6.6. Rubber band the airbill to the bag of specimens or place in the sleeve of the plastic bag. Make sure the airbill is facing out.
6.7. If the sample(s) is a Forensic case place in the blue forensic container.
6.8. If samples are non-frozen:
6.8.1. Place samples in specified Clinical container marked with your initials.
6.8.2. When container is full place on Clinical tower.
6.8.3. If the samples are to be received with a cold pack and no cold pack was received, write 'No CP' on the airbill and initial and date.
NOTE: This usually pertains to Umbilical Cords
6.8.3.1. It will be necessary to retake your photo so this information is documented.
6.9. If samples are frozen:
6.9.1. Place samples in Styrofoam container with dry ice and place on Clinical Accessioning cart.
6.9.1.1. Do not overfill or allow samples to protrude above the top of the Styrofoam containers to ensure samples remain frozen.
6.9.2. If the samples are received with a 'dry ice' placard and no dry ice remains ***and the samples are frozen,*** write "No ice remains – samples still frozen' on the airbill and initial and date.

**Title: Receiving and Opening in Specimen Processing**

6.9.3. If the samples are received with a 'dry ice' placard and no dry ice remains***, and the samples are thawed,*** write 'No ice remains – samples thawed' on the airbill and initial and date.
6.9.4. For steps 6.9.2 and 6.9.3 Retake the photo of the airbill using the IPad
6.10. If packages contain cords:
6.10.1. Place samples in specified Cord container (non-frozen) or Styrofoam Cord container (frozen)

**7. Forensic Packages**
7.1. Using the IPad, take a photo of the complete airbill including some of the box / bag. This allows us to see what type of package the samples arrived in.
7.2 Place packages into the appropriate bin, then place the bin onto the accessioning tower

**8. Handling of Shipping Containers**
8.1. Place the excess cold pack(s) and waste in the appropriate bins for discard.
8.2. Cardboard boxes are to be flattened and placed in the cardboard bin.
8.2.1. The cardboard bin will be put in the warehouse and tagged with the date and time of fill. The bin of outer cardboard will be held for a minimum of 24 hours past the date and time written on the tag. All other waste (including trash, recycling, biohazard, shipping bags and inner cardboard) will be held for a minimum of 48 hours past the date and time written on the tag.
8.3. Styrofoam or any package / box with a lid must be separated from their bottom half and checked to make sure no paperwork or samples are inside.
8.3.1 See maintenance SOP# 60206 for further disposal guidelines.
8.4. If the client wants the packaging returned:
8.4.1. Make sure the box is void of specimens.
8.4.1.1. Place the yellow label, which states "Box was double checked prior to Sendout by", on the box.
8.4.1.2. Remove any labels previously placed there.
8.4.1.3. Ask a 2nd Processor to double check the box making sure there are no samples inside.
8.4.1.4. 2nd Processor is to initial and date the yellow label.
8.4.2. Place the empty box and cold packs (if provided) in the designated area for the Receiving department to pick up later that day.

**9. FED EX TRACKER**
9.1. FedEx will send an electronic manifest of the day's delivery. NMS will compare this list to the Excel file scanned that day. This program is designed to find any discrepancies between what packages NMS receives to the FedEx electronic manifest.
9.2. Once this is completed the discrepancies are highlighted in blue. Discrepancies are first double checked in Horizon to see if they were missed during the initial

**Title: Receiving and Opening in Specimen Processing**

scanning process. Any remaining discrepancies are emailed to our contact at FedEx.

**10. PROFICIENCIES**

10.1. Scan into Federal Express Tracker
10.2. Take Photo
10.3. Place in Proficiency refrigerator / freezer
10.4. Email the “Proficiency” team

**11. JAX**

11.1. Scan into Federal Express Tracker
11.2. Place package on the Aliquot Cart.

**PURPOSE:** To provide a standardized process for logging in Clinical and Forensic samples.

**SCOPE:** To be used by NMS-Core Specimen Processing and IFS-JAX when receiving and logging in Clinical/Forensic specimens.

**PROCEDURE:**

CAUTION: During this procedure you will be working with potentially infectious materials (blood, etc.) and potentially hazardous chemicals. You must follow the safety procedures for handling these materials.

**1. RECEIVING**
**1.1.** Packages are received by Specimen Processing (See Receiving and Opening SOP 10976).

**2. HORIZON USER GUIDE**
**2.1.** When F1 is used in any field, Horizon Help User Guide will appear for that field.
2.1.1. **NOTE:** This does not work in the NMS Login Form.
**2.2.** Do not use shortcut key Ctrl-S when saving information. Click on SAVE.

**3. HORIZON LOGIN**
**3.1.** Open Microsoft Edge, click on NMS Apps, then click on HORIZON.
**3.2.** In NMS Login Form box, click to open.
**3.3.** Make sure the correct color labels are in the printer.
3.3.1. Pink – Clinical
3.3.2. Blue – Forensics

**4. CLIENT SUBMISSIONS**
**4.1.** There are two workflows:
4.1.1. **Clinical**
4.1.1.1. Electronic Data Interchange (EDI)
4.1.1.2. Web Portal (NMS)
4.1.1.3. Manual
4.1.2. **Forensic**
4.1.2.1. Web Portal (NMS)
4.1.2.2. Manual
4.1.2.3. MDI/Other Electronic Submissions
4.1.2.4. LabLynx
4.1.2.5. Police
4.1.2.6. Jacksonville
**4.2.** For all workflows there are multiple ways a client can communicate their information to NMS:
4.2.1. Electronic Orders - The client populates most of the required fields.

4.2.1.1. If the client prints their requisition, then makes edits after transmission, login as transmitted and make changes in Horizon. This allows us to see the changes in the Audit Trail.
4.2.2. Manual - clients who send NMS requisitions or their own paperwork.
4.2.2.1. For all submissions, information is entered from the client's requisition.
4.2.3. The requisition is considered the primary source of information. If information is not provided for a required field, enter NP.
4.2.4. Requisition type is indicated in the bottom right-hand corner. This indicates the type of submission. Ex. CL (clinical), COC (clinical), FR (police), PM (postmortem)
4.2.5. If client uses a manifest for submission
4.2.5.1. Place manifest in clear sleeve.
4.2.5.2. While accessioning, use sleeve to mark off samples as they are logged in.
4.2.5.3. This process is to reduce errors.
4.2.6. If clients add labels with additional information, the processor will only enter information that is a required field (Work ID and Last Name), see Reference Guide Section 4: 015 and Section 8: 023.
4.2.6.1. **NOTE:** This does not apply to auto populated fields.
4.2.7. If paperwork is received soiled, photocopy paperwork and notate "original paperwork received soiled and discarded" with initials and date.

**5. ENTERING DATA INTO LOGIN FORM**
**5.1. CLINICAL LOGIN**
5.1.1. EDI Submissions
5.1.1.1. Log in one sample at a time.
5.1.2. Webportal Submissions
5.1.2.1. Log in one submission at a time.
5.1.3. Manual Submissions
5.1.3.1. Login in one requisition/patient at a time – the processor reads all information on paperwork (requisition, manifest or client forms) and compares it to the specimen(s).
**6. PACKAGE SECTION**
**6.1.** Airbill: Scan/enter the tracker number.
6.1.1. If internal login, enter NMS.
**6.2.** Carrier: Auto populates based off the photo taken.
**6.3.** Airbill Received: Auto populates based off the photo taken.
**6.4.** If airbill does not scan:
6.4.1. Try all barcodes available.
6.4.2. Try to enter the main 12 digits.
6.4.3. Take to Team Leader
**6.5. NOTE:** If customs paperwork is received, attach to the airbill.

**7. WORKORDER SECTION**
**7.1. EDI**
7.1.1. Scan or enter client accession number.
7.1.2. If nothing populates, enter an EDI problem in the Help Desk
7.1.3. See Reference Guide Section 4: 004

**Title: Specimen Processing Accessioning**

**7.2. WebPortal**
7.2.1. Scan or enter Client Portal number (NMSCPxxxxxx)
7.2.2. If nothing populates, log in Manually.

**7.3. Manual**
7.3.1. Enter information from submitted paperwork.
7.3.2. If no paperwork received with sample, enter information from the sample. Make a photocopy of the sample(s). This is now your manual paperwork.

**7.4. Workorder ID**
7.4.1. Client case number / Accession number
7.4.2. Do NOT copy and paste this information in the Login Form.
7.4.3. Data enter exactly as submitted.
7.4.3.1. **NOTE:** There is a 30-character limitation
7.4.4. If ID does not fit, enter SEE COMMENT
7.4.4.1. Enter complete ID as a comment and make reportable (see section 8.13)
7.4.4.1.1. Ex. Work ID: XXXXXXXXXXXXXX

**7.5. Profile**
7.5.1. Client account number followed by profile (ML / PR).
7.5.2. Do NOT copy and paste this information in the Login Form.
7.5.3. Add 00000 followed by profile when:
7.5.3.1. The client does not provide an account number.
7.5.3.2. The account number and name do not match.
7.5.3.3. The account number provided is invalid/inactive.
7.5.3.4. **NOTE:** NEWACCTRV will automatically be selected on the login form. Do not unselect.
7.5.4. If account number needs to be updated after login, see Reference Guide Section 4: 025.

**7.6. Client**
7.6.1. This information will auto-populate once Profile has been entered.

**7.7. Chain of Custody**: (Alternate ID)
7.7.1. This field is only used when clients require three unique identifiers.
7.7.1.1. Examples:
7.7.1.1.1. Control Number labels
7.7.1.1.2. Client Protocol Number
7.7.2. If an auto-generated number populates – Do not delete.
7.7.3. If a third unique identifier is also provided, enter as a reportable comment.

**7.8. Purchase Order**
7.8.1. This signifies a payment.
7.8.2. Purchase order - Data enter PO number as: XXXX
7.8.3. Auto-generated PO numbers:
7.8.3.1. If an auto-generated PO number populates - Do not delete.
7.8.4. Credit Card: Data enter as: CC


Dependencies:

7.8.4.1. If a credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
7.8.5. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

**7.9. Last Name / First Name / Middle Name/Suffix**
7.9.1. EDI – Auto-populates as transmitted.
7.9.1.1. Check to ensure any secondary label(s) match the patient information scanned.
7.9.2. Webportal – Auto-populates as transmitted.
7.9.2.1. Check to ensure any secondary label(s) match the patient information scanned.
7.9.3. Manual - Populate the fields as provided.
7.9.3.1. Check to ensure sample label(s) match the patient information entered.
7.9.4. One identifier must be provided on sample label.
7.9.4.1. If identifier does not match paperwork, Clarify.
7.9.4.2. If there is no label on sample, Cancel. see Reference Guide Section 4: 011
7.9.5. If a name is not supplied in the name field, however, other characters are, enter as provided.
7.9.6. For manifest, if *last, first* name format is used, apply to appropriate fields. If not, enter name as listed into last name field only.

**7.10. Date of Birth (DOB)**
7.10.1. Enter DOB as mm/dd/yyyy

**7.11. Sex**
7.11.1. Select from drop down box:
7.11.1.1. Male ♂
7.11.1.2. Female ♀
7.11.1.3. If sex indicated on paperwork is not available, add as a reportable comment.

**7.12. Disposition**
7.12.1. Client Disposition
7.12.1.1. Auto populates when applicable.

**8. SAMPLES SECTION**
**8.1. Login Alerts**
8.1.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**8.2. For EDI Clients**
8.2.1. For single test:
8.2.1.1. Testing will populate.
8.2.1.2. Click on the box in front of the testing. A check mark will appear.
8.2.1.2.1. If “Wild” test, override with test supplied by client in Login Alert or on client paperwork.
8.2.1.2.1.1. If overriding a “Wild” with a STOPVOL or STOPFRZ test, the alert will not populate on the screen.

**Title: Specimen Processing Accessioning**

*8.2.1.2.2.* If no tests supplied - Clarify
8.2.1.3. If sample leaked in transit, add LEAKY test code.
8.2.2. For multiple tests:
8.2.2.1. Click the box in front of the test(s) being ordered based on matrix. A check mark will appear.
8.2.2.2. The client may send one sample, or multiple samples, for multiple tests. You will need to know which option the client chose before ordering the tests. These samples should be set aside to be logged in last in that airbill.
8.2.3. If questions arise during login see Trainer or Supervisor.
8.2.4. All options will be discussed during initial training.

**8.3. For Webportal Clients**
8.3.1. All transmitted testing will populate.
8.3.2. If sample leaked in transit, add LEAKY test code.
8.3.3. If testing is assigned to a specific sample, the box in front of that test(s) needs to be checked.
8.3.3.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
8.3.4. If testing is requested on any sample, the box in front of the test(s) **and** the box in front of the STORE associated with sample need to be checked.
8.3.4.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.

**8.4. For Manual Clients**
8.4.1. +AddTest
8.4.2. Add all requested test(s) via test codes supplied on paperwork.
8.4.3. If no paperwork is submitted, add a Clarify.
8.4.4. If test is not available, add a Clarify.
8.4.5. If only test name is supplied, without a test code, add a Clarify.
8.4.6. If test name and test code do not match, add a Clarify.
8.4.7. If no sample is received, Cancel. – see Reference Guide Section 4: 011
8.4.8. If paperwork lists multiple samples and only one is received, log in other sample(s) as NSR (no sample received) and STORE.
8.4.8.1. Document “no sample received” on paperwork, initial and date.
8.4.9. If test request and matrix do not match, Cancel. (see section 8.7)
8.4.10. If sample leaked in transit, add LEAKY test code.

**8.5. For all submissions.**
8.5.1. **if no testing is required:**
8.5.1.1. Add STORE if there is testing on another sample on the Workorder.
8.5.1.2. Add NOTEST if there are no tests ordered on the Workorder.
8.5.1.3. If there are any questions concerning this login:
8.5.1.3.1. assign a CLARIFYM for clinical samples.
8.5.1.3.2. assign a CLARIFYUC for cord samples.

**8.6. Collection Date/Time (Enter as military time)**


Dependencies:

8.6.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
8.6.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
8.6.2. Estimated times should not be entered.

8.6.3. **For EDI Clients**
8.6.3.1. If sample is a Store, no date or time is entered.

**8.7. Matrix**
8.7.1. The matrix of the test ordered must match the matrix received.
8.7.1.1. Examples
8.7.1.1.1. 1234**R** and RBCs received.
8.7.1.1.2. 1234**SP** and Serum and/or Plasma received.
8.7.1.2. **NOTE:** 24 Hour Urine and Random Urine are two different matrices.

8.7.2. **For EDI Clients**
8.7.2.1. If sample is a Store, enter Matrix as Other.
8.7.2.2. Enter Reportable Comment indicating the color of the fluid received.

8.7.3. **If matrix on paperwork and sample do not match:**
8.7.3.1. **For EDI Clients**
8.7.3.1.1. Accept what was transmitted.
8.7.3.1.2. Enter Reportable Comment indicating the color of the fluid received.
8.7.3.1.3. Order testing as requested.
8.7.3.1.4. Cancel testing – see Reference Guide Section 4: 011

8.7.3.2. **For Webportal Clients**
8.7.3.2.1. Accept what was transmitted.
8.7.3.2.2. Enter Reportable Comment indicating the color of the fluid received.
8.7.3.2.3. Order testing as requested.
8.7.3.2.4. Cancel testing – see Reference Guide Section 4: 011

8.7.3.3. **For Manual Clients**
8.7.3.3.1. Log in matrix as Other.
8.7.3.3.2. Enter Reportable Comment indicating the color of the fluid/matrix received.
8.7.3.3.3. Order testing as requested.
8.7.3.3.4. Cancel testing – see Reference Guide Section 4: 011

**8.8. Matrix Source**
8.8.1. When provided, enter Source from paperwork.
8.8.2. If no paperwork provided and Source is clearly indicated on sample, enter information in source field.
8.8.3. If the client indicates Left and/or Right source on the requisition or sample, document in Reportable Comment field.

**8.9. Turn**
8.9.1. Defaults to client's specifications.


Dependencies:

8.9.2. If paperwork states sample(s) are to be returned or results faxed – change Turn code to appropriate option **only** if R (routine handling) is pre-populated.
8.9.2.1. RR – Return
8.9.2.1.1. If Return place a Return sticker on sample
8.9.2.2. RF – Fax Client

**8.10. Container Type**
8.10.1. Container field represents:
8.10.1.1. Color of cap: first two letters
8.10.1.1.1. For Clear caps with colored stopper always use the color of the stopper
8.10.1.2. Type of container: Plastic or Glass
8.10.1.3. Description: (one of the three below)
8.10.1.3.1. C Container
8.10.1.3.2. T Tube
8.10.1.3.3. S Stopper
8.10.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag
8.10.3. If sample(s) are received in a Serum Separator Tube (SST) testing will be cancelled once Lab ID is created. see Reference Guide Section 4: 011

**8.11. Sample Preservative**
8.11.1. Defaults to none
8.11.2. Light Protected – L
8.11.2.1. Samples are considered light protected if:
8.11.2.1.1. Brown vial
8.11.2.1.2. Amber Sarstedt Transfer vial
8.11.2.1.3. Amber or Brown Containers
8.11.2.1.4. Foil wrapped
8.11.2.1.5. Wrapped with material to obstruct light.
8.11.2.1.5.1. Must be fully wrapped.
8.11.2.1.6. Both the tube and the outer wrapping need to be labeled.
8.11.3. Frozen – F
8.11.4. Light Protected and Frozen – B
8.11.5. All samples received frozen are to be kept frozen at login.
8.11.6. If samples are not received in the required condition the testing will be cancelled once Lab ID is created. See Reference Guide Section 4: 011

**8.12. Volume**
8.12.1. Not entered.

**8.13. + Add comments**
8.13.1. Predefined comments
8.13.1.1. If SST received: add appropriate comment.
8.13.1.2. For list of Predefined Comments, see Reference Guide Section 4: 001
8.13.2. Free text comments
8.13.2.1. Examples of Free Text comment:
8.13.2.1.1. Complete workorder ID when over 30 characters


Dependencies:

8.13.3. **NOTE:** If a comment needs to be on the report, check Rpt. Box.

**8.14. Label Count**
8.14.1. Defaults to 1, however, can be changed.
8.14.2. Label(s) will print.

**8.15. Lab I.D. (Container) Label**
8.15.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
8.15.2. Additional preprinted colored labels may be required for cases.
8.15.3. Place labels on parent containers near the top.
8.15.3.1. Return: for samples being returned
8.15.4. If cancellation is necessary, see Reference Guide Section 4: 011
8.15.5. Labeled specimens will be placed in appropriate rack / basket.
8.15.5.1. Multiples
8.15.5.2. Transport
8.15.5.3. Store

**8.16. Choose one of the following to continue:**
8.16.1. If multiple samples were received for the same requisition, Proceed to section 8. When final sample is logged in proceed to section 8.16.
8.16.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 7. When final sample is logged in proceed to section 8.16.
8.16.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 6.

8.16.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
8.16.4.1. This is NMS's unique identifier.
8.16.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
8.16.6. Check the workorder and the workorder I.D. on the label to assure correct labeling.
8.16.7. Place the workorder label on each document associated with case / patient.
8.16.8. For additional workorder / lab ID labels see Printing Labels in Horizon User Guide.
8.16.9. Write the number of pages on the label and circle the number.
8.16.10. You only need to do this on this on one form (preferably the requisition).
8.16.11. The total number is the total number of pages, not documents.

8.16.12. **For EDI Clients**
8.16.12.1. If paperwork is used, a requisition label must be applied.

8.16.13. **For Webportal Clients**
8.16.13.1. If paperwork is supplied, a requisition label must be applied.

8.16.14. **For Manual Clients**


Dependencies:

8.16.14.1. A requisition label must be applied to the paperwork used for login and any additional paperwork supplied.

**9. ENTERING DATA INTO LOGIN FORM**
**9.1. FORENSIC LOGIN**
9.1.1. Webportal Submissions
9.1.1.1. Log in one submission at a time.
9.1.2. Manual Submissions
9.1.2.1. Log in one submission at a time.
9.1.3. MDI/Other Electronic Submissions
9.1.3.1. Log in one submission at a time.
9.1.4. LabLynx
9.1.4.1. Log in one submission at a time.
9.1.5. Police
9.1.5.1. Log in one submission at a time.
9.1.6. Jacksonville
9.1.6.1. Log in one submission at a time.

9.1.7. All paperwork must be reviewed prior to login to address any outliers of importance.
9.1.7.1. Examples:
9.1.7.1.1. Court order
9.1.7.1.2. Returns
9.1.7.1.3. Hair Segmentation
9.1.8. If there is an issue with a sample submission during accessioning, refer to SOP 10966 Clarify Procedures to process a problem sample.
9.1.9. If a sample is submitted improperly, a Client Opportunity can be sent to Remote Staff to be entered in Compliance Software.
9.1.10. If outside packaging evidence/chain of custody received:
9.1.10.1. If filled out, make a photocopy for OnBase.
9.1.10.2. If blank, discard
9.1.11. If a property receipt is received, see Reference Guide Section 8: 031
9.1.12. If a packing list is received, check off all cases received and file.
9.1.12.1. If there is a discrepancy, bring to a Team Leader.
9.1.13. If return airbill is received, see Reference Guide Section 8: 033
9.1.14. If outside packaging needs to be returned, see Reference Guide Section 8: 039

**10. FORENSIC PRE-LOGIN ORDER**
**10.1.** If multiple types of samples are received, log in the order below. **NOTE:** This usually is not the order listed on the requisition.
10.1.1. Hospital/antemortem/admission
10.1.2. Postmortem (includes Donor)
10.1.3. Outside Packaging

**10.2.** Hospital/antemortem/admission
10.2.1. Sort by matrix then collection date and time within the matrix.


Dependencies:

10.2.1.1. Blood /Serum / Plasma
10.2.1.2. Fluid
10.2.1.3. Urine
10.2.2. *Preferred tube type
10.2.3. Volume

**10.3.** Postmortem (includes Donor)
10.3.1. Sort by matrix, then source within the matrix
10.3.1.1. Blood / Serum / Plasma
10.3.1.2. Fluid
10.3.1.3. Vitreous
10.3.1.3.1. If contains viscous material, add comment.
10.3.1.4. Urine
10.3.1.5. Other Fluids
10.3.1.5.1. Blood related fluid
10.3.1.5.1.1. see Reference Guide Section 8: 007
10.3.1.5.2. Bile
10.3.1.5.2.1. If contains gallbladder, see Reference Guide Section 8: 032
10.3.1.5.3. Gastric
10.3.1.5.3.1. If contains pills, see Reference Guide Section 8: 005
10.3.1.5.4. Spleen (fluid or tissue)
10.3.1.5.4.1. see Reference Guide Section 8: 021
10.3.1.6. Tissue
10.3.1.6.1. If contains maggots, add Note.
10.3.1.7. Any Other Matrices
10.3.1.7.1. Hair
10.3.1.7.2. Nails
10.3.1.7.3. Pills
10.3.2. Collection date and time (if applicable)
10.3.3. *Preferred tube type
10.3.4. Volume

**10.4.** *Preferred tube type Order
10.4.1. **NOTE:** Every color tube top is not listed; these are the most common.
10.4.2. Gray Top/White NMS
10.4.3. Lavender Top
10.4.4. Pink Top
10.4.5. Blue Top
10.4.6. Green Top
10.4.7. All other color tops.
10.4.8. Red Top - Use last.
10.4.9. Cup in a Vial is not an acceptable tube type, see Reference Guide Section 8: 002

**10.5.** Specific Tube Preferences for commonly ordered tests:
10.5.1. Alcohol: Gray Top




Dependencies:

10.5.1.1. Screen and confirmation should be done on the same tube.
10.5.2. Anticoagulant poisoning panel: Any tube
10.5.2.1. Gray and Lavender *NOT recommended.
10.5.3. Carbon Monoxide: Lavender Top (preferred), Gray Top, Green Top
10.5.4. Cocaine: Gray Top
10.5.4.1. Red Top or other non-gray top tubes are *NOT recommended.
10.5.5. Cyanide: Gray Top
10.5.6. Drug Facilitated Crime Panel: Gray or Lavender are preferred.
10.5.6.1. Yellow top and Light Blue top are *NOT recommended.
10.5.7. Metals: Royal Blue Top Trace Metal Free
10.5.8. Oxalate: Gray Top *NOT recommended
10.5.9. Synthetic Cannabinoids: Lavender Top
10.5.10. Vitreous Electrolytes and Glucose: Red Top
10.5.10.1. Gray Tops *NOT recommended.
10.5.11. VRL Send-Outs: Red Top required, see Reference Guide Section 8: 034

10.5.12. *If only a *NOT recommended* tube is submitted, proceed with testing.

10.5.13. Sealed vs Unsealed.
10.5.13.1. Sealed Samples are preferred for testing over unsealed samples.

**10.6. PACKAGE SECTION**
10.6.1. Airbill: Scan/enter the tracker number.
10.6.1.1. If internal login, enter NMS.
10.6.2. Carrier: Auto populates based off the photo taken.
10.6.3. Airbill Received: Auto populates based off the photo taken.
10.6.4. If airbill does not scan:
10.6.4.1. Try all barcodes available.
10.6.4.2. Try to enter the main 12 digits.
10.6.4.3. Take to Team Leader
10.6.5. **NOTE:** If customs paperwork is received, discard with the airbill.

**11. Forensic Sample Submission Types**
**11.1. Webportal**
**11.2. Manuals**
**11.3. MDI/Other Electronic Submissions**
**11.4. Lablynx**
**11.5. Police**
**11.6. Jacksonville**

**12. Webportal**
**12.1. EDI**
12.1.1. Scan or enter Client Portal number from paperwork.
12.1.2. If there is no transmission, proceed with Manual login.

12.1.3. If there is no paperwork, scan or enter Client Portal number from sample.

**12.2. Workorder ID**
12.2.1. Information auto populates.

**12.3. Profile**
12.3.1. Information auto populates.
12.3.2. If profile is crossed out and a new account number is written, accept the order and update to 00000 in Horizon, see Reference Guide Section 8: 030

**12.4. Client**
12.4.1. Information auto populates.

**12.5. Chain of Custody:** (Alternate ID)
12.5.1. This field auto populates with the Client Portal number (NMSCPxxxx) – Do not delete.
12.5.2. If a third unique identifier is provided, enter as a comment and make reportable.
12.5.2.1. Example:
12.5.2.1.1. Control Number labels.

**12.6. Purchase Order**
12.6.1. This signifies a payment.
12.6.2. Purchase order - Data enter PO number as: XXX
12.6.3. Auto-generated PO numbers:
12.6.3.1. If there is an auto-generated PO number - Do not delete.
12.6.4. *Check: Data enter check number as: CKXXX
12.6.5. *Money Order: Data enter Money order number as: MOXXX
12.6.6. Credit Card: Data enter as: CC
12.6.6.1. If credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
12.6.7. Letter of Intent: Data enter as: Letter of Intent
12.6.8. *Checks and money orders must be taped onto Check Form located in NMS Intranet (Microsoft Edge -> Intranet -> Shared Documents -> Online Forms -> Specimen Processing -> Check Form).
12.6.9. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

**12.7. Last Name / First Name / Middle Name/Suffix**
12.7.1. Auto-populates as transmitted.

**12.8. Date of Birth (DOB)**
12.8.1. Auto-populates as transmitted.

**12.9. Sex**
12.9.1. Auto-populates as transmitted.

**12.10. Disposition**


Dependencies:

12.10.1. Disposition Override:
12.10.1.1. Auto populates into Horizon when applicable.
12.10.2. Client Disposition:
12.10.2.1. Auto populates when applicable.

**12.11. Package**
12.11.1. Package field is defined as the case-specific, primary packaging.
12.11.2. Package Sealed: (Y or N)
12.11.3. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are host of ways to "seal" evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
12.11.4. Package Seal Initialed: (Y or N)
12.11.4.1. Can be initialed or signed.
12.11.5. Package Seal Dated: (Y or N)
12.11.6. Package Condition Notes: Documenting unusual packaging conditions.
12.11.6.1. Examples:
12.11.6.1.1. FedEx Bag not sealed.
12.11.6.1.2. Package appeared to be opened.
12.11.6.1.3. No dry ice remains.

**12.12. Login Alerts**
12.12.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**12.13. Test Section**
12.13.1. All transmitted testing will populate.
12.13.2. If additional testing is indicated on the requisition:
12.13.2.1. +Add Tests
12.13.3. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
12.13.4. For volume guidelines, see Reference Guide Section 8: 043
12.13.5. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
12.13.5.1. **NOTE:** What was physically received is documented in Horizon
12.13.6. Antemortem vs Postmortem
12.13.7. Unless otherwise indicated, when both Antemortem and Postmortem are submitted, test the Antemortem first. If there is not sufficient antemortem volume for the test(s), then use Postmortem.
12.13.8. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
12.13.8.1. **NOTE:** For required volumes refer to QNS Sheet
12.13.9. If sample leaked in transit, add LEAKY test code.


Dependencies:

12.13.10. If sample is a STOPVOL, see Reference Guide Section 8: 038
12.13.11. Check to see if sample is clotted by inverting the sample 5 to 6 times and/or visual inspection.
12.13.11.1. If clotted, add CLOTTED comment (see section 12.22) and create a homogenate bottle. See Reference Guide Section 8: 036
12.13.11.2. **NOTE:** Subdural and Spleen samples will always be homogenized
12.13.12. If sample needs to be homogenized for a test but also has a Metals or Iron Ratio test ordered, place a SHARED label on both parent and homogenate. See Reference Guide Section 8: 045
12.13.13. If the client lists a sample on the paperwork and does not send that sample:
12.13.13.1. If testing was added to this sample – Clarify and document on the requisition / paperwork the sample was not received, initial and date.
12.13.13.2. If testing was not added to this sample - Document on the requisition / paperwork the sample was not received, initial and date.
12.13.14. If client requests Screen/Confirm – Clarify
12.13.14.1. see Reference Guide Section 8: 037
12.13.15. If client orders a Special Request – Clarify
12.13.15.1. See Reference Guide Section 8: 044
12.13.16. If there are any questions concerning this login:
12.13.16.1. assign a CLARIFYF using the appropriate clarify reason.
12.13.16.2. For a list of clarify reasons, see Reference Guide Section 8: 008
12.13.17. If testing is assigned to a specific sample, the box in front of that test(s) needs to be checked.
12.13.17.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
12.13.18. If testing is requested on any sample, the box in front of the test(s) **and** the box in front of the STORE associated with sample need to be checked.
12.13.18.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
12.13.19. For Serum/Plasma tests only: When the transmitted test matrix (S/P) does not match the sample matrix (S or P), update the matrix to S/P

**12.14. Collection Date/Time (Enter as military time)**
12.14.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
12.14.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
12.14.2. This will auto populate for all transmitted samples.
12.14.3. The collection date/time is taken from the requisition:
12.14.3.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
12.14.3.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.


Dependencies:

12.14.3.3. If the collection date/time is not provided on the requisition, leave blank.

12.14.4. Collection date/time cannot be taken from the requisition:
12.14.4.1. If collection information is incomplete, leave blank.
12.14.4.1.1. Ex. incomplete year, future date or no date provided.
12.14.4.2. Document in Misc. Info (Reportable) field:
12.14.4.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/time(s)
12.14.4.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
12.14.4.2.2.1. Document the date/time(s) located on the sample.
12.14.4.2.3. If no paperwork, document dates/times visible on sample label
12.14.4.2.4. If sample is not listed on requisition, document dates/times visible on sample label.
12.14.5. **NOTE:** Dates and times on Hospital samples are subjective

**12.15. Matrix**
12.15.1. Whether or not paperwork is received, matrix should be verified to the sample.
12.15.2. Matrix will auto populate with test code selected.
12.15.3. If the matrix received is not consistent with paperwork and:
12.15.3.1. The matrix is obvious, log in what was actually received.
12.15.3.1.1. Do not enter a collection date/time.
12.15.3.1.2. Enter note stating the matrix received and what was indicated on the label.
12.15.3.1.2.1. Ex. blood sample with vitreous label
12.15.3.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
12.15.4. If matrix received is not on paperwork, the matrix can be taken from the sample.
12.15.5. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
12.15.5.1. Document, in the Misc. Info (Reportable), what was on packaging.
12.15.5.1.1. Example: Urine recorded on package
12.15.5.2. Make a copy of the packaging.
12.15.6. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
12.15.7. If matrix on paperwork and sample do not match and testing is requested on this sample (except for blood vs serum/plasma):
12.15.7.1. Uncheck the test code requested.
12.15.7.2. Click +AddTest
12.15.7.3. Enter and Select CLARIFYF
12.15.7.4. Click close.
12.15.7.5. Check the box in front of CLARIFYF.
12.15.7.6. Do not enter a collection date/time.
12.15.7.7. Update Matrix to what is physically received.
12.15.7.8. If blood vs serum/plasma:
12.15.7.8.1. Log in what is physically received and order testing on that matrix, if available.
12.15.7.8.2. If not available follow steps above.




Dependencies:

**Title: Specimen Processing Accessioning**

**12.16. Matrix Source**

12.16.1. Order of Source Preference (when volume is not an issue).
12.16.1.1. Peripheral
12.16.1.2. Subclavian
12.16.1.3. Central
12.16.1.4. Other
12.16.2. The source will always be taken from the paperwork.
12.16.3. If no paperwork received, the source may be taken from the sample.
12.16.4. If the source on the paperwork does not match what is provided on the tube:
12.16.4.1. Enter Source from paperwork.
12.16.4.2. Type Source listed on tube in Misc. Info (Reportable).
12.16.5. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
12.16.5.1. Example: Left/Right
12.16.6. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
12.16.6.1. Example of comment: Femoral recorded on package
12.16.7. **NOTE:** Subdural and Spleen should always be homogenized when tested

12.16.8. Blood Source Chart in preferred order:

| PERIPHERAL Sources | Comment |
|---|---|
| Femoral | |
| Iliac | |
| Peripheral | Arm/Leg |
| Peritoneal | |
| Subdermal | |
| **CENTRAL Sources** | |
| Cardiac | |
| Heart | |
| Aortic | |
| IVC (Inferior Vena Cava) | |
| Central | |
| Jugular | |
| Spleen | |
| Cavity | * |
| Chest | * |
| Pleural | * |




Dependencies:

| | |
|---|---|
| Pulmonary | * |
| Abdomen | * |
| Thoracic | * |
| **Both Sources** | |
| Antemortem | |
| Subclavian | |
| Donor | |
| Mixed | * |
| Subdural | N/A |
| Brain | N/A |

12.16.8.1. * These are ***not*** preferred samples and should be used as a last resort.

12.16.8.2. **NOTE:** Antemortem / Donor / Mixed can be from either location.
12.16.9. Drawings, abbreviations and miscellaneous letters are not acceptable substitutes for spelling out the source.
12.16.9.1. Examples:
12.16.9.1.1. Per
12.16.9.1.2.
12.16.9.1.3. Sub
12.16.9.1.4. CAR
12.16.10. However, common sources (i.e., Fem (Femoral) and VIT (vitreous)) can be used.

12.16.11. **Tissue, Fluid and Solid Sources**
12.16.11.1. Any tissue, fluid or solid source may be taken from the sample if it is not listed on the requisition.
12.16.11.2. If the source name on the paperwork does not match what is provided on the sample - Clarify
12.16.11.3. **NOTE:** Gastric should always be homogenized when tested

12.16.12. Tissue Source Charts in Preferred Order:
12.16.12.1. **Tissue Drug Testing Source Chart**

| Source |
|---|
| Liver |
| Other Organs |
| *Brain |

12.16.12.2. **Tissue CO Testing Source Chart**

| Source |
|---|
| Muscle |
| Spleen |

**Title: Specimen Processing Accessioning**

| |
|---|
| Kidney |
| Heart |
| *Liver |

12.16.12.3. *These are **not** preferred samples and should be used as a last resort.

**12.17. Turn**
12.17.1. Defaults to client's specifications.
12.17.2. If paperwork lists any of the below scenarios, change Turn code:
12.17.2.1. RF – Fax/Email Results
12.17.2.2. RC - Call Client

**12.18. Container Type**
12.18.1. Container field represents:
12.18.1.1. Color of cap: first two letters
12.18.1.1.1. For Clear caps with colored stopper always use the color of the stopper
12.18.1.2. Type of container: Plastic or Glass
12.18.1.3. Description: (one of the three below)
12.18.1.3.1. C Container
12.18.1.3.2. T Tube
12.18.1.3.3. S Stopper
12.18.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

**12.19. Sample Preservative**
12.19.1. Defaults to none.
12.19.2. Light Protected – L
12.19.2.1. Samples are considered light protected if:
12.19.2.1.1. Brown vial
12.19.2.1.2. Amber Sarstedt Transfer vial
12.19.2.1.3. Amber or Brown Container
12.19.2.1.4. Foil wrapped
12.19.2.1.5. Wrapped with material to obstruct light.
12.19.2.1.5.1. Must be fully wrapped.
12.19.2.1.6. Both the tube and the outer wrapping need to be labeled
12.19.3. Frozen – F
12.19.4. Light Protected and Frozen – B
12.19.5. If samples are not received in the required condition for testing:
12.19.5.1. Not Light protected – foil wrap
12.19.5.2. Not Frozen – place into NMS provided container.
12.19.6. Predefined comment will be added (see section 12.22)

**12.20. Hair**
12.20.1. Weigh and measure, in centimeters, hair sample. Record all information on the Hair Login Form. (Addendum xxx)
12.20.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.




Dependencies:

**12.21. Volume**
12.21.1. Volume is estimated.
12.21.2. If volume cannot be taken, leave blank and enter Note (see section 12.31)
12.21.3. If no volume received, enter volume as zero (0) and enter comment (see section 12.22)

**12.22. + Add comments**
12.22.1. Predefined comments
12.22.1.1. If no paperwork received: NOPAPER
12.22.1.2. If SST received: add appropriate comment.
12.22.1.3. If clotted sample: CLOTTED
12.22.1.4. If no volume received: EMPTY
12.22.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
12.22.2. Free text comments
12.22.2.1. Alternate ID
12.22.2.2. P=XXX, H=XXX
12.22.3. **NOTE:** If comment needs to be on report, check Rpt. box

**12.23. + Add additional Data – (Orange box)**
12.23.1. Hair length

**12.24. Sample Sealed** - (Y or N)
12.24.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are host of ways to “seal” evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
12.24.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

**12.25. Unique Identifiers**
12.25.1. Case ID
12.25.2. Patient ID/Name
12.25.3. Alternate ID
12.25.3.1. Web Portal number
12.25.3.2. MRN or MR Number
12.25.3.3. Donor ID

12.25.4. If the above unique identifiers are not available, Date of Birth and/or Initials are acceptable.

**12.26. Sample Labeled** – (Y, N, X, D or U)

12.26.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

12.26.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 12.22).

12.26.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

12.26.4. **Y (Yes)**
12.26.4.1. Defined as: All the unique identifiers on paperwork match the sample label.
12.26.4.1.1. **NOTE:** The sample label may have additional identifiers.

12.26.5. **N (No)**
12.26.5.1. Defined as: No label on the sample.

12.26.6. **X (Not Applicable)**
12.26.6.1. Containers created by NMS.
12.26.6.1.1. Examples: hair segmentation, oral fluids, and homogenates
12.26.6.2. Client shipping containers

12.26.7. **D (Discrepant)**
12.26.7.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label, match and other unique identifiers do not.
12.26.7.2. Documentation of a difference between the sample label and paperwork submitted.

12.26.8. **U (Unverified)**
12.26.8.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label match, or handwriting is illegible, or the label was no longer attached.

12.26.8.2. The unique identifier(s) are visible on primary label and don't match the identifiers on the secondary label (WebPortal label).

12.26.8.3. Make a copy of all sample labels that are discrepant.
12.26.8.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
12.26.8.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

12.26.8.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

**12.27. Documentation of Sample Labeled As**: – (Y, N, X, D or U)

12.27.1. Enter unique identifiers found on sample label according to the priority order.
12.27.1.1. Case ID
12.27.1.2. Patient Name

12.27.1.3. Alternate ID

12.27.2. If identifying letters are provided on both sample label and submitted paperwork, add the letter in the Sample Labeled As field.
12.27.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

12.27.4. **Y (Yes)**
12.27.4.1. Enter unique identifier from sample label of highest priority.

12.27.5. **N (No)**
12.27.5.1. Enter "NO LABEL"
12.27.5.2. The discrepancy will be documented in Horizon, refer to 12.36.

12.27.6. **X (Not Applicable)**
12.27.6.1. leave this field blank.

12.27.7. **D (Discrepant)**
12.27.7.1. Enter unique identifier from sample label of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

12.27.8. **U (Unverified)**
12.27.8.1. Enter all discrepant identifiers from sample label separated by a backslash (/).
12.27.8.1.1. If sample is labeled but cannot be read, write "ILLEGIBLE".
12.27.8.1.2. If sample is labeled with a barcode only, write "BARCODE ONLY"
12.27.8.1.3. If sample label is no longer attached and sample is not contained individually, write "LABEL NOT ATTACHED"
12.27.8.1.3.1. Make a photocopy of label and discard label.
12.27.8.2. The discrepancy will be documented in Horizon, refer to section 12.36.

**12.28. Sample Dated** – (Y or N)
12.28.1. This question applies to the seal.

**12.29. Sample Initialed** – (Y or N)
12.29.1. This question applies to the seal.
12.29.1.1. Can be initialed or signed.

**12.30. Sample Timed** – (Y or N)
12.30.1. This question applies to the label.

**12.31. Notes**
12.31.1. This information appears on the Login Verification form. This is internal documentation for NMS.
12.31.2. Enter notes pertaining to the sample that may help address an oddity:
12.31.2.1. Examples:
12.31.2.1.1. WO previously received under a different workorder.
12.31.2.1.2. Hair segmentation notes.


Dependencies:

12.31.2.1.3. Weight not taken due to nature of sample.
12.31.2.1.4. Return packaging notes.
12.31.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: ____grams*** when some of the tissue could not be returned to the original container.

**12.32. Misc. Info (Reportable)**
12.32.1. This information appears on the client's report.
12.32.2. Enter any information concerning the sample, login information or conflicts with login information.
12.32.2.1. Examples:
12.32.2.1.1. Collection date and time discrepancies
12.32.2.1.2. Additional source information on paperwork
12.32.2.1.3. Source discrepancies.
12.32.2.1.4. Sample descriptions.
12.32.2.1.5. Sources not available in Horizon
12.32.2.1.5.1. Examples: Pupa, Placenta

**12.33. CONF Notes**
12.33.1. Internal notes regarding handling of the specimen.
12.33.1.1. Example:
12.33.1.1.1. Micro and Consume
12.33.1.1.2. Limited Confs or Hold Confs
12.33.1.1.3. Do Not Use
12.33.1.1.4. One Shot Deal

**12.34. Label Count**
12.34.1. Defaults to 1, however, can be changed.
12.34.2. Label(s) will print.

**12.35. Lab I.D. (Container) Label**
12.35.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
12.35.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
12.35.2. Additional preprinted colored labels may be required for cases.
12.35.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
12.35.3.1. Examples:
12.35.3.1.1. Micro: for limited volume samples
12.35.3.1.2. Return: for samples being returned
12.35.3.1.3. Additional Specimen: when clients send additional samples for a specific workorder already in house.
12.35.4. Labeled specimens will be placed in appropriate rack / basket.
12.35.4.1. Aliquot

12.35.4.2. Store

**12.36. Documenting a discrepancy in Horizon**
12.36.1. For ClarifyFDU:
12.36.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
12.36.1.2. Click on Additional Information and scroll to ClarifyFDU.
12.36.1.3. Go to notes/instructions field to enter discrepancy.
12.36.1.4. Enter discrepancy as: paperwork vs sample label
12.36.1.5. Document only in the first sample unless it varies from sample to sample.
12.36.1.5.1. If it varies, add a description to the corresponding sample.
12.36.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
12.36.2. For ClarifyFDN:
12.36.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
12.36.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

**12.37. Choose one of the following to continue:**
12.37.1. If multiple samples were received for the same requisition, Proceed to section 12.12. When final sample is logged in proceed to section 12.37.
12.37.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 12.37.
12.37.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

12.37.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
12.37.4.1. This is NMS's unique identifier.
12.37.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
12.37.6. If paperwork is supplied or created (ie photocopies), a requisition label must be applied.
12.37.7. Check the workorder and the workorder I.D. on the label to assure correct labeling.
12.37.8. Place the workorder label on each document associated with case / patient.
12.37.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
12.37.10. Write the number of pages on the label and circle the number.
12.37.11. You only need to do this on one form (preferably the requisition).
12.37.12. The total number is the total number of pages, not documents.

## 13. Manuals
### 13.1. EDI
13.1.1. Field is not used.

13.1.2. If no paperwork received with sample, enter information from the sample. Make a photocopy of the sample(s). This is now your manual paperwork.
13.1.3. If Additional Sample Submission Form is received, see Reference Guide Section 8: 018

### 13.2. Workorder ID
13.2.1. Client case number / Accession number


Dependencies:

13.2.2. Do NOT copy and paste this information in the Login Form.
13.2.3. Data enter exactly as submitted.
13.2.3.1. **NOTE:** There is a 30-character limitation
13.2.4. If ID does not fit, enter SEE COMMENT
13.2.4.1. Enter complete ID as a comment and make reportable (see section 13.23)
13.2.4.1.1. Ex. Work ID: XXXXXXXXXXXXXX

**13.3. Profile**
13.3.1. Client account number followed by profile (FR).
13.3.1.1. Do NOT copy and paste this information in the Login Form.
13.3.2. Add 00000 followed by profile when:
13.3.2.1. The client does not provide an account number.
13.3.2.2. The account number and name do not match.
13.3.2.3. The account number provided is invalid/inactive.
13.3.3. **NOTE:** NEWACCTRV will automatically be selected on the login form. Do not unselect.
13.3.4. If account number needs to be updated after login, see Reference Guide Section 8: 030

**13.4. Client**
13.4.1. This information will auto-populate once Profile has been entered.

**13.5. Chain of Custody**: (Alternate ID)
13.5.1. This field is only used when clients require three unique identifiers.
13.5.2. If more than three unique identifier(s) are provided, enter as a comment and make reportable.
13.5.2.1. Examples:
13.5.2.1.1. Control Number labels.
13.5.2.1.2. Client Specific identifiers (indicated on requisition)

**13.6. Purchase Order**
13.6.1. This signifies a payment.
13.6.2. Purchase order - Data enter PO number as: XXX
13.6.3. Auto-generated PO numbers:
13.6.3.1. If there is an auto-generated PO number - Do not delete.
13.6.4. *Check: Data enter check number as: CKXXX
13.6.5. *Money Order: Data enter Money order number as: MOXXX
13.6.6. Credit Card: Data enter as: CC
13.6.6.1. If the credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
13.6.7. Letter of Intent: Data enter as: Letter of Intent
13.6.8. *Checks and money orders must be taped onto Check Form located in NMS Intranet (Microsoft Edge -> Intranet -> Shared Documents -> Online Forms -> Specimen Processing -> Check Form).
13.6.9. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

**13.7. Last Name / First Name / Middle Name/Suffix**


Dependencies:

13.7.1. Populate the fields as provided.
13.7.2. If a name is not supplied in the name field, however, other characters are, enter as provided.
13.7.3. If a suffix is supplied, enter in suffix field.
13.7.3.1. Ex. Sr, Jr, III etc.
13.7.4. If other characters are attached to the name, then apply to the field they are attached to.
13.7.5. For manifest, if *last, first* name format is used, apply to appropriate fields. If not, enter name as listed into last name field only.

13.7.6. When a label containing patient information is provided on the requisition, see Reference Guide Section 8: 023

**13.8. Date of Birth (DOB)**
13.8.1. Enter DOB as mm/dd/yyyy

**13.9. Sex**
13.9.1. Select from drop down box:
13.9.1.1. Male ♂
13.9.1.2. Female ♀

**13.10. Disposition**
13.10.1. Disposition Override:
13.10.1.1. If indications appear on paperwork, such as “return” or “pick up,” use drop down box to select appropriate instruction.
13.10.2. Client Disposition:
13.10.2.1. Auto populates when applicable.

**13.11. Package**
13.11.1. Package field is defined as the case-specific, primary packaging.
13.11.2. If receiving an Additional Sample(s) to existing workorder, complete Package Data form. (Addendum XX) see Reference Guide Section 8: 018
13.11.3. Package Sealed: (Y or N)
13.11.4. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
13.11.5. Package Seal Initialed: (Y or N)
13.11.5.1. Can be initialed or signed.
13.11.6. Package Seal Dated: (Y or N)
13.11.7. Package Condition Notes: Documenting unusual packaging conditions.
13.11.7.1. Examples:
13.11.7.1.1. FedEx Bag not sealed.
13.11.7.1.2. Package appeared to be opened.
13.11.7.1.3. No dry ice remains.


Dependencies:

13.11.7.1.4. Package opened by QA.

**13.12. COMM Data (if applicable)**
13.12.1. Enter County into the County field.
13.12.2. Enter Physician/Pathologist name into the Physician/Pathologist Name field.
13.12.3. If COMM Data is missed at login, see Reference Guide Section 8: 035

**13.13. Login Alerts**
13.13.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**13.14. Test Section**
13.14.1. +Add Tests:
13.14.2. Add all requested test(s).
13.14.3. Add NOTEST if client paperwork indicates no testing is required on this workorder.
13.14.4. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
13.14.5. For volume guidelines, see Reference Guide Section 8: 043
13.14.6. If no paperwork is submitted, add a CLARIFYF.
13.14.7. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
13.14.7.1. **NOTE:** What was physically received is documented in Horizon.
13.14.8. Antemortem vs Postmortem
13.14.9. Unless otherwise indicated, when both Antemortem and Postmortem are submitted, test the Antemortem first. If there is not sufficient antemortem volume for the test(s), then use Postmortem.
13.14.10. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
13.14.10.1. **NOTE:** For required volumes refer to QNS Sheet
13.14.11. If sample leaked in transit, add LEAKY test code.
13.14.12. If sample is a STOPVOL, see Reference Guide Section 8: 038
13.14.13. Check to see if sample is clotted by inverting the sample 5 or 6 times and/or visual inspection.
13.14.13.1. If clotted, add CLOTTED comment (see section 13.23) and create a homogenate bottle. See Reference Guide Section 8: 036
13.14.13.2. **NOTE:** Subdural and Spleen samples will always be homogenized
13.14.14. If sample needs to be homogenized for a test but also has a Metals or Iron Ratio test ordered, place a SHARED label on both parent and homogenate. See Reference Guide Section 8: 045
13.14.15. If the client lists a sample on the paperwork and does not send that sample:
13.14.15.1. If testing was added to this sample – Clarify.
13.14.15.2. If testing was not added to this sample: Document on the requisition / paperwork the sample was not received, initial and date.
13.14.16. If client requests Screen/Confirm – Clarify.
13.14.16.1. see Reference Guide Section 8: 037

13.14.17. If client orders a Special Request – Clarify
13.14.17.1. See Reference Guide Section 8: 044
13.14.18. If there are any questions concerning this login:
13.14.18.1. assign a CLARIFYF using the appropriate clarify reason.
13.14.18.2. For a list of clarify reasons, see Reference Guide Section 8: 008
13.14.18.2.1. Including but not limited to:
13.14.18.2.1.1. No return address provided on Sample Submission Form
13.14.18.2.1.2. No Testing marked on paperwork.
13.14.19. The box in front of the test(s) needs to be checked.
13.14.19.1. If no testing is assigned to a sample, check the box in front of the STORE.

**13.15. Collection Date/Time (Enter as military time)**
13.15.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
13.15.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
13.15.2. Estimated times should not be entered.
13.15.3. The collection date/time is taken from the requisition:
13.15.3.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
13.15.3.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
13.15.3.3. If the collection date/time is not provided on the requisition, leave blank.

13.15.4. Collection date/time cannot be taken from the requisition:
13.15.4.1. If collection information is incomplete, leave blank.
13.15.4.1.1. Ex. incomplete year, future date or no date provided.
13.15.4.2. Document in Misc. Info (Reportable) field:
13.15.4.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/time(s)
13.15.4.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
13.15.4.2.2.1. Document the date/time(s) located on the sample.
13.15.4.2.3. If no paperwork, document dates/times visible on sample label
13.15.4.2.4. If sample is not listed on requisition, document dates/times visible on sample label.

13.15.5. **NOTE:** Dates and times on Hospital samples are subjective

**13.16. Matrix**
13.16.1. Log in what is actually received.
13.16.2. If the matrix received is not consistent with paperwork and:
13.16.2.1. The matrix is obvious, log in what was actually received.
13.16.2.1.1. Do not enter a collection date/time.
13.16.2.1.2. Enter note stating the matrix received and what was indicated on the label.
13.16.2.1.2.1. Ex. blood sample with vitreous label




Dependencies:

13.16.2.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
13.16.3. If matrix received is not on paperwork, the matrix can be taken from the sample.
13.16.4. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
13.16.4.1. Document, in the Misc. Info (Reportable), what was on packaging.
13.16.4.1.1. Example: Urine recorded on package
13.16.4.2. Make a copy of the packaging.
13.16.5. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
13.16.6. If matrix on paperwork and sample do not match and testing is requested on this sample (except for blood vs serum/plasma)
13.16.6.1. Uncheck the test code requested.
13.16.6.2. Click +AddTest
13.16.6.3. Enter and Select CLARIFYF
13.16.6.4. Click close.
13.16.6.5. Check the box in front of CLARIFYF.
13.16.6.6. Do not enter a collection date/time.
13.16.6.7. Update Matrix to what is physically received.
13.16.6.8. If blood vs serum/plasma:
13.16.6.8.1. Log in what is physically received and order testing on that matrix, if available.
13.16.6.8.2. If not available, follow steps above.

**13.17. Matrix Source**
13.17.1. Order of Source Preference (when volume is not an issue).
13.17.1.1. Peripheral
13.17.1.2. Subclavian
13.17.1.3. Central
13.17.1.4. Other
13.17.2. The source will always be taken from the paperwork.
13.17.3. If multiple sources are listed, report the source that best represents the location of the draw and document the second source in Misc. Info (Reportable).
13.17.3.1. Example:
13.17.3.1.1. If Hospital is listed in source field and Peripheral is listed elsewhere, add *Peripheral* as the source and *Hospital* in Misc. Info (Reportable).
13.17.4. If no paperwork received, the source may be taken from the sample.
13.17.5. If the source name on the paperwork does not match what is provided on the tube:
13.17.5.1. Enter Source from paperwork.
13.17.5.2. Type Source listed on tube in Misc. Info (Reportable).
13.17.6. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
13.17.6.1. Example: Left/Right
13.17.7. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
13.17.7.1. Example of comment: Femoral recorded on package

**Title: Specimen Processing Accessioning**

13.17.8. **NOTE:** Subdural and Spleen should always be homogenized

13.17.9. Blood Source Chart in preferred order:

| PERIPHERAL Sources | Comment |
|---|---|
| Femoral | |
| Iliac | |
| Peripheral | Arm/Leg |
| Peritoneal | |
| Subdermal | |
| **CENTRAL Sources** | |
| Cardiac | |
| Heart | |
| Aortic | |
| IVC (Inferior Vena Cava) | |
| Central | |
| Jugular | |
| Spleen | |
| Cavity | * |
| Chest | * |
| Pleural | * |
| Pulmonary | * |
| Abdomen | * |
| Thoracic | * |
| **Both Sources** | |
| Antemortem | |
| Subclavian | |
| Donor | |
| Mixed | * |
| Subdural | N/A |
| Brain | N/A |

13.17.9.1. *These are ***not*** preferred samples and should be used as a last resort.

13.17.9.2. **NOTE:** Antemortem / Donor / Mixed can be from either location.




Dependencies:

13.17.10. Drawings, abbreviations and miscellaneous letters are not acceptable substitutes for spelling out the source.
13.17.10.1. Examples:
13.17.10.1.1. Per
13.17.10.1.2. 
13.17.10.1.3. Sub
13.17.10.1.4. CAR
13.17.11. However, common sources ie. Fem (Femoral) and VIT (vitreous) can be used.

13.17.12. **Tissue, Fluid and Solid Sources**
13.17.12.1. Any tissue, fluid or solid source may be taken from the sample if it is not listed on the requisition.
13.17.12.2. If the source name on the paperwork does not match what is provided on the sample - Clarify
13.17.12.3. **NOTE:** Gastric should always be homogenized when tested

13.17.13. Tissue Source Charts in Preferred Order:
13.17.13.1. **Tissue Drug Testing Source Chart**

| Source |
|---|
| Liver |
| Other Organs |
| *Brain |

13.17.13.2. **Tissue CO Testing Source Chart**

| Source |
|---|
| Muscle |
| Spleen |
| Kidney |
| Heart |
| *Liver |

13.17.13.3. *These are **not** preferred samples and should be used as a last resort.

**13.18. Turn**
13.18.1. Defaults to client's specifications.
13.18.2. If paperwork lists any of the below scenarios, change Turn code:
13.18.2.1. RF – Fax/Email Results
13.18.2.2. RC - Call Client

**13.19. Container Type**
13.19.1. Container field represents:
13.19.1.1. Color of cap: first two letters
13.19.1.1.1. For Clear caps with colored stopper always use the color of the stopper
13.19.1.2. Type of container: Plastic or Glass
13.19.1.3. Description: (one of the three below)


Dependencies:

13.19.1.3.1. C Container
13.19.1.3.2. T Tube
13.19.1.3.3. S Stopper
13.19.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

**13.20. Sample Preservative**
13.20.1. Defaults to none.
13.20.2. Light Protected – L
13.20.2.1. Samples are considered light protected if:
13.20.2.1.1. Brown vial
13.20.2.1.2. Amber Sarstedt Transfer vial
13.20.2.1.3. Amber or Brown Container
13.20.2.1.4. Foil wrapped
13.20.2.1.5. Wrapped with material to obstruct light.
13.20.2.1.5.1. Must be fully wrapped.
13.20.2.1.6. Both the tube and the outer wrapping need to be labeled
13.20.3. Frozen – F
13.20.4. Light Protected and Frozen – B
13.20.5. If samples are not received in the required condition for testing:
13.20.5.1. Not Light protected – foil wrap
13.20.5.2. Not Frozen – place into NMS provided container.
13.20.6. Predefined comment will be added (see section 13.23)

**13.21. Hair**
13.21.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
13.21.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

**13.22. Volume**
13.22.1. Volume is estimated.
13.22.2. If volume cannot be taken, leave blank and enter Note (see section 13.32)
13.22.3. If no volume received, enter volume as zero (0) and enter comment (see section 13.23)

**13.23. + Add comments**
13.23.1. Predefined comments
13.23.1.1. If SST received: add appropriate comment.
13.23.1.2. If clotted sample: CLOTTED
13.23.1.3. If no volume received: EMPTY
13.23.1.4. If additional sample: ADDITIONAL
13.23.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
13.23.2. Free text comments
13.23.2.1. Alternate ID
13.23.2.2. P=XXX, H=XXX
13.23.3. **NOTE:** If comment needs to be on report, check Rpt. box

**13.24. + Add additional Data – (Orange box)**
13.24.1. Hair length

**13.25. Sample Sealed** - (Y or N)
13.25.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to "seal" evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

13.25.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

**13.26. Unique Identifiers**
13.26.1. Case ID
13.26.2. Patient ID/Name
13.26.3. Alternate ID
13.26.3.1. MRN or MR Number
13.26.3.2. Donor ID

13.26.4. If the above unique identifiers are not available, Date of Birth and/or Initials are acceptable.

**13.27. Sample Labeled** – (Y, N, X, D or U)

13.27.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

13.27.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 13.23).

13.27.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

13.27.4. **Y (Yes)**
13.27.4.1. Defined as: All the unique identifiers on paperwork match the sample label.
13.27.4.1.1. **NOTE:** The sample label may have additional identifiers.

13.27.5. **N (No)**
13.27.5.1. Defined as: No label on the sample.

13.27.6. **X (Not Applicable)**
13.27.6.1. Containers created by NMS.
13.27.6.1.1. i.e.: hair segmentation, oral fluids, and homogenates
13.27.6.2. Client shipping containers


Dependencies:

13.27.7. **D (Discrepant)**
13.27.7.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label, match and other unique identifier(s) do not.
13.27.7.2. Documentation of a difference between the sample label and paperwork submitted.

13.27.8. **U (Unverified)**
13.27.8.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label match, or handwriting is illegible, or the label was no longer attached.

13.27.8.2. The unique identifier(s) are visible on primary label and don't match the identifiers on a secondary label.

13.27.8.3. Make a copy of all sample labels that are discrepant.
13.27.8.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
13.27.8.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

13.27.8.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

**13.28. Documentation of Sample Labeled As**: – (Y, N, X, D or U)

13.28.1. Enter unique identifiers found on sample label according to the priority order.
13.28.1.1. Case ID
13.28.1.2. Patient Name
13.28.1.3. Alternate ID

13.28.2. If identifying letters are provided on both sample label and submitted paperwork, add the letter in the Sample Labeled As field.
13.28.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

13.28.4. **Y (Yes)**
13.28.4.1. Enter unique identifier from sample label of highest priority.

13.28.5. **N (No)**
13.28.5.1. Enter "NO LABEL"
13.28.5.2. The discrepancy will be documented in Horizon, refer to 13.37

13.28.6. **X (Not Applicable)**
13.28.6.1. leave this field blank.

13.28.7. **D (Discrepant)**

13.28.7.1. Enter unique identifier from sample label of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

13.28.8. **U (Unverified)**
13.28.8.1. Enter all discrepant identifiers from sample label separated by a backslash (/).
13.28.8.1.1. If sample is labeled but cannot be read, write “ILLEGIBLE”.
13.28.8.1.2. If sample is labeled with a barcode only, write “BARCODE ONLY”
13.28.8.1.3. If sample label is no longer attached and sample is not contained individually, write “LABEL NOT ATTACHED”
13.28.8.1.3.1. Make a photocopy of label and discard label.
13.28.8.2. The discrepancy will be documented in Horizon, refer to section 13.37.

**13.29. Sample Dated** – (Y or N)
13.29.1. This question applies to the seal.

**13.30. Sample Initialed** – (Y or N)
13.30.1. This question applies to the seal.
13.30.1.1. Can be initialed or signed.

**13.31. Sample Timed** – (Y or N)
13.31.1. This question applies to the label.

**13.32. Notes**
13.32.1. This information appears on the Login Verification form. This is internal documentation for NMS.
13.32.2. Enter notes pertaining to the sample that may help address an oddity:
13.32.2.1. Examples:
13.32.2.1.1. WO previously received under a different workorder.
13.32.2.1.2. Hair segmentation notes
13.32.2.1.3. Weight not taken due to nature of sample.
13.32.2.1.4. Return packaging notes.
13.32.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: ____grams*** when some of the tissue could not be returned to the original container.

**13.33. Misc. Info (Reportable)**
13.33.1. This information appears on the clients’ report.
13.33.2. Enter any information concerning the sample, login information or conflicts with login information.
13.33.2.1. Examples:
13.33.2.1.1. Collection date and time discrepancies
13.33.2.1.2. Additional source information on paperwork
13.33.2.1.3. Source discrepancies
13.33.2.1.4. Sample descriptions
13.33.2.1.5. Sources not available in Horizon
13.33.2.1.5.1. Ex. Pupa, Placenta




Dependencies:

**13.34. CONF Notes**
13.34.1. Internal notes regarding handling of the specimen.
13.34.1.1. Example:
13.34.1.1.1. Micro and Consume
13.34.1.1.2. Limited Confs or Hold Confs
13.34.1.1.3. Do Not Use
13.34.1.1.4. One Shot Deal

**13.35. Label Count**
13.35.1. Defaults to 1, however, can be changed.
13.35.2. Label(s) will print.

**13.36. Lab I.D. (Container) Label**
13.36.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
13.36.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
13.36.2. Additional preprinted colored labels may be required for cases.
13.36.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
13.36.3.1. Examples:
13.36.3.1.1. Micro: for limited volume samples
13.36.3.1.2. Return: for samples being returned
13.36.3.1.3. Additional Specimen: when clients send additional samples for a specific workorder already in house.
13.36.4. Labeled specimens will be placed in appropriate rack / basket.
13.36.4.1. Aliquot
13.36.4.2. Store

**13.37. Documenting a discrepancy in Horizon**
13.37.1. For ClarifyFDU:
13.37.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
13.37.1.2. Click on Additional Information and scroll to ClarifyFDU.
13.37.1.3. Go to notes/instructions field to enter discrepancy.
13.37.1.4. Enter discrepancy as: paperwork vs sample label
13.37.1.5. Document only in the first sample unless it varies from sample to sample.
13.37.1.5.1. If it varies, add a description to the corresponding sample.
13.37.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
13.37.2. For ClarifyFDN:
13.37.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
13.37.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

**13.38. Choose one of the following to continue:**


Dependencies:

13.38.1. If multiple samples were received for the same requisition, Proceed to section 13.13. When final sample is logged in proceed to section 13.38.
13.38.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 13.38.
13.38.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

13.38.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
13.38.4.1. This is NMS's unique identifier.
13.38.5. Label Count – defaults to 1.
13.38.6. If paperwork is supplied, a requisition label must be applied.
13.38.7. Check the workorder and the workorder I.D. on the label to ensure correct labeling.
13.38.8. Place the workorder label on each document associated with case / patient.
13.38.9. For additional workorder / lab i.d. labels see Printing Labels in Horizon User Guide.
13.38.10. Write the number of pages on the label and circle the number.
13.38.11. You only need to do this on this on one form (preferably the requisition).
13.38.12. The total number is the total number of pages, not documents.

**14. MDI/Other electronic submissions**
**14.1. EDI**
14.1.1. Scan or enter appropriate Number from paperwork.
14.1.2. If MDI and a case is transmitted and information is missing, Horizon Login Form will not allow the case to be logged in. Add NP to the blank required field.
14.1.3. If there is no transmission, proceed with Manual login.
14.1.4. If there is no paperwork, scan or enter appropriate number from sample.

**14.2. Workorder ID**
14.2.1. Information auto populates.

**14.3. Profile**
14.3.1. Information auto populates.
14.3.2. If profile is crossed out and a new account number is written, accept the order and update to 00000 in Horizon, see Reference Guide Section 8: 030

**14.4. Client**
14.4.1. Information auto populates.

**14.5. Chain of Custody**: (Alternate ID)
14.5.1. If MDI, field auto populates with the MDI Number – Do not delete.
14.5.2. If other electronic submission, field auto populates with the number used for transmission - Do not delete.
14.5.3. If a third unique identifier is provided, enter as a comment and make reportable.
14.5.3.1. Example:
14.5.3.1.1. Control Number labels.


Dependencies:

**14.6. Purchase Order**
14.6.1. This signifies a payment.
14.6.2. Purchase order - Data enter PO number as: XXX
14.6.3. Auto-generated PO numbers:
14.6.3.1. If there is an auto-generated PO number - Do not delete.
14.6.4. *Check: Data enter check number as: CKXXX
14.6.5. *Money Order: Data enter Money order number as: MOXXX
14.6.6. Credit Card: Data enter as: CC
14.6.6.1. If the credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
14.6.7. Letter of Intent: Data enter as: Letter of Intent
14.6.8. *Checks and money orders must be taped onto Check Form located in NMS Intranet (Microsoft Edge -> Intranet -> Shared Documents -> Online Forms -> Specimen Processing -> Check Form).
14.6.9. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

**14.7. Last Name / First Name / Middle Name/Suffix**
14.7.1. Auto populates as transmitted.

**14.8. Date of Birth (DOB)**
14.8.1. Auto populates as transmitted.

**14.9. Sex**
14.9.1. Auto populates as transmitted.

**14.10. Disposition**
14.10.1. Disposition Override:
14.10.1.1. Auto populates into Horizon when applicable.
14.10.2. Client Disposition:
14.10.2.1. Auto populates when applicable.

**14.11. Package**
14.11.1. Package field is defined as the case-specific, primary packaging.
14.11.2. Package Sealed: (Y or N)
14.11.3. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
14.11.4. Package Seal Initialed: (Y or N)
14.11.4.1. Can be initialed or signed.
14.11.5. Package Seal Dated: (Y or N)
14.11.6. Package Condition Notes: Documenting unusual packaging conditions.


Dependencies:

14.11.6.1. Examples:
14.11.6.1.1. FedEx Bag not sealed.
14.11.6.1.2. Package appeared to be opened.
14.11.6.1.3. No dry ice remains.

**14.12. Login Alerts**
14.12.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**14.13. Test Section**
14.13.1. All transmitted testing will populate.
14.13.2. If additional testing is indicated on the requisition:
14.13.2.1. +Add Tests
14.13.3. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
14.13.4. For volume guidelines, see Reference Guide Section 8: 043
14.13.5. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
14.13.5.1. Container Type: The terms *Bottle* and *Vial* are generalizations used on submitted paperwork and are not considered a discrepancy.
14.13.5.2. **NOTE:** What was physically received is documented in Horizon.
14.13.6. Antemortem vs Postmortem
14.13.7. Unless otherwise indicated, when both Antemortem and Postmortem are submitted, test the Antemortem first. If there is not sufficient antemortem volume for the test(s), then use Postmortem.
14.13.8. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
14.13.8.1. **NOTE:** For required volumes refer to QNS Sheet
14.13.9. If sample leaked in transit, add LEAKY test code.
14.13.10. If sample is a STOPVOL, see Reference Guide Section 8: 038
14.13.11. Check to see if sample is clotted by inverting the sample 5 or 6 times and/or visual inspection.
14.13.11.1. If clotted, add CLOTTED comment (see section 14.22) and create a homogenate bottle. See Reference Guide Section 8: 036
14.13.11.2. **NOTE:** Subdural and Spleen samples will always be homogenized
14.13.12. If sample needs to be homogenized for a test but also has a Metals or Iron Ratio test ordered, place a SHARED label on both parent and homogenate, see Reference Guide Section 8: 045
14.13.13. If the client lists a sample on the paperwork and does not send that sample:
14.13.13.1. If testing was added to this sample – Clarify.
14.13.13.2. If testing was not added to this sample: Document on the requisition / paperwork the samples was not received, initial and date.
14.13.14. If client requests Screen/Confirm – Clarify
14.13.14.1. See Reference Guide Section 8: 037
14.13.15. If client orders a Special Request – Clarify


Dependencies:

14.13.15.1. See Reference Guide Section 8: 044
14.13.16. If there are any questions concerning this login:
14.13.16.1. assign a CLARIFYF using the appropriate clarify reason.
14.13.16.2. For a list of clarify reasons, see Reference Guide Section 8: 008
14.13.17. The box in front of the test(s) **and** the box in front of the STORE associated with sample need to be checked.
14.13.17.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
14.13.18. (For Serum/Plasma tests only) When the transmitted test matrix (S/P) does not match the sample matrix (S or P), update the matrix to S/P

**14.14. Collection Date/Time (Enter as military time)**
14.14.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
14.14.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
14.14.2. This will auto populate for all transmitted samples.
14.14.3. The collection date/time is taken from the requisition:
14.14.3.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
14.14.3.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
14.14.3.3. If the collection date/time is not provided on the requisition, leave blank.

14.14.4. Collection date/time cannot be taken from the requisition:
14.14.4.1. If collection information is incomplete, leave blank.
14.14.4.1.1. Ex. incomplete year, future date or no date provided.
14.14.4.2. Document in Misc. Info (Reportable) field:
14.14.4.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/time(s)
14.14.4.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
14.14.4.2.2.1. Document the date/time(s) located on the sample.
14.14.4.2.3. If no paperwork, document dates/times visible on sample label.
14.14.4.2.4. If sample is not listed on requisition, document dates/times visible on sample label.

14.14.5. **NOTE:** Dates and times on Hospital samples are subjective

**14.15. Matrix**
14.15.1. Whether or not paperwork is received, matrix should be verified to the sample.
14.15.2. Matrix will auto populate with test code selected.
14.15.3. If the matrix received is not consistent with paperwork and:
14.15.3.1. The matrix is obvious, log in what was actually received.
14.15.3.1.1. Do not enter a collection date/time.
14.15.3.1.2. Enter note stating the matrix received and what was indicated on the label.


Dependencies:

14.15.3.1.2.1. Ex. blood sample with vitreous label
14.15.3.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
14.15.4. If matrix received is not on paperwork, the matrix can be taken from the sample.
14.15.5. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
14.15.5.1. Document, in the Misc. Info (Reportable), what was on packaging.
14.15.5.1.1. Example: Urine recorded on package
14.15.5.2. Make a copy of the packaging.
14.15.6. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
14.15.7. If matrix on paperwork and sample do not match and testing is requested on this sample (with the exception of blood vs serum/plasma):
14.15.7.1. Uncheck the test code requested.
14.15.7.2. Click +AddTest
14.15.7.3. Enter and Select CLARIFYF
14.15.7.4. Click close.
14.15.7.5. Check the box in front of CLARIFYF.
14.15.7.6. Do not enter a collection date/time.
14.15.7.7. Update Matrix to what is physically received.
14.15.7.8. If blood vs serum/plasma:
14.15.7.8.1. Log in what is physically received and order testing on that matrix, if available.
14.15.7.8.2. If not available follow steps above.

**14.16. Matrix Source**
14.16.1. Order of Source Preference (when volume is not an issue).
14.16.1.1. Peripheral
14.16.1.2. Subclavian
14.16.1.3. Central
14.16.1.4. Other
14.16.2. The source will always be taken from the paperwork.
14.16.3. If no paperwork received, the source may be taken from the sample.
14.16.4. If the source name on the paperwork does not match what is provided on the tube:
14.16.4.1. Enter Source from paperwork.
14.16.4.2. Type Source listed on tube in Misc. Info (Reportable).
14.16.5. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
14.16.5.1. Example: Left/Right
14.16.6. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
14.16.6.1. Example of comment: Femoral recorded on package

14.16.7. **NOTE:** Subdural and Spleen should always be homogenized when tested

14.16.8. Blood Source Chart in preferred order:


Dependencies:

**Title: Specimen Processing Accessioning**

| PERIPHERAL Sources | Comment |
|---|---|
| Femoral | |
| Iliac | |
| Peripheral | Arm/Leg |
| Peritoneal | |
| Subdermal | |
| **CENTRAL Sources** | |
| Cardiac | |
| Heart | |
| Aortic | |
| IVC (Inferior Vena Cava) | |
| Central | |
| Jugular | |
| Spleen | |
| Cavity | * |
| Chest | * |
| Pleural | * |
| Pulmonary | * |
| Abdomen | * |
| Thoracic | * |
| **Both Sources** | |
| Antemortem | |
| Subclavian | |
| Donor | |
| Mixed | * |
| Subdural | N/A |
| Brain | N/A |

14.16.8.1. *These are ***not*** preferred samples and should be used as a last resort.

14.16.8.2. **NOTE:** Antemortem / Donor / Mixed can be from either location.
14.16.9. Drawings, abbreviations and miscellaneous letters are not acceptable substitutes for spelling out the source.
14.16.9.1. Examples:
14.16.9.1.1. Per


Dependencies:

**Title: Specimen Processing Accessioning**

14.16.9.2. 
14.16.9.3. Sub
14.16.9.4. CAR
14.16.10. However, common sources ie. Fem (Femoral) and VIT (vitreous) can be used.

14.16.11. **Tissue, Fluid and Solid Sources**
14.16.11.1. Any tissue, fluid or solid source may be taken from the sample if it is not listed on the requisition.
14.16.11.2. If the source name on the paperwork does not match what is provided on the sample - Clarify
14.16.11.3. **NOTE:** Gastric should always be homogenized when tested

14.16.12. Tissue Source Charts in Preferred Order:
14.16.12.1. **Tissue Drug Testing Source Chart**

| Source |
|---|
| Liver |
| Other Organs |
| *Brain |

14.16.12.2. **Tissue CO Testing Source Chart**

| Source |
|---|
| Muscle |
| Spleen |
| Kidney |
| Heart |
| *Liver |

14.16.12.3. *These are **not** preferred samples and should be used as a last resort.

**14.17. Turn**
14.17.1. Defaults to client's specifications.
14.17.2. If paperwork lists any of the below scenarios, change Turn code:
14.17.2.1. RF – Fax/Email Results
14.17.2.2. RC - Call Client

**14.18. Container Type**
14.18.1. Container field represents:
14.18.1.1. Color of cap: first two letters
14.18.1.1.1. For Clear caps with colored stopper always use the color of the stopper
14.18.1.2. Type of container: Plastic or Glass
14.18.1.3. Description: (one of the three below)
14.18.1.3.1. C Container
14.18.1.3.2. T Tube
14.18.1.3.3. S Stopper
14.18.2. **NOTE:** Misc container types can also be found in the drop down. Ex: PB – Plastic Bag

**14.19. Sample Preservative**
14.19.1. Defaults to none.
14.19.2. Light Protected – L
14.19.2.1. Samples are considered light protected if:
14.19.2.1.1. Brown vial
14.19.2.1.2. Amber Sarstedt Transfer vial
14.19.2.1.3. Amber or Brown Container
14.19.2.1.4. Foil wrapped
14.19.2.1.5. Wrapped with material to obstruct light.
14.19.2.1.5.1. Must be fully wrapped.
14.19.2.1.6. Both the tube and the outer wrapping need to be labeled
14.19.3. Frozen – F
14.19.4. Light Protected and Frozen – B
14.19.5. If samples are not received in the required condition for testing;
14.19.5.1. Not Light protected – foil wrap
14.19.5.2. Not Frozen – place into NMS provided container.
14.19.6. Predefined comment will be added (see section 14.22)

**14.20. Hair**
14.20.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
14.20.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

**14.21. Volume**
14.21.1. Volume is estimated.
14.21.2. If volume cannot be taken, leave blank and enter Note (see section 14.31)
14.21.3. If no volume received, enter volume as zero (0) and enter comment (see section 14.22)

**14.22. + Add comments**
14.22.1. Predefined comments
14.22.1.1. If no paperwork received: NOPAPER
14.22.1.2. If SST received: add appropriate comment.
14.22.1.3. If clotted sample: CLOTTED
14.22.1.4. If no volume received: EMPTY
14.22.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
14.22.2. Free text comments
14.22.2.1. Alternate ID
14.22.2.2. P=XXX, H=XXX
14.22.3. **NOTE:** If comment needs to be on report, check Rpt. box

**14.23. + Add additional Data – (Orange box)**
14.23.1. Hair length

**14.24. Sample Sealed** - (Y or N)


Dependencies:

14.24.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to "seal" evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

14.24.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

**14.25. Unique Identifiers**
14.25.1. Case ID
14.25.2. Patient ID/Name
14.25.3. Alternate ID
14.25.3.1. MDI number
14.25.3.2. MRN or MR Number
14.25.3.3. Donor ID

14.25.4. If above unique identifiers are not available Date of Birth and/or Initials are acceptable.

**14.26. Sample Labeled** – (Y, N, X, D or U)

14.26.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

14.26.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 14.22).

14.26.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

14.26.4. **Y (Yes)**
14.26.4.1. Defined as: All the unique identifiers on paperwork match the sample label.
14.26.4.1.1. **NOTE:** The sample label may have additional identifiers.

14.26.5. **N (No)**
14.26.5.1. Defined as: No label on the sample.

14.26.6. **X (Not Applicable)**
14.26.6.1. Containers created by NMS.
14.26.6.1.1. Examples.: hair segmentation, oral fluids, and homogenates
14.26.6.2. Client shipping containers

14.26.7. **D (Discrepant)**
14.26.7.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label, match and other unique identifiers do not.


Dependencies:

14.26.7.2. Documentation of a difference between the sample label and paperwork submitted.

14.26.8. **U (Unverified)**
14.26.8.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label match, or handwriting is illegible, or the label was no longer attached.

14.26.8.2. The unique identifier(s) are visible on primary label and don't match the identifiers on the secondary label (MDI label).

14.26.8.3. Make a copy of all sample labels that are discrepant.
14.26.8.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
14.26.8.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

14.26.8.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

**14.27. Documentation of Sample Labeled As**: – (Y, N, X, D or U)

14.27.1. Enter unique identifiers found on sample label according to the priority order.
14.27.1.1. Case ID
14.27.1.2. Patient Name
14.27.1.3. Alternate ID

14.27.2. If identifying letters are provided on both sample label and submitted paperwork, add the letter in the Sample Labeled As field.
14.27.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

14.27.4. **Y (Yes)**
14.27.4.1. Enter unique identifier from sample label of highest priority.

14.27.5. **N (No)**
14.27.5.1. Enter "NO LABEL"
14.27.5.2. The discrepancy will be documented in Horizon, refer to 14.36.

14.27.6. **X (Not Applicable)**
14.27.6.1. leave this field blank.

14.27.7. **D (Discrepant)**
14.27.7.1. Enter unique identifier from sample label of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

14.27.8. **U (Unverified)**
14.27.8.1. Enter all discrepant identifiers from sample label separated by a backslash (/).

14.27.8.1.1. If sample is labeled but cannot be read, write “ILLEGIBLE”.
14.27.8.1.2. If sample is labeled with a barcode only, write “BARCODE ONLY”
14.27.8.1.3. If sample label is no longer attached and sample is not contained individually, write “LABEL NOT ATTACHED”
14.27.8.1.3.1. Make a photocopy of label and discard label.
14.27.8.2. The discrepancy will be documented in Horizon, refer to section 14.36.

**14.28. Sample Dated** – (Y or N)
14.28.1. This question applies to the seal.

**14.29. Sample Initialed** – (Y or N)
14.29.1. This question applies to the seal.
14.29.1.1. Can be initialed or signed.

**14.30. Sample Timed** – (Y or N)
14.30.1. This question applies to the label.

**14.31. Notes**
14.31.1. This information appears on the Login Verification form. This is internal documentation for NMS.
14.31.2. Enter notes pertaining to the sample that may help address an oddity:
14.31.2.1. Examples:
14.31.2.1.1. WO previously received under a different workorder.
14.31.2.1.2. Hair segmentation notes
14.31.2.1.3. Weight not taken due to nature of sample.
14.31.2.1.4. Return packaging notes.
14.31.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: ____grams*** when some of the tissue could not be returned to the original container.

**14.32. Misc. Info (Reportable)**
14.32.1. This information appears on the clients’ report.
14.32.2. Enter any information concerning the sample, login information or conflicts with login information.
14.32.2.1. Examples:
14.32.2.1.1. Collection date and time discrepancies
14.32.2.1.2. Additional source information on paperwork
14.32.2.1.3. Source discrepancies
14.32.2.1.4. Sample descriptions
14.32.2.1.5. Sources not available in Horizon
14.32.2.1.5.1. Ex. Pupa, Placenta

**14.33. CONF Notes**
14.33.1. Internal notes regarding handling of the specimen.
14.33.1.1. Example:
14.33.1.1.1. Micro and Consume


Dependencies:

14.33.1.1.2. Limited Confs or Hold Confs
14.33.1.1.3. Do Not Use
14.33.1.1.4. One Shot Deal

**14.34. Label Count**
14.34.1. Defaults to 1, however, can be changed.
14.34.2. Label(s) will print.

**14.35. Lab I.D. (Container) Label**
14.35.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
14.35.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
14.35.2. Additional preprinted colored labels may be required for cases.
14.35.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
14.35.3.1. Examples:
14.35.3.1.1. Micro: for limited volume samples
14.35.3.1.2. Return: for samples being returned
14.35.3.1.3. Additional Specimen: when clients send additional samples for a specific workorder already in house.
14.35.4. Labeled specimens will be placed in appropriate rack / basket.
14.35.4.1. Aliquot
14.35.4.2. Store

**14.36. Documenting a discrepancy in Horizon**
14.36.1. For ClarifyFDU:
14.36.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
14.36.1.2. Click on Additional Information and scroll to ClarifyFDU.
14.36.1.3. Go to notes/instructions field to enter discrepancy.
14.36.1.4. Enter discrepancy as: paperwork vs sample label
14.36.1.5. Document only in the first sample unless it varies from sample to sample.
14.36.1.5.1. If it varies, add a description to the corresponding sample.
14.36.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
14.36.2. For ClarifyFDN:
14.36.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
14.36.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

**14.37. Choose one of the following to continue:**
14.37.1. If multiple samples were received for the same requisition, Proceed to section 14.12. When final sample is logged in proceed to section 14.37.
14.37.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 14.37.

14.37.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

14.37.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
14.37.4.1. This is NMS's unique identifier.
14.37.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
14.37.6. If paperwork is supplied or created (ie photocopies), a requisition label must be applied.
14.37.7. Check the workorder and the workorder I.D. on the label to assure correct labeling.
14.37.8. Place the workorder label on each document associated with case / patient.
14.37.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
14.37.10. Write the number of pages on the label and circle the number.
14.37.11. You only need to do this on this on one form (preferably the requisition).
14.37.12. The total number is the total number of pages, not documents.

**15. Lablynx**
**15.1. EDI**
15.1.1. Enter Workorder ID/Case number.
15.1.2. If there is no transmission, proceed with Manual login.
15.1.3. If there is no paperwork, enter Case number from sample.

**15.2. Workorder ID**
15.2.1. Information auto populates.

**15.3. Profile**
15.3.1. Information auto populates.

**15.4. Client**
15.4.1. Information auto populates.

**15.5. Chain of Custody**: (Alternate ID)
15.5.1. This field auto populates with the Workorder ID number – Do not delete.
15.5.2. If a third unique identifier is provided, enter as a comment and make reportable.
15.5.2.1. Example:
15.5.2.1.1. Control Number labels.

**15.6. Purchase Order**
15.6.1. This will remain blank.

**15.7. Last Name / First Name / Middle Name/Suffix:**
15.7.1. Auto populates as transmitted.

**15.8. Date of Birth (DOB)**
15.8.1. Auto populates as transmitted.


Dependencies:

**15.9. Sex**
15.9.1. Auto populates as transmitted.

**15.10. Disposition**
15.10.1. Disposition Override:
15.10.1.1. If special instructions appear on paperwork, such as “return” or “pick up,” use drop down box to select appropriate instruction.
15.10.2. Client Disposition
15.10.2.1. Auto populates when applicable.

**15.11. Package**
15.11.1. Package field is defined as the case-specific, primary packaging.
15.11.2. Package Sealed: (Y or N)
15.11.3. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
15.11.4. Package Seal Initialed: (Y or N)
15.11.4.1. Can be initialed or signed.
15.11.5. Package Seal Dated: (Y or N)
15.11.6. Package Condition Notes: Documenting unusual packaging conditions.
15.11.6.1. Examples:
15.11.6.1.1. FedEx Bag not sealed.
15.11.6.1.2. Package appeared to be opened.
15.11.6.1.3. No dry ice remains.

**15.12. COMM Data**
15.12.1. Enter Pathologist name into the Physician/Pathologist Name field.
15.12.2. If COMM Data is missed at login, see Reference Guide Section 8: 035

**15.13. Login Alerts**
15.13.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**15.14. Test Section**
15.14.1. All transmitted testing will populate.
15.14.2. If additional testing is indicated on the requisition:
15.14.2.1. +Add Tests
15.14.3. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
15.14.4. For volume guidelines, see Reference Guide Section 8: 043




Dependencies:

15.14.5. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
15.14.5.1. **NOTE:** What was physically received is documented in Horizon
15.14.6. Antemortem vs Postmortem
15.14.7. Unless otherwise indicated, when both Antemortem and Postmortem are submitted, test the Antemortem first. If there is not sufficient antemortem volume for the test(s), then use Postmortem.
15.14.8. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
15.14.8.1. **NOTE:** For required volumes refer to QNS Sheet
15.14.9. If sample leaked in transit, add LEAKY test code.
15.14.10. If sample is a STOPVOL, see Reference Guide Section 8: 038
15.14.11. Check to see if sample is clotted by inverting the sample 5 or 6 times and/or visual inspection.
15.14.11.1. If clotted, add CLOTTED comment (see section 15.23) and create a homogenate bottle. see Reference Guide Section 8: 036
15.14.11.2. **NOTE:** Subdural and Spleen samples will always be homogenized
15.14.12. If sample needs to be homogenized for a test but also has a Metals or Iron Ratio test ordered, place a SHARED label on both parent and homogenate, see Reference Guide Section 8: 045
15.14.13. If the client lists a sample on the paperwork and does not send that sample:
15.14.13.1. If testing was added to this sample – Clarify.
15.14.13.2. If testing was not added to this sample: Document on the requisition / paperwork the samples was not received, initial and date.
15.14.14. If client requests Screen/Confirm – Clarify
15.14.14.1. See Reference Guide Section 8: 037
15.14.15. If client orders a Special Request – Clarify
15.14.15.1. See Reference Guide Section 8: 044
15.14.16. If there are any questions concerning this login:
15.14.16.1. assign a CLARIFYF using the appropriate clarify reason.
15.14.16.2. For a list of clarify reasons, see Reference Guide Section 8: 008
15.14.17. The box in front of the test(s) needs to be checked.
15.14.17.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
15.14.18. (For Serum/Plasma test only) When the transmitted test matrix (S/P) does not match the sample matrix (S or P), update the matrix to S/P

**15.15. Collection Date/Time (Enter as military time)**
15.15.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
15.15.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
15.15.2. This will auto populate for all transmitted samples.
15.15.3. If there is a discrepancy between the transmitted time and time on requisition, use transmitted time.

15.15.4. The collection date/time is taken from the requisition:
15.15.4.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
15.15.4.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
15.15.4.3. If the collection date/time is not provided on the requisition, leave blank.

15.15.5. Collection date/time cannot be taken from the requisition:
15.15.5.1. If collection information is incomplete, leave blank.
15.15.5.1.1. Ex. Incomplete year, future date or no date provided.
15.15.5.2. Document in Misc. Info (Reportable) field:
15.15.5.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/time(s)
15.15.5.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
15.15.5.2.2.1. Document the date/time(s) located on the sample.
15.15.5.2.3. If no paperwork, document dates/times visible on sample label
15.15.5.2.4. If samples is not listed on requisition, document dates/times visible on sample label

15.15.6. **NOTE:** Dates and times on Hospital samples are subjective

**15.16. Matrix**
15.16.1. Whether or not paperwork is received, matrix should be verified to the sample.
15.16.2. Matrix will auto populate with test code selected.
15.16.3. If the matrix received is not consistent with paperwork and:
15.16.3.1. The matrix is obvious, log in what was actually received.
15.16.3.1.1. Do not enter a collection date/time.
15.16.3.1.2. Enter note stating the matrix received and what was indicated on the label.
15.16.3.1.2.1. Ex. blood sample with vitreous label
15.16.3.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
15.16.4. If matrix received is not on paperwork, the matrix can be taken from the sample.
15.16.5. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
15.16.5.1. Document, in the Misc. Info (Reportable), what was on packaging.
15.16.5.1.1. Example: Urine recorded on package
15.16.5.2. Make a copy of the packaging.
15.16.6. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
15.16.7. If matrix on paperwork and sample do not match and testing is requested on this sample (except for blood vs serum/plasma):
15.16.7.1. Uncheck the test code requested.
15.16.7.2. Click +AddTest
15.16.7.3. Enter and Select CLARIFYF
15.16.7.4. Click close.

15.16.7.5. Check the box in front of CLARIFYF.
15.16.7.6. Do not enter a collection date/time.
15.16.7.7. Update Matrix to what is physically received.
15.16.7.8. If blood vs serum/plasma:
15.16.7.8.1. Log in what is physically received and order testing on that matrix, if available.
15.16.7.8.2. If not available, follow steps above.

**15.17. Matrix Source:**
15.17.1. Order of Source Preference (when volume is not an issue).
15.17.1.1. Peripheral
15.17.1.2. Subclavian
15.17.1.3. Central
15.17.1.4. Other
15.17.2. The source will always be taken from the paperwork.
15.17.3. If no paperwork received, the source may be taken from the sample.
15.17.4. If the source name on the paperwork does not match what is provided on the tube:
15.17.4.1. Enter Source from paperwork.
15.17.4.2. Type Source listed on tube in Misc. Info (Reportable).
15.17.5. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
15.17.5.1. Example: Left/Right
15.17.6. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
15.17.6.1. Example of comment: Femoral recorded on package

15.17.7. **NOTE:** Subdural and Spleen should always be homogenized when tested

15.17.8. Blood Source Chart in preferred order:

| **PERIPHERAL Sources** | **Comment** |
|---|---|
| Femoral | |
| Iliac | |
| Peripheral | Arm/Leg |
| Peritoneal | |
| Subdermal | |
| **CENTRAL Sources** | |
| Cardiac | |
| Heart | |
| Aortic | |
| IVC (Inferior Vena Cava) | |


Dependencies:

| | |
|---|---|
| Central | |
| Jugular | |
| Spleen | |
| Cavity | * |
| Chest | * |
| Pleural | * |
| Pulmonary | * |
| Abdomen | * |
| Thoracic | * |
| **Both Sources** | |
| Antemortem | |
| Subclavian | |
| Donor | |
| Mixed | * |
| Subdural | N/A |
| Brain | N/A |

15.17.8.1. *These are ***not*** preferred samples and should be used as a last resort.

15.17.8.2. **NOTE:** Antemortem / Donor / Mixed can be from either location.
15.17.9. Drawings, abbreviations and miscellaneous letters are not acceptable substitutes for spelling out the source.
15.17.9.1. Examples:
15.17.9.1.1. Per

15.17.9.1.2.
15.17.9.1.3. Sub
15.17.9.1.4. CAR
15.17.10. However, common sources ie. Fem (Femoral) and VIT (vitreous) can be used.

15.17.11. **Tissue, Fluid and Solid Sources**
15.17.11.1. Any tissue, fluid or solid source may be taken from the sample if it is not listed on the requisition.
15.17.11.2. If the source name on the paperwork does not match what is provided on the sample - Clarify
15.17.11.3. **NOTE:** Gastric should always be homogenized when tested

15.17.12. Tissue Source Charts in Preferred Order:
15.17.12.1. **Tissue Drug Testing Source Chart**

| **Source** |
|---|
| Liver |


Dependencies:

**Title: Specimen Processing Accessioning**

| |
|---|
| Other Organs |
| *Brain |

15.17.12.2. **Tissue CO Testing Source Chart**

| Source |
|---|
| Muscle |
| Spleen |
| Kidney |
| Heart |
| *Liver |

15.17.12.3. *These are **not** preferred samples and should be used as a last resort.

**15.18. Turn**
15.18.1. Defaults to client's specifications.
15.18.2. If paperwork lists any of the below scenarios, change Turn code:
15.18.2.1. RF – Fax/Email Results
15.18.2.2. RC - Call Client

**15.19. Container Type**
15.19.1. Container field represents:
15.19.1.1. Color of cap: first two letters
15.19.1.1.1. For Clear caps with colored stopper always use the color of the stopper
15.19.1.2. Type of container: Plastic or Glass
15.19.1.3. Description: (one of the three below)
15.19.1.3.1. C Container
15.19.1.3.2. T Tube
15.19.1.3.3. S Stopper
15.19.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

**15.20. Sample Preservative**
15.20.1. Defaults to none.
15.20.2. Light Protected – L
15.20.2.1. Samples are considered light protected if:
15.20.2.1.1. Brown vial
15.20.2.1.2. Amber Sarstedt Transfer vial
15.20.2.1.3. Amber or Brown Container
15.20.2.1.4. Foil wrapped
15.20.2.1.5. Wrapped with material to obstruct light.
15.20.2.1.5.1. Must be fully wrapped.
15.20.2.1.6. Both the tube and the outer wrapping need to be labeled
15.20.3. Frozen – F
15.20.4. Light Protected and Frozen – B
15.20.5. If samples are not received in the required condition for testing;
15.20.5.1. Not Light protected – foil wrap
15.20.5.2. Not Frozen – place into NMS provided container.


Dependencies:

15.20.6. Predefined comment will be added (see section 15.23)

**15.21. Hair**
15.21.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
15.21.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

**15.22. Volume**
15.22.1. Volume is estimated.
15.22.2. If volume cannot be taken, leave blank and enter Note (see section 15.32)
15.22.3. If no volume received, enter volume as zero (0) and enter comment (see section 15.23)

**15.23. + Add comments**
15.23.1. Predefined comments
15.23.1.1. If no paperwork received: NOPAPER
15.23.1.2. If SST received: add appropriate comment.
15.23.1.3. If clotted sample: CLOTTED
15.23.1.4. If no volume received: EMPTY
15.23.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
15.23.2. Free text comments
15.23.2.1. Alternate ID
15.23.2.2. P=XXX, H=XXX
15.23.3. **NOTE:** If comment needs to be on report, check Rpt. box

**15.24. + Add additional Data – (Orange box)**
15.24.1. Hair length

**15.25. Sample Sealed** - (Y or N)
15.25.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

15.25.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

**15.26. Unique Identifiers**
15.26.1. Case ID
15.26.2. Patient ID/Name
15.26.3. Alternate ID
15.26.3.1. MRN or MR Number
15.26.3.2. Donor ID

15.26.4. If the above unique identifiers are not available Date of Birth and /or Initials are acceptable.


Dependencies:

**15.27. Sample Labeled** – (Y, N, X, D or U)

15.27.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

15.27.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 15.23).

15.27.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

15.27.4. **Y (Yes)**
15.27.4.1. Defined as: All the unique identifiers on paperwork match the sample label.
15.27.4.1.1. **NOTE:** The sample label may have additional identifiers.

15.27.5. **N (No)**
15.27.5.1. Defined as: No label on the sample.

15.27.6. **X (Not Applicable)**
15.27.6.1. Containers created by NMS.
15.27.6.1.1. i.e.: hair segmentation, oral fluids, and homogenates
15.27.6.2. Client shipping containers

15.27.7. **D (Discrepant)**
15.27.7.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label, match and other unique identifiers do not.
15.27.7.2. Documentation of a difference between the sample label and paperwork submitted.

15.27.8. **U (Unverified)**
15.27.8.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label match, or handwriting is illegible, or the label was no longer attached.

15.27.8.2. The unique identifier(s) are visible on the primary label and don't match the identifiers on a secondary label.

15.27.8.3. Make a copy of all sample labels that are discrepant.
15.27.8.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
15.27.8.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

15.27.8.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

**Title: Specimen Processing Accessioning**

**15.28. Documentation of Sample Labeled As**: – (Y, N, X, D or U)

15.28.1. Enter unique identifiers found on sample label according to the priority order.
15.28.1.1. Case ID
15.28.1.2. Patient Name
15.28.1.3. Alternate ID
15.28.1.3.1. Must include full ID number.
15.28.1.3.1.1. Example: ME2024-12345**-01-15**

15.28.2. If identifying letters are provided on both sample label and submitted paperwork, add the letter in the Sample Labeled As field.
15.28.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

15.28.4. **Y (Yes)**
15.28.4.1. Enter unique identifier from sample label of highest priority.

15.28.5. **N (No)**
15.28.5.1. Enter “NO LABEL”
15.28.5.2. The discrepancy will be documented in Horizon, refer to 15.37

15.28.6. **X (Not Applicable)**
15.28.6.1. leave this field blank.

15.28.7. **D (Discrepant)**
15.28.7.1. Enter unique identifier from sample label of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

15.28.8. **U (Unverified)**
15.28.8.1. Enter all discrepant identifiers from sample label separated by a backslash (/).
15.28.8.1.1. If sample is labeled but cannot be read, write “ILLEGIBLE”.
15.28.8.1.2. If sample is labeled with a barcode only, write “BARCODE ONLY”
15.28.8.1.3. If sample label is no longer attached and sample is not contained individually, write “LABEL NOT ATTACHED”
15.28.8.1.3.1. Make a photocopy of label and discard label.
15.28.8.2. The discrepancy will be documented in Horizon, refer to section 15.37.

**15.29. Sample Dated** – (Y or N)
15.29.1. This question applies to the seal.

**15.30. Sample Initialed** – (Y or N)
15.30.1. This question applies to the seal.
15.30.1.1. Can be initialed or signed.

**15.31. Sample Timed** – (Y or N)
15.31.1. This question applies to the label.




Dependencies:

**15.32. Notes**

15.32.1. This information appears on the Login Verification. This is internal documentation for NMS.

15.32.2. Enter notes pertaining to the sample that may help address an oddity:

15.32.2.1. Examples:

15.32.2.1.1. WO previously received under a different workorder.

15.32.2.1.2. Hair segmentation notes

15.32.2.1.3. Weight not taken due to nature of sample.

15.32.2.1.4. Return packaging notes.

15.32.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: ____grams*** when some of the tissue could not be returned to the original container.

**15.33. Misc. Info (Reportable)**

15.33.1. This information appears on the clients' report.

15.33.2. Enter any information concerning the sample, login information or conflicts with login information.

15.33.2.1. Examples:

15.33.2.1.1. Collection date and time discrepancies

15.33.2.1.2. Additional source information on paperwork

15.33.2.1.3. Source discrepancies

15.33.2.1.4. Sample descriptions

15.33.2.1.5. Sources not available in Horizon

15.33.2.1.5.1. Ex. Pupa, Placenta

**15.34. CONF Notes**

15.34.1. Internal notes regarding handling of the specimen.

15.34.1.1. Example:

15.34.1.1.1. Micro and Consume

15.34.1.1.2. Limited Confs or Hold Confs

15.34.1.1.3. Do Not Use

15.34.1.1.4. One Shot Deal

**15.35. Label Count**

15.35.1. Defaults to 1, however, can be changed.

15.35.2. Label(s) will print.

**15.36. Lab I.D. (Container) Label**

15.36.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)

15.36.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.

15.36.2. Additional preprinted colored labels may be required for cases.

15.36.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
15.36.3.1. Examples:
15.36.3.1.1. Micro: for limited volume samples
15.36.3.1.2. Return: for samples being returned
15.36.3.1.3. Additional Specimen: when clients provide additional samples for a specific workorder already in house.
15.36.4. Labeled specimens will be placed in appropriate rack / basket.
15.36.4.1. Aliquot
15.36.4.2. Store

**15.37. Documenting a discrepancy in Horizon**
15.37.1. For ClarifyFDU:
15.37.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
15.37.1.2. Click on Additional Information and scroll to ClarifyFDU.
15.37.1.3. Go to notes/instructions field to enter discrepancy.
15.37.1.4. Enter discrepancy as: paperwork vs sample label
15.37.1.5. Document only in the first sample unless it varies from sample to sample.
15.37.1.5.1. If it varies, add a description to the corresponding sample.
15.37.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
15.37.2. For ClarifyFDN:
15.37.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
15.37.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

**15.38. Choose one of the following to continue:**
15.38.1. If multiple samples were received for the same requisition, Proceed to section 15.13. When final sample is logged in proceed to section 15.38.
15.38.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 15.38.
15.38.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

15.38.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
15.38.4.1. This is NMS's unique identifier.
15.38.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
15.38.6. If paperwork is supplied, a requisition label must be applied.
15.38.7. Check the workorder and the workorder I.D. on the label to assure correct labeling.
15.38.8. Place the workorder label on each document associated with case / patient.
15.38.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
15.38.10. Write the number of pages on the label and circle the number.
15.38.11. You only need to do this on this on one form (preferably the requisition).
15.38.12. The total number is the total number of pages, not documents.




Dependencies:

**Title: Specimen Processing Accessioning**

**16. Police and non-postmortem**

16.1.1. If outside packaging evidence/chain of custody received:
16.1.1.1. If filled out, make a photocopy for OnBase.
16.1.1.2. If blank, discard

**16.2. Manuals**
16.2.1. **EDI**
16.2.1.1. Field is not used.

16.2.2. If no paperwork received with sample, enter information from the sample. Make a photocopy of the sample(s). This is now your manual paperwork.
16.2.3. If Additional Sample Submission Form is received, see Reference Guide Section 8: 018

16.2.4. **Workorder ID**
16.2.4.1. Client case number / Accession number
16.2.4.2. Do NOT copy and paste this information in the Login Form.
16.2.4.3. Data enter exactly as submitted.
16.2.4.3.1. **NOTE:** There is a 30-character limitation
16.2.4.4. If ID does not fit, enter SEE COMMENT
16.2.4.4.1. Enter complete ID as a comment and make reportable (see section 16.2.25)
16.2.4.4.1.1. Ex. Work ID: XXXXXXXXXXXXXX

16.2.5. **Profile**
16.2.5.1. Client account number followed by profile (FR).
16.2.5.1.1. Do NOT copy and paste this information in the Login Form.
16.2.5.2. Add 00000 followed by profile when:
16.2.5.2.1. The client does not provide an account number.
16.2.5.2.2. The account number and name do not match.
16.2.5.2.3. The account number provided is invalid/inactive.
16.2.5.3. **NOTE:** NEWACCTRV will automatically be selected on the login form. Do not unselect.
16.2.5.4. If account number needs to be updated after login, see Reference Guide Section 8: 030

16.2.6. **Client**
16.2.6.1. This information will auto-populate once Profile has been entered.

16.2.7. **Chain of Custody**: (Alternate ID)
16.2.7.1. This field is only used when clients require three unique identifiers.
16.2.7.1.1. Example: Control Number labels

16.2.8. **Purchase Order**
16.2.8.1. This signifies a payment.
16.2.8.2. Purchase order - Data enter PO number as: XXX


Dependencies:

16.2.8.3. Auto-generated PO numbers:
16.2.8.3.1. If there is an auto-generated PO number - Do not delete.
16.2.8.4. *Check: Data enter check number as: CKXXX
16.2.8.5. *Money Order: Data enter Money order number as: MOXXX
16.2.8.6. Credit Card: Data enter as: CC
16.2.8.6.1. If the credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
16.2.8.7. Letter of Intent: Data enter as: Letter of Intent
16.2.8.8. *Checks and money orders must be taped onto Check Form located in NMS Intranet (Microsoft Edge -> Intranet -> Shared Documents -> Online Forms -> Specimen Processing -> Check Form).
16.2.8.9. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

16.2.9. **Last Name / First Name / Middle Name/Suffix**
16.2.9.1. Populate the fields as provided.
16.2.9.2. If a name is not supplied in the name field, however, other characters are, enter as provided.
16.2.9.3. If a suffix is supplied, enter in suffix field.
16.2.9.3.1. Ex. Sr, Jr, III etc.
16.2.9.4. If other characters are attached to the name, then apply to the field they are attached to.

16.2.10. **Date of Birth (DOB)**
16.2.10.1. Enter DOB as mm/dd/yyyy

16.2.11. **Sex**
16.2.11.1. Select from drop down box:
16.2.11.1.1. Male ♂
16.2.11.1.2. Female ♀

16.2.12. **Disposition**
16.2.12.1. Disposition Override:
16.2.12.1.1. If indications appear on paperwork, such as “return” or “pick up,” use drop down box to select appropriate instruction.
16.2.12.2. Client Disposition
16.2.12.2.1. Auto populates when applicable.

16.2.13. **Package**
16.2.13.1. Package field is defined as the case-specific, primary packaging.
16.2.13.2. If receiving an Additional Sample(s) to existing workorder, complete Package Data form. (Addendum XX) see Reference Guide Section 8: 018
16.2.13.3. Package Sealed: (Y or N)
16.2.13.4. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is

not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

16.2.13.5. Package Seal Initialed: (Y or N)
16.2.13.5.1. Can be initialed or signed.
16.2.13.6. Package Seal Dated: (Y or N)
16.2.13.7. Package Condition Notes: Documenting unusual packaging conditions.
16.2.13.7.1. Examples:
16.2.13.7.1.1. FedEx Bag not sealed.
16.2.13.7.1.2. Package appeared to be opened.
16.2.13.7.1.3. No dry ice remains.

16.2.14. **COMM Data (if applicable)**
16.2.14.1. Enter Investigating Officer into the Police Dept./Officer field.
16.2.14.2. If COMM Data is missed at login, see Reference Guide Section 8: 035

16.2.15. **Login Alerts**
16.2.15.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

16.2.16. **Test Section**
16.2.16.1. +Add Tests:
16.2.16.2. Add all requested test(s).
16.2.16.3. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
16.2.16.4. For volume guidelines, see Reference Guide Section 8: 043
16.2.16.5. If no paperwork is submitted, add a CLARIFYF.
16.2.16.6. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
16.2.16.6.1. **NOTE:** What was physically received is documented in Horizon.
16.2.16.7. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
16.2.16.7.1. **NOTE:** For required volumes refer to QNS Sheet
16.2.16.8. If sample leaked in transit, add LEAKY test code.
16.2.16.9. If sample is a STOPVOL, see Reference Guide Section 8: 038
16.2.16.10. Check to see if sample is clotted by inverting the sample 5 o5 6 times and/or visual inspection.
16.2.16.10.1. If clotted, add CLOTTED comment (see section 16.2.25) and create a homogenate bottle. See Reference Guide Section 8: 036
16.2.16.11. If the client lists a sample on the paperwork and does not send that sample:
16.2.16.11.1. If testing was added to this sample – Clarify.
16.2.16.11.2. If testing was not added to this sample: Document on the requisition / paperwork the samples was not received, initial and date.




Dependencies:

**Title: Specimen Processing Accessioning**

16.2.16.12. If client requests Screen/Confirm – Clarify
16.2.16.12.1. See Reference Guide Section 8: 037
16.2.16.13. If client orders a Special Request – Clarify
16.2.16.13.1. See Reference Guide Section 8: 044
16.2.16.14. If there are any questions concerning this login:
16.2.16.14.1. assign a CLARIFYF using the appropriate clarify reason.
16.2.16.14.2. For a list of clarify reasons, see Reference Guide Section 8: 008
16.2.16.14.2.1. Including but not limited to:
16.2.16.14.2.1.1. No Testing Marked on paperwork.
16.2.16.14.2.1.2. Additional written requests with no test code provided.
16.2.16.15. The box in front of the test(s) needs to be checked.
16.2.16.15.1. If no testing is assigned to a sample, check the box in front of the STORE.

16.2.17. **Collection Date/Time (Enter as military time)**
16.2.17.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
16.2.17.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
16.2.17.2. Estimated times should not be entered.
16.2.17.3. The collection date/time is taken from the requisition:
16.2.17.3.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
16.2.17.3.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
16.2.17.3.3. If the collection date/time is not provided on the requisition, leave blank.
16.2.17.4. Collection date/time cannot be taken from the requisition:
16.2.17.4.1. If collection information is incomplete, leave blank.
16.2.17.4.1.1. Ex. incomplete year, future date or no date provided.
16.2.17.4.2. Document in Misc. Info (Reportable) field:
16.2.17.4.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/times(s)
16.2.17.4.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
16.2.17.4.2.2.1. Document the date/time(s) located on the sample.
16.2.17.4.3. If no paperwork, document dates/times visible on sample label
16.2.17.4.4. If sample is not listed on requisition, document dates/times visible on sample label.
16.2.17.5. **NOTE:** Dates and times on Hospital samples are subjective.

16.2.18. **Matrix**
16.2.18.1. Log in what is actually received.
16.2.18.2. If the matrix received is not consistent with paperwork and:
16.2.18.2.1. The matrix is obvious, log in what was actually received.
16.2.18.2.1.1. Do not enter a collection date/time.
16.2.18.2.1.2. Enter note stating the matrix received and what was indicated on the label.




Dependencies:

16.2.18.2.1.2.1. Ex. blood sample with vitreous label
16.2.18.2.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
16.2.18.3. If matrix received is not on paperwork, the matrix can be taken from the sample.
16.2.18.4. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
16.2.18.4.1. Document, in the Misc. Info (Reportable), what was on packaging.
16.2.18.4.1.1. Example: Urine recorded on package
16.2.18.4.2. Make a copy of the packaging.
16.2.18.5. If the matrix is unknown log in as fluid, document description in Misc. Info (Reportable).
16.2.18.6. If blood vs serum/plasma:
16.2.18.6.1. Log in what is physically received and order testing on that matrix, if available.
16.2.18.6.2. If not available:
16.2.18.6.2.1. Uncheck the test code requested.
16.2.18.6.2.2. Click +AddTest
16.2.18.6.2.3. Enter and Select CLARIFYF
16.2.18.6.2.4. Click close.
16.2.18.6.2.5. Check the box in front of CLARIFYF.
16.2.18.6.2.6. Do not enter a collection date/time.
16.2.18.6.2.7. Update Matrix to what is physically received.

16.2.19. **Matrix Source: (if applicable)**
16.2.19.1. The source will always be taken from the paperwork.
16.2.19.2. If multiple sources are listed, report the source that best represents the location of the draw and document the second source in Misc. Info (Reportable).
16.2.19.2.1. Example:
16.2.19.2.1.1. If Hospital is listed in source field and Peripheral is listed elsewhere, add *Peripheral* as the source and *Hospital* in Misc. Info (Reportable).
16.2.19.3. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
16.2.19.3.1. Example: Left/Right
16.2.19.4. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
16.2.19.4.1. Example of comment: Hospital recorded on package.

16.2.20. **Turn**
16.2.20.1. Defaults to client's specifications.
16.2.20.2. If paperwork states any of the below scenarios, change Turn code:
16.2.20.2.1. RF - Fax Results
16.2.20.2.2. RC - Call Client

16.2.21. **Container Type**
16.2.21.1. Container field represents:
16.2.21.1.1. Color of cap: first two letters


Dependencies:

16.2.21.1.1.1. For Clear caps with colored stopper always use the color of the stopper
16.2.21.1.2. Type of container: Plastic or Glass
16.2.21.1.3. Description: (one of the three below)
16.2.21.1.3.1. C Container
16.2.21.1.3.2. T Tube
16.2.21.1.3.3. S Stopper
16.2.21.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

16.2.22. **Sample Preservative**
16.2.22.1. Defaults to none.
16.2.22.2. Light Protected – L
16.2.22.2.1. Samples are considered light protected if:
16.2.22.2.1.1. Brown vial
16.2.22.2.1.2. Amber Sarstedt Transfer vial
16.2.22.2.1.3. Amber or Brown Container
16.2.22.2.1.4. Foil wrapped
16.2.22.2.1.5. Wrapped with material to obstruct light.
16.2.22.2.1.5.1. Must be fully wrapped.
16.2.22.2.1.6. Both the tube and the outer wrapping need to be labeled
16.2.22.3. Frozen – F
16.2.22.4. Light Protected and Frozen – B
16.2.22.5. If samples are not received in the required condition for testing;
16.2.22.5.1. Not Light protected – foil wrap
16.2.22.5.2. Not Frozen – place into NMS provided container.
16.2.22.6. Predefined comment will be added (see section 16.2.25)

16.2.23. **Hair**
16.2.23.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
16.2.23.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

16.2.24. **Volume**
16.2.24.1. Volume is estimated.
16.2.24.2. If volume cannot be taken, leave blank and enter Note (see section 16.2.34)
16.2.24.3. If no volume received, enter volume as zero (0) and enter comment (see section 16.2.25)

16.2.25. **+ Add comments**
16.2.25.1. Predefined comments
16.2.25.1.1. If SST received: add appropriate comment.
16.2.25.1.2. If clotted sample: CLOTTED
16.2.25.1.3. If no volume received: EMPTY
16.2.25.1.4. For a list of all Predefined comments, see Reference Guide Section 8: 003
16.2.25.2. Free text comments

**Title: Specimen Processing Accessioning**

16.2.25.2.1. Alternate ID
16.2.25.2.2. P=XXX, H=XXX
16.2.25.3. **NOTE:** if comment needs to be on report, check Rpt. box

16.2.26. **+ Add additional Data – (Orange box)**
16.2.26.1. Hair length

16.2.27. **Sample Sealed** - (Y or N)
16.2.27.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to "seal" evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

16.2.27.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

16.2.28. **Unique Identifiers**
16.2.28.1. Case ID
16.2.28.2. Patient ID/Name
16.2.28.3. Alternate ID
16.2.28.3.1. MRN or MR Number
16.2.28.3.2. Donor ID

16.2.28.4. If the above unique identifiers are not available, Date of Birth and/or Initials are acceptable.

16.2.29. **Sample Labeled** – (Y, N, X, D or U)

16.2.29.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

16.2.29.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 16.2.25)

16.2.29.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

16.2.29.4. If there is no label on the sample but there is a seal with identifiers, it may be used to identify the sample.

16.2.29.5. **Y (Yes)**
16.2.29.5.1. Defined as: All the unique identifiers on paperwork match the sample label/seal.
16.2.29.5.1.1. **NOTE:** The sample label may have additional identifiers.

16.2.29.6. **N (No)**
16.2.29.6.1. Defined as: No label on the sample.

16.2.29.7. **X (Not Applicable)**
16.2.29.7.1. Containers created by NMS.
16.2.29.7.1.1. i.e.: hair segmentation, oral fluids, and homogenates
16.2.29.7.2. Client shipping containers

16.2.29.8. **D (Discrepant)**
16.2.29.8.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label/seal, match and other unique identifier(s) do not.
16.2.29.8.2. Documentation of a difference between the sample label and paperwork submitted.

16.2.29.9. **U (Unverified)**
16.2.29.9.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label/seal match, or handwriting is illegible, or the label was no longer attached.

16.2.29.9.2. The unique identifier(s) are visible on primary label and don't match the identifiers on the secondary label/seal.

16.2.29.9.3. Make a copy of all sample labels/seal that are discrepant.
16.2.29.9.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
16.2.29.9.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

16.2.29.9.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

16.2.30. **Documentation of Sample Labeled As**: – (Y, N, X, D or U)

16.2.30.1. Enter unique identifiers found on sample label/seal according to the priority order.
16.2.30.1.1. Case ID
16.2.30.1.2. Patient Name
16.2.30.1.3. Alternate ID

16.2.30.2. If identifying letters are provided on both sample label/seal and submitted paperwork, add the letter in the Sample Labeled As field.
16.2.30.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

16.2.30.4. **Y (Yes)**
16.2.30.4.1. Enter unique identifier from sample label/seal of highest priority.

**Title: Specimen Processing Accessioning**

16.2.30.5. **N (No)**
16.2.30.5.1. Enter “NO LABEL”
16.2.30.5.2. The discrepancy will be documented in Horizon, refer to section 16.2.39.

16.2.30.6. **X (Not Applicable)**
16.2.30.6.1. leave this field blank.

16.2.30.7. **D (Discrepant)**
16.2.30.7.1. Enter unique identifier from sample label/seal of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

16.2.30.8. **U (Unverified)**
16.2.30.8.1. Enter all discrepant identifiers from sample label/seal separated by a backslash (/).
16.2.30.8.1.1. If sample is labeled but cannot be read, write “ILLEGIBLE”.
16.2.30.8.1.2. If sample is labeled with a barcode only, write “BARCODE ONLY”
16.2.30.8.1.3. If sample label is no longer attached and sample is not contained individually, write “LABEL NOT ATTACHED”
16.2.30.8.1.3.1. Make a photocopy of label and discard label.
16.2.30.8.2. The discrepancy will be documented in Horizon, refer to section 16.2.39.

16.2.31. **Sample Dated** – (Y or N)
16.2.31.1. This question applies to the seal.

16.2.32. **Sample Initialed** – (Y or N)
16.2.32.1. This question applies to the seal.
16.2.32.1.1. Can be initialed or signed.

16.2.33. **Sample Timed** – (Y or N)
16.2.33.1. This question applies to the label.

16.2.34. **Notes**
16.2.34.1. This information appears on the Login Verification form. This is internal documentation for NMS.
16.2.34.2. Enter notes pertaining to the sample that may help address an oddity:
16.2.34.2.1. Examples:
16.2.34.2.1.1. WO previously received under a different workorder.
16.2.34.2.1.2. Hair segmentation notes
16.2.34.2.1.3. Weight no taken due to nature of sample.
16.2.34.2.1.4. Return packaging notes.
16.2.34.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: _____grams*** when some of the tissue could not be returned to the original container.

16.2.35. **Misc. Info (Reportable)**
16.2.35.1. This information appears on the clients’ report.




Dependencies:

16.2.35.2. Enter any information concerning the sample, login information or conflicts with login information.
16.2.35.2.1. Examples:
16.2.35.2.1.1. Collection date and time discrepancies
16.2.35.2.1.2. Additional source information on paperwork
16.2.35.2.1.3. Source discrepancies.
16.2.35.2.1.4. Sample descriptions.
16.2.35.2.1.5. Sources not available in Horizon
16.2.35.2.1.5.1. Ex. Pupa, Placenta

16.2.36. **CONF Notes**
16.2.36.1. Internal notes regarding handling of the specimen.
16.2.36.1.1. Example:
16.2.36.1.1.1. Micro and Consume
16.2.36.1.1.2. Limited Confs or Hold Confs
16.2.36.1.1.3. Do Not Use
16.2.36.1.1.4. One Shot Deal

16.2.37. **Label Count**
16.2.37.1. Defaults to 1, however, can be changed.
16.2.37.2. Label(s) will print.

16.2.38. **Lab I.D. (Container) Label**
16.2.38.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
16.2.38.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
16.2.38.2. Additional preprinted colored labels may be required for cases.
16.2.38.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
16.2.38.3.1. Examples:
16.2.38.3.1.1. Micro: for limited volume samples
16.2.38.3.1.2. Return: for samples being returned
16.2.38.3.1.3. Additional Specimen: when clients provide additional samples for a specific workorder already in house.
16.2.38.4. Labeled specimens will be placed in appropriate rack / basket.
16.2.38.4.1. Aliquot
16.2.38.4.2. Store

16.2.39. **Documenting a discrepancy in Horizon**
16.2.39.1. For ClarifyFDU:
16.2.39.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
16.2.39.1.2. Click on Additional Information and scroll to ClarifyFDU.
16.2.39.1.3. Go to notes/instructions field to enter discrepancy.
16.2.39.1.4. Enter discrepancy as: paperwork vs sample label


Dependencies:

16.2.39.1.5. Document only in the first sample unless it varies from sample to sample.
16.2.39.1.5.1. If it varies, add a description to the corresponding sample.
16.2.39.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
16.2.39.2. For ClarifyFDN:
16.2.39.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
16.2.39.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

16.2.40. **Choose one of the following to continue:**
16.2.40.1. If multiple samples were received for the same requisition, Proceed to section 16.2.15. When final sample is logged in proceed to section 16.2.40.
16.2.40.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 16.2.40.
16.2.40.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

16.2.40.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
16.2.40.4.1. This is NMS's unique identifier.
16.2.40.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
16.2.40.6. If paperwork is supplied, a requisition label must be applied.
16.2.40.7. Check the workorder and the workorder I.D. on the label to assure correct labeling.
16.2.40.8. Place the workorder label on each document associated with case / patient.
16.2.40.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
16.2.40.10. Write the number of pages on the label and circle the number.
16.2.40.11. You only need to do this on this on one form (preferably the requisition).
16.2.40.12. The total number is the total number of pages, not documents.

**16.3. Webportal**

16.3.1. **EDI**
16.3.1.1. Scan or enter Client Portal number from paperwork.
16.3.1.2. If there is no transmission, proceed with Manual login.
16.3.1.3. If there is no paperwork, scan or enter Client Portal number from sample.

16.3.2. **Workorder ID**
16.3.2.1. Information auto populates.

16.3.3. **Profile**
16.3.3.1. Information auto populates.
16.3.3.2. If profile is crossed out and a new account number is written, accept the order and update to 00000 in Horizon, see Reference Guide Section 8: 030

16.3.4. **Client**
16.3.4.1. Information auto populates.


Dependencies:

16.3.5. **Chain of Custody**: (Alternate ID)
16.3.5.1. This field auto populates with the Client Portal number (NMSCPxxxx) – Do not delete.
16.3.5.2. If a third unique identifier is provided, enter as a comment and make reportable.
16.3.5.2.1. Example:
16.3.5.2.1.1. Control Number labels

16.3.6. **Purchase Order**
16.3.6.1. This signifies a payment.
16.3.6.2. Purchase order - Data enter PO number as: XXX
16.3.6.3. *Check: Data enter check number as: CKXXX
16.3.6.4. *Money Order: Data enter Money order number as: MOXXX
16.3.6.5. Credit Card: Data enter as: CC
16.3.6.5.1. If the credit card form is received incomplete or blank, label for OnBase and leave Purchase Order field blank.
16.3.6.6. Lab Work Verification Form: Data enter as: LW
16.3.6.7. Letter of Intent: Data enter as: Letter of Intent
16.3.6.8. *Checks and money orders must be taped onto Check Form located in NMS Intranet (Microsoft Edge -> Intranet -> Shared Documents -> Online Forms -> Specimen Processing -> Check Form).
16.3.6.9. If check, money order, or credit card are indicated, but not received, add notes to requisition and leave Purchase Order field blank.

16.3.7. **Last Name / First Name / Middle Name/Suffix**
16.3.7.1. Auto populates as transmitted.

16.3.8. **Date of Birth (DOB)**
16.3.8.1. Auto populates as transmitted.

16.3.9. **Sex**
16.3.9.1. Auto populates as transmitted.

16.3.10. **Disposition:**
16.3.10.1. Disposition Override:
16.3.10.1.1. Auto populates into Horizon when applicable.
16.3.10.2. Client Disposition:
16.3.10.2.1. Auto populations when applicable.

16.3.11. **Package**
16.3.11.1. Package field is defined as the case-specific, primary packaging.
16.3.11.2. Package Sealed: (Y or N)
16.3.11.3. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is

obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
16.3.11.4. Package Seal Initialed: (Y or N)
16.3.11.4.1. Can be initialed or signed.
16.3.11.5. Package Seal Dated: (Y or N)
16.3.11.6. Package Condition Notes: Documenting unusual packaging conditions.
16.3.11.6.1. Examples:
16.3.11.6.1.1. FedEx Bag not sealed.
16.3.11.6.1.2. Package appeared to be opened.
16.3.11.6.1.3. No dry ice remains.

16.3.12. **Login Alerts**
16.3.12.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

16.3.13. **Test Section**
16.3.13.1. All transmitted testing will populate.
16.3.13.2. If additional testing is written on the requisition:
16.3.13.2.1. +Add Tests
16.3.13.3. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
16.3.13.4. For volume guidelines, see Reference Guide Section 8: 043
16.3.13.5. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
16.3.13.5.1. **NOTE:** What was physically received is documented in Horizon
16.3.13.6. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
16.3.13.6.1. **NOTE:** For required volumes refer to QNS Sheet
16.3.13.7. If sample leaked in transit, add LEAKY test code.
16.3.13.8. If sample is a STOPVOL, see Reference Guide Section 8: 038
16.3.13.9. Check to see if sample is clotted by inverting the sample 5 or 6 times and/or visual inspection.
16.3.13.9.1. If clotted, add CLOTTED comment (see section 16.3.22) and create a homogenate bottle. See Reference Guide Section 8: 036
16.3.13.10. If the client lists a sample on the paperwork and does not send that sample:
16.3.13.10.1. If testing was added to this sample – Clarify.
16.3.13.10.2. If testing was not added to this sample: Document on the requisition / paperwork the samples was not received, initial and date.
16.3.13.11. If client requests Screen/Confirm – Clarify
16.3.13.11.1. See Reference Guide Section 8: 037
16.3.13.12. If client orders a Special Request – Clarify
16.3.13.12.1. See Reference Guide Section 8: 044
16.3.13.13. If there are any questions concerning this login:

16.3.13.13.1. assign a CLARIFYF using the appropriate clarify reason.
16.3.13.13.2. For a list of clarify reasons, see Reference Guide Section 8: 008
16.3.13.14. If testing is assigned to a specific sample, the box in front of that test(s) needs to be checked.
16.3.13.14.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
16.3.13.15. If testing is requested on any sample, the box in front of the test(s) **and** the box in front of the STORE associated with sample need to be checked.
16.3.13.15.1. If no testing is assigned to a sample, check the box in front of the STORE associated with the sample.
16.3.13.16. (For Serum/Plasma tests only) When the transmitted test matrix (S/P) does not match the sample matrix (S or P), update matrix to S/P

16.3.14. **Collection Date/Time (Enter as military time)**
16.3.14.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
16.3.14.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
16.3.14.2. The collection date/time is taken from the requisition:
16.3.14.2.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
16.3.14.2.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
16.3.14.2.3. If the collection date/time is not provided on the requisition, leave blank.
16.3.14.3. Collection date/time cannot be taken from the requisition:
16.3.14.3.1. If collection information is incomplete, leave blank.
16.3.14.3.1.1. Ex. incomplete year, future date or no date provided.
16.3.14.3.2. Document in Misc. Info (Reportable) field:
16.3.14.3.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/times(s)
16.3.14.3.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
16.3.14.3.2.2.1. Document the date/time(s) located on the sample.
16.3.14.3.2.3. If no paperwork, document dates/times visible on sample label
16.3.14.3.2.4. If sample is not listed on requisition, document dates/times visible on sample label.
16.3.14.4. **NOTE:** Dates and times on Hospital samples are subjective.

16.3.15. **Matrix**
16.3.15.1. Whether or not paperwork is received, matrix should be verified to the sample.
16.3.15.2. Matrix will auto populate with test code selected.
16.3.15.3. If matrix received is not consistent with paperwork and:
16.3.15.3.1. The matrix is obvious, log in what was actually received.
16.3.15.3.1.1. Do not enter a collection date/time.


Dependencies:

16.3.15.3.1.2. Enter note stating the matrix received and what was indicated on the label.
16.3.15.3.1.2.1. Ex. blood sample with vitreous label
16.3.15.3.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable).
16.3.15.4. If matrix received is not on paperwork, the matrix can be taken from the sample.
16.3.15.5. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
16.3.15.5.1. Document, in the Misc. Info (Reportable), what was on packaging.
16.3.15.5.1.1. Example: Urine recorded on package
16.3.15.5.2. Make a copy of the packaging.
16.3.15.6. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
16.3.15.7. If matrix on paperwork and sample do not match and testing is requested on this sample (except for blood vs serum/plasma):
16.3.15.7.1. Uncheck the test code requested.
16.3.15.7.2. Click +AddTest
16.3.15.7.3. Enter and Select CLARIFYF
16.3.15.7.4. Click close.
16.3.15.7.5. Check the box in front of CLARIFYF.
16.3.15.7.6. Do not enter a collection date/time.
16.3.15.7.7. Update Matrix to what is physically received.
16.3.15.7.8. If blood vs serum/plasma:
16.3.15.7.8.1. Log in what was physically received and order testing on that matrix, if available.
16.3.15.7.8.2. If not available, follow steps above.

16.3.16. **Matrix Source: (if applicable)**
16.3.16.1. The source will always be taken from the paperwork.
16.3.16.2. If multiple sources are listed, report the source that best represents the location of the draw and document the second source in Misc. Info (Reportable).
16.3.16.2.1. Example:
16.3.16.2.1.1. If Hospital is listed in source field and Peripheral is listed elsewhere, add *Peripheral* as the source and *Hospital* in Misc. Info (Reportable).
16.3.16.3. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
16.3.16.3.1. Example: Left/Right
16.3.16.4. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
16.3.16.5. Example of comment: Hospital recorded on package.

16.3.17. **Turn**
16.3.17.1. Defaults to client's specifications.
16.3.17.2. If paperwork lists any of the below scenarios, change Turn code:
16.3.17.2.1. RF - Fax Results
16.3.17.2.2. RC - Call Client

16.3.18. **Container Type**

**Title: Specimen Processing Accessioning**

16.3.18.1. Container field represents:
16.3.18.1.1. Color of cap: first two letters
16.3.18.1.1.1. For Clear caps with colored stopper always use the color of the stopper
16.3.18.1.2. Type of container: Plastic or Glass
16.3.18.1.3. Description: (one of the three below)
16.3.18.1.3.1. C Container
16.3.18.1.3.2. T Tube
16.3.18.1.3.3. S Stopper
16.3.18.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

16.3.19. **Sample Preservative**
16.3.19.1. Defaults to none.
16.3.19.2. Light Protected – L
16.3.19.2.1. Samples are considered light protected if:
16.3.19.2.1.1. Brown vial
16.3.19.2.1.2. Amber Sarstedt Transfer vial
16.3.19.2.1.3. Amber or Brown Container
16.3.19.2.1.4. Foil wrapped
16.3.19.2.1.5. Wrapped with material to obstruct light.
16.3.19.2.1.5.1. Must be fully wrapped.
16.3.19.2.1.6. Both the tube and the outer wrapping need to be labeled
16.3.19.3. Frozen – F
16.3.19.4. Light Protected and Frozen – B
16.3.19.5. If samples are not received in the required condition for testing;
16.3.19.5.1. Not Light protected – foil wrap
16.3.19.5.2. Not Frozen – place into NMS provided container.
16.3.19.6. Predefined comment will be added (see section 16.3.22)

16.3.20. **Hair**
16.3.20.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
16.3.20.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

16.3.21. **Volume**
16.3.21.1. Volume is estimated.
16.3.21.2. If volume cannot be taken, leave blank and enter Note (see section 16.3.27.12)
16.3.21.3. If no volume received, enter volume as zero (0) and enter comment (see section 16.3.22)

16.3.22. **+ Add comments**
16.3.22.1. Predefined comments
16.3.22.1.1. If no paperwork: NOPAPER
16.3.22.1.2. If SST received: add appropriate comment.
16.3.22.1.3. If clotted sample: CLOTTED




Dependencies:

16.3.22.1.4. If no volume received: EMPTY
16.3.22.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
16.3.22.2. Free text comments
16.3.22.2.1. Alternate ID
16.3.22.2.2. P=XXX, H=XXX
16.3.22.3. **NOTE:** If comment needs to be on report, check Rpt. box

16.3.23. **+ Add additional Data – (Orange box)**
16.3.23.1. Hair length

16.3.24. **Sample Sealed** - (Y or N)
16.3.24.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to "seal" evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

16.3.24.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

16.3.25. **Unique Identifiers**
16.3.25.1. Case ID
16.3.25.2. Patient ID/Name
16.3.25.3. Alternate ID
16.3.25.3.1. Web Portal number
16.3.25.3.2. MRN or MR number
16.3.25.3.3. Donor ID

16.3.25.4. If the above unique identifiers are not available, Date of Birth and/or Initials are acceptable.

16.3.26. **Sample Labeled** – (Y, N, X, D or U)

16.3.26.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

16.3.26.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 16.3.22).

16.3.26.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

16.3.26.4. If there is no label on the sample but there is a seal with unique identifiers, it may be used to identify the sample.

16.3.26.5. **Y (Yes)**
16.3.26.5.1. Defined as: All the unique identifiers on paperwork match the sample label/seal.
16.3.26.5.1.1. **NOTE:** The sample label may have additional identifiers.

16.3.26.6. **N (No)**
16.3.26.6.1. Defined as: No label on the sample.

16.3.26.7. **X (Not Applicable)**
16.3.26.7.1. Containers created by NMS.
16.3.26.7.1.1. Examples: hair segmentation, oral fluids, and homogenates
16.3.26.7.2. Client shipping containers

16.3.26.8. **D (Discrepant)**
16.3.26.8.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label/seal, match and other unique identifier(s) do not.
16.3.26.8.2. Documentation of a difference between the sample label and paperwork submitted.

16.3.26.9. **U (Unverified)**
16.3.26.9.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label/seal match, or handwriting is illegible, or the label was no longer attached.

16.3.26.9.2. The unique identifier(s) are visible on primary label and don't match the identifiers on the secondary label/seal.

16.3.26.9.3. Make a copy of all sample labels that are discrepant.
16.3.26.9.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
16.3.26.9.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

16.3.26.9.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

16.3.27. **Documentation of Sample Labeled As**: – (Y, N, X, D or U)

16.3.27.1. Enter unique identifiers found on sample label/seal according to the priority order.
16.3.27.1.1. Case ID
16.3.27.1.2. Patient Name
16.3.27.1.3. Alternate ID

16.3.27.2. If identifying letters are provided on both sample label/seal and submitted paperwork, add the letter in the Sample Labeled As field.
16.3.27.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.


Dependencies:

16.3.27.4. **Y (Yes)**
16.3.27.4.1. Enter unique identifier from sample label/seal of highest priority.

16.3.27.5. **N (No)**
16.3.27.5.1. Enter “NO LABEL”
16.3.27.5.2. The discrepancy will be documented in Horizon, refer to 16.3.32.

16.3.27.6. **X (Not Applicable)**
16.3.27.6.1. leave this field blank.

16.3.27.7. **D (Discrepant)**
16.3.27.7.1. Enter unique identifier from sample label/seal of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).

16.3.27.8. **U (Unverified)**
16.3.27.8.1. Enter all discrepant identifiers from sample label/seal separated by a backslash (/).
16.3.27.8.1.1. If sample is labeled but cannot be read, write “ILLEGIBLE”.
16.3.27.8.1.2. If sample is labeled with a barcode only, write “BARCODE ONLY”
16.3.27.8.1.3. If sample label is no longer attached and sample is not contained individually, write “LABEL NOT ATTACHED”
16.3.27.8.1.3.1. Make a photocopy of label and discard label.
16.3.27.8.2. The discrepancy will be documented in Horizon, refer to 16.3.32.

16.3.27.9. **Sample Dated** – (Y or N)
16.3.27.9.1. This question applies to the seal.

16.3.27.10. **Sample Initialed** – (Y or N)
16.3.27.10.1. This question applies to the seal.
16.3.27.10.1.1. Can be initialed or signed.

16.3.27.11. **Sample Timed** – (Y or N)
16.3.27.11.1. This question applies to the label.

16.3.27.12. **Notes**
16.3.27.12.1. This information appears on the Login Verification form. This is internal documentation for NMS.
16.3.27.12.2. Enter notes pertaining to the sample that may help address an oddity:
16.3.27.12.2.1. Examples:
16.3.27.12.2.1.1. WO previously received under a different workorder.
16.3.27.12.2.1.2. Hair segmentation notes
16.3.27.12.2.1.3. Weight not taken due to nature of sample.
16.3.27.12.2.1.4. Return packaging notes.
16.3.27.12.2.1.5. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: _____grams*** when some of the tissue could not be returned to the original container.


Dependencies:

**Title: Specimen Processing Accessioning**

16.3.28. **Misc. Info (Reportable)**
16.3.28.1. This information appears on the clients' report.
16.3.28.2. Enter any information concerning the sample, login information or conflicts with login information.
16.3.28.2.1. Examples:
16.3.28.2.1.1. Collection date and time discrepancies
16.3.28.2.1.2. Additional source information on paperwork
16.3.28.2.1.3. Source discrepancies
16.3.28.2.1.4. Sample descriptions
16.3.28.2.1.5. Sources not available in Horizon
16.3.28.2.1.5.1. Ex. Pupa, Placenta

16.3.29. **CONF Notes**
16.3.29.1. Internal notes regarding handling of the specimen.
16.3.29.1.1. Example:
16.3.29.1.1.1. Micro and Consume
16.3.29.1.1.2. Limited Confs or Hold Confs
16.3.29.1.1.3. Do not use
16.3.29.1.1.4. One Shot Deal

16.3.30. **Label Count**
16.3.30.1. Defaults to 1, however, can be changed.
16.3.30.2. Label(s) will print.

16.3.31. **Lab I.D. (Container) Label**
16.3.31.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
16.3.31.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
16.3.31.2. Additional preprinted colored labels may be required for cases.
16.3.31.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
16.3.31.3.1. Examples:
16.3.31.3.1.1. Micro: for limited volume samples
16.3.31.3.1.2. Return: for samples being returned
16.3.31.3.1.3. Additional Specimen: when clients provide additional samples for a specific workorder already in house.
16.3.31.4. Labeled specimens will be placed in appropriate rack / basket.
16.3.31.4.1. Aliquot
16.3.31.4.2. Store

16.3.32. **Documenting a discrepancy in Horizon**
16.3.32.1. For ClarifyFDU:
16.3.32.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.


Dependencies:

16.3.32.1.2. Click on Additional Information and scroll to ClarifyFDU.
16.3.32.1.3. Go to notes/instructions field to enter discrepancy.
16.3.32.1.4. Enter discrepancy as: paperwork vs sample label
16.3.32.1.5. Document only in the first sample unless it varies from sample to sample.
16.3.32.1.5.1. If it varies, add a description to the corresponding sample.
16.3.32.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
16.3.32.2. For ClarifyFDN:
16.3.32.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
16.3.32.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

16.3.33. **Choose one of the following to continue:**
16.3.33.1. If multiple samples were received for the same requisition, proceed to section 16.3.12. When final sample is logged in proceed to section 16.3.33.
16.3.33.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 16.3.33.
16.3.33.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

16.3.33.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
16.3.33.4.1. This is NMS's unique identifier.
16.3.33.5. Label Count – defaults to 1, however, can be changed or bypassed (for clients who do not send paperwork i.e., EDI clients).
16.3.33.6. If paperwork is supplied, a requisition label must be applied.
16.3.33.7. Check the workorder and the workorder I.D. on the label to ensure correct labeling.
16.3.33.8. Place the workorder label on each document associated with case / patient.
16.3.33.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
16.3.33.10. Write the number of pages on the label and circle the number.
16.3.33.11. You only need to do this on this on one form (preferably the requisition).
16.3.33.12. The total number is the total number of pages, not documents.

**17. Jacksonville**
**17.1. EDI**
17.1.1. Field is not used.

17.1.2. If no paperwork received with sample, enter information from the sample. Make a photocopy of the sample(s). This is now your manual paperwork.
17.1.3. If Additional Sample Submission Form is received, see Reference Guide Section 8: 018

**17.2. Workorder ID**
17.2.1. Client case number / Accession number
17.2.2. Do NOT copy and paste this information in the Login Form.
17.2.3. Data enter exactly as submitted.
17.2.3.1. **NOTE:** There is a 30-character limitation
17.2.4. If ID does not fit, enter SEE COMMENT


Dependencies:

17.2.4.1. Enter complete ID as a comment and make reportable (see section 17.22)
17.2.4.1.1. Ex. Work ID: XXXXXXXXXXXXX

**17.3. Profile**
17.3.1. Client account number followed by profile (FR).
17.3.2. Do NOT copy and paste this information in the Login Form.

**17.4. Client**
17.4.1. This information will auto-populate once Profile has been entered.

**17.5. Chain of Custody**: (Alternate ID)
17.5.1. This field is only used when clients require three unique identifiers.
17.5.2. If more than three unique identifier(s) are provided, enter as a comment and make reportable. (see section 17.22)
17.5.2.1. Examples:
17.5.2.1.1. Control Number labels
17.5.2.1.2. Client Specific identifiers (indicated on requisition)

**17.6. Purchase Order**
17.6.1. This signifies a payment.
17.6.2. Purchase order - Data enter PO number as: XXX
17.6.3. Auto-generated PO numbers:
17.6.4. If there is an auto-generated PO number - Do not delete.

**17.7. Last Name / First Name / Middle Name/Suffix**
17.7.1. Populate the fields as provided.
17.7.2. If a name is not supplied in the name field, however, other characters are, enter as provided.
17.7.3. If a suffix is supplied, enter in suffix field.
17.7.3.1. Ex. Sr, Jr, III etc.
17.7.4. If other characters are attached to the name, then apply to the field they are attached to.
17.7.5. For manifest, if *last, first* name format is used, apply to appropriate fields. If not, enter name as listed into last name field only.
17.7.6. When a label containing patient information is provided on the requisition, see Reference Guide Section 8: 023

**17.8. Date of Birth (DOB)**
17.8.1. Enter DOB as mm/dd/yyyy

**17.9. Sex**
17.9.1. Select from drop down box:
17.9.1.1. Male ♂
17.9.1.2. Female ♀

**17.10. Disposition**
17.10.1. Disposition Override:


Dependencies:

17.10.1.1. If indications appear on paperwork, such as “return” or “pick up,” use drop down box to select appropriate instruction.
17.10.2. Client Disposition:
17.10.2.1. Auto populates when applicable.

**17.11. Package**
17.11.1. Package field is defined as the case-specific, primary packaging.
17.11.2. If receiving an Additional Sample(s) to existing workorder, complete Package Data form. (Addendum XX) see Reference Guide Section 8: 018
17.11.3. Package Sealed: (Y or N)
17.11.4. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. Seals can be on outer packaging, on independent pieces of evidence, etc. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.
17.11.5. Package Seal Initialed: (Y or N)
17.11.5.1. Can be initialed or signed.
17.11.6. Package Seal Dated: (Y or N)
17.11.7. Package Condition Notes: Documenting unusual packaging conditions.
17.11.7.1. Examples:
17.11.7.1.1. FedEx Bag not sealed.
17.11.7.1.2. Package appeared to be opened.
17.11.7.1.3. No dry ice remains.

**17.12. Login Alerts**
17.12.1. If the client has special instructions, a login alert will appear on the screen. When applicable, follow instructions.

**17.13. Test Section**
17.13.1. +Add Tests:
17.13.2. Add all requested test(s).
17.13.3. If the sample being tested is in Horsham, order SRTEST.
17.13.4. In Horizon, add notes to the Received Task line.
17.13.5. Add NOTEST if client paperwork indicates no testing is required on this workorder.
17.13.6. Based on the Pre-Login order (see section 10) and client requisition determine which sample will be tested
17.13.7. For volume guidelines, see Reference Guide Section 8: 043
17.13.8. If no paperwork is submitted, add a CLARIFYZ.
17.13.9. If there are discrepancies (blood vs serum/plasma, blood vs fluid, container types, identifying letters) between client requisition and samples received, single line strikethrough, initial and date paperwork.
17.13.9.1. **NOTE:** What was physically received is documented in Horizon.
17.13.10. Antemortem vs Postmortem

17.13.11. Unless otherwise indicated, when both Antemortem and Postmortem are submitted, test the Antemortem first. If there is not sufficient antemortem volume for the test(s), then use Postmortem.
17.13.12. When multiple collection date(s)/times are submitted, and client does not assign testing, start with earliest time based on volume.
17.13.12.1. **NOTE:** For required volumes refer to QNS Sheet
17.13.13. If sample leaked in transit, add LEAKY test code.
17.13.14. If sample is a STOPVOL, see Reference Guide Section 8: 038
17.13.15. Check to see if sample is clotted by inverting the sample 5 or 6 times and/or visual inspection.
17.13.15.1. If clotted, add CLOTTED comment (see section 17.22) and create a homogenate bottle. See Reference Guide Section 8: 036
17.13.15.2. **NOTE:** Subdural and Spleen samples will always be homogenized
17.13.16. If sample needs to be homogenized for a test but also has a Metals or Iron Ratio test ordered, place a SHARED label on both parent and homogenate, see Reference Guide Section 8: 045
17.13.17. If the client lists a sample on the paperwork and does not send that sample:
17.13.17.1. If testing was added to this sample – Clarify.
17.13.17.2. If testing was not added to this sample: Document on the requisition / paperwork the sample was not received, initial and date.
17.13.18. If client requests Screen/Confirm – Clarify
17.13.18.1. see Reference Guide Section 8: 037
17.13.19. If client orders a Special Request – Clarify
17.13.19.1. See Reference Guide Section 8: 044
17.13.20. If there are any questions concerning this login:
17.13.20.1. assign a CLARIFYZ using the appropriate clarify reason.
17.13.20.2. For a list of clarify reasons, see Reference Guide Section 8: 008
17.13.20.3. Including but not limited to:
17.13.20.3.1. No return address provided on Sample Submission Form
17.13.20.3.2. No Testing marked on paperwork.
17.13.21. The box in front of the test(s) needs to be checked.
17.13.21.1. If no testing is assigned to a sample, check the box in front of the STORE.

**17.14. Collection Date/Time (Enter as military time)**
17.14.1. Time on requisition is to be read as military time unless otherwise indicated by the client.
17.14.1.1. **NOTE:** Midnight and Not Provided are both entered as 00:00
17.14.2. Estimated times should not be entered.
17.14.3. The collection date/time is taken from the requisition:
17.14.3.1. If the client indicates all samples were collected at the same time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
17.14.3.2. If the client provides a single collection date/time and it corresponds to the date/time provided on sample labels or there is no date/time on sample labels, enter date/time.
17.14.3.3. If the collection date/time is not provided on the requisition, leave blank.


Dependencies:

17.14.4. Collection date/time cannot be taken from the requisition:
17.14.4.1. If collection information is incomplete, leave blank
17.14.4.1.1. Ex. incomplete year, future date or no date provided.
17.14.4.2. Document in Misc. Info (Reportable) field:
17.14.4.2.1. If collection date/time is not provided on requisition but provided on the sample, document date/time(s)
17.14.4.2.2. If the date/time on the sample does not match the paperwork, remove collection time or date/time.
17.14.4.2.2.1. Document the date/time(s) located on the sample.
17.14.4.2.3. If no paperwork, document dates/times visible on sample label
17.14.4.2.4. If sample is not listed on requisition, document dates/times visible on sample label.

17.14.5. **NOTE:** Dates and times on Hospital samples are subjective

**17.15. Matrix**
17.15.1. Log in what is actually received.
17.15.2. If the matrix received is not consistent with paperwork and:
17.15.2.1. The matrix is obvious, log in what was actually received.
17.15.2.1.1. Do not enter a collection date/time.
17.15.2.1.2. Enter note stating the matrix received and what was indicated on the label.
17.15.2.1.2.1. Ex. blood sample with vitreous label
17.15.2.2. The matrix is not obvious, Clarify and document description in Misc. Info (Reportable)
17.15.3. If matrix received is not on paperwork, the matrix can be taken from the sample.
17.15.4. If matrix information is not provided on paperwork or sample, but is provided on packaging, the matrix can be entered into Horizon.
17.15.4.1. Document, in the Misc. Info (Reportable), what was on packaging.
17.15.4.1.1. Example: Urine recorded on package
17.15.4.2. Make a copy of the packaging.
17.15.5. If matrix is unknown log in as fluid, document description in Misc. Info (Reportable)
17.15.6. If matrix on paperwork and sample do not match and testing is requested on this sample (except for blood vs serum/plasma)
17.15.6.1. Uncheck the test code requested.
17.15.6.2. Click +AddTest
17.15.6.3. Enter and Select CLARIFYZ
17.15.6.4. Click close.
17.15.6.5. Check the box in front of CLARIFYZ.
17.15.6.6. Do not enter a collection date/time.
17.15.6.7. Update Matrix to what is physically received.
17.15.6.8. If blood vs serum/plasma:
17.15.6.8.1. Log in what is physically received and order testing on that matrix, if available.
17.15.6.8.2. If not available, follow steps above.

**17.16. Matrix Source**


Dependencies:

**Title: Specimen Processing Accessioning**

17.16.1. Order of Source Preference (when volume is not an issue).
17.16.1.1. Peripheral
17.16.1.2. Subclavian
17.16.1.3. Central
17.16.1.4. Other
17.16.2. The source will always be taken from the paperwork.
17.16.3. If multiple sources are listed, report the source that best represents the location of the draw and document the second source in Misc. Info (Reportable).
17.16.3.1. Example:
17.16.3.1.1. If Hospital is listed in source field and Peripheral is listed elsewhere, add *Peripheral* as the source and *Hospital* in Misc. Info (Reportable).
17.16.4. If no paperwork received, the source may be taken from the sample.
17.16.5. If the source name on the paperwork does not match what is provided on the tube:
17.16.5.1. Enter Source from paperwork.
17.16.5.2. Type Source listed on tube in Misc. Info (Reportable).
17.16.6. If, at any time, additional information is provided on paperwork or on tube, document in Misc. Info (Reportable).
17.16.6.1. Example: Left/Right
17.16.7. If source information is provided on packaging, document in the Misc. Info (Reportable) and make a copy of the packaging.
17.16.7.1. Example of comment: Femoral recorded on package

17.16.8. **NOTE:** Subdural and Spleen should always be homogenized

17.16.9. Blood Source Chart in preferred order:

| **PERIPHERAL Sources** | **Comment** |
|---|---|
| Femoral | |
| Iliac | |
| Peripheral | Arm/Leg |
| Peritoneal | |
| Subdermal | |
| **CENTRAL Sources** | |
| Cardiac | |
| Heart | |
| Aortic | |
| IVC (Inferior Vena Cava) | |
| Central | |
| Jugular | |


Dependencies:

**Title: Specimen Processing Accessioning**

| | |
|---|---|
| Spleen | |
| Cavity | * |
| Chest | * |
| Pleural | * |
| Pulmonary | * |
| Abdomen | * |
| Thoracic | * |
| **Both Sources** | |
| Antemortem | |
| Subclavian | |
| Donor | |
| Mixed | * |
| Subdural | N/A |
| Brain | N/A |

17.16.9.1. *These are ***not*** preferred samples and should be used as a last resort.

17.16.9.2. **NOTE:** Antemortem / Donor / Mixed can be from either location.
17.16.10. Drawings, abbreviations and miscellaneous letters are not acceptable substitutes for spelling out the source.
17.16.10.1. Examples:
17.16.10.1.1. Per

17.16.10.1.2.
17.16.10.1.3. Sub
17.16.10.1.4. CAR
17.16.11. However, common sources ie. Fem (Femoral) and VIT (vitreous) can be used.

17.16.12. **Tissue, Fluid and Solid Sources**
17.16.12.1. Any tissue, fluid or solid source may be taken from the sample if it is not listed on the requisition.
17.16.12.2. If the source name on the paperwork does not match what is provided on the sample - Clarify
17.16.12.3. **NOTE:** Gastric should always be homogenized when tested

17.16.13. Tissue Source Charts in Preferred Order:
17.16.13.1. **Tissue Drug Testing Source Chart**

| Source |
|---|
| Liver |
| Other Organs |
| *Brain |

17.16.13.2. **Tissue CO Testing Source Chart**

| Source |
|---|
| Muscle |
| Spleen |
| Kidney |
| Heart |
| *Liver |

17.16.13.3. *These are **not** preferred samples and should be used as a last resort.

**17.17. Turn**
17.17.1. Defaults to client's specifications.
17.17.2. If paperwork lists any of the below scenarios, change Turn code:
17.17.2.1. RF – Fax/Email Results
17.17.2.2. RC - Call Client

**17.18. Container Type**
17.18.1. Container field represents:
17.18.1.1. Color of cap: first two letters
17.18.1.1.1. For Clear caps with colored stopper always use the color of the stopper
17.18.1.2. Type of container: Plastic or Glass
17.18.1.3. Description: (one of the three below)
17.18.1.3.1. C Container
17.18.1.3.2. T Tube
17.18.1.3.3. S Stopper
17.18.2. **NOTE:** Misc. container types can also be found in the drop down. Ex: PB – Plastic Bag

**17.19. Sample Preservative**
17.19.1. Defaults to none.
17.19.2. Light Protected – L
17.19.2.1. Samples are considered light protected if:
17.19.2.1.1. Brown vial
17.19.2.1.2. Amber Sarstedt Transfer vial
17.19.2.1.3. Amber or Brown Container
17.19.2.1.4. Foil wrapped
17.19.2.1.5. Wrapped with material to obstruct light.
17.19.2.1.5.1. Must be fully wrapped.
17.19.2.1.6. Both the tube and the outer wrapping need to be labeled
17.19.3. Frozen – F
17.19.4. Light Protected and Frozen – B
17.19.5. If samples are not received in the required condition for testing;
17.19.5.1. Not Light protected – foil wrap
17.19.5.2. Not Frozen – place into NMS provided container.
17.19.6. Predefined comment will be added (see section 17.22)




Dependencies:

**Title: Specimen Processing Accessioning**

**17.20. Hair**
17.20.1. Weigh and measure, in centimeters, hair sample. Record all information on the hair login form. (Addendum xxx)
17.20.1.1. **NOTE:** Dreadlocks, weaves, oily/dirty or hair with debris must be clarified.

**17.21. Volume**
17.21.1. Volume is estimated.
17.21.2. If volume cannot be taken, leave blank and enter Note (see section 17.31)
17.21.3. If no volume received, enter volume as zero (0) and enter comment (see section 17.22)

**17.22. + Add comments**
17.22.1. Predefined comments
17.22.1.1. If SST received: add appropriate comment.
17.22.1.2. If clotted sample: CLOTTED
17.22.1.3. If no volume received: EMPTY
17.22.1.4. If additional sample: ADDITIONAL
17.22.1.5. For a list of all Predefined comments, see Reference Guide Section 8: 003
17.22.2. Free text comments
17.22.2.1. Alternate ID
17.22.2.2. P=XXX, H=XXX
17.22.3. **NOTE:** If comment needs to be on report, check Rpt. box

**17.23. + Add additional Data – (Orange box)**
17.23.1. Hair length

**17.24. Sample Sealed** - (Y or N)
17.24.1. Sealed is defined as: a physical means to ensure that evidence has not been subject to manipulation. There are a host of ways to “seal” evidence and one way is not necessarily better than another way. The seal mechanism should be such that it is obvious that it has been physically altered in a way that gives ready, unauthorized access to evidence.

17.24.2. **NOTE:** When handling samples, labels should not be peeled back. Only visible information is to be used.

**17.25. Unique Identifiers**
17.25.1. Case ID
17.25.2. Patient ID/Name
17.25.3. Alternate ID
17.25.3.1. MRN or MR Number
17.25.3.2. Donor ID

17.25.4. If the above unique identifiers are not available, Date of Birth and/or Initials are acceptable.

**17.26. Sample Labeled** – (Y, N, X, D or U)


Dependencies:

17.26.1. If no unique identifiers are on the submitted paperwork, NP populates in Horizon: The NP (Not Provided) cannot be compared to any data on the sample.

17.26.2. If two samples share one label, it can be used for both samples. Document in the Comments field (see section 17.22).

17.26.3. It is acceptable to use other identifying information on the sample label if none of the above unique identifiers are available and it is provided by the client on the paperwork.

17.26.4. **Y (Yes)**
17.26.4.1. Defined as: All the unique identifiers on paperwork match the sample label.
17.26.4.1.1. **NOTE:** The sample label may have additional identifiers.

17.26.5. **N (No)**
17.26.5.1. Defined as: No label on the sample.

17.26.6. **X (Not Applicable)**
17.26.6.1. Containers created by NMS.
17.26.6.1.1. i.e.: hair segmentation, oral fluids, and homogenates
17.26.6.2. Client shipping containers

17.26.7. **D (Discrepant)**
17.26.7.1. Defined as: One of the provided unique identifiers, submitted on paperwork and sample label, match and other unique identifier(s) do not.
17.26.7.2. Documentation of a difference between the sample label and paperwork submitted.

17.26.8. **U (Unverified)**
17.26.8.1. Defined as: None of the provided unique identifiers submitted on the paperwork and sample label match, or handwriting is illegible, or the label was no longer attached.

17.26.8.2. The unique identifier(s) are visible on primary label and don't match the identifiers on a secondary label.

17.26.8.3. Make a copy of all sample labels that are discrepant.
17.26.8.3.1. If all samples have the same discrepancy, place all samples side by side on copier and make one copy.
17.26.8.3.2. If samples have different discrepancies, a separate copy of each discrepancy is needed.

17.26.8.4. If an update to the information in the Sample Labeled field is needed, after saving your workorder, see Reference Guide Section 8: 029

**17.27. Documentation of Sample Labeled As**: – (Y, N, X, D or U)


Dependencies:

17.27.1. Enter specimen number found on sample label.

17.27.2. If identifying letters are provided on both sample label and submitted paperwork, add the letter in the Sample Labeled As field.
17.27.3. If it is not part of the unique identifier place a backslash (/) between identifier and letter.

17.27.4. **Y (Yes)**
17.27.4.1. Enter specimen number provided on sample label.

17.27.5. **N (No)**
17.27.5.1. Enter "NO LABEL"
17.27.5.2. The discrepancy will be documented in Horizon, refer to 17.36.

17.27.6. **X (Not Applicable)**
17.27.6.1. Enter specimen number provided on parent sample label.

17.27.7. **D (Discrepant)**
17.27.7.1. Enter specimen number provided on sample label.
17.27.7.2. The discrepancy will be documented in Notes, refer to 17.31.

17.27.8. **U (Unverified)**
17.27.8.1. Enter specimen number provided on sample label.
17.27.8.1.1. If sample is labeled but cannot be read, write "ILLEGIBLE".
17.27.8.1.2. If sample is labeled with a barcode only, write "BARCODE ONLY"
17.27.8.1.3. If sample label is no longer attached and sample is not contained individually, write "LABEL NOT ATTACHED"
17.27.8.1.3.1. Make a photocopy of label and discard label.
17.27.8.2. The discrepancy will be documented in Horizon, refer to 17.36.

**17.28. Sample Dated** – (Y or N)
17.28.1. This question applies to the seal.

**17.29. Sample Initialed** – (Y or N)
17.29.1. This question applies to the seal.
17.29.1.1. Can be initialed or signed.

**17.30. Sample Timed** – (Y or N)
17.30.1. This question applies to the label.

**17.31. Notes**
17.31.1. This information appears on the Login Verification form. This is internal documentation for NMS.
17.31.2. Enter notes pertaining to the sample that may help address an oddity:
17.31.2.1. Examples:

17.31.2.1.1. If discrepant: Enter unique identifier from sample label of highest priority that matches, then the unique identifier from sample label that is different separated by a backslash (/).
17.31.2.1.2. WO previously received under a different workorder.
17.31.2.1.3. Hair segmentation notes
17.31.2.1.4. Weight not taken due to nature of sample.
17.31.2.1.5. Return packaging notes.
17.31.2.1.6. ***Discarded a portion of the tissue due to inadequate container size and/or contamination. Amount discarded: ____grams*** when some of the tissue could not be returned to the original container.

**17.32. Misc. Info (Reportable)**
17.32.1. This information appears on the clients' report.
17.32.2. Enter any information concerning the sample, login information or conflicts with login information.
17.32.2.1. Examples:
17.32.2.1.1. Collection date and time discrepancies
17.32.2.1.2. Additional source information on paperwork
17.32.2.1.3. Source discrepancies
17.32.2.1.4. Sample descriptions
17.32.2.1.5. Sources not available in Horizon
17.32.2.1.5.1. Ex. Pupa, Placenta

**17.33. CONF Notes**
17.33.1. Internal notes regarding handling of the specimen.
17.33.1.1. Example:
17.33.1.1.1. Micro and Consume
17.33.1.1.2. Limited Confs or Hold Confs
17.33.1.1.3. Do Not Use
17.33.1.1.4. One Shot Deal

**17.34. Label Count**
17.34.1. Defaults to 1, however, can be changed.
17.34.2. Label(s) will print.

**17.35. Lab I.D. (Container) Label**
17.35.1. When applying label to specimen cover as little information as possible. Placing the label over the clients' barcode is preferred. (This removes the chance of scanning the clients' barcode instead of the NMS barcode.)
17.35.1.1. **NOTE:** Sample "Return" clients may request their barcodes not be covered. These clients will have login alerts stating this.
17.35.2. Additional preprinted colored labels may be required for cases.
17.35.3. Place labels on parent containers near the top. Be careful not to cover the NMS barcode.
17.35.3.1. Examples:
17.35.3.1.1. Micro: for limited volume samples


Dependencies:

17.35.3.1.2. Return: for samples being returned
17.35.3.1.3. Additional Specimen: when clients send additional samples for a specific workorder already in house.
17.35.4. Labeled specimens will be placed in appropriate rack / basket.
17.35.4.1. Aliquot
17.35.4.2. Store

**17.36. Documenting a discrepancy in Horizon**
17.36.1. For ClarifyFDU:
17.36.1.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
17.36.1.2. Click on Additional Information and scroll to ClarifyFDU.
17.36.1.3. Go to notes/instructions field to enter discrepancy.
17.36.1.4. Enter discrepancy as: paperwork vs sample label
17.36.1.5. Document only in the first sample unless it varies from sample to sample.
17.36.1.5.1. If it varies, add a description to the corresponding sample.
17.36.1.6. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.
17.36.2. For ClarifyFDN:
17.36.2.1. Click on hyperlink of sample which takes you to the sample screen in Horizon.
17.36.2.2. Remove all testing (A, P and C tasks) from the sample – unless it's a STORE.

**17.37. Choose one of the following to continue:**
17.37.1. If multiple samples were received for the same requisition, proceed to section 17.12. When final sample is logged in proceed to section 17.37.
17.37.2. If logging in a new case under the same airbill, click on New Workorder (or Ctrl O). Proceed to section 10. When final sample is logged in proceed to section 17.37.
17.37.3. If logging in a new case with a new airbill, click on New Package or (Ctrl B). Proceed to section 10.

17.37.4. Workorder (Requisition) labels will print when New Workorder or New Package is selected.
17.37.4.1. This is NMS's unique identifier.
17.37.5. Label Count – defaults to 1.
17.37.6. If paperwork is supplied, a requisition label must be applied.
17.37.7. Check the workorder and the workorder I.D. on the label to ensure correct labeling.
17.37.8. Place the workorder label on each document associated with case / patient.
17.37.9. For additional workorder / lab I.D. labels see Printing Labels in Horizon User Guide.
17.37.10. Write the number of pages on the label and circle the number.
17.37.11. You only need to do this on this on one form (preferably the requisition).
17.37.12. The total number is the total number of pages, not documents.




Dependencies:

**Title: Electronic Chain of Custody and Transporting Samples**

**PURPOSE:** To define and describe the process of electronically documenting Chain-of-Custody of specimens and transporting specimens from the processing area to the laboratory.

**SCOPE:** To be used by NMS-Core personnel transferring specimens.

**PROCEDURE:**

CAUTION: During this procedure you will be working with potentially infectious materials (blood, etc.), and potentially hazardous chemicals. You must follow the safety procedures for handling these materials as detailed in NMS Lab's Bloodborne Pathogen Exposure Control Plan and Chemical Hygiene Plan.

**1. Overview of Electronic Chain of Custody**

1.1. Documenting chain of custody is intended to provide a record of the handling and storage of each specimen from its arrival at NMS Labs to its final disposition. This includes the date and purpose each time a specimen is handled or transferred and identification of each individual who handled or transferred the specimen. This documentation can be created and stored manually on hard copy forms or electronically using computer software approved for such use. This procedure describes the electronic creation and storage of chain of custody records.

**2. Login**

2.1. By default, the location assigned to all samples by the Laboratory Information Management System (LIMS) when they are logged in is LOGIN. All samples in the system will have LOGIN as their first electronically documented location.

2.2. Once specimens are logged in, they will be transferred to storage, a workstation or to the lab. Transfers of samples between workstations and the lab are recorded using the Container Transfer function in the LIMS. Transfers of samples into and out of storage are recorded using the Specimen Storage Application.

**3. Transferring Specimens Between Workstations and Departments**

3.1. Follow the Transfer instructions found in the LIMS User Guide.

3.2. The person who entered the transfer information then delivers the samples to the location entered in LIMS.

**4. Transferring Specimens to and from Storage**

4.1. Refer to SOP 10984 for instructions on use of the Specimen Storage application.




Dependencies: (66587) Batch Chain of Custody Revision Form, (66588) Workorder Chain of Custody Revision Form

**Title: Electronic Chain of Custody and Transporting Samples**

**5. Delivering Samples to the Workstation or Lab Storage Location**

5.1. The person who entered the transport information then delivers the samples to the location entered in LIMS.

**6. Chain of Custody Revision**

6.1. All corrections to chain of custody must be documented.

6.2. Two Chain of Custody Revision forms are available, and the appropriate form is to be completed as applicable. The forms are available in the compliance software and can be accessed through the Favorites menu or by searching by the document ID.

6.2.1. ID 66587 Batch Chain of Custody Revision Form is used when an entire batch requires revision of chain of custody at any step in the process.

6.2.2. ID 66588 Workorder Chain of Custody Revision Form is used when a single workorder requires revision of chain of custody at any step in the process. Multiple forms are required when multiple workorders require chain of custody revision and are not associated with a batch.

6.3. If more appropriate, a memo or addendum containing the appropriate information can be used to describe the revision.

6.4. All documentation (memo and/or Chain of Custody Revision form) must be included in the respective case file(s) in Onbase.

6.4.1. Scan the documentation into OnBase.

6.4.2. Scanning a Batch COC Form requires the user to use the scan queue LAB – Lab Documents, as it uses an HBN to index properly.

6.4.3. Scanning a Workorder COC Form requires the user to change the scan queue to LAB- WO COC Discrepancy. This automatically sets the document type to SP – COC Discrepancy. Both changes are required for OnBase to properly index the document.

6.4.4. Verify within the batch or workorder in OnBase that all forms were indexed properly.

6.4.5. Return the scan queue to the default for the department using that scanner, if applicable.

**7. Sample History Report**

7.1. Paper documentation of Electronic Chain of Custody can be produced using the Sample History Report. This step is only necessary if requested by Expert Services.

7.2. Using Microsoft Edge - open the NMS Intranet.

7.3. Select Reports/Lab Reports/COC Sample History Report.

7.4. Enter the Workorder for the report required.




Dependencies: (66587) Batch Chain of Custody Revision Form, (66588) Workorder Chain of Custody Revision Form

**COMPANY NAME: NMS Labs**

This checklist is provided for Bidder's convenience and identifies the documents to be submitted with each proposal.

***THE FOLLOWING ARE MANDATORY AND MUST BE PROVIDED FOR THE PROPOSAL TO BE CONSIDERED RESPONSIVE.***

***Signatures accepted: PDF Certified or wet-ink scanned***

☒ Letter of Submittal **/ hard signature and in PDF format**

☒ Proposal submitted on or before the date and time indicated within the *Anticipated Procurement Schedule* on page one of this Solicitation, or as amended.

☒ Appendix A: Bidder's Checklist

☒ Appendix B: Certifications **/ PDF Certified or wet-ink scanned signature and in PDF Format INCLUDE ALL REQUIRED DOCUMENTS**

☒ Appendix C: Bidder Questionnaire

☒ Appendix C1: Laboratory Questionnaire

☒ Appendix D: Price Sheet (**PDF Certified or wet-ink scanned signature and in PDF Format INCLUDE PRICE LIST**).

☒ Appendix E: Bidder's Profile

☒ Appendix F: Bidder's Reference Form

☒ Appendix G: Exceptions to Model Contract **/ PDF Certified or wet-ink scanned signature and in PDF Format**

☒ Certificate and Scope of ISO 17025 and ABFT Accreditation by ANAB

☒ Traceability and Quality Control Processes

☒ Standard Operating Procedures and/or relevant policies

☒ Example test report for the requested tests/scope of testing

☒ Example litigation package and litigation package and expert testimony pricing

**DOCUMENTS REQUIRED BEFORE CONTRACT CAN BE SIGNED:**

☒ A copy of the bidder's Washington Business License **/ in PDF format**

**NOTE:** *Corporate filing with the Washington Secretary of State is not a Washington Business License. Business license must be obtained from the Department of Revenue.*

☐ Copy of OMWBE certificate, if you have one **/ in PDF format**

☒ Proof of Liability Insurance

Bidder's Company Name: NMS Labs

Bidder has read and understands all information contained within this entire Solicitation package.

Bidder makes the following Certifications as a required element of the response to which it is attached, understanding that the truthfulness of the facts affirmed here and declare that all answers and statements made in the proposal are true and correct and the continuing compliance with these requirements are conditions precedent to the award or continuation of the related contracts.

## SECTION 1: GENERAL

***Check the boxes below to indicate understanding and acceptance of each certification below:***

☒ The prices and/or cost data/bid Interest information has been determined independently, without consultation, communication, or agreement with others for the purpose of restricting competition. However, Bidder may freely join with other persons or organizations for the purpose of presenting a single bid. No attempt has been made or will be made by the Bidder to induce any other person or firm to submit or not to submit a proposal for the purpose of restricting competition.

Unless otherwise required by law, the prices and/or cost data which have been submitted have not been knowingly disclosed by the Bidder and will not knowingly be disclosed by Bidder, directly or indirectly to any other Vendor or to any competitor until after a Contract has been executed.

☒ In preparing this proposal, Bidder had not been assisted by any current or former employee of the state of Washington whose duties relate (or did relate) to this proposal or prospective contract. Any exceptions to these assurances are described in full detail on a separate page and attached to this document.

☒ Bidder further offers to furnish materials, equipment or services in compliance with all terms, conditions, and specifications herein including all amendments.

☒ Bidder understands that WSP will not reimburse Bidder for any costs incurred in the preparation of this proposal. All proposals become the property of WSP, and Bidder claims no proprietary right to the ideas, writings, items, or samples, unless so stated in this proposal.

☒ Bidder agrees that submission of the attached proposal with an authorized signature constitutes complete understanding and acceptance of the solicitation contents and all incorporated and attached appendices, attachments, schedules, and amendments including the sample contract and general terms and conditions. Bidder further certifies that all necessary facilities or personnel are available and established at the time of bid submission. If there are any exceptions to these terms, Bidder has described those exceptions in detail in its proposal.

☒ The proposal submitted in response to this solicitation is a firm offer for a period of 180 days following receipt and it may be accepted by WSP without further negotiation except where obviously required by lack of certainty in key terms) at any time within the 180-day period.

## SECTION 2: DEBARMENT

☒ ***No Debarment***. Bidder and/or its principals, agents, or any subcontractor providing services under this procurement are <u>not</u> presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from contracting with any federal, state, or local governmental entity.

***OR***

☐ ***Debarment.*** As detailed on the attached explanation (Bidder to provide), Bidder and/or its principals, agents, or subcontractors, presently are debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from contracting with a federal, state, or local governmental entity.

## SECTION 3: EMPLOYEE RIGHTS

*Pursuant to the Washington State Governor's Executive Order 18-03 (dated June 12, 2018), the Washington State Patrol is seeking to contract with qualified entities and business owners who certify that their employees are not, as a condition of employment, subject to mandatory individual arbitration clauses and class or collective action waivers.*

I hereby certify, on behalf of the firm identified below, as follows (check one):

☒ NO MANDATORY INDIVIDUAL ARBITRATION CLAUSES AND CLASS OR COLLECTIVE ACTION WAIVERS FOR EMPLOYEES: This firm does NOT require its employees, as a condition of employment, to sign or agree to mandatory individual arbitration clauses or class or collective action waivers.

***OR***

☐ MANDATORY INDIVIDUAL ARBITRATION CLAUSES AND CLASS OR COLLECTIVE ACTION WAIVERS FOR EMPLOYEES: This firm requires its employees, as a condition of employment, to sign or agree to mandatory individual arbitration clauses or class or collection action waivers.

## SECTION 4: WAGE THEFT PREVENTION

Prior to awarding a contract, agencies are required to determine that a bidder is a 'responsible bidder.' See RCW 39.26.160(2) & (4). Pursuant to legislative enactment in 2017, the responsible bidder criteria include a contractor certification that the contractor has not willfully violated Washington's wage laws. See Chap. 258, 2017 Laws (enacting SSB 5301).

☒ **NO WAGE VIOLATIONS**. This firm has NOT been determined by a final and binding citation and notice of assessment issued by the Washington Department of Labor and Industries or through a civil judgment entered by a court of limited or general jurisdiction to have willfully violated, as defined in RCW 49.48.082, any provision of RCW chapters 49.46, 49.48, or 49.52 within three (3) years prior to the date of the above-referenced procurement solicitation date.

***OR***

☐ **VIOLATIONS OF WAGE LAWS**. This firm has been determined by a final and binding citation and notice of assessment issued by the Washington Department of Labor and Industries or through a civil judgment entered by a court of limited or general jurisdiction to have willfully violated, as defined in RCW 49.48.082, a provision of RCW chapters 49.46, 49.48, or 49.52 within three (3) years prior to the date of the above-referenced procurement solicitation date.

## SECTION 5: SMALL BUSINESS

***Washington Small Business***

☐ *Washington Small Business.* Bidder is a Washington Small Business as defined in RCW 39.26.010. To qualify as a Washington Small Business, Bidder must meet three (3) requirements:

- Location. Bidder's principal office/place of business must be located in and identified as being in the State of Washington. A principal office or principal place of business is a firm's headquarters where business decisions are made and the location for the firm's books and records as well as the firm's senior management personnel.
- Size. Bidder must be owned and operated independently from all other businesses and have either: (a) fifty (50) or fewer employees; or (b) gross revenue of less than seven million dollars ($7,000,000) annually as reported on Bidder's federal income tax return or its return filed with the Washington State Department of Revenue over the previous three consecutive years.
- WEBS Certification. Bidder must have certified its Washington Small Business status in Washington's Electronic Business Solution (WEBS).

***OR***

☒ *Not Washington Small Business.* Bidder is not a Washington Small Business as defined in RCW 39.26.010.

## SECTION 6: CERTIFIED VETERAN -OWNED BUSINESS

☐ *Certified Veteran-Owned Business.* Bidder is a Certified Veteran-Owned Business under RCW 43.60A.190. To qualify as a Certified Veteran-Owned Business, Bidder must meet four (4) requirements:

- 51% Ownership. Bidder must be at least fifty-one percent (51%) owned and controlled by:
  - A veteran as defined as every person who at the time he or she seeks certification has received a discharge with an honorable characterization or received a discharge for medical reasons with an honorable record, where applicable, and who has served in at least one of the capacities listed in RCW 41.04.007;
  - A person who is in receipt of disability compensation or pension from the department of veterans affairs; or
  - An active or reserve member in any branch of the armed forces of the United States, including the national guard, coast guard, and armed forces reserves.
- Washington Incorporation/Location. Bidder must be either an entity that is incorporated in the state of Washington as a Washington domestic corporation or, if not incorporated, an entity whose principal place of business is located within the State of Washington.
- WEBS Certification. Bidder must have certified its Veteran-Owned business status in Washington's Electronic Business Solution (WEBS).
- WDVA Certification. Bidder must have provided certification documentation to the Washington Department of Veterans' Affairs WDVA) and be certified by WDVA and listed as such on WDVA's website (WDVA – Veteran-Owned Businesses).

***OR***

☒ *Not A Certified Veteran-Owned Business.* Bidder is not a Certified Veteran-Owned Business under RCW 43.60A.190.

## SECTION 7: OFFICE OF MINORITY AND WOMEN OWNED BUSINESSES (OMWBE)

☐ Bidder is Certified as a small or minority business with the OMWBE

***OR***

☒ Bidder is NOT Certified as a small or minority business with the OMWBE

I hereby certify, under penalty of perjury under the laws of the State of Washington, that the certifications herein are true and correct and that I am authorized to make these certifications on behalf of the firm listed herein.

| | | |
|---|---|---|
| National Medical Services, Inc. dba NMS Labs | 200 Welsh Road<br>Horsham, PA 19044 | nms@nmslabs.com |
| Full Legal Name of Bidder | Business Address | Email Address |
| David Delia, President and CEO | | 4/17/25 |
| Full Name, Title | Bidder's Signature | Date |

**WSP-TLD** | **LABORATORY QUESTIONNAIRE**

**RFQQ APPENDIX C1**

| | | | |
|---|---|---|---|
| LABORATORY NAME: | NMS Labs | | |
| ADDRESS: | 200 Welsh Road | | |
| CITY: | Horsham | STATE: | PA |
| PHONE: | (215) 657-4900 | ZIP CODE : | 19044 |
| WEBSITE: | www.nmslabs.com | | |

Prospective laboratories: Complete this form for those forensic toxicology testing services listed below, as requested by the Washington State Patrol (WSP) Toxicology Laboratory Division. Where applicable, evidence of accreditation status, traceability and quality control processes must be included in your response. Copies of standard operating procedures or relevant policies must also be included as supporting material for answers to those questions below. The WSP Toxicology Laboratory Division may request additional documentation for evaluation/quality review of the prospective laboratory.

---

***Test/scope of testing requested by the WSP Toxicology Laboratory Division***: Testing is required for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases. Bidders must have the ability to perform comprehensive testing for a broad array of therapeutic drugs and drugs of abuse (to include differentiation of delta-9 THC from cannabinoid analogs) and update their scope of testing periodically to include emerging drugs.

---

***Question 1, Accreditation (Mandatory, Scored)***: List the current accreditation status of the laboratory, including accrediting body(ies). Provide the laboratory's certificate and scope of accreditation (however named) for the requested tests/scope of testing (or reference to documents located on the laboratory's website).

**Response**: NMS Labs has always followed the most stringent standards available to assure our postmortem clients that we produce superior quality results guided by accepted professional standards. NMS Labs is accredited by ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 for:

- Toxicology
- Seized Drugs

This supports our goal of providing the highest quality forensic science services in a timely, confidential and professional manner. NMS Labs also holds national laboratory accreditations and licensures through the College of American Pathologists (CAP) Laboratory Accreditation Program (LAP), and College of American Pathologists (CAP) ISO 15189.

See complete list of licensures as well as copies of our ANAB/ASLCD-LAB certificates in Section 3 of the Letter of Submittal. Also, licensure can be found on our website at https://www.nmslabs.com/resources/accreditations-and-licensures.

***Question 2, Traceability (Mandatory, Scored)***: Does the laboratory demonstrate traceability of reference materials/reference standards to SI units of measurement? If so, describe the laboratory's traceability policies and procedures.

**Response**: NMS Labs addresses the need for traceability of our reference materials/reference standards in our Quality Manual (SOP 10913), Section 8. Our reference analytical standards are purchased from a competent vendor and when possible, chosen to be NIST-traceable or standards with a Certificate of Analysis taking priority. Analytical standards will be appropriately maintained to prevent deterioration, which is further supported by our SOP 11017 – Preparation of Analytical Standards. Reference standard purity will be part of the Uncertainty of Measurement calculation. See NMS Labs' SOP 10913 Quality Manual in the Letter of Submittal, Section 5. NMS Labs will make any additional SOP available for review upon request.

**RFQQ APPENDIX C1**

***Question 3, Uncertainty of Measurement (Mandatory, Scored)***: Does the laboratory provide uncertainty of measurement for the requested tests/scope of testing? If so, describe the laboratory's policies and procedures for determination and reporting of uncertainty of measurement.

**Response**: NMS labs is fully compliant with the ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 requirements for reporting Measurement Uncertainty. NMS Labs provides the uncertainty of measurement calculation on all of our Driving Under the Influence of Drugs analysis panels. See NMS Labs' SOP 10934 Determination of Uncertainty of Measurement in the Letter of Submittal, Section 5.

***Question 4, Quality (Mandatory, Scored)***: Describe the processes whereby the laboratory assures the quality of the test results in the requested tests/scope of testing (e.g. use of quality controls, method validation, proficiency testing).

**Response**: NMS Labs understands that Quality Assurance and Quality Control are an integral part of the laboratory. NMS Labs Quality Assurance department monitors and administers all internal and external QA/QC protocols. NMS Labs participates in comprehensive external proficiency testing programs, which compares our performance with other laboratories performing the same analysis. These programs are supplemented by a comprehensive internal blind proficiency program that challenges analyses that are not formally evaluated by the external program. All data generated by these programs are remediated, as necessary, and approved by various management levels of review.

Additionally, all departments are subject to live audits by the Quality Assurance department on a rotating basis to assess compliance with our quality assurance program. All audits are documented in audit reports and are reviewed and approved by various levels of management. A complete listing of NMS Labs proficiency programs can be found on our website at: https://www.nmslabs.com/resources/accreditations-and-licensures, or is available upon request.

See SOP 10913 Quality Manual in the Letter of Submittal, Section 5.

***Question 5, Test Results (Mandatory, Scored)***: Does the laboratory's report of results include the evidence identifier, date of testing and test method used? If no, is this information documented in the laboratory's testing records and available upon request? Please provide an example of the test report for the requested tests/scope of testing.

**Response**: NMS Labs provides a comprehensive report containing the results of each test requested. The reports will include an evidence identifier, date of testing, and the test method(s) used in generating the data. NMS Labs has provided a sample report for both postmortem and DUID toxicology testing in the Letter of Submittal, Section 4.

***Question 6, Turnaround Time (Mandatory, Scored)***: State the average or median turnaround time for case completion (to include confirmation results). Provide any relevant details.

**Response**: NMS Labs provides quantitated results on forensic panel tests within 2 weeks on average from the time of receipt. NMS Labs current production schedules support an expected turnaround time of 14-18 business days after receiving samples for analysis of our routine postmortem and DUID/DRE toxicology panels. Esoteric and special request testing may exceed 18 days. NMS Labs will make every effort to handle every case received from the WSP in an expeditious manner. Our online test catalog publishes turnaround times by test code: https://www.nmslabs.com/tests.

| | |
|---|---|
| Authorized Signature: | Date Signed: 4/17/25 |
| Name and Title: David Delia, President and CEO | |

**1. Bidder Organization (MANDATORY)**

Describe Organization, including size, areas of services, number of years in business, customer base, and any other pertinent information that would aid evaluators in formulating a determination about the capability, stability, and strength of the Bidder's organization.

***RESPONSE:***

NMS Labs was founded in 1970 and has since earned the reputation as a high-quality bioanalytical toxicology and forensic laboratory. For 54 years, NMS Labs has served the medicolegal community by providing broad-based forensic toxicological analyses. NMS Labs also supports the medicolegal community by offering drug identification testing and expert forensic services.

NMS Labs has a wealth of experience working with postmortem specimens, servicing medical examiners and coroners, law enforcement, attorneys, clinical laboratories, hospitals, private industry, and public crime labs. The scope of toxicology testing capabilities at NMS Labs is the broadest available in the United States from a private laboratory. NMS Labs toxicology capabilities include the analysis for drugs, metals and elements, solvents and environmental toxins in biological samples. Our lab routinely handles alternative samples necessary in death investigations such as tissue, decomposition fluid, gastric fluids, insect larvae and many other matrices.

The type of work NMS Labs performs for our forensic clients includes: all postmortem testing for a Medical Examiner or Coroner, law enforcement testing for drug and alcohol cases, reference toxicology testing for clients that have their own toxicology laboratories, backlog reduction of autopsy cases on a project basis and long-term outsourcing contracts from state and county agencies. NMS Labs also supports the death investigation needs of agencies with drug chemistry analysis of general unknown non-biological substances.

NMS Labs currently employs more than 450 highly trained professionals. NMS Labs has a staff dedicated to our forensic business including: 12 doctoral level toxicologists that are board certified Fellows by the American Board of Forensic Toxicology (F-ABFT), specially trained forensic specimen processors, forensic client support staff, criminalists and scientists, forensic sales and marketing representatives and expert services department. This dedicated forensic staffing allows NMS Labs to give individual attention to each of our forensic clients when necessary. In addition, our administrative support departments of quality assurance, accounting, expert services and business development are all able to support the specific needs of this anticipated contract. NMS Labs does not have any history of defaults, contract terminations or bankruptcies.

NMS Labs has always followed the most stringent standards available to assure our postmortem clients that we produce superior quality results guided by accepted professional standards. NMS Labs is accredited by ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 for:

- Toxicology
- Seized Drugs

This supports our goal of providing the highest quality forensic science services in a timely, confidential and professional manner. NMS Labs also holds national laboratory accreditations and licensures through the College of American Pathologists (CAP) Laboratory Accreditation Program (LAP), and College of American Pathologists (CAP) ISO 15189.

See complete list of licensures as well as copies of our ANAB/ASLCD-LAB certificates in Section 3 of the Letter of Submittal.

NMS Labs forensic services extend beyond our main facilities in Horsham, PA. NMS Labs currently operates multiple secured forensic laboratories within the states of Texas, North Carolina, Pennsylvania and Florida. ANAB ISO 17025 accredits all of these facilities. NMS Labs combined resources offer a

unique network of accredited laboratories which provide increased capacity, economies of efficiency and the operational flexibility to assist clients.

**2. Bidder Qualifications and Experience (MANDATORY/SCORED)**

Describe qualifications and experiences performing similar projects in terms of similar scope, services, government program, size, and project characteristics. Provide explanation of how Bidder meets minimum qualifications; i.e., include Bidder's experience and history with providing services described in this RFQQ.

Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

***RESPONSE:***

Postmortem Toxicology Testing Services

NMS Labs currently provides analysis on over 2,700 therapeutic drugs, illicit drugs and other drugs of abuse and their metabolites, newly emerging synthetic designer drug compounds (synthetic cannabinoids, bath salts, and novel psychoactive stimulants), metals, poisons, inhalation drugs, and other toxic compounds. Analysis can be performed on routine and non-routine samples including:

- Fluids – blood, serum, plasma, urine, vitreous, gastric, bile
- Solids – tissues, all solid organs, bone, injection sites, hair, nails, teeth, decomposed tissue, embalmed bodies, exhumed bodies, insect larvae, bone marrow
- Biological stains on materials (clothing, paper, sheets, carpeting, etc.) for presence of compounds of toxicological interest
- Non-Biological Testing capabilities – tablets, powders, liquids, syringes, and other drug paraphernalia
- Documentable proof of method development capabilities for unique analytes

The NMS Labs portfolio of routine postmortem toxicology panels test for the presence of common drugs of abuse and therapeutic drugs. These panels are offered at a flat-fee price to include all screening and quantitative confirmation testing for compounds included in the scope of the requested toxicology panel. The postmortem portfolio of panels consists of Basic, Expanded, and TotalTox™. Basic and Expanded panels can be ordered with vitreous alcohol confirmation testing. We also offer specific testing panels for inhalational drugs, and carboxyhemoglobin testing. Testing for additional compounds beyond the scope of the routine panels can be requested on an 'a la carte' basis as needed for a specific case.

The primary postmortem panels that are used by NMS Labs clients are the Basic and Expanded Postmortem panels. These panels were developed by our toxicologists specifically to be applied to postmortem samples and results are reported with useful comments to assist death investigators in the interpretation of findings. These panels range in scope from common drugs of abuse (Basic panel) that includes Alcohols and 12 Classes of common drugs of abuse including Fentanyl, to an Expanded panel with over 250 compounds. Drug categories for the Expanded panel include, but are not limited to: Analgesics, Anesthetics, Anticonvulsants, Antidepressants, Antihistamines, Antipsychotics, Bath Salts, Cardiovascular, Gastrointestinal, Narcotics, Neurological, Novel Psychoactive Substances (NPS), Opiates, Sedatives/Hypnotics, Stimulants, and Urological.

See Postmortem Toxicology Scope of Testing in Section 3 of the Letter of Submittal for a list of compounds in each panel.

Human Performance Toxicology Testing Services

NMS Labs has toxicology testing services specifically designed for Drug Recognition Experts (DRE) and law enforcement agencies to investigate suspected incidents of drug-impaired driving and drug facilitated crimes. Our specialized testing services were developed with the oversight of Dr. Barry Logan, PhD, F-ABFT who is nationally recognized for his leadership and contributions to the IACP-DRE program. NMS Labs offers a broad scope of testing at sensitive reporting limits for the most relevant substances typically involved in impaired driving incidents. Additional testing related to the seven (7) DRE Drug Categories outlined by the International Drug Evaluation and Classification Program (DECP) may be added to the initial analysis request to expand the scope of testing.

NMS Labs has a Drug Facilitated Crimes (DFC) panel, previously named Drug Facilitated Sexual Assault panel. All testing performed includes a screen and quantitative confirmation analysis.

The unique features of NMS Labs DRE panels that will be available to the WSP include:

- Scope of Blood Testing - Broad scope of testing at sensitive reporting limits for the most relevant substances typically involved in impaired driving incidents. Additional testing related to the seven (7) DRE Drug Categories outlined by the International Drug Evaluation and Classification Program (DECP) may be added to the initial analysis request to expand the scope of testing. All testing performed includes a screen and quantitative confirmation. NMS Labs extensive menu of tests prevents the need to outsource any testing to other labs for additional toxicology testing.

- Delta-9 Cannabinoid Isomer Resolution is a test that will provide quantitative results for Delta-8 THC and Delta-8 carboxyl THC, Delta-9 THC, Delta-9 carboxy THC and 11-OH Delta-9 THC. The Uncertainty of Measurement will be provided with this result.

- Urine testing is available and will report qualitatively.

- Interpretive Information – NMS Labs Drug Impaired Driving toxicology panels include specific comments authored by our toxicologists that relate to potential drug impairment while driving. These comments will generally relate the toxicological findings to the physical signs, symptoms and behaviors observed in typical DRE evaluations. The specific reference comments are included when applicable on reports at no additional charge. An Uncertainty of Measurement will be provided on all quantitative testing reported.

- Uncertainty of Measurement – NMS Labs has the ability to calculate Uncertainty of Measurement as a standard practice for testing panels specific for drug impairment cases. The Uncertainty of Measurement can be reported for other tests as needed.

See DUID/DRE Toxicology Scope of Testing in Section 3 of the Letter of Submittal for a list of compounds in each panel.

Additional Testing Panels

In addition to our Postmortem and DUID Toxicology panels, NMS Labs has specially designed panels specific for Fire Death, Drug Facilitated Crime, Novel Psychoactive Substances (NPS), Bath Salts, Synthetic Cannabinoids, metals, abused gases, solvents, insecticides and pesticides and a comprehensive metal and metalloids panel. NMS Labs also has targeted analysis methods that can detect and quantitate thousands of drugs and compounds. Refer to the 2025 NMS Labs Fee Schedule for a complete list of test offerings.

Novel Psychoactive Substances

The introduction of new Novel Psychoactive Substances (NPS) has created challenges for all laboratories due to their evolving development and discontinuations. NMS Labs is constantly evaluating information from the media, drug user forums and casework to identify NPS compounds, which may be of interest

and develop mechanisms to report these findings to our clients when appropriate. Giving proper emphasis to this national phenomenon, we have developed a focused developmental team for the NPS drug market.

The NMS Labs' NPS Strategy Team tracks the changing NPS market, identifying novel and emerging drugs and anticipating the most popular new substances. Using a broad range of information resources including the latest medical and scientific literature, data from our forensic drug chemistry casework and monitoring chatter from online drug user networks, the mission of this group is to listen, anticipate and proactively provide analytical solutions for the needs of our customers. It is designed to monitor the state of analytical science practice in the United States and internationally; steer the development of new tests, technologies and market opportunities; and ensure that the needs of both the public safety and public health clients for innovative tests are being met in a timely manner.

In addition to the compounds listed in our Expanded Postmortem panel, NMS Labs has identified several NPS substances that may be detected as part of the analytical work performed in this analysis. All samples tested through our Expanded Postmortem panel, which undergo our LC/TOF-MS screen, are evaluated using an internally developed secondary library specific to new and emerging NPS compounds to identify potential analytes of interest.

As of 10/28/24, the NMS Labs Surveillance Library includes the following as compounds that may be detected in forensic cases:

Expanded Panel Surveillance Compounds: 2-Furanylfentanyl, 2-Methyl AP-237, 3-hydroxy-PCP, 3-MeO-PCP, 3-Fluorophenmetrazine, Acrylfentanyl, alpha-PHP/alpha-PiHP, alpha-PVP, Amoxapine, AP-238, Benztropine, Bropheniramine, Brorphine, Bromazolam, Butylone, Butyrlfentanyl, Chloroquine, cis-3 Methylfentanyl, Cyclopropylfentanyl, Delorazepam, Deschloroetizolam, Diclazepam, Ethylone, Eutylone, Flecainide, Flualprazolam, Fluphenazine, Flurazepam, Fluvoxamine, Hydroxychloroquine, Hydroxyethylflurazepam, Hydroxytriazolam, Isotonitazene / Protonitazene, MDEA, Meclonazepam, Meperidine, Mesoridazine, Metaxolone, Methaqualone, Metonitazene, N-desethyl Isotonitazene, N-ethyl Pentylone, N,N-Dimethylpentylone, N-pyrrolidino Etonitazene, N-pyrrolidino Protonitazene, Normeperidine, Norpropoxyphene, para-Fluoroisobutyrylfentanyl, Pentylone, Perphenazine, Phenacetin, Phenazepam, Pheniramine, Propoxyphene, Pyrazolam, Quinidine, Tianeptine, Tizanidine, Theophylline, Thioridazine, trans-3-Methylfentanyl, Trifluoperazine, Trimipramine, Tripolidine, Vardenafil, Yohimbine, Zaleplon

NMS TotalTox Surveillance Compounds: 2-Methyl AP-237, 3-Fluorophenmetrazine, AP-238, Brorphine, Chloroquine, Deschloroetizolam, Meclonazepam, Pyrazolam, Tianeptine

In situations where NMS Labs may detect the presence of these compounds, the client will be notified to consult with us on next steps given the case history and testing capabilities at the time. Additional fees will apply for confirmation testing of the above-listed compounds. It is expected that with our dedicated approach to identifying NPS compounds of interest, this library of compounds will be dynamic and will change over time.

See NPS Scope of Testing in Section 3 of the Letter of Submittal for a list of compounds in NMS Labs panels.

True Forensic Testing
The scope of compounds and metabolites specified in NMS Labs forensic panels are analyzed by initial screening tests for preliminary identification and confirmed by more specific testing methods to provide quantitative identification of specific compounds identified by the initial screening. This includes using two analytical techniques on two separate aliquots.

The following is a list of the analytical techniques in general use within NMS Labs for screening and confirmation testing:

Screening
ELISA (Enzyme Linked Immunosorbent Assay)
EMIT (Enzyme Multiplied Immunoassay Technique)
FPIA (Fluorescence Polarized Immunoassay)
TLC (Thin-layer Chromatography)
Microdiffusion
Spectrophotometry
LC/MS/MS-TOF (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry/Time of Flight)
LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)
HPLC (High Performance Liquid Chromatography) with various forms of detection (UV, Fluorescence, Electrochemical)
GC/MS (Gas Chromatography/Mass Spectrometry)
GC (Gas Chromatography) with various forms of detection (NPD, FID, ECD)
ICP/MS (Inductively Coupled Plasma Mass Spectrometry)
GFAAS (Graphite Furnace Atomic Absorption Spectrophotometry)

Confirmation
LC/MS/MS (Liquid Chromatography/Mass Spectrometry/Mass Spectrometry)
LC/MS/MS-TOF (TOF = Time of Flight)
GC/MS (Gas Chromatography/Mass Spectrometry)
ICP/MS (Inductively Coupled Plasma Mass Spectrometry)

**Non-Biological Testing Capabilities**

NMS Labs is capable and has experience performing non-biological testing. NMS Labs holds a DEA licensure and is currently accredited by ANAB (ANSI National Accreditation Board) ISO/IEC 17025:2017 for laboratory analysis in the discipline of Seized Drugs.

Services that NMS Labs offers to assist the Washington State Patrol include:

- Detection of tampering and physical or chemical contamination in foods, beverages, drugs and other consumer products.
- Identification and evaluations of pills, powders, potions, poisons, plants and drug paraphernalia.

**Method Development for Unique Analytes**

NMS Labs is the leading independent provider of clinical and forensic toxicology, and criminalistics laboratory services for the health care and forensic sciences communities. Since 1970, we have built a reputation as a provider of innovative, first-to-market and hard-to-find testing that has evolved to a broad menu of over 2,500 laboratory tests with documentable proof of method development. Customers worldwide have recognized NMS Labs for its world-class, full-service facility and emphasis on research and development.

Offering one of the largest arrays of esoteric laboratory testing and services, NMS Labs is the only commercial source for many new and hard-to-find tests in the areas of:

- Postmortem toxicology
- Clinical toxicology, including pain management and hundreds of monitored therapeutic drugs
- Environmental exposure and occupational monitoring, including volatile organics and metals
- Drug identification; investigation of drug diversion, tampering and fraud

### 3. Quality Assurance (MANDATORY/SCORED)

Proposal must describe Bidder's approach to Quality Assurance and how Bidder will implement quality control.

***RESPONSE:***

NMS Labs understands that Quality Assurance and Quality Control are an integral part of the laboratory. NMS Labs Quality Assurance department monitors and administers all internal and external QA/QC protocols.

NMS Labs participates in comprehensive external proficiency testing programs, which compares our performance with other laboratories performing the same analysis. These programs are supplemented by a comprehensive internal blind proficiency program that challenges analyses that are not formally evaluated by the external program. All data generated by these programs are remediated, as necessary, and approved by various management levels of review.

Additionally, all departments are subject to live audits by the Quality Assurance department on a rotating basis to assess compliance with our quality assurance program. All audits are documented in audit reports and are reviewed and approved by various levels of management. A complete listing of NMS Labs proficiency programs can be found on our website at: https://www.nmslabs.com/resources/accreditations-and-licensures, or is available upon request.

See SOP 10913 Quality Manual in Section 5.

### 4. Approach/Strategy (MANDATORY/SCORED)

Describe the Bidder's approach to the work as outlined in Section 1 Introduction of the solicitation. Proposals must show bidder's capacity to test for common or emerging drugs and/or alcohol in death and impaired driving/DUI investigation cases, Bidder's ability to test for a vast array of novel, emerging drugs, how bidder updates their scope of testing frequently, and Bidder's ability to distinguish between the delta-8 and delta-9 isomers of THC (marijuana).

***RESPONSE:***

Please see response to #2 Bidder Qualifications and Experience.

### 5. Related Information (MANDATORY)

**5.1 State Contracts.** Has the Bidder or any subcontractor contracted with the state of Washington during the past 24 months?

☐ No ☒ Yes

If Yes, indicate the name of the agency, the contract number and project description and/or other information available to identify the contract.

> Washington State Patrol, Contract # K16171, Forensic Testing of Toxicology Biological Samples Contract Start 8/15/2020 – Contract End 8/14/2025.
> Contract Details: Provide analysis of common and emerging drugs that Washington State Patrol Toxicology Laboratory Division (TLD) does not currently have the methodology and/or instrumentation to perform in-house and/or assist in reducing a backlog of casework.

Has the Bidder ever been terminated for default in the last five years?

☒ No ☐ Yes

If Yes, describe such incident. Termination for default is defined as notice to stop performance due to the Bidder's non-performance or poor performance and the issue of performance was either (a) not litigated due to inaction on the part of the Bidder, or (b) litigated and such litigation determined that the Bidder was in default. Submit full details of the terms for default including the other party's name, address, and phone number. Present the Bidder's position on the matter. WSP will evaluate the facts and may, at its sole discretion, reject the response on the grounds of the past experience. If no such termination for default has been experienced by the Bidder in the past five years, so indicate.

***N/A***

**5.2 State Employees.** Is anyone in the Bidder's staff or subcontractor's staff a former employee of the state of Washington during the past 24 months, or is currently a Washington State employee?

☒ No ☐ Yes

If Yes, identify the individual by name, the agency previously or currently employed by, job title or position held and separation date. Also identify any State employees or former State employees employed or on the Bidder's governing board as of the date of the response. Include their position and responsibilities within the Bidder's organization. Include any staff member(s) who will perform work on this contract and has retired from the State of Washington under the provisions of the 2008 Early Retirement Factors legislation. If following a review of this information, it is determined by WSP that a conflict of interest exists, the Bidder may be disqualified from further consideration for the award of a contract.

***N/A***

1. ***COST:***

Although cost is a consideration when selecting the Apparent Successful Bidder, the evaluation process is designed to award this procurement not necessarily to the Bidder of least cost, but rather to the Bidder whose proposals best meet the requirements of this Solicitation.

2. ***PRICING:***

Bid amounts must include all cost components needed to provide services as described in this Solicitation, including travel, labor and supplies. All costs associated with services must be incorporated into the price of the Bidder's Response, for the initial contract period and all potential contract extensions. Failure to identify all costs in a manner consistent with the instructions in this Solicitation will result in rejection of bidder's proposal as nonresponsive.

The Apparent Successful Bidder's (ASB) Quotation must remain fixed for the awarded Contract's period of performance. Price increases may occur at the time of contract renewal by mutual agreement of the parties, but in no case more than 5%.

Proposed costs shall include any applicable Washington State taxes associated with the contract work that the Bidders are required to pay. Bidders are required to collect and pay state taxes as applicable.

3. **BIDDER'S PRICE LIST:**

Bidder shall include with the proposal a complete list of testing services provided and the cost of each service.

**Response:** See NMS Labs RFQQ Pricing in Section 2 of the Letter of Submittal. See also NMS Labs 2025 Fee Schedule included with our response.

| | |
|---|---|
| Company Name: NMS Labs | |
| Authorized Signature: | Date Signed: 4/17/25 |
| Name and Title: David Delia, President and CEO | |

| | | |
|---|---|---|
| Legal Company Name | National Medical Services, Inc. | |
| Doing Business As | NMS Labs | |
| Legal Status | Subchapter S corporation | |
| Year Company Established | 1970 | |
| Washington State Tax ID Number<br>OR<br>Universal Business Identifier Number (UBI) | 604420457 001 0001 | |
| Statewide Vending Number | SWV0101036-00 | |
| Washington Business License Number | See attached | Expiration Date<br>Not listed |
| If you do not have a Washington Business License, please explain the status of your application. | Click here to enter text. | |
| Website URL Address | www.nmslabs.com | |
| Street Address | 200 Welsh Road, Horsham, PA 19044 | |
| Mailing Address, if different from Street Address | Click here to enter text. | |
| Billing Address | 200 Welsh Road, Horsham, PA 19044 | |
| Company Contact Name | Cami Green | |
| Contact Phone Number | (215) 657-4900 | |
| Email | nms@nmslabs.com | |

**The following attachments are required:**

- Organizational chart
- List of principal officers including Name, Title, Address, and Telephone number
- Copy of Washington Business License
    - Note: A Washington Business License is required before a contract can be signed. If you do not have a business license, you may apply for one at the Washington Department of Revenue.

# NMS LABS ORGANIZATION CHART
# MARCH 2025

*NMS Labs Organizational Chart is created using Visio and is too large to print in page format. Below is the org chart data in table format. The electronic Visio file can be provided upon request.*

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Dave Delia | President & CEO |
| Adam Rapoport | Aaron Katz | Analyst III |
| | Amanda Burkey | Analyst I |
| | Dylan Schimpf | Technical Team Leader-PA |
| | Emily Anderson | Remote Analyst II |
| | Esther Kolade | Analyst II |
| | Jenna Sadowski | Analyst I |
| | Rebecca Turner | Remote Analyst III |
| | Ronae Foxworth | Analyst III |
| | Siera Cruz | Lab Support Specialist |
| Allison Vaughan | Ashton Smith | Analyst I |
| | Erin Rohrbach | Analyst III |
| | Faith Kaniewski | Analyst II |
| | Josephine Gottal | Technical Team Leader-JAX |
| | Kira Bochard | Analyst II |
| | Makayla LoChiatto | Analyst III |
| | Melanie Murphy | Analyst III |
| | Mia Baumgarten | Analyst I |
| | Michelle Cancel Baez | Analyst I |
| | Nancy Shubbar | Analyst IV |
| | Patricia Fernandez | Analyst III |
| Amanda Andrews | Branden Brunner | Forensic Drug Chemistry Training Specialist |
| | Marissa Penney Smith | Forensic Drug Chem Training Specialist-DFW |
| | Nicole Lattanzio | Forensic Chemistry Technical Director |
| Angelica Stoto | Cara Nicodemus | Analyst IV |
| | Danica Martin | Analyst III |
| | Emily Ashe | Analyst I |
| | Ian Rhines | Lab Support Specialist |
| | Kourtney Albert | Analyst II |
| | Marielle Barstow | Analyst II |
| | Rachael Beemer | Analyst I |
| | Talya Parker | Analyst III |
| | Zachary Shaner | Lab Support Specialist |
| Ayako Chan-Hosokawa | Amanda D'Orazio | Toxicologist I (Local-Horsham) |
| | Emily Fenton | Toxicologist I (Local-Horsham) |
| | Jolene Bierly | Toxicologist III (Local-Horsham) |
| | Kari Midthun | Toxicologist IV (Local-Horsham) |
| | Meaghan Hessler | Toxicologist II (Local-Horsham) |
| | Michael Lamb | Toxicologist III (Local-Horsham) |
| | Nicholas Laraia | Toxicologist I (Local-Horsham) |
| | Sherri Kacinko | Toxicologist V (Local-Horsham) |
| | Stephanie Marco | Toxicologist II (Local-Horsham) |
| | Victoria Hill | Toxicologist I (Local-Horsham) |
| Barbara Hovanec | Claudia Linares | HR Intern |
| | Jennifer Winter | HR Intern |
| | Natalie Czeredarczuk | HR Coordinator |
| Barry Logan | Catherine Chuff | Administrative Assistant |
| | Erin Spargo | Director of Toxicological Services |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Laura Labay | Principal Toxicologist |
| Brian Holsey | Alexis McCrossan | Analyst III |
| | Barera Hasan | Lab Support Specialist |
| | Cristina Carrico | Technical Team Leader-PA |
| | Eleni Karasek | Analyst IV |
| | Emily Pribila | Lab Support Specialist |
| | Gabriel Yucel | Lab Support Specialist |
| | Lauren Bogiatzis | Lab Support Specialist |
| | Mark Shadle | Analyst III |
| | Marykathryn Moody | Validation Analyst III |
| | Nichell Glover | Lab Support Specialist |
| | Revelle Paul-Roper | Analyst II |
| | Rozwell Johnson | Analyst II |
| | Susan Crookham | Analyst IV |
| Bridget McGinty | Hamil Patel | Forensic Chemist I |
| | Jenna Schindler | Forensic Chemist I |
| | Joshua Folger | Remote Forensic Chemist Reviewer III-PA |
| | Mackenzie Overholser | Forensic Chemist I |
| | Marilyn Aguilar Mejia | Forensic Chemist I |
| | Melanie Liston | Forensic Chemist III |
| | Melvin Lartey | Forensic Chemist I |
| | Reece Firestone | Evidence Processing Specialist I-PA |
| Brittany Casey | Brianna Peterson | Toxicologist IV (Remote) |
| | Chelsey Deisher | Toxicologist I (Remote) |
| | Daniel Anderson | Toxicologist IV (Remote) |
| | Daniel Isenschmid | Toxicologist V (Remote) |
| | Estuardo Miranda | Toxicologist III (Remote) |
| | Jennifer Swatek | Toxicologist II (Remote) |
| | Justin Brower | Toxicologist IV (Remote) |
| | Kristopher Graf | Toxicologist II (Local-Remote) |
| | Scott Larson | Toxicologist IV (Remote) |
| | William Schroeder | Toxicologist II (Remote) |
| Bruce Whiteman | Micah Butler | Contract Administrator |
| Bryant Jones | Justin Korbal | QC Summer Intern |
| | Ramsunder Iyer | Lab Supervisor |
| Carriena Anaya | Elena Davydov | Accounts Receivable Analyst II |
| | Michele Griffin | A/R Collections Specialist |
| Christopher Martin | James Foote | Facilities Supervisor- MGR |
| Christopher Mercer | Allison Rosengarden | Analyst III |
| | Bailey Songer | Analyst I |
| | Clarissa Trainer | Lab Support Specialist |
| | Devin Lee | Remote Analyst III |
| | Gabrielle Sawick | Remote Analyst III |
| | Kiara Jackson | Analyst III |
| | Matthew Zuchero | Analyst IV |
| | Megan Mann | Analyst II |
| | Parul Shah | Validation Analyst III |
| | Patrick Ditto | Analyst I |
| | Rebecca Stout | Analyst IV |
| Christopher Siegle | Alyssa Reyes | Specimen Processor II |
| | Ashlee Barnett | Specimen Processor II |
| | Bingen Chen | Specimen Processor II |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Brandon Jackson-Shorts | Specimen Processor II |
| | Cole Straley | Specimen Processor I |
| | Cynthia Morales | Specimen Processor II |
| | Jessica McManus | Specimen Processor III |
| | Joselyn Richner | Specimen Processor III |
| | Julia Smith | Team Leader Specimen Processing |
| | Kristen Sonnie | Specimen Processor II |
| | Lauren Gletty | Specimen Processor III |
| | Nina McCullough | Team Leader Specimen Processing |
| | Nneka Jones | Specimen Processor III |
| | Renytzabelle Ortega-Cotto | Specimen Processor II |
| | Stephen Dyson | Specimen Processor II |
| | Susan Durphy | Specimen Processor I |
| | Teresa Kang | Specimen Processor I |
| | Tram Nguyen | Specimen Processor IV |
| | Yariana Martinez Nieves | Specimen Processor I |
| Cynthia Shannon | Amanda Andrews | Continuous Improvement/Technical Manager |
| | Debra De Young | Expert Services Supervisor |
| | Sally Ullman | Forensic Lab Operations Manager |
| Daniel Reed | Claire Fazio | Business Analyst II |
| | Cynthia Shannon | Director, Drug Chemistry Business |
| | Deirdre O'Neill | Director of Lab Informatics |
| | Gregg Moist | Customer Experience Director |
| | Keith Hoerth | SVP Core Lab Operations |
| | Lindsey Blender | Business Analyst I |
| | William Sweeney | Director of IT Infrastructure |
| Debra De Young | Jaclyn Jarman | Litigation Support Specialist I |
| | Maria Ryan | Litigation Support Specialist III |
| | Natasha Lis Holsey | Litigation Support Specialist III |
| | Nicole Day | Litigation Support Specialist I |
| | Sara DePue | Litigation Support Specialist I |
| | Susan Goldsworthy | Litigation Support Assistant |
| Deirdre O'Neill | Diane Ellmore | Technical Product Manager |
| | Michael Losacco | IT Systems Support Manager |
| Diane Ellmore | Evelyn Burke | SR. Technical Product Owner |
| | Janet Cole | Senior Systems Business Analyst |
| Dipesh Bhatt | Bernard Hudson | Network Engineer I |
| | Nnamdi Aduba | Cybersecurity Engineer |
| | Robert Yaich | Network Engineer III |
| Edward Finn | Van Nguyen | Lead Developer |
| | Vijaykumar Bhatt | Network Engineer IV |
| Elisa Rodgers | Elizabeth Conlon | Marketing Intern |
| | Leslie Pell | Trade Show Coordinator |
| | Ryan White | Sr. Product Manager |
| | Tiffany Scott | SR Marketing Manager, Forensic |
| Erin Spargo | Ayako Chan-Hosokawa | Toxicology Team Manager |
| | Brittany Casey | Toxicology Team Manager |
| | Donna Papsun | Business Scientist/Tox Liaison |
| Dave Delia | Barry Logan | SVP Chief Scientist & Lab Dir., For.Drug Chem |
| | Daniel Reed | SVP Chief Operating Officer |
| | Gregory Schuh | Controller |
| | Jennifer Charlton | SVP of Human Resources |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Kitti Neumann | VP of Quality |
| | Marianne Jackson | SVP Chief Commercial Officer |
| | Robert Middleberg | SVP Laboratory Director of Record |
| Gregg Moist | Ashley Molina | Customer Experience Innovation Lead |
| | Michelle Dyson | Customer Integration Manager |
| | Mildred Danno | Client Support Supervisor |
| | Samantha Wilson | Client Support Supervisor |
| Gregory Schuh | Bruce Whiteman | SR. Contract Manager |
| | Joseph Noonan | Assistant Controller |
| | Kristin Moroski | Senior Financial Analyst |
| | Kristy Boone | Procurement Director |
| | Sean Mallon | SR. Business Analyst |
| Heidi Schimmelbusch | Abigail Hulse | Associate Analytical Training Specialist II |
| | Amanda Cooke | Technical Lead |
| | Anna Steiner | Associate Analytical Training Specialist II |
| | Beth Slaybaugh | Technical Lead |
| | Casey Mulcahy | SR. Analytical Training Specialist I |
| | Cherie Trail | Lab Operations Training Coordinator |
| | Christian Krumenacker | Laboratory Service Engineer II |
| | Gregory Coates | Bioanalytical Engineer II |
| | Hannah Grossmann | Associate Analytical Training Specialist II |
| | Jaron Quinlan | Technical Lead |
| | Leonard Vinci | Bioanalytical Engineer II |
| | Lindsay Pinkstone | SR. Analytical Training Specialist I |
| | Melanie Belinsky | SR. Analytical Training Specialist I |
| | Olivia Tarlo | Technical Lead |
| | Phuong Truong | Technical Lead |
| | Ross Charlton | Operational Technical Improvement Intern |
| | William Ofsa | Bioanalytical Engineer III |
| Ian Hall | Gabrielle McWilliams | Analyst III |
| | Haley Bibey | Analyst I |
| | Niah Washington | Analyst III |
| | Rachel Barrett | Analyst II |
| | Samantha Curran | Remote Analyst III |
| | Shayna Kasher | Analyst II |
| | Tayler Chowns | Analyst II |
| | Victoria Onimus | Analyst IV |
| James Foote | Dantae Williams | Facilities Services Associate |
| | James Brooks | Facilities Services Associate |
| | John Gosselin | Facilities Team Leader |
| | Serena Denmark | Building Services Team Leader |
| Jennifer Charlton | Barbara Hovanec | Recruiting Supervisor |
| | Jennifer Miller | HR Business Partner & Compliance Lead |
| | Marilyn Rudolph | HR Business Partner & Training & Dev Lead |
| | Rose Ann Annand | HR Business Partner & Comp and Benefits Lead |
| Joseph Noonan | Ann Leopold | Senior Accountant |
| | Carriena Anaya | AR Collections Supervisor |
| | Harriet Cohen | Accounts Receivable Analyst III |
| | Matthew Bellamy | Senior Accountant |
| | Steven Schwartz | Accounting Assistant |
| | Xingshu Chen | SR. A/P Lead Analyst |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| Justine Drake | Calaya Zhou | Analyst I |
| | Courtney Rush | Analyst II |
| | Courtney Scharer | Remote Analyst II |
| | Gabrielle Arnold | Analyst I |
| | Jamie Haggard | Analyst II |
| | Jessica Mauser | Analyst III |
| | Joseph Russo | Remote Analyst II |
| | Olivia Lopez | Analyst I |
| Kara Bennett | Claudia Roldan | Forensic Chemist II- ELP |
| | Harley Johnson | Forensic Chemist I- ELP |
| | Jared Sharp | Forensic Chemist I- DFW |
| | Marilyn Giesalhart | Forensic Chemist I- ELP |
| Karen Weed | Chae No | SR. Digital Marketing Manager |
| | Ellie Halterman | Marketing Intern |
| | Jasmine Jones | HR Marketing Intern |
| | Judith Hadley | Sr. Product Manager |
| | Megan Holt | SR Marketing Manager, Clinical |
| | Sophia DiBattista | Marketing Intern |
| Keith Hoerth | Bryant Jones | Lab Operations Manager |
| | Christopher Martin | Facilities Manager |
| | Heidi Schimmelbusch | Lab Operations Manager |
| | Kristina Long | Lab Operations Manager |
| | Linay Williams | Lab Operations Manager |
| | Renee LaFord | Lab Operations Manager |
| | Tiara Green | Administrative Assistant- Lab Ops |
| | Xiaoning Lu | VP of R&D |
| Keith-Dane Temporal | Alexandra Sawyer | Forensic Chemist I- DFW |
| | Hailey Spurgeon | Forensic Chemist II- DFW |
| | Kathryn Baxter | Forensic Chemist II- DFW |
| | Kayle Aldana | Forensic Chemist I- DFW |
| | Lauren DeJong | Forensic Chemist I- DFW |
| | Shelia Kennard | Forensic Chemist II- DFW |
| Kitti Neumann | Alexandria Shults | QA Regulatory Technical Specialist III |
| | Ann Meadows | QA Regulatory Affairs Supervisor |
| | Kaitlyn Carrillo | QA Compliance Technical Specialist II |
| | Mary Heater | QA Compliance Technical Specialist II |
| | Meredith Atkins | Quality Assurance Compliance Supervisor |
| | Sara Bodnar | QA Technical Specialist I |
| Kristin Johndreau | Alexis Blankenship | Forensic Chemist III- NC |
| | Ashley Clements | Forensic Chemist II-NC |
| Kristina Long | Adam Rapoport | Lab Supervisor |
| | Brian Holsey | Lab Supervisor |
| | Rachel Davidovics | Lab Supervisor |
| | Rachel Reilly | Lab Supervisor |
| | Sara Gagen | Lab Supervisor |
| | Stacey DeJoseph | Lab Supervisor |
| | Thanh Huynh | Lab/IT System Support Analyst |
| Kristy Boone | Elizabeth Grapin | Shipping & Client Supplies Clerk |
| | Laura Kennedy | Category Manager |
| | Mark Crandall | Receiving/Inventory Clerk |
| | Stephanie Kane | Buyer |
| | Tyler Fritsch | Associate Materials Manager |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| Kyle Brown | Adam Badinger | Forensic Chemist II |
| | Armani Brathwaite | Forensic Chemist I |
| | Hsuan-Ni Wang | Forensic Chemist I |
| | Katherine Harkins | Forensic Chemist II |
| | Maeve Picariello | Forensic Chemist I |
| | Matthew Hewes | Forensic Chemist II |
| | Michael Kanwischer | Forensic Chemist I |
| | Sean Ball | Forensic Chemist II |
| Linay Williams | Allison Vaughan | Lab Supervisor |
| | Christopher Mercer | Lab Supervisor |
| | Christopher Siegle | Specimen Processing Supervisor |
| | Elizabeth Schafer | Specimen Processor I |
| | Erin Keller | Specimen Processor II |
| | Hector Martinez | Specimen Processor II |
| | James Czerpak | Specimen Processor I |
| | Janeline Vasquez | Specimen Processor III |
| | Jonae Savage-Hall | Specimen Processor II |
| | Kevin Doherty | Courier |
| | Kimberly Libus | Specimen Processor I |
| | Marlene Doyle | Specimen Processor II |
| | Megan Kha | Specimen Processor II |
| | Moronica Teng | Specimen Processor III |
| | Myhanh Tram | Specimen Processor III |
| | Rachel Crouthamel | Specimen Processing Supervisor |
| | Reneliza Ortega | Specimen Processor IV |
| | Sean Howe | Specimen Processor I |
| | Susan Boun | Specimen Processor IV |
| | Trang Le | Specimen Processor III |
| Linda Gott | Camilla Green | SR Territory Manager |
| | Danielle Farina | Account Manager |
| | J. Eric White | SR Territory Manager |
| | Jenna Lock | Account Manager |
| | Kristin Kendrick | Territory Manager |
| | Nicole McNutt | Account Manager |
| Lindsay Cheeseman | Danielle DeMauro | Analyst IV |
| | Davy-Anna Phosouvank-Chamroeunphorn | Analyst II |
| | Emily Kopp | Analyst IV |
| | Geoffrey Beane | Lab Support Specialist |
| | Justin Davis | Lab Support Specialist |
| | Kathryn Rawski | Analyst II |
| | Michael Ruiz | Analyst I |
| | Paige D'Elia | Analyst II |
| | Zachary Digman | Analyst II |
| Lisa Woolcott | Blake Mallett-Fuina | IT Project Manager III |
| | Gannon Holmgren | Project Manager II |
| | Lori Rosen | Project Manager II |
| Marianne Jackson | Elisa Rodgers | Marketing Director, Forensics Division |
| | Karen Weed | Marketing Director, Clinical Division |
| | Lisa Woolcott | Program Director |
| | Michael Baker | National Sales Director-Forensic |
| | Michael Schooley | National Sales Director-Clinical |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| Megan Bergauff | Abigail Cervantes | R&D Scientist III |
| | Carrie Despotovich | R&D Scientist III |
| Megan Holt | Halle Brown | Marketing Specialist |
| Meredith Atkins | Amanda Hackman | QA Compliance Technical Specialist II |
| | Mark Lafferty | Chemical Hygiene and Safety Lead |
| Michael Baker | Kacie Tross | Territory Manager |
| | Lauren LaFord | Sales Support Specialist |
| | Laurie Caubet | Senior Sales Support Specialist |
| | Linda Gott | Sales Manager |
| | Lori Knops | National Account Manager-Forensics |
| Michael Losacco | Eric Mullen | IT Systems Support Lead |
| | Gerald Johnson | Lab Informatics Analyst II |
| | Igor Lashinker | Lab Informatics Analyst III |
| | Kimberly Kruth | CRM Administrator |
| | Tammy Widdemer | Lab Informatics Analyst III |
| Michael Schooley | Billy Sifford Martinez | Business Development Manager-Laboratory |
| | Eric Alexy | SR. Manager of Lab Studies |
| | Lauren Pollick | Business Development Manager-Laboratory |
| | Matthew King | Business Development Manager-Environmental Ex |
| | Roger McCombs | Business Development Manager-Laboratory |
| | Tobie Brown | Business Development Manager-Laboratory |
| | Varen Herman | Strategic Business Director |
| Michelle Dyson | Allison Blum | Customer Integration Specialist |
| | Caroline Kelch | Customer Integration Specialist |
| Mildred Danno | Cathleen Soltys | Client Services Associate, Clinical |
| | Constance Barnes-Edwards | Client Services Associate, Clinical |
| | Jasmin Chandler | SR Client Services Specialist, Clinical |
| | Jennifer Jarman | Client Services Associate, Clinical |
| | Joan Wood | Front Desk Coordinator |
| | Lyneve Lopez | Client Services Associate, Clinical |
| Nina Salazar | Abbey Lutz | Forensic Chemist II- DFW |
| | Erin Jeffrey | Forensic Chemist III-DFW |
| | Jackson Hill | Forensic Chemist I- DFW |
| | Katelyn Klein | Forensic Chemist II- DFW |
| | Linsey Wilkins | Forensic Chemist I- DFW |
| | Rachel Freemon | Forensic Chemist I- DFW |
| | Rachel Matte | Forensic Chemist I- DFW |
| Rachel Crouthamel | Bethann Vanderslice | Remote Specimen Processor II |
| | Bianca White | Specimen Processor I |
| | Caitlyn McGrellis | Remote Specimen Processor II |
| | Calina Navarro | Specimen Processor I |
| | Eric Rotondella | Specimen Processing Training Specialist |
| | Jodi Leach | Specimen Processing Training Specialist II |
| | Kelly Schulz | Specimen Processor II |
| | Laura Norman | Remote Specimen Processor II |
| | Michael Chell | Specimen Processor I |
| | Richelle Valentin | SP Lab Assistant |
| | Sarah Esselburn | Client Clarify Specialist |
| | Savannah Tarlo | Specimen Processor II |
| | Shannon Schumann | Specimen Processing Training Specialist II |
| | Stephanie Machiesky | Client Clarify Specialist |
| | Tatyana Kandova | Specimen Processor II |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Virginia Wilson | Remote Specimen Processor II |
| | Vy Le | Specimen Processor II |
| | William Butler | Specimen Processor I |
| | Yomira Custodio Minyety | SP Lab Assistant |
| Rachel Davidovics | Anya Burke | Analyst I |
| | Dawn Sherwood | Analyst IV |
| | Devin Ball | Analyst II |
| | Elizabeth Hutnick | Analyst II |
| | Gabriela Sacchi | Remote Analyst III |
| | Melissa Rogers | Analyst IV |
| | Paige Roth | Analyst III |
| | Rachel Burns | Analyst III |
| | Shane Kullen | Analyst I |
| Rachel Reilly | Brian Klock | Lab Support Specialist |
| | Colleen O'Neill | Analyst IV |
| | Esteban Sanchez-Pastor | Analyst III |
| | Kathleen Frederick | Analyst IV |
| | Leila Okazaki | Analyst II |
| | Lin-Lon Yang | Analyst IV |
| | Olivia Dremann | Analyst II |
| | Princess McCorvey | Analyst II |
| | Raven Johnson | Analyst III |
| Ramsunder Iyer | David Wolf | QC Specialist |
| | Lauren Palmer | QC Specialist II |
| | Lisa Notheis | Quality Control Training Specialist |
| | Lorena Alvarez | QC Analyst |
| | Noah Clark | Validation Analyst I |
| | Sienna Gutierrez | QC Analyst |
| | Tina Reiber | QC Analyst |
| | Zachary Langley | QC Specialist |
| Renee LaFord | Angelica Stoto | Lab Supervisor |
| | Ian Hall | Lab Supervisor |
| | Justine Drake | Lab Supervisor |
| | Lindsay Cheeseman | Lab Supervisor |
| | Robert Hessler | Lab Supervisor |
| Robert Hessler | Aaliyah Bangura | Analyst III |
| | Adam Pastroski | Analyst I |
| | Anna Andoos | Analyst II |
| | Annette Ervin | Validation Analyst III |
| | Arinze Akpom | Analyst I |
| | Ashley Paster | Analyst III |
| | Charles DiMaggio | Analyst IV |
| | Karissa Sanfratello | Lab Support Specialist |
| | Shannon Rose | Analyst II |
| Robert Middleberg | Lee Blum | Assistant Lab Director |
| | Robert Boorstein | Assistant Lab Director |
| Sally Ullman | Brandon Abrahamson | Evidence Processing Specialist II - TX |
| | Bridget McGinty | Forensic Chemistry Site Supervisor-PA |
| | Conager Robb | Forensic Chemist II- DFW |
| | Danielle Dela Cruz | Forensic Chemistry Site Supervisor-DFW |
| | Kara Bennett | Forensic Chemistry Site Supervisor-EL PASO |
| | Keith-Dane Temporal | Forensic Chemistry Supervisor-DFW |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| | Kristin Johndreau | Forensic Chemistry Site Supervisor-WIN |
| | Nina Salazar | Forensic Chemistry Supervisor-DFW |
| | Sergio Guevara | Evidence Processing Specialist I- TX |
| | Tamar Craine | Forensic Chemistry Site Supervisor-PA |
| Samantha Wilson | Alyson Klees | Client Services Associate, Forensic |
| | Christina Hartley | SR Client Services Specialist, Forensic |
| | Esther Dede | Client Services Associate, Forensic |
| | Jessica Wikstrom | Client Services Associate, Forensic |
| | Kristin Schroeder | Client Services Specialist, Forensic-SE |
| | Renae Andreen | Client Services Associate, Forensic-NC |
| | Tanya Kirkpatrick-Jones | Client Services Specialist, Forensic-SE |
| | Tiffanie Sanchez | Client Services Associate, Forensic |
| | Tiffany Hertzberg | Client Services Specialist, Forensic |
| Sara Gagen | Alexis Eley | Analyst II |
| | Allison Durphy | Lab Assistant Team Leader |
| | Amanda Patel | Analyst IV |
| | Antoinette Bacon | Lab Assistant II |
| | Brandon Nelson | Remote Analyst III |
| | Dorothy Desanto | Lab Assistant III |
| | Emily Latshaw | Lab Intern |
| | Jared Rapoport | Analyst II |
| | Kevin Williams | Lab Assistant II |
| | Mary-Ann Xavier | Lab Assistant III |
| | Michael Peprah | Analyst III |
| | Nathan Holliday | Lab Support Specialist |
| | Rebecca Lowery | Analyst II |
| | Rosa De Jesus | Remote Analyst III |
| | Sharon Patterson | Lab Assistant III |
| Stacey DeJoseph | Adin Reilly | Analyst I |
| | Brendan Minick | Analyst I |
| | Caitlin Campbell | Analyst II |
| | Christopher Lloyd | Validation Analyst II |
| | Daniel Razzo | Analyst I |
| | Devon Hart | Analyst IV |
| | Emily Thompson | Analyst III |
| | Kyle Miller | Technical Team Leader-PA |
| | Ling Ni | Analyst I |
| | Tammy Welch | Analyst IV |
| Tamar Craine | Anna Price | Evidence Processing Specialist II-PA |
| | Ashton Marini | Forensic Chemist I |
| | Casey Kroliczak | Team Leader, Evidence Processing-PA |
| | Ekatarina Richter | Forensic Chemist I |
| | Hannah Ferner | Forensic Chemist I |
| | Jonathan Presuto | Forensic Chemist I |
| | Joseph Rubino | Forensic Chemist I |
| | Kyle Brown | Forensic Chemistry Supervisor-PA |
| Van Nguyen | Amal Sabirov | Software Engineer II |
| | Frederick Emmitt | Software Engineer I |
| William Sweeney | Dipesh Bhatt | Network Manager |
| | Edward Finn | Mgr, App Devt & Enterprise Architecture |

**NMS LABS ORGANIZATION CHART**
**MARCH 2025**

| Reports To | Employee Name | Job Title |
|---|---|---|
| Xiaoning Lu | Heng Shi | Principal R&D Scientist II |
| | Joseph Homan | Principal R&D Scientist II |
| | Loan Nguyen | Principal R&D Scientist II |
| | Mark Annand | Principal R&D Scientist I |
| | Megan Bergauff | Principal R&D Scientist II |
| | Thanh-Duyen Lam | Principal R&D Scientist I |
| | Xueyou Duan | Principal R&D Scientist I |
| Xueyou Duan | Ketie Chen | R&D Scientist II |

## PRINCIPAL OFFICERS

| Name | Title | Address | Phone Number |
|---|---|---|---|
| Delia, David | President and CEO | 60 Little Silver Point Road<br>Little Silver, NJ 07739 | (800) 522-6671 ext. 1377 |
| Riders, Maria | Chairwoman of the Board | 900 Hill Road<br>Rushland, PA 18956 | (800) 522-6671 |
| Rieders, Michael F. | Treasurer | 8100 Accomac Road<br>Wyncote, PA 19095 | (800) 522-6671 |
| Cassigneul, Pierre | Corporate Secretary | 268 Cherry Lane<br>Doylestown, PA 18901 | (800) 522-6671 |

STATE OF WASHINGTON

# BUSINESS LICENSE

Unified Business ID #: 604420457
Business ID #: 001
Location: 0001

Corporation

NATIONAL MEDICAL SERVICES, INC.
NMS LABS
200 WELSH RD
HORSHAM, PA 19044-2208

TAX REGISTRATION - ACTIVE

REGISTERED TRADE NAMES:
NMS LABS

This document lists the registrations, endorsements, and licenses authorized for the business named above. By accepting this document, the licensee certifies the information on the application was complete, true, and accurate to the best of his or her knowledge, and that business will be conducted in compliance with all applicable Washington state, county, and city regulations.

Vicki Smith
Director, Department of Revenue

STATE OF WASHINGTON

UBI: 604420457 001 0001

NATIONAL MEDICAL SERVICES, INC.
NMS LABS
200 WELSH RD
HORSHAM, PA 19044-2208

TAX REGISTRATION - ACTIVE

Vicki Smith

**BIDDER'S COMPANY NAME: NMS LABS**

WSP will conduct reference checks on top two or three scoring Bidders. Bidder shall furnish a minimum of three (3) references from different entities for which Bidder has performed or provided comparable service, similar in scope to this Solicitation. ***Do not use WSP as a reference***.

The WSP may contact one or more of the references provided. WSP will attempt to make contact with a Bidder's reference a maximum of two (2) times. If contact cannot be established then the reference may be deemed non-responsive and no further attempts will be made to contact that particular reference. If references give significant negative feedback, Bidder may be rejected and no longer considered for contract award.

The WSP reserves the right to solicit and substitute other references to determine the sufficiency of the Bidder's level of responsibility.

## Reference 1

| | |
|---|---|
| Company Name | Oregon State Police Forensic Laboratory |
| Company Address | 13309 SE 84th Ave Suite 200 Clackamas, OR 97015 |
| Contact Person's Name and Title | Robert Jones, Program Manager |
| Phone Number (Best # to reach them) | 971-673-8266 |
| Email address | robert.jones@osp.oregon.gov |
| Time period you provided services | April 2019 to Current |
| Brief description of the services provided to this reference:<br><br>NMS Labs has provided forensic toxicology services for over 6 years on an average of 800 cases annually. NMS Labs provides Postmortem testing for the laboratory's backlog, in addition to specialty testing for their in-house postmortem and DUID testing needs. | |

## Reference 2

| | |
|---|---|
| Company Name | Maricopa County Medical Examiner |
| Company Address | 701 W. Jefferson St. Phoenix, AZ |
| Contact Person's Name and Title | Jeffrey Johnston, Chief Medical Examiner |
| Phone Number (Best # to reach them) | 602-506-0524 |
| Email address | jeffrey.johnston@maricopa.gov |
| Time period you provided services | March 2019 to Current |
| Brief description of the services provided to this reference:<br><br>NMS Labs has provided forensic toxicology services and toxicology consulting through our DirecTox™ program for over 6 years on volumes of 4500 cases annually. Services delivered range from Comprehensive postmortem toxicological surveys to ante mortem testing and targeted specialized testing. Services include supplying collection kits, analytical testing, and report resulting. Secured storage of samples, forensic client support via phone and consultation as required. This client uses our DirecTox™ program which allows the client to have access to their toxicologist for questions and/or case review, sample collection guidance, test recommendations and interpretation of findings. Monthly reports provided as needed for turnaround time reports for NAME accreditation along with quarterly utilization reports | |

## Reference 3

| | |
|---|---|
| Company Name | Clark County Coroner/Medical Examiner |
| Company Address | 1704 Pinto Lane, Las Vegas, NV 89106 |
| Contact Person's Name and Title | Melanie Rouse, Coroner |
| Phone Number (Best # to reach them) | 702-455-3210 |
| Email address | Melanie.Rouse@ClarkCountyNV.gov |
| Time period you provided services | July 2010 to Current |

Brief description of the services provided to this reference:

NMS Labs has provided forensic toxicology services for over 14 years on volumes of approximately 3,000 cases annually. We provide support for all death investigations in Clark and surrounding counties in the state of Nevada. Death Investigations in Nevada are handled through Coroners Offices that are staffed with Forensic Pathologists. Services delivered range from Comprehensive postmortem toxicological surveys to ante mortem testing and targeted specialized testing. Services include supplying collection kits, analytical testing, report resulting via direct upload to VertiQ Coroner case management software, secured storage of samples, forensic client support via phone and consultation as required. Client is on a DirecTox program which allows the client to have access to their "person" toxicologist for questions and/or case review, sample collection guidance, test recommendations and interpretation of findings. Monthly reports provided as needed for turnaround time reports for NAME accreditation along with quarterly utilization reports.

## Company Name: NMS Labs

Bidders should use the following table for Appendix I: Exceptions to Model Contract.

| ID No. | Contract Section | Issue | Reasons for Proposed Change | Exact Proposed Alternative or Additional Language for the Contract (use track changes on text) |
|---|---|---|---|---|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |

# CERTIFICATE OF LIABILITY INSURANCE

DATE (MM/DD/YYYY) 08/19/2024

THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER.

IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must have ADDITIONAL INSURED provisions or be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such endorsement(s).

| | |
|---|---|
| PRODUCER<br>Willis Towers Watson Northeast, Inc.<br>c/o 26 Century Blvd<br>P.O. Box 305191<br>Nashville, TN 372305191 USA | CONTACT NAME: WTW Certificate Center<br>PHONE (A/C, No, Ext): 1-877-945-7378 FAX (A/C, No): 1-888-467-2378<br>E-MAIL ADDRESS: certificates@wtwco.com |
| INSURED<br>National Medical Services, Inc. dba NMS Labs<br>200 Welsh Road<br>Horsham, PA 19044 | INSURER(S) AFFORDING COVERAGE / NAIC #<br>INSURER A : Evanston Insurance Company 35378<br>INSURER B : Travelers Property Casualty Company of Ame 25674<br>INSURER C : Phoenix Insurance Company 25623<br>INSURER D :<br>INSURER E :<br>INSURER F : |

**COVERAGES** **CERTIFICATE NUMBER:** W34491788 **REVISION NUMBER:**

THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS.

| INSR LTR | TYPE OF INSURANCE | ADDL INSD | SUBR WVD | POLICY NUMBER | POLICY EFF (MM/DD/YYYY) | POLICY EXP (MM/DD/YYYY) | LIMITS | |
|---|---|---|---|---|---|---|---|---|
| A | X COMMERCIAL GENERAL LIABILITY<br>☐ CLAIMS-MADE ☒ OCCUR<br>X CONTRACTUAL LIABILITY<br>X INCLUDED<br>GEN'L AGGREGATE LIMIT APPLIES PER:<br>X POLICY ☐ PRO-JECT ☐ LOC<br>☐ OTHER: | | | MKLV1PHP000007 | 08/15/2024 | 08/15/2025 | EACH OCCURRENCE<br>DAMAGE TO RENTED PREMISES (Ea occurrence)<br>MED EXP (Any one person)<br>PERSONAL & ADV INJURY<br>GENERAL AGGREGATE<br>PRODUCTS - COMP/OP AGG<br>$ | $ 1,000,000<br>$ 50,000<br>$ 5,000<br>$ 1,000,000<br>$ 3,000,000<br>$ 3,000,000<br>$ |
| B | AUTOMOBILE LIABILITY<br>X ANY AUTO<br>☐ OWNED AUTOS ONLY ☐ SCHEDULED AUTOS<br>☐ HIRED AUTOS ONLY ☐ NON-OWNED AUTOS ONLY | | | BA-3N062901-24-I2-G | 08/15/2024 | 08/15/2025 | COMBINED SINGLE LIMIT (Ea accident)<br>BODILY INJURY (Per person)<br>BODILY INJURY (Per accident)<br>PROPERTY DAMAGE (Per accident)<br>$ | $ 1,000,000<br>$<br>$<br>$<br>$ |
| A | X UMBRELLA LIAB ☒ OCCUR<br>EXCESS LIAB ☐ CLAIMS-MADE<br>X DED ☐ RETENTION $ 0 | | | MKLV1UHC000034 | 08/15/2024 | 08/15/2025 | EACH OCCURRENCE<br>AGGREGATE<br>$ | $ 5,000,000<br>$ 5,000,000<br>$ |
| C | WORKERS COMPENSATION AND EMPLOYERS' LIABILITY<br>ANYPROPRIETOR/PARTNER/EXECUTIVE OFFICER/MEMBER EXCLUDED? Y / N: No<br>(Mandatory in NH)<br>If yes, describe under DESCRIPTION OF OPERATIONS below | N / A | | UB-8K529095-24-I2-G | 08/15/2024 | 08/15/2025 | X PER STATUTE ☐ OTH-ER<br>E.L. EACH ACCIDENT<br>E.L. DISEASE - EA EMPLOYEE<br>E.L. DISEASE - POLICY LIMIT | <br>$ 1,000,000<br>$ 1,000,000<br>$ 1,000,000 |
| A | ERRORS & OMISSIONS | | | MKLV1PHP000007 | 08/15/2024 | 08/15/2025 | Per Claim<br>Aggregate | $1,000,000<br>$3,000,000 |

DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (ACORD 101, Additional Remarks Schedule, may be attached if more space is required)

**CERTIFICATE HOLDER**

NMS Labs

**CANCELLATION**

SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS.

AUTHORIZED REPRESENTATIVE



NMS LABS

800.522.6671 nmslabs.com

# 2025 FEE SCHEDULE

VER. 241025.1

EFFECTIVE JANUARY 1, 2025

# NMS Labs

2025 List Fee Schedule

## Sample Matrix / Suffix Key

| Suffix | Sample Matrix |
|---|---|
| B | Blood |
| BO | Bone |
| D | Dialysis Fluid |
| F | Fat |
| FL | Fluid |
| GS | Gas |
| H | Hair |
| N | Nails |
| LI | Liquid |
| ME | Meconium |
| O | Other |
| OF | Oral Fluid |
| P | Plasma |
| PT | Paint |
| R | Red Blood Cells (RBC) |
| SL | Solid |
| SP | Serum/Plasma |
| ST | Stool |
| TH | Teeth |
| U | Urine |
| UC | Umbilical Cord Tissue |
| UH | 24 Hour Urine |

The tests listed in this Fee Schedule are the most commonly ordered by our clients. All test prices are in US dollars. Some tests offered by NMS Labs may not be listed in this Fee Schedule. If a test of interest does not appear in this fee schedule, please contact Client Support at (800) 522-6671 or clientsupport@nmslabs.com for information.

NOTE: The tests listed in this Fee Schedule were available at the time of publication. Tests may be added to our test menu or discontinued after the publication of the Fee Schedule. Please check for a current listing of tests available via NMS Labs on-line test catalog at www.nmslabs.com/test-catalog.

## Contact phone numbers and email addresses:

- Clinical & Research Clients: 1.866.522.2206 / clinical@nmslabs.com
- Forensic Clients: 1.866.522.2216 / forensics@nmslabs.com
- Expert Service Clients: 1.844.276.0768 / expertservices@nmslabs.com
- Billing Inquiries: 1.800.522.6671 / billingTIQ@nmslabs.com
- Crime Lab Clients: 1.844.276.1182 / crimelab@nmslabs.com

# NMS Labs

2025 List Fee Schedule

**Table of Contents**

| Test | Test Name | List Price |
|---|---|---|
| 2358U | 1-Hydroxypyrene, Urine | $ 399.00 |
| 3124SP | 1-Naphthol, Serum/Plasma | $ 277.00 |
| 0094U | 2,5-Hexanedione, Urine | $ 309.00 |
| 0010B | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Blood | $ 286.00 |
| 0010SP | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Serum/Plasma | $ 179.00 |
| 0010U | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Urine | $ 179.00 |
| 0015B | 2-methyl AP-237 & AP-238, Blood | $ 556.00 |
| 0015SP | 2-methyl AP-237 & AP-238, Serum/Plasma | $ 556.00 |
| 0015U | 2-methyl AP-237 & AP-238, Urine | $ 556.00 |
| 0014B | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Blood | $ 286.00 |
| 0014SP | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Serum/Plasma | $ 179.00 |
| 0014U | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Urine | $ 179.00 |
| 0276SP | 4-Aminopyridine Exposure, Serum/Plasma | $ 648.00 |
| 0276U | 4-Aminopyridine Exposure, Urine | $ 648.00 |
| 8665B | 6-Monoacetylmorphine - Free (Unconjugated), Blood | $ 385.00 |
| 8665FL | 6-Monoacetylmorphine - Free (Unconjugated), Fluid | $ 331.00 |
| 8665SP | 6-Monoacetylmorphine - Free (Unconjugated), Serum/Plasma | $ 385.00 |
| 8665U | 6-Monoacetylmorphine - Free (Unconjugated), Urine | $ 385.00 |
| 0325U | 8-Hydroxy Amoxapine, Urine | $ 302.00 |
| 0013SP | Acamprosate, Serum/Plasma | $ 262.00 |
| 0012B | Acebutolol, Blood | $ 488.00 |
| 0012SP | Acebutolol, Serum/Plasma | $ 427.00 |
| 9101B | Acepromazine Screen, Blood | $ 297.00 |
| 9101SP | Acepromazine Screen, Serum/Plasma | $ 519.00 |
| 9101U | Acepromazine Screen, Urine | $ 359.00 |
| 0017B | Acepromazine, Blood | $ 515.00 |
| 0017SP | Acepromazine, Serum/Plasma | $ 323.00 |
| 0017U | Acepromazine, Urine | $ 323.00 |
| 0021B | Acetaldehyde, Blood | $ 137.00 |
| 0021SP | Acetaldehyde, Serum/Plasma | $ 87.00 |
| 0021U | Acetaldehyde, Urine | $ 123.00 |
| 0032B | Acetaminophen Screen, Blood | $ 103.00 |
| 0032SP | Acetaminophen Screen, Serum/Plasma | $ 107.00 |
| 0032U | Acetaminophen Screen, Urine | $ 64.00 |
| 0030B | Acetaminophen, Blood | $ 66.00 |
| 0030FL | Acetaminophen, Fluid | $ 281.00 |
| 0030SP | Acetaminophen, Serum/Plasma | $ 66.00 |
| 1788SP | Acetaminophen, Serum/Plasma | $ 110.00 |
| 0030TI | Acetaminophen, Tissue | $ 353.00 |
| 0030U | Acetaminophen, Urine | $ 66.00 |
| 0050B | Acetazolamide, Blood | $ 96.00 |
| 0050SP | Acetazolamide, Serum/Plasma | $ 142.00 |
| 0050U | Acetazolamide, Urine | $ 152.00 |
| 0060SP | Acetoacetate, Serum/Plasma | $ 208.00 |
| 0060U | Acetoacetate, Urine | $ 330.00 |
| 0080B | Acetone, Blood | $ 62.00 |
| 0080FL | Acetone, Fluid | $ 99.00 |
| 0080SP | Acetone, Serum/Plasma | $ 62.00 |
| 0080U | Acetone, Urine | $ 62.00 |
| 0088B | Acetonitrile Exposure Profile, Blood | $ 505.00 |
| 0088U | Acetonitrile Exposure Profile, Urine | $ 468.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0100SP | Acetophenazine, Serum/Plasma | $ 500.00 |
| 0205U | Acetyl Fentanyl and Metabolite, Urine | $ 192.00 |
| 9105B | Acetyl Fentanyl Screen, Blood | $ 192.00 |
| 9105SP | Acetyl Fentanyl Screen, Serum/Plasma | $ 192.00 |
| 9105U | Acetyl Fentanyl Screen, Urine | $ 192.00 |
| 0205B | Acetyl Fentanyl, Blood | $ 192.00 |
| 0205FL | Acetyl Fentanyl, Fluid | $ 386.00 |
| 0205SP | Acetyl Fentanyl, Serum/Plasma | $ 192.00 |
| 0205TI | Acetyl Fentanyl, Tissue | $ 386.00 |
| 0148B | Acrylonitrile Exposure Profile, Blood | $ 326.00 |
| 0148U | Acrylonitrile Exposure Profile, Urine | $ 411.00 |
| 0166B | Acyclovir, Blood | $ 334.00 |
| 0158SP | Acyclovir, Serum/Plasma | $ 197.00 |
| 0158U | Acyclovir, Urine | $ 197.00 |
| 0165B | Albuterol, Blood | $ 331.00 |
| 0165FL | Albuterol, Fluid | $ 401.00 |
| 0165SP | Albuterol, Serum/Plasma | $ 499.00 |
| 0165TI | Albuterol, Tissue | $ 436.00 |
| 0175B | Alcohol (DUID/DRE), Blood (Forensic) | $ 139.00 |
| 0175SP | Alcohol (DUID/DRE), Serum/Plasma (Forensic) | $ 228.00 |
| 0175U | Alcohol (DUID/DRE), Urine (Forensic) | $ 228.00 |
| 0170B | Alcohol Panel, Blood | $ 95.00 |
| 0170FL | Alcohol Panel, Fluid | $ 134.00 |
| 0170SP | Alcohol Panel, Serum/Plasma | $ 95.00 |
| 0170TI | Alcohol Panel, Tissue | $ 197.00 |
| 0170U | Alcohol Panel, Urine | $ 77.00 |
| 0171B | Alcohol Screen, Blood | $ 47.00 |
| 0171FL | Alcohol Screen, Fluid | $ 85.00 |
| 0171SP | Alcohol Screen, Serum/Plasma | $ 79.00 |
| 0171TI | Alcohol Screen, Tissue | $ 123.00 |
| 0171U | Alcohol Screen, Urine | $ 47.00 |
| 0230B | Alcohol with reflex to DUID Screen, Blood (Forensic) | $ 126.00 |
| 0190B | Aldrin/Dieldrin, Blood | $ 208.00 |
| 0190SP | Aldrin/Dieldrin, Serum/Plasma | $ 208.00 |
| 9103U | Alfentanil Screen, Urine | $ 330.00 |
| 0200B | Alfentanil, Blood | $ 252.00 |
| 0200SP | Alfentanil, Serum/Plasma | $ 412.00 |
| 0213SP | Allopurinol and Metabolite, Serum/Plasma | $ 167.00 |
| 3780B | Alpha-Pinene, Blood | $ 311.00 |
| 8646B | Alprazolam and Metabolite, Blood | $ 386.00 |
| 8646FL | Alprazolam and Metabolite, Fluid | $ 331.00 |
| 8646SP | Alprazolam and Metabolite, Serum/Plasma | $ 371.00 |
| 8646U | Alprazolam and Metabolite, Urine | $ 371.00 |
| 0260B | Alprazolam, Blood | $ 114.00 |
| 0260FL | Alprazolam, Fluid | $ 326.00 |
| 0260SP | Alprazolam, Serum/Plasma | $ 114.00 |
| 0260TI | Alprazolam, Tissue | $ 396.00 |
| 0264UH | Aluminum, 24 Hour Urine | $ 96.00 |
| 0264B | Aluminum, Blood | $ 167.00 |
| 0264FL | Aluminum, Fluid | $ 516.00 |
| 0264H | Aluminum, Hair | $ 541.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0264LI | Aluminum, Liquid | $ 482.00 |
| 0264R | Aluminum, RBCs | $ 93.00 |
| 0264SP | Aluminum, Serum/Plasma | $ 93.00 |
| 0264TI | Aluminum, Tissue | $ 499.00 |
| 0264U | Aluminum, Urine | $ 175.00 |
| 9308SP | Amantadine Screen, Serum/Plasma | $ 176.00 |
| 0265B | Amantadine, Blood | $ 159.00 |
| 0265FL | Amantadine, Fluid | $ 369.00 |
| 0265SP | Amantadine, Serum/Plasma | $ 104.00 |
| 0265U | Amantadine, Urine | $ 159.00 |
| 0269SP | Aminocaproic Acid, Serum/Plasma | $ 452.00 |
| 0307B | Amiodarone and Metabolite, Blood | $ 494.00 |
| 0307SP | Amiodarone and Metabolite, Serum/Plasma | $ 494.00 |
| 0308SP | Amisulpride, Serum/Plasma | $ 265.00 |
| 9432B | Amitriptyline and Metabolite Screen, Blood | $ 220.00 |
| 9432SP | Amitriptyline and Metabolite Screen, Serum/Plasma | $ 192.00 |
| 9432U | Amitriptyline and Metabolite Screen, Urine | $ 212.00 |
| 0310B | Amitriptyline and Metabolite, Blood | $ 132.00 |
| 0310FL | Amitriptyline and Metabolite, Fluid | $ 420.00 |
| 0310SP | Amitriptyline and Metabolite, Serum/Plasma | $ 209.00 |
| 0310TI | Amitriptyline and Metabolite, Tissue | $ 438.00 |
| 0310U | Amitriptyline and Metabolite, Urine | $ 209.00 |
| 0315B | Amlodipine, Blood | $ 371.00 |
| 0315SP | Amlodipine, Serum/Plasma | $ 371.00 |
| 0315TI | Amlodipine, Tissue | $ 396.00 |
| 0320SP | Amobarbital, Serum/Plasma | $ 209.00 |
| 0320U | Amobarbital, Urine | $ 132.00 |
| 0325B | Amoxapine and Metabolite, Blood | $ 302.00 |
| 0325SP | Amoxapine and Metabolite, Serum/Plasma | $ 456.00 |
| 0329B | Amphetamines (D/L Differentiation), Blood | $ 358.00 |
| 0329FL | Amphetamines (D/L Differentiation), Fluid | $ 560.00 |
| 0329SP | Amphetamines (D/L Differentiation), Serum/Plasma | $ 358.00 |
| 0329U | Amphetamines (D/L Differentiation), Urine | $ 358.00 |
| 8600ME | Amphetamines Panel (Qualitative), Meconium | $ 312.00 |
| 8890OF | Amphetamines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8600B | Amphetamines Panel, Blood | $ 256.00 |
| 8600FL | Amphetamines Panel, Fluid | $ 625.00 |
| 8600SP | Amphetamines Panel, Serum/Plasma | $ 256.00 |
| 8600TI | Amphetamines Panel, Tissue | $ 545.00 |
| 8600U | Amphetamines Panel, Urine | $ 256.00 |
| 0337B | Amphetamines Screen, Blood | $ 137.00 |
| 0337FL | Amphetamines Screen, Fluid | $ 347.00 |
| 6924H | Amphetamines Screen, Hair | $ 493.00 |
| 0337SP | Amphetamines Screen, Serum/Plasma | $ 149.00 |
| 0337U | Amphetamines Screen, Urine | $ 149.00 |
| 9306U | Anabolic Steroids Screen, Urine | $ 159.00 |
| 0406B | Anticoagulant Poisoning Panel (Qualitative), Blood | $ 1,377.00 |
| 0406SP | Anticoagulant Poisoning Panel (Qualitative), Serum/Plasma | $ 890.00 |
| 0406TI | Anticoagulant Poisoning Panel (Qualitative), Tissue | $ 1,162.00 |
| 4655B | Antidepressants Panel 1, Blood | $ 402.00 |
| 4655FL | Antidepressants Panel 1, Fluid | $ 476.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4655SP | Antidepressants Panel 1, Serum/Plasma | $ 402.00 |
| 4655TI | Antidepressants Panel 1, Tissue | $ 476.00 |
| 8700B | Antidepressants Panel, Blood | $ 483.00 |
| 8700SP | Antidepressants Panel, Serum/Plasma | $ 334.00 |
| 8700U | Antidepressants Panel, Urine | $ 334.00 |
| 9431B | Antidepressants Screen, Blood | $ 305.00 |
| 9431SP | Antidepressants Screen, Serum/Plasma | $ 264.00 |
| 9431U | Antidepressants Screen, Urine | $ 184.00 |
| 0410B | Antimony, Blood | $ 93.00 |
| 0410H | Antimony, Hair | $ 541.00 |
| 0410LI | Antimony, Liquid | $ 324.00 |
| 0410N | Antimony, Nails | $ 541.00 |
| 0410R | Antimony, RBCs | $ 93.00 |
| 0410SP | Antimony, Serum/Plasma | $ 93.00 |
| 0410U | Antimony, Urine | $ 93.00 |
| 0425B | Antipyrine, Blood | $ 519.00 |
| 0425SP | Antipyrine, Serum/Plasma | $ 337.00 |
| 0448SP | Apixaban, Serum/Plasma | $ 266.00 |
| 0451B | Aripiprazole, Blood | $ 215.00 |
| 0451SP | Aripiprazole, Serum/Plasma | $ 215.00 |
| 0785B | Aromatic Solvents Exposure Panel, Blood | $ 107.00 |
| 2416U | Aromatic Solvents Metabolites Panel, Urine | $ 249.00 |
| 0460UH | Arsenic, 24 Hour Urine | $ 115.00 |
| 0460B | Arsenic, Blood | $ 115.00 |
| 0460FL | Arsenic, Fluid | $ 327.00 |
| 0460H | Arsenic, Hair | $ 710.00 |
| 0460N | Arsenic, Nails | $ 487.00 |
| 0460R | Arsenic, RBCs | $ 115.00 |
| 0460SP | Arsenic, Serum/Plasma | $ 115.00 |
| 0460TI | Arsenic, Tissue | $ 398.00 |
| 0468UH | Arsenic, Total Inorganic, 24 Hour Urine | $ 168.00 |
| 0468U | Arsenic, Total Inorganic, Urine | $ 168.00 |
| 0460U | Arsenic, Urine | $ 115.00 |
| 0474SP | Asenapine, Serum/Plasma | $ 281.00 |
| 0483B | Atenolol, Blood | $ 220.00 |
| 0483SP | Atenolol, Serum/Plasma | $ 354.00 |
| 0483TI | Atenolol, Tissue | $ 502.00 |
| 0483U | Atenolol, Urine | $ 354.00 |
| 0486B | Atomoxetine, Blood | $ 545.00 |
| 0486SP | Atomoxetine, Serum/Plasma | $ 270.00 |
| 0486U | Atomoxetine, Urine | $ 270.00 |
| 0487SP | Atovaquone, Serum/Plasma | $ 506.00 |
| 0485B | Atrazine, Blood | $ 505.00 |
| 0485SP | Atrazine, Serum/Plasma | $ 398.00 |
| 0485U | Atrazine, Urine | $ 398.00 |
| 9109B | Atropine Screen, Blood | $ 791.00 |
| 9109SP | Atropine Screen, Serum/Plasma | $ 650.00 |
| 9109U | Atropine Screen, Urine | $ 761.00 |
| 0490B | Atropine, Blood | $ 749.00 |
| 0490SP | Atropine, Serum/Plasma | $ 749.00 |
| 0490U | Atropine, Urine | $ 749.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2111B | Baclofen, Blood | $ 371.00 |
| 2111FL | Baclofen, Fluid | $ 499.00 |
| 2111SP | Baclofen, Serum/Plasma | $ 233.00 |
| 2111TI | Baclofen, Tissue | $ 615.00 |
| 2111U | Baclofen, Urine | $ 371.00 |
| 0500B | Barbital, Blood | $ 542.00 |
| 0500SP | Barbital, Serum/Plasma | $ 440.00 |
| 0500U | Barbital, Urine | $ 542.00 |
| 8620ME | Barbiturates Panel (Qualitative), Meconium | $ 465.00 |
| 8620B | Barbiturates Panel, Blood | $ 233.00 |
| 8620FL | Barbiturates Panel, Fluid | $ 421.00 |
| 8620SP | Barbiturates Panel, Serum/Plasma | $ 371.00 |
| 8620TI | Barbiturates Panel, Tissue | $ 484.00 |
| 8620U | Barbiturates Panel, Urine | $ 233.00 |
| 0512B | Barbiturates Screen, Blood | $ 137.00 |
| 6921H | Barbiturates Screen, Hair | $ 501.00 |
| 0512SP | Barbiturates Screen, Serum/Plasma | $ 95.00 |
| 0512U | Barbiturates Screen, Urine | $ 149.00 |
| 0519B | Barium, Blood | $ 208.00 |
| 0519FL | Barium, Fluid | $ 213.00 |
| 0519H | Barium, Hair | $ 597.00 |
| 0519SP | Barium, Serum/Plasma | $ 138.00 |
| 0519TI | Barium, Tissue | $ 547.00 |
| 0519U | Barium, Urine | $ 138.00 |
| 9351UC | Basic Drug Screen, Umbilical Cord Tissue | $ 439.00 |
| 2626B | Bath Salts Panel (Qualitative), Blood | $ 271.00 |
| 2626SP | Bath Salts Panel (Qualitative), Serum/Plasma | $ 172.00 |
| 2626U | Bath Salts Panel (Qualitative), Urine | $ 172.00 |
| 0520B | Belladonna Alkaloids Panel, Blood | $ 427.00 |
| 0520SP | Belladonna Alkaloids Panel, Serum/Plasma | $ 452.00 |
| 0520U | Belladonna Alkaloids Panel, Urine | $ 452.00 |
| 0542U | Benzene Incident, Urine (OSHA) | $ 217.00 |
| 0543U | Benzene OSHA Exposure Panel, Urine | $ 121.00 |
| 0541B | Benzene, Blood | $ 105.00 |
| 0541TI | Benzene, Tissue | $ 383.00 |
| 0556U | Benzidine, Urine | $ 516.00 |
| 0560B | Benzocaine, Blood | $ 466.00 |
| 0560FL | Benzocaine, Fluid | $ 526.00 |
| 0560P | Benzocaine, Plasma | $ 268.00 |
| 0560U | Benzocaine, Urine | $ 170.00 |
| 9329ME | Benzodiazepines Panel (Qualitative), Meconium | $ 308.00 |
| 8891OF | Benzodiazepines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 9329B | Benzodiazepines Panel, Blood | $ 249.00 |
| 9329FL | Benzodiazepines Panel, Fluid | $ 285.00 |
| 9329SP | Benzodiazepines Panel, Serum/Plasma | $ 249.00 |
| 9329TI | Benzodiazepines Panel, Tissue | $ 321.00 |
| 9329U | Benzodiazepines Panel, Urine | $ 249.00 |
| 0568B | Benzodiazepines Screen, Blood | $ 189.00 |
| 0568FL | Benzodiazepines Screen, Fluid | $ 353.00 |
| 6922H | Benzodiazepines Screen, Hair | $ 502.00 |
| 0568SP | Benzodiazepines Screen, Serum/Plasma | $ 116.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0568U | Benzodiazepines Screen, Urine | $ 61.00 |
| 0585B | Benzonatate, Blood | $ 655.00 |
| 0585SP | Benzonatate, Serum/Plasma | $ 868.00 |
| 0585U | Benzonatate, Urine | $ 655.00 |
| 0610B | Benzphetamine as Metabolites, Blood | $ 236.00 |
| 0610SP | Benzphetamine as Metabolites, Serum/Plasma | $ 214.00 |
| 0610U | Benzphetamine as Metabolites, Urine | $ 149.00 |
| 0620B | Benztropine, Blood | $ 166.00 |
| 0620FL | Benztropine, Fluid | $ 215.00 |
| 0620SP | Benztropine, Serum/Plasma | $ 114.00 |
| 0620TI | Benztropine, Tissue | $ 407.00 |
| 0620U | Benztropine, Urine | $ 114.00 |
| 0638B | Beryllium, Blood | $ 96.00 |
| 0638LI | Beryllium, Liquid | $ 394.00 |
| 0638SP | Beryllium, Serum/Plasma | $ 96.00 |
| 0638U | Beryllium, Urine | $ 149.00 |
| 3227B | Beta-Blockers Panel, Blood | $ 366.00 |
| 3227SP | Beta-Blockers Panel, Serum/Plasma | $ 354.00 |
| 3227U | Beta-Blockers Panel, Urine | $ 354.00 |
| 0420B | Betahydroxybutyric Acid, Blood | $ 227.00 |
| 0420FL | Betahydroxybutyric Acid, Fluid | $ 297.00 |
| 0642SP | Betahydroxybutyric Acid, Serum/Plasma | $ 111.00 |
| 0642U | Betahydroxybutyric Acid, Urine | $ 111.00 |
| 0645FL | Bicarbonate, Fluid | $ 309.00 |
| 0645U | Bicarbonate, Urine | $ 96.00 |
| 7031B | Bio-Rad Geenius HIV 1/2 Supplemental Assay (Confirmation Test) - Send out | $ 409.00 |
| 0680B | Bismuth, Blood | $ 242.00 |
| 0680SP | Bismuth, Serum/Plasma | $ 93.00 |
| 0680U | Bismuth, Urine | $ 149.00 |
| 0690SP | Bisphenol A - Free (Unconjugated), Serum/Plasma | $ 296.00 |
| 0690U | Bisphenol A - Total (Conjugated/Unconjugated), Urine | $ 304.00 |
| 0711B | Boron, Blood | $ 74.00 |
| 0711SP | Boron, Serum/Plasma | $ 74.00 |
| 0711U | Boron, Urine | $ 74.00 |
| 0716SP | Brexpiprazole, Serum/Plasma | $ 227.00 |
| 0718B | Brivaracetam, Blood | $ 136.00 |
| 0718SP | Brivaracetam, Serum/Plasma | $ 136.00 |
| 0413B | Brodifacoum (Qualitative), Blood | $ 267.00 |
| 0413SP | Brodifacoum (Qualitative), Serum/Plasma | $ 267.00 |
| 0414SP | Bromadiolone (Qualitative), Serum/Plasma | $ 296.00 |
| 0719U | Bromazolam (Qualitative), Urine | $ 338.00 |
| 0719B | Bromazolam, Blood | $ 338.00 |
| 0719SP | Bromazolam, Serum/Plasma | $ 338.00 |
| 0720B | Bromine - Total, Blood | $ 431.00 |
| 0720SP | Bromine - Total, Serum/Plasma | $ 105.00 |
| 0720U | Bromine - Total, Urine | $ 173.00 |
| 9118B | Brompheniramine Screen, Blood | $ 153.00 |
| 0770B | Brompheniramine, Blood | $ 268.00 |
| 0770SP | Brompheniramine, Serum/Plasma | $ 268.00 |
| 0770TI | Brompheniramine, Tissue | $ 326.00 |
| 0770U | Brompheniramine, Urine | $ 244.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0771B | Brorphine, Blood | $ 477.00 |
| 0771SP | Brorphine, Serum/Plasma | $ 477.00 |
| 0771U | Brorphine, Urine | $ 477.00 |
| 0796B | Bumetanide, Blood | $ 706.00 |
| 0796SP | Bumetanide, Serum/Plasma | $ 861.00 |
| 0800B | Bupivacaine, Blood | $ 128.00 |
| 0800FL | Bupivacaine, Fluid | $ 336.00 |
| 0800SP | Bupivacaine, Serum/Plasma | $ 128.00 |
| 0800U | Bupivacaine, Urine | $ 212.00 |
| 0802B | Buprenorphine and Metabolite - Free (Unconjugated) Screen, Blood | $ 354.00 |
| 0802SP | Buprenorphine and Metabolite - Free (Unconjugated) Screen, Serum/Plasma | $ 354.00 |
| 0801B | Buprenorphine and Metabolite - Free (Unconjugated), Blood | $ 209.00 |
| 0801SP | Buprenorphine and Metabolite - Free (Unconjugated), Serum/Plasma | $ 209.00 |
| 0801ME | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 472.00 |
| 0801U | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 209.00 |
| 4127ME | Buprenorphine and Metabolite - Total (Qualitative), Meconium | $ 472.00 |
| 0802U | Buprenorphine Screen, Urine | $ 354.00 |
| 9122B | Bupropion and Metabolite Screen, Blood | $ 267.00 |
| 9122SP | Bupropion and Metabolite Screen, Serum/Plasma | $ 259.00 |
| 9122TI | Bupropion and Metabolite Screen, Tissue | $ 510.00 |
| 9122U | Bupropion and Metabolite Screen, Urine | $ 259.00 |
| 0803B | Bupropion and Metabolite, Blood | $ 160.00 |
| 0803FL | Bupropion and Metabolite, Fluid | $ 370.00 |
| 0803SP | Bupropion and Metabolite, Serum/Plasma | $ 160.00 |
| 0803TI | Bupropion and Metabolite, Tissue | $ 440.00 |
| 0803U | Bupropion and Metabolite, Urine | $ 259.00 |
| 0805B | Buspirone, Blood | $ 138.00 |
| 0805SP | Buspirone, Serum/Plasma | $ 138.00 |
| 0805U | Buspirone, Urine | $ 218.00 |
| 0820SP | Busulfan, Serum/Plasma | $ 257.00 |
| 0810B | Butabarbital, Blood | $ 311.00 |
| 0810SP | Butabarbital, Serum/Plasma | $ 209.00 |
| 0810U | Butabarbital, Urine | $ 190.00 |
| 0830B | Butalbital, Blood | $ 209.00 |
| 0830SP | Butalbital, Serum/Plasma | $ 213.00 |
| 0830U | Butalbital, Urine | $ 190.00 |
| 0835B | Butane and Isobutane, Blood | $ 426.00 |
| 0850B | Butanols, n-, iso-, Sec- and Tert, Blood | $ 194.00 |
| 0850SP | Butanols, n-, iso-, Sec- and Tert, Serum/Plasma | $ 194.00 |
| 0850U | Butanols, n-, iso-, Sec- and Tert, Urine | $ 194.00 |
| 0885B | Butorphanol - Free (Unconjugated), Blood | $ 527.00 |
| 0885SP | Butorphanol - Free (Unconjugated), Serum/Plasma | $ 330.00 |
| 0885U | Butorphanol - Total (Conjugated/Unconjugated), Urine | $ 330.00 |
| 0921UH | Cadmium, 24 Hour Urine | $ 92.00 |
| 0921B | Cadmium, Blood | $ 63.00 |
| 0921H | Cadmium, Hair | $ 436.00 |
| 0921N | Cadmium, Nails | $ 436.00 |
| 0921R | Cadmium, RBCs | $ 63.00 |
| 0921SP | Cadmium, Serum/Plasma | $ 63.00 |
| 0921TI | Cadmium, Tissue | $ 345.00 |
| 0921U | Cadmium, Urine | $ 67.00 |

| Test | Test Name | List Price |
|---|---|---|
| 0930B | Caffeine, Blood | $ 159.00 |
| 0930FL | Caffeine, Fluid | $ 369.00 |
| 0930SP | Caffeine, Serum/Plasma | $ 159.00 |
| 0930U | Caffeine, Urine | $ 159.00 |
| 0939B | Calcium - Total, Postmortem, Blood (Forensic) | $ 130.00 |
| 0938FL | Calcium - Total, Postmortem, Fluid (Forensic) | $ 303.00 |
| 0938R | Calcium - Total, RBCs | $ 97.00 |
| 0938U | Calcium - Total, Urine | $ 159.00 |
| 0962B | Cannabidiol, Blood | $ 390.00 |
| 0962SP | Cannabidiol, Serum/Plasma | $ 390.00 |
| 0964U | Cannabinoid Metabolite, Urine | $ 176.00 |
| 92250 | Cannabinoids and Contaminants Profile - Send Out | $ 655.00 |
| 0960ME | Cannabinoids Panel (Qualitative), Meconium | $ 354.00 |
| 0960B | Cannabinoids Panel, Blood | $ 257.00 |
| 0960FL | Cannabinoids Panel, Fluid | $ 327.00 |
| 0960SP | Cannabinoids Panel, Serum/Plasma | $ 257.00 |
| 0960TI | Cannabinoids Panel, Tissue | $ 393.00 |
| 9356B | Cannabinoids Screen, Blood | $ 110.00 |
| 9356FL | Cannabinoids Screen, Fluid | $ 321.00 |
| 9356SP | Cannabinoids Screen, Serum/Plasma | $ 110.00 |
| 9356U | Cannabinoids Screen, Urine | $ 61.00 |
| 0966B | Cannabis Plus Recent Use Markers, Blood | $ 371.00 |
| 0966SP | Cannabis Plus Recent Use Markers, Serum/Plasma | $ 371.00 |
| 4207B | Canrenone (Spironolactone metabolite), Blood | $ 330.00 |
| 4207SP | Canrenone (Spironolactone metabolite), Serum/Plasma | $ 208.00 |
| 0971SP | Carbamazepine and Metabolite - Free, Serum/Plasma | $ 114.00 |
| 0972SP | Carbamazepine and Metabolite - Total/Free/Bound, Serum/Plasma | $ 208.00 |
| 0970B | Carbamazepine and Metabolite, Blood | $ 105.00 |
| 0970FL | Carbamazepine and Metabolite, Fluid | $ 319.00 |
| 0970SP | Carbamazepine and Metabolite, Serum/Plasma | $ 178.00 |
| 0970TI | Carbamazepine and Metabolite, Tissue | $ 390.00 |
| 0975SP | Carbamazepine-10,11-Epoxide, Serum/Plasma | $ 130.00 |
| 0975U | Carbamazepine-10,11-Epoxide, Urine | $ 81.00 |
| 0980SP | Carbaryl and Metabolite, Serum/Plasma | $ 350.00 |
| 0985B | Carbinoxamine, Blood | $ 179.00 |
| 0995U | Carbon Disulfide Exposure (TTCA), Urine | $ 509.00 |
| 1005B | Carbon Monoxide Exposure Screen, Blood | $ 224.00 |
| 1009B | Carbon Monoxide Exposure, Blood | $ 170.00 |
| 1006B | Carbon Monoxide Profile for Non-standard Samples, Blood | $ 503.00 |
| 1006TI | Carbon Monoxide Profile for Non-standard Samples, Tissue | $ 691.00 |
| 1002B | Carbon Monoxide Screen, Confirmation Separate Fee, Blood | $ 140.00 |
| 1010B | Carbon Tetrachloride, Blood | $ 262.00 |
| 1000B | Carboxy-, Met- and Sulf-Hemoglobin, Blood | $ 124.00 |
| 1019B | Carbrital Profile, Blood | $ 290.00 |
| 1019SP | Carbrital Profile, Serum/Plasma | $ 463.00 |
| 9129B | Carisoprodol and Metabolite Screen, Blood | $ 257.00 |
| 9129FL | Carisoprodol and Metabolite Screen, Fluid | $ 427.00 |
| 9129SP | Carisoprodol and Metabolite Screen, Serum/Plasma | $ 257.00 |
| 1030B | Carisoprodol and Metabolite, Blood | $ 160.00 |
| 1030FL | Carisoprodol and Metabolite, Fluid | $ 603.00 |
| 1030SP | Carisoprodol and Metabolite, Serum/Plasma | $ 259.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1030U | Carisoprodol and Metabolite, Urine | $ 160.00 |
| 1033ST | Cathartic Laxatives Profile, Stool | $ 330.00 |
| 1029SP | CBD, Serum/Plasma | $ 390.00 |
| 1055B | Celecoxib, Blood | $ 445.00 |
| 1055SP | Celecoxib, Serum/Plasma | $ 431.00 |
| 1056B | Cenobamate, Blood | $ 179.00 |
| 1056SP | Cenobamate, Serum/Plasma | $ 261.00 |
| 1042B | Cesium, Blood | $ 175.00 |
| 1042SP | Cesium, Serum/Plasma | $ 175.00 |
| 1042U | Cesium, Urine | $ 284.00 |
| 1040B | Cetirizine, Blood | $ 539.00 |
| 1040SP | Cetirizine, Serum/Plasma | $ 518.00 |
| 1040U | Cetirizine, Urine | $ 518.00 |
| 8031U | Child Drug Exposure Screen, Urine | $ 520.00 |
| 1044B | Chloral Hydrate, Blood | $ 179.00 |
| 1044SP | Chloral Hydrate, Serum/Plasma | $ 174.00 |
| 1050SP | Chloramphenicol, Serum/Plasma | $ 133.00 |
| 1070B | Chlordane and Metabolites, Blood | $ 184.00 |
| 1070SP | Chlordane and Metabolites, Serum/Plasma | $ 184.00 |
| 1080B | Chlordiazepoxide and Metabolite, Blood | $ 268.00 |
| 1080SP | Chlordiazepoxide and Metabolite, Serum/Plasma | $ 283.00 |
| 1080U | Chlordiazepoxide and Metabolite, Urine | $ 310.00 |
| 1111U | Chlorobenzene Exposure (p-Chlorophenol), Urine | $ 281.00 |
| 1110B | Chlorobenzene, Blood | $ 281.00 |
| 1110SP | Chlorobenzene, Serum/Plasma | $ 176.00 |
| 1130B | Chloroform, Blood | $ 201.00 |
| 0415SP | Chlorophacinone (Qualitative), Serum/Plasma | $ 296.00 |
| 1140B | Chloroquine, Blood | $ 470.00 |
| 1140P | Chloroquine, Plasma | $ 285.00 |
| 1140U | Chloroquine, Urine | $ 285.00 |
| 1180B | Chlorothiazide, Blood | $ 235.00 |
| 1180SP | Chlorothiazide, Serum/Plasma | $ 228.00 |
| 1190B | Chlorpheniramine, Blood | $ 209.00 |
| 1190SP | Chlorpheniramine, Serum/Plasma | $ 199.00 |
| 1190U | Chlorpheniramine, Urine | $ 209.00 |
| 9136B | Chlorpromazine Screen, Blood | $ 217.00 |
| 9136SP | Chlorpromazine Screen, Serum/Plasma | $ 131.00 |
| 9136U | Chlorpromazine Screen, Urine | $ 188.00 |
| 1210B | Chlorpromazine, Blood | $ 128.00 |
| 8681B | Chlorpromazine, Blood | $ 564.00 |
| 1210FL | Chlorpromazine, Fluid | $ 460.00 |
| 1210SP | Chlorpromazine, Serum/Plasma | $ 128.00 |
| 1210TI | Chlorpromazine, Tissue | $ 407.00 |
| 1210U | Chlorpromazine, Urine | $ 212.00 |
| 1220SP | Chlorpropamide, Serum/Plasma | $ 137.00 |
| 1250B | Chlorthalidone, Blood | $ 144.00 |
| 1250SP | Chlorthalidone, Serum/Plasma | $ 228.00 |
| 1255B | Chlorzoxazone, Blood | $ 695.00 |
| 1255SP | Chlorzoxazone, Serum/Plasma | $ 672.00 |
| 1265B | Chromium and Cobalt, Blood | $ 204.00 |
| 1265SP | Chromium and Cobalt, Serum/Plasma | $ 197.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1265U | Chromium and Cobalt, Urine | $ 197.00 |
| 1261B | Chromium, Blood | $ 138.00 |
| 1261FL | Chromium, Fluid | $ 343.00 |
| 1261H | Chromium, Hair | $ 431.00 |
| 1261N | Chromium, Nails | $ 431.00 |
| 1261R | Chromium, RBCs | $ 138.00 |
| 1261SP | Chromium, Serum/Plasma | $ 138.00 |
| 1261TI | Chromium, Tissue | $ 411.00 |
| 1261U | Chromium, Urine | $ 138.00 |
| 1262B | Cimetidine, Blood | $ 223.00 |
| 1262SP | Cimetidine, Serum/Plasma | $ 215.00 |
| 1262U | Cimetidine, Urine | $ 223.00 |
| 1272B | Citalopram, Blood | $ 201.00 |
| 1272FL | Citalopram, Fluid | $ 411.00 |
| 1272SP | Citalopram, Serum/Plasma | $ 201.00 |
| 1272TI | Citalopram, Tissue | $ 480.00 |
| 1272U | Citalopram, Urine | $ 320.00 |
| 7813B | Citrate Agar Confirmation - Send Out | $ 191.00 |
| 1269SP | Clobazam and Metabolite, Serum/Plasma | $ 172.00 |
| 1267B | Clobazam, Blood | $ 287.00 |
| 1267U | Clobazam, Urine | $ 287.00 |
| 9437B | Clomipramine and Metabolite Screen, Blood | $ 217.00 |
| 9437SP | Clomipramine and Metabolite Screen, Serum/Plasma | $ 217.00 |
| 9437U | Clomipramine and Metabolite Screen, Urine | $ 131.00 |
| 1268B | Clomipramine and Metabolite, Blood | $ 149.00 |
| 8707B | Clomipramine and Metabolite, Blood | $ 564.00 |
| 1268SP | Clomipramine and Metabolite, Serum/Plasma | $ 154.00 |
| 8707SP | Clomipramine and Metabolite, Serum/Plasma | $ 341.00 |
| 1268TI | Clomipramine and Metabolite, Tissue | $ 431.00 |
| 1268U | Clomipramine and Metabolite, Urine | $ 152.00 |
| 9139B | Clonazepam and Metabolite Screen, Blood | $ 301.00 |
| 9139FL | Clonazepam and Metabolite Screen, Fluid | $ 267.00 |
| 9139SP | Clonazepam and Metabolite Screen, Serum/Plasma | $ 302.00 |
| 1270B | Clonazepam and Metabolite, Blood | $ 97.00 |
| 1270FL | Clonazepam and Metabolite, Fluid | $ 134.00 |
| 1270SP | Clonazepam and Metabolite, Serum/Plasma | $ 97.00 |
| 1270TI | Clonazepam and Metabolite, Tissue | $ 170.00 |
| 9139U | Clonazepam as Metabolite Screen, Urine | $ 191.00 |
| 1270U | Clonazepam as Metabolite, Urine | $ 97.00 |
| 1271U | Clonazolam & 8-Aminoclonazolam (Qualitative), Urine | $ 338.00 |
| 1271B | Clonazolam & 8-Aminoclonazolam, Blood | $ 338.00 |
| 1271SP | Clonazolam & 8-Aminoclonazolam, Serum/Plasma | $ 338.00 |
| 1275B | Clonidine, Blood | $ 305.00 |
| 1275SP | Clonidine, Serum/Plasma | $ 305.00 |
| 1275U | Clonidine, Urine | $ 460.00 |
| 1280U | Clorazepate as Metabolite, Urine | $ 210.00 |
| 1287B | Clozapine and Metabolite, Blood | $ 147.00 |
| 1287FL | Clozapine and Metabolite, Fluid | $ 358.00 |
| 1287SP | Clozapine and Metabolite, Serum/Plasma | $ 147.00 |
| 1287TI | Clozapine and Metabolite, Tissue | $ 428.00 |
| 1287U | Clozapine and Metabolite, Urine | $ 233.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1290UH | Cobalt, 24 Hour Urine | $ 137.00 |
| 1290B | Cobalt, Blood | $ 114.00 |
| 1290FL | Cobalt, Fluid | $ 319.00 |
| 1290H | Cobalt, Hair | $ 486.00 |
| 1290N | Cobalt, Nails | $ 486.00 |
| 1290R | Cobalt, RBCs | $ 114.00 |
| 1290SP | Cobalt, Serum/Plasma | $ 114.00 |
| 1290TI | Cobalt, Tissue | $ 389.00 |
| 1290U | Cobalt, Urine | $ 186.00 |
| 1300ME | Cocaine and Metabolites (Qualitative), Meconium | $ 452.00 |
| 8893OF | Cocaine and Metabolites (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 0606B | Cocaine and Metabolites Screen, Blood | $ 159.00 |
| 0606FL | Cocaine and Metabolites Screen, Fluid | $ 332.00 |
| 6920H | Cocaine and Metabolites Screen, Hair | $ 737.00 |
| 0606SP | Cocaine and Metabolites Screen, Serum/Plasma | $ 100.00 |
| 0606U | Cocaine and Metabolites Screen, Urine | $ 100.00 |
| 1300B | Cocaine and Metabolites, Blood | $ 243.00 |
| 1300FL | Cocaine and Metabolites, Fluid | $ 432.00 |
| 1300SP | Cocaine and Metabolites, Serum/Plasma | $ 243.00 |
| 1300TI | Cocaine and Metabolites, Tissue | $ 495.00 |
| 1300U | Cocaine and Metabolites, Urine | $ 243.00 |
| 1303B | Cocaine and Products Panel, Blood | $ 553.00 |
| 1303SP | Cocaine and Products Panel, Serum/Plasma | $ 501.00 |
| 1303U | Cocaine and Products Panel, Urine | $ 501.00 |
| 1306U | Codeine - Total (Conjugated/Unconjugated) Screen, Urine | $ 235.00 |
| 8661B | Codeine and Metabolite - Free (Unconjugated), Blood | $ 330.00 |
| 8661SP | Codeine and Metabolite - Free (Unconjugated), Serum/Plasma | $ 218.00 |
| 8661U | Codeine and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 348.00 |
| 1320B | Colchicine, Blood | $ 926.00 |
| 1320SP | Colchicine, Serum/Plasma | $ 788.00 |
| 1320TI | Colchicine, Tissue | $ 1,187.00 |
| 9145UC | Comprehensive Drug Screen, Umbilical Cord Tissue | $ 745.00 |
| 2423B | Comprehensive Volatiles Panel, Blood | $ 515.00 |
| 2423TI | Comprehensive Volatiles Panel, Tissue | $ 536.00 |
| 1333SP | Copper - Free, Serum/Plasma | $ 105.00 |
| 1330B | Copper, Blood | $ 58.00 |
| 1330FL | Copper, Fluid | $ 267.00 |
| 1330H | Copper, Hair | $ 430.00 |
| 1330R | Copper, RBCs | $ 58.00 |
| 1330SP | Copper, Serum/Plasma | $ 58.00 |
| 1330TI | Copper, Tissue | $ 339.00 |
| 1330U | Copper, Urine | $ 58.00 |
| 3157U | Cotinine and Anabasine from Secondary Exposure, Urine | $ 262.00 |
| 1348U | Creatinine, Urine | $ 45.00 |
| 9142B | Cyanide Screen, Blood | $ 79.00 |
| 1380B | Cyanide, Blood | $ 79.00 |
| 1390B | Cyclizine and Metabolite, Blood | $ 288.00 |
| 1405B | Cyclobenzaprine, Blood | $ 114.00 |
| 1405FL | Cyclobenzaprine, Fluid | $ 326.00 |
| 1405SP | Cyclobenzaprine, Serum/Plasma | $ 114.00 |
| 1405TI | Cyclobenzaprine, Tissue | $ 396.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1405U | Cyclobenzaprine, Urine | $ 114.00 |
| 1407B | Cyclohexane, Blood | $ 309.00 |
| 1410U | Cyclohexanol - Total, Urine | $ 254.00 |
| 1409B | Cyclohexanone, Blood | $ 312.00 |
| 1409SP | Cyclohexanone, Serum/Plasma | $ 301.00 |
| 1409U | Cyclohexanone, Urine | $ 301.00 |
| 1415B | Cyclosporine, Blood | $ 315.00 |
| 1425B | Cyproheptadine, Blood | $ 297.00 |
| 1425SP | Cyproheptadine, Serum/Plasma | $ 288.00 |
| 1425U | Cyproheptadine, Urine | $ 232.00 |
| 0275SP | Dalfampridine, Serum/Plasma | $ 648.00 |
| 0275U | Dalfampridine, Urine | $ 648.00 |
| 1439B | Dantrolene, Blood | $ 336.00 |
| 1439SP | Dantrolene, Serum/Plasma | $ 129.00 |
| 1440B | Dapsone and Metabolite, Blood | $ 750.00 |
| 1440SP | Dapsone and Metabolite, Serum/Plasma | $ 427.00 |
| 1470B | DDT, DDD and DDE, Blood | $ 249.00 |
| 1470F | DDT, DDD and DDE, Fat | $ 529.00 |
| 1470SP | DDT, DDD and DDE, Serum/Plasma | $ 249.00 |
| 1479B | Delta-8 and Delta-9 Cannabinoids Panel (DUID/DRE), Blood (Forensic) | $ 395.00 |
| 1478B | Delta-8 and Delta-9 Cannabinoids Panel, Blood | $ 350.00 |
| 1476B | Delta-8 Cannabinoids Panel (DUID/DRE), Blood (Forensic) | $ 289.00 |
| 1477B | Delta-8 Cannabinoids Panel, Blood | $ 244.00 |
| 8892OF | Delta-9 THC (Qualitative), Oral Fluid (Saliva) | $ 80.00 |
| 8900OF | Delta-9 THC (Quantitative), Oral Fluid (Saliva) | $ 214.00 |
| 1483U | Desalkylgidazepam (Qualitative), Urine | $ 338.00 |
| 1483B | Desalkylgidazepam, Blood | $ 338.00 |
| 1483SP | Desalkylgidazepam, Serum/Plasma | $ 338.00 |
| 1481U | Deschloroetizolam, Meclonazepam, and Pyrazolam (Qualitative), Urine | $ 359.00 |
| 1481B | Deschloroetizolam, Meclonazepam, and Pyrazolam, Blood | $ 359.00 |
| 1481SP | Deschloroetizolam, Meclonazepam, and Pyrazolam, Serum/Plasma | $ 359.00 |
| 0570U | Designer Benzodiazepines (Qualitative), Urine | $ 361.00 |
| 0571B | Designer Benzodiazepines DUID/DRE Add-On, Blood (Forensic) | $ 215.00 |
| 0570B | Designer Benzodiazepines, Blood | $ 361.00 |
| 0570SP | Designer Benzodiazepines, Serum/Plasma | $ 361.00 |
| 1480U | Designer Opioids (Qualitative), Urine | $ 374.00 |
| 1480B | Designer Opioids, Blood | $ 374.00 |
| 1480SP | Designer Opioids, Serum/Plasma | $ 374.00 |
| 1490B | Desipramine, Blood | $ 140.00 |
| 8704B | Desipramine, Blood | $ 564.00 |
| 1490SP | Desipramine, Serum/Plasma | $ 140.00 |
| 1490U | Desipramine, Urine | $ 138.00 |
| 8704U | Desipramine, Urine | $ 543.00 |
| 1496U | Desmethylsertraline, Urine | $ 115.00 |
| 1491B | Desvenlafaxine, Blood | $ 262.00 |
| 1491SP | Desvenlafaxine, Serum/Plasma | $ 262.00 |
| 1491U | Desvenlafaxine, Urine | $ 262.00 |
| 2915U | Dextro / Levo Methorphan - Total, Urine | $ 225.00 |
| 9205U | Dextro / Levo Methorphan Screen - Total, Urine | $ 220.00 |
| 9205SP | Dextro / Levo Methorphan Screen, Serum/Plasma | $ 135.00 |
| 2915B | Dextro/Levo Methorphan, Blood | $ 132.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2915SP | Dextro/Levo Methorphan, Serum/Plasma | $ 199.00 |
| 2915TI | Dextro/Levo Methorphan, Tissue | $ 412.00 |
| 2917U | Dextromethorphan and Metabolite Ratio - Total, Urine | $ 317.00 |
| 9206U | Dextrorphan / Levorphanol Screen - Total, Urine | $ 293.00 |
| 2506B | Dextrorphan / Levorphanol Screen, Blood | $ 500.00 |
| 2506SP | Dextrorphan / Levorphanol Screen, Serum/Plasma | $ 482.00 |
| 1501B | Diazepam and Metabolites, Blood | $ 188.00 |
| 1501SP | Diazepam and Metabolites, Serum/Plasma | $ 188.00 |
| 1515B | Diazoxide, Blood | $ 407.00 |
| 1515SP | Diazoxide, Serum/Plasma | $ 496.00 |
| 1546B | Dichlorobenzenes, Blood | $ 194.00 |
| 1546SP | Dichlorobenzenes, Serum/Plasma | $ 322.00 |
| 1549U | Dichlorobenzidine, Urine | $ 360.00 |
| 1550B | Dichloroethane, Blood | $ 278.00 |
| 1560B | Dichloromethane and Carboxyhemoglobin, Blood | $ 197.00 |
| 1561B | Dichloromethane, Blood | $ 228.00 |
| 1561U | Dichloromethane, Urine | $ 239.00 |
| 1567U | Dichlorophenol 2,5-, Urine | $ 341.00 |
| 1569B | Diclofenac, Blood | $ 369.00 |
| 1569SP | Diclofenac, Serum/Plasma | $ 570.00 |
| 0416SP | Dicumarol (Qualitative), Serum/Plasma | $ 407.00 |
| 1575B | Dicyclomine, Blood | $ 330.00 |
| 1575SP | Dicyclomine, Serum/Plasma | $ 330.00 |
| 1575U | Dicyclomine, Urine | $ 330.00 |
| 1580B | Dieldrin, Blood | $ 218.00 |
| 1580SP | Dieldrin, Serum/Plasma | $ 209.00 |
| 1590B | Diethyl Ether, Blood | $ 189.00 |
| 1590SP | Diethyl Ether, Serum/Plasma | $ 210.00 |
| 1589B | Diethylene Glycol, Blood | $ 478.00 |
| 1589SP | Diethylene Glycol, Serum/Plasma | $ 478.00 |
| 1589U | Diethylene Glycol, Urine | $ 432.00 |
| 1482B | Diethyl-M-Toluamide, Blood | $ 901.00 |
| 1482SP | Diethyl-M-Toluamide, Serum/Plasma | $ 568.00 |
| 1482U | Diethyl-M-Toluamide, Urine | $ 901.00 |
| 1600B | Diethylpropion, Blood | $ 194.00 |
| 1600SP | Diethylpropion, Serum/Plasma | $ 236.00 |
| 1600U | Diethylpropion, Urine | $ 215.00 |
| 0417SP | Difenacoum (Qualitative), Serum/Plasma | $ 213.00 |
| 1613SP | Digitoxin, Serum/Plasma | $ 87.00 |
| 1615B | Digoxin, Blood | $ 374.00 |
| 1615FL | Digoxin, Fluid | $ 587.00 |
| 1615SP | Digoxin, Serum/Plasma | $ 468.00 |
| 1615TI | Digoxin, Tissue | $ 436.00 |
| 1615U | Digoxin, Urine | $ 567.00 |
| 8662B | Dihydrocodeine - Free (Unconjugated), Blood | $ 482.00 |
| 8662SP | Dihydrocodeine - Free (Unconjugated), Serum/Plasma | $ 482.00 |
| 8662U | Dihydrocodeine - Total (Conjugated/Unconjugated), Urine | $ 482.00 |
| 1640B | Diltiazem, Blood | $ 330.00 |
| 1640SP | Diltiazem, Serum/Plasma | $ 509.00 |
| 1640U | Diltiazem, Urine | $ 509.00 |
| 1683SP | Dimethadione, Serum/Plasma | $ 168.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1690B | Dimethylsulfoxide, Blood | $ 202.00 |
| 1690SP | Dimethylsulfoxide, Serum/Plasma | $ 324.00 |
| 1690U | Dimethylsulfoxide, Urine | $ 322.00 |
| 1693B | Dimethyltryptamine, Blood | $ 467.00 |
| 1693SP | Dimethyltryptamine, Serum/Plasma | $ 467.00 |
| 1693U | Dimethyltryptamine, Urine | $ 467.00 |
| 1740B | Dioxane-1,4, Blood | $ 298.00 |
| 1740SP | Dioxane-1,4, Serum/Plasma | $ 298.00 |
| 1740TI | Dioxane-1,4, Tissue | $ 545.00 |
| 0418SP | Diphacinone (Qualitative), Serum/Plasma | $ 296.00 |
| 1760B | Diphenhydramine, Blood | $ 95.00 |
| 1760FL | Diphenhydramine, Fluid | $ 308.00 |
| 1760SP | Diphenhydramine, Serum/Plasma | $ 95.00 |
| 1760TI | Diphenhydramine, Tissue | $ 381.00 |
| 1760U | Diphenhydramine, Urine | $ 149.00 |
| 1777B | Dipyridamole, Blood | $ 250.00 |
| 1777SP | Dipyridamole, Serum/Plasma | $ 239.00 |
| 1789B | Diquat, Blood | $ 2,052.00 |
| 1789SP | Diquat, Serum/Plasma | $ 2,052.00 |
| 9159B | Disopyramide Screen, Blood | $ 217.00 |
| 9159SP | Disopyramide Screen, Serum/Plasma | $ 188.00 |
| 1790SP | Disulfiram (DEDTC Metabolite) (Qualitative), Serum/Plasma | $ 417.00 |
| 1804SP | Diuretics Panel, Serum/Plasma | $ 142.00 |
| 9318U | Diuretics Screen, Urine | $ 196.00 |
| 1812B | Donepezil, Blood | $ 379.00 |
| 1812FL | Donepezil, Fluid | $ 446.00 |
| 1812SP | Donepezil, Serum/Plasma | $ 379.00 |
| 1905B | Dothiepin, Blood | $ 710.00 |
| 1815B | Doxazosin, Blood | $ 805.00 |
| 1815SP | Doxazosin, Serum/Plasma | $ 502.00 |
| 9435B | Doxepin and Metabolite Screen, Blood | $ 220.00 |
| 9435U | Doxepin and Metabolite Screen, Urine | $ 212.00 |
| 1810B | Doxepin and Metabolite, Blood | $ 144.00 |
| 8705B | Doxepin and Metabolite, Blood | $ 488.00 |
| 1810FL | Doxepin and Metabolite, Fluid | $ 355.00 |
| 1810SP | Doxepin and Metabolite, Serum/Plasma | $ 167.00 |
| 1810TI | Doxepin and Metabolite, Tissue | $ 433.00 |
| 1810U | Doxepin and Metabolite, Urine | $ 159.00 |
| 8705U | Doxepin and Metabolite, Urine | $ 341.00 |
| 9163B | Doxylamine Screen, Blood | $ 192.00 |
| 9163SP | Doxylamine Screen, Serum/Plasma | $ 135.00 |
| 1817B | Doxylamine, Blood | $ 190.00 |
| 1817FL | Doxylamine, Fluid | $ 401.00 |
| 1817SP | Doxylamine, Serum/Plasma | $ 209.00 |
| 1817TI | Doxylamine, Tissue | $ 438.00 |
| 1817U | Doxylamine, Urine | $ 209.00 |
| 1826SP | Dronabinol, Serum/Plasma | $ 414.00 |
| 1828B | Dronedarone, Blood | $ 184.00 |
| 1828SP | Dronedarone, Serum/Plasma | $ 184.00 |
| 8030B | Drug Facilitated Crime Panel, Blood (Forensic) | $ 551.00 |
| 8030SP | Drug Facilitated Crime Panel, Serum/Plasma (Forensic) | $ 551.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8030U | Drug Facilitated Crime Panel, Urine (Forensic) | $ 551.00 |
| 1876B | Drug Screen - Expanded, Blood | $ 426.00 |
| 1876FL | Drug Screen - Expanded, Fluid | $ 621.00 |
| 1876SP | Drug Screen - Expanded, Serum/Plasma | $ 426.00 |
| 1876U | Drug Screen - Expanded, Urine | $ 426.00 |
| 1874B | Drug Screen (10 Panel), Blood | $ 391.00 |
| 1874U | Drug Screen (9 Panel), Urine | $ 391.00 |
| 8098B | Drug Screen (GC/MS), Blood | $ 562.00 |
| 8098SP | Drug Screen (GC/MS), Serum/Plasma | $ 544.00 |
| 8098U | Drug Screen (GC/MS), Urine | $ 541.00 |
| 1858B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 130.00 |
| 8091B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 452.00 |
| 8101B | Drugs of Abuse (10 Panel) and Alcohol Screen, Blood | $ 189.00 |
| 1858FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 370.00 |
| 8091FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 642.00 |
| 8101FL | Drugs of Abuse (10 Panel) and Alcohol Screen, Fluid | $ 399.00 |
| 1858SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 130.00 |
| 8091SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 452.00 |
| 8101SP | Drugs of Abuse (10 Panel) and Alcohol Screen, Serum/Plasma | $ 189.00 |
| 1858TI | Drugs of Abuse (10 Panel) and Alcohol Screen, Tissue | $ 440.00 |
| 8091TI | Drugs of Abuse (10 Panel) and Alcohol Screen, Tissue | $ 711.00 |
| 8091U | Drugs of Abuse (11 Panel) and Alcohol Screen, Urine | $ 452.00 |
| 8101U | Drugs of Abuse (11 Panel) and Alcohol Screen, Urine | $ 189.00 |
| 8898OF | Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva) | $ 94.00 |
| 8897OF | Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva) | $ 146.00 |
| 1858U | Drugs of Abuse (9 Panel) and Alcohol Screen, Urine | $ 160.00 |
| 8096B | Drugs of Abuse Screen (10 Panel), Blood | $ 437.00 |
| 1864ME | Drugs of Abuse Screen (10 Panel), Meconium | $ 227.00 |
| 8096SP | Drugs of Abuse Screen (10 Panel), Serum/Plasma | $ 437.00 |
| 1864U | Drugs of Abuse Screen (10 Panel), Urine | $ 123.00 |
| 1864B | Drugs of Abuse Screen (11 Panel), Blood | $ 121.00 |
| 1864FL | Drugs of Abuse Screen (11 Panel), Fluid | $ 362.00 |
| 1864SP | Drugs of Abuse Screen (11 Panel), Serum/Plasma | $ 121.00 |
| 1864TI | Drugs of Abuse Screen (11 Panel), Tissue | $ 575.00 |
| 8096U | Drugs of Abuse Screen (11 Panel), Urine | $ 700.00 |
| 6943H | Drugs of Abuse Screen (6 Panel), Hair | $ 604.00 |
| 1861U | Drugs of Abuse Screen (6 Panel), Urine | $ 215.00 |
| 1861B | Drugs of Abuse Screen (7 Panel), Blood | $ 215.00 |
| 6904ME | Drugs of Abuse Screen (7 Panel), Meconium | $ 193.00 |
| 6946H | Drugs of Abuse Screen (9 Panel), Hair | $ 722.00 |
| 8158B | DUID/DRE Expanded Drug Screen (w/Alcohol), Blood (Forensic) | $ 457.00 |
| 8075U | DUID/DRE Expanded Drug Screen Add-On (Qualitative), Urine (Forensic) | $ 152.00 |
| 8152B | DUID/DRE Expanded Drug Screen Add-On, Blood (Forensic) | $ 166.00 |
| 8159B | DUID/DRE Expanded Drug Screen, Blood (Forensic) | $ 436.00 |
| 8082B | DUID/DRE Inhalants Add-On, Blood (Forensic) | $ 334.00 |
| 8071U | DUID/DRE Panel (Qualitative), Urine (Forensic) | $ 276.00 |
| 8070U | DUID/DRE Panel (w/Alcohol) (Qualitative), Urine (Forensic) | $ 298.00 |
| 8151B | DUID/DRE Panel (w/Alcohol), Blood (Forensic) | $ 365.00 |
| 8170U | DUID/DRE Panel (w/Alcohol), Urine (Forensic) | $ 335.00 |
| 8150B | DUID/DRE Panel, Blood (Forensic) | $ 344.00 |
| 8171U | DUID/DRE Panel, Urine (Forensic) | $ 313.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4666B | Duloxetine, Blood | $ 267.00 |
| 4666SP | Duloxetine, Serum/Plasma | $ 267.00 |
| 1900B | Dyazide, Blood | $ 419.00 |
| 1900SP | Dyazide, Serum/Plasma | $ 254.00 |
| 1919FL | Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic) | $ 119.00 |
| 7025U | Electrolytes Panel, Urine - Send Out | $ 123.00 |
| 1920B | Endrin, Blood | $ 173.00 |
| 1920SP | Endrin, Serum/Plasma | $ 173.00 |
| 1923B | Enflurane, Blood | $ 389.00 |
| 8103B | Environmental Exposure Screen, Blood | $ 915.00 |
| 9165B | Ephedrine Screen, Blood | $ 179.00 |
| 1950B | Ephedrine, Blood | $ 199.00 |
| 1950SP | Ephedrine, Serum/Plasma | $ 213.00 |
| 1950U | Ephedrine, Urine | $ 213.00 |
| 4023B | Ephedrines Panel, Blood | $ 310.00 |
| 4023SP | Ephedrines Panel, Serum/Plasma | $ 296.00 |
| 4023U | Ephedrines Panel, Urine | $ 283.00 |
| 2022SP | Eplerenone, Serum/Plasma | $ 166.00 |
| 1965B | Escitalopram, Blood | $ 320.00 |
| 1965FL | Escitalopram, Fluid | $ 355.00 |
| 1965SP | Escitalopram, Serum/Plasma | $ 201.00 |
| 1965U | Escitalopram, Urine | $ 320.00 |
| 1958B | Estazolam, Blood | $ 446.00 |
| 1958SP | Estazolam, Serum/Plasma | $ 446.00 |
| 1958U | Estazolam, Urine | $ 446.00 |
| 1968B | Eszopiclone / Zopiclone, Blood | $ 478.00 |
| 1968SP | Eszopiclone / Zopiclone, Serum/Plasma | $ 331.00 |
| 1968TI | Eszopiclone / Zopiclone, Tissue | $ 436.00 |
| 1968U | Eszopiclone / Zopiclone, Urine | $ 331.00 |
| 1959SP | Ethambutol, Serum/Plasma | $ 224.00 |
| 7542B | Ethanol - Title 17, Blood - Send Out | $ 142.00 |
| 7542SP | Ethanol - Title 17, Serum/Plasma - Send Out | $ 142.00 |
| 7542U | Ethanol - Title 17, Urine - Send Out | $ 142.00 |
| 1970U | Ethchlorvynol Overdose, Urine | $ 560.00 |
| 1970SP | Ethchlorvynol, Serum/Plasma | $ 417.00 |
| 1980B | Ethinamate, Blood | $ 104.00 |
| 1980SP | Ethinamate, Serum/Plasma | $ 159.00 |
| 9171B | Ethosuximide Screen, Blood | $ 152.00 |
| 9171SP | Ethosuximide Screen, Serum/Plasma | $ 217.00 |
| 9171U | Ethosuximide Screen, Urine | $ 152.00 |
| 2000B | Ethosuximide, Blood | $ 168.00 |
| 2000SP | Ethosuximide, Serum/Plasma | $ 217.00 |
| 2000U | Ethosuximide, Urine | $ 202.00 |
| 2010B | Ethotoin, Blood | $ 420.00 |
| 2010SP | Ethotoin, Serum/Plasma | $ 152.00 |
| 9146UC | Ethyl Glucuronide Screen, Umbilical Cord Tissue | $ 339.00 |
| 9361U | Ethyl Glucuronide Screen, Urine | $ 160.00 |
| 2081U | Ethyl Glucuronide, Urine | $ 160.00 |
| 9025U | Ethyl Sulfate Screen, Urine | $ 170.00 |
| 2029U | Ethylbenzene Exposure Biouptake, Urine | $ 249.00 |
| 2030B | Ethylbenzene, Blood | $ 230.00 |

| Test | Test Name | List Price |
|---|---|---|
| 1038B | Ethylene Glycol Monobutyl Ether, Blood | $ 340.00 |
| 1038SP | Ethylene Glycol Monobutyl Ether, Serum/Plasma | $ 219.00 |
| 1039B | Ethylene Glycol Monoethyl Ether, Blood | $ 350.00 |
| 1039SP | Ethylene Glycol Monoethyl Ether, Serum/Plasma | $ 212.00 |
| 2055B | Ethylene Glycol Overexposure Profile, Blood | $ 423.00 |
| 2055SP | Ethylene Glycol Overexposure Profile, Serum/Plasma | $ 437.00 |
| 2062B | Ethylene Glycol, Blood | $ 254.00 |
| 2062FL | Ethylene Glycol, Fluid | $ 324.00 |
| 2062SP | Ethylene Glycol, Serum/Plasma | $ 159.00 |
| 2062TI | Ethylene Glycol, Tissue | $ 346.00 |
| 2062U | Ethylene Glycol, Urine | $ 236.00 |
| 2064SP | Ethylmorphine, Serum/Plasma | $ 401.00 |
| 2067B | Etodolac, Blood | $ 832.00 |
| 2067SP | Etodolac, Serum/Plasma | $ 804.00 |
| 2063B | Etomidate, Blood | $ 388.00 |
| 2063FL | Etomidate, Fluid | $ 580.00 |
| 2063P | Etomidate, Plasma | $ 431.00 |
| 1022U | Eutylone (Qualitative), Urine | $ 292.00 |
| 1022B | Eutylone, Blood | $ 292.00 |
| 1022SP | Eutylone, Serum/Plasma | $ 292.00 |
| 1022TI | Eutylone, Tissue | $ 540.00 |
| 2066B | Everolimus, Blood | $ 216.00 |
| 9352UC | Expanded Drug Screen, Umbilical Cord Tissue | $ 586.00 |
| 4025SP | Ezogabine and Metabolite, Serum/Plasma | $ 268.00 |
| 2068B | Famotidine, Blood | $ 806.00 |
| 2069B | Felbamate, Blood | $ 496.00 |
| 2069SP | Felbamate, Serum/Plasma | $ 209.00 |
| 2082SP | Fenoprofen, Serum/Plasma | $ 464.00 |
| 2079ME | Fentanyl and Metabolite (Qualitative), Meconium | $ 387.00 |
| 9176B | Fentanyl and Metabolite Screen, Blood | $ 132.00 |
| 9176FL | Fentanyl and Metabolite Screen, Fluid | $ 340.00 |
| 9176SP | Fentanyl and Metabolite Screen, Serum/Plasma | $ 132.00 |
| 9176TI | Fentanyl and Metabolite Screen, Tissue | $ 412.00 |
| 2079B | Fentanyl and Metabolite, Blood | $ 132.00 |
| 2079FL | Fentanyl and Metabolite, Fluid | $ 168.00 |
| 2079SP | Fentanyl and Metabolite, Serum/Plasma | $ 132.00 |
| 2079TI | Fentanyl and Metabolite, Tissue | $ 203.00 |
| 2079U | Fentanyl and Metabolite, Urine | $ 132.00 |
| 9291H | Fentanyl Screen, Hair | $ 1,242.00 |
| 6303B | Firefighter Core Baseline Profile, Blood | $ 341.00 |
| 6303U | Firefighter Core Baseline Profile, Urine | $ 526.00 |
| 2088B | Flecainide, Blood | $ 217.00 |
| 2088SP | Flecainide, Serum/Plasma | $ 208.00 |
| 2088U | Flecainide, Urine | $ 131.00 |
| 2089B | Fluconazole, Blood | $ 707.00 |
| 2089SP | Fluconazole, Serum/Plasma | $ 456.00 |
| 2085SP | Flucytosine, Serum/Plasma | $ 456.00 |
| 9341B | Flunitrazepam and Metabolites Screen, Blood | $ 267.00 |
| 9341SP | Flunitrazepam and Metabolites Screen, Serum/Plasma | $ 267.00 |
| 9341TI | Flunitrazepam and Metabolites Screen, Tissue | $ 371.00 |
| 9341U | Flunitrazepam and Metabolites Screen, Urine | $ 267.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2041U | Flunitrazepam and Metabolites, Urine | $ 326.00 |
| 2092B | Fluoride Preservative Determination, Blood | $ 488.00 |
| 2090LI | Fluoride Preservative Determination, Liquid | $ 503.00 |
| 2090B | Fluoride, Blood | $ 213.00 |
| 2090FL | Fluoride, Fluid | $ 213.00 |
| 2090SP | Fluoride, Serum/Plasma | $ 123.00 |
| 2090U | Fluoride, Urine | $ 93.00 |
| 2100B | Fluorocarbon 113, Blood | $ 464.00 |
| 2100TI | Fluorocarbon 113, Tissue | $ 386.00 |
| 9179B | Fluoxetine and Metabolite Screen, Blood | $ 212.00 |
| 9179SP | Fluoxetine and Metabolite Screen, Serum/Plasma | $ 201.00 |
| 9179U | Fluoxetine and Metabolite Screen, Urine | $ 212.00 |
| 2105B | Fluoxetine and Metabolite, Blood | $ 124.00 |
| 2105FL | Fluoxetine and Metabolite, Fluid | $ 205.00 |
| 2105SP | Fluoxetine and Metabolite, Serum/Plasma | $ 199.00 |
| 2105TI | Fluoxetine and Metabolite, Tissue | $ 192.00 |
| 2105U | Fluoxetine and Metabolite, Urine | $ 121.00 |
| 2110B | Fluphenazine, Blood | $ 205.00 |
| 2115SP | Fluphenazine, Serum/Plasma | $ 119.00 |
| 2110TI | Fluphenazine, Tissue | $ 457.00 |
| 2120B | Flurazepam and Metabolites, Blood | $ 310.00 |
| 2120SP | Flurazepam and Metabolites, Serum/Plasma | $ 368.00 |
| 2120U | Flurazepam as Metabolites, Urine | $ 368.00 |
| 2095SP | Flurbiprofen, Serum/Plasma | $ 191.00 |
| 2124B | Fluvoxamine, Blood | $ 201.00 |
| 2124FL | Fluvoxamine, Fluid | $ 411.00 |
| 2124SP | Fluvoxamine, Serum/Plasma | $ 128.00 |
| 2124U | Fluvoxamine, Urine | $ 128.00 |
| 2134B | Formic Acid, Blood | $ 140.00 |
| 2134SP | Formic Acid, Serum/Plasma | $ 140.00 |
| 2134U | Formic Acid, Urine | $ 173.00 |
| 2136B | Fosphenytoin as Metabolite, Blood | $ 159.00 |
| 2136SP | Fosphenytoin as Metabolite, Serum/Plasma | $ 159.00 |
| 2140B | Furosemide, Blood | $ 220.00 |
| 2140SP | Furosemide, Serum/Plasma | $ 139.00 |
| 2140U | Furosemide, Urine | $ 220.00 |
| 2143B | Gabapentin, Blood | $ 150.00 |
| 2143FL | Gabapentin, Fluid | $ 345.00 |
| 2143SP | Gabapentin, Serum/Plasma | $ 150.00 |
| 2143TI | Gabapentin, Tissue | $ 402.00 |
| 2143U | Gabapentin, Urine | $ 203.00 |
| 2148B | Galantamine, Blood | $ 386.00 |
| 2148SP | Galantamine, Serum/Plasma | $ 386.00 |
| 2150B | Gallium, Blood | $ 430.00 |
| 2150SP | Gallium, Serum/Plasma | $ 261.00 |
| 2150U | Gallium, Urine | $ 261.00 |
| 9326B | Gamma-Hydroxybutyric Acid Screen, Blood | $ 305.00 |
| 9326FL | Gamma-Hydroxybutyric Acid Screen, Fluid | $ 341.00 |
| 9326SP | Gamma-Hydroxybutyric Acid Screen, Serum/Plasma | $ 305.00 |
| 9326U | Gamma-Hydroxybutyric Acid Screen, Urine | $ 305.00 |
| 2187SP | Ganaxolone, Serum/Plasma | $ 482.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2162B | Ganciclovir, Blood | $ 276.00 |
| 2154SP | Ganciclovir, Serum/Plasma | $ 254.00 |
| 2154U | Ganciclovir, Urine | $ 640.00 |
| 2156SP | Germanium, Serum/Plasma | $ 411.00 |
| 2156U | Germanium, Urine | $ 394.00 |
| 2159B | Glimepiride, Blood | $ 137.00 |
| 2159SP | Glimepiride, Serum/Plasma | $ 137.00 |
| 2158B | Glipizide, Blood | $ 468.00 |
| 2158SP | Glipizide, Serum/Plasma | $ 281.00 |
| 2164FL | Glucose (Vitreous), Fluid (Forensic) | $ 25.00 |
| 7027SP | Glucose, Serum/Plasma - Send Out | $ 105.00 |
| 7027U | Glucose, Urine - Send Out | $ 107.00 |
| 9443B | Glutethimide Screen, Blood | $ 190.00 |
| 9443SP | Glutethimide Screen, Serum/Plasma | $ 242.00 |
| 2160B | Glutethimide, Blood | $ 152.00 |
| 2160SP | Glutethimide, Serum/Plasma | $ 220.00 |
| 2163SP | Glyburide, Serum/Plasma | $ 218.00 |
| 2165B | Glycols Panel, Blood | $ 331.00 |
| 2165FL | Glycols Panel, Fluid | $ 618.00 |
| 2165LI | Glycols Panel, Liquid | $ 673.00 |
| 2165SP | Glycols Panel, Serum/Plasma | $ 331.00 |
| 2165TI | Glycols Panel, Tissue | $ 716.00 |
| 2165U | Glycols Panel, Urine | $ 628.00 |
| 2171B | Gold, Blood | $ 93.00 |
| 2171SP | Gold, Serum/Plasma | $ 93.00 |
| 2171U | Gold, Urine | $ 93.00 |
| 7029O | Gram Stain (GRST) - Send Out | $ 107.00 |
| 2180SP | Griseofulvin, Serum/Plasma | $ 635.00 |
| 2185B | Guaifenesin, Blood | $ 411.00 |
| 2185SP | Guaifenesin, Serum/Plasma | $ 411.00 |
| 2185TI | Guaifenesin, Tissue | $ 561.00 |
| 2185U | Guaifenesin, Urine | $ 411.00 |
| 2186B | Guanfacine, Blood | $ 307.00 |
| 2186SP | Guanfacine, Serum/Plasma | $ 307.00 |
| 2186U | Guanfacine, Urine | $ 307.00 |
| HAIR KIT | Hair Kit/ Forensic | $ 19.00 |
| HAIRSEG | Hair Segmentation | $ 189.00 |
| HAIRSEG2 | Hair Segmentation II | $ 189.00 |
| 8758B | Hallucinogens Screen, Blood | $ 267.00 |
| 8758SP | Hallucinogens Screen, Serum/Plasma | $ 327.00 |
| 8758U | Hallucinogens Screen, Urine | $ 267.00 |
| 2212B | Halocarbons Panel, Blood | $ 284.00 |
| 9182B | Haloperidol Screen, Blood | $ 154.00 |
| 9182SP | Haloperidol Screen, Serum/Plasma | $ 138.00 |
| 2220B | Haloperidol, Blood | $ 105.00 |
| 2220FL | Haloperidol, Fluid | $ 304.00 |
| 2220SP | Haloperidol, Serum/Plasma | $ 173.00 |
| 2220TI | Haloperidol, Tissue | $ 390.00 |
| 2220U | Haloperidol, Urine | $ 304.00 |
| 7814B | Hemoglobin Cascade Confirmation - Send Out | $ 343.00 |
| 7812B | Hemoglobinopathy Screen (HGEL) - Send Out | $ 116.00 |

| Test | Test Name | List Price |
|---|---|---|
| 7026B | Hepatitis A Antibody, Blood - Send Out | $ 148.00 |
| 7072B | Hepatitis B Core Antibody, Blood - Send Out | $ 111.00 |
| 7047B | Hepatitis B Surface Antibody, Blood - Send Out | $ 177.00 |
| 7048B | Hepatitis B Surface Antigen Confirmatory Assay, Blood - Send Out | $ 456.00 |
| 7053B | Hepatitis B Surface Antigen, Blood - Send Out | $ 99.00 |
| 7049B | Hepatitis C Antibody, Blood - Send Out | $ 109.00 |
| 2260SP | Heptachlor and Metabolite, Serum/Plasma | $ 132.00 |
| 2270B | Heptane, n-, Blood | $ 309.00 |
| 2270SP | Heptane, n-, Serum/Plasma | $ 340.00 |
| 2278B | Herbicides Panel 2, Blood | $ 311.00 |
| 2278SP | Herbicides Panel 2, Serum/Plasma | $ 311.00 |
| 2278U | Herbicides Panel 2, Urine | $ 311.00 |
| 2276B | Heroin Metabolites - Free (Unconjugated), Blood | $ 320.00 |
| 2276SP | Heroin Metabolites - Free (Unconjugated), Serum/Plasma | $ 320.00 |
| 2276U | Heroin Metabolites - Free (Unconjugated), Urine | $ 320.00 |
| 9343B | Heroin Screen, Blood | $ 189.00 |
| 9343SP | Heroin Screen, Serum/Plasma | $ 116.00 |
| 9343U | Heroin Screen, Urine | $ 116.00 |
| 2283B | Hexachlorobenzene, Blood | $ 201.00 |
| 2283SP | Hexachlorobenzene, Serum/Plasma | $ 201.00 |
| 2290B | Hexane, n-, Blood | $ 189.00 |
| 2290SP | Hexane, n-, Serum/Plasma | $ 301.00 |
| 2291U | Hexanol - Total, 1 and 2-, Urine | $ 362.00 |
| 2306U | Hippuric Acid and Methylhippuric Acid, Urine | $ 212.00 |
| 2300U | Hippuric Acid, Urine | $ 120.00 |
| 7033B | HIV-1/HIV-2 Plus O EIA - Send Out | $ 100.00 |
| 7086O | Human metapneumovirus (HMPVP) - Send Out | $ 1,054.00 |
| 2308SP | Hydralazine, Serum/Plasma | $ 776.00 |
| 2321B | Hydrocarbon and Oxygenated Volatiles Panel, Blood | $ 119.00 |
| 2321FL | Hydrocarbon and Oxygenated Volatiles Panel, Fluid | $ 192.00 |
| 2321TI | Hydrocarbon and Oxygenated Volatiles Panel, Tissue | $ 239.00 |
| 2321U | Hydrocarbon and Oxygenated Volatiles Panel, Urine | $ 182.00 |
| 2330B | Hydrochlorothiazide, Blood | $ 220.00 |
| 2330SP | Hydrochlorothiazide, Serum/Plasma | $ 220.00 |
| 2330U | Hydrochlorothiazide, Urine | $ 220.00 |
| 2340B | Hydrocodone - Free (Unconjugated), Blood | $ 177.00 |
| 2340FL | Hydrocodone - Free (Unconjugated), Fluid | $ 173.00 |
| 2340SP | Hydrocodone - Free (Unconjugated), Serum/Plasma | $ 177.00 |
| 8663B | Hydrocodone and Metabolites - Free (Unconjugated), Blood | $ 257.00 |
| 8663FL | Hydrocodone and Metabolites - Free (Unconjugated), Fluid | $ 327.00 |
| 8663SP | Hydrocodone and Metabolites - Free (Unconjugated), Serum/Plasma | $ 257.00 |
| 8663TI | Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Tissue | $ 362.00 |
| 8663U | Hydrocodone and Metabolites - Total (Conjugated/Unconjugated), Urine | $ 257.00 |
| 9332B | Hydrocodone Screen, Blood | $ 190.00 |
| 9332SP | Hydrocodone Screen, Serum/Plasma | $ 190.00 |
| 8664B | Hydromorphone - Free (Unconjugated), Blood | $ 426.00 |
| 8664FL | Hydromorphone - Free (Unconjugated), Fluid | $ 362.00 |
| 8664SP | Hydromorphone - Free (Unconjugated), Serum/Plasma | $ 426.00 |
| 8664TI | Hydromorphone - Free (Unconjugated), Tissue | $ 396.00 |
| 8664U | Hydromorphone - Total (Conjugated/Unconjugated), Urine | $ 266.00 |
| 2362B | Hydroxychloroquine, Blood | $ 281.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2362FL | Hydroxychloroquine, Fluid | $ 317.00 |
| 2362SP | Hydroxychloroquine, Serum/Plasma | $ 281.00 |
| 2362TI | Hydroxychloroquine, Tissue | $ 353.00 |
| 2362U | Hydroxychloroquine, Urine | $ 402.00 |
| 2365B | Hydroxyzine and Metabolite, Blood | $ 132.00 |
| 2365FL | Hydroxyzine and Metabolite, Fluid | $ 348.00 |
| 2365SP | Hydroxyzine and Metabolite, Serum/Plasma | $ 209.00 |
| 2365U | Hydroxyzine and Metabolite, Urine | $ 209.00 |
| 2365TI | Hydroxyzine, Tissue | $ 387.00 |
| 2369B | Hyoscyamine, Blood | $ 347.00 |
| 2369SP | Hyoscyamine, Serum/Plasma | $ 217.00 |
| 2369U | Hyoscyamine, Urine | $ 217.00 |
| 4261B | Hypoglycemic Panel, Blood | $ 423.00 |
| 4261SP | Hypoglycemic Panel, Serum/Plasma | $ 423.00 |
| 2390B | Ibuprofen, Blood | $ 138.00 |
| 2390FL | Ibuprofen, Fluid | $ 348.00 |
| 2390SP | Ibuprofen, Serum/Plasma | $ 138.00 |
| 2390TI | Ibuprofen, Tissue | $ 370.00 |
| 2390U | Ibuprofen, Urine | $ 104.00 |
| 2395B | Iloperidone, Blood | $ 215.00 |
| 2395SP | Iloperidone, Serum/Plasma | $ 215.00 |
| 9434B | Imipramine and Metabolite Screen, Blood | $ 135.00 |
| 9434SP | Imipramine and Metabolite Screen, Serum/Plasma | $ 212.00 |
| 9434U | Imipramine and Metabolite Screen, Urine | $ 220.00 |
| 2400B | Imipramine and Metabolite, Blood | $ 128.00 |
| 8703B | Imipramine and Metabolite, Blood | $ 564.00 |
| 2400SP | Imipramine and Metabolite, Serum/Plasma | $ 137.00 |
| 8703SP | Imipramine and Metabolite, Serum/Plasma | $ 543.00 |
| 2400U | Imipramine and Metabolite, Urine | $ 92.00 |
| 8703U | Imipramine and Metabolite, Urine | $ 341.00 |
| 7028SP | Immunoglobulin E, Serum/Plasma - Send Out | $ 105.00 |
| 2397SP | Indapamide, Serum/Plasma | $ 176.00 |
| 2406B | Indium, Blood | $ 228.00 |
| 2406R | Indium, RBCs | $ 152.00 |
| 2406SP | Indium, Serum/Plasma | $ 228.00 |
| 2406U | Indium, Urine | $ 152.00 |
| 2410B | Indomethacin, Blood | $ 178.00 |
| 2410SP | Indomethacin, Serum/Plasma | $ 167.00 |
| 2410U | Indomethacin, Urine | $ 178.00 |
| 2412B | Inhalants Panel, Alkane Gases, Blood | $ 194.00 |
| 2412TI | Inhalants Panel, Alkane Gases, Tissue | $ 284.00 |
| 2421B | Inhalants Panel, Anesthetics, Blood | $ 854.00 |
| 2414B | Inhalants Panel, Halocarbons, Blood | $ 214.00 |
| 2414TI | Inhalants Panel, Halocarbons, Tissue | $ 319.00 |
| 2411B | Inhalants Panel, Solvents, Blood | $ 114.00 |
| 2411TI | Inhalants Panel, Solvents, Tissue | $ 225.00 |
| 6364R | Inorganic Panel 64, RBCs | $ 505.00 |
| 2428U | Iodine - Total, Urine | $ 139.00 |
| 2428FL | Iodine, Fluid | $ 335.00 |
| 2428SP | Iodine, Serum/Plasma | $ 139.00 |
| 2425B | Ipecac Use Markers Screen, Blood | $ 1,142.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2425FL | Ipecac Use Markers Screen, Fluid | $ 1,191.00 |
| 2425SP | Ipecac Use Markers Screen, Serum/Plasma | $ 967.00 |
| 2425U | Ipecac Use Markers Screen, Urine | $ 1,142.00 |
| 2430UH | Iron, 24 Hour Urine | $ 79.00 |
| 2430B | Iron, Blood | $ 79.00 |
| 2430SP | Iron, Serum/Plasma | $ 79.00 |
| 2430ST | Iron, Stool | $ 284.00 |
| 2430U | Iron, Urine | $ 79.00 |
| 2457SP | Isavuconazole, Serum/Plasma | $ 467.00 |
| 2436SP | Isobutanol, Serum/Plasma | $ 156.00 |
| 2437B | Isoflurane, Blood | $ 201.00 |
| 2440SP | Isoniazid, Serum/Plasma | $ 226.00 |
| 2445B | Isopropanol and Acetone, Blood | $ 77.00 |
| 2445SP | Isopropanol and Acetone, Serum/Plasma | $ 77.00 |
| 2445U | Isopropanol and Acetone, Urine | $ 77.00 |
| 2458SP | Isotretinoin and Metabolite, Serum/Plasma | $ 277.00 |
| 2456SP | Isotretinoin, Serum/Plasma | $ 242.00 |
| 2460B | Itraconazole, Blood | $ 750.00 |
| 2460SP | Itraconazole, Serum/Plasma | $ 480.00 |
| 9188B | Ketamine and Metabolite Screen, Blood | $ 119.00 |
| 9188SP | Ketamine and Metabolite Screen, Serum/Plasma | $ 119.00 |
| 9188U | Ketamine and Metabolite Screen, Urine | $ 119.00 |
| 2479B | Ketamine and Metabolite, Blood | $ 128.00 |
| 2479FL | Ketamine and Metabolite, Fluid | $ 196.00 |
| 2479SP | Ketamine and Metabolite, Serum/Plasma | $ 128.00 |
| 2479TI | Ketamine and Metabolite, Tissue | $ 407.00 |
| 2479U | Ketamine and Metabolite, Urine | $ 123.00 |
| 9190B | Ketoacidosis Screen, Postmortem, Blood (Forensic) | $ 176.00 |
| 9190FL | Ketoacidosis Screen, Postmortem, Fluid (Forensic) | $ 246.00 |
| 2485B | Ketoconazole, Blood | $ 577.00 |
| 2485SP | Ketoconazole, Serum/Plasma | $ 431.00 |
| 2480SP | Ketone Bodies Panel, Serum/Plasma | $ 339.00 |
| 2481B | Ketone Panel, Blood | $ 363.00 |
| 2481FL | Ketone Panel, Fluid | $ 313.00 |
| 2481U | Ketone Panel, Urine | $ 363.00 |
| 2486B | Ketoprofen, Blood | $ 457.00 |
| 2486SP | Ketoprofen, Serum/Plasma | $ 472.00 |
| 2482B | Ketorolac, Blood | $ 423.00 |
| 2482FL | Ketorolac, Fluid | $ 591.00 |
| 2482SP | Ketorolac, Serum/Plasma | $ 423.00 |
| 2488B | Labetalol, Blood | $ 613.00 |
| 2488FL | Labetalol, Fluid | $ 680.00 |
| 2488SP | Labetalol, Serum/Plasma | $ 420.00 |
| 2527B | Lacosamide, Blood | $ 213.00 |
| 2527FL | Lacosamide, Fluid | $ 421.00 |
| 2527SP | Lacosamide, Serum/Plasma | $ 213.00 |
| 2527U | Lacosamide, Urine | $ 213.00 |
| 2484B | Lamotrigine, Blood | $ 93.00 |
| 2484FL | Lamotrigine, Fluid | $ 290.00 |
| 2484SP | Lamotrigine, Serum/Plasma | $ 93.00 |
| 2484U | Lamotrigine, Urine | $ 142.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2499U | Laxatives Panel (Qualitative), Urine | $ 343.00 |
| 81868B | LC-TOF Add-On (Qualitative), Blood | $ 109.00 |
| 81868SP | LC-TOF Add-On (Qualitative), Serum/Plasma | $ 109.00 |
| 81868U | LC-TOF Add-On (Qualitative), Urine | $ 109.00 |
| 2490B | Lead and ZPP, Blood | $ 72.00 |
| 2492UH | Lead, 24 Hour Urine | $ 102.00 |
| 2492B | Lead, Blood | $ 50.00 |
| 2492FL | Lead, Fluid | $ 259.00 |
| 2492H | Lead, Hair | $ 420.00 |
| 2492LI | Lead, Liquid | $ 160.00 |
| 2492N | Lead, Nails | $ 420.00 |
| 2492R | Lead, RBCs | $ 85.00 |
| 2492SP | Lead, Serum/Plasma | $ 102.00 |
| 2492TI | Lead, Tissue | $ 330.00 |
| 2492U | Lead, Urine | $ 102.00 |
| 2532B | Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood | $ 346.00 |
| 2532SP | Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma | $ 346.00 |
| 2531B | Leflunomide as Metabolite (Therapeutic Drug Monitoring), Blood | $ 346.00 |
| 2531SP | Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma | $ 346.00 |
| 2501B | Levamisole, Blood | $ 326.00 |
| 2501SP | Levamisole, Serum/Plasma | $ 326.00 |
| 2501U | Levamisole, Urine | $ 326.00 |
| 2505B | Levetiracetam, Blood | $ 139.00 |
| 2505SP | Levetiracetam, Serum/Plasma | $ 139.00 |
| 2517B | Levocetirizine, Blood | $ 545.00 |
| 2517SP | Levocetirizine, Serum/Plasma | $ 602.00 |
| 2504SP | Levodopa, Serum/Plasma | $ 243.00 |
| 9317B | Lidocaine and Metabolite (MEGX) Screen, Blood | $ 252.00 |
| 9317SP | Lidocaine and Metabolite (MEGX) Screen, Serum/Plasma | $ 243.00 |
| 9317U | Lidocaine and Metabolite (MEGX) Screen, Urine | $ 243.00 |
| 2512B | Lidocaine and Metabolite (MEGX), Blood | $ 199.00 |
| 2512FL | Lidocaine and Metabolite (MEGX), Fluid | $ 409.00 |
| 2512SP | Lidocaine and Metabolite (MEGX), Serum/Plasma | $ 190.00 |
| 2512TI | Lidocaine and Metabolite (MEGX), Tissue | $ 479.00 |
| 2512U | Lidocaine and Metabolite (MEGX), Urine | $ 190.00 |
| 2511SP | Lidocaine, Serum/Plasma | $ 97.00 |
| 2516B | Lindane, Blood | $ 457.00 |
| 2516SP | Lindane, Serum/Plasma | $ 262.00 |
| 2800B | Lisdexamfetamine as Metabolite, Blood | $ 233.00 |
| 2800SP | Lisdexamfetamine as Metabolite, Serum/Plasma | $ 259.00 |
| 2800U | Lisdexamfetamine as Metabolite, Urine | $ 257.00 |
| 2534U | Lithium Exposure , Urine | $ 55.00 |
| 2534B | Lithium Exposure, Blood | $ 55.00 |
| 2534SP | Lithium Exposure, Serum/Plasma | $ 55.00 |
| 2520B | Lithium, Blood | $ 58.00 |
| 2520FL | Lithium, Fluid | $ 267.00 |
| 2520R | Lithium, RBCs | $ 92.00 |
| 2520SP | Lithium, Serum/Plasma | $ 58.00 |
| 2520TI | Lithium, Tissue | $ 339.00 |
| 2520U | Lithium, Urine | $ 58.00 |
| 2533B | Loperamide and Metabolite, Blood | $ 416.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2533SP | Loperamide and Metabolite, Serum/Plasma | $ 416.00 |
| 2525B | Loratadine and Metabolite, Blood | $ 304.00 |
| 2525SP | Loratadine and Metabolite, Serum/Plasma | $ 482.00 |
| 2525U | Loratadine and Metabolite, Urine | $ 482.00 |
| 2535B | Lorazepam, Blood | $ 184.00 |
| 2535FL | Lorazepam, Fluid | $ 358.00 |
| 2535SP | Lorazepam, Serum/Plasma | $ 113.00 |
| 2535U | Lorazepam, Urine | $ 173.00 |
| 2538B | Loxapine, Blood | $ 472.00 |
| 2538SP | Loxapine, Serum/Plasma | $ 302.00 |
| 2538U | Loxapine, Urine | $ 444.00 |
| 2541B | LSD Screen, Blood | $ 96.00 |
| 2541SP | LSD Screen, Serum/Plasma | $ 152.00 |
| 2541U | LSD Screen, Urine | $ 96.00 |
| 2540B | LSD Trace Analysis, Blood | $ 396.00 |
| 2540SP | LSD Trace Analysis, Serum/Plasma | $ 385.00 |
| 2540U | LSD Trace Analysis, Urine | $ 242.00 |
| 2543B | Lurasidone, Blood | $ 210.00 |
| 2543SP | Lurasidone, Serum/Plasma | $ 210.00 |
| 2551B | Magnesium - Total, Blood | $ 62.00 |
| 2551FL | Magnesium - Total, Fluid | $ 271.00 |
| 2551H | Magnesium - Total, Hair | $ 433.00 |
| 2551R | Magnesium - Total, RBCs | $ 62.00 |
| 2551SP | Magnesium - Total, Serum/Plasma | $ 62.00 |
| 2551ST | Magnesium - Total, Stool | $ 433.00 |
| 2551TI | Magnesium - Total, Tissue | $ 274.00 |
| 2551U | Magnesium - Total, Urine | $ 118.00 |
| 2570B | Manganese, Blood | $ 103.00 |
| 2570FL | Manganese, Fluid | $ 310.00 |
| 2570H | Manganese, Hair | $ 472.00 |
| 2570LI | Manganese, Liquid | $ 587.00 |
| 2570N | Manganese, Nails | $ 716.00 |
| 2570R | Manganese, RBCs | $ 103.00 |
| 2570SP | Manganese, Serum/Plasma | $ 103.00 |
| 2570TI | Manganese, Tissue | $ 381.00 |
| 2570U | Manganese, Urine | $ 103.00 |
| 2573B | Maprotiline, Blood | $ 399.00 |
| 2573SP | Maprotiline, Serum/Plasma | $ 386.00 |
| 2573U | Maprotiline, Urine | $ 243.00 |
| 9196SP | Meclizine Screen, Serum/Plasma | $ 199.00 |
| 2590B | Meclizine, Blood | $ 212.00 |
| 2590SP | Meclizine, Serum/Plasma | $ 184.00 |
| 2590TI | Meclizine, Tissue | $ 462.00 |
| 2595B | Mefloquine, Blood | $ 763.00 |
| 2595SP | Mefloquine, Serum/Plasma | $ 531.00 |
| 2604B | Melatonin, Blood | $ 292.00 |
| 2604FL | Melatonin, Fluid | $ 482.00 |
| 2604SP | Melatonin, Serum/Plasma | $ 292.00 |
| 2604TI | Melatonin, Tissue | $ 540.00 |
| 2604U | Melatonin, Urine | $ 292.00 |
| 2581B | Memantine, Blood | $ 379.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2581SP | Memantine, Serum/Plasma | $ 379.00 |
| 2605B | Menthol, Blood | $ 322.00 |
| 2605SP | Menthol, Serum/Plasma | $ 464.00 |
| 9440B | Meperidine and Metabolite Screen, Blood | $ 212.00 |
| 9440SP | Meperidine and Metabolite Screen, Serum/Plasma | $ 135.00 |
| 2610B | Meperidine and Metabolite, Blood | $ 209.00 |
| 8721B | Meperidine and Metabolite, Blood | $ 554.00 |
| 2610SP | Meperidine and Metabolite, Serum/Plasma | $ 209.00 |
| 8721SP | Meperidine and Metabolite, Serum/Plasma | $ 483.00 |
| 2610U | Meperidine and Metabolite, Urine | $ 132.00 |
| 8721U | Meperidine and Metabolite, Urine | $ 534.00 |
| 9444U | Meperidine Screen, Urine | $ 96.00 |
| 9200SP | Mepivacaine Screen, Serum/Plasma | $ 230.00 |
| 2640B | Mepivacaine, Blood | $ 192.00 |
| 2640SP | Mepivacaine, Serum/Plasma | $ 187.00 |
| 2650B | Meprobamate, Blood | $ 281.00 |
| 2650SP | Meprobamate, Serum/Plasma | $ 168.00 |
| 2650U | Meprobamate, Urine | $ 268.00 |
| 2665B | Mercaptopurine and Metabolites, Blood | $ 286.00 |
| 2670UH | Mercury, 24 Hour Urine | $ 77.00 |
| 2670B | Mercury, Blood | $ 55.00 |
| 2670FL | Mercury, Fluid | $ 267.00 |
| 2670H | Mercury, Hair | $ 623.00 |
| 2670LI | Mercury, Liquid | $ 270.00 |
| 2670N | Mercury, Nails | $ 430.00 |
| 2670R | Mercury, RBCs | $ 55.00 |
| 2670SP | Mercury, Serum/Plasma | $ 55.00 |
| 2670TI | Mercury, Tissue | $ 339.00 |
| 2670U | Mercury, Urine | $ 124.00 |
| 2680B | Mescaline Screen, Blood | $ 140.00 |
| 2680SP | Mescaline Screen, Serum/Plasma | $ 219.00 |
| 2680U | Mescaline Screen, Urine | $ 140.00 |
| 2679B | Mescaline, Blood | $ 482.00 |
| 2679SP | Mescaline, Serum/Plasma | $ 480.00 |
| 2679U | Mescaline, Urine | $ 303.00 |
| 2689SP | Mesoridazine, Serum/Plasma | $ 212.00 |
| 2664UH | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), 24 Hour Urine | $ 379.00 |
| 2664U | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), Urine | $ 379.00 |
| 2693B | Metals/Metalloids Acute Poisoning Panel, Blood | $ 465.00 |
| 2693FL | Metals/Metalloids Acute Poisoning Panel, Fluid | $ 680.00 |
| 2693H | Metals/Metalloids Acute Poisoning Panel, Hair | $ 661.00 |
| 2693R | Metals/Metalloids Acute Poisoning Panel, RBCs | $ 465.00 |
| 2693SP | Metals/Metalloids Acute Poisoning Panel, Serum/Plasma | $ 465.00 |
| 2693TI | Metals/Metalloids Acute Poisoning Panel, Tissue | $ 725.00 |
| 2693U | Metals/Metalloids Acute Poisoning Panel, Urine | $ 465.00 |
| 2661B | Metals/Metalloids Panel 1, Blood | $ 271.00 |
| 2661H | Metals/Metalloids Panel 1, Hair | $ 504.00 |
| 2661N | Metals/Metalloids Panel 1, Nails | $ 504.00 |
| 2661SP | Metals/Metalloids Panel 1, Serum/Plasma | $ 301.00 |
| 2661U | Metals/Metalloids Panel 1, Urine | $ 311.00 |
| 2662B | Metals/Metalloids Panel 2, Blood | $ 379.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2662H | Metals/Metalloids Panel 2, Hair | $ 583.00 |
| 2662N | Metals/Metalloids Panel 2, Nails | $ 583.00 |
| 2662SP | Metals/Metalloids Panel 2, Serum/Plasma | $ 379.00 |
| 2662U | Metals/Metalloids Panel 2, Urine | $ 598.00 |
| 2663B | Metals/Metalloids Panel 3, Blood | $ 419.00 |
| 2663H | Metals/Metalloids Panel 3, Hair | $ 631.00 |
| 2663N | Metals/Metalloids Panel 3, Nails | $ 631.00 |
| 2663SP | Metals/Metalloids Panel 3, Serum/Plasma | $ 432.00 |
| 2663U | Metals/Metalloids Panel 3, Urine | $ 668.00 |
| 2720B | Metaxalone, Blood | $ 236.00 |
| 2720SP | Metaxalone, Serum/Plasma | $ 236.00 |
| 2720U | Metaxalone, Urine | $ 236.00 |
| 2740B | Metformin, Blood | $ 180.00 |
| 2740FL | Metformin, Fluid | $ 387.00 |
| 2740SP | Metformin, Serum/Plasma | $ 180.00 |
| 2740U | Metformin, Urine | $ 270.00 |
| 2760ME | Methadone and Metabolite (Qualitative), Meconium | $ 358.00 |
| 8894OF | Methadone and Metabolite (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8722B | Methadone and Metabolite, Blood | $ 268.00 |
| 8722FL | Methadone and Metabolite, Fluid | $ 340.00 |
| 8722SP | Methadone and Metabolite, Serum/Plasma | $ 268.00 |
| 8722TI | Methadone and Metabolite, Tissue | $ 373.00 |
| 8722U | Methadone and Metabolite, Urine | $ 268.00 |
| 9324B | Methadone Screen, Blood | $ 154.00 |
| 9324SP | Methadone Screen, Serum/Plasma | $ 152.00 |
| 9324U | Methadone Screen, Urine | $ 149.00 |
| 9522B | Methamphetamine and Amphetamine Screen, Blood | $ 179.00 |
| 9522SP | Methamphetamine and Amphetamine Screen, Serum/Plasma | $ 179.00 |
| 9522U | Methamphetamine and Amphetamine Screen, Urine | $ 107.00 |
| 2810B | Methamphetamine and Metabolite, Blood | $ 243.00 |
| 2810FL | Methamphetamine and Metabolite, Fluid | $ 402.00 |
| 2810SP | Methamphetamine and Metabolite, Serum/Plasma | $ 160.00 |
| 2810U | Methamphetamine and Metabolite, Urine | $ 197.00 |
| 2745B | Methane, Blood | $ 602.00 |
| 2836U | Methanol Exposure Profile, Urine | $ 189.00 |
| 2837B | Methanol Poisoning Profile, Blood | $ 446.00 |
| 2837SP | Methanol Poisoning Profile, Serum/Plasma | $ 462.00 |
| 2835B | Methanol, Blood | $ 130.00 |
| 2835FL | Methanol, Fluid | $ 199.00 |
| 2835SP | Methanol, Serum/Plasma | $ 81.00 |
| 2835U | Methanol, Urine | $ 81.00 |
| 2849B | Methaqualone, Blood | $ 310.00 |
| 2849SP | Methaqualone, Serum/Plasma | $ 188.00 |
| 2849U | Methaqualone, Urine | $ 188.00 |
| 2860B | Metharbital and Metabolite, Blood | $ 420.00 |
| 2860SP | Metharbital and Metabolite, Serum/Plasma | $ 230.00 |
| 2860U | Metharbital and Metabolite, Urine | $ 420.00 |
| 2863SP | Methazolamide, Serum/Plasma | $ 190.00 |
| 2887B | Methemoglobin, Blood | $ 209.00 |
| 2892B | Methimazole, Blood | $ 463.00 |
| 2892SP | Methimazole, Serum/Plasma | $ 228.00 |

| Test | Test Name | List Price |
|---|---|---|
| 2900B | Methocarbamol, Blood | $ 168.00 |
| 2900FL | Methocarbamol, Fluid | $ 379.00 |
| 2900SP | Methocarbamol, Serum/Plasma | $ 173.00 |
| 0649SP | Methotrexate, Serum/Plasma | $ 212.00 |
| 2930B | Methoxychlor, Blood | $ 152.00 |
| 2950B | Methsuximide as Metabolite, Blood | $ 452.00 |
| 2950SP | Methsuximide as Metabolite, Serum/Plasma | $ 159.00 |
| 4630B | Methyl Chloroform, Blood | $ 209.00 |
| 2990B | Methyl Ethyl Ketone, Blood | $ 149.00 |
| 2990SP | Methyl Ethyl Ketone, Serum/Plasma | $ 95.00 |
| 2990U | Methyl Ethyl Ketone, Urine | $ 69.00 |
| 2982B | Methyl Isobutyl Ketone, Blood | $ 257.00 |
| 2982U | Methyl Isobutyl Ketone, Urine | $ 257.00 |
| 2984U | Methyl n-Butyl Ketone Exposure Monitoring, Urine | $ 166.00 |
| 2980B | Methyl n-Butyl Ketone, Blood | $ 179.00 |
| 2051B | Methyl Tertiary Butyl Ether and Metabolite, Blood | $ 480.00 |
| 2051U | Methyl Tertiary Butyl Ether and Metabolite, Urine | $ 742.00 |
| 2050B | Methyl Tertiary Butyl Ether, Blood | $ 488.00 |
| 3005B | Methylchloroform Exposure, Blood | $ 149.00 |
| 3005SP | Methylchloroform Exposure, Serum/Plasma | $ 149.00 |
| 2986U | Methylenedianiline, Urine | $ 448.00 |
| 2584B | Methylenedioxyamphetamine, Blood | $ 427.00 |
| 2584SP | Methylenedioxyamphetamine, Serum/Plasma | $ 259.00 |
| 2584U | Methylenedioxyamphetamine, Urine | $ 259.00 |
| 9293B | Methylenedioxymethamphetamine and Metabolite Screen, Blood | $ 149.00 |
| 9293SP | Methylenedioxymethamphetamine and Metabolite Screen, Serum/Plasma | $ 228.00 |
| 9293U | Methylenedioxymethamphetamine and Metabolite Screen, Urine | $ 149.00 |
| 2585B | Methylenedioxymethamphetamine and Metabolite, Blood | $ 393.00 |
| 2585SP | Methylenedioxymethamphetamine and Metabolite, Serum/Plasma | $ 393.00 |
| 2585U | Methylenedioxymethamphetamine and Metabolite, Urine | $ 249.00 |
| 9193U | Methylphenidate and Metabolite Screen, Urine | $ 249.00 |
| 3020B | Methylphenidate and Metabolite, Blood | $ 131.00 |
| 3020SP | Methylphenidate and Metabolite, Serum/Plasma | $ 131.00 |
| 3020TI | Methylphenidate and Metabolite, Tissue | $ 235.00 |
| 3020U | Methylphenidate and Metabolite, Urine | $ 131.00 |
| 3041B | Metoclopramide, Blood | $ 601.00 |
| 3041SP | Metoclopramide, Serum/Plasma | $ 601.00 |
| 3041U | Metoclopramide, Urine | $ 601.00 |
| 3042B | Metolazone, Blood | $ 235.00 |
| 3042SP | Metolazone, Serum/Plasma | $ 228.00 |
| 3043B | Metoprolol, Blood | $ 153.00 |
| 3043FL | Metoprolol, Fluid | $ 224.00 |
| 3043SP | Metoprolol, Serum/Plasma | $ 248.00 |
| 3043U | Metoprolol, Urine | $ 248.00 |
| 3048SP | Metribuzin, Serum/Plasma | $ 463.00 |
| 3050B | Metronidazole, Blood | $ 405.00 |
| 3050SP | Metronidazole, Serum/Plasma | $ 386.00 |
| 9211B | Mexiletine Screen, Blood | $ 281.00 |
| 9211SP | Mexiletine Screen, Serum/Plasma | $ 268.00 |
| 3055B | Mexiletine, Blood | $ 640.00 |
| 3055SP | Mexiletine, Serum/Plasma | $ 107.00 |

| Test | Test Name | List Price |
|---|---|---|
| MICRO | Micro Specimen Surcharge | $ 95.00 |
| 3057U | Midazolam as Metabolite, Urine | $ 128.00 |
| 3057B | Midazolam, Blood | $ 128.00 |
| 3057FL | Midazolam, Fluid | $ 196.00 |
| 3057SP | Midazolam, Serum/Plasma | $ 201.00 |
| 3061B | Milnacipran/Levomilnacipran, Blood | $ 213.00 |
| 3061SP | Milnacipran/Levomilnacipran, Serum/Plasma | $ 213.00 |
| 3061U | Milnacipran/Levomilnacipran, Urine | $ 213.00 |
| 3066B | Mineral Profile, Blood | $ 610.00 |
| 3066R | Mineral Profile, RBCs | $ 394.00 |
| 3066SP | Mineral Profile, Serum/Plasma | $ 394.00 |
| 3075B | Mirtazapine, Blood | $ 132.00 |
| 3075SP | Mirtazapine, Serum/Plasma | $ 132.00 |
| 3075U | Mirtazapine, Urine | $ 209.00 |
| 3059B | Mitotane, Blood | $ 514.00 |
| 3059SP | Mitotane, Serum/Plasma | $ 153.00 |
| 3078U | Mitragynine (Qualitative), Urine | $ 187.00 |
| 3064B | Mitragynine, Blood | $ 196.00 |
| 3064SP | Mitragynine, Serum/Plasma | $ 196.00 |
| 3081U | MOCA and MDA Exposure Profile, Urine | $ 332.00 |
| 3080U | MOCA, Urine | $ 431.00 |
| 3045B | Modafinil / Armodafinil, Blood | $ 248.00 |
| 3045SP | Modafinil / Armodafinil, Serum/Plasma | $ 153.00 |
| 3082B | Molindone, Blood | $ 413.00 |
| 3082SP | Molindone, Serum/Plasma | $ 139.00 |
| 3082U | Molindone, Urine | $ 139.00 |
| 3090B | Molybdenum, Blood | $ 79.00 |
| 3090H | Molybdenum, Hair | $ 448.00 |
| 3090R | Molybdenum, RBCs | $ 79.00 |
| 3090SP | Molybdenum, Serum/Plasma | $ 79.00 |
| 3090U | Molybdenum, Urine | $ 92.00 |
| 3098U | Mono-n-butyl phthalate (MNBP), Urine | $ 296.00 |
| 3092SP | Moricizine, Serum/Plasma | $ 197.00 |
| 8666B | Morphine - Free (Unconjugated), Blood | $ 373.00 |
| 8666FL | Morphine - Free (Unconjugated), Fluid | $ 324.00 |
| 8666SP | Morphine - Free (Unconjugated), Serum/Plasma | $ 261.00 |
| 8666U | Morphine - Free (Unconjugated), Urine | $ 414.00 |
| 8673B | Morphine - Free and Total, Blood | $ 516.00 |
| 8673SP | Morphine - Free and Total, Serum/Plasma | $ 568.00 |
| 8673U | Morphine - Free and Total, Urine | $ 568.00 |
| 8672B | Morphine - Total (Conjugated/Unconjugated), Blood | $ 230.00 |
| 8672SP | Morphine - Total (Conjugated/Unconjugated), Serum/Plasma | $ 230.00 |
| 8672U | Morphine - Total (Conjugated/Unconjugated), Urine | $ 230.00 |
| 3085B | Morphine and Glucuronide Metabolites, Blood | $ 358.00 |
| 3085SP | Morphine and Glucuronide Metabolites, Serum/Plasma | $ 358.00 |
| 3063B | Mycophenolic Acid and Metabolite, Blood | $ 545.00 |
| 3063SP | Mycophenolic Acid and Metabolite, Serum/Plasma | $ 393.00 |
| 3063U | Mycophenolic Acid and Metabolite, Urine | $ 545.00 |
| 3060U | N,N-Dimethylacetamide Exposure (N-Methylacetamide), Urine | $ 742.00 |
| 3070U | N,N-Dimethylformamide (DMF) Exposure (N-Monomethylformamide), Urine | $ 285.00 |
| 3218B | N,N-Dimethylpentylone & Pentylone, Blood | $ 338.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3218SP | N,N-Dimethylpentylone & Pentylone, Serum/Plasma | $ 338.00 |
| 3218U | N,N-Dimethylpentylone & Pentylone, Urine | $ 338.00 |
| 3107B | Nabumetone as Metabolite, Blood | $ 212.00 |
| 3107SP | Nabumetone as Metabolite, Serum/Plasma | $ 201.00 |
| 3107U | Nabumetone as Metabolite, Urine | $ 212.00 |
| 3103B | Nadolol, Blood | $ 248.00 |
| 3103SP | Nadolol, Serum/Plasma | $ 248.00 |
| 3103U | Nadolol, Urine | $ 254.00 |
| 3110B | Nalbuphine - Free (Unconjugated), Blood | $ 346.00 |
| 3110SP | Nalbuphine - Free (Unconjugated), Serum/Plasma | $ 534.00 |
| 3110U | Nalbuphine - Total (Conjugated/Unconjugated), Urine | $ 550.00 |
| 3111B | Naloxone - Free (Unconjugated), Blood | $ 97.00 |
| 3111SP | Naloxone - Free (Unconjugated), Serum/Plasma | $ 97.00 |
| 3113U | Naloxone - Total (Conjugated/Unconjugated) Screen, Urine | $ 358.00 |
| 3111U | Naloxone - Total (Conjugated/Unconjugated), Urine | $ 97.00 |
| 3116B | Naltrexone and Metabolite - Free (Unconjugated), Blood | $ 486.00 |
| 3116SP | Naltrexone and Metabolite - Free (Unconjugated), Serum/Plasma | $ 468.00 |
| 3116U | Naltrexone and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 470.00 |
| 3130B | Naproxen, Blood | $ 119.00 |
| 3130FL | Naproxen, Fluid | $ 330.00 |
| 3130SP | Naproxen, Serum/Plasma | $ 190.00 |
| 3130U | Naproxen, Urine | $ 190.00 |
| 3118B | Nateglinide, Blood | $ 137.00 |
| 3118SP | Nateglinide, Serum/Plasma | $ 137.00 |
| 3145B | Nefazodone, Blood | $ 176.00 |
| 3145SP | Nefazodone, Serum/Plasma | $ 160.00 |
| 3145U | Nefazodone, Urine | $ 107.00 |
| 2292U | n-Hexane Exposure Monitoring, Urine | $ 312.00 |
| 3140B | Nickel, Blood | $ 79.00 |
| 3140FL | Nickel, Fluid | $ 284.00 |
| 3140H | Nickel, Hair | $ 448.00 |
| 3140N | Nickel, Nails | $ 448.00 |
| 3140R | Nickel, RBCs | $ 129.00 |
| 3140SP | Nickel, Serum/Plasma | $ 79.00 |
| 3140TI | Nickel, Tissue | $ 355.00 |
| 3140U | Nickel, Urine | $ 110.00 |
| 9404B | Nicotine and Metabolite Screen, Blood | $ 154.00 |
| 9404SP | Nicotine and Metabolite Screen, Serum/Plasma | $ 107.00 |
| 9404U | Nicotine and Metabolite with Anabasine Screen, Urine | $ 115.00 |
| 3150U | Nicotine and Metabolite with Anabasine, Urine | $ 132.00 |
| 3150B | Nicotine and Metabolite, Blood | $ 113.00 |
| 3150FL | Nicotine and Metabolite, Fluid | $ 324.00 |
| 3150SP | Nicotine and Metabolite, Serum/Plasma | $ 113.00 |
| 3150TI | Nicotine and Metabolite, Tissue | $ 394.00 |
| 3158B | Nifedipine, Blood | $ 345.00 |
| 3158SP | Nifedipine, Serum/Plasma | $ 385.00 |
| 3168B | Nitazenes Panel, Blood | $ 378.00 |
| 3168SP | Nitazenes Panel, Serum/Plasma | $ 378.00 |
| 3174B | Nitrate/Nitrite (Qualitative), Blood (Forensic) | $ 355.00 |
| 3174SP | Nitrate/Nitrite (Qualitative), Serum/Plasma | $ 355.00 |
| 9215B | Nitrazepam and Metabolite Screen, Blood | $ 271.00 |

| Test | Test Name | List Price |
|---|---|---|
| 9215SP | Nitrazepam and Metabolite Screen, Serum/Plasma | $ 189.00 |
| 3175B | Nitrazepam and Metabolite, Blood | $ 465.00 |
| 3175SP | Nitrazepam and Metabolite, Serum/Plasma | $ 448.00 |
| 3175U | Nitrazepam and Metabolite, Urine | $ 284.00 |
| 3214A | Nitrous Oxide, Air | $ 561.00 |
| 3214B | Nitrous Oxide, Blood | $ 527.00 |
| 3214FL | Nitrous Oxide, Fluid | $ 588.00 |
| 3214TI | Nitrous Oxide, Tissue | $ 631.00 |
| 3214U | Nitrous Oxide, Urine | $ 561.00 |
| 8054B | NMS TotalTox™ Panel, Blood (Forensic) | $ 595.00 |
| NONBIO/LIQ | Non-biological Fee (Liquid) | $ 146.00 |
| NONBIO/SOL | Non-biological Fee (Solid) | $ 214.00 |
| 3223SP | Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma | $ 457.00 |
| 3219B | Norchlorcyclizine, Blood | $ 258.00 |
| 3219FL | Norchlorcyclizine, Fluid | $ 258.00 |
| 3219SP | Norchlorcyclizine, Serum/Plasma | $ 258.00 |
| 3219TI | Norchlorcyclizine, Tissue | $ 285.00 |
| 3219U | Norchlorcyclizine, Urine | $ 258.00 |
| 3216B | Nordiazepam and Metabolite, Blood | $ 315.00 |
| 3216SP | Nordiazepam and Metabolite, Serum/Plasma | $ 315.00 |
| 3216U | Nordiazepam and Metabolite, Urine | $ 302.00 |
| 9433B | Nortriptyline Screen, Blood | $ 128.00 |
| 9433U | Nortriptyline Screen, Urine | $ 92.00 |
| 3220B | Nortriptyline, Blood | $ 137.00 |
| 8702B | Nortriptyline, Blood | $ 534.00 |
| 3220FL | Nortriptyline, Fluid | $ 333.00 |
| 3220SP | Nortriptyline, Serum/Plasma | $ 137.00 |
| 3220TI | Nortriptyline, Tissue | $ 418.00 |
| 3220U | Nortriptyline, Urine | $ 90.00 |
| 8702U | Nortriptyline, Urine | $ 534.00 |
| 8756B | Novel Psychoactive Substances (NPS) Screen 1, Blood | $ 389.00 |
| 8756SP | Novel Psychoactive Substances (NPS) Screen 1, Serum/Plasma | $ 389.00 |
| 8756U | Novel Psychoactive Substances (NPS) Screen 1, Urine | $ 389.00 |
| 3224B | NPS Stimulants (Qualitative), Blood | $ 286.00 |
| 3224SP | NPS Stimulants (Qualitative), Serum/Plasma | $ 179.00 |
| 3224U | NPS Stimulants (Qualitative), Urine | $ 179.00 |
| 3225SP | Nuedexta®, Serum/Plasma | $ 401.00 |
| 1352U | o-Cresol, Urine | $ 187.00 |
| 3226B | Olanzapine and Metabolite, Blood | $ 366.00 |
| 3226SP | Olanzapine and Metabolite, Serum/Plasma | $ 191.00 |
| 3226FL | Olanzapine, Fluid | $ 550.00 |
| 3226TI | Olanzapine, Tissue | $ 617.00 |
| 3232B | Omeprazole / Esomeprazole, Blood | $ 640.00 |
| 3232SP | Omeprazole / Esomeprazole, Serum/Plasma | $ 730.00 |
| 3241B | Opiates - Free (Unconjugated), Blood | $ 490.00 |
| 8660B | Opiates - Free (Unconjugated), Blood | $ 320.00 |
| 8660FL | Opiates - Free (Unconjugated), Fluid | $ 390.00 |
| 8660SP | Opiates - Free (Unconjugated), Serum/Plasma | $ 320.00 |
| 8660TI | Opiates - Free (Unconjugated), Tissue | $ 426.00 |
| 8660U | Opiates - Free (Unconjugated), Urine | $ 259.00 |
| 8671B | Opiates - Free and Total, Blood | $ 541.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8671SP | Opiates - Free and Total, Serum/Plasma | $ 541.00 |
| 8671U | Opiates - Free and Total, Urine | $ 541.00 |
| 8670ME | Opiates - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 373.00 |
| 8670B | Opiates - Total (Conjugated/Unconjugated), Blood | $ 315.00 |
| 8670FL | Opiates - Total (Conjugated/Unconjugated), Fluid | $ 350.00 |
| 8670SP | Opiates - Total (Conjugated/Unconjugated), Serum/Plasma | $ 315.00 |
| 8670TI | Opiates - Total (Conjugated/Unconjugated), Tissue | $ 488.00 |
| 8670U | Opiates - Total (Conjugated/Unconjugated), Urine | $ 315.00 |
| 8895OF | Opiates (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 3236B | Opiates Screen, Blood | $ 96.00 |
| 3236FL | Opiates Screen, Fluid | $ 309.00 |
| 6923H | Opiates Screen, Hair | $ 493.00 |
| 3236SP | Opiates Screen, Serum/Plasma | $ 152.00 |
| 3236TI | Opiates Screen, Tissue | $ 383.00 |
| 3236U | Opiates Screen, Urine | $ 100.00 |
| 3243B | Organochlorine Pesticides, Blood | $ 208.00 |
| 3243F | Organochlorine Pesticides, Fat | $ 699.00 |
| 3243SP | Organochlorine Pesticides, Serum/Plasma | $ 208.00 |
| 3243TI | Organochlorine Pesticides, Tissue | $ 587.00 |
| 9219B | Orphenadrine Screen, Blood | $ 246.00 |
| 3248B | Orphenadrine, Blood | $ 213.00 |
| 3248SP | Orphenadrine, Serum/Plasma | $ 220.00 |
| 3248U | Orphenadrine, Urine | $ 212.00 |
| 1355U | o-Toluidine, Urine | $ 331.00 |
| 3250SP | Oxalate, Serum/Plasma | $ 188.00 |
| 3286B | Oxaprozin, Blood | $ 506.00 |
| 3286SP | Oxaprozin, Serum/Plasma | $ 554.00 |
| 3260B | Oxazepam, Blood | $ 310.00 |
| 3260SP | Oxazepam, Serum/Plasma | $ 296.00 |
| 3260U | Oxazepam, Urine | $ 268.00 |
| 3265B | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Blood | $ 96.00 |
| 3265FL | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Fluid | $ 293.00 |
| 3265SP | Oxcarbazepine / Eslicarbazepine Acetate as Metabolite, Serum/Plasma | $ 96.00 |
| 3266B | Oxybutynin and Metabolite, Blood | $ 500.00 |
| 3266SP | Oxybutynin and Metabolite, Serum/Plasma | $ 534.00 |
| 3266U | Oxybutynin and Metabolite, Urine | $ 534.00 |
| 3270B | Oxycodone - Free (Unconjugated), Blood | $ 132.00 |
| 3270FL | Oxycodone - Free (Unconjugated), Fluid | $ 203.00 |
| 3270SP | Oxycodone - Free (Unconjugated), Serum/Plasma | $ 132.00 |
| 8667B | Oxycodone and Metabolite - Free (Unconjugated), Blood | $ 162.00 |
| 8667FL | Oxycodone and Metabolite - Free (Unconjugated), Fluid | $ 199.00 |
| 8667SP | Oxycodone and Metabolite - Free (Unconjugated), Serum/Plasma | $ 162.00 |
| 8667TI | Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Tissue | $ 302.00 |
| 8667U | Oxycodone and Metabolite - Total (Conjugated/Unconjugated), Urine | $ 162.00 |
| 9132B | Oxycodone Screen, Blood | $ 209.00 |
| 9132SP | Oxycodone Screen, Serum/Plasma | $ 209.00 |
| 8668B | Oxymorphone - Free (Unconjugated), Blood | $ 386.00 |
| 8668SP | Oxymorphone - Free (Unconjugated), Serum/Plasma | $ 385.00 |
| 8668U | Oxymorphone - Total (Conjugated/Unconjugated), Urine | $ 242.00 |
| 4113B | Paliperidone, Blood | $ 268.00 |
| 4113SP | Paliperidone, Serum/Plasma | $ 168.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4113TI | Paliperidone, Tissue | $ 420.00 |
| 4113U | Paliperidone, Urine | $ 281.00 |
| 3292B | Palladium, Blood | $ 225.00 |
| 3292SP | Palladium, Serum/Plasma | $ 187.00 |
| 3292U | Palladium, Urine | $ 187.00 |
| 9222B | Papaverine Screen, Blood | $ 179.00 |
| 3300B | Papaverine, Blood | $ 334.00 |
| 3300SP | Papaverine, Serum/Plasma | $ 302.00 |
| 3310B | Paraldehyde and Metabolite, Blood | $ 188.00 |
| 3310SP | Paraldehyde and Metabolite, Serum/Plasma | $ 123.00 |
| 3310U | Paraldehyde and Metabolite, Urine | $ 196.00 |
| 3320SP | Paramethadione, Serum/Plasma | $ 231.00 |
| 3325B | Paraquat, Blood | $ 2,052.00 |
| 3325SP | Paraquat, Serum/Plasma | $ 2,052.00 |
| 3360B | Paroxetine, Blood | $ 116.00 |
| 3360FL | Paroxetine, Fluid | $ 329.00 |
| 3360SP | Paroxetine, Serum/Plasma | $ 116.00 |
| 3360TI | Paroxetine, Tissue | $ 399.00 |
| 3360U | Paroxetine, Urine | $ 189.00 |
| 3371SP | PCB Panel, Congeners, Serum/Plasma | $ 156.00 |
| 3381SP | Penciclovir, Serum/Plasma | $ 398.00 |
| 3385B | Pentachlorophenol, Blood | $ 292.00 |
| 3385SP | Pentachlorophenol, Serum/Plasma | $ 292.00 |
| 3384U | Pentachlorophenol, Urine | $ 278.00 |
| 9441B | Pentazocine Screen, Blood | $ 135.00 |
| 9441SP | Pentazocine Screen, Serum/Plasma | $ 213.00 |
| 9441U | Pentazocine Screen, Urine | $ 220.00 |
| 3400B | Pentazocine, Blood | $ 135.00 |
| 8723B | Pentazocine, Blood | $ 341.00 |
| 3400FL | Pentazocine, Fluid | $ 347.00 |
| 3400SP | Pentazocine, Serum/Plasma | $ 209.00 |
| 3400TI | Pentazocine, Tissue | $ 389.00 |
| 3400U | Pentazocine, Urine | $ 132.00 |
| 3410B | Pentobarbital, Blood | $ 149.00 |
| 3410SP | Pentobarbital, Serum/Plasma | $ 149.00 |
| 3410U | Pentobarbital, Urine | $ 93.00 |
| 3433FL | Perampanel, Fluid | $ 514.00 |
| 3433SP | Perampanel, Serum/Plasma | $ 253.00 |
| 3432U | Perchloroethylene Exposure, Urine | $ 181.00 |
| 3436B | Percodan®, Blood | $ 199.00 |
| 3436SP | Percodan®, Serum/Plasma | $ 199.00 |
| 3427SP | Perfluoroalkyl Substances (PFAS), Serum/Plasma | $ 468.00 |
| 3426B | Perfluorooctanoic Acid, Blood | $ 662.00 |
| 3440B | Perphenazine, Blood | $ 189.00 |
| 3440SP | Perphenazine, Serum/Plasma | $ 116.00 |
| 3434SP | PFASure FT, Serum/Plasma | $ 510.00 |
| 3429SP | PFASure TM Expanded, Serum/Plasma | $ 551.00 |
| 3428SP | PFASure TM, Serum/Plasma | $ 510.00 |
| 3510B | Phenacetin and Metabolite, Blood | $ 142.00 |
| 3510U | Phenacetin and Metabolite, Urine | $ 285.00 |
| 3525B | Phenazopyridine, Blood | $ 212.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3525SP | Phenazopyridine, Serum/Plasma | $ 237.00 |
| 3525U | Phenazopyridine, Urine | $ 237.00 |
| 8761ME | Phencyclidine (Qualitative), Meconium | $ 439.00 |
| 8896OF | Phencyclidine and Dextromethorphan (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 3532B | Phencyclidine Screen, Blood | $ 167.00 |
| 3532FL | Phencyclidine Screen, Fluid | $ 374.00 |
| 6925H | Phencyclidine Screen, Hair | $ 501.00 |
| 3532SP | Phencyclidine Screen, Serum/Plasma | $ 188.00 |
| 3532U | Phencyclidine Screen, Urine | $ 100.00 |
| 8761B | Phencyclidine, Blood | $ 362.00 |
| 8761FL | Phencyclidine, Fluid | $ 314.00 |
| 8761SP | Phencyclidine, Serum/Plasma | $ 452.00 |
| 8761TI | Phencyclidine, Tissue | $ 353.00 |
| 8761U | Phencyclidine, Urine | $ 362.00 |
| 3550B | Phenelzine, Blood | $ 941.00 |
| 3550SP | Phenelzine, Serum/Plasma | $ 941.00 |
| 3550U | Phenelzine, Urine | $ 941.00 |
| 3560B | Pheniramine, Blood | $ 252.00 |
| 3582SP | Phenobarbital - Total/Unbound/Bound, Serum/Plasma | $ 201.00 |
| 3581SP | Phenobarbital - Unbound, Serum/Plasma | $ 128.00 |
| 9416B | Phenobarbital Screen, Blood | $ 220.00 |
| 3580B | Phenobarbital, Blood | $ 142.00 |
| 8633B | Phenobarbital, Blood | $ 564.00 |
| 3580SP | Phenobarbital, Serum/Plasma | $ 149.00 |
| 8633SP | Phenobarbital, Serum/Plasma | $ 488.00 |
| 8633U | Phenobarbital, Urine | $ 341.00 |
| 3621B | Phenol - Free and Total, Blood | $ 173.00 |
| 3621SP | Phenol - Free and Total, Serum/Plasma | $ 173.00 |
| 3621U | Phenol Exposure, Urine | $ 135.00 |
| 3623B | Phenol, Free, Blood | $ 138.00 |
| 3623SP | Phenol, Free, Serum/Plasma | $ 138.00 |
| 3624B | Phenol, Total, Blood | $ 138.00 |
| 9233B | Phensuximide Screen, Blood | $ 152.00 |
| 9233U | Phensuximide Screen, Urine | $ 152.00 |
| 3680B | Phensuximide, Blood | $ 310.00 |
| 3680SP | Phensuximide, Serum/Plasma | $ 230.00 |
| 3680U | Phensuximide, Urine | $ 420.00 |
| 3690B | Phentermine, Blood | $ 230.00 |
| 3690SP | Phentermine, Serum/Plasma | $ 147.00 |
| 3690U | Phentermine, Urine | $ 233.00 |
| 3704SP | Phenylephrine, Serum/Plasma | $ 432.00 |
| 3707B | Phenylethylmalonamide, Blood | $ 610.00 |
| 3707SP | Phenylethylmalonamide, Serum/Plasma | $ 201.00 |
| 9237U | Phenylpropanolamine Screen, Urine | $ 196.00 |
| 3720B | Phenylpropanolamine, Blood | $ 176.00 |
| 3720SP | Phenylpropanolamine, Serum/Plasma | $ 168.00 |
| 3720U | Phenylpropanolamine, Urine | $ 168.00 |
| 3740B | Phenyltoloxamine, Blood | $ 206.00 |
| 3740SP | Phenyltoloxamine, Serum/Plasma | $ 124.00 |
| 3743B | Phenytoin, Blood | $ 123.00 |
| 3743FL | Phenytoin, Fluid | $ 332.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3743SP | Phenytoin, Serum/Plasma | $ 110.00 |
| 3743TI | Phenytoin, Tissue | $ 402.00 |
| 3752B | Phosphatidylethanol, Blood | $ 137.00 |
| 3765B | Phosphorus - Total, Blood | $ 276.00 |
| 3765FL | Phosphorus - Total, Fluid | $ 488.00 |
| 3765SP | Phosphorus - Total, Serum/Plasma | $ 276.00 |
| 3765ST | Phosphorus - Total, Stool | $ 232.00 |
| 3765U | Phosphorus - Total, Urine | $ 276.00 |
| 3099U | Phthalates Panel, Urine | $ 396.00 |
| 3776B | Pimozide, Blood | $ 483.00 |
| 3776SP | Pimozide, Serum/Plasma | $ 483.00 |
| 3779B | Pioglitazone, Blood | $ 137.00 |
| 3779SP | Pioglitazone, Serum/Plasma | $ 137.00 |
| 3781B | Piroxicam, Blood | $ 537.00 |
| 3781SP | Piroxicam, Serum/Plasma | $ 554.00 |
| 3781U | Piroxicam, Urine | $ 346.00 |
| 3783B | Platinum, Blood | $ 191.00 |
| 3783FL | Platinum, Fluid | $ 394.00 |
| 3783SP | Platinum, Serum/Plasma | $ 191.00 |
| 3783U | Platinum, Urine | $ 315.00 |
| 3790B | Posaconazole, Blood | $ 707.00 |
| 3790SP | Posaconazole, Serum/Plasma | $ 456.00 |
| 8064B | Postmortem BHB and Alcohol Profile, Blood (Forensic) | $ 246.00 |
| 8155U | Postmortem Designer Opioids Add-On (Qualitative), Urine (Forensic) | $ 201.00 |
| 8155B | Postmortem Designer Opioids Add-On, Blood (Forensic) | $ 211.00 |
| 8155SP | Postmortem Designer Opioids Add-On, Serum/Plasma (Forensic) | $ 201.00 |
| 8063B | Postmortem, Basic to Expanded Upgrade, Blood (Forensic) | $ 182.00 |
| 8063FL | Postmortem, Basic to Expanded Upgrade, Fluid (Forensic) | $ 417.00 |
| 8063SP | Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic) | $ 182.00 |
| 8063TI | Postmortem, Basic to Expanded Upgrade, Tissue (Forensic) | $ 494.00 |
| 8063U | Postmortem, Basic to Expanded Upgrade, Urine (Forensic) | $ 182.00 |
| 8136B | Postmortem, Basic w/6-MAM Confirmation, Blood (Forensic) | $ 337.00 |
| 8061B | Postmortem, Basic w/o Alcohol, Blood (Forensic) | $ 239.00 |
| 8061TI | Postmortem, Basic w/o Alcohol, Tissue (Forensic) | $ 505.00 |
| 8061U | Postmortem, Basic w/o Alcohol, Urine (Forensic) | $ 239.00 |
| 8083B | Postmortem, Basic w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 375.00 |
| 8041B | Postmortem, Basic w/Vitreous Alcohol Confirmation, Blood (Forensic) | $ 337.00 |
| 8051B | Postmortem, Basic, Blood (Forensic) | $ 290.00 |
| 8051FL | Postmortem, Basic, Fluid (Forensic) | $ 443.00 |
| 8051SP | Postmortem, Basic, Serum/Plasma (Forensic) | $ 290.00 |
| 8051TI | Postmortem, Basic, Tissue (Forensic) | $ 520.00 |
| 8051U | Postmortem, Basic, Urine (Forensic) | $ 290.00 |
| 8135B | Postmortem, Expanded w/6-MAM Confirmation, Blood (Forensic) | $ 469.00 |
| 8062B | Postmortem, Expanded w/o Alcohol, Blood (Forensic) | $ 379.00 |
| 8062FL | Postmortem, Expanded w/o Alcohol, Fluid (Forensic) | $ 648.00 |
| 8062TI | Postmortem, Expanded w/o Alcohol, Tissue (Forensic) | $ 714.00 |
| 8062U | Postmortem, Expanded w/o Alcohol, Urine (Forensic) | $ 379.00 |
| 8084B | Postmortem, Expanded w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 508.00 |
| 8042B | Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) | $ 469.00 |
| 8052B | Postmortem, Expanded, Blood (Forensic) | $ 430.00 |
| 8052FL | Postmortem, Expanded, Fluid (Forensic) | $ 705.00 |

| Test | Test Name | List Price |
|---|---|---|
| 8052SP | Postmortem, Expanded, Serum/Plasma (Forensic) | $ 430.00 |
| 8052TI | Postmortem, Expanded, Tissue (Forensic) | $ 780.00 |
| 8052U | Postmortem, Expanded, Urine (Forensic) | $ 430.00 |
| 8104B | Postmortem, Fire Death Screen, Blood (Forensic) | $ 514.00 |
| 8092B | Postmortem, Prescription Drugs Screen, Blood (Forensic) | $ 742.00 |
| 8092FL | Postmortem, Prescription Drugs Screen, Fluid (Forensic) | $ 941.00 |
| 8092SP | Postmortem, Prescription Drugs Screen, Serum/Plasma (Forensic) | $ 742.00 |
| 8092TI | Postmortem, Prescription Drugs Screen, Tissue (Forensic) | $ 1,007.00 |
| 8092U | Postmortem, Prescription Drugs Screen, Urine (Forensic) | $ 742.00 |
| 8043B | Postmortem, Prescription Screen w/Vitreous Alcohol, Blood (Forensic) | $ 760.00 |
| 8133B | Postmortem, TotalTox™ w/6-MAM Confirmation, Blood (Forensic) | $ 627.00 |
| 8130B | Postmortem, TotalTox™ w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic) | $ 666.00 |
| 8044B | Postmortem, TotalTox™ w/Vitreous Alcohol, Blood (Forensic) | $ 627.00 |
| 8050U | Postmortem, Urine Screen Add-On (6-MAM Quantification only) (Forensic) | $ 43.00 |
| 3784B | Potassium - Total, Blood (Forensic) | $ 92.00 |
| 3784FL | Potassium - Total, Fluid | $ 213.00 |
| 3784R | Potassium - Total, RBCs | $ 92.00 |
| 3788B | Prazosin, Blood | $ 778.00 |
| 3788SP | Prazosin, Serum/Plasma | $ 483.00 |
| 3795B | Pregabalin, Blood | $ 345.00 |
| 3795SP | Pregabalin, Serum/Plasma | $ 168.00 |
| 3795U | Pregabalin, Urine | $ 460.00 |
| 3900B | Primidone, Phenobarbital and PEMA, Blood | $ 159.00 |
| 3900FL | Primidone, Phenobarbital and PEMA, Fluid | $ 369.00 |
| 3900SP | Primidone, Phenobarbital and PEMA, Serum/Plasma | $ 159.00 |
| 3901SP | Primidone, Serum/Plasma | $ 58.00 |
| 3950B | Prochlorperazine, Blood | $ 137.00 |
| 3950SP | Prochlorperazine, Serum/Plasma | $ 95.00 |
| 3957B | Procyclidine, Blood | $ 179.00 |
| 3957SP | Procyclidine, Serum/Plasma | $ 279.00 |
| 3957U | Procyclidine, Urine | $ 179.00 |
| 3970B | Promethazine, Blood | $ 168.00 |
| 3970SP | Promethazine, Serum/Plasma | $ 168.00 |
| 3970TI | Promethazine, Tissue | $ 446.00 |
| 3970U | Promethazine, Urine | $ 168.00 |
| 3976B | Propafenone, Blood | $ 218.00 |
| 3976SP | Propafenone, Serum/Plasma | $ 132.00 |
| 3974B | Propane, Blood | $ 374.00 |
| 9327B | Propane, Blood | $ 894.00 |
| 3974TI | Propane, Tissue | $ 383.00 |
| 3975B | Propanol, n-, Blood | $ 178.00 |
| 3975SP | Propanol, n-, Serum/Plasma | $ 173.00 |
| 3975U | Propanol, n-, Urine | $ 153.00 |
| 4018U | Propofol Glucuronide, Urine | $ 240.00 |
| 9253B | Propofol Screen, Blood | $ 204.00 |
| 9253SP | Propofol Screen, Serum/Plasma | $ 204.00 |
| 4015B | Propofol, Blood | $ 250.00 |
| 4015SP | Propofol, Serum/Plasma | $ 250.00 |
| 3990B | Propoxyphene and Metabolite, Blood | $ 194.00 |
| 3990FL | Propoxyphene and Metabolite, Fluid | $ 265.00 |
| 3990SP | Propoxyphene and Metabolite, Serum/Plasma | $ 310.00 |

| Test | Test Name | List Price |
|---|---|---|
| 3990U | Propoxyphene and Metabolite, Urine | $ 194.00 |
| 9247B | Propranolol Screen, Blood | $ 96.00 |
| 9247SP | Propranolol Screen, Serum/Plasma | $ 129.00 |
| 4000B | Propranolol, Blood | $ 105.00 |
| 4000FL | Propranolol, Fluid | $ 314.00 |
| 4000SP | Propranolol, Serum/Plasma | $ 152.00 |
| 4000TI | Propranolol, Tissue | $ 383.00 |
| 4000U | Propranolol, Urine | $ 152.00 |
| 4003B | Propylene Glycol, Blood | $ 292.00 |
| 4003SP | Propylene Glycol, Serum/Plasma | $ 194.00 |
| 4003U | Propylene Glycol, Urine | $ 312.00 |
| 9436B | Protriptyline Screen, Blood | $ 190.00 |
| 9436SP | Protriptyline Screen, Serum/Plasma | $ 123.00 |
| 4010B | Protriptyline, Blood | $ 190.00 |
| 8706B | Protriptyline, Blood | $ 488.00 |
| 4010SP | Protriptyline, Serum/Plasma | $ 132.00 |
| 8706SP | Protriptyline, Serum/Plasma | $ 341.00 |
| 9248B | Pseudoephedrine Screen, Blood | $ 184.00 |
| 9248SP | Pseudoephedrine Screen, Serum/Plasma | $ 178.00 |
| 9248U | Pseudoephedrine Screen, Urine | $ 178.00 |
| 9249B | Pseudoephedrine vs Ephedrine Differentiation Screen, Blood | $ 315.00 |
| 9249U | Pseudoephedrine vs Ephedrine Differentiation Screen, Urine | $ 191.00 |
| 4020B | Pseudoephedrine, Blood | $ 154.00 |
| 4020SP | Pseudoephedrine, Serum/Plasma | $ 107.00 |
| 4020U | Pseudoephedrine, Urine | $ 107.00 |
| 4029B | Psilocybin as Psilocin (Qualitative), Blood | $ 467.00 |
| 4029SP | Psilocybin as Psilocin (Qualitative), Serum/Plasma | $ 467.00 |
| 4029U | Psilocybin as Psilocin (Qualitative), Urine | $ 467.00 |
| 4033SP | Pyrazinamide, Serum/Plasma | $ 573.00 |
| 4030B | Pyridine, Blood | $ 418.00 |
| 4030SP | Pyridine, Serum/Plasma | $ 642.00 |
| 4030U | Pyridine, Urine | $ 580.00 |
| 4038B | Pyridostigmine, Blood | $ 868.00 |
| 4038SP | Pyridostigmine, Serum/Plasma | $ 521.00 |
| 4038U | Pyridostigmine, Urine | $ 521.00 |
| 4045B | Pyrimethamine, Blood | $ 502.00 |
| 4045SP | Pyrimethamine, Serum/Plasma | $ 502.00 |
| 4047B | Pyrrolidinophenone Panel, Blood | $ 348.00 |
| 4047SP | Pyrrolidinophenone Panel, Serum/Plasma | $ 348.00 |
| 8088B | Qsymia®, Blood | $ 246.00 |
| 8088SP | Qsymia®, Serum/Plasma | $ 246.00 |
| 81869B | QTOF (MS/MS) Add-On (Qualitative), Blood | $ 107.00 |
| 4051B | Quetiapine, Blood | $ 180.00 |
| 4051FL | Quetiapine, Fluid | $ 391.00 |
| 4051SP | Quetiapine, Serum/Plasma | $ 180.00 |
| 4051TI | Quetiapine, Tissue | $ 462.00 |
| 4051U | Quetiapine, Urine | $ 297.00 |
| 4071B | Quinidine, Blood | $ 579.00 |
| 4071SP | Quinidine, Serum/Plasma | $ 386.00 |
| 4080B | Quinine, Blood | $ 181.00 |
| 4080SP | Quinine, Serum/Plasma | $ 181.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4080U | Quinine, Urine | $ 183.00 |
| 4075B | Quinine/Quinidine Differentiation, Blood | $ 228.00 |
| 4075SP | Quinine/Quinidine Differentiation, Serum/Plasma | $ 241.00 |
| 4086B | Ramelteon and Metabolite, Blood | $ 276.00 |
| 4086SP | Ramelteon and Metabolite, Serum/Plasma | $ 276.00 |
| 4086U | Ramelteon and Metabolite, Urine | $ 276.00 |
| 4085B | Ranitidine, Blood | $ 729.00 |
| 4085SP | Ranitidine, Serum/Plasma | $ 729.00 |
| 4085U | Ranitidine, Urine | $ 729.00 |
| 7064SP | Rapid Plasma Reagin Reflex (RPR) - Send Out | $ 78.00 |
| 7074SP | Rapid Plasma Reagin Titer Reflex (RPRT), Serum/Plasma - Send Out | $ 78.00 |
| 0965B | Recent Cannabis Use Markers, Blood | $ 343.00 |
| 0965SP | Recent Cannabis Use Markers, Serum/Plasma | $ 343.00 |
| 4101B | Repaglinide, Blood | $ 137.00 |
| 4101SP | Repaglinide, Serum/Plasma | $ 137.00 |
| 7087O | Respiratory Pathogen Profile (RP2P1) - Send Out | $ 672.00 |
| 7088O | Rhinovirus (RHINO) - Send Out | $ 1,054.00 |
| 4110SP | Rifampin, Serum/Plasma | $ 224.00 |
| 4105B | Risperidone and Metabolite, Blood | $ 177.00 |
| 4105FL | Risperidone and Metabolite, Fluid | $ 388.00 |
| 4105SP | Risperidone and Metabolite, Serum/Plasma | $ 177.00 |
| 4105TI | Risperidone and Metabolite, Tissue | $ 459.00 |
| 4105U | Risperidone and Metabolite, Urine | $ 292.00 |
| 4114SP | Rivaroxaban, Serum/Plasma | $ 266.00 |
| 4114U | Rivaroxaban, Urine | $ 457.00 |
| 4115B | Ropinirole, Blood | $ 246.00 |
| 4115SP | Ropinirole, Serum/Plasma | $ 246.00 |
| 4120B | Ropivacaine, Blood | $ 329.00 |
| 4120SP | Ropivacaine, Serum/Plasma | $ 348.00 |
| 4120U | Ropivacaine, Urine | $ 329.00 |
| 4102B | Rosiglitazone, Blood | $ 137.00 |
| 4102SP | Rosiglitazone, Serum/Plasma | $ 137.00 |
| 4124B | Rubidium, Blood | $ 228.00 |
| 4124R | Rubidium, RBCs | $ 344.00 |
| 4124SP | Rubidium, Serum/Plasma | $ 228.00 |
| 4124U | Rubidium, Urine | $ 228.00 |
| 4125B | Rufinamide, Blood | $ 208.00 |
| 4125SP | Rufinamide, Serum/Plasma | $ 213.00 |
| 4137B | Salicylate, Blood | $ 248.00 |
| 4137FL | Salicylate, Fluid | $ 226.00 |
| 4137SP | Salicylate, Serum/Plasma | $ 248.00 |
| 4137U | Salicylate, Urine | $ 248.00 |
| 8001B | Salicylates Screen, Blood | $ 80.00 |
| 8001FL | Salicylates Screen, Fluid | $ 290.00 |
| 8001SP | Salicylates Screen, Serum/Plasma | $ 47.00 |
| 8001TI | Salicylates Screen, Tissue | $ 361.00 |
| 8001U | Salicylates Screen, Urine | $ 80.00 |
| 9261B | Scopolamine Screen, Blood | $ 650.00 |
| 9261SP | Scopolamine Screen, Serum/Plasma | $ 650.00 |
| 9261U | Scopolamine Screen, Urine | $ 650.00 |
| 4160B | Scopolamine, Blood | $ 933.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4160SP | Scopolamine, Serum/Plasma | $ 764.00 |
| 4160U | Scopolamine, Urine | $ 764.00 |
| 4170B | Secobarbital, Blood | $ 83.00 |
| 4170SP | Secobarbital, Serum/Plasma | $ 135.00 |
| 4170U | Secobarbital, Urine | $ 132.00 |
| 4180B | Selenium, Blood | $ 113.00 |
| 4180H | Selenium, Hair | $ 541.00 |
| 4180LI | Selenium, Liquid | $ 686.00 |
| 4180N | Selenium, Nails | $ 541.00 |
| 4180R | Selenium, RBCs | $ 113.00 |
| 4180SP | Selenium, Serum/Plasma | $ 113.00 |
| 4180U | Selenium, Urine | $ 132.00 |
| 6317U | Semi Conductor Panel, Urine | $ 631.00 |
| 4195B | Sertraline and Desmethylsertraline, Blood | $ 116.00 |
| 4195FL | Sertraline and Desmethylsertraline, Fluid | $ 329.00 |
| 4195SP | Sertraline and Desmethylsertraline, Serum/Plasma | $ 116.00 |
| 4195TI | Sertraline and Desmethylsertraline, Tissue | $ 399.00 |
| 4195U | Sertraline, Urine | $ 163.00 |
| SHPCHG | Shipping Charge | $ 43.00 |
| 4197B | Sildenafil and Metabolite, Blood | $ 514.00 |
| 4197SP | Sildenafil and Metabolite, Serum/Plasma | $ 514.00 |
| 4197U | Sildenafil and Metabolite, Urine | $ 514.00 |
| 4190B | Silicon, Blood | $ 140.00 |
| 4190SP | Silicon, Serum/Plasma | $ 140.00 |
| 4190U | Silicon, Urine | $ 140.00 |
| 4200B | Silver, Blood | $ 103.00 |
| 4200SP | Silver, Serum/Plasma | $ 103.00 |
| 4200U | Silver, Urine | $ 103.00 |
| 4205SP | Sinemet®, Serum/Plasma | $ 414.00 |
| 4193B | Sirolimus, Blood | $ 216.00 |
| 0641B | Sotalol, Blood | $ 281.00 |
| 0641SP | Sotalol, Serum/Plasma | $ 176.00 |
| 7727SA | Special Request (ME) | $ 898.00 |
| HANDLING | Specimen Handling Fee | $ 49.00 |
| SPEC RET | Specimen Retention | $ 2,600.00 |
| RETURN | Specimen Return/Handling | $ 66.00 |
| 3475U | S-Phenylmercapturic Acid, Urine | $ 243.00 |
| 4211B | Stiripentol, Blood | $ 309.00 |
| 4211SP | Stiripentol, Serum/Plasma | $ 309.00 |
| 4212B | Strontium, Blood | $ 100.00 |
| 4212SP | Strontium, Serum/Plasma | $ 58.00 |
| 4212U | Strontium, Urine | $ 57.00 |
| 4215B | Strychnine, Blood | $ 179.00 |
| 4215FL | Strychnine, Fluid | $ 380.00 |
| 4215SP | Strychnine, Serum/Plasma | $ 179.00 |
| 4215TI | Strychnine, Tissue | $ 427.00 |
| 4215U | Strychnine, Urine | $ 179.00 |
| 4213U | Styrene Exposure Profile, Urine | $ 162.00 |
| 4232B | Styrene, Blood | $ 298.00 |
| 4232SP | Styrene, Serum/Plasma | $ 248.00 |
| 4127B | Suboxone® - Free, Blood | $ 402.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4127FL | Suboxone® - Free, Fluid | $ 441.00 |
| 4127SP | Suboxone® - Free, Serum/Plasma | $ 402.00 |
| 4127TI | Suboxone® - Total, Tissue | $ 470.00 |
| 4127U | Suboxone® - Total, Urine | $ 402.00 |
| 1021B | Substituted Cathinone Panel, Blood | $ 304.00 |
| 1021SP | Substituted Cathinone Panel, Serum/Plasma | $ 304.00 |
| 1021U | Substituted Cathinone Panel, Urine | $ 304.00 |
| 9264B | Sufentanil Screen, Blood | $ 301.00 |
| 9264U | Sufentanil Screen, Urine | $ 334.00 |
| 4240B | Sufentanil, Blood | $ 345.00 |
| 4240FL | Sufentanil, Fluid | $ 531.00 |
| 4240SP | Sufentanil, Serum/Plasma | $ 334.00 |
| 4240U | Sufentanil, Urine | $ 334.00 |
| 4235B | Sulfhemoglobin, Blood | $ 311.00 |
| 4235R | Sulfhemoglobin, RBCs | $ 197.00 |
| 4239SP | Sulfide Exposure Biouptake Marker, Serum/Plasma | $ 496.00 |
| 4245SP | Sulfonamides, Undifferentiated, Serum/Plasma | $ 138.00 |
| 4275B | Sumatriptan, Blood | $ 516.00 |
| 4275SP | Sumatriptan, Serum/Plasma | $ 500.00 |
| 4275U | Sumatriptan, Urine | $ 516.00 |
| 4236B | Suvorexant, Blood | $ 304.00 |
| 4236SP | Suvorexant, Serum/Plasma | $ 311.00 |
| 9562U | Synthetic Cannabinoid Metabolites Screen - Expanded, Urine | $ 140.00 |
| 4283U | Synthetic Cannabinoid Metabolites-Expanded (Qualitative), Urine | $ 104.00 |
| 4282SP | Synthetic Cannabinoids (Qualitative), Serum/Plasma | $ 304.00 |
| 9566B | Synthetic Cannabinoids Screen (Add-On), Blood | $ 204.00 |
| 9560B | Synthetic Cannabinoids Screen, Blood | $ 284.00 |
| 7073SP | Syphilis Serology (SYPHL), Serum/Plasma - Send Out | $ 109.00 |
| 4305B | Tacrine, Blood | $ 534.00 |
| 4305SP | Tacrine, Serum/Plasma | $ 550.00 |
| 4306B | Tacrolimus, Blood | $ 216.00 |
| 4297B | Tadalafil, Blood | $ 640.00 |
| 4297SP | Tadalafil, Serum/Plasma | $ 640.00 |
| 4300B | Talbutal, Blood | $ 261.00 |
| 4303U | Talwin® Nx, Urine | $ 346.00 |
| 4311B | Tamoxifen and Metabolites, Blood | $ 783.00 |
| 4311SP | Tamoxifen and Metabolites, Serum/Plasma | $ 487.00 |
| 4312B | Tapentadol - Free, Blood | $ 414.00 |
| 4312SP | Tapentadol - Free, Serum/Plasma | $ 208.00 |
| 4312U | Tapentadol - Total, Urine | $ 208.00 |
| 4320B | Tellurium, Blood | $ 249.00 |
| 4320SP | Tellurium, Serum/Plasma | $ 249.00 |
| 4320U | Tellurium, Urine | $ 249.00 |
| 4323B | Temazepam and Metabolite, Blood | $ 188.00 |
| 4323SP | Temazepam and Metabolite, Serum/Plasma | $ 188.00 |
| 4323U | Temazepam and Metabolite, Urine | $ 188.00 |
| 4329B | Terazosin, Blood | $ 778.00 |
| 4329SP | Terazosin, Serum/Plasma | $ 778.00 |
| 4326SP | Terbutaline, Serum/Plasma | $ 336.00 |
| 4367B | Teriflunomide (Pre-Pregnancy Monitoring), Blood | $ 346.00 |
| 4367SP | Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma | $ 346.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4366B | Teriflunomide (Therapeutic Drug Monitoring), Blood | $ 346.00 |
| 4366SP | Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma | $ 346.00 |
| 4327B | Terpineol, Blood | $ 271.00 |
| 4333B | Tetrachloroethane, Blood | $ 317.00 |
| 3430B | Tetrachloroethylene, Blood | $ 124.00 |
| 4351B | Tetrafluoroethane and Difluoroethane Panel Add-On, Blood | $ 371.00 |
| 1611A | Tetrafluoroethane and Difluoroethane Panel, Air | $ 478.00 |
| 1611B | Tetrafluoroethane and Difluoroethane Panel, Blood | $ 441.00 |
| 1611FL | Tetrafluoroethane and Difluoroethane Panel, Fluid | $ 623.00 |
| 1611TI | Tetrafluoroethane and Difluoroethane Panel, Tissue | $ 680.00 |
| 1611U | Tetrafluoroethane and Difluoroethane Panel, Urine | $ 478.00 |
| 4355B | Tetrahydrofuran, Blood | $ 249.00 |
| 4355SP | Tetrahydrofuran, Serum/Plasma | $ 292.00 |
| 4355U | Tetrahydrofuran, Urine | $ 264.00 |
| 4350B | Tetrahydrozoline, Blood | $ 405.00 |
| 4350SP | Tetrahydrozoline, Serum/Plasma | $ 405.00 |
| 4350U | Tetrahydrozoline, Urine | $ 405.00 |
| 4370B | Thallium, Blood | $ 149.00 |
| 4370H | Thallium, Hair | $ 414.00 |
| 4370LI | Thallium, Liquid | $ 366.00 |
| 4370N | Thallium, Nails | $ 414.00 |
| 4370SP | Thallium, Serum/Plasma | $ 93.00 |
| 4370U | Thallium, Urine | $ 98.00 |
| 9272B | Thebaine Screen, Blood | $ 831.00 |
| 9272U | Thebaine Screen, Urine | $ 831.00 |
| 4376B | Thebaine, Blood | $ 538.00 |
| 4380B | Theobromine, Blood | $ 176.00 |
| 4380SP | Theobromine, Serum/Plasma | $ 168.00 |
| 4380U | Theobromine, Urine | $ 176.00 |
| 4387B | Theophylline, Blood | $ 138.00 |
| 4387SP | Theophylline, Serum/Plasma | $ 138.00 |
| 4387U | Theophylline, Urine | $ 123.00 |
| 6945H | Therapeutic and Drugs of Abuse Screen, Hair | $ 1,473.00 |
| 4440B | Thiocyanate, Blood | $ 146.00 |
| 4440SP | Thiocyanate, Serum/Plasma | $ 105.00 |
| 4440U | Thiocyanate, Urine | $ 173.00 |
| 9419B | Thiopental and Metabolite Screen, Blood | $ 243.00 |
| 9419SP | Thiopental and Metabolite Screen, Serum/Plasma | $ 170.00 |
| 4450B | Thiopental and Metabolite, Blood | $ 226.00 |
| 8636B | Thiopental and Metabolite, Blood | $ 353.00 |
| 4450SP | Thiopental and Metabolite, Serum/Plasma | $ 215.00 |
| 8636SP | Thiopental and Metabolite, Serum/Plasma | $ 353.00 |
| 9427B | Thioridazine and Metabolite Screen, Blood | $ 190.00 |
| 9427SP | Thioridazine and Metabolite Screen, Serum/Plasma | $ 209.00 |
| 4461B | Thioridazine and Metabolite, Blood | $ 199.00 |
| 8689B | Thioridazine and Metabolite, Blood | $ 564.00 |
| 4461SP | Thioridazine and Metabolite, Serum/Plasma | $ 119.00 |
| 8689SP | Thioridazine and Metabolite, Serum/Plasma | $ 341.00 |
| 4461TI | Thioridazine and Metabolite, Tissue | $ 287.00 |
| 4461U | Thioridazine and Metabolite, Urine | $ 119.00 |
| 4472B | Thiosulfate, Blood | $ 257.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4472SP | Thiosulfate, Serum/Plasma | $ 257.00 |
| 4472U | Thiosulfate, Urine | $ 257.00 |
| 9276B | Thiothixene (Cis Isomer) Screen, Blood | $ 114.00 |
| 9276SP | Thiothixene (Cis Isomer) Screen, Serum/Plasma | $ 184.00 |
| 9276U | Thiothixene (Cis Isomer) Screen, Urine | $ 114.00 |
| 4469B | Thiothixene (Cis Isomer), Blood | $ 122.00 |
| 4469SP | Thiothixene (Cis Isomer), Serum/Plasma | $ 122.00 |
| 4469U | Thiothixene (Cis Isomer), Urine | $ 122.00 |
| 4478SP | Thorium, Serum/Plasma | $ 158.00 |
| 4478U | Thorium, Urine | $ 263.00 |
| 4479B | Tiagabine, Blood | $ 188.00 |
| 4479SP | Tiagabine, Serum/Plasma | $ 135.00 |
| 4483B | Tianeptine, Blood | $ 338.00 |
| 4483SP | Tianeptine, Serum/Plasma | $ 338.00 |
| 4483U | Tianeptine, Urine | $ 338.00 |
| 4482B | Timolol, Blood | $ 259.00 |
| 4482SP | Timolol, Serum/Plasma | $ 427.00 |
| 4485B | Tin - Total, Blood | $ 148.00 |
| 4485H | Tin - Total, Hair | $ 503.00 |
| 4485SP | Tin - Total, Serum/Plasma | $ 148.00 |
| 4485TI | Tin - Total, Tissue | $ 95.00 |
| 4485U | Tin - Total, Urine | $ 148.00 |
| 4486B | Titanium, Blood | $ 152.00 |
| 4486FL | Titanium, Fluid | $ 356.00 |
| 4486SP | Titanium, Serum/Plasma | $ 152.00 |
| 4486U | Titanium, Urine | $ 228.00 |
| 4487B | Tizanidine, Blood | $ 505.00 |
| 4487SP | Tizanidine, Serum/Plasma | $ 505.00 |
| 4489B | Tofacitinib, Blood | $ 315.00 |
| 4489SP | Tofacitinib, Serum/Plasma | $ 315.00 |
| 4490SP | Tolazamide, Serum/Plasma | $ 390.00 |
| 4500SP | Tolbutamide, Serum/Plasma | $ 390.00 |
| 4505B | Tolmetin, Blood | $ 412.00 |
| 4505SP | Tolmetin, Serum/Plasma | $ 456.00 |
| 4513U | Toluene Exposure, Urine | $ 190.00 |
| 4510B | Toluene, Blood | $ 124.00 |
| 4519B | Topiramate, Blood | $ 147.00 |
| 4519FL | Topiramate, Fluid | $ 217.00 |
| 4519SP | Topiramate, Serum/Plasma | $ 147.00 |
| 4519TI | Topiramate, Tissue | $ 399.00 |
| 4519U | Topiramate, Urine | $ 233.00 |
| 4525B | Torsemide, Blood | $ 168.00 |
| 4525SP | Torsemide, Serum/Plasma | $ 139.00 |
| 0470UH | Total, Inorganic Arsenic, 24 Hour Urine (+Creatinine) | $ 168.00 |
| 9288B | Tramadol and Metabolite Screen, Blood | $ 142.00 |
| 9288FL | Tramadol and Metabolite Screen, Fluid | $ 340.00 |
| 9288SP | Tramadol and Metabolite Screen, Serum/Plasma | $ 152.00 |
| 4531B | Tramadol and Metabolite, Blood | $ 341.00 |
| 4531SP | Tramadol and Metabolite, Serum/Plasma | $ 153.00 |
| 4533U | Tramadol and Metabolite, Urine | $ 341.00 |
| 9287U | Tramadol Screen, Urine | $ 96.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4535B | Trazodone and mCPP, Blood | $ 95.00 |
| 4535SP | Trazodone and mCPP, Serum/Plasma | $ 95.00 |
| 4535U | Trazodone and mCPP, Urine | $ 95.00 |
| 4535FL | Trazodone, Fluid | $ 308.00 |
| 4535TI | Trazodone, Tissue | $ 381.00 |
| 4540B | Triamterene, Blood | $ 750.00 |
| 4540SP | Triamterene, Serum/Plasma | $ 779.00 |
| 4543B | Triazolam and Metabolite, Blood | $ 168.00 |
| 4543SP | Triazolam and Metabolite, Serum/Plasma | $ 268.00 |
| 4543U | Triazolam as Metabolite, Urine | $ 168.00 |
| 4624B | Trichloroacetic Acid, Blood | $ 401.00 |
| 4624SP | Trichloroacetic Acid, Serum/Plasma | $ 401.00 |
| 4624U | Trichloroacetic Acid, Urine | $ 158.00 |
| 4640B | Trichloroethanol - Free, Blood | $ 431.00 |
| 4640SP | Trichloroethanol - Free, Serum/Plasma | $ 431.00 |
| 4658U | Trichloroethylene Exposure, Urine | $ 344.00 |
| 4650B | Trichloroethylene, Blood | $ 220.00 |
| 4650SP | Trichloroethylene, Serum/Plasma | $ 354.00 |
| 4660B | Trifluoperazine, Blood | $ 573.00 |
| 4660SP | Trifluoperazine, Serum/Plasma | $ 184.00 |
| 4680B | Trihexyphenidyl, Blood | $ 232.00 |
| 4680SP | Trihexyphenidyl, Serum/Plasma | $ 232.00 |
| 4680U | Trihexyphenidyl, Urine | $ 232.00 |
| 4700B | Trimethadione and Metabolite, Blood | $ 152.00 |
| 4700SP | Trimethadione and Metabolite, Serum/Plasma | $ 168.00 |
| 4700U | Trimethadione and Metabolite, Urine | $ 188.00 |
| 4704B | Trimethoprim, Blood | $ 190.00 |
| 4704SP | Trimethoprim, Serum/Plasma | $ 184.00 |
| 4704U | Trimethoprim, Urine | $ 184.00 |
| 4706B | Trimipramine and Metabolite, Blood | $ 218.00 |
| 8708B | Trimipramine and Metabolite, Blood | $ 341.00 |
| 4706SP | Trimipramine and Metabolite, Serum/Plasma | $ 209.00 |
| 8708SP | Trimipramine and Metabolite, Serum/Plasma | $ 564.00 |
| 4706U | Trimipramine and Metabolite, Urine | $ 132.00 |
| 8708U | Trimipramine and Metabolite, Urine | $ 488.00 |
| 4720B | Triprolidine, Blood | $ 159.00 |
| 4720SP | Triprolidine, Serum/Plasma | $ 259.00 |
| 7030SP | Tryptase, Serum/Plasma - Send Out | $ 154.00 |
| 4730B | Tungsten, Blood | $ 188.00 |
| 4730SP | Tungsten, Serum/Plasma | $ 188.00 |
| 4730U | Tungsten, Urine | $ 188.00 |
| 4755UH | Uranium, 24 Hour Urine | $ 188.00 |
| 4755U | Uranium, Urine | $ 188.00 |
| 4766SP | Valacyclovir as Metabolite, Serum/Plasma | $ 250.00 |
| 4759SP | Valproic Acid - Unbound and Total, Serum/Plasma | $ 205.00 |
| 4757B | Valproic Acid, Blood | $ 172.00 |
| 4757FL | Valproic Acid, Fluid | $ 240.00 |
| 4757SP | Valproic Acid, Serum/Plasma | $ 172.00 |
| 4757TI | Valproic Acid, Tissue | $ 451.00 |
| 4761SP | Valproic Acid, Unbound, Serum/Plasma | $ 130.00 |
| 4757U | Valproic Acid, Urine | $ 172.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4765B | Vanadium, Blood | $ 113.00 |
| 4765R | Vanadium, RBCs | $ 113.00 |
| 4765SP | Vanadium, Serum/Plasma | $ 113.00 |
| 4765U | Vanadium, Urine | $ 119.00 |
| 4764B | Vardenafil and Metabolite, Blood | $ 604.00 |
| 4764SP | Vardenafil and Metabolite, Serum/Plasma | $ 604.00 |
| 9447B | Venlafaxine and Metabolite Screen, Blood | $ 287.00 |
| 9447U | Venlafaxine and Metabolite Screen, Urine | $ 287.00 |
| 4767B | Venlafaxine and Metabolite, Blood | $ 347.00 |
| 4767FL | Venlafaxine and Metabolite, Fluid | $ 385.00 |
| 4767SP | Venlafaxine and Metabolite, Serum/Plasma | $ 347.00 |
| 4767TI | Venlafaxine and Metabolite, Tissue | $ 616.00 |
| 4767U | Venlafaxine and Metabolite, Urine | $ 536.00 |
| 4770B | Verapamil, Blood | $ 209.00 |
| 4770FL | Verapamil, Fluid | $ 366.00 |
| 4770SP | Verapamil, Serum/Plasma | $ 132.00 |
| 4770TI | Verapamil, Tissue | $ 438.00 |
| 4770U | Verapamil, Urine | $ 132.00 |
| 4774SP | Vigabatrin, Serum/Plasma | $ 445.00 |
| 4790B | Vilazodone, Blood | $ 254.00 |
| 4790SP | Vilazodone, Serum/Plasma | $ 254.00 |
| 4778U | Vinyl Chloride Metabolite, Urine | $ 464.00 |
| 4780SP | Vitamin B3 (Niacin and Metabolites), Serum/Plasma | $ 229.00 |
| 4783B | Voclosporin, Blood | $ 205.00 |
| 2415B | Volatile and Halocarbon Intoxicants, Blood | $ 131.00 |
| 2415FL | Volatile and Halocarbon Intoxicants, Fluid | $ 182.00 |
| 2415TI | Volatile and Halocarbon Intoxicants, Tissue | $ 212.00 |
| 4782B | Voriconazole, Blood | $ 190.00 |
| 4782SP | Voriconazole, Serum/Plasma | $ 467.00 |
| 4791FL | Vortioxetine, Fluid | $ 408.00 |
| 4791SP | Vortioxetine, Serum/Plasma | $ 215.00 |
| 4800B | Warfarin, Blood | $ 110.00 |
| 4800SP | Warfarin, Serum/Plasma | $ 110.00 |
| 4815B | Xylazine, Blood | $ 347.00 |
| 4815SP | Xylazine, Serum/Plasma | $ 347.00 |
| 4815TI | Xylazine, Tissue | $ 648.00 |
| 4815U | Xylazine, Urine | $ 347.00 |
| 4821U | Xylene Exposure Panel, Urine | $ 173.00 |
| 4820B | Xylenes Panel, Blood | $ 131.00 |
| 4830B | Yohimbine, Blood | $ 868.00 |
| 4830SP | Yohimbine, Serum/Plasma | $ 552.00 |
| 4830U | Yohimbine, Urine | $ 552.00 |
| 4835B | Zaleplon, Blood | $ 267.00 |
| 4835SP | Zaleplon, Serum/Plasma | $ 259.00 |
| 4835U | Zaleplon, Urine | $ 259.00 |
| 4844B | Zinc, Blood | $ 69.00 |
| 4844FL | Zinc, Fluid | $ 276.00 |
| 4844H | Zinc, Hair | $ 405.00 |
| 4844LI | Zinc, Liquid | $ 555.00 |
| 4844N | Zinc, Nails | $ 405.00 |
| 4844R | Zinc, RBCs | $ 69.00 |

| Test | Test Name | List Price |
|---|---|---|
| 4844SP | Zinc, Serum/Plasma | $ 69.00 |
| 4844U | Zinc, Urine | $ 113.00 |
| 4860B | Ziprasidone, Blood | $ 158.00 |
| 4860SP | Ziprasidone, Serum/Plasma | $ 158.00 |
| 4870SP | Zirconium, Serum/Plasma | $ 203.00 |
| 2478U | Zolpidem and Metabolites, Urine | $ 267.00 |
| 2483B | Zolpidem, Blood | $ 203.00 |
| 2483FL | Zolpidem, Fluid | $ 412.00 |
| 2483SP | Zolpidem, Serum/Plasma | $ 203.00 |
| 2483TI | Zolpidem, Tissue | $ 482.00 |
| 4884B | Zonisamide, Blood | $ 208.00 |
| 4884SP | Zonisamide, Serum/Plasma | $ 208.00 |
| 4885B | ZPP (Zinc Protoporphyrin), Blood | $ 77.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING**<br>*NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5441B | Acepromazine Confirmation (Qualitative), Blood | $ 149.00 |
| 5441SP | Acepromazine Confirmation (Qualitative), Serum/Plasma | $ 149.00 |
| 5441U | Acepromazine Confirmation (Qualitative), Urine | $ 149.00 |
| 5401B | Acetaminophen Confirmation, Blood | $ 167.00 |
| 5401SP | Acetaminophen Confirmation, Serum/Plasma | $ 167.00 |
| 5401U | Acetaminophen Confirmation, Urine | $ 167.00 |
| 53250B | Alcohols and Acetone Confirmation, Blood | $ 92.00 |
| 53250FL | Alcohols and Acetone Confirmation, Fluid | $ 128.00 |
| 53250SP | Alcohols and Acetone Confirmation, Serum/Plasma | $ 92.00 |
| 53250U | Alcohols and Acetone Confirmation, Urine | $ 111.00 |
| 53249FL | Alcohols and Acetone Confirmation, Vitreous Fluid (Forensic) | $ 109.00 |
| 5659U | Alfentanil Confirmation, Urine | $ 131.00 |
| 5444SP | Amantadine Confirmation (Qualitative), Serum/Plasma | $ 262.00 |
| 5446B | Amitriptyline and Metabolite Confirmation (Qualitative), Blood | $ 151.00 |
| 5446SP | Amitriptyline and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 151.00 |
| 5446U | Amitriptyline and Metabolite Confirmation (Qualitative), Urine | $ 151.00 |
| 5684ME | Amphetamines Confirmation (Qualitative), Meconium | $ 284.00 |
| 5684B | Amphetamines Confirmation, Blood | $ 230.00 |
| 5684FL | Amphetamines Confirmation, Fluid | $ 440.00 |
| 5684SP | Amphetamines Confirmation, Serum/Plasma | $ 230.00 |
| 5684TI | Amphetamines Confirmation, Tissue | $ 370.00 |
| 5684U | Amphetamines Confirmation, Urine | $ 230.00 |
| 5223U | Amphetamines Quantitation/Confirmation, Urine | $ 213.00 |
| 5125U | Anabasine Confirmation, Urine | $ 135.00 |
| 5450B | Antidepressants Confirmation (Qualitative), Blood | $ 175.00 |
| 5450SP | Antidepressants Confirmation (Qualitative), Serum/Plasma | $ 175.00 |
| 5450U | Antidepressants Confirmation (Qualitative), Urine | $ 175.00 |
| 5454B | Atropine Confirmation, Blood | $ 590.00 |
| 5454SP | Atropine Confirmation, Serum/Plasma | $ 590.00 |
| 5454U | Atropine Confirmation, Urine | $ 590.00 |
| 5652ME | Barbiturates Confirmation (Qualitative), Meconium | $ 292.00 |
| 5652B | Barbiturates Confirmation, Blood | $ 292.00 |
| 5652FL | Barbiturates Confirmation, Fluid | $ 471.00 |
| 5652SP | Barbiturates Confirmation, Serum/Plasma | $ 292.00 |
| 5652TI | Barbiturates Confirmation, Tissue | $ 529.00 |
| 5652U | Barbiturates Confirmation, Urine | $ 201.00 |
| 5641ME | Benzodiazepines Confirmation (Qualitative), Meconium | $ 277.00 |
| 5641B | Benzodiazepines Confirmation, Blood | $ 224.00 |
| 5641FL | Benzodiazepines Confirmation, Fluid | $ 293.00 |
| 5641SP | Benzodiazepines Confirmation, Serum/Plasma | $ 224.00 |
| 5641TI | Benzodiazepines Confirmation, Tissue | $ 330.00 |
| 5641U | Benzodiazepines Confirmation, Urine | $ 218.00 |
| 5463B | Brompheniramine Confirmation (Qualitative), Blood | $ 172.00 |
| 53167U | Buprenorphine and Metabolite - Total (Conjugated/Unconjugated) Confirmation, Urine | $ 93.00 |
| 5466B | Bupropion and Metabolite Confirmation, Blood | $ 160.00 |
| 5466SP | Bupropion and Metabolite Confirmation, Serum/Plasma | $ 160.00 |
| 5466TI | Bupropion and Metabolite Confirmation, Tissue | $ 440.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING**<br>*NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5466U | Bupropion and Metabolite Confirmation, Urine | $ 160.00 |
| 5646ME | Cannabinoids Confirmation (Qualitative), Meconium | $ 285.00 |
| 5646B | Cannabinoids Confirmation, Blood | $ 232.00 |
| 5646FL | Cannabinoids Confirmation, Fluid | $ 302.00 |
| 5646SP | Cannabinoids Confirmation, Serum/Plasma | $ 232.00 |
| 5646TI | Cannabinoids Confirmation, Tissue | $ 339.00 |
| 5646U | Cannabinoids Confirmation, Urine | $ 177.00 |
| 5654B | Carbon Monoxide Exposure Biouptake Confirmation, Blood | $ 104.00 |
| 5656B | Carbon Monoxide Exposure Biouptake Confirmation, Blood (Forensic) | $ 108.00 |
| 5479B | Carisoprodol and Metabolite Confirmation, Blood | $ 248.00 |
| 5479FL | Carisoprodol and Metabolite Confirmation, Fluid | $ 459.00 |
| 5479SP | Carisoprodol and Metabolite Confirmation, Serum/Plasma | $ 248.00 |
| 5485B | Chlorpromazine Confirmation (Qualitative), Blood | $ 220.00 |
| 5485SP | Chlorpromazine Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5485U | Chlorpromazine Confirmation (Qualitative), Urine | $ 220.00 |
| 5487B | Clomipramine and Metabolite Confirmation (Qualitative), Blood | $ 220.00 |
| 5487SP | Clomipramine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5487U | Clomipramine and Metabolite Confirmation (Qualitative), Urine | $ 220.00 |
| 5488B | Clonazepam and Metabolite Confirmation, Blood | $ 412.00 |
| 5488FL | Clonazepam and Metabolite Confirmation, Fluid | $ 332.00 |
| 5488SP | Clonazepam and Metabolite Confirmation, Serum/Plasma | $ 261.00 |
| 5489U | Clonazepam as Metabolite Confirmation, Urine | $ 261.00 |
| 5637ME | Cocaine and Metabolites Confirmation (Qualitative), Meconium | $ 271.00 |
| 5637B | Cocaine and Metabolites Confirmation, Blood | $ 218.00 |
| 5637FL | Cocaine and Metabolites Confirmation, Fluid | $ 408.00 |
| 5637SP | Cocaine and Metabolites Confirmation, Serum/Plasma | $ 218.00 |
| 5637TI | Cocaine and Metabolites Confirmation, Tissue | $ 470.00 |
| 5637U | Cocaine and Metabolites Confirmation, Urine | $ 218.00 |
| 5415U | Codeine - Total (Conjugated/Unconjugated) Confirmation, Urine | $ 248.00 |
| 5636B | Cyanide Confirmation (Qualitative), Blood | $ 112.00 |
| 5647B | Cyanide Confirmation, Blood (Forensic) | $ 104.00 |
| 5495U | Dextro / Levo Methorphan Confirmation - Total, Urine | $ 243.00 |
| 5495SP | Dextro / Levo Methorphan Confirmation, Serum/Plasma | $ 243.00 |
| 5506B | Disopyramide Confirmation (Qualitative), Blood | $ 124.00 |
| 5506SP | Disopyramide Confirmation (Qualitative), Serum/Plasma | $ 124.00 |
| 5509B | Doxepin and Metabolite Confirmation (Qualitative), Blood | $ 155.00 |
| 5509U | Doxepin and Metabolite Confirmation (Qualitative), Urine | $ 155.00 |
| 5510B | Doxylamine Confirmation (Qualitative), Blood | $ 196.00 |
| 5510SP | Doxylamine Confirmation (Qualitative), Serum/Plasma | $ 196.00 |
| 5511B | Ephedrine Confirmation, Blood | $ 154.00 |
| 53251B | Ethanol Confirmation, Blood | $ 93.00 |
| 53251FL | Ethanol Confirmation, Fluid | $ 130.00 |
| 53251SP | Ethanol Confirmation, Serum/Plasma | $ 93.00 |
| 53251TI | Ethanol Confirmation, Tissue | $ 166.00 |
| 53251U | Ethanol Confirmation, Urine | $ 114.00 |
| 5517B | Ethosuximide Confirmation (Qualitative), Blood | $ 189.00 |
| 5517SP | Ethosuximide Confirmation (Qualitative), Serum/Plasma | $ 189.00 |
| 5517U | Ethosuximide Confirmation (Qualitative), Urine | $ 189.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5643B | Fentanyl and Acetyl Fentanyl Confirmation, Blood | $ 232.00 |
| 5643FL | Fentanyl and Acetyl Fentanyl Confirmation, Fluid | $ 302.00 |
| 5643SP | Fentanyl and Acetyl Fentanyl Confirmation, Serum/Plasma | $ 232.00 |
| 5643TI | Fentanyl and Acetyl Fentanyl Confirmation, Tissue | $ 330.00 |
| 5643U | Fentanyl and Acetyl Fentanyl Confirmation, Urine | $ 232.00 |
| 5640B | Fentanyl and Metabolite Confirmation, Blood | $ 173.00 |
| 5640FL | Fentanyl and Metabolite Confirmation, Fluid | $ 242.00 |
| 5640SP | Fentanyl and Metabolite Confirmation, Serum/Plasma | $ 173.00 |
| 5640TI | Fentanyl and Metabolite Confirmation, Tissue | $ 276.00 |
| 5728B | Flunitrazepam and Metabolites Confirmation, Blood | $ 249.00 |
| 5728SP | Flunitrazepam and Metabolites Confirmation, Serum/Plasma | $ 249.00 |
| 5728TI | Flunitrazepam and Metabolites Confirmation, Tissue | $ 354.00 |
| 5728U | Flunitrazepam and Metabolites Confirmation, Urine | $ 249.00 |
| 5524B | Fluoxetine and Metabolite Confirmation, Blood | $ 139.00 |
| 5524SP | Fluoxetine and Metabolite Confirmation, Serum/Plasma | $ 139.00 |
| 5524U | Fluoxetine and Metabolite Confirmation, Urine | $ 139.00 |
| 5526B | Glutethimide Confirmation (Qualitative), Blood | $ 139.00 |
| 5526SP | Glutethimide Confirmation (Qualitative), Serum/Plasma | $ 139.00 |
| 5527B | Haloperidol Confirmation, Blood | $ 230.00 |
| 5527SP | Haloperidol Confirmation, Serum/Plasma | $ 230.00 |
| 5686B | Heroin Metabolites - Free (Unconjugated) Confirmation, Blood | $ 319.00 |
| 5686SP | Heroin Metabolites - Free (Unconjugated) Confirmation, Serum/Plasma | $ 319.00 |
| 5707U | Heroin Metabolites - Free (Unconjugated) Confirmation, Urine | $ 315.00 |
| 5536B | Hydrocodone and Metabolites - Free (Unconjugated) Confirmation, Blood | $ 235.00 |
| 5536SP | Hydrocodone and Metabolites - Free (Unconjugated) Confirmation, Serum/Plasma | $ 235.00 |
| 5532B | Imipramine and Metabolite Confirmation (Qualitative), Blood | $ 146.00 |
| 5532SP | Imipramine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 146.00 |
| 5532U | Imipramine and Metabolite Confirmation (Qualitative), Urine | $ 146.00 |
| 5534B | Ketamine and Metabolite Confirmation, Blood | $ 218.00 |
| 5534SP | Ketamine and Metabolite Confirmation, Serum/Plasma | $ 218.00 |
| 5534U | Ketamine and Metabolite Confirmation, Urine | $ 218.00 |
| 5613B | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Blood | $ 209.00 |
| 5613SP | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Serum/Plasma | $ 209.00 |
| 5613U | Lidocaine and Metabolite (MEGX) Confirmation (Qualitative), Urine | $ 209.00 |
| 5811B | LSD Confirmation, Blood | $ 191.00 |
| 5811SP | LSD Confirmation, Serum/Plasma | $ 191.00 |
| 5811U | LSD Confirmation, Urine | $ 191.00 |
| 5553SP | Meclizine Confirmation, Serum/Plasma | $ 166.00 |
| 5555B | Meperidine and Metabolite Confirmation (Qualitative), Blood | $ 146.00 |
| 5555SP | Meperidine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 146.00 |
| 5555U | Meperidine and Metabolite Confirmation, Urine | $ 220.00 |
| 5560SP | Mepivacaine Confirmation (Qualitative), Serum/Plasma | $ 188.00 |
| 5417B | Mescaline Confirmation (Qualitative), Blood | $ 248.00 |
| 5417SP | Mescaline Confirmation (Qualitative), Serum/Plasma | $ 248.00 |
| 5417U | Mescaline Confirmation (Qualitative), Urine | $ 248.00 |
| 5682ME | Methadone and Metabolite Confirmation (Qualitative), Meconium | $ 305.00 |
| 5682B | Methadone and Metabolite Confirmation, Blood | $ 268.00 |
| 5682FL | Methadone and Metabolite Confirmation, Fluid | $ 340.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5682SP | Methadone and Metabolite Confirmation, Serum/Plasma | $ 268.00 |
| 5682TI | Methadone and Metabolite Confirmation, Tissue | $ 373.00 |
| 5682U | Methadone and Metabolite Confirmation, Urine | $ 268.00 |
| 5687B | Methamphetamine and Metabolite Confirmation, Blood | $ 191.00 |
| 5687SP | Methamphetamine and Metabolite Confirmation, Serum/Plasma | $ 160.00 |
| 5687U | Methamphetamine and Metabolite Confirmation, Urine | $ 356.00 |
| 5696B | Methylenedioxymethamphetamine and Metabolite Confirmation, Blood | $ 132.00 |
| 5696SP | Methylenedioxymethamphetamine and Metabolite Confirmation, Serum/Plasma | $ 132.00 |
| 5696U | Methylenedioxymethamphetamine and Metabolite Confirmation, Urine | $ 132.00 |
| 5584B | Mexiletine Confirmation (Qualitative), Blood | $ 150.00 |
| 5584SP | Mexiletine Confirmation (Qualitative), Serum/Plasma | $ 150.00 |
| 5674B | Nicotine and Metabolite Confirmation, Blood | $ 135.00 |
| 5674SP | Nicotine and Metabolite Confirmation, Serum/Plasma | $ 135.00 |
| 5674U | Nicotine and Metabolite with Anabasine Confirmation, Urine | $ 135.00 |
| 5589B | Nitrazepam and Metabolite Confirmation, Blood | $ 365.00 |
| 5589SP | Nitrazepam and Metabolite Confirmation, Serum/Plasma | $ 284.00 |
| 5593B | Nortriptyline Confirmation (Qualitative), Blood | $ 90.00 |
| 5593U | Nortriptyline Confirmation (Qualitative), Urine | $ 90.00 |
| 5645B | Opiates - Free (Unconjugated) Confirmation, Blood | $ 267.00 |
| 5645FL | Opiates - Free (Unconjugated) Confirmation, Fluid | $ 399.00 |
| 5645SP | Opiates - Free (Unconjugated) Confirmation, Serum/Plasma | $ 267.00 |
| 5645U | Opiates - Free (Unconjugated) Confirmation, Urine | $ 285.00 |
| 5645ME | Opiates - Total (Conjugated/Unconjugated) Confirmation (Qualitative), Meconium | $ 386.00 |
| 5698TI | Opiates - Total (Conjugated/Unconjugated) Confirmation, Tissue | $ 456.00 |
| 5612B | Orphenadrine Confirmation (Qualitative), Blood | $ 220.00 |
| 5557B | Oxycodone and Metabolite - Free (Unconjugated) Confirmation, Blood | $ 190.00 |
| 5557SP | Oxycodone and Metabolite - Free (Unconjugated) Confirmation, Serum/Plasma | $ 116.00 |
| 5615B | Papaverine Confirmation (Qualitative), Blood | $ 203.00 |
| 5618B | Pentazocine Confirmation (Qualitative), Blood | $ 146.00 |
| 5618SP | Pentazocine Confirmation (Qualitative), Serum/Plasma | $ 220.00 |
| 5618U | Pentazocine Confirmation (Qualitative), Urine | $ 146.00 |
| 5657ME | Phencyclidine Confirmation (Qualitative), Meconium | $ 346.00 |
| 5657B | Phencyclidine Confirmation, Blood | $ 285.00 |
| 5657FL | Phencyclidine Confirmation, Fluid | $ 355.00 |
| 5657SP | Phencyclidine Confirmation, Serum/Plasma | $ 285.00 |
| 5657TI | Phencyclidine Confirmation, Tissue | $ 390.00 |
| 5657U | Phencyclidine Confirmation, Urine | $ 285.00 |
| 5544B | Phenobarbital Confirmation, Blood | $ 187.00 |
| 5546B | Phensuximide Confirmation (Qualitative), Blood | $ 189.00 |
| 5546U | Phensuximide Confirmation (Qualitative), Urine | $ 189.00 |
| 5548U | Phenylpropanolamine Confirmation, Urine | $ 104.00 |
| 5726B | Propofol Confirmation (Qualitative), Blood | $ 204.00 |
| 5726SP | Propofol Confirmation (Qualitative), Serum/Plasma | $ 204.00 |
| 5433B | Propranolol Confirmation, Blood | $ 96.00 |
| 5433SP | Propranolol Confirmation, Serum/Plasma | $ 96.00 |
| 5566B | Protriptyline Confirmation (Qualitative), Blood | $ 196.00 |
| 5566SP | Protriptyline Confirmation (Qualitative), Serum/Plasma | $ 196.00 |
| 5568B | Pseudoephedrine Confirmation, Blood | $ 139.00 |

| Test | Test Name | List Price |
|---|---|---|
| **REFLEX CONFIRMATION TESTING** *NOTE: Codes beginning with the number 5 are not orderable. They are reserved for reflex confirmations only.* | | |
| 5568SP | Pseudoephedrine Confirmation, Serum/Plasma | $ 139.00 |
| 5568U | Pseudoephedrine Confirmation, Urine | $ 139.00 |
| 5569B | Pseudoephedrine vs Ephedrine Differentiation Confirmation, Blood | $ 230.00 |
| 5569U | Pseudoephedrine vs Ephedrine Differentiation Confirmation, Urine | $ 230.00 |
| 5438B | Salicylate Confirmation, Blood | $ 144.00 |
| 5438FL | Salicylate Confirmation, Fluid | $ 215.00 |
| 5438SP | Salicylate Confirmation, Serum/Plasma | $ 144.00 |
| 5438TI | Salicylate Confirmation, Tissue | $ 250.00 |
| 5438U | Salicylate Confirmation, Urine | $ 144.00 |
| 5583B | Scopolamine Confirmation, Blood | $ 836.00 |
| 5583SP | Scopolamine Confirmation, Serum/Plasma | $ 650.00 |
| 5583U | Scopolamine Confirmation, Urine | $ 650.00 |
| 5579B | Sufentanil Confirmation, Blood | $ 203.00 |
| 5579U | Sufentanil Confirmation, Urine | $ 320.00 |
| 5596B | Thebaine Confirmation (Qualitative), Blood | $ 228.00 |
| 5596U | Thebaine Confirmation (Qualitative), Urine | $ 228.00 |
| 5600B | Thiopental and Metabolite Confirmation (Qualitative), Blood | $ 193.00 |
| 5600SP | Thiopental and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 193.00 |
| 5693B | Thioridazine and Metabolite Confirmation (Qualitative), Blood | $ 148.00 |
| 5693SP | Thioridazine and Metabolite Confirmation (Qualitative), Serum/Plasma | $ 224.00 |
| 5602B | Thiothixene (Cis Isomer) Confirmation (Qualitative), Blood | $ 193.00 |
| 5602SP | Thiothixene (Cis Isomer) Confirmation (Qualitative), Serum/Plasma | $ 305.00 |
| 5602U | Thiothixene (Cis Isomer) Confirmation (Qualitative), Urine | $ 193.00 |
| 5626B | Tramadol and Metabolite Confirmation, Blood | $ 311.00 |
| 5626FL | Tramadol and Metabolite Confirmation, Fluid | $ 383.00 |
| 5626SP | Tramadol and Metabolite Confirmation, Serum/Plasma | $ 311.00 |
| 5626U | Tramadol and Metabolite Confirmation, Urine | $ 311.00 |
| 5727B | Venlafaxine and Metabolite Confirmation, Blood | $ 317.00 |
| 5727U | Venlafaxine and Metabolite Confirmation, Urine | $ 317.00 |

**CRIME LABORATORY SERVICES**

NMS Labs Crime Laboratory has a full menu of forensic chemistry services available, including illicit and pharmaceutical drug identification. For a current fee schedules for crime laboratory services, please contact us via email: forensics@nmslabs.com or by phone at:1-866-522-2216.

**EXPERT SERVICES**

NMS Labs scientists are available to provide expert opinions and scientifically sound support at various points in the investigation process including depositions, expert courtroom testimony and independent case review. For a current fee schedule for Expert Services, please contact us via emal: expertservices@nmslabs.com or by phone at 1-844-276-0768.

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 0264UH | Aluminum, 24 Hour Urine | $ 96.00 |
| 0264B | Aluminum, Blood | $ 167.00 |
| 0264FL | Aluminum, Fluid | $ 516.00 |
| 0264H | Aluminum, Hair | $ 541.00 |
| 0264LI | Aluminum, Liquid | $ 482.00 |
| 0264R | Aluminum, RBCs | $ 93.00 |
| 0264SP | Aluminum, Serum/Plasma | $ 93.00 |
| 0264TI | Aluminum, Tissue | $ 499.00 |
| 0264U | Aluminum, Urine | $ 175.00 |
| 0410B | Antimony, Blood | $ 93.00 |
| 0410H | Antimony, Hair | $ 541.00 |
| 0410LI | Antimony, Liquid | $ 324.00 |
| 0410N | Antimony, Nails | $ 541.00 |
| 0410R | Antimony, RBCs | $ 93.00 |
| 0410SP | Antimony, Serum/Plasma | $ 93.00 |
| 0410U | Antimony, Urine | $ 93.00 |
| 0460UH | Arsenic, 24 Hour Urine | $ 115.00 |
| 0460B | Arsenic, Blood | $ 115.00 |
| 0460FL | Arsenic, Fluid | $ 327.00 |
| 0460H | Arsenic, Hair | $ 710.00 |
| 0460N | Arsenic, Nails | $ 487.00 |
| 0460R | Arsenic, RBCs | $ 115.00 |
| 0460SP | Arsenic, Serum/Plasma | $ 115.00 |
| 0460TI | Arsenic, Tissue | $ 398.00 |
| 0468UH | Arsenic, Total Inorganic, 24 Hour Urine | $ 168.00 |
| 0468U | Arsenic, Total Inorganic, Urine | $ 168.00 |
| 0460U | Arsenic, Urine | $ 115.00 |
| 0519B | Barium, Blood | $ 208.00 |
| 0519FL | Barium, Fluid | $ 213.00 |
| 0519H | Barium, Hair | $ 597.00 |
| 0519SP | Barium, Serum/Plasma | $ 138.00 |
| 0519TI | Barium, Tissue | $ 547.00 |
| 0519U | Barium, Urine | $ 138.00 |
| 0638B | Beryllium, Blood | $ 96.00 |
| 0638LI | Beryllium, Liquid | $ 394.00 |
| 0638SP | Beryllium, Serum/Plasma | $ 96.00 |
| 0638U | Beryllium, Urine | $ 149.00 |
| 0680B | Bismuth, Blood | $ 242.00 |
| 0680SP | Bismuth, Serum/Plasma | $ 93.00 |
| 0680U | Bismuth, Urine | $ 149.00 |
| 0711B | Boron, Blood | $ 74.00 |
| 0711SP | Boron, Serum/Plasma | $ 74.00 |
| 0711U | Boron, Urine | $ 74.00 |
| 0720B | Bromine - Total, Blood | $ 431.00 |
| 0720SP | Bromine - Total, Serum/Plasma | $ 105.00 |
| 0720U | Bromine - Total, Urine | $ 173.00 |
| 0921UH | Cadmium, 24 Hour Urine | $ 92.00 |
| 0921B | Cadmium, Blood | $ 63.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 0921H | Cadmium, Hair | $ 436.00 |
| 0921N | Cadmium, Nails | $ 436.00 |
| 0921R | Cadmium, RBCs | $ 63.00 |
| 0921SP | Cadmium, Serum/Plasma | $ 63.00 |
| 0921TI | Cadmium, Tissue | $ 345.00 |
| 0921U | Cadmium, Urine | $ 67.00 |
| 0939B | Calcium - Total, Postmortem, Blood (Forensic) | $ 130.00 |
| 0938FL | Calcium - Total, Postmortem, Fluid (Forensic) | $ 303.00 |
| 0938R | Calcium - Total, RBCs | $ 97.00 |
| 0938U | Calcium - Total, Urine | $ 159.00 |
| 1006TI | Carbon Monoxide Profile for Non-standard Samples, Tissue | $ 691.00 |
| 1042B | Cesium, Blood | $ 175.00 |
| 1042SP | Cesium, Serum/Plasma | $ 175.00 |
| 1042U | Cesium, Urine | $ 284.00 |
| 1130B | Chloroform, Blood | $ 201.00 |
| 1265B | Chromium and Cobalt, Blood | $ 204.00 |
| 1265SP | Chromium and Cobalt, Serum/Plasma | $ 197.00 |
| 1265U | Chromium and Cobalt, Urine | $ 197.00 |
| 1261B | Chromium, Blood | $ 138.00 |
| 1261FL | Chromium, Fluid | $ 343.00 |
| 1261H | Chromium, Hair | $ 431.00 |
| 1261N | Chromium, Nails | $ 431.00 |
| 1261R | Chromium, RBCs | $ 138.00 |
| 1261SP | Chromium, Serum/Plasma | $ 138.00 |
| 1261TI | Chromium, Tissue | $ 411.00 |
| 1261U | Chromium, Urine | $ 138.00 |
| 1290UH | Cobalt, 24 Hour Urine | $ 137.00 |
| 1290B | Cobalt, Blood | $ 114.00 |
| 1290FL | Cobalt, Fluid | $ 319.00 |
| 1290H | Cobalt, Hair | $ 486.00 |
| 1290N | Cobalt, Nails | $ 486.00 |
| 1290R | Cobalt, RBCs | $ 114.00 |
| 1290SP | Cobalt, Serum/Plasma | $ 114.00 |
| 1290TI | Cobalt, Tissue | $ 389.00 |
| 1290U | Cobalt, Urine | $ 186.00 |
| 1333SP | Copper - Free, Serum/Plasma | $ 105.00 |
| 1330B | Copper, Blood | $ 58.00 |
| 1330FL | Copper, Fluid | $ 267.00 |
| 1330H | Copper, Hair | $ 430.00 |
| 1330R | Copper, RBCs | $ 58.00 |
| 1330SP | Copper, Serum/Plasma | $ 58.00 |
| 1330TI | Copper, Tissue | $ 339.00 |
| 1330U | Copper, Urine | $ 58.00 |
| 1919FL | Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic) | $ 119.00 |
| 8103B | Environmental Exposure Screen, Blood | 915 |
| 2090SP | Fluoride, Serum/Plasma | $ 123.00 |
| 2090U | Fluoride, Urine | $ 93.00 |
| 2150B | Gallium, Blood | $ 430.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 2150SP | Gallium, Serum/Plasma | $ 261.00 |
| 2150U | Gallium, Urine | $ 261.00 |
| 2156SP | Germanium, Serum/Plasma | $ 411.00 |
| 2156U | Germanium, Urine | $ 394.00 |
| 2171B | Gold, Blood | $ 93.00 |
| 2171SP | Gold, Serum/Plasma | $ 93.00 |
| 2171U | Gold, Urine | $ 93.00 |
| 2406B | Indium, Blood | $ 228.00 |
| 2406R | Indium, RBCs | $ 152.00 |
| 2406SP | Indium, Serum/Plasma | $ 228.00 |
| 2406U | Indium, Urine | $ 152.00 |
| 6364R | Inorganic Panel 64, RBCs | $ 505.00 |
| 2428U | Iodine - Total, Urine | $ 139.00 |
| 2428FL | Iodine, Fluid | $ 335.00 |
| 2428SP | Iodine, Serum/Plasma | $ 139.00 |
| 2430UH | Iron, 24 Hour Urine | $ 79.00 |
| 2430B | Iron, Blood | $ 79.00 |
| 2430SP | Iron, Serum/Plasma | $ 79.00 |
| 2430ST | Iron, Stool | $ 284.00 |
| 2430U | Iron, Urine | $ 79.00 |
| 2490B | Lead and ZPP, Blood | $ 72.00 |
| 2492UH | Lead, 24 Hour Urine | $ 102.00 |
| 2492B | Lead, Blood | $ 50.00 |
| 2492FL | Lead, Fluid | $ 259.00 |
| 2492H | Lead, Hair | $ 420.00 |
| 2492LI | Lead, Liquid | $ 160.00 |
| 2492N | Lead, Nails | $ 420.00 |
| 2492R | Lead, RBCs | $ 85.00 |
| 2492SP | Lead, Serum/Plasma | $ 102.00 |
| 2492TI | Lead, Tissue | $ 330.00 |
| 2492U | Lead, Urine | $ 102.00 |
| 2534U | Lithium Exposure , Urine | $ 55.00 |
| 2534B | Lithium Exposure, Blood | $ 55.00 |
| 2534SP | Lithium Exposure, Serum/Plasma | $ 55.00 |
| 2520B | Lithium, Blood | $ 58.00 |
| 2520FL | Lithium, Fluid | $ 267.00 |
| 2520R | Lithium, RBCs | $ 92.00 |
| 2520SP | Lithium, Serum/Plasma | $ 58.00 |
| 2520TI | Lithium, Tissue | $ 339.00 |
| 2520U | Lithium, Urine | $ 58.00 |
| 2551B | Magnesium - Total, Blood | $ 62.00 |
| 2551FL | Magnesium - Total, Fluid | $ 271.00 |
| 2551H | Magnesium - Total, Hair | $ 433.00 |
| 2551R | Magnesium - Total, RBCs | $ 62.00 |
| 2551SP | Magnesium - Total, Serum/Plasma | $ 62.00 |
| 2551ST | Magnesium - Total, Stool | $ 433.00 |
| 2551TI | Magnesium - Total, Tissue | $ 274.00 |
| 2551U | Magnesium - Total, Urine | $ 118.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 2570B | Manganese, Blood | $ 103.00 |
| 2570FL | Manganese, Fluid | $ 310.00 |
| 2570H | Manganese, Hair | $ 472.00 |
| 2570LI | Manganese, Liquid | $ 587.00 |
| 2570N | Manganese, Nails | $ 716.00 |
| 2570R | Manganese, RBCs | $ 103.00 |
| 2570SP | Manganese, Serum/Plasma | $ 103.00 |
| 2570TI | Manganese, Tissue | $ 381.00 |
| 2570U | Manganese, Urine | $ 103.00 |
| 2670UH | Mercury, 24 Hour Urine | $ 77.00 |
| 2670B | Mercury, Blood | $ 55.00 |
| 2670FL | Mercury, Fluid | $ 267.00 |
| 2670H | Mercury, Hair | $ 623.00 |
| 2670LI | Mercury, Liquid | $ 270.00 |
| 2670N | Mercury, Nails | $ 430.00 |
| 2670R | Mercury, RBCs | $ 55.00 |
| 2670SP | Mercury, Serum/Plasma | $ 55.00 |
| 2670TI | Mercury, Tissue | $ 339.00 |
| 2670U | Mercury, Urine | $ 124.00 |
| 2664UH | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), 24 Hour Urine | $ 379.00 |
| 2664U | Metals Panel 4 (Arsenic, Cadmium, Lead, Mercury), Urine | $ 379.00 |
| 2693B | Metals/Metalloids Acute Poisoning Panel, Blood | $ 465.00 |
| 2693FL | Metals/Metalloids Acute Poisoning Panel, Fluid | $ 680.00 |
| 2693H | Metals/Metalloids Acute Poisoning Panel, Hair | $ 661.00 |
| 2693R | Metals/Metalloids Acute Poisoning Panel, RBCs | $ 465.00 |
| 2693SP | Metals/Metalloids Acute Poisoning Panel, Serum/Plasma | $ 465.00 |
| 2693TI | Metals/Metalloids Acute Poisoning Panel, Tissue | $ 725.00 |
| 2693U | Metals/Metalloids Acute Poisoning Panel, Urine | $ 465.00 |
| 2661B | Metals/Metalloids Panel 1, Blood | $ 271.00 |
| 2661H | Metals/Metalloids Panel 1, Hair | $ 504.00 |
| 2661N | Metals/Metalloids Panel 1, Nails | $ 504.00 |
| 2661SP | Metals/Metalloids Panel 1, Serum/Plasma | $ 301.00 |
| 2661U | Metals/Metalloids Panel 1, Urine | $ 311.00 |
| 2662B | Metals/Metalloids Panel 2, Blood | $ 379.00 |
| 2662H | Metals/Metalloids Panel 2, Hair | $ 583.00 |
| 2662N | Metals/Metalloids Panel 2, Nails | $ 583.00 |
| 2662SP | Metals/Metalloids Panel 2, Serum/Plasma | $ 379.00 |
| 2662U | Metals/Metalloids Panel 2, Urine | $ 598.00 |
| 2663B | Metals/Metalloids Panel 3, Blood | $ 419.00 |
| 2663H | Metals/Metalloids Panel 3, Hair | $ 631.00 |
| 2663N | Metals/Metalloids Panel 3, Nails | $ 631.00 |
| 2663SP | Metals/Metalloids Panel 3, Serum/Plasma | $ 432.00 |
| 2663U | Metals/Metalloids Panel 3, Urine | $ 668.00 |
| 3066B | Mineral Profile, Blood | $ 610.00 |
| 3066R | Mineral Profile, RBCs | $ 394.00 |
| 3066SP | Mineral Profile, Serum/Plasma | $ 394.00 |
| 3090B | Molybdenum, Blood | $ 79.00 |
| 3090H | Molybdenum, Hair | $ 448.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 3090R | Molybdenum, RBCs | $ 79.00 |
| 3090SP | Molybdenum, Serum/Plasma | $ 79.00 |
| 3090U | Molybdenum, Urine | $ 92.00 |
| 3140B | Nickel, Blood | $ 79.00 |
| 3140FL | Nickel, Fluid | $ 284.00 |
| 3140H | Nickel, Hair | $ 448.00 |
| 3140N | Nickel, Nails | $ 448.00 |
| 3140R | Nickel, RBCs | $ 129.00 |
| 3140SP | Nickel, Serum/Plasma | $ 79.00 |
| 3140TI | Nickel, Tissue | $ 355.00 |
| 3140U | Nickel, Urine | $ 110.00 |
| 3292B | Palladium, Blood | $ 225.00 |
| 3292SP | Palladium, Serum/Plasma | $ 187.00 |
| 3292U | Palladium, Urine | $ 187.00 |
| 3765B | Phosphorus - Total, Blood | $ 276.00 |
| 3765FL | Phosphorus - Total, Fluid | $ 488.00 |
| 3765SP | Phosphorus - Total, Serum/Plasma | $ 276.00 |
| 3765ST | Phosphorus - Total, Stool | $ 232.00 |
| 3765U | Phosphorus - Total, Urine | $ 276.00 |
| 3783B | Platinum, Blood | $ 191.00 |
| 3783FL | Platinum, Fluid | $ 394.00 |
| 3783SP | Platinum, Serum/Plasma | $ 191.00 |
| 3783U | Platinum, Urine | $ 315.00 |
| 3784B | Potassium - Total, Blood (Forensic) | $ 92.00 |
| 3784FL | Potassium - Total, Fluid | $ 213.00 |
| 3784R | Potassium - Total, RBCs | $ 92.00 |
| 4124B | Rubidium, Blood | $ 228.00 |
| 4124R | Rubidium, RBCs | $ 344.00 |
| 4124SP | Rubidium, Serum/Plasma | $ 228.00 |
| 4124U | Rubidium, Urine | $ 228.00 |
| 4180B | Selenium, Blood | $ 113.00 |
| 4180H | Selenium, Hair | $ 541.00 |
| 4180LI | Selenium, Liquid | $ 686.00 |
| 4180N | Selenium, Nails | $ 541.00 |
| 4180R | Selenium, RBCs | $ 113.00 |
| 4180SP | Selenium, Serum/Plasma | $ 113.00 |
| 4180U | Selenium, Urine | $ 132.00 |
| 6317U | Semi Conductor Panel, Urine | $ 631.00 |
| 4190B | Silicon, Blood | $ 140.00 |
| 4190SP | Silicon, Serum/Plasma | $ 140.00 |
| 4190U | Silicon, Urine | $ 140.00 |
| 4200B | Silver, Blood | $ 103.00 |
| 4200SP | Silver, Serum/Plasma | $ 103.00 |
| 4200U | Silver, Urine | $ 103.00 |
| 4212B | Strontium, Blood | $ 100.00 |
| 4212SP | Strontium, Serum/Plasma | $ 58.00 |
| 4212U | Strontium, Urine | $ 57.00 |
| 4320B | Tellurium, Blood | $ 249.00 |

| Test | Test Name | List Price |
|---|---|---|
| **METALS/ELEMENTS TESTING SERVICES** | | |
| 4320SP | Tellurium, Serum/Plasma | $ 249.00 |
| 4320U | Tellurium, Urine | $ 249.00 |
| 4370B | Thallium, Blood | $ 149.00 |
| 4370H | Thallium, Hair | $ 414.00 |
| 4370LI | Thallium, Liquid | $ 366.00 |
| 4370N | Thallium, Nails | $ 414.00 |
| 4370SP | Thallium, Serum/Plasma | $ 93.00 |
| 4370U | Thallium, Urine | $ 98.00 |
| 4478SP | Thorium, Serum/Plasma | $ 158.00 |
| 4478U | Thorium, Urine | $ 263.00 |
| 4485B | Tin - Total, Blood | $ 148.00 |
| 4485H | Tin - Total, Hair | $ 503.00 |
| 4485SP | Tin - Total, Serum/Plasma | $ 148.00 |
| 4485TI | Tin - Total, Tissue | $ 95.00 |
| 4485U | Tin - Total, Urine | $ 148.00 |
| 4486B | Titanium, Blood | $ 152.00 |
| 4486FL | Titanium, Fluid | $ 356.00 |
| 4486SP | Titanium, Serum/Plasma | $ 152.00 |
| 4486U | Titanium, Urine | $ 228.00 |
| 0470UH | Total, Inorganic Arsenic, 24 Hour Urine (+Creatinine) | $ 168.00 |
| 4730B | Tungsten, Blood | $ 188.00 |
| 4730SP | Tungsten, Serum/Plasma | $ 188.00 |
| 4730U | Tungsten, Urine | $ 188.00 |
| 4755UH | Uranium, 24 Hour Urine | $ 188.00 |
| 4755U | Uranium, Urine | $ 188.00 |
| 4765B | Vanadium, Blood | $ 113.00 |
| 4765R | Vanadium, RBCs | $ 113.00 |
| 4765SP | Vanadium, Serum/Plasma | $ 113.00 |
| 4765U | Vanadium, Urine | $ 119.00 |
| 4844B | Zinc, Blood | $ 69.00 |
| 4844FL | Zinc, Fluid | $ 276.00 |
| 4844H | Zinc, Hair | $ 405.00 |
| 4844LI | Zinc, Liquid | $ 555.00 |
| 4844N | Zinc, Nails | $ 405.00 |
| 4844R | Zinc, RBCs | $ 69.00 |
| 4844SP | Zinc, Serum/Plasma | $ 69.00 |
| 4844U | Zinc, Urine | $ 113.00 |
| 4870SP | Zirconium, Serum/Plasma | $ 203.00 |
| 4885B | ZPP (Zinc Protoporphyrin), Blood | $ 77.00 |

| Test | Test Name | List Price |
|---|---|---|
| **MISCELLANEOUS SERVICES** | | |
| HAIR KIT | Hair Kit/ Forensic | $ 19.00 |
| HAIRSEG | Hair Segmentation | $ 189.00 |
| HAIRSEG2 | Hair Segmentation II | $ 189.00 |
| MICRO | Micro Specimen Surcharge | $ 95.00 |
| NONBIO/LIQ | Non-biological Fee (Liquid) | $ 146.00 |
| NONBIO/SOL | Non-biological Fee (Solid) | $ 214.00 |
| SHPCHG | Shipping Charge | $ 43.00 |
| HANDLING | Specimen Handling Fee | $ 49.00 |
| SPEC RET | Specimen Retention | $ 2,600.00 |
| RETURN | Specimen Return/Handling | $ 66.00 |
| **NEWBORN TOXICOLOGY** | | |
| 8600ME | Amphetamines Panel (Qualitative), Meconium | $ 312.00 |
| 8620ME | Barbiturates Panel (Qualitative), Meconium | $ 465.00 |
| 9351UC | Basic Drug Screen, Umbilical Cord Tissue | $ 439.00 |
| 9329ME | Benzodiazepines Panel (Qualitative), Meconium | $ 308.00 |
| 4127ME | Buprenorphine and Metabolite - Total (Qualitative), Meconium | $ 472.00 |
| 0960ME | Cannabinoids Panel (Qualitative), Meconium | $ 354.00 |
| 1300ME | Cocaine and Metabolites (Qualitative), Meconium | $ 452.00 |
| 9145UC | Comprehensive Drug Screen, Umbilical Cord Tissue | $ 745.00 |
| 1864ME | Drugs of Abuse Screen (10 Panel), Meconium | $ 227.00 |
| 6904ME | Drugs of Abuse Screen (7 Panel), Meconium | $ 193.00 |
| 9146UC | Ethyl Glucuronide Screen, Umbilical Cord Tissue | $ 339.00 |
| 9352UC | Expanded Drug Screen, Umbilical Cord Tissue | $ 586.00 |
| 2079ME | Fentanyl and Metabolite (Qualitative), Meconium | $ 387.00 |
| 2760ME | Methadone and Metabolite (Qualitative), Meconium | $ 358.00 |
| 8670ME | Opiates - Total (Conjugated/Unconjugated) (Qualitative), Meconium | $ 373.00 |
| 8761ME | Phencyclidine (Qualitative), Meconium | $ 439.00 |
| **NOVEL PSYCHOACTIVE SUBSTANCES (NPS)** | | |
| 0010B | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Blood | $ 286.00 |
| 0010SP | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Serum/Plasma | $ 179.00 |
| 0010U | 2-fluoro Deschloroketamine and Deschloroketamine (Qualitative), Urine | $ 179.00 |
| 0015B | 2-methyl AP-237 & AP-238, Blood | $ 556.00 |
| 0015SP | 2-methyl AP-237 & AP-238, Serum/Plasma | $ 556.00 |
| 0015U | 2-methyl AP-237 & AP-238, Urine | $ 556.00 |
| 0014B | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Blood | $ 286.00 |
| 0014SP | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Serum/Plasma | $ 179.00 |
| 0014U | 3-MeO-PCP and 3-hydroxy-PCP (Qualitative), Urine | $ 179.00 |
| 0205U | Acetyl Fentanyl and Metabolite, Urine | $ 192.00 |
| 9105B | Acetyl Fentanyl Screen, Blood | $ 192.00 |
| 9105SP | Acetyl Fentanyl Screen, Serum/Plasma | $ 192.00 |
| 9105U | Acetyl Fentanyl Screen, Urine | $ 192.00 |
| 0205B | Acetyl Fentanyl, Blood | $ 192.00 |
| 0205FL | Acetyl Fentanyl, Fluid | $ 386.00 |
| 0205SP | Acetyl Fentanyl, Serum/Plasma | $ 192.00 |
| 0205TI | Acetyl Fentanyl, Tissue | $ 386.00 |
| 2626B | Bath Salts Panel (Qualitative), Blood | $ 271.00 |

| Test | Test Name | List Price |
|---|---|---|
| **NOVEL PSYCHOACTIVE SUBSTANCES (NPS)** | | |
| 2626SP | Bath Salts Panel (Qualitative), Serum/Plasma | $ 172.00 |
| 2626U | Bath Salts Panel (Qualitative), Urine | $ 172.00 |
| 0771B | Brorphine, Blood | $ 477.00 |
| 0771SP | Brorphine, Serum/Plasma | $ 477.00 |
| 0771U | Brorphine, Urine | $ 477.00 |
| 1483U | Desalkylgidazepam (Qualitative), Urine | $ 338.00 |
| 1483B | Desalkylgidazepam, Blood | $ 338.00 |
| 1483SP | Desalkylgidazepam, Serum/Plasma | $ 338.00 |
| 1481U | Deschloroetizolam, Meclonazepam, and Pyrazolam (Qualitative), Urine | $ 359.00 |
| 1481B | Deschloroetizolam, Meclonazepam, and Pyrazolam, Blood | $ 359.00 |
| 1481SP | Deschloroetizolam, Meclonazepam, and Pyrazolam, Serum/Plasma | $ 359.00 |
| 0570U | Designer Benzodiazepines (Qualitative), Urine | $ 361.00 |
| 0570B | Designer Benzodiazepines, Blood | $ 361.00 |
| 0570SP | Designer Benzodiazepines, Serum/Plasma | $ 361.00 |
| 1480U | Designer Opioids (Qualitative), Urine | $ 374.00 |
| 1480B | Designer Opioids, Blood | $ 374.00 |
| 1480SP | Designer Opioids, Serum/Plasma | $ 374.00 |
| 1022U | Eutylone (Qualitative), Urine | $ 292.00 |
| 1022B | Eutylone, Blood | $ 292.00 |
| 1022SP | Eutylone, Serum/Plasma | $ 292.00 |
| 1022TI | Eutylone, Tissue | $ 540.00 |
| 3078U | Mitragynine (Qualitative), Urine | $ 187.00 |
| 3064B | Mitragynine, Blood | $ 196.00 |
| 3064SP | Mitragynine, Serum/Plasma | $ 196.00 |
| 3218B | N,N-Dimethylpentylone & Pentylone, Blood | $ 338.00 |
| 3218SP | N,N-Dimethylpentylone & Pentylone, Serum/Plasma | $ 338.00 |
| 3218U | N,N-Dimethylpentylone & Pentylone, Urine | $ 338.00 |
| 3168B | Nitazenes Panel, Blood | $ 378.00 |
| 3168SP | Nitazenes Panel, Serum/Plasma | $ 378.00 |
| 8756B | Novel Psychoactive Substances (NPS) Screen 1, Blood | $ 389.00 |
| 8756SP | Novel Psychoactive Substances (NPS) Screen 1, Serum/Plasma | $ 389.00 |
| 8756U | Novel Psychoactive Substances (NPS) Screen 1, Urine | $ 389.00 |
| 3224B | NPS Stimulants (Qualitative), Blood | $ 286.00 |
| 3224SP | NPS Stimulants (Qualitative), Serum/Plasma | $ 179.00 |
| 3224U | NPS Stimulants (Qualitative), Urine | $ 179.00 |
| 4047B | Pyrrolidinophenone Panel, Blood | $ 348.00 |
| 4047SP | Pyrrolidinophenone Panel, Serum/Plasma | $ 348.00 |
| 1021B | Substituted Cathinone Panel, Blood | $ 304.00 |
| 1021SP | Substituted Cathinone Panel, Serum/Plasma | $ 304.00 |
| 1021U | Substituted Cathinone Panel, Urine | $ 304.00 |
| 9562U | Synthetic Cannabinoid Metabolites Screen - Expanded, Urine | $ 140.00 |
| 4283U | Synthetic Cannabinoid Metabolites-Expanded (Qualitative), Urine | $ 104.00 |
| 4282SP | Synthetic Cannabinoids (Qualitative), Serum/Plasma | $ 304.00 |
| 9566B | Synthetic Cannabinoids Screen (Add-On), Blood | $ 204.00 |
| 9560B | Synthetic Cannabinoids Screen, Blood | $ 284.00 |

| Test | Test Name | List Price |
|---|---|---|
| **ORAL FLUID TESTING SERVICES** | | |
| 8890OF | Amphetamines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8891OF | Benzodiazepines Panel (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8893OF | Cocaine and Metabolites (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8892OF | Delta-9 THC (Qualitative), Oral Fluid (Saliva) | $ 80.00 |
| 8900OF | Delta-9 THC (Quantitative), Oral Fluid (Saliva) | $ 214.00 |
| 8898OF | Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva) | $ 94.00 |
| 8897OF | Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva) | $ 146.00 |
| 8894OF | Methadone and Metabolite (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8895OF | Opiates (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| 8896OF | Phencyclidine and Dextromethorphan (Qualitative), Oral Fluid (Saliva) | $ 71.00 |
| **PFAS TESTING SERVICES** | | |
| 3429SP | PFASure™ Expanded, Serum/Plasma | $ 551.00 |
| 3434SP | PFASure FT, Serum/Plasma | $ 510.00 |
| 3428SP | PFASure™, Serum/Plasma | $ 510.00 |
| 3427SP | Perfluoroalkyl Substances (PFAS), Serum/Plasma | $ 468.00 |
| 3426B | Perfluorooctanoic Acid, Blood | $ 662.00 |

NMS LABS

Expert Services

NMSlabs.com

# Expert Services Professional Support

Effective January 1 to December 31, 2025*

## Documents for Legal Proceedings

These are optional documents that may require subpoenas. Litigation Packages and Discovery Documentation require 4 to 6 weeks before trial to gather and process information within the laboratory.

| Documents | Fee |
|---|---|
| Affidavits | $93/each |
| Certified Lab Reports | $93/each |
| Litigation Package | $93/each |
| Discovery Documentation—Hourly Rate | $93/hour |

## Expert Opinions

NMS Labs toxicologists provide written reports that support analytical testing services. Fee includes the expert's time for consultation, documentation review, research, and preparation of a written report.

| Expert Opinion | Fee |
|---|---|
| Senior Toxicologist Review | $486/hour |
| Toxicologist Review | $426/hour |

## Court Testimony and Depositions

In-person or video testimony, depositions, pre-trial preparation, wait time, and travel time are all included.

| Expert Testimony | Fee |
|---|---|
| Hourly Rate | $305/hour |
| Daily Rate | $3,656/day |

Client is responsible for all travel-related expenses, mileage, meals, flights, hotels, etc. *All fees are calculated on an hourly basis. Daily rate will be applied after 10 hours of time is spent on any of the above activities, per day, related to each testimony event.*

For questions call Expert Services at **844.276.0768**

or email **ExpertServices@NMSlabs.com** for more information.

*Other terms and conditions may apply.


**Contact**

NMS Labs
200 Welsh Road, Horsham, PA 19044

T: 844.276.0768
F: 215.657.2972

www.NMSlabs.com

**WSP Contract No.: K21620**
**Exhibit F**
**Subcontractor and Business Diversity Certifications**

| **Check all boxes that apply to your business, sign, and return this completed form.** | |
|---|---|
| **SUBCONTRACTOR CERTIFICATION** | |
| **Enter Your Company Name**: National Medical Services, Inc. | **Check One** |
| **Contractor/Vendor -**Will you use Subcontractor(s) for any part the contract work? If yes, please check box.<br>This Contract is subject to compliance tracking using the State's business diversity management system, Access Equity. Access Equity is web-based and can be accessed at the Office of Minority and Women's Business Enterprises at https://omwbe.diversitycompliance.com/. | ☐ |
| **Contractor/Vendor** -- If Contractor will **NOT** use subcontractors, please check box. | ☑ |
| **BUSINESS DIVERSITY CERTIFICATION** | |
| Washington State agencies are encouraged to contract with Washington small business, microbusiness, minibusiness, minority-, women-, and veteran-owned businesses.<br>**OMWBE** Certified Business is a Business certified with the office of Women and Minority Businesses Enterprises under Chapter **39.19** RCW.<br>Please provide your Certifications: OMWBE: ____ WDVA: ____. WSP will confirm certification. | **Check All That Apply** |
| Business **does no**t qualify for any of the Diverse Businesses as set forth below. | ☑ |
| **Small Business** is an in-state (Washington) business (including sole proprietorship, a corporation, partnership, or other legal entity,) that is owned and operated independently from all other business, and limited to firms that meet the three requirements with location, size and WEBS certification. | ☐ |
| **Microbusiness Size Requirement:** Defined by, RCW 39.26.010(16). The firm must be owned and operated independently from all other businesses and has a gross revenue of less than one million dollars ($1,000,000) annually as reported on the firm's federal income tax return or its return filed with the DOR. See, RCW 39.26.010(16) | ☐ |
| **Minibusiness Size Requirement:** Defined by RCW 39.26.010 a business entity, including a sole proprietorship, corporation, partnership, or other legal entity, that: (a) Is owned and operated independently from all other businesses; **and** (b) has a gross revenue of more than one million ($1,000,000) **and** less than three million ($3,000,000) dollars annually as reported on its federal tax return or its return filed with the DOR. | ☐ |
| **Minority Owned**: is a small business as defined above which at least 51% owned by one or more minority individuals, and certified by the Washington State Office of Minority and Women's Business Enterprises (OMWBE) as a minority-owned business (MBE). *See*, RCW 39.19.120 and WAC 326-20. | ☐ |
| **Women Owned Business**: is a small business as defined above which at least 51% owned by a one or more women. Firm must be certified by the OMWBE as a MBE. *See*, RCW 39.19.120 and WAC 326-20 | ☐ |
| **Certified Veteran Owned Business** is limited to firms certified by the Washington State Department of Veterans Affairs (WDVA) as a Certified Veteran-Owned Business. *See*, RCW 43.60A.010(7) & RCW 43.60A.190 or a business considered a veteran-owned business under 38 C.F.R. Part 74. | ☐ |

I hereby certify, under penalty of perjury under the laws of the State of Washington, on behalf of the above-referenced company**,** that the certifications checked above herein are true and correct and that I am authorized to make these certifications on behalf of the named contractor.

| ***Authorized Signature*** | Gregory Schuh<br>***Print Name*** | 7/17/25<br>***Date*** |
|---|---|---|